NCT Number,Study Title,Study URL,Study Status,Study Results,Conditions,Interventions,Sponsor,Collaborators,Sex,Age,Enrollment,Funder Type,Study Type,Study Design,Start Date,Completion Date,Locations
NCT06807762,Safety and Pharmacokinetics of Extrato De Cannabis Sativa GreenCare,https://clinicaltrials.gov/study/NCT06807762,RECRUITING,NO,Healthy,DRUG: Cannabis oil,GreenCare Pharma,,ALL,"ADULT, OLDER_ADULT",72,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2025-03-10,2025-12,"GreenCare Pharma, Vinhedo, Sao Paulo, 13288006, Brazil"
NCT04855526,THC + CBD and Memory Study,https://clinicaltrials.gov/study/NCT04855526,UNKNOWN,NO,Marijuana Use|Cannabis Use|Cannabis Intoxication,DRUG: High THC/No CBD Marihuana|DRUG: High THC/High CBD Marihuana|DRUG: No THC/No CBD Marihuana,Hartford Hospital,Yale University,ALL,ADULT,9,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2022-04-01,2022-06-30,
NCT00580671,Treatment for Adolescent Marijuana Abuse,https://clinicaltrials.gov/study/NCT00580671,COMPLETED,YES,Marijuana Abuse,BEHAVIORAL: MET/CBT|BEHAVIORAL: CM|BEHAVIORAL: BPT,Dartmouth-Hitchcock Medical Center,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",153,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2007-11,2013-12,"Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, 03756, United States"
NCT03813602,Detection of Cannabis Impairment With an Eye Tracker,https://clinicaltrials.gov/study/NCT03813602,COMPLETED,NO,Cannabis Intoxication,DRUG: Cannabis Sativa,Centre for Addiction and Mental Health,,ALL,ADULT,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2019-08-15,2019-11-15,"Center for Addiction and Mental Health, Toronto, Ontario, M5S 2S1, Canada"
NCT04693884,Cannabis Inhalation: Effects on Cardiovascular Function During Rest and Exercise,https://clinicaltrials.gov/study/NCT04693884,ACTIVE_NOT_RECRUITING,NO,Cannabis|Cardiovascular Risk Factor,DRUG: Cannabis|DRUG: Cannabis|DRUG: Cannabis|DRUG: Cannabis,Jamie Burr,,ALL,ADULT,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,2021-09-01,2023-12,"University of Guelph, Guelph, Ontario, N1G2W1, Canada"
NCT03247244,Safety and Efficacy of Cannabis in Tourette Syndrome,https://clinicaltrials.gov/study/NCT03247244,TERMINATED,NO,Tourette Syndrome,DRUG: Cannabis|DRUG: Cannabis|DRUG: Cannabis,"University Health Network, Toronto",,ALL,"ADULT, OLDER_ADULT",15,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-01-15,2020-01-27,"Toronto Western Hospital - Tourette Syndrome Neurodevelopmental Clinic, Toronto, Ontario, M5T2S8, Canada"
NCT01748799,Fixed or Self-Titrated Dosages of Sativex on Cannabis Users,https://clinicaltrials.gov/study/NCT01748799,COMPLETED,YES,Cannabis Dependence,DRUG: Sativex|DRUG: Placebo,Centre for Addiction and Mental Health,Canadian Institutes of Health Research (CIHR),ALL,ADULT,16,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-02,2014-09,"Centre for Addiction and Mental Health, Toronto, Ontario, M5S 2S1, Canada"
NCT04841993,Pharmacokinetics and Pharmacological Effects of a Standardized Cannabis Preparation,https://clinicaltrials.gov/study/NCT04841993,COMPLETED,NO,Cannabis Use|Healthy Subjects,DRUG: Cannabis decoction|DRUG: Cannabis oil|DRUG: Vaporized cannabis,Germans Trias i Pujol Hospital,Fundació Institut Germans Trias i Pujol|Istituto Superiore di Sanità,ALL,ADULT,43,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,2018-12-10,2021-02-28,"Germans Trias i Pujol Hospital, Badalona, Barcelona, 08916, Spain"
NCT01323569,Abuse Potential of Sativex,https://clinicaltrials.gov/study/NCT01323569,COMPLETED,NO,Evaluation of Abuse Potential of Sativex,DRUG: Sativex|DRUG: Sativex|DRUG: Sativex|DRUG: Placebo|DRUG: Marinol|DRUG: Marinol,Jazz Pharmaceuticals,,ALL,ADULT,58,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2008-02,2008-06,"DecisionLine Clinical Research Corporation, Toronto, Ontario, M5V 2T3, Canada"
NCT00158249,Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals,https://clinicaltrials.gov/study/NCT00158249,COMPLETED,YES,Marijuana Abuse,DRUG: citicoline|DRUG: placebo,Mclean Hospital,National Institute on Drug Abuse (NIDA),ALL,ADULT,21,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-09,2014-10,"McLean Hospital, Department of Psychiatry, Belmont, Massachusetts, 02478 9106, United States"
NCT05234814,Fire Dragon Pot Moxibustion,https://clinicaltrials.gov/study/NCT05234814,COMPLETED,NO,Insomnia|Perimenopause,OTHER: Traditional Chinese Medicine auricular acupuncture point buried seeds therapy plus the fire dragon pot moxibustion therapy.|OTHER: Traditional Chinese Medicine auricular acupuncture point buried seeds therapy,Weihua Yu,,FEMALE,"CHILD, ADULT, OLDER_ADULT",70,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-01-01,2020-10-30,"The Third Affiliated Hospital of Anhui Medical University (The first people ' s Hospital of Hefei), Hefei, Anhui, China"
NCT03581058,Neural Correlates of Driving and Cannabis,https://clinicaltrials.gov/study/NCT03581058,UNKNOWN,NO,Cannabis Use|Driving Impaired,DRUG: Cannabis,Unity Health Toronto,"University Health Network, Toronto",ALL,ADULT,12,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2018-08-08,2020-12-31,"University Health Network, Toronto, Ontario, M5G 2C4, Canada"
NCT02849587,The Impact and Detection of Driving Impairments Associated With Acute Cannabis Smoking,https://clinicaltrials.gov/study/NCT02849587,COMPLETED,YES,Cannabis Intoxication,DRUG: Cannabis,"University of California, San Diego",,ALL,ADULT,199,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING",2017-02-24,2019-06-17,"Center for Medicinal Cannabis Research, UC San Diego, San Diego, California, 92103, United States"
NCT04997395,Feasibility of Cannabidiol for the Treatment of Long COVID,https://clinicaltrials.gov/study/NCT04997395,COMPLETED,NO,Long COVID,DRUG: MediCabilis Cannabis sativa 50,Bod Australia,"Drug Science, UK",ALL,"ADULT, OLDER_ADULT",12,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-04-14,2023-01-06,"Drug Science, York, United Kingdom"
NCT00743145,Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana,https://clinicaltrials.gov/study/NCT00743145,COMPLETED,YES,Marijuana Smoking,DRUG: Inactive Marijuana (0% THC)|DRUG: Active Marijuana (5.5% THC)|DRUG: Active Marijuana (6.2% THC)|DRUG: Naltrexone|DRUG: Placebo naltrexone,New York State Psychiatric Institute,"Research Foundation for Mental Hygiene, Inc.|National Institute on Drug Abuse (NIDA)",ALL,ADULT,23,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2008-05,2009-09,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT04113096,Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer,https://clinicaltrials.gov/study/NCT04113096,UNKNOWN,NO,Stage IV Prostate Cancer|Stage IV Colon Cancer|Stage IV Breast Cancer|Stage IV Cancer of the Cervix,DRUG: Dibenzyl trisulphide capsules|DRUG: Dibenzyl trisulphide capsules|DRUG: Dibenzyl trisulphide capsules|DRUG: Dibenzyl trisulphide capsules|DRUG: Stage IV Breast Cancer Placebo|DRUG: Stage IV: Colon Cancer Placebo|DRUG: Cervical Cancer Stage IV Placebo|DRUG: Cancer of the Prostate Placebo,The University of The West Indies,,ALL,"CHILD, ADULT, OLDER_ADULT",104,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-10-01,2020-09-30,"Faculty of Medial Sciences, Kingston, Jamaica"
NCT03099005,Effect of Cannabis and Endocannabinoids on HIV Neuropathic Pain,https://clinicaltrials.gov/study/NCT03099005,COMPLETED,YES,Cannabis|HIV Neuropathy|Pain Syndrome,DRUG: Cannabis,"University of California, San Diego",,ALL,"ADULT, OLDER_ADULT",5,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-07-01,2022-12-31,"UC Center for Medicinal Cannabis Research, UC San Diego, San Diego, California, 92103, United States"
NCT01798186,Pharmacokinetic and Pharmacodynamic Effects of Passive Cannabis Inhalation,https://clinicaltrials.gov/study/NCT01798186,COMPLETED,YES,Cannabis Toxicology,DRUG: Cannabis,Johns Hopkins University,Substance Abuse and Mental Health Services Administration (SAMHSA)|RTI International,ALL,ADULT,26,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC,2013-05,2013-08,"Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland, 21224, United States"
NCT00683488,Integrated Treatment of Marijuana Abuse for HIV+ Youth,https://clinicaltrials.gov/study/NCT00683488,COMPLETED,NO,HIV Infections,BEHAVIORAL: Focus Group|BEHAVIORAL: First Intervention Trial|BEHAVIORAL: Intervention Trial 2,"University of North Carolina, Chapel Hill",National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH),ALL,"CHILD, ADULT",46,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-04,2011-04,"Childrens Hospital of Los Angeles, Los Angeles, California, 90027, United States|Mount Sinai Medical Center, New York, New York, 10128, United States|Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States"
NCT04316598,Cannabis Effects on Electroencephalography,https://clinicaltrials.gov/study/NCT04316598,TERMINATED,NO,Healthy Volunteers,DRUG: Cannabis Sativa|DRUG: Cannabis placebo,Parc de Salut Mar,,ALL,ADULT,16,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: OTHER",2020-03-03,2020-07-09,"IMIM (Hospital del Mar Medical Research Institute), Barcelona, 08003, Spain"
NCT01322464,Study to Assess Food Effect on Sativex Bioavailability,https://clinicaltrials.gov/study/NCT01322464,COMPLETED,NO,Food Effect,DRUG: Sativex|DRUG: Sativex|DRUG: Sativex|DRUG: Sativex,Jazz Pharmaceuticals,,MALE,ADULT,25,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2008-01,2008-02,"Guy's Drug Research Unit, Quintiles Ltd., London, SE1 1YR, United Kingdom"
NCT03191084,Examine the Feasibility of a Standardized Field Test for Marijuana Impairment: Laboratory Evaluations,https://clinicaltrials.gov/study/NCT03191084,COMPLETED,NO,Marijuana Impairment,DRUG: Low Dose THC Marijuana|DRUG: High Dose THC Marijuana|DRUG: Placebo Marijuana,Yale University,National Highway Traffic Safety Administration (NHTSA)|Hartford Hospital|Montana State University|Maastricht University|The Mind Research Network|National Institute on Drug Abuse (NIDA),ALL,ADULT,26,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2017-12-01,2020-03-30,"Olin Neuropsychiatry Research Center, Hartford, Connecticut, 06106, United States"
NCT01037088,Effects of Vaporized Marijuana on Neuropathic Pain,https://clinicaltrials.gov/study/NCT01037088,COMPLETED,YES,Neuropathic Pain|Reflex Sympathetic Dystrophy|Peripheral Neuropathy|Post-herpetic Neuralgia|Spinal Cord Injury|Multiple Sclerosis,DRUG: Mild dose cannabis|DRUG: Low dose cannabis|DRUG: Cannabis,"University of California, Davis",Center for Medicinal Cannabis Research|VA Northern California Health Care System,ALL,"ADULT, OLDER_ADULT",44,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-12,2012-11,"CTSC Clinical Research Center, Sacramento VA Medical Center, Sacramento, California, 95817, United States"
NCT01983267,Evaluation Prospectively the Level of Reduction in Cognitive Functions of Cancer Patients Who Are on Active Oncology Treatments and Use Cannabis. The Second Goal is to Identify High-risk Groups for Cognitive Impairment Due to Cannabis Use.,https://clinicaltrials.gov/study/NCT01983267,COMPLETED,NO,1- Cancer Patients During Chemotherapy Treatment|2- Use of Cannabis Comparing to Control Without Cannabis Use,DRUG: cannabis,Rambam Health Care Campus,,ALL,"ADULT, OLDER_ADULT",100,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2013-11,2017-04-26,"Oncology Institute, Rambam Health Care Campus, Haifa, 31096, Israel"
NCT03122691,Differences in Cannabis Impairment and Its Measurement Due to Route of Administration,https://clinicaltrials.gov/study/NCT03122691,COMPLETED,YES,Behavioral Pharmacology of Cannabis,DRUG: cannabis,Johns Hopkins University,RTI International|U.S. Department of Justice|National Institute on Drug Abuse (NIDA),ALL,ADULT,23,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2018-05-01,2020-02-01,"Johns Hopkins University School of Medicine, Baltimore, Maryland, 21231, United States"
NCT03676166,Pharmacokinetic and Pharmacodynamic Effects of Smoked and Vaporized Cannabis,https://clinicaltrials.gov/study/NCT03676166,COMPLETED,NO,Cannabis,DRUG: Cannabis,Johns Hopkins University,,ALL,ADULT,18,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2016-06-16,2017-01-17,"Johns Hopkins School of Medicine Behavioral Pharmacology Research Unit, Baltimore, Maryland, 21224, United States"
NCT04800159,Cannabis Effects on Antiretroviral Therapy Pharmacokinetics and Neurotoxicity,https://clinicaltrials.gov/study/NCT04800159,RECRUITING,NO,HIV|Cannabis Use,DRUG: THC Cannabis|DRUG: CBD Cannabis|DRUG: Placebo,"University of California, San Diego",Center for Medicinal Cannabis Research,ALL,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2021-02-19,2025-04-30,"Ucsd Hnrp-Cmcr, San Diego, California, 92103, United States"
NCT04230460,Cannabis Impairment Detection Application (CIDA),https://clinicaltrials.gov/study/NCT04230460,COMPLETED,NO,Driving Under the Influence|Marijuana Intoxication|Alcohol Intoxication,DRUG: Cannabis (THC) (Inhaled) Placebo|DRUG: Cannabis (High% THC) (Inhaled)|DRUG: Cannabis (Very High% THC) (Inhaled)|DRUG: Alcohol (oral),"Advanced Brain Monitoring, Inc.",University of Iowa,ALL,ADULT,124,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2020-09-01,2021-05-27,"University of Iowa. National Advanced Driving Simulator, Iowa City, Iowa, 52242, United States"
NCT02757313,Neuroscience of Marijuana Impaired Driving,https://clinicaltrials.gov/study/NCT02757313,COMPLETED,NO,Marijuana Impairment,DRUG: Low dose THC marijuana|DRUG: High dose THC marijuana|DRUG: Placebo marijuana,Yale University,Hartford Hospital|National Institute on Drug Abuse (NIDA)|Montana State University|Maastricht University|The Mind Research Network,ALL,ADULT,62,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2016-10,2021-05,"Olin Neuropsychiatry Research Center, Hartford, Connecticut, 06106, United States"
NCT01776970,Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease,https://clinicaltrials.gov/study/NCT01776970,COMPLETED,NO,Motor Neuron Disease|Amyotrophic Lateral Sclerosis (ALS),DRUG: Cannabis Sativa extract Oromucosal spray,Ospedale San Raffaele,Fondazione Salvatore Maugeri|Niguarda Hospital|University of Padova,ALL,"ADULT, OLDER_ADULT",60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2013-01,2015-12,"San Raffaele Scientific Institute, Milan, 20132, Italy|Fondazione Salvatore Maugeri IRCCS, Istituto Scientifico, Milan, Italy|NEuroMuscular Omnicentre (NEMO), Fondazione Serena - H Cà granda, Milan, Italy|Universita' Degli Studi Di Padova, Azienda Ospedaliera Di Padova, Neurologic Department;, Padova, Italy"
NCT04945031,The Study of Pharmacological Treatment Pattern for Cannabis-induced Psychosis,https://clinicaltrials.gov/study/NCT04945031,COMPLETED,NO,Cannabis,OTHER: cannabis,Mahidol University,,ALL,"CHILD, ADULT, OLDER_ADULT",317,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-11-08,2020-12-31,"Onrumpha Chuenchom, Thanyaburi, Pathum Thani, 12110, Thailand"
NCT01592409,Cannabis Effects on Driving-related Skills of Young Drivers,https://clinicaltrials.gov/study/NCT01592409,COMPLETED,YES,Psychomotor Impairment,DRUG: delta-9-tetrahydrocannabinol|DRUG: Placebo,Centre for Addiction and Mental Health,Canadian Institutes of Health Research (CIHR)|Health Canada,ALL,ADULT,99,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2012-07,2016-09,"Centre for Addiction and Mental Health, Toronto, Ontario, M5S 2S1, Canada"
NCT05522205,Regulated Cannabis Access in Basel,https://clinicaltrials.gov/study/NCT05522205,ACTIVE_NOT_RECRUITING,NO,Cannabis Use Disorder|Mental Health Disorder|Physical Illness,OTHER: Regulated cannabis access in pharmacies,Health Department of the Canton of Basel-Stadt,University of Basel|University Psychiatric Clinics Basel|Psychiatric Services Aargau AG,ALL,"ADULT, OLDER_ADULT",374,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-01-31,2025-07-31,"Canton Basel-Stadt, Basel, Basel-Stadt, Switzerland"
NCT04576507,Repeated Cannabis Administration on Experimental Pain and Abuse Liability,https://clinicaltrials.gov/study/NCT04576507,SUSPENDED,NO,Cannabis|Pain|Tolerance|Hyperalgesia,DRUG: Cannabis,New York State Psychiatric Institute,"Alkermes, Inc.",ALL,ADULT,16,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-06-01,2025-12-31,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT04596644,Impact of Repeatedly-Administered THC-cannabis on Experimental Pain and Abuse Liability in Humans,https://clinicaltrials.gov/study/NCT04596644,SUSPENDED,NO,Cannabis|Pain|Tolerance|Hyperalgesia,DRUG: Cannabis,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,ADULT,16,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-08-01,2025-08-31,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT06120855,Study on Regulated Cannabis Sales in Pharmacies,https://clinicaltrials.gov/study/NCT06120855,RECRUITING,NO,Marijuana Smoking|Cannabis|Cannabis Use,DRUG: Regulated cannabis from authorized pharmacies|DRUG: Cannabis from the illicit market,University of Bern,Universität Luzern,ALL,"ADULT, OLDER_ADULT",1091,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-11-22,2026-09,"University of Bern, Bern, 3012, Switzerland|Zentrum für Hausarztmedizin und Community Care, University of Lucerne, Lucerne, Switzerland"
NCT05563948,Repeated Administration of Cannabis Varying in THC and CBD,https://clinicaltrials.gov/study/NCT05563948,SUSPENDED,NO,Cannabis,DRUG: Cannabis,New York State Psychiatric Institute,,ALL,"ADULT, OLDER_ADULT",100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2025-05-01,2034-05-31,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT05849636,Alerta Cannabis: Evaluation of Web-based Tailored Intervention,https://clinicaltrials.gov/study/NCT05849636,RECRUITING,NO,Cannabis Use|Adolescent Behavior|E-health,BEHAVIORAL: ALERTA CANNABIS,University of Seville,"Ministerio de Ciencia, Innovación y Universidades|Maastricht University",ALL,"CHILD, ADULT",1850,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-10-01,2024-01-31,"University of Sevilla, Sevilla, 41009, Spain"
NCT04982965,Brain Mechanisms Supporting Cannabis-induced Pain Relief,https://clinicaltrials.gov/study/NCT04982965,RECRUITING,NO,"Pain, Acute",DRUG: Active Cannabis|DRUG: Placebo Cannabis,"University of California, San Diego",,ALL,"ADULT, OLDER_ADULT",100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2021-05-07,2027-03-15,"Altman Clinical and Translational Research Institute, La Jolla, California, 92093, United States|University of California, San Diego, San Diego, California, 92093, United States"
NCT04100590,Eye Tracking as a Biomarker of Cannabis Effects,https://clinicaltrials.gov/study/NCT04100590,TERMINATED,YES,"Cannabis Use|Pain, Acute",DRUG: Cannabis,New York State Psychiatric Institute,,ALL,ADULT,1,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2019-10-01,2020-01-31,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT00373399,Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks,https://clinicaltrials.gov/study/NCT00373399,COMPLETED,YES,Marijuana Use Disorder,DRUG: Inactive Marijuana (0% THC)|DRUG: Low THC marijuana (1.8 %THC)|DRUG: High THC marijuana (3.9% THC),New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,ADULT,36,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2006-05,2008-03,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT06059677,Cannabis Consumption and Driving Impairment Assessment on a Closed Course,https://clinicaltrials.gov/study/NCT06059677,RECRUITING,NO,Cannabis Smoking|Driving Impaired,DRUG: Active smoked cannabis|DRUG: Placebo smoked cannabis,"Bayliss J. Camp, PhD",,ALL,ADULT,300,OTHER_GOV,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2023-10-03,2024-12-31,"California Department of Motor Vehicles Headquarters, Sacramento, California, 95818-2606, United States"
NCT05084105,Cannabis and Aging,https://clinicaltrials.gov/study/NCT05084105,COMPLETED,NO,Cannabis Use,,Thorsten Rudroff,,ALL,"ADULT, OLDER_ADULT",60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-02-01,2021-11-01,"Department of Health and Human Physiology, Iowa City, Iowa, 52242, United States"
NCT06743373,"Cannabis Effects on Sleep, Circadian Rhythms, and Light Sensitivity in Young Adults",https://clinicaltrials.gov/study/NCT06743373,NOT_YET_RECRUITING,NO,Cannabis Use|Sleep|Circadian Rhythm,BEHAVIORAL: Cannabis Discontinuation,University of Pittsburgh,National Institute on Drug Abuse (NIDA),ALL,ADULT,180,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2025-01,2029-04-30,"Western Psychiatric Hospital (Thomas Detre Hall), Pittsburgh, Pennsylvania, 15213, United States"
NCT03948074,Cannabis For Cancer-Related Symptoms,https://clinicaltrials.gov/study/NCT03948074,RECRUITING,NO,Pain|Nausea|Anxiety|Sleep Disturbance,DRUG: Cannabis,Pippa Hawley,,ALL,"ADULT, OLDER_ADULT",150,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02-01,2025-03-01,"Tom Baker Cancer Centre, Calgary, Alberta, T2N 4N2, Canada|BC Cancer Center of the North, Prince George, British Columbia, V2M 7E9, Canada|BC Cancer Vancouver, Vancouver, British Columbia, V5Z 4E6, Canada|BC Cancer - Victoria, Victoria, British Columbia, V8R 6V5, Canada|CancerCare Manitoba, Winnipeg, Manitoba, R3E 0V9, Canada|Kingston Health Sciences Centre - Kingston General Hospital Site, Kingston, Ontario, K7L 2V7, Canada|Ottawa Hospital Cancer Centre, Ottawa, Ontario, K1H 8L6, Canada|Santé Cannabis, Montréal, Quebec, H3Z 2Y5, Canada"
NCT01747850,Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence,https://clinicaltrials.gov/study/NCT01747850,COMPLETED,YES,Cannabis Dependence,BEHAVIORAL: Motivational Enhancement/Cognitive Behavioral Therapy|DRUG: Sativex|DRUG: Placebo spray,Centre for Addiction and Mental Health,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",45,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-03,2015-11,"Centre for Addiction and Mental Health, Toronto, Ontario, M5S 2S1, Canada"
NCT06190470,Effects of Marijuana on Neuropathic Pain and Spasticity in Spinal Cord Injury Patients,https://clinicaltrials.gov/study/NCT06190470,ENROLLING_BY_INVITATION,NO,Spinal Cord Injury,DRUG: Cannabis|DRUG: Placebo,Khon Kaen University,,ALL,ADULT,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-01-02,2024-06-30,"Faculty of Medicine Khon Kaen University, Khon Kaen, 40002, Thailand"
NCT03224468,Effect of Medical Marijuana on Neurocognition and Escalation of Use,https://clinicaltrials.gov/study/NCT03224468,COMPLETED,YES,Pain|Insomnia|Depression|Anxiety,DRUG: Medical Marijuana,Massachusetts General Hospital,,ALL,"ADULT, OLDER_ADULT",269,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-07-01,2022-11-01,"Massachusetts General Hospital, Boston, Massachusetts, 02114, United States"
NCT05833230,Investigating Real-world Stress-related Mechanisms in Heavy Cannabis Users,https://clinicaltrials.gov/study/NCT05833230,RECRUITING,NO,Cannabis Use|Cannabis|Cannabis Abuse,OTHER: Intensive Day Monitoring,Yale University,Robert E. Leet and Clara Guthrie Patterson Trust Mentored Research Award,ALL,"ADULT, OLDER_ADULT",60,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-06-01,2025-01-30,"Yale Stress Center, New Haven, Connecticut, 06519, United States"
NCT04385082,Cannabis Effects as a Function of Sex (CanSex),https://clinicaltrials.gov/study/NCT04385082,RECRUITING,NO,"Pain|Abuse, Drug",DRUG: Active Cannabis|DRUG: Placebo Cannabis,"University of California, Los Angeles",National Institute on Drug Abuse (NIDA),ALL,ADULT,160,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2021-07-08,2026-06-30,"University of California, Los Angeles, Los Angeles, California, 90095, United States"
NCT05401929,Transcranial Magnetic Brain Stimulation to Reduce Cannabis Use in Heavy Cannabis Users,https://clinicaltrials.gov/study/NCT05401929,SUSPENDED,NO,Cannabis,DEVICE: iTBS|DEVICE: iTBS,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,ADULT,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-06-01,2029-07,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT03964974,Reducing Cannabis Use for Sleep Among Adults Using Medical Cannabis,https://clinicaltrials.gov/study/NCT03964974,COMPLETED,YES,Insomnia Chronic|Cannabis Use,BEHAVIORAL: Cognitive Behavioral Therapy for Insomnia in Cannabis Users (CBTi-CB)|BEHAVIORAL: Sleep Hygiene Education (SHE),University of Michigan,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",57,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-02-10,2021-07-13,"Bloom City Club, Ann Arbor, Michigan, 48103, United States|Om of Medicine, Ann Arbor, Michigan, 48104, United States"
NCT06222268,Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery,https://clinicaltrials.gov/study/NCT06222268,NOT_YET_RECRUITING,NO,PTSD|Post Traumatic Stress Disorder,DRUG: Cannabidiol (CBD) only|DRUG: Placebo only|DRUG: Delta-9-tetrahydrocannabinol (THC) only|DRUG: THC:CBD 1:1|DRUG: THC:CBD 1:10,Wayne State University,,ALL,ADULT,350,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2024-08,2027-09,"Tolan Park Medical Building, Detroit, Michigan, 48201, United States|Wayne State University Eugene Applebaum College of Pharmacy & Health Sciences, Detroit, Michigan, 48201, United States|WSU MR Research Facility DMC Harper University Hospital, Detroit, Michigan, 48201, United States"
NCT03705559,Opioid and Cannabinoid Interactions,https://clinicaltrials.gov/study/NCT03705559,COMPLETED,NO,Marijuana Usage|Opioid Use,DRUG: Vaporized Marijuana|DRUG: Opioid Agonist,"Shanna Babalonis, PhD",National Institute on Drug Abuse (NIDA),ALL,ADULT,9,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2019-06-21,2024-02-15,"University of Kentucky, Lexington, Kentucky, 40508, United States"
NCT04923230,Pilot Test of Parent-Focused Cannabis-Related Actions and Practices Intervention for Adolescent Marijuana Abuse,https://clinicaltrials.gov/study/NCT04923230,COMPLETED,NO,"Cannabis Use Disorder, Mild|Cannabis Use Disorder, Moderate",BEHAVIORAL: Cannabis Actions and Practices Resource for Parents,Oregon Research Institute,,ALL,"CHILD, ADULT, OLDER_ADULT",120,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-06-01,2023-06-30,"Center for Family and Adolescent Research, Albuquerque, New Mexico, 87103, United States"
NCT02341300,Use of Cast Iron Pots to Improve Maternal Anemia,https://clinicaltrials.gov/study/NCT02341300,TERMINATED,NO,Iron-deficiency Anemia,DEVICE: Cast Iron Pot|DEVICE: Alumnium Pot,Weill Medical College of Cornell University,,FEMALE,ADULT,34,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-07-15,2020-07-15,"New York Prebyterian Hospital Weill Cornell, New York, New York, 10021, United States"
NCT01322139,Sativex Thorough QT/QTc Study,https://clinicaltrials.gov/study/NCT01322139,COMPLETED,NO,Effects of Sativex on ECG,DRUG: Placebo spray and oral moxifloxacin placebo|DRUG: Sativex spray and oral moxifloxacin placebo|DRUG: Sativex spray and oral moxifloxacin placebo|DRUG: Placebo spray and moxifloxacin,Jazz Pharmaceuticals,,ALL,ADULT,258,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2007-12,2008-06,"DecisionLine Clinical Research Corporation, Toronto, Ontario, M5V 2T3, Canada"
NCT03078309,The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients,https://clinicaltrials.gov/study/NCT03078309,UNKNOWN,NO,Retinitis Pigmentosa|Retinal Degeneration|Cannabis,DRUG: cannabis,Hadassah Medical Organization,Hebrew University of Jerusalem,ALL,"ADULT, OLDER_ADULT",50,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE,2018-09-01,2021-12,"Hadassah Medical Center, Jerusalem, Israel"
NCT05485012,Reinforcing Effects of Marijuana and Opioids,https://clinicaltrials.gov/study/NCT05485012,RECRUITING,NO,Marijuana Use|Opioid Use,DRUG: Marijuana|DRUG: Opioid,"Shanna Babalonis, PhD",National Institute on Drug Abuse (NIDA),ALL,ADULT,12,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2023-08-03,2026-10,"University of Kentucky, Lexington, Kentucky, 40506, United States"
NCT06588972,Analgesic Effects of a Treatment with Cannabis Sativa Extract in Patients with Knee Osteoarthritis - CANOA (Cannabis for Osteoarthritis),https://clinicaltrials.gov/study/NCT06588972,RECRUITING,NO,OSTEOARTHRITIS of the KNEE,DIETARY_SUPPLEMENT: Medium Chain Triglyceride solution|OTHER: Cannabis|OTHER: Cannabis Sativa,Federal University of Latin American Integration,,ALL,"ADULT, OLDER_ADULT",50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-04-01,2024-10-12,"Federal University of Latin American Integration, Foz do Iguaçu, Paraná, 85870-650, Brazil"
NCT03073291,Intervening to Prevent Youth Access to Marijuana Phase II,https://clinicaltrials.gov/study/NCT03073291,COMPLETED,NO,Cannabis,BEHAVIORAL: Responsible Marijuana Vendor Training,"Klein Buendel, Inc.",Pacific Institute for Research and Evaluation,ALL,"ADULT, OLDER_ADULT",448,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2016-06,2019-05-31,"Pacific Institute for Research and Evaluation, Oakland, California, 94612, United States|Klein Buendel, Inc., Golden, Colorado, 80401, United States"
NCT05503147,Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients (CanPan),https://clinicaltrials.gov/study/NCT05503147,UNKNOWN,NO,"Malnutrition|Anorexia|Cannabis|Aging|Emergency Service, Hospital|Renal Function|Pharmacokinetics",DRUG: Sativex,Ove Andersen,"University Hospital Bispebjerg and Frederiksberg|Regionshospital Nordjylland|University of Copenhagen|Region Hovedstadens Apotek|Glostrup University Hospital, Copenhagen",ALL,OLDER_ADULT,17,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-03-24,2023-09-01,"Clinical Research Centre, Hvidovre, 2650, Denmark"
NCT04325958,Age Differences in the Effects of Cannabis on Simulated Driving,https://clinicaltrials.gov/study/NCT04325958,RECRUITING,NO,Cannabis,DRUG: Cannabis|DRUG: Placebos,Centre for Addiction and Mental Health,,ALL,ADULT,128,OTHER,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2024-03-27,2027-03,"Centre for Addiction and Mental Health, Toronto, Ontario, M5S 2S1, Canada"
NCT04827992,Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain,https://clinicaltrials.gov/study/NCT04827992,RECRUITING,NO,Opioid Use|Pain|Marijuana Use,DRUG: Medical Marijuana|BEHAVIORAL: Prescription Opioid Taper Support (POTS),Massachusetts General Hospital,Cambridge Health Alliance|MaineHealth|National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",120,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-08-23,2025-11,"Maine Medical Center, Portland, Maine, 04102, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114-2523, United States|Cambridge Health Alliance, Cambridge, Massachusetts, 02139, United States"
NCT02735954,Colorado Marijuana Users Health Cohort,https://clinicaltrials.gov/study/NCT02735954,UNKNOWN,NO,COPD|Insomnia|Cannabis,OTHER: Marijuana,National Jewish Health,Colorado Department of Public Health and Environment,ALL,"ADULT, OLDER_ADULT",2000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-09,2019-12,"National Jewish Health, Denver, Colorado, 80206, United States"
NCT01771731,Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease,https://clinicaltrials.gov/study/NCT01771731,COMPLETED,YES,Sickle Cell Disease,DRUG: Cannabis,"University of California, San Francisco","National Heart, Lung, and Blood Institute (NHLBI)|University of Minnesota",ALL,"ADULT, OLDER_ADULT",27,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-08,2017-05-19,"San Francisco General Hospital, San Francisco, California, 94110, United States"
NCT04989205,Community Based Cannabis Cessation Program,https://clinicaltrials.gov/study/NCT04989205,COMPLETED,NO,Cannabis Use,BEHAVIORAL: Cannabis cessation Program,Sorlandet Hospital HF,City of Oslo|Municipality of Kristiansand|Norway Centre for Addiction Research,ALL,"CHILD, ADULT, OLDER_ADULT",102,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-06-02,2017-01-31,"Social Services, Fredrikstad Municipality, Fredrikstad, Norway|Kristiansand Municipality, Cannabis Cessation Program, Kristiansand, Norway|City Centre Outreach Service, Agency for Social and Welfare Services, Oslo, Norway"
NCT05273658,Effects of Cannabis/Alcohol on Driving Performance and Field Sobriety Tests,https://clinicaltrials.gov/study/NCT05273658,WITHDRAWN,NO,Driving Impaired|Alcohol Intoxication|Driving Under the Influence|Cannabis Intoxication,DRUG: Cannabis|DRUG: Alcohol,"University of California, San Diego",,ALL,ADULT,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING",2022-08,2023-06,
NCT00781001,Efficacy of Inhaled Cannabis in Diabetic Painful Peripheral Neuropathy,https://clinicaltrials.gov/study/NCT00781001,COMPLETED,NO,Painful Diabetic Neuropathy,DRUG: Cannabis,Center for Medicinal Cannabis Research,,ALL,"ADULT, OLDER_ADULT",17,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-07,2011-06,"UC San Diego, Hillcrest Medical Center, San Diego, California, 92103, United States"
NCT04429568,THC Crossover Study,https://clinicaltrials.gov/study/NCT04429568,COMPLETED,NO,"THC|Cannabis|Cannabis Smoking|Cannabis Use, Unspecified|Cigarette Smoking|Tobacco Use|Nicotine Dependence|Nicotine Withdrawal|Cardiovascular Risk Factor",OTHER: Smoked Cannabis|OTHER: Vaped Cannabis|OTHER: Tobacco Cigarette,"University of California, San Francisco",Tobacco Related Disease Research Program,ALL,"ADULT, OLDER_ADULT",14,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-10-30,2024-06-25,"Zuckerberg San Francisco General Hospital, San Francisco, California, 94110, United States|University of California, San Francisco, San Francisco, California, 94143, United States"
NCT05436236,Effect of Cannabis (Marijuana) on Stomach Emptying Before Surgery,https://clinicaltrials.gov/study/NCT05436236,WITHDRAWN,NO,Gastric Emptying|Cannabis,,The Guthrie Clinic,,ALL,"ADULT, OLDER_ADULT",0,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-12-01,2026-12-01,
NCT05389930,Cannabis' Impact on Alcohol Consumption,https://clinicaltrials.gov/study/NCT05389930,RECRUITING,NO,Alcohol Drinking|Cannabis Use|Cannabis|Alcohol Use Disorder,DRUG: THC-dominant cannabis|DRUG: CBD-dominant cannabis|DRUG: Cannabis placebo|DRUG: Alcohol|DRUG: Alcohol placebo,Brown University,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,ADULT,350,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2023-03-16,2027-03-31,"Brown University, Providence, Rhode Island, 02912, United States"
NCT02073474,An Observational Post-Marketing Safety Registry of Sativex®,https://clinicaltrials.gov/study/NCT02073474,COMPLETED,NO,Multiple Sclerosis|Diabetes|Cancer|Neuropathic Pain,DRUG: Sativex®,Jazz Pharmaceuticals,,ALL,"CHILD, ADULT, OLDER_ADULT",978,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-02,2015-01,
NCT00374127,Comparison Between Marijuana Smoked in Cigarette Paper Versus Cigar Paper,https://clinicaltrials.gov/study/NCT00374127,COMPLETED,YES,Marijuana Dependence,DRUG: Marijuana blunt|DRUG: marijuana cigarette,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,ADULT,35,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2004-12,2008-08,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT04968275,A Cannabis Harm Reduction e-Intervention for Young Cannabis Users With Early Psychosis,https://clinicaltrials.gov/study/NCT04968275,COMPLETED,NO,Psychotic Disorder|Marijuana Use|Young Adult,BEHAVIORAL: CHAMPS,Centre hospitalier de l'Université de Montréal (CHUM),Ministere de la Sante et des Services Sociaux,ALL,ADULT,101,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-08-23,2023-10-24,"Foothills Medical Centre Early Psychosis Intervention Program, Unit 24, 1403-29 Street NW, Calgary, Alberta, T2N 2T9, Canada|Nova Scotia Early Psychosis Program, 3rd Floor, Abbie Lane Bldg 5909 Veterans' Memorial Lane, Halifax, Nova Scotia, B3H 2E2, Canada|Clinic Connec-T - Institut universitaire en santé mentale de Montréal, 7401 rue Hochelaga, Montreal, Quebec, H1N 3M5, Canada|Clinique JAP, Centre hospitalier de l'Université de Montréal, 1051, rue Sanguinet, Montreal, Quebec, H2X 3E4, Canada|Clinic Notre-Dame des Victoires - Centre de Recherche CERVO, 2601 chemin de la Canardière, Québec, Quebec, G1J 2G3, Canada"
NCT06381180,Warrior CARE: Cannabis Behavioral Health,https://clinicaltrials.gov/study/NCT06381180,NOT_YET_RECRUITING,NO,Post Traumatic Stress Disorder|Cannabis Use|Suicide|Veterans|Marijuana,DRUG: Tetrahydrocannabinol|DRUG: Cannabidiol|DRUG: Placebo,Wayne State University,,ALL,"ADULT, OLDER_ADULT",500,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2024-09-01,2030-12-31,"Wayne State University, Detroit, Michigan, 48201, United States"
NCT04124432,Behavioral Pharmacology of Cannabis and Nicotine,https://clinicaltrials.gov/study/NCT04124432,COMPLETED,YES,Cannabis|Nicotine,DRUG: Cannabis|DRUG: Nicotine,Johns Hopkins University,National Institute on Drug Abuse (NIDA),ALL,ADULT,26,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2020-09-15,2023-08-31,"Johns Hopkins University, Baltimore, Maryland, 21224, United States"
NCT00254761,Effects of Smoked Marijuana on Neuropathic Pain,https://clinicaltrials.gov/study/NCT00254761,COMPLETED,NO,Neuropathic Pain,DRUG: Cannabis,Center for Medicinal Cannabis Research,,ALL,"ADULT, OLDER_ADULT",28,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2003-11,2006-02,"UC Davis Medical Center, Sacramento, California, 95817, United States"
NCT03859089,Cannabis for Opioid Substitution Trial,https://clinicaltrials.gov/study/NCT03859089,UNKNOWN,NO,Pain Syndrome|Opioid Use|Cannabis Use,OTHER: Medical Cannabis,Cannabis Research Associates,,ALL,"ADULT, OLDER_ADULT",1200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-10-10,2019-10-31,"Synergy Health Services Inc., Hamilton, Ontario, Canada"
NCT03546790,"Laboratory Smoking of Marijuana ""Blunts""",https://clinicaltrials.gov/study/NCT03546790,COMPLETED,NO,Cannabis,DRUG: Marijuana,Battelle Memorial Institute,,ALL,ADULT,8,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2019-04-10,2019-09-30,"Battelle Memorial Institute, Baltimore, Maryland, 21209, United States"
NCT01109563,Teen Marijuana Check-Up,https://clinicaltrials.gov/study/NCT01109563,COMPLETED,NO,Cannabis Use Disorder,BEHAVIORAL: Marijuana Check-Ins,Denise Walker,Virginia Polytechnic Institute and State University|National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",252,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-03,2014-09,
NCT06595576,Cannabis Edibles and Simulated Driving,https://clinicaltrials.gov/study/NCT06595576,NOT_YET_RECRUITING,NO,Cannabis|Driving Under the Influence,DRUG: Cannabis - Placebo Dose (0 mg)|DRUG: Cannabis - Low Dose (2 mg)|DRUG: Cannabis - Medium Dose (10 mg)|DRUG: Cannabis - High Dose (20 mg),Centre for Addiction and Mental Health,,ALL,ADULT,50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2024-10-01,2025-03-31,"Center for Addiction and Mental Health, Toronto, Ontario, M5S 2S1, Canada"
NCT02165176,Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabis,https://clinicaltrials.gov/study/NCT02165176,COMPLETED,NO,Cannabis,DRUG: Oral cannabis,Johns Hopkins University,Substance Abuse and Mental Health Services Administration (SAMHSA)|RTI International,ALL,ADULT,24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2014-06,2014-09,"Johns Hopkins School of Medicine Behavioral Pharmacology Research Unit, Baltimore, Maryland, 21224, United States"
NCT06755346,The Effects of Cannabis on Male Reproductive Functions,https://clinicaltrials.gov/study/NCT06755346,NOT_YET_RECRUITING,NO,Male Reproductive Problem,DRUG: Cannabis plant (THC 20mg)|DRUG: Cannabis (0%/ THC / 0% CBD)|DRUG: Cannabis plant (THC 40mg),Kanako Hayashi,Washington State University,MALE,ADULT,100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2025-04-01,2027-03-30,"Washington State University, Pullman, Washington, 99164, United States"
NCT01620177,Effects of Inhaled Cannabis on Driving Performance,https://clinicaltrials.gov/study/NCT01620177,COMPLETED,YES,Alcohol Drinking|Cannabis,DRUG: Alcohol(oral) and placebo|DRUG: Cannabis(THC)(Inhaled) and Placebo,Gary R Gaffney,National Highway Traffic Safety Administration (NHTSA)|National Institute on Drug Abuse (NIDA),ALL,ADULT,98,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2012-07,2014-03,"National Advanced Driving Simulator, Iowa City, Iowa, 52242, United States"
NCT03681353,Impact of Reduced Cannabis Use on Functional Outcomes,https://clinicaltrials.gov/study/NCT03681353,COMPLETED,YES,Cannabis|Cannabis Use,"BEHAVIORAL: Mobile Contingency Management, active",Duke University,,ALL,"ADULT, OLDER_ADULT",25,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2019-04-04,2020-09-23,"Duke University Medical Center, Durham, North Carolina, 27706, United States"
NCT04402554,Survey of Cannabis Use in Patients With Chronic Inflammatory Arthritis,https://clinicaltrials.gov/study/NCT04402554,COMPLETED,NO,Rheumatoid Arthritis|Ankylosing Spondylitis|Psoriatic Arthritis,BEHAVIORAL: Cannabis questionnaire,"University Hospital, Clermont-Ferrand",,ALL,"ADULT, OLDER_ADULT",501,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-05-19,2021-03-19,"Chu Clermont Ferrand, Clermont-Ferrand, 63003, France"
NCT03274440,Effects of Marijuana on Symptoms of OCD,https://clinicaltrials.gov/study/NCT03274440,COMPLETED,YES,Obsessive-Compulsive Disorder,DRUG: Cannabis|OTHER: Placebo,New York State Psychiatric Institute,,ALL,ADULT,14,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-10-01,2020-10-29,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT05999344,Alcohol and Cannabis Concentrates Co-Administration,https://clinicaltrials.gov/study/NCT05999344,COMPLETED,NO,Alcohol Use Disorder|Cannabis Use,OTHER: commercially available cannabis administered prior to commercially available alcohol|OTHER: commercially available alcohol administered prior to commercially available cannabis,Colorado State University,"Institute of Cannabis Research (ICR)--Colorado State University, Pueblo",ALL,"ADULT, OLDER_ADULT",88,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-12-16,2024-08-01,"Colorado State University, Fort Collins, Colorado, 80523, United States"
NCT02177513,Effects of Cannabis Administration Routes on Human Performance and Pharmacokinetics,https://clinicaltrials.gov/study/NCT02177513,COMPLETED,NO,Cannabis Use,DRUG: Placebo + Placebo|DRUG: Oral Cannabis + Placebo|DRUG: Placebo + Inhaled Cannabis|DRUG: Placebo + Smoked Cannabis|DRUG: 6.9% cannabis oral,National Institute on Drug Abuse (NIDA),,ALL,ADULT,28,NIH,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2014-06-14,2016-04-27,"National Institute on Drug Abuse, Baltimore, Maryland, 21224, United States"
NCT03154580,Marijuana Cue-Reactivity & Seeking Behavior in Regular Cannabis Users,https://clinicaltrials.gov/study/NCT03154580,COMPLETED,NO,Marijuana Abuse,DRUG: N-acetyl cysteine,Wayne State University,,ALL,ADULT,21,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2017-05-01,2023-06-27,"Tolan Park Medical Building, Detroit, Michigan, 48201, United States"
NCT03699540,Marijuana Effects on Simulated Driving Performance,https://clinicaltrials.gov/study/NCT03699540,COMPLETED,YES,Cannabis|Cannabis Use|Marijuana|Marijuana Usage|Alcohol Drinking,DRUG: Marijuana|DRUG: Alcohol|DRUG: placebo alcohol|DRUG: Inactive marijuana,"Shanna Babalonis, PhD",National Institute on Drug Abuse (NIDA),ALL,ADULT,10,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2019-07-01,2023-01-01,"University of Kentucky, Lexington, Kentucky, 40508, United States"
NCT00946348,Cannabis and Schizophrenia: Self-Medication and Agonist Treatment,https://clinicaltrials.gov/study/NCT00946348,COMPLETED,YES,Schizophrenia|Dual Diagnosis|Schizoaffective Disorder|Psychotic Disorder|Cannabis Use Disorder,DRUG: Dronabinol|DRUG: Cannabis,Dartmouth-Hitchcock Medical Center,"National Institute on Drug Abuse (NIDA)|Indiana University|Columbia University|University of Vermont|University of Massachusetts, Worcester",ALL,ADULT,12,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2009-12,2012-10,"Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States"
NCT05310981,A Cannabis E-intervention for Young Cannabis Users With Early Psychosis (iCC),https://clinicaltrials.gov/study/NCT05310981,ACTIVE_NOT_RECRUITING,NO,Cannabis Use Disorder,BEHAVIORAL: iCanChange,Centre hospitalier de l'Université de Montréal (CHUM),Ministere de la Sante et des Services Sociaux,ALL,ADULT,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-07-06,2024-07-31,"Foothills Medical Centre Early Psychosis Intervention Program, Calgary, Alberta, T2N2T9, Canada|Nova Scotia Early Psychosis Program, Halifax, Nova Scotia, B3H2E2, Canada|Clinic Connec-T - Institut universitaire en santé mentale de Montréal, Montréal, Quebec, H1N3M5, Canada|Clinique JAP, Centre hospitalier de l'Université de Montréal, Montréal, Quebec, H2X 3E4, Canada|Clinic Notre-Dame des Victoires - Centre de Recherche CERVO, Québec, Quebec, G1J2G3, Canada"
NCT00893074,The Effect of Prescription Medications in Marijuana Users,https://clinicaltrials.gov/study/NCT00893074,COMPLETED,YES,Marijuana Abuse,DRUG: Dronabinol 30mg/day|DRUG: Dronabinol 60mg/day|DRUG: Dronabinol 120mg/day|DRUG: Placebo,Johns Hopkins University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2009-04,2011-10,"Behavioral Pharmacology Research Unit, Baltimore, Maryland, 21224, United States"
NCT06575751,Cannabidiol and Cannabis Concentrate Users,https://clinicaltrials.gov/study/NCT06575751,RECRUITING,NO,Cannabis Use Disorder,DRUG: Broad Spectrum Cannabidiol (bsCBD) 400 mg|DRUG: Broad Spectrum Cannabidiol (bsCBD) 200 mg|DRUG: Placebo,"University of Colorado, Denver",National Institute on Drug Abuse (NIDA),ALL,ADULT,120,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2024-12-04,2028-06-30,"University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, United States"
NCT02759185,Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD,https://clinicaltrials.gov/study/NCT02759185,COMPLETED,YES,Posttraumatic Stress Disorder,DRUG: High THC cannabis|DRUG: High CBD cannabis|DRUG: THC/CBD cannabis|DRUG: Placebo cannabis,Multidisciplinary Association for Psychedelic Studies,,ALL,"ADULT, OLDER_ADULT",80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-01-02,2019-01,"Scottsdale Research Institute, Phoenix, Arizona, 85027, United States"
NCT01347762,Nabilone for Cannabis Dependence: A Pilot Study,https://clinicaltrials.gov/study/NCT01347762,COMPLETED,YES,Cannabis Dependence|Marijuana Dependence,DRUG: Nabilone|DRUG: Placebo,Mclean Hospital,National Institute on Drug Abuse (NIDA),ALL,ADULT,84,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-06,2017-06-09,"McLean Hospital, Belmont, Massachusetts, 02478, United States"
NCT00943930,Marijuana Drug Discrimination and Self-Administration,https://clinicaltrials.gov/study/NCT00943930,COMPLETED,NO,Marijuana Abuse,"DRUG: THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC",Wayne State University,National Institute on Drug Abuse (NIDA),ALL,ADULT,29,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-04,2014-12,"Wayne State University, Detroit, Michigan, 48201, United States"
NCT06351540,Examining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance,https://clinicaltrials.gov/study/NCT06351540,NOT_YET_RECRUITING,NO,Cannabis Use|Impaired Driving|Cognitive Impairment,DRUG: Cannabis,Johns Hopkins University,National Institute on Drug Abuse (NIDA),ALL,ADULT,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2025-03-01,2025-12-01,"Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland, 21224, United States"
NCT00241592,Vaporization as a Smokeless Cannabis Delivery System,https://clinicaltrials.gov/study/NCT00241592,COMPLETED,NO,Healthy Volunteers,DRUG: Cannabis,Center for Medicinal Cannabis Research,"University of California, San Francisco",ALL,ADULT,18,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT,2004-08,2005-05,"UCSF Community Consortium, San Francisco, California, 94110, United States"
NCT00395044,Gabapentin Treatment of Cannabis Dependence,https://clinicaltrials.gov/study/NCT00395044,COMPLETED,YES,Cannabis Dependence,DRUG: Placebo|DRUG: Gabapentin,The Scripps Research Institute,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-08,2008-07,"The Scripps Research Institute, La Jolla, California, 92037, United States"
NCT04601207,A Study Investigating the Bioavailability of CBD and THC in an Emulsion Product in a Healthy Population,https://clinicaltrials.gov/study/NCT04601207,COMPLETED,NO,Healthy|Cannabis,DRUG: Cannabis Preparation|DRUG: Cannabis Preparation,New Age Ventures LLC,KGK Science Inc.,ALL,ADULT,32,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2020-06-19,2020-11-30,"KGK Science Inc., London, Ontario, N6A 5R8, Canada"
NCT05322941,Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD),https://clinicaltrials.gov/study/NCT05322941,COMPLETED,NO,Marijuana Abuse,DRUG: AEF0117|DRUG: Placebo oral capsule,Aelis Farma,,ALL,"ADULT, OLDER_ADULT",333,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-05-06,2024-07-22,"Cedar clinical research, Phoenix, Arizona, 85021, United States|CenExel CNR, Garden Grove, California, 82845, United States|UCLA Department of Psychiatry and Biobehavioral Sciences, Los Angeles, California, 90095, United States|Yale Stress Center - Addiction Program, New Haven, Connecticut, 06520, United States|Segal Trial, Lauderhill, Florida, 33319, United States|Behavioral Clinical Research, Miami Lakes, Florida, 33016, United States|The Substance Treatment and Research Service (S.T.A.R.S.) of Columbia University/NYSPI., New York, New York, 10032, United States|CODA, Inc Research Department, Portland, Oregon, 97214, United States|Addiction Sciences Division Department of Psychiatry and Behavioral Sciences Medical University of South Carolina, Charleston, South Carolina, 29425-8640, United States|Department of Psychiatry and Behavioral Sciences at UT Health San Antonio., San Antonio, Texas, 78218, United States|Cedar Clinical Research, Draper, Utah, 84020, United States"
NCT03186664,The Role of SAtivex® in Robotic-Rehabilitation,https://clinicaltrials.gov/study/NCT03186664,COMPLETED,NO,Rehabilitation,DEVICE: Lokomat training|DRUG: Sativex,IRCCS Centro Neurolesi Bonino Pulejo,,ALL,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-12-28,2018-06,"IRCCS Centro Neurolesi Bonino-Pulejo"", Messina, Sicily, 98123, Italy"
NCT05836857,The Use of Cannabis (Marijuana) and Cannabidiol (CBD) Among Cancer Patients: a Pilot Study,https://clinicaltrials.gov/study/NCT05836857,ACTIVE_NOT_RECRUITING,NO,Cancer,BEHAVIORAL: Cannabis (Marijuana)|BEHAVIORAL: Cannabidiol (CBD),M.D. Anderson Cancer Center,,ALL,"ADULT, OLDER_ADULT",100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-01-30,2025-05-31,"M D Anderson Cancer Center, Houston, Texas, 77030, United States"
NCT05999383,Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration,https://clinicaltrials.gov/study/NCT05999383,NOT_YET_RECRUITING,NO,THC|Cannabis|Cannabis Use|Cannabis Smoking|Tobacco Use|Vaping,DRUG: Cannabis|DRUG: Nicotine|DEVICE: Pax Loose Leaf Vaporizer|OTHER: Placebo Marijuana,"University of California, San Francisco",National Institute on Drug Abuse (NIDA)|National Institutes of Health (NIH)|Food and Drug Administration (FDA),ALL,"ADULT, OLDER_ADULT",48,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2025-03-01,2027-12-01,"Zuckerberg San Francisco General Hospital, San Francisco, California, 94110, United States"
NCT02080676,Effects of Marihuana Use on Optic Nerve Parameters and Ocular Blood Flow,https://clinicaltrials.gov/study/NCT02080676,UNKNOWN,NO,Intra Ocular Pressure,,Carmel Medical Center,,ALL,"ADULT, OLDER_ADULT",100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-03,2016-05,"Carmel Medical Center, Haifa, Israel"
NCT00308555,Opioid and Cannabinoid Pharmacokinetic Interactions,https://clinicaltrials.gov/study/NCT00308555,COMPLETED,YES,Pain,DRUG: Cannabis,"University of California, San Francisco",National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",24,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-05,2009-03,"Community Consortium, San Francisco, California, 94110, United States"
NCT03204305,Brain Imaging of Cannabinoid Receptors,https://clinicaltrials.gov/study/NCT03204305,COMPLETED,YES,"Cannabis Use Disorder|Cannabis Dependence, Continuous",DRUG: 11C-OMAR|DRUG: Cannabis,Johns Hopkins University,National Institute on Drug Abuse (NIDA),FEMALE,ADULT,28,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,2017-09-14,2020-03-31,"Johns Hopkins Bayview Medical Center, Baltimore, Maryland, 21224, United States"
NCT03633721,Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected Women,https://clinicaltrials.gov/study/NCT03633721,COMPLETED,NO,HIV|AIDS|Aging,DRUG: Cannabis|OTHER: Placebo,Albert Einstein College of Medicine,National Institute on Aging (NIA),FEMALE,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: OTHER",2020-10-23,2022-05-31,"Montefiore Medical Center, Bronx, New York, 10461, United States"
NCT05407285,A Study of Ingested Cannabidiol in Healthy Occasional Cannabis Users,https://clinicaltrials.gov/study/NCT05407285,COMPLETED,NO,Cannabis,"DRUG: cannabis 0 mg, placebo|DRUG: Cannabis 20 mg,|DRUG: Cannabis 50 mg|DRUG: Cannabis 100 mg|DRUG: Cannabis 200 mg",Centre hospitalier de l'Université de Montréal (CHUM),,ALL,"ADULT, OLDER_ADULT",70,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-07-22,2023-11-14,"Centre de recherche du Centre Hospitalier Universitaire de Montréal, Montréal, Quebec, H2X0A9, Canada"
NCT06518434,A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients,https://clinicaltrials.gov/study/NCT06518434,RECRUITING,NO,Hepatocellular Carcinoma|Cannabis,DRUG: Medical Cannabis,University Medical Center Groningen,,ALL,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-04-15,2027-04-15,"University Medical Center Groningen, Groningen, 9713 GZ, Netherlands"
NCT00743119,Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers,https://clinicaltrials.gov/study/NCT00743119,COMPLETED,YES,Pain Threshold|Mood,DRUG: Placebo capsules|DRUG: Inactive marijuana (0% THC)|DRUG: Low dose Dronabinol|DRUG: High dose Dronabinol|DRUG: Low THC marijuana|DRUG: High THC marijuana,New York State Psychiatric Institute,"Research Foundation for Mental Hygiene, Inc.|National Institute on Drug Abuse (NIDA)",FEMALE,ADULT,34,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2008-06,2013-05,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT04856566,Examine the Feasibility of a Standardized Field Test for Marijuana and Alcohol Impairment: Laboratory Evaluations,https://clinicaltrials.gov/study/NCT04856566,ACTIVE_NOT_RECRUITING,NO,Marijuana Impairment|Alcohol Impairment,"DRUG: Low Marijuana, Hash, THC, or Grass|DRUG: High Marijuana, Hash, THC, or Grass|DRUG: Placebo|DRUG: 0.05 BAC Alcohol|DRUG: 0.08 BAC Alcohol",Yale University,National Highway Traffic Safety Administration (NHTSA)|Hartford Hospital|National Institute on Drug Abuse (NIDA),ALL,ADULT,12,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2021-07-28,2025-04,"Hartford Hospital, Hartford, Connecticut, 06106, United States"
NCT05276232,Detection of Cannabis Impairment With ISBRG's SpotLight-THC,https://clinicaltrials.gov/study/NCT05276232,UNKNOWN,NO,Cannabis,DRUG: Cannabis(THC) inhaled,ISBRG Corp,National Advanced Driving Simulator,ALL,"ADULT, OLDER_ADULT",75,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-03,2022-08,"National Advanced Driving Simulator, Iowa City, Iowa, 52242, United States"
NCT02777502,Effects of Cannabidiol on Marijuana-seeking in Humans,https://clinicaltrials.gov/study/NCT02777502,COMPLETED,NO,Marijuana Abuse,,Wayne State University,,ALL,ADULT,30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-01-01,2019-01-31,"Tolan Park Medical Building, Detroit, Michigan, 48201, United States"
NCT02817698,Imaging the Neurochemistry of Drug Addiction With PET,https://clinicaltrials.gov/study/NCT02817698,COMPLETED,YES,Smoking|Cannabis,DRUG: cannabis,Yale University,National Institute on Drug Abuse (NIDA),ALL,ADULT,25,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2017-11-29,2024-06-14,"Connecticut Mental Health Center, New Haven, Connecticut, 06519, United States|Yale Magnetic Resonance Research Center, New Haven, Connecticut, 06519, United States|Yale PET Center, New Haven, Connecticut, 06519, United States"
NCT04139668,Vivitrol Treatment for Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT04139668,TERMINATED,YES,Cannabis Use Disorder,DRUG: Naltrexone 380 MG [Vivitrol]|BEHAVIORAL: Motivational Enhancement Therapy and Cognitive Behavioral Therapy,Centre for Addiction and Mental Health,,ALL,ADULT,1,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06-09,2022-06-13,"Centre for Addiction and Mental Health, Toronto, Ontario, M5S2S1, Canada"
NCT05212493,The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder,https://clinicaltrials.gov/study/NCT05212493,COMPLETED,NO,Autism Spectrum Disorder,DRUG: Cannabis oil,Assaf-Harofeh Medical Center,Seach Sarid Ltd|Canndoc Ltd,ALL,"CHILD, ADULT",128,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-11-14,2023-12-31,"Assaf Harofeh Medical Center, Zerifin, 70300, Israel"
NCT05384470,Detecting Drugs of Abuse Via Exhaled Breath Samples Using Differential Mobility Spectrometry,https://clinicaltrials.gov/study/NCT05384470,RECRUITING,NO,Opiate Abuse|Marijuana Abuse,DRUG: Marihuana|DEVICE: BID2 Instrument - breathalyzer,Mclean Hospital,VOX BIOMEDICAL LLC,ALL,ADULT,50,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-07-01,2024-10-30,"McLean Hospital, Belmont, Massachusetts, 02478, United States"
NCT05432206,MEDical CANnabis for Improving Symptoms During Severe DEMentia Disorders in Long-term Care Facility in Geneva,https://clinicaltrials.gov/study/NCT05432206,COMPLETED,NO,Dementia with Behavioral Disturbance,DRUG: Cannabis Sativa Oil|DRUG: Placebo,Fondation pour l'accueil et l'hébérement des personnes âgées,"University Hospital, Geneva",ALL,"ADULT, OLDER_ADULT",27,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-09-29,2024-11-29,"FAHPA, Geneva, 1206, Switzerland"
NCT03717272,Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects,https://clinicaltrials.gov/study/NCT03717272,COMPLETED,NO,Marijuana Abuse,DRUG: AEF0117|DRUG: Placebo oral capsule,Aelis Farma,"National Institute on Drug Abuse (NIDA)|Columbia University|New York State Psychiatric Institute|ClinStar, LLC",ALL,ADULT,29,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-10-23,2021-01-01,"Substance Use Research Center, New York, New York, 10032, United States"
NCT05899946,An Integrated Program to Promote Anti-cannabis Messages,https://clinicaltrials.gov/study/NCT05899946,NOT_YET_RECRUITING,NO,Cannabis,OTHER: A community-based network training program,The Hong Kong Polytechnic University,,ALL,"CHILD, ADULT, OLDER_ADULT",200,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-09,2025-03-01,"Katherine Lam, Hong Kong, Hong Kong,China, 0000, Hong Kong"
NCT04965012,Testing the Efficacy of an Online Treatment Program for Heavy Cannabis Use,https://clinicaltrials.gov/study/NCT04965012,COMPLETED,NO,Marijuana Use|Marijuana Dependence,BEHAVIORAL: Online CBT with MET treatment|BEHAVIORAL: CBT without MET treatment,York University,University of Manitoba,ALL,"ADULT, OLDER_ADULT",152,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-25,2023-10-01,"University of Manitoba, Winnipeg, Manitoba, Canada|York University, Toronto, Ontario, Canada"
NCT00255580,Medicinal Cannabis for Painful HIV Neuropathy,https://clinicaltrials.gov/study/NCT00255580,COMPLETED,NO,Neuropathic Pain,DRUG: Smoked cannabis,Center for Medicinal Cannabis Research,,ALL,"ADULT, OLDER_ADULT",28,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2001-09,2006-11,"UC San Diego, Hillcrest Medical Center, San Diego, California, 92103, United States"
NCT05578313,Inflammatory Bowel Diseases (IBD) Cannabis Registry,https://clinicaltrials.gov/study/NCT05578313,UNKNOWN,NO,Crohn Disease|Ulcerative Colitis|Pouchitis|Healthy,DRUG: Medical Cannabis,"Eli Sprecher, MD",,ALL,"ADULT, OLDER_ADULT",1000,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-07-10,2024-07-10,"Dep. of Gastroenterology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"
NCT05472818,SV2A Density Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT05472818,RECRUITING,NO,Cannabis Use Disorder|Healthy,DRUG: [11C]APP311,Yale University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",42,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-05-01,2032-05,"Yale University School of Medicine, New Haven, Connecticut, 06511, United States"
NCT06808048,Medical Cannabis and Behavior,https://clinicaltrials.gov/study/NCT06808048,NOT_YET_RECRUITING,NO,Chronic Pain Patients|Medical Cannabis Users,BEHAVIORAL: Cognitive testing|BEHAVIORAL: Task-based fMRI measure of inhibitory control|BEHAVIORAL: Task-based fMRI measure of face-name learning,University of Minnesota,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",180,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2025-02-15,2029-05-31,"University of Minnesota, Minneapolis, Minnesota, 55455, United States"
NCT05219370,"Treatment With Cannabis Oil Containing CBD, THC, CBDV or CBG vs. Placebo of Persons With ADHD",https://clinicaltrials.gov/study/NCT05219370,TERMINATED,NO,ADHD|Hyperactivity|Attention Deficit,DRUG: Cannabis oil,Brlev Agricultural Crops Ltd,Bio-Sciences Pharma Ltd.,ALL,"ADULT, OLDER_ADULT",8,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-07-31,2022-12-31,"Shamir (Assaf Harofeh) Medical Center, Be'er Ya'aqov, Israel"
NCT01964404,"Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?",https://clinicaltrials.gov/study/NCT01964404,COMPLETED,NO,Schizophrenia|Dual Diagnosis|Psychotic Disorder|Cannabis Use Disorder,DRUG: Marijuana|DRUG: Dronabinol|DRUG: Placebo,Dartmouth-Hitchcock Medical Center,Columbia University|Harvard Medical School (HMS and HSDM)|Massachusetts Institute of Technology|Massachusetts General Hospital|Nathan Kline Institute for Psychiatric Research|University of Vermont|National Institute on Drug Abuse (NIDA),ALL,ADULT,261,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2014-07,2021-09-18,"Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|University of Vermont, Burlington, Vermont, 05401, United States"
NCT01697709,Quetiapine Pharmacotherapy for Cannabis Dependence,https://clinicaltrials.gov/study/NCT01697709,COMPLETED,YES,Cannabis Dependence,DRUG: Quetiapine|DRUG: Placebo,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,ADULT,130,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-10-01,2017-04-30,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT06293040,Vaporized Cannabis Administration and Co-Administration of Alcohol on Impairment,https://clinicaltrials.gov/study/NCT06293040,RECRUITING,NO,Cannabis Intoxication|Alcohol Intoxication,DRUG: Cannabis|DRUG: Alcohol|DRUG: Placebo Cannabis|DRUG: Placebo Alcohol,Johns Hopkins University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",90,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2024-09-26,2027-12,"Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland, 21224, United States"
NCT00403117,Effects of a Range of Naltrexone Doses in Combination With Smoked Marijuana,https://clinicaltrials.gov/study/NCT00403117,COMPLETED,YES,Marijuana Use,DRUG: Placebo + Inactive Marijuana (0% THC)|DRUG: Placebo + Active Marijuana (3.27% THC)|DRUG: Naltrexone 12 Mg+ Active Marijuana (3.27% THC)|DRUG: Naltrexone 25 Mg + Active Marijuana (3.27% THC)|DRUG: Naltrexone 50 Mg+ Active Marijuana (3.27% THC)|DRUG: Naltrexone 100 Mg+ Active Marijuana (3.27% THC)|DRUG: Naltrexone 12 Mg + Inactive Marijuana (0% THC)|DRUG: Naltrexone 25 Mg + Inactive Marijuana (0% THC)|DRUG: Naltrexone 50 Mg + Inactive Marijuana (0% THC)|DRUG: Naltrexone 100 Mg + Inactive Marijuana (0% THC),New York State Psychiatric Institute,"Research Foundation for Mental Hygiene, Inc.|National Institute on Drug Abuse (NIDA)",ALL,ADULT,49,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2006-12,2010-08,
NCT03430050,Progesterone for Cannabis Withdrawal,https://clinicaltrials.gov/study/NCT03430050,COMPLETED,YES,Cannabis Use Disorder|Cannabis Withdrawal,DRUG: Progesterone|DRUG: Placebo,Medical University of South Carolina,National Institute on Drug Abuse (NIDA)|National Institutes of Health (NIH),FEMALE,ADULT,8,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-10-16,2018-04-04,"Medical University of South Carolina, Charleston, South Carolina, 29403, United States"
NCT03629990,Approach Bias Modification for the Treatment of Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT03629990,COMPLETED,YES,Cannabis Use Disorder,BEHAVIORAL: Approach Bias Modification (ABM)|BEHAVIORAL: Sham ABM|BEHAVIORAL: Psychosocial therapy for cannabis use disorder.,Medical University of South Carolina,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",104,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-01-16,2023-10-30,"Medial University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT05488509,Acute Effects of Cannabis on Everyday Life Memory,https://clinicaltrials.gov/study/NCT05488509,RECRUITING,NO,Cannabis Use,DRUG: Cannabis|DRUG: Placebo,Washington State University,,ALL,"ADULT, OLDER_ADULT",156,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2023-08-21,2024-12-01,"Washington State University, Pullman, Washington, 99163, United States"
NCT03106363,Combined Alcohol and Cannabis Effects on Skills of Young Drivers,https://clinicaltrials.gov/study/NCT03106363,COMPLETED,NO,Psychomotor Impairment,DRUG: delta 9 tetrahydrocannabinol|DRUG: placebo delta 9 tetrahydrocannabinol|DRUG: Alcohol|DRUG: Placebo alcohol,Centre for Addiction and Mental Health,Canadian Institutes of Health Research (CIHR)|Health Canada,ALL,ADULT,85,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2017-07-04,2020-01-17,"Centre for Addiction and Mental Health, Toronto, Ontario, M5S 2S1, Canada"
NCT00373295,Effect of Baclofen on Marijuana Withdrawal and Relapse,https://clinicaltrials.gov/study/NCT00373295,COMPLETED,YES,Marijuana Dependence,DRUG: Baclofen|DRUG: Marijuana|DRUG: Placebo,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,ADULT,13,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2006-05,2010-01,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT06259916,"Distinguishing Alcohol Intoxication, Cannabis Intoxication and Co-intoxication Using Electroencephalography (EEG)",https://clinicaltrials.gov/study/NCT06259916,RECRUITING,NO,"Cannabis Use|Alcohol Use, Unspecified",OTHER: Alcohol|OTHER: Cannabis,Colorado State University,,ALL,ADULT,99,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2024-01-05,2026-05-30,"Colorado State University, Fort Collins, Colorado, 80523, United States"
NCT04629716,Reactions of Older Adults Driving After Cannabis Exposure,https://clinicaltrials.gov/study/NCT04629716,COMPLETED,NO,Chronic Pain,OTHER: Medical Cannabis,Florida State University,,ALL,"ADULT, OLDER_ADULT",44,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-04-23,2023-08-31,"Smart House at Oak Hammock, Gainesville, Florida, 32608, United States"
NCT05521321,Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit,https://clinicaltrials.gov/study/NCT05521321,ENROLLING_BY_INVITATION,NO,Cannabis Use,BEHAVIORAL: Stanford Cannabis Awareness and Prevention curriculum,Stanford University,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",600,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-10-01,2024-11-30,"Stanford University, Palo Alto, California, 94304, United States"
NCT03994926,Evaluation of an Eye Tracking Sensor to Detect Cannabis Impairment,https://clinicaltrials.gov/study/NCT03994926,TERMINATED,NO,Cannabis Intoxication,DEVICE: Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye|DRUG: Cannabis cigarette - 4.0% THC,Battelle Memorial Institute,,ALL,ADULT,3,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY,2020-02-03,2020-03-13,"Battelle Memorial Institute, Baltimore, Maryland, 21209, United States"
NCT03522467,Cannabis Oil for Pain Effectiveness,https://clinicaltrials.gov/study/NCT03522467,UNKNOWN,NO,Cancer|Chronic Pain,DRUG: MRCP001,Aurora Cannabis Inc,Ontario Clinical Oncology Group (OCOG)|Hamilton Health Sciences Corporation,ALL,"ADULT, OLDER_ADULT",40,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-07-25,2020-09,"Juravinski Cancer Centre, Hamilton, Ontario, L8V 5C2, Canada"
NCT04567238,Impact of Reduced Cannabis Use on Functional Outcomes (R33 Phase),https://clinicaltrials.gov/study/NCT04567238,COMPLETED,YES,Cannabis|Cannabis Use,BEHAVIORAL: Mobile contingency management,Duke University,,ALL,"ADULT, OLDER_ADULT",60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-19,2023-11-22,"Duke University Medical Center, Durham, North Carolina, 27706, United States"
NCT05430490,"Cannabis, HIV and Mental Processing Systems",https://clinicaltrials.gov/study/NCT05430490,RECRUITING,NO,HIV Infections|Cannabis,PROCEDURE: MRI|OTHER: NeuroPsychological Testing|PROCEDURE: Blood Draw|OTHER: Questionnaires|PROCEDURE: Lumbar Puncture,Washington University School of Medicine,Temple University,ALL,"ADULT, OLDER_ADULT",320,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-03-23,2025-06-30,"Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, 19140, United States"
NCT06159387,"Randomized, Double-blind, Placebo-controlled Cannabis Extract x Placebo for Cocaine Addicts",https://clinicaltrials.gov/study/NCT06159387,RECRUITING,NO,Cocaine Dependence,DRUG: Cannabis Extract Oil SR Capsule,University of Sao Paulo General Hospital,,ALL,"ADULT, OLDER_ADULT",60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-10-23,2025-10-23,"Instituto Perdizes, São Paulo, Sao Paulo, 05021-001,, Brazil"
NCT05526196,"Combined and Separate Effects of Cannabis and Tobacco: Psychomotor, Subjective and Physiological Outcomes",https://clinicaltrials.gov/study/NCT05526196,NOT_YET_RECRUITING,NO,Driving Under the Influence,DRUG: Cannabis|DRUG: Tobacco|DRUG: Cannabis tobacco|DRUG: Placebo,Centre for Addiction and Mental Health,,ALL,ADULT,60,OTHER,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2024-08-01,2027-03-01,
NCT04931095,The Impact of Oral Cannabis Administration and Co-Administration of Alcohol on Impairment,https://clinicaltrials.gov/study/NCT04931095,RECRUITING,NO,Cannabis Intoxication|Alcohol Intoxication,DRUG: Cannabis|DRUG: Alcohol,Johns Hopkins University,National Institute on Drug Abuse (NIDA),ALL,ADULT,90,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2022-02-17,2025-05-01,"Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland, 21224, United States"
NCT01110434,Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents,https://clinicaltrials.gov/study/NCT01110434,COMPLETED,YES,Cannabis Abuse|Cannabis Dependence,DRUG: Topiramate|DRUG: Placebo,Brown University,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",66,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-12,2012-05,"Brown University, Center for Alcohol and Addiction Studies, Providence, Rhode Island, 02912, United States"
NCT01542723,Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy,https://clinicaltrials.gov/study/NCT01542723,COMPLETED,NO,Deep Venous Thrombosis|Pulmonary Embolism,DRUG: LMWH,"Suzanne C. Cannegieter, MD PhD",ZonMw: The Netherlands Organisation for Health Research and Development,ALL,"ADULT, OLDER_ADULT",1500,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2012-05,2016-09,"Isala Klinieken, Zwolle, Overijsel, 8011 JW, Netherlands|Alrijne Ziekenhuis, Leiderdorp, Zuid Holland, 2353 GA, Netherlands|Orthopedium, Delft, Zuid-Holland, 2616 LS, Netherlands|Reinier de Graaf Groep, Delft, Zuid-Holland, 2625 AD, Netherlands|Medisch Centrum Haaglanden, Den Haag, Zuid-Holland, 2512 VA, Netherlands|HagaZiekenhuis, Den Haag, Zuid-Holland, 2566 MJ, Netherlands|Groene Hart Ziekenhuis, Gouda, Zuid-Holland, 2803 HH, Netherlands|Leiden University Medical Center, Leiden, Zuid-Holland, 2333 ZA, Netherlands|PARK MC, Rotterdam, Zuid-Holland, 3067 GH, Netherlands"
NCT03518567,Behavioral Economic Analysis of Demand for Marijuana,https://clinicaltrials.gov/study/NCT03518567,COMPLETED,YES,Marijuana Smoking,DRUG: Smoked marijuana cigarettes: High THC dose (6% THC),Brown University,,ALL,ADULT,133,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2018-10-15,2021-05-24,"Brown University, Providence, Rhode Island, 02903, United States"
NCT02324777,Cannabinoid Profile Investigation of Vapourized Cannabis in Patients With Osteoarthritis of the Knee,https://clinicaltrials.gov/study/NCT02324777,UNKNOWN,NO,"Osteoarthritis, Knee",DRUG: Cannabis|DEVICE: Volcano® Medic Vapourizer,Prairie Plant Systems Inc.,McGill University Health Centre/Research Institute of the McGill University Health Centre|Dalhousie University|Algorithme Pharma Inc|Research Institute of the McGill University Health Center,ALL,"ADULT, OLDER_ADULT",40,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-06,2019-06,"Pain Management Unit, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, B3H 1V7, Canada|Montreal General Hospital - McGill University Health Centre, Montreal, Quebec, H3G 1A4, Canada"
NCT00350285,The Teen Marijuana Check-Up,https://clinicaltrials.gov/study/NCT00350285,COMPLETED,NO,Cannabis Abuse|Cannabis Dependence,BEHAVIORAL: Motivational enhancement therapy|BEHAVIORAL: Marijuana education,University of Washington,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",310,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2004-09,2008-06,
NCT05106504,Effect of Medical Cannabis for Non-motor Symptoms of Parkinson's Disease,https://clinicaltrials.gov/study/NCT05106504,UNKNOWN,NO,"Bladder, Overactive|Parkinson Disease",DRUG: Medical Cannabis,Sheba Medical Center,,ALL,"ADULT, OLDER_ADULT",100,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-09-02,2024-08,"Sheba Medical Center, Ramat-Gan, 52621, Israel"
NCT05072795,Stress-Reactivity and Cannabis Use in Cannabis-Using Older Adults,https://clinicaltrials.gov/study/NCT05072795,COMPLETED,YES,Cannabis Use,BEHAVIORAL: Trier Social Stress Task (TSST),Medical University of South Carolina,National Institute on Aging (NIA)|National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",47,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2021-11-19,2023-06-07,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT05836207,Rewards for Cannabis Abstinence-study,https://clinicaltrials.gov/study/NCT05836207,RECRUITING,NO,Cannabis Use Disorder,BEHAVIORAL: Abstinence-focused Contingency Management (CM) - stand alone|BEHAVIORAL: Standard Outpatient Cognitive Behavioural Therapy (CBT),Parnassia Addiction Research Centre,Leiden University Medical Center|Brijder Verslavingszorg|Antes|Novadic-Kentron|Amsterdam University of Applied Sciences|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Trimbos|Het Zwarte Gat,ALL,"CHILD, ADULT",154,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-21,2027-01,"Antes Youz, Rotterdam, 3024 BH, Netherlands|Brijder, the Hague, Netherlands|Novadic-Kentron, Vught, 5361LX, Netherlands"
NCT02635568,Duration of Marijuana Concentration in Breast Milk- A Pilot Study,https://clinicaltrials.gov/study/NCT02635568,COMPLETED,NO,Cannabis|Pregnancy|Breast Feeding,OTHER: Cannabis Use,"University of Colorado, Denver",Centers for Disease Control and Prevention,FEMALE,"ADULT, OLDER_ADULT",30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-11,2019-06-30,"Children's Hospital Colorado, Aurora, Colorado, 80045, United States|University of Colorado Denver, Aurora, Colorado, 80045, United States"
NCT03980561,UH3 Varenicline for Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT03980561,COMPLETED,YES,Cannabis Use Disorder,DRUG: Varenicline|DRUG: Placebo,Medical University of South Carolina,,ALL,"ADULT, OLDER_ADULT",174,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-01-31,2023-12-01,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Behavioral Health Services of Pickens County, Pickens, South Carolina, 29671, United States"
NCT06206252,Can Medical Cannabis Affect Opioid Use?,https://clinicaltrials.gov/study/NCT06206252,RECRUITING,NO,Chronic Pain|Pain,OTHER: Medical Cannabis,Thomas Jefferson University,,ALL,"ADULT, OLDER_ADULT",110,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-09-07,2025-02,"Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, 19107, United States"
NCT04851392,Do Adolescents and Adults Differ in Their Acute Response to Cannabis?,https://clinicaltrials.gov/study/NCT04851392,COMPLETED,NO,Cannabis|Cannabis Intoxication|Cannabis Use|Cannabis Dependence|Marijuana|THC|CBD|Adolescent Development,DRUG: Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)|DRUG: Cannabis with THC without CBD|DRUG: Placebo cannabis,"University College, London",Medical Research Council|Invicro,ALL,"CHILD, ADULT",48,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2019-03-11,2021-06-16,"University College London, London, WC1E 7HB, United Kingdom"
NCT05116527,THC Memory & Reward Learning Pilot,https://clinicaltrials.gov/study/NCT05116527,RECRUITING,NO,Marijuana|THC|Cannabis,"DRUG: Marijuana, Hash, THC, or Grass|DRUG: Placebo",Hartford Hospital,Yale University,ALL,ADULT,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2022-07-07,2025-12,"Hartford Hospital, Hartford, Connecticut, 06102, United States"
NCT01039415,Attempts to Stop/Reduce Marijuana Among Dependent Users,https://clinicaltrials.gov/study/NCT01039415,COMPLETED,NO,Marijuana Abuse|Marijuana Dependence,,University of Vermont,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",234,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-06,2012-10,"University of Vermont, Burlington, Vermont, 05401, United States"
NCT05320367,A Study of Inhaled Cannabidiol in Healthy Occasional Cannabis Users,https://clinicaltrials.gov/study/NCT05320367,NOT_YET_RECRUITING,NO,Cannabis,"DRUG: Cannabis, placebo",Centre hospitalier de l'Université de Montréal (CHUM),,ALL,ADULT,80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2025-03,2026-12,
NCT06605430,Medical Cannabis in Patients With Advanced Pancreatic Cancer,https://clinicaltrials.gov/study/NCT06605430,RECRUITING,NO,Pancreatic Ductal Adenocarcinoma (PDAC),DRUG: Medical Cannabis,HealthPartners Institute,University of Minnesota,ALL,"ADULT, OLDER_ADULT",32,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-09-16,2026-12,"HealthPartners Cancer Research Center, Saint Louis Park, Minnesota, 55426, United States"
NCT03656029,Dose-response of Cannabis and Driving,https://clinicaltrials.gov/study/NCT03656029,COMPLETED,NO,Driving Impaired|Cognitive Impairment|Abuse Cannabis,DRUG: Cannabis|DRUG: Placebo,Centre for Addiction and Mental Health,,ALL,ADULT,36,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2021-06-04,2022-06-14,"Center for Addiction and Mental Health, Toronto, Ontario, M5S 2S1, Canada"
NCT01618656,Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal,https://clinicaltrials.gov/study/NCT01618656,COMPLETED,YES,Cannabis Dependence,DRUG: PF-04457845|DRUG: Placebo,Yale University,National Institute on Drug Abuse (NIDA),MALE,ADULT,70,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-09-12,2016-03-11,"Yale University School of Medicine, New Haven, Connecticut, 06511, United States"
NCT03679949,Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia,https://clinicaltrials.gov/study/NCT03679949,COMPLETED,NO,"Pain|Abuse, Drug",DRUG: Oxycodone|DRUG: Cannabis (THC:CBD = ~ 1:0)|DRUG: Cannabis (THC:CBD = ~ 0:1)|DRUG: Cannabis (THC:CBD = ~ 1:1)|DRUG: Placebo,New York State Psychiatric Institute,,ALL,ADULT,26,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2019-04-01,2022-12-06,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT05863910,Real World Evidence on the Use of Medical Cannabis in Pediatrics,https://clinicaltrials.gov/study/NCT05863910,RECRUITING,NO,Cancer|Epilepsy|Neurodevelopmental Disorders,DRUG: Medical Cannabis,University of Manitoba,The Canadian Collaborative for Childhood Cannabinoid Therapeutics|Canadian Cancer Society (CCS)|Canadian Institutes of Health Research (CIHR),ALL,CHILD,500,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-11-20,2027-12-31,"U Manitoba, Winnipeg, Manitoba, R3E0T6, Canada"
NCT04965740,"Exploring Medically Perceived Benefits, Use and Interest in Psychedelics and Cannabinoids",https://clinicaltrials.gov/study/NCT04965740,COMPLETED,NO,PTSD|Anxiety|Anxiety Disorders|Depression|Depressive Disorder|Psychological|Psychedelic Experiences|Psychedelic Drug Dependence,DRUG: Cannabis,Empower Research Inc,,ALL,"ADULT, OLDER_ADULT",102,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-06-04,2022-02-15,"Centre for Neurology Studies, Surrey, British Columbia, V3V 0C6, Canada"
NCT03253926,Effect of Lorcaserin on Cannabis Withdrawal and Self-administration,https://clinicaltrials.gov/study/NCT03253926,COMPLETED,YES,Cannabis Use,DRUG: Lorcaserin|DRUG: Placebo|DRUG: Marijuana,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,ADULT,15,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2017-09-05,2021-12-31,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT01574183,Vilazodone Treatment for Marijuana Dependence,https://clinicaltrials.gov/study/NCT01574183,COMPLETED,YES,Marijuana Dependence,DRUG: Vilazodone|DRUG: Placebo,Medical University of South Carolina,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",76,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-08,2016-02,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT02102230,CBT-I for Cannabis Use,https://clinicaltrials.gov/study/NCT02102230,TERMINATED,YES,Marijuana Abuse|Sleep Initiation and Maintenance Disorders,BEHAVIORAL: Cognitive Behavioral Therapy for Insomnia (CBT-I)|BEHAVIORAL: Cognitive Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA)|BEHAVIORAL: Desensitization Treatment for Insomnia,VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",111,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2014-11-03,2017-03-24,"VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, 94304-1290, United States"
NCT02408640,Internet-Based Treatment for Individuals With Regular Cannabis Use: A Randomized Controlled Trial,https://clinicaltrials.gov/study/NCT02408640,COMPLETED,NO,Cannabis,BEHAVIORAL: Cannabishjalpen.se,Karolinska Institutet,,ALL,"CHILD, ADULT, OLDER_ADULT",303,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2015-06-26,2017-12-31,"Center for Psychiatric Research, Stockholm, 113 64, Sweden"
NCT01975688,A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis,https://clinicaltrials.gov/study/NCT01975688,TERMINATED,NO,Head and Neck Squamous Cell Carcinoma,DRUG: Sativex,GW Pharmaceuticals Ltd,,ALL,"ADULT, OLDER_ADULT",10,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-02,2015-06,"Quintiles London Drug Research Unit, London, SE1 1YR, United Kingdom"
NCT01762696,"A Real-time, Contextual Intervention Using Mobile Technology to Reduce Marijuana Use in Youth",https://clinicaltrials.gov/study/NCT01762696,COMPLETED,NO,Marijuana Abuse,BEHAVIORAL: MET|BEHAVIORAL: MOMENT,Boston Children's Hospital,,ALL,"CHILD, ADULT",70,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2013-05,2016-05,"Boston Children's Hospital Adolescent/Young Adult Medical Clinic, Boston, Massachusetts, 02115, United States|Martha Eliot Health Center Adolescent Clinic, Jamaica Plain, Massachusetts, 02130, United States"
NCT01041170,Antagonist-Elicited Cannabis Withdrawal,https://clinicaltrials.gov/study/NCT01041170,COMPLETED,NO,Cannabis|Dependence,DRUG: THC|DRUG: Rimonobant|DRUG: Rimonabant,National Institute on Drug Abuse (NIDA),,ALL,ADULT,,NIH,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: OTHER,2006-04-16,2010-01-11,"University of Maryland, Baltimore, Baltimore, Maryland, 21201-1595, United States|National Institute on Drug Abuse, Biomedical Research Center (BRC), Baltimore, Maryland, 21224, United States"
NCT05784961,Impact of tDCS on Cannabis Craving in Schizophrenia,https://clinicaltrials.gov/study/NCT05784961,NOT_YET_RECRUITING,NO,Schizophrenia|Cannabis Use Disorder,DEVICE: tDCS,"Centre hospitalier de Ville-Evrard, France",,ALL,"ADULT, OLDER_ADULT",138,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-03-01,2027-06-20,"Youcef Bencherif, Neuilly sur Marne, 93330, France|Ch Ville Evrard, Neuilly-sur-Marne, 93330, France"
NCT00656487,Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults,https://clinicaltrials.gov/study/NCT00656487,COMPLETED,YES,Cannabis Dependence|Cannabis Withdrawal,DRUG: rimonabant|DRUG: placebo,The Scripps Research Institute,National Institute on Drug Abuse (NIDA),ALL,ADULT,66,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2008-04-30,2011-01-06,"The Scripps Research Institute, La Jolla, California, 92037, United States"
NCT05115318,"The Effect of Medical Cannabis on Tics, Premonitory Urge and Psychiatric Comorbidity in Adults With Tourette Syndrome",https://clinicaltrials.gov/study/NCT05115318,COMPLETED,NO,Tourette Syndrome|Cannabis,DRUG: Medical Cannabis,Tel-Aviv Sourasky Medical Center,,ALL,"ADULT, OLDER_ADULT",18,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-07-01,2021-03-31,"Tel-Aviv Medical Center, Tel Aviv, 5522621, Israel"
NCT01812603,A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma,https://clinicaltrials.gov/study/NCT01812603,COMPLETED,NO,Cancer,DRUG: Sativex,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",6,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-09,2016-06,"The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, CH63 4JY, United Kingdom|St James's Institute of Oncology, St James's University Hospital, Leeds, Yorkshire, LS9 7TF, United Kingdom|Bristol Haematology & Oncology Centre, Bristol, BS2 8ED, United Kingdom|Guy's and St Thomas NHS Foundation Trust, of St Thomas' Hospital, London, SE1 7EH, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom"
NCT05602649,The Impact of Product Formulation on the Pharmacokinetics and Pharmacodynamics of Cannabis Edibles,https://clinicaltrials.gov/study/NCT05602649,RECRUITING,NO,Cannabis Use,DRUG: Cannabis|DRUG: Placebo,Johns Hopkins University,National Institute on Drug Abuse (NIDA),ALL,ADULT,80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2024-07-10,2026-01,"Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland, 21224, United States"
NCT06358144,Cannabis Edibles Packaging Imagery Experiment,https://clinicaltrials.gov/study/NCT06358144,COMPLETED,NO,Cannabis Use,BEHAVIORAL: Packaging imagery|BEHAVIORAL: No Imagery (Control),Wake Forest University Health Sciences,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2024-05-23,2024-06-19,"Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27157, United States"
NCT02240160,"A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy Subjects",https://clinicaltrials.gov/study/NCT02240160,TERMINATED,NO,Healthy Volunteers,DRUG: Sativex,GW Pharmaceuticals Ltd,,ALL,ADULT,6,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2014-08,2015-10,
NCT05620433,Joint Effort 2.0: a Mobile Application With University Students,https://clinicaltrials.gov/study/NCT05620433,RECRUITING,NO,"Cannabis Use|Cannabis|Cannabis Dependence|Cannabis Smoking|Cannabis Use, Unspecified",OTHER: Joint Effort|OTHER: Brief normative feedback and standard information,Centre hospitalier de l'Université de Montréal (CHUM),,ALL,ADULT,800,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-02-08,2025-01,"Université de Montréal, Montréal, Quebec, Canada"
NCT01887301,Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients,https://clinicaltrials.gov/study/NCT01887301,COMPLETED,NO,Hepatic Impairment,DRUG: Sativex,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",32,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-07,2014-05,"Anaheim Clinical Trials, LLC, Anaheim, California, CA 92801, United States|Clinical Pharmacology of Miami, Inc., Miami, Florida, FL 33014-3616, United States"
NCT01598896,Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia,https://clinicaltrials.gov/study/NCT01598896,TERMINATED,YES,Cannabis Dependence|Marijuana Dependence,DRUG: Dronabinol|DRUG: Clonidine|DRUG: Placebo,Mclean Hospital,Brain & Behavior Research Foundation,ALL,ADULT,12,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-05,2017-08,"McLean Hospital, Belmont, Massachusetts, 02478, United States"
NCT03883360,"Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis",https://clinicaltrials.gov/study/NCT03883360,WITHDRAWN,NO,Schizophrenia Spectrum Disorders|Cannabis Use,DRUG: Cannabidiol (CBD)|DRUG: Placebo,"University of Maryland, Baltimore","Sheppard Pratt Health System|University of California, Los Angeles",ALL,ADULT,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2050-01,2050-03,"Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, 90095, United States|Sheppard Pratt Health System, Baltimore, Maryland, 21204, United States|Maryland Psychiatric Research Center, Catonsville, Maryland, 21228, United States"
NCT02946489,Facilitating the Behavioral Treatment of Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT02946489,COMPLETED,YES,Cannabis Dependence,DRUG: CI-581a,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,ADULT,8,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2016-10,2018-08,"NYSPI, New York, New York, 10032, United States"
NCT06733792,A Mobile App to Reduce And/or Quit Cannabis Use,https://clinicaltrials.gov/study/NCT06733792,RECRUITING,NO,Cannabis Dependence,BEHAVIORAL: CBT-based intervention|BEHAVIORAL: Self-help guide,"Alba González-Roz, PhD",Delegación del Gobierno para el Plan Nacional sobre Drogas,ALL,ADULT,120,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-12-13,2027-03,"Faculty of Psychology, University of Oviedo, Oviedo, Asturias, 33003, Spain|University of Oviedo, Oviedo, Asturias, 33003, Spain"
NCT00743366,Effect of Quetiapine on Marijuana Withdrawal and Relapse,https://clinicaltrials.gov/study/NCT00743366,COMPLETED,YES,Marijuana Smoking,DRUG: Marijuana|DRUG: Quetiapine|DRUG: Placebo oral capsule,New York State Psychiatric Institute,"Research Foundation for Mental Hygiene, Inc.|National Institute on Drug Abuse (NIDA)",ALL,ADULT,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2008-08,2009-03,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT02567344,Excitatory rTMS to the Left Dorsolateral Pre-Frontal Cortex to Reduce Cannabis-Cue Induced Craving,https://clinicaltrials.gov/study/NCT02567344,COMPLETED,NO,Cannabis,DEVICE: Repetitive Transcranial Magnetic Stimulation (rTMS)|DEVICE: Sham Repetitive Transcranial Magnetic Stimulation,Medical University of South Carolina,,ALL,ADULT,18,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2015-10,2016-03,
NCT03366909,Mindfulness Meditation and Cannabis Dependence : Therapy Effectiveness,https://clinicaltrials.gov/study/NCT03366909,UNKNOWN,NO,Addiction|Cannabis Use|Cannabis Dependence,BEHAVIORAL: Mindfulness based relapse prevention (MBRP)|BEHAVIORAL: classic therapy,"Central Hospital, Nancy, France",,ALL,ADULT,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-05-01,2020-02-27,
NCT00270803,The Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana,https://clinicaltrials.gov/study/NCT00270803,COMPLETED,NO,Marijuana Dependence,DRUG: Tetra Hydro Cannabinol (THC),Tel-Aviv Sourasky Medical Center,Hadassah Medical Organization,ALL,"ADULT, OLDER_ADULT",12,OTHER_GOV,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2004-07,2005-12,"Department of Nuclear Medicine, Tel Aviv, 64239, Israel"
NCT05188404,"Aging and Marijuana: Benefits, Effects, and Risks",https://clinicaltrials.gov/study/NCT05188404,RECRUITING,NO,Cannabis Use,BEHAVIORAL: Choice of cannabis product,"University of Colorado, Boulder",,ALL,"ADULT, OLDER_ADULT",350,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-09-20,2026-01-31,"University of Colorado Boulder, Boulder, Colorado, 80309, United States"
NCT05288010,CANPAIN Feasibility Study Pragmatic Real World Trial Investigating CBMP in Chronic Pain Patients,https://clinicaltrials.gov/study/NCT05288010,UNKNOWN,NO,Chronic Pain,COMBINATION_PRODUCT: Cannabis,Harley Street (CPC) Limited,,ALL,"ADULT, OLDER_ADULT",100,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-15,2022-06-30,"LVL Health, London, W1G 9HH, United Kingdom"
NCT03614637,Cannabis Use and Epigenetic Alterations in Human Male Sperm Cells,https://clinicaltrials.gov/study/NCT03614637,COMPLETED,NO,Cannabis Use,OTHER: Cannabis use abstinence for 11 weeks,Duke University,John Templeton Foundation,MALE,ADULT,42,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-11-07,2020-03-16,"Duke Child and Family Study Center, Durham, North Carolina, 27705, United States"
NCT03766971,Influence of Tobacco Use on Cannabis Use,https://clinicaltrials.gov/study/NCT03766971,SUSPENDED,NO,Cannabis Use|Tobacco Use,BEHAVIORAL: 7 days of Tobacco Cessation|BEHAVIORAL: 21 days of Tobacco Cessation|DRUG: Cannabis,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,ADULT,160,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2020-02-01,2026-11-30,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT03522324,Pain Research: Innovative Strategies With Marijuana,https://clinicaltrials.gov/study/NCT03522324,COMPLETED,NO,Chronic Pain|Chronic Low Back Pain|Cannabis Use,DRUG: Cannabis Edible,"University of Colorado, Boulder","University of Colorado, Denver|Colorado State University",ALL,"ADULT, OLDER_ADULT",268,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-06-01,2023-10-12,"Center for Innovation and Creativity, Boulder, Colorado, 80304, United States"
NCT00218517,Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1,https://clinicaltrials.gov/study/NCT00218517,COMPLETED,NO,Marijuana Abuse,DRUG: Selegiline hydrochloride|DRUG: Placebo,National Institute on Drug Abuse (NIDA),,ALL,"ADULT, OLDER_ADULT",19,NIH,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-03,2007-07,"MRU, New Haven, Connecticut, 06519, United States"
NCT01020019,Combined Pharmacotherapy for Cannabis Dependency,https://clinicaltrials.gov/study/NCT01020019,COMPLETED,YES,Cannabis Dependence|Marijuana Dependence,DRUG: Dronabinol|DRUG: Placebo|DRUG: Lofexidine,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,ADULT,156,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-01,2014-09,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT05413187,A Trial to Assess the Efficacy and Safety of Medical Grade Cannabis in Children Diagnosed With Autism Spectrum Disorder,https://clinicaltrials.gov/study/NCT05413187,WITHDRAWN,NO,Autistic Disorder,DRUG: Medical Grade Cannabis oil|DRUG: Placebos,TO Pharmaceuticals,,ALL,CHILD,0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-09-01,2022-09-01,"Soroka University Medical Center, Beer Sheva, 8410101, Israel"
NCT03154567,Effects of Stress and Drug-cue Exposure (SCM),https://clinicaltrials.gov/study/NCT03154567,COMPLETED,NO,Marijuana Abuse,DRUG: Yohimbine,Wayne State University,,ALL,ADULT,12,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2017-11-01,2023-10-27,"Tolan Park Medical Building, Detroit, Michigan, 48201, United States"
NCT05969314,To Check Safety of Ayurvedic Oral Cannabis in Breast and Head and Neck Cancer,https://clinicaltrials.gov/study/NCT05969314,ACTIVE_NOT_RECRUITING,NO,Breast Cancer|Oral Cancer,DRUG: Cannabis capsules,Tata Memorial Hospital,,ALL,"ADULT, OLDER_ADULT",12,OTHER_GOV,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-06-08,2025-06-30,"Tata Memorial Center, Mumbai, Maharashtra, 400012, India|Tata Memorial Hospital, Mumbai, Maharastra, 400012, India"
NCT06137365,Cannabis for Obesity Trial,https://clinicaltrials.gov/study/NCT06137365,NOT_YET_RECRUITING,NO,Obesity,DRUG: Cannabis|DRUG: Placebo,University of Kentucky,,ALL,"CHILD, ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2025-02,2026-01,
NCT04187989,Social Media Intervention for Cannabis Use in Emerging Adults,https://clinicaltrials.gov/study/NCT04187989,COMPLETED,YES,Cannabis Use,BEHAVIORAL: Social Media Intervention,University of Michigan,National Institute on Drug Abuse (NIDA),ALL,ADULT,149,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-02-03,2020-12-18,"University of Michigan, Ann Arbor, Michigan, 48109, United States"
NCT01875796,Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders,https://clinicaltrials.gov/study/NCT01875796,COMPLETED,NO,Cannabis Dependence|Anxiety Disorders|Cannabis Use Disorder|Cannabis Abuse,BEHAVIORAL: Cognitive-Behavioral Therapy|BEHAVIORAL: Motivation Enhancement Therapy|BEHAVIORAL: Integrated Cannabis and Anxiety Reduction Treatment|BEHAVIORAL: False Safety Behavior Elimination Therapy,Louisiana State University and A&M College,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",68,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2013-06,,"Louisiana State University Anxiety & Addictive Behaviors Clinic, Baton Rouge, Louisiana, 70803, United States"
NCT01323465,"Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex",https://clinicaltrials.gov/study/NCT01323465,COMPLETED,NO,Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4|Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4|Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor,DRUG: Sativex and rifampicin|DRUG: Sativex and rifampicin|DRUG: Sativex and ketoconazole|DRUG: Sativex and ketoconazole|DRUG: Sativex and omeprazole|DRUG: Sativex and omeprazole,Jazz Pharmaceuticals,,MALE,ADULT,36,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2008-02,2008-03,"Guy's Drug Research Unit, Quintiles Ltd., London, SE1 1YR, United Kingdom"
NCT03104257,The Neural Correlates of Cannabis Use,https://clinicaltrials.gov/study/NCT03104257,COMPLETED,NO,Cannabis Dependence|Healthy,DRUG: [11-C]OMAR,Yale University,National Institute on Drug Abuse (NIDA),ALL,ADULT,162,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-12,2022-04-27,"Conneticut Mental Health Center, New Haven, Connecticut, 06519, United States"
NCT04376437,The Kinetics of Endocannabinoids in Patients With Chemotherapy Induced Peripheral Neuropathy by Using Medical Cannabis.,https://clinicaltrials.gov/study/NCT04376437,UNKNOWN,NO,Chemotherapy-induced Peripheral Neuropathy,DRUG: medical cannabis,"HaEmek Medical Center, Israel","Technion, Israel Institute of Technology|Syqe Medical",ALL,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-03-15,2023-12-01,"Haemek MC, Afula, North, Israel"
NCT04721353,Reducing Cannabis Overuse With Prazosin,https://clinicaltrials.gov/study/NCT04721353,RECRUITING,NO,Cannabis Dependence|Posttraumatic Stress Disorder|Cannabis Use Disorder,DRUG: Prazosin Hydrochloride,VA Puget Sound Health Care System,"University of Washington|VA Mental Illness Research, Education and Clinical Centers",ALL,"ADULT, OLDER_ADULT",20,FED,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-11-09,2025-06-30,"VA Puget Sound Health Care System, Seattle, Washington, 98108, United States"
NCT04866004,Contingency Management for Cannabis Use for Persons With HIV,https://clinicaltrials.gov/study/NCT04866004,RECRUITING,NO,Marijuana|HIV Infections,BEHAVIORAL: Contingency Management - Cannabis,The University of Texas Health Science Center at San Antonio,"The University of Texas Health Sciences Center, Houston|National Institute on Drug Abuse (NIDA)",ALL,"ADULT, OLDER_ADULT",45,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-08-01,2025-06-01,"Center for Neurobehavioral Research on Addiction, Houston, Texas, 77054, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78229, United States"
NCT04106336,Cortical Excitability and Role of rTMS in Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT04106336,UNKNOWN,NO,"Cannabis Use Disorder, Moderate",DEVICE: rTMS,Assiut University,,MALE,ADULT,60,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-10-01,2020-12-30,
NCT06395389,A Brief Intervention for Cannabis Use,https://clinicaltrials.gov/study/NCT06395389,RECRUITING,NO,Cannabis Use Disorder,BEHAVIORAL: Health Education (HealthEdu)|BEHAVIORAL: Values in Action (VIA),Medical University of South Carolina,National Institute on Drug Abuse (NIDA),ALL,ADULT,62,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2024-10-18,2029-05,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT01969474,Effectiveness of Cannabis in the Treatment of Tinnitus Patients,https://clinicaltrials.gov/study/NCT01969474,WITHDRAWN,NO,Tinnitus,DRUG: Cannabis|DRUG: Placebo,Wolfson Medical Center,,ALL,"ADULT, OLDER_ADULT",0,OTHER_GOV,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-12,,"Wolfson Medical Centre, Holon, Israel"
NCT04567394,Cannabis Use Disorder Treatment Study,https://clinicaltrials.gov/study/NCT04567394,ACTIVE_NOT_RECRUITING,NO,"Cannabis Use Disorder, Mild|Cannabis Use Disorder, Moderate|Cannabis Use Disorder, Severe",BEHAVIORAL: Peer Network Counseling-txt,"The University of Tennessee, Knoxville",Colorado State University,ALL,ADULT,1077,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-07,2025-05-31,"Colorado State University, Fort Collins, Colorado, 80523, United States|University of Tennessee Knoxvile, Knoxville, Tennessee, 37996, United States"
NCT02744118,Helping Eliminate Marijuana Use Through Pediatric Practice,https://clinicaltrials.gov/study/NCT02744118,COMPLETED,NO,Marijuana,OTHER: 5A's Model|OTHER: Healthy Internet Use Model,American Academy of Pediatrics,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",620,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: SUPPORTIVE_CARE",2016-04,2020-03,"American Academy of Pediatrics, Elk Grove Village, Illinois, 60007, United States"
NCT04202146,Cannabis Use and Relapse After One Week of Contingency Management Therapy,https://clinicaltrials.gov/study/NCT04202146,COMPLETED,NO,Cannabis Dependence,BEHAVIORAL: Contingency Management + Motivational Interviewing,Yale University,,ALL,ADULT,49,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-07-15,2019-09-15,"The Yale Stress Center: Yale University, New Haven, Connecticut, 06519, United States"
NCT06171399,Cannabis Edibles Packaging Descriptors Experiment,https://clinicaltrials.gov/study/NCT06171399,COMPLETED,NO,Cannabis Use,"BEHAVIORAL: ""All Natural"" descriptor|BEHAVIORAL: ""Gluten-free"" descriptor|BEHAVIORAL: ""Vegan"" descriptor|BEHAVIORAL: ""100% Organic"" descriptor|BEHAVIORAL: ""Handcrafted"" descriptor|BEHAVIORAL: ""Made with live resin"" descriptor|BEHAVIORAL: ""Fast-acting"" descriptor|BEHAVIORAL: ""Relax"" descriptor|BEHAVIORAL: ""Energy Boost"" descriptor|BEHAVIORAL: No descriptor (control)",Wake Forest University Health Sciences,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",2731,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2024-03-15,2024-04-15,"Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27157, United States"
NCT00534716,Cannabis Cigarettes Used for Doping: Delta-9-Tetrahydrocannabinol (THC) Urine Detection,https://clinicaltrials.gov/study/NCT00534716,COMPLETED,NO,Healthy,,"Federal Office of Sports, Switzerland",,MALE,ADULT,12,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-09,2008-05,"Clinical Investigation Unit (CIU), University Hospital (""Inselspital""), Bern, CH-3010, Switzerland"
NCT02892110,Varenicline Treatment for Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT02892110,COMPLETED,YES,Substance Use Disorder,DRUG: Varenicline|DRUG: Placebo,Medical University of South Carolina,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",72,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-02-13,2018-11-27,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT03867786,Resistance Exercise and Cannabis Use,https://clinicaltrials.gov/study/NCT03867786,UNKNOWN,NO,Cannabis Use Disorder,BEHAVIORAL: Exercise|BEHAVIORAL: Video Control,Penn State University,,ALL,ADULT,40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2023-02-01,2024-12-01,
NCT03637842,Lorcaserin for Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT03637842,TERMINATED,YES,Cannabis Use Disorder,DRUG: Lorcaserin|DRUG: Placebo oral capsule,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",5,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-08-01,2020-02-29,"Columbia Substance Treatment and Research Service, New York, New York, 10019, United States"
NCT00675948,Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain,https://clinicaltrials.gov/study/NCT00675948,COMPLETED,YES,Pain|Cancer,DRUG: Sativex|DRUG: GW-2000-02,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",43,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2002-04,2006-09,"Shropshire and Mid-Wales Hospice, Shrewsbury, SY3 8HS, United Kingdom"
NCT03538288,Feasibility Trial of rTMS for Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT03538288,COMPLETED,NO,Cannabis,DEVICE: rTMS,Medical University of South Carolina,,FEMALE,ADULT,3,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY,2016-10-01,2017-07-01,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT06267131,Transcutaneous Pulse Oximetry Brain Monitoring Study (US),https://clinicaltrials.gov/study/NCT06267131,RECRUITING,NO,Acute Brain Injury,DEVICE: Brain Pulse Oximeter,Cyban Pty Ltd,,ALL,"ADULT, OLDER_ADULT",15,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-10-27,2024-11,"Cleveland Clinic, Neurological Institute, Cleveland, Ohio, 44195, United States"
NCT05382273,Cannabis Tolerance Break Resource Study: T-Break Guide,https://clinicaltrials.gov/study/NCT05382273,COMPLETED,NO,Cannabis Use|Tolerance|Cannabis Withdrawal,BEHAVIORAL: T-Break Guide,University of Vermont,Dartmouth College|Rutgers University,ALL,"ADULT, OLDER_ADULT",151,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-04-22,2021-08-01,"University of Vermont, Burlington, Vermont, 05405, United States"
NCT00249509,Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals,https://clinicaltrials.gov/study/NCT00249509,COMPLETED,NO,Marijuana Abuse,DRUG: Nefazodone|DRUG: Bupropion,National Institute on Drug Abuse (NIDA),,ALL,"ADULT, OLDER_ADULT",132,NIH,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2000-09,2004-09,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT04280289,CBD Cannabis Extract: Pharmacokinetic Studies,https://clinicaltrials.gov/study/NCT04280289,COMPLETED,NO,Epilepsy,DRUG: cannabidiol extract,"University of Mississippi, Oxford",,ALL,ADULT,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-02-01,2021-12-01,"University of Mississippi, University, Mississippi, 38677, United States"
NCT04320537,Brain Neurochemical Profile During Marijuana Abstinence,https://clinicaltrials.gov/study/NCT04320537,COMPLETED,NO,Brain Metabolic Changes During Marijuana Abstinence,OTHER: abstinence from use of marijuana and other abused drugs,Mclean Hospital,"Scott E. Lukas, PhD, McLean Hospital",ALL,ADULT,37,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-07-01,2020-01-31,"Chun Zuo, Belmont, Massachusetts, 02478, United States"
NCT05939466,Medical Cannabis for Treating Pain Related to Fibromyalgia,https://clinicaltrials.gov/study/NCT05939466,COMPLETED,NO,Fibromyalgia,"DRUG: Bedrocan®-type cannabis (22% THC, <1% CBD)",Universita degli Studi della Basilicata,"San Carlo Public Hospital, Potenza, Italy",ALL,"ADULT, OLDER_ADULT",30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-01,2021-09-30,"Pain Therapy Unit, San Carlo Hospital, Potenza, 85100, Italy"
NCT05309226,Cannabis Use in Pregnancy and Downstream Effects on Maternal and Infant Health,https://clinicaltrials.gov/study/NCT05309226,RECRUITING,NO,Cannabis Use|Marijuana Use,OTHER: Cannabis use in pregnancy or cannabis exposure in utero,Ottawa Hospital Research Institute,Queen's University|Children's Hospital of Eastern Ontario Research Institute,ALL,"CHILD, ADULT, OLDER_ADULT",100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-10-10,2025-06,"Kingston Health Sciences Centre, Kingston, Ontario, K7L 2V7, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, K1H 8L1, Canada|The Ottawa Hospital - Civic Campus, Ottawa, Ontario, K1H 8L6, Canada|The Ottawa Hospital - General Campus, Ottawa, Ontario, K1H 8L6, Canada"
NCT01040910,Cannabis for Inflammatory Bowel Disease,https://clinicaltrials.gov/study/NCT01040910,UNKNOWN,NO,Crohn's Disease|Ulcerative Colitis,DRUG: smoking of cannabis|DRUG: smoking cigarettes with placebo,Meir Medical Center,,ALL,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-01,2012-07,"Meir hospital, Kefar Saba, 44281, Israel|Meir Medical center, Kfar Saba, Israel"
NCT06669585,"Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 3",https://clinicaltrials.gov/study/NCT06669585,RECRUITING,NO,Cannabis|Memory|Electroencephalography,DRUG: Cannabis (smoked flower),L. Cinnamon Bidwell,National Institute on Drug Abuse (NIDA),ALL,ADULT,64,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-10-09,2026-01,"Center for Innovation and Creativity (CINC), Boulder, Colorado, 80301, United States"
NCT00260741,Cannabis for Spasticity in Multiple Sclerosis,https://clinicaltrials.gov/study/NCT00260741,TERMINATED,NO,Multiple Sclerosis,DRUG: Smoked Cannabis,Center for Medicinal Cannabis Research,,ALL,"ADULT, OLDER_ADULT",60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2003-03,2006-01,"UC Davis Medical Center, Sacramento, California, 95817, United States"
NCT02249299,Experimental Medicine in ADHD - Cannabinoids,https://clinicaltrials.gov/study/NCT02249299,COMPLETED,NO,Attention Deficit Hyperactivity Disorder (ADHD),DRUG: Sativex Oromucosal Spray|DRUG: Placebo,King's College London,South London and Maudsley NHS Foundation Trust,ALL,ADULT,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2014-08,2015-12,"Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, SE5 8AF, United Kingdom"
NCT06107062,Longitudinal Outpatient Treatment for Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT06107062,RECRUITING,NO,Cannabis Use Disorder,DRUG: Cannabidiol - fsCBD|DRUG: Placebo|DRUG: Cannabidiol - bsCBD,"University of Colorado, Boulder",National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",165,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2024-05-16,2029-03-31,"University of Colorado Boulder, Boulder, Colorado, 80301, United States"
NCT02283281,Anesthetic Premedication With a Cannabis Extract (Cannapremed),https://clinicaltrials.gov/study/NCT02283281,RECRUITING,NO,"Pain, Postoperative|Postoperative Nausea and Vomiting|Anxiety",DRUG: Tetrahydrocannabinol|DRUG: Dummy oromucosal,Hadassah Medical Organization,Jazz Pharmaceuticals,ALL,ADULT,200,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-05,2024-12,"Hasassah - Hebrew University Ein Kerem Medical Center, Jerusalem, 12000, Israel"
NCT03845842,Using Implementation Intentions to Reduce Cannabis Use,https://clinicaltrials.gov/study/NCT03845842,COMPLETED,NO,Cannabis Use,BEHAVIORAL: Volitional help sheet,University of Manchester,,ALL,"ADULT, OLDER_ADULT",311,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION,2019-02-14,2020-11-30,"The University of Manchester, Manchester, M13 9PL, United Kingdom"
NCT02325011,An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience.,https://clinicaltrials.gov/study/NCT02325011,COMPLETED,NO,Healthy Subjects,DRUG: Sativex® (Treatment A)|DRUG: Sativex® and fluconazole concomitantly (Treatment B),Jazz Pharmaceuticals,,ALL,ADULT,14,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2014-11,2015-02,"Anaheim Clinical Trials, Anaheim, California, 92801, United States"
NCT03617692,Cannabis Use in Cancer Patients,https://clinicaltrials.gov/study/NCT03617692,COMPLETED,YES,"Solid Tumor, Adult",,"University of Colorado, Denver",,ALL,"ADULT, OLDER_ADULT",27,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-12-04,2022-12-12,"University of Colorado Hospital, Aurora, Colorado, 80045, United States|University of Colorado Boulder, Boulder, Colorado, 80309, United States"
NCT04060602,Personalized Feedback Intervention to Reduce Risky Cannabis Use.,https://clinicaltrials.gov/study/NCT04060602,COMPLETED,NO,Cannabis Use,BEHAVIORAL: Personalized Feedback|BEHAVIORAL: Education,Centre for Addiction and Mental Health,,ALL,"ADULT, OLDER_ADULT",747,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-09-03,2020-10-15,"Centre for Addiction Mental Health, Toronto, Ontario, M5S 2S1, Canada"
NCT01603992,Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms,https://clinicaltrials.gov/study/NCT01603992,COMPLETED,NO,Cannabis Abuse|Cannabis Dependence,,National Institute on Drug Abuse (NIDA),,ALL,"ADULT, OLDER_ADULT",822,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2005-11-08,2012-05-03,"National Institute on Drug Abuse, Biomedical Research Center (BRC), Baltimore, Maryland, 21224, United States|Maryland Psychiatric Research Center (MPRC) 55 Wade Avenue, Catonsville, Maryland, 21228, United States|Medical University of S. Carolina, Charleston, South Carolina, 29425, United States"
NCT01439828,Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal,https://clinicaltrials.gov/study/NCT01439828,TERMINATED,NO,Cannabis Dependence|Cannabis Abuse,DRUG: N-acetylcystein,Assistance Publique - Hôpitaux de Paris,,ALL,ADULT,6,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-02,2015-02,"Service de Psychiatrie - Hôpital Lariboisière, Paris, 75010, France"
NCT01400243,Nicotine Patch for Marijuana Withdrawal,https://clinicaltrials.gov/study/NCT01400243,COMPLETED,YES,Marijuana Dependence,DRUG: Nicotine|DRUG: Placebo Patch,Southern Illinois University Carbondale,National Institute on Drug Abuse (NIDA),ALL,ADULT,127,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2011-04,2014-06,"Southern Illinois University, Carbondale, Illinois, 62901, United States"
NCT03481959,Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity,https://clinicaltrials.gov/study/NCT03481959,TERMINATED,NO,Attention Deficit Hyperactivity Disorder (ADHD),DRUG: Methylphenidate|OTHER: Matching Placebo,Assistance Publique - Hôpitaux de Paris,,ALL,"CHILD, ADULT",3,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-05-07,2020-09-01,"Peyret, Paris, 75019, France"
NCT05528380,Development of a Lifestyle Physical Activity Intervention to Reduce Risk for Perinatal Cannabis Use,https://clinicaltrials.gov/study/NCT05528380,ACTIVE_NOT_RECRUITING,NO,Pregnancy|Cannabis,BEHAVIORAL: LPA + Fitbit Intervention,Butler Hospital,,FEMALE,"ADULT, OLDER_ADULT",16,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-30,2025-05,"Butler Hospital, Providence, Rhode Island, 02906, United States"
NCT00217971,Dronabinol Treatment for Marijuana Addiction,https://clinicaltrials.gov/study/NCT00217971,COMPLETED,YES,Marijuana Abuse,DRUG: Dronabinol|DRUG: Placebo,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,ADULT,156,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-03,2009-12,"Research Foundation for Mental Hygiene, Inc., New York, New York, 10032, United States"
NCT03060993,CAN BREATHE in COPD Trial,https://clinicaltrials.gov/study/NCT03060993,UNKNOWN,NO,Chronic Obstructive Pulmonary Disease (COPD)|Breathlessness|Exercise Intolerance,DRUG: Cannabis|DRUG: Placebo,McGill University,,ALL,"ADULT, OLDER_ADULT",16,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-03-01,2018-04-30,"McConnell Centre for Innovative Medicine, Research Institute of the McGill University Health Centre, Montreal, Quebec, H4A 3J1, Canada"
NCT01639872,Clozapine for Cannabis Use in Schizophrenia,https://clinicaltrials.gov/study/NCT01639872,COMPLETED,YES,Schizophrenia|Cannabis Abuse|Cannabis Dependence|Dual Diagnosis,DRUG: Clozapine|DRUG: Risperidone,Dartmouth-Hitchcock Medical Center,"University of South Carolina|Michigan State University|University of Miami|University of Massachusetts, Worcester",ALL,ADULT,49,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-05-01,2017-03-29,"CNS Network Inc, Garden Grove, California, 92845, United States|Pacific Research Partners, Oakland, California, 94607, United States|University of Miami, Miami, Florida, 33136, United States|Unversity of Massachusetts Medical School, Worcester, Massachusetts, 01605, United States|Michigan State University / Cherry Street Health Services, Grand Rapids, Michigan, 49503, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|University of North Carolina/UNC Center for Excellence in Community Mental Health, Raleigh, North Carolina, 27610, United States|University of South Carolina, Columbia, South Carolina, 29203, United States|Rutland Regional Medical Center, Rutland, Vermont, 05701, United States"
NCT02723149,Marijuana Approach Bias Retraining and Neural Response in Youth,https://clinicaltrials.gov/study/NCT02723149,COMPLETED,NO,Alcohol Approach/Avoidance Task|Sham Approach/Avoidance Task,BEHAVIORAL: Marijuana Approach Avoidance Training,Medical University of South Carolina,,ALL,"CHILD, ADULT",41,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2015-11,2017-10,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT03944447,Outcomes Mandate National Integration With Cannabis as Medicine,https://clinicaltrials.gov/study/NCT03944447,RECRUITING,NO,Chronic Pain|Chronic Pain Syndrome|Chronic Pain Due to Injury|Chronic Pain Due to Trauma|Fibromyalgia|Seizures|Hepatitis C|Cancer|Crohn Disease|HIV/AIDS|Multiple Sclerosis|Traumatic Brain Injury|Sickle Cell Disease|Post Traumatic Stress Disorder|Tourette Syndrome|Ulcerative Colitis|Glaucoma|Epilepsy|Inflammatory Bowel Diseases|Parkinson Disease|Amyotrophic Lateral Sclerosis|Chronic Traumatic Encephalopathy|Anxiety|Depression|Insomnia|Autism|Opioid-use Disorder|Bipolar Disorder|Covid19|SARS-CoV Infection|COVID-19|Corona Virus Infection|Coronavirus,"DRUG: Cannabis, Medical|DEVICE: RYAH-Medtech Inhaler","OMNI Medical Services, LLC",OMNI Medical Services Inc,ALL,"CHILD, ADULT, OLDER_ADULT",200000,NETWORK,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-12-01,2025-12-31,"OMNI Medical Services, Boca Raton, Florida, 33433, United States|OMNI Medical Services, Bradenton, Florida, 34209, United States|OMNI Medical Services, Fort Lauderdale, Florida, 33308, United States|OMNI Medical Services, Fort Myers, Florida, 34135, United States|OMNI Medical Services, Gainesville, Florida, 36201, United States|OMNI Medical Services, Merritt Island, Florida, 32952, United States|OMNI Medical Services, Miami, Florida, 33137, United States|OMNI Medical Services, Ocoee, Florida, 34761, United States|OMNI Medical Services, Pensacola, Florida, 32505, United States|OMNI Medical Services, Pompano Beach, Florida, 33060, United States|OMNI Medical Services, Tampa, Florida, 33614, United States|OMNI Medical Services, Wesley Chapel, Florida, 33544, United States|OMNI Medical Services, Beechwood, Ohio, 44122, United States|OMNI Medical Services, Bowling Green, Ohio, 43402, United States|OMNI Medical Services, Sandusky, Ohio, 44870, United States|OMNI Medical Services, Toledo, Ohio, 43604, United States|OMNI Medical Services, Toledo, Ohio, 43611, United States"
NCT06030674,Measuring Environmental Tobacco and Cannabis: Pollutants and Exposures,https://clinicaltrials.gov/study/NCT06030674,NOT_YET_RECRUITING,NO,Healthy,OTHER: Secondhand cannabis emissions/smoke exposure,"University of California, San Francisco",,ALL,ADULT,200,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-09-01,2026-06-30,"Zuckerberg San Francisco General Hospital, San Francisco, California, 94110, United States"
NCT05115513,Standardized Field Test for Marijuana Impairment II,https://clinicaltrials.gov/study/NCT05115513,ACTIVE_NOT_RECRUITING,NO,Marijuana Impairment,DRUG: Medium THC|DRUG: Placebo THC,Yale University,National Highway Traffic Safety Administration (NHTSA)|Hartford Hospital|National Institute on Drug Abuse (NIDA),ALL,ADULT,32,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2022-08-25,2025-02,"Olin Neuropsychiatry Research Center, Hartford, Connecticut, 06106, United States"
NCT03432013,Affective Management Training for Cannabis Misuse,https://clinicaltrials.gov/study/NCT03432013,COMPLETED,NO,Cannabis Use Disorder,BEHAVIORAL: CUD-AMT|BEHAVIORAL: SUD-CBT,"University of California, Los Angeles",National Institute on Drug Abuse (NIDA),ALL,ADULT,51,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-02-15,2021-06-30,"Matrix Institute on Addictions, Los Angeles, California, 90025, United States|University of California-Los Angeles, Department of Psychiatry and Biobehavioral Sciences, Los Angeles, California, 90025, United States"
NCT02432612,A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT02432612,WITHDRAWN,NO,Advanced Cancer,DRUG: Sativex,GW Pharmaceuticals Ltd,,ALL,"ADULT, OLDER_ADULT",0,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-10,2016-10,
NCT02869451,Mobile Contingency Management for Marijuana and Tobacco Cessation,https://clinicaltrials.gov/study/NCT02869451,COMPLETED,YES,Cigarette Smoking|Marijuana Abuse,DRUG: bupropion|DRUG: transdermal nicotine patch|DRUG: Nicotine polacrilex|DRUG: nicotine lozenge|BEHAVIORAL: counseling for marijuana and smoking cessation|BEHAVIORAL: mobile contingency management,Duke University,,ALL,"ADULT, OLDER_ADULT",7,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-08,2017-05-17,"Duke University Medical Center, Durham, North Carolina, 27706, United States"
NCT03608137,Cannabis and Thought Disorder in Schizophrenia,https://clinicaltrials.gov/study/NCT03608137,TERMINATED,NO,Schizophrenia,OTHER: Cannabis and thought disorder in schizophrenia:clinical and neuroimaging relationships,Hôpital le Vinatier,,ALL,"ADULT, OLDER_ADULT",63,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2018-12-07,2022-12-31,"Centre Hospitalier Le Vinatier, Bron, Auvergne Rhone Alpes, 69678 cedex, France"
NCT01071616,"Oral Fluid, Plasma and Whole Pharmacokinetics and Stability Following Smoked Cannabis",https://clinicaltrials.gov/study/NCT01071616,COMPLETED,NO,Cannabis Use|Drug Abuse,DRUG: Cannabis Cigarette,National Institute on Drug Abuse (NIDA),,ALL,ADULT,45,NIH,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2010-01-22,2013-11-29,"National Institute on Drug Abuse, Biomedical Research Center (BRC), Baltimore, Maryland, 21224, United States"
NCT05160688,Changes in Cognition and Psychiatric Disorder Symptoms During Cannabis Abstinence Using a Novel Discordant Twin Design,https://clinicaltrials.gov/study/NCT05160688,ENROLLING_BY_INVITATION,NO,Cannabis,BEHAVIORAL: Contingency management,"University of Colorado, Denver","University of Colorado, Boulder",ALL,ADULT,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-05-05,2026-02-01,"Jessica M Ross, Aurora, Colorado, 80045, United States"
NCT00974376,Gabapentin Treatment of Cannabis Dependence,https://clinicaltrials.gov/study/NCT00974376,COMPLETED,YES,Cannabis Dependence|Cannabis Withdrawal|Cognitive Deficits,DRUG: gabapentin 1200mg/day|DRUG: Placebo|BEHAVIORAL: Manual-guided behavioral counseling,The Scripps Research Institute,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",150,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-11-04,2016-05-19,"The Scripps Research Institute, La Jolla, California, 92037, United States"
NCT00878852,Efficacy of Contingency Management in the Treatment of Adolescents With Cannabis Use Disorders,https://clinicaltrials.gov/study/NCT00878852,UNKNOWN,NO,Marijuana Abuse,BEHAVIORAL: Standard treatment|BEHAVIORAL: Standard Treatment Plus Contingency Management Program,Hospital Clinic of Barcelona,,ALL,"CHILD, ADULT",30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2009-04,,"Hospital Clinic Barcelona, Barcelona, 08015, Spain"
NCT03699527,Medical Cannabis Registry and Pharmacology,https://clinicaltrials.gov/study/NCT03699527,COMPLETED,NO,Autism|ASD,BEHAVIORAL: Multiple questionnaires administered,Children's Hospital of Philadelphia,Zelda Therapeutics,ALL,"CHILD, ADULT",119,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-07-15,2020-01-15,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States"
NCT06021613,The MARY-JANE Cannabis and Heart Rhythm Trial,https://clinicaltrials.gov/study/NCT06021613,RECRUITING,NO,Premature Atrial Contractions|Premature Ventricular Contractions,BEHAVIORAL: Randomized instructions,"University of California, San Francisco",,ALL,"ADULT, OLDER_ADULT",100,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-01-18,2026-11,"UCSF Medical Center at Parnassus, San Francisco, California, 94143, United States|UCSF Medical Center at Mission Bay, San Francisco, California, 94158, United States"
NCT00279604,INCA - Intervention and Neuropsychology in Cannabis Abuse,https://clinicaltrials.gov/study/NCT00279604,UNKNOWN,NO,Marijuana Abuse,BEHAVIORAL: 'Problem Profile Intervention' vs. WHO-Brief Intervention,"University Hospital, Bonn",German Federal Ministry of Education and Research,ALL,"CHILD, ADULT",160,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2005-07,2007-10,"Friedrich-Wilhelms-University, Department of Psychiatry, Bonn, NRW, 53105, Germany|University of Essen, Department of Psychiatry and Psychotherapy, Essen, NRW, 45147, Germany"
NCT06290063,Cannabidiol and Older Adult Cannabis Users,https://clinicaltrials.gov/study/NCT06290063,RECRUITING,NO,Sleep|Anxiety|Depression|Pain,DRUG: fsCBD Cannabidiol|DRUG: bsCBD Cannabidiol|DRUG: Placebo,"University of Colorado, Boulder",,ALL,"ADULT, OLDER_ADULT",385,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-05-01,2028-08-31,"University of Colorado at Boulder, Boulder, Colorado, 80309, United States"
NCT02059083,Biofeedback for Adolescent Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT02059083,WITHDRAWN,NO,Adolescent Cannabis Use Disorder,BEHAVIORAL: Heart rate variability biofeedback|BEHAVIORAL: CBT,Denver Health and Hospital Authority,,ALL,"CHILD, ADULT",0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-09,2014-09,
NCT06661031,Developing a Telehealth + MHealth Cannabis Use Intervention for Young Adults,https://clinicaltrials.gov/study/NCT06661031,ENROLLING_BY_INVITATION,NO,Cannabis Use Disorder,BEHAVIORAL: Motivational Enhancement Therapy plus Ecological Momentary Intervention|BEHAVIORAL: Enhanced Usual Care,Boston Children's Hospital,National Institute on Drug Abuse (NIDA),ALL,ADULT,65,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2024-12-10,2027-05,"Boston Children's Hospital, Boston, Massachusetts, 02115, United States"
NCT06576076,"Cannabis, Linked Emotions, and Adolescent Risk Study",https://clinicaltrials.gov/study/NCT06576076,RECRUITING,NO,Cannabis Use|Depression|Suicidal Ideation|Adolescent Behavior,BEHAVIORAL: Contingency management for cannabis abstinence,Massachusetts General Hospital,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE,2025-02-15,2028-12,"Massachusetts General Hopsital, Boston, Massachusetts, 02114, United States"
NCT03729869,Impact of Progesterone on Stress Reactivity and Cannabis Use,https://clinicaltrials.gov/study/NCT03729869,COMPLETED,YES,Cannabis Use,DRUG: Progesterone|DRUG: Placebo,Medical University of South Carolina,National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA),ALL,ADULT,148,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-01-18,2022-11-09,"Medical University of South Carolina, Charleston, South Carolina, 29403, United States"
NCT04360044,Efficacy of Inhaled Cannabis for Acute Migraine Treatment,https://clinicaltrials.gov/study/NCT04360044,COMPLETED,NO,Migraine|Cannabis|THC|CBD,DRUG: THC ~5%|DRUG: CBD ~12%|DRUG: THC ~5% and CBD ~12%|DRUG: Sham Cannabis,"University of California, San Diego",Migraine Research Foundation,ALL,"ADULT, OLDER_ADULT",92,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11-20,2023-02-23,"Center for Pain Medicine, UC San Diego, La Jolla, California, 92037, United States"
NCT00373503,Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse,https://clinicaltrials.gov/study/NCT00373503,COMPLETED,NO,Marijuana Dependence,DRUG: Lofexidine|DRUG: dronabinol|DRUG: Marijuana,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,ADULT,8,OTHER,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2005-08,2008-09,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT02325024,"A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function.",https://clinicaltrials.gov/study/NCT02325024,WITHDRAWN,NO,Renal Insufficiency|Kidney Disease,DRUG: Sativex,GW Pharmaceuticals Ltd,,ALL,"ADULT, OLDER_ADULT",0,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2016-01,2016-10,
NCT05559424,Comparison of Results Achieved by Different Ballooning Techniques in Bifurcation Stenting,https://clinicaltrials.gov/study/NCT05559424,UNKNOWN,NO,Ischemic Heart Disease,DIAGNOSTIC_TEST: OCT,Catholic University of the Sacred Heart,,ALL,"ADULT, OLDER_ADULT",60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-10,2023-07,"Policlinico A. Gemelli. Università Cattolica del Sacro Cuore, Rome, 00168, Italy"
NCT05581368,Studying the Effects of Cannabis on Vasculature,https://clinicaltrials.gov/study/NCT05581368,RECRUITING,NO,Cardiovascular Diseases|Inflammation|Atherosclerosis,OTHER: Chronic Cannabis use,London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's,Academic Medical Organization of Southwestern Ontario|Canadian Cardiovascular Society,ALL,"ADULT, OLDER_ADULT",100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-12-01,2024-12,"London Regional Health Science Centre, London, Ontario, N6A 5A5, Canada"
NCT00872144,Sativex for Treatment of Chemotherapy Induced Neuropathic Pain,https://clinicaltrials.gov/study/NCT00872144,COMPLETED,NO,Neuropathic Pain,DRUG: Sativex,Mary Lynch,,ALL,"ADULT, OLDER_ADULT",16,OTHER,INTERVENTIONAL,"Allocation: |Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-06,2013-03,"Queen Elizabeth II Health Sciences Centre, Pain Management Unit, Halifax, Nova Scotia, B3H 2Y9, Canada"
NCT06567873,Gastric Ultrasound Assessment for Patients Taking Cannabis,https://clinicaltrials.gov/study/NCT06567873,ACTIVE_NOT_RECRUITING,NO,Gastric Ultrasound|Point of Care Ultrasound|Cannabis Use,OTHER: Gastric Ultrasound Exam,"Hospital for Special Surgery, New York",,ALL,"ADULT, OLDER_ADULT",40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-07-16,2026-07,"Hospital for Special Surgery, New York, New York, 10021, United States"
NCT05729932,Cannabis and Opioid Use Disorder,https://clinicaltrials.gov/study/NCT05729932,RECRUITING,NO,Opioid Use Disorder,DRUG: Inhaled vaporized cannabis|DRUG: Intransal opioid,University of Kentucky,National Institute on Drug Abuse (NIDA),ALL,ADULT,15,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2024-09-10,2027-06-30,"Center on Drug and Alcohol Research, Lexington, Kentucky, 40508, United States"
NCT02030665,Marijuana Treatment Project 4,https://clinicaltrials.gov/study/NCT02030665,COMPLETED,NO,Marijuana Dependence,BEHAVIORAL: Contingency Management|BEHAVIORAL: Individualized Assessment & Treatment|BEHAVIORAL: Cognitive-Behavioral Treatment,UConn Health,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",198,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2013-02,2018-04,"University of Connecticut Health Center, Farmington, Connecticut, 06030, United States"
NCT00875836,Buspirone Treatment for Marijuana Dependence,https://clinicaltrials.gov/study/NCT00875836,COMPLETED,YES,Marijuana Dependence,DRUG: Buspirone|DRUG: Placebo,Medical University of South Carolina,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",175,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-09,2016-03,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT01096303,Effects of Marijuana Used on Lung Function in Persons With Chronic Obstructive Pulmonary Disease (COPD),https://clinicaltrials.gov/study/NCT01096303,COMPLETED,NO,Chronic Obstructive Pulmonary Disease,,"The University of Texas Health Science Center, Houston",,ALL,"ADULT, OLDER_ADULT",200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-11,2016-12-31,"Lyndon B Johnson General Hospital, Houston, Texas, 77026, United States|The University of Texas- Health Science Center at Houston, Houston, Texas, 77030, United States"
NCT06334016,Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream,https://clinicaltrials.gov/study/NCT06334016,NOT_YET_RECRUITING,NO,Cannabis Dependence,PROCEDURE: Biospecimen Collection|DRUG: Cannabis sativa Extract|DRUG: Nicotine|DRUG: Placebo Administration|OTHER: Questionnaire Administration,Roswell Park Cancer Institute,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2025-03-27,2028-03-01,"Roswell Park Cancer Institute, Buffalo, New York, 14263, United States"
NCT05885542,SCORE Emerging Adult Cannabis Use & Stress,https://clinicaltrials.gov/study/NCT05885542,RECRUITING,NO,Cannabis Use Disorder,DRUG: Cannabidiol oral solution|DRUG: Placebo,Medical University of South Carolina,,ALL,ADULT,148,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11-01,2028-07-31,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT04587700,Analgesic Consumption in Chronic Marijuana Users Following Orthopedic Trauma Surgery,https://clinicaltrials.gov/study/NCT04587700,COMPLETED,NO,Cannabis|Marijuana,,University of Alberta,,ALL,"ADULT, OLDER_ADULT",5,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-09-21,2023-07-05,"University of Alberta, Edmonton, Alberta, T6G 2R3, Canada"
NCT00218504,Responses to Marijuana-Related Cues Versus Neutral Cues in Adults Taking Tetrahydrocannabinol (THC) - 2,https://clinicaltrials.gov/study/NCT00218504,COMPLETED,NO,Marijuana Abuse,DRUG: Tetrahydrocannabinol,Wayne State University,National Institute on Drug Abuse (NIDA),ALL,ADULT,20,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2005-12,2009-10,"Wayne State University, Detroit, Michigan, 48207, United States"
NCT03102918,Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT03102918,COMPLETED,YES,Cannabis Use Disorder,DRUG: Cannabidiol|DRUG: Placebo,Mclean Hospital,,ALL,"ADULT, OLDER_ADULT",10,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2016-02-20,2017-08-30,"McLean Hospital, Belmont, Massachusetts, 02478, United States"
NCT02816034,Cerebellar Alterations in Individuals With a Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT02816034,COMPLETED,NO,Cannabis,BEHAVIORAL: Visuo-motor rotation|BEHAVIORAL: Explicit strategy,Universitat Pompeu Fabra,Hospital Clinic of Barcelona|Institut d'Investigacions Biomèdiques August Pi i Sunyer,ALL,ADULT,32,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2016-06,2017-04,
NCT05005013,A Teleheath tDCS Approach to Decrease Cannabis Use,https://clinicaltrials.gov/study/NCT05005013,COMPLETED,NO,Cannabis Use Disorder|Multiple Sclerosis,OTHER: Transcranial Direct Current Stimulation (tDCS)|OTHER: Sham - Transcranial Direct Current Stimulation (tDCS)|OTHER: Mindfulness,NYU Langone Health,,FEMALE,"ADULT, OLDER_ADULT",52,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-09-13,2024-05-22,"NYU Langone Health, New York, New York, 10017, United States"
NCT05427630,Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment,https://clinicaltrials.gov/study/NCT05427630,SUSPENDED,NO,Migraine|Cannabis|THC,DRUG: THC ~2.5%|DRUG: THC ~5%|DRUG: THC ~10%|DRUG: Sham Cannabis,"University of California, San Diego",,ALL,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-02-15,2024-06-01,"Center for Pain Medicine, UC San Diego, La Jolla, California, 92037, United States"
NCT01025700,Nabilone & Marijuana Addiction,https://clinicaltrials.gov/study/NCT01025700,COMPLETED,NO,Marijuana Smoking,DRUG: Cesemat,University of British Columbia,,ALL,"ADULT, OLDER_ADULT",35,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-06,2010-10,"Vancouver General Hospital - Psychiatry Outpatient, Vancouver, British Columbia, Canada"
NCT00218478,Evaluating Responses to Drug-Related Cues Versus Neutral Cues to Understand the Effects of Marijuana Craving - 1,https://clinicaltrials.gov/study/NCT00218478,COMPLETED,NO,Marijuana Abuse,BEHAVIORAL: Cue Desensitization,Wayne State University,National Institute on Drug Abuse (NIDA),ALL,ADULT,15,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2004-09,2008-07,"Wayne State University, Detroit, Michigan, 48207, United States"
NCT00252980,CANDIS - Targeted Treatment for Cannabis Disorders,https://clinicaltrials.gov/study/NCT00252980,UNKNOWN,NO,Cannabis Use Disorder,BEHAVIORAL: Psychotherapy,Technische Universität Dresden,,ALL,"CHILD, ADULT, OLDER_ADULT",210,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2006-01,2007-03,"Department for Clinical Psychology and Psychotherapy; Technical University of Dresden, Dresden, Germany"
NCT00114439,Lithium Cannabis Withdrawal Study,https://clinicaltrials.gov/study/NCT00114439,COMPLETED,NO,Cannabis Dependence|Substance Withdrawal Syndrome,DRUG: Lithium carbonate,Sydney South West Area Health Service,The University of New South Wales,ALL,ADULT,25,OTHER_GOV,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-09,2006-09,"Corella Drug Treatment Service, Fairfield, New South Wales, 2176, Australia"
NCT01555983,Vaporized Cannabis and Spinal Cord Injury Pain,https://clinicaltrials.gov/study/NCT01555983,COMPLETED,YES,Spinal Cord Injuries|Spinal Cord Diseases,DRUG: Vaporization of Cannabis,Barth Wilsey,"VA Northern California Health Care System|University of California, San Diego|National Institute on Drug Abuse (NIDA)",ALL,"ADULT, OLDER_ADULT",42,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-07,2014-08,"UC Davis CTSC Clinical Research Center , Sacramento VA Medical Center, Mather, California, 95655, United States"
NCT03431987,Neuroscience of Alcohol and Marijuana Impaired Driving,https://clinicaltrials.gov/study/NCT03431987,UNKNOWN,NO,Marijuana Usage|Alcohol Drinking,DRUG: One day with a dose of placebo cannabis paired with alcohol|DRUG: One day with a dose of active THC cannabis paired with alcohol,Hartford Hospital,,ALL,ADULT,13,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-07-01,2023-12,"Olin Neuropsychiatry Research Center, Institute of Living, Hartford Hospital, Hartford, Connecticut, 06108, United States"
NCT00682929,Cannabis for Spasticity in Multiple Sclerosis,https://clinicaltrials.gov/study/NCT00682929,TERMINATED,YES,Multiple Sclerosis,DRUG: Inhaled Cannabis|DRUG: Oral THC|DRUG: Oral Placebo|DRUG: Inhaled placebo,"University of California, Davis",National Multiple Sclerosis Society,ALL,"ADULT, OLDER_ADULT",41,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2004-04-14,2011-08-17,"University of California Davis Medical Center, Sacramento, California, 95817, United States"
NCT06548477,Human Albumin for Clinical Outcome in Aneurysmal Subarachnoid Hemorrhages,https://clinicaltrials.gov/study/NCT06548477,RECRUITING,NO,Aneurysmal Subarachnoid Hemorrhage,DRUG: Human albumin,Hamad Medical Corporation,,ALL,"ADULT, OLDER_ADULT",84,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2024-08-01,2027-07-31,"Hamad General Hospital, Doha, Qatar"
NCT03886532,GI Medical Cannabis Study on IBD,https://clinicaltrials.gov/study/NCT03886532,WITHDRAWN,NO,Inflammatory Bowel Diseases|Neuropathic Pain,OTHER: Medical Marijuana,Children's Hospital of Philadelphia,,ALL,"CHILD, ADULT, OLDER_ADULT",0,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-11-01,2020-12-31,
NCT05445180,Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use,https://clinicaltrials.gov/study/NCT05445180,RECRUITING,NO,Psychotic Disorders|Cannabis Use Disorder|Cannabis Dependence|Cannabis Use|Schizophrenia; Psychosis|Cognitive Dysfunction|Memory Impairment|Neuroimaging,BEHAVIORAL: Contingency management,Douglas Mental Health University Institute,,ALL,"CHILD, ADULT, OLDER_ADULT",134,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE,2022-04-21,2027-05,"Douglas Mental Health University Institute, Montréal, Quebec, H4H 1R3, Canada"
NCT06255054,Novel Approaches to Assessing Cannabis Impaired Driving (NAACID),https://clinicaltrials.gov/study/NCT06255054,RECRUITING,NO,Cannabis Use,,Colorado School of Public Health,,ALL,ADULT,130,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-06-20,2025-05,"Driving Study Lab, Denver, Colorado, 80220, United States"
NCT00484302,Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis,https://clinicaltrials.gov/study/NCT00484302,COMPLETED,NO,Marijuana Abuse|Psychotic Disorders|Schizophrenia,BEHAVIORAL: Cognitive behavioral therapy with motivational interviewing|BEHAVIORAL: Non-manualized standard treatment,Bispebjerg Hospital,"Copenhagen Trial Unit, Center for Clinical Intervention Research|Sygekassernes Helsefond|Københavns Kommune|Lundbeck Foundation|Psychiatric Center Copenhagen",ALL,ADULT,103,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-09,2011-01,"Psychiatric Center Copenhagen, Forskningsenheden, Copenhagen, 2400, Denmark"
NCT03111667,A Hybrid Effectiveness-Implementation Trial of a School-Based Teen Marijuana Checkup,https://clinicaltrials.gov/study/NCT03111667,COMPLETED,NO,Cannabis Use,BEHAVIORAL: Teen Marijuana Check Up|OTHER: Treatment as Usual|BEHAVIORAL: Gold Standard Coaching|BEHAVIORAL: As Needed Coaching,University of Washington,,ALL,"CHILD, ADULT, OLDER_ADULT",264,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-05-15,2023-02-28,"University of Washington Innovative Programs Research Group, Seattle, Washington, 98105, United States"
NCT05868213,"Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 1",https://clinicaltrials.gov/study/NCT05868213,COMPLETED,NO,Cannabis|Memory|Electroencephalography,DRUG: Cannabis (smoked flower),"University of Colorado, Boulder",National Institute on Drug Abuse (NIDA),ALL,ADULT,96,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-08-17,2024-12-15,"Center for Innovation and Creativity, Boulder, Colorado, 80301, United States"
NCT00107588,Marijuana Treatment Project - 3,https://clinicaltrials.gov/study/NCT00107588,COMPLETED,NO,Marijuana Dependence,BEHAVIORAL: Reinforcement for homework completion|BEHAVIORAL: Reinforcement for Abstinence|BEHAVIORAL: Case Management,UConn Health,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",215,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2007-02,2012-08,"University of Connecticut Health Center, Farmington, Connecticut, 06030-3910, United States"
NCT04526093,Real-World Evidence in Patient-Reported Outcomes for Medical Cannabis (MC-RWE),https://clinicaltrials.gov/study/NCT04526093,RECRUITING,NO,Pain|Sleep|Anxiety|Depression|Epilepsy,OTHER: Medical Cannabis,"University Health Network, Toronto",Avicanna Inc,ALL,"ADULT, OLDER_ADULT",1000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-07-15,2025-07,"Toronto General Hospital, UHN, Toronto, Ontario, M5G 2C4, Canada"
NCT01611948,Treatment for Cannabis Withdrawal and Dependence,https://clinicaltrials.gov/study/NCT01611948,COMPLETED,YES,Cannabis Dependence,DRUG: Aprepitant|DRUG: Placebo|BEHAVIORAL: Manual-guided behavioral counseling,The Scripps Research Institute,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",70,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-05,2015-10,"The Scripps Research Institute, La Jolla, California, 92037, United States"
NCT02439814,Pregnenolone and Marijuana Dependence,https://clinicaltrials.gov/study/NCT02439814,COMPLETED,YES,Marijuana Dependence,DRUG: Pregnenolone|OTHER: Placebo,Medical University of South Carolina,,ALL,"ADULT, OLDER_ADULT",21,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-06,2016-04,"Medical University of South Carolina, Charleston, South Carolina, 29403, United States"
NCT02579421,Hormones and Reduction in Co-users of Marijuana and Nicotine,https://clinicaltrials.gov/study/NCT02579421,COMPLETED,YES,Marijuana Dependence,DRUG: Progesterone|DRUG: placebo,University of Minnesota,,ALL,ADULT,58,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-11,2017-07-27,"Delaware Clinical Research Unit, University of Minnesota, Minneapolis, Minnesota, 55455, United States"
NCT05486234,CARS: Cannabis and Alcohol Reduction Study,https://clinicaltrials.gov/study/NCT05486234,RECRUITING,NO,"Cannabis Use|Alcohol Use, Unspecified|Substance Use|Substance Use Disorders","BEHAVIORAL: modified Approach-Avoidance Task (mAAT), which aims to modify automatic approach bias|BEHAVIORAL: modified Approach-Avoidance Task (mAAT) that does not aim to modify automatic approach bias.",Medical University of South Carolina,National Institute on Drug Abuse (NIDA),ALL,CHILD,52,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2023-01-25,2026-03,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT03167021,Survey on the Place of Community Pharmacists in the Detection of Cannabis Use: a Student's Point of View,https://clinicaltrials.gov/study/NCT03167021,COMPLETED,NO,Cannabis Use,OTHER: Survey,"University Hospital, Clermont-Ferrand",,ALL,"ADULT, OLDER_ADULT",150,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-04-05,2017-06-02,"CHU Clermont-Ferrand, Clermont-Ferrand, Auvergne, 63003, France"
NCT02711371,Social and Emotional Brain Function in Cannabis Users,https://clinicaltrials.gov/study/NCT02711371,COMPLETED,NO,Cannabis Dependence,OTHER: fMRI,University of Electronic Science and Technology of China,"German Research Foundation|University Hospital, Bonn",ALL,ADULT,43,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-07,2016-12,"University of Bonn / Department of Psychiatry, Bonn, NRW, 53111, Germany"
NCT00046709,Marijuana for Cancer Pain,https://clinicaltrials.gov/study/NCT00046709,TERMINATED,NO,Neoplasms,DRUG: Smoked Marijuana,Center for Medicinal Cannabis Research,"University of California, San Francisco",ALL,"ADULT, OLDER_ADULT",16,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2002-09,2004-10,"University of California, San Francisco, San Francisco, California, 94110, United States"
NCT06236815,High Confusion: Cannabis & Driving,https://clinicaltrials.gov/study/NCT06236815,RECRUITING,NO,"Impairment, Cognitive|Impairment of Attention|Impairment, Psychomotor",DRUG: Delta-9-THC|DRUG: Delta-8-THC|DRUG: Placebo,"University of Wisconsin, Madison",,ALL,ADULT,5,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2025-01-25,2025-04,"University of Wisconsin, Madison, Wisconsin, 53792, United States"
NCT05957848,Guanfacine Extended-release for Adolescents With Cannabis Use,https://clinicaltrials.gov/study/NCT05957848,RECRUITING,NO,Cannabis Use Disorder,DRUG: Guanfacine Extended Release Oral Tablet|BEHAVIORAL: Residential withdrawal|BEHAVIORAL: Engagement with alcohol and other drug services|DRUG: Placebo,Orygen,Youth Support and Advocacy Service|University of Melbourne,ALL,"CHILD, ADULT",100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-07-27,2026-06-30,"Orygen, Parkville, Victoria, 3052, Australia"
NCT00241579,Analgesic Efficacy of Smoked Cannabis,https://clinicaltrials.gov/study/NCT00241579,COMPLETED,NO,Pain|Hyperalgesia,DRUG: Smoked Cannabis,Center for Medicinal Cannabis Research,,ALL,"ADULT, OLDER_ADULT",15,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT,2002-02,2004-01,"UC San Diego Medical Center, San Diego, California, 92093, United States"
NCT03629106,Effects of Cannabis Abstinence on Symptomology and Cognition in Bipolar Disorder,https://clinicaltrials.gov/study/NCT03629106,WITHDRAWN,NO,Cannabis Use Disorder|Bipolar Disorder|Cognition,BEHAVIORAL: Weekly Behavioral Coaching Session,Centre for Addiction and Mental Health,,ALL,ADULT,0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-10-01,2022-08-31,"Centre for Addiction and Mental Health, Toronto, Ontario, M6J1H4, Canada"
NCT05219825,Breathwork-assisted Treatment for Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT05219825,ACTIVE_NOT_RECRUITING,NO,Addiction|Substance Abuse|Cannabis Use Disorder|Cannabis Use|Cannabis Dependence|Cannabis Abuse,BEHAVIORAL: Breathwork workshop,Elias Dakwar,,ALL,"ADULT, OLDER_ADULT",10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-02-06,2025-12-31,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT00678730,Pharmacogenetics of Cannabinoid Response,https://clinicaltrials.gov/study/NCT00678730,COMPLETED,NO,COMT Gene Polymorphism,DRUG: delta 9 tetrahydrocannabinol,Yale University,National Institute on Drug Abuse (NIDA),ALL,ADULT,72,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2007-08-23,2014-09-11,"VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT01118364,Effect of Cannabis on Simulated and Actual Driving in Healthy Subjects,https://clinicaltrials.gov/study/NCT01118364,COMPLETED,NO,Healthy,OTHER: Cannabis|OTHER: tobacco,Assistance Publique Hopitaux De Marseille,,MALE,ADULT,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2010-05,2011-12,"Assistance Hôpitaux de Marseille, Marseille, France"
NCT06570928,Use of a Cannabinoids as a Treatment Strategy for Alzheimer's Disease,https://clinicaltrials.gov/study/NCT06570928,RECRUITING,NO,Alzheimer Disease,OTHER: Cannabis|OTHER: Placebo,Federal University of Latin American Integration,,ALL,"ADULT, OLDER_ADULT",72,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2024-08-13,2025-03-27,"Federal University of Latin American Integration, Foz do Iguaçu, Paraná, 85870-650, Brazil"
NCT05322213,THC Effects on Glucose in Type 2 Diabetes,https://clinicaltrials.gov/study/NCT05322213,NOT_YET_RECRUITING,NO,Type 2 Diabetes,DRUG: THC|DRUG: Placebo,"University of California, San Diego",Center for Medicinal Cannabis Research,ALL,"ADULT, OLDER_ADULT",30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2024-03-01,2027-06-30,"UC San Diego Altman Clinical & Translational Research Institute, La Jolla, California, 92037, United States"
NCT02764827,Comparison of Skin Prick Testing Results of Local and Imported Pollen Allergen Extracts and Specific IgE,https://clinicaltrials.gov/study/NCT02764827,COMPLETED,NO,Immediate Type Hypersensitivity,BIOLOGICAL: Pollen sensitization,Mahidol University,,ALL,ADULT,68,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-11,2016-04,
NCT03251326,Nabilone in Cannabis Users With PTSD,https://clinicaltrials.gov/study/NCT03251326,TERMINATED,YES,Cannabis|Post Traumatic Stress Disorder,DRUG: Nabilone|DRUG: Cannabis|DRUG: Propranolol|DRUG: Placebo,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,ADULT,4,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2015-10,2019-06,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT05554146,Pain Inflammation and Cannabis in HIV,https://clinicaltrials.gov/study/NCT05554146,COMPLETED,NO,HIV Infections|Neuropathic Pain|Cannabis,OTHER: Receipt of Coupon for Placebo Soft-Gel Capsule|OTHER: Receipt of Coupon for High THC Soft-Gel Capsule|OTHER: Receipt of Coupon for Equal THC and CBD Soft-Gel Capsule|OTHER: Receipt of Coupon for High CBD Soft-Gel Capsule,Montefiore Medical Center,"National Institute on Drug Abuse (NIDA)|University of Colorado, Boulder|University of Pittsburgh",ALL,"ADULT, OLDER_ADULT",35,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-10-28,2024-05-03,"Montefiore Health System, Bronx, New York, 10467, United States"
NCT05287256,Comparative Pharmacokinetic and Pharmacodynamic Effects of Delta-8 and Delta-9 THC,https://clinicaltrials.gov/study/NCT05287256,COMPLETED,NO,Behavioral Pharmacology of Cannabis,DRUG: Oral Delta-8-THC Cannabis|DRUG: Oral Delta-9-THC Cannabis|DRUG: Oral Placebo|DRUG: Vaporized Delta-8-THC Cannabis|DRUG: Vaporized Delta-9-THC Cannabis|DRUG: Vaporized Placebo,Johns Hopkins University,Substance Abuse and Mental Health Services Administration (SAMHSA),ALL,ADULT,28,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: BASIC_SCIENCE",2022-05-23,2024-10-02,"Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland, 21224, United States"
NCT02683018,Investigation of Cannabis for Chronic Pain and Palliative Care,https://clinicaltrials.gov/study/NCT02683018,WITHDRAWN,NO,Chronic Pain,DRUG: Smoked Cannabis High CBD/low THC|DRUG: Smoked Placebo Cannabis Low CBD/low THC,New York State Psychiatric Institute,,ALL,ADULT,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",,2021-10-28,
NCT05294263,Varenicline for the Treatment of Cannabis and Tobacco Use Disorders in Veterans,https://clinicaltrials.gov/study/NCT05294263,WITHDRAWN,NO,Tobacco Use Disorder|Cannabis Use Disorder,DRUG: Varenicline|DRUG: Placebo,VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",0,FED,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-04-17,2024-07-17,"Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, 29401-5703, United States"
NCT00838448,Interactions Between Physical Activity and Cannabis Use in Adults,https://clinicaltrials.gov/study/NCT00838448,COMPLETED,NO,Cannabis Dependence,BEHAVIORAL: Exercise,Vanderbilt University,,ALL,ADULT,30,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2009-01,2013-06,"Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States"
NCT01394185,Effects of Dronabinol (Oral THC) on Cannabis Use,https://clinicaltrials.gov/study/NCT01394185,COMPLETED,YES,Marijuana Smoking,DRUG: Dronabinol 120mg/day|DRUG: Placebo|DRUG: Dronabinol 240mg/day,Johns Hopkins University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",25,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2011-02,2012-09,"Johns Hopkins University (Bayview Campus), Baltimore, Maryland, 21224, United States"
NCT03639064,Cannabis Oil for Pain in Parkinson's Disease,https://clinicaltrials.gov/study/NCT03639064,UNKNOWN,NO,Parkinson Disease,DRUG: Cannabis Oil,"University Health Network, Toronto",Parkinson Society Canada,ALL,"ADULT, OLDER_ADULT",15,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-01,2022-12,"Parkinson's Disease and Movement Disorders Clinic - Ottawa Hospital Research Institute, Ottawa, Ontario, K1Y 4E9, Canada|Movement Disorders Clinic, Toronto Western Hospital, 399, Bathurst St, Toronto, Ontario, M5V 2T8, Canada"
NCT05664763,Understanding Effects of Cannabis Use and Abstinence on Neural Glutamate Homeostasis,https://clinicaltrials.gov/study/NCT05664763,TERMINATED,NO,Cannabis Use Disorder,DRUG: [18F]FPEB with PET|BEHAVIORAL: Cannabis abstinence,Yale University,National Institute on Drug Abuse (NIDA),ALL,ADULT,6,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-03-01,2024-07-12,"The Anlyan Center, New Haven, Connecticut, 06510, United States"
NCT01686022,Grass Sensitisation and Allergic Rhinitis in Thai Patients,https://clinicaltrials.gov/study/NCT01686022,COMPLETED,NO,Allergy to Grass Pollen|Allergic Rhinitis Due to Weed Pollens,OTHER: Immunoblot,Mahidol University,National Research Council of Thailand,ALL,"CHILD, ADULT",40,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-10,2015-10,"Siriraj Hospital, Bangkoknoi, Bangkok, 10700, Thailand"
NCT05451017,The Effect of Food on the Oral Bioavailability of AEF0117 in Healthy Volunteers,https://clinicaltrials.gov/study/NCT05451017,TERMINATED,NO,Marijuana Abuse,DRUG: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition|DRUG: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition,Aelis Farma,National Institute on Drug Abuse (NIDA),ALL,ADULT,24,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-01-04,2023-06-28,"Substance Use Research Center, New York, New York, 10032, United States"
NCT00842985,Dronabinol Interactions With Cognitive Enhancing Drug in Humans,https://clinicaltrials.gov/study/NCT00842985,COMPLETED,YES,Cannabis|Marijuana Abuse,DRUG: drug condition,Yale University,VA Office of Research and Development|National Institute on Drug Abuse (NIDA),ALL,ADULT,53,OTHER,INTERVENTIONAL,Allocation: |Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2008-09,2009-10,"Department of Veterans Affairs Hospital, West Haven, Connecticut, 06516, United States"
NCT03994640,Myorelaxant Effect of Cannabis Cream Topical Skin Application in Patients With TMD,https://clinicaltrials.gov/study/NCT03994640,COMPLETED,NO,Temporomandibular Disorder|Myofascial Pain|Cannabis|Electromyography,COMBINATION_PRODUCT: Cannabis Cream|COMBINATION_PRODUCT: Placebo Cream,Medical University of Silesia,,ALL,ADULT,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2018-01-01,2019-01-01,"Department of TMD Silesian Medical University, Zabrze, 41-800, Poland"
NCT06235632,Responsible Marijuana Sales Practices to Reduce the Risk of Selling to Intoxicated Customers,https://clinicaltrials.gov/study/NCT06235632,NOT_YET_RECRUITING,NO,Alcoholic Intoxication|Automobile Accident|Cannabis,BEHAVIORAL: Policy and Training Intervention|BEHAVIORAL: Usual and Customary Policy and Training (UC-PT) (Control) Condition,"Klein Buendel, Inc.",National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Pacific Institute for Research and Evaluation|National Opinion Research Center,ALL,"ADULT, OLDER_ADULT",229,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2025-01-15,2027-08-31,"Klein Buendel, Inc., Golden, Colorado, 80401, United States"
NCT00046722,Marijuana for HIV-Related Peripheral Neuropathy,https://clinicaltrials.gov/study/NCT00046722,COMPLETED,NO,Peripheral Nervous System Diseases|HIV Infections,DRUG: Smoked Marijuana,Center for Medicinal Cannabis Research,,ALL,"ADULT, OLDER_ADULT",50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2003-01,2005-04,"University of California, San Francisco Community Consortium, San Francisco, California, 94110, United States"
NCT00713323,A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.,https://clinicaltrials.gov/study/NCT00713323,COMPLETED,YES,Pain|Peripheral Neuropathy,DRUG: Sativex®,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",380,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2005-10,2007-06,"Pain Management Research, Clinical Trials Unit, Netherwood House, Solihull Hospital, Solihull, West Midlands, B91 2JL,, United Kingdom"
NCT00360191,A Placebo-Controlled Trial of Buspirone for Treatment of Marijuana Dependence,https://clinicaltrials.gov/study/NCT00360191,COMPLETED,NO,Marijuana Abuse,DRUG: Buspirone|PROCEDURE: Motivational enhancement therapy,Medical University of South Carolina,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",81,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE|Primary Purpose: TREATMENT,2004-04,2007-12,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT01204723,Medications Development for the Treatment of Cannabis Related Disorders,https://clinicaltrials.gov/study/NCT01204723,COMPLETED,NO,Nicotine Withdrawal|Marijuana Dependence|Cannabis Dependence|Nicotine Dependence|Cannabis Abuse,DRUG: Placebo Aprepitant|DRUG: Active Aprepitant,University of Virginia,National Institute on Drug Abuse (NIDA),ALL,ADULT,63,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2009-08,2012-04,"Clinical Pharmacological Research Unit (CPRU), University of Virginia School of Medicine, Charlottesville, Virginia, 22903, United States|University of Virginia Center for Addiction Education and Treatment (UVA CARE), Charlottesville, Virginia, 22908, United States"
NCT05615389,Pilot Study of MC in Paediatric Palliative Care,https://clinicaltrials.gov/study/NCT05615389,RECRUITING,NO,Palliative Care,DRUG: Medicinal Cannabis - C12T12|DRUG: Medicinal Cannabis - C20T5,Murdoch Childrens Research Institute,,ALL,"CHILD, ADULT",10,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2024-02-19,2025-12,"Royal Children's Hospital / Murdoch Children's Research Institute, Parkville, Victoria, 3052, Australia"
NCT00498550,Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual,https://clinicaltrials.gov/study/NCT00498550,COMPLETED,YES,Schizophrenia|Dual Diagnosis|Schizoaffective Disorder|Psychotic Disorder|Cannabis Abuse,DRUG: Clozapine|DRUG: Treatment as usual,Dartmouth-Hitchcock Medical Center,"National Institute on Drug Abuse (NIDA)|University of Missouri, Kansas City|VA Medical Center-West Los Angeles|University of South Carolina",ALL,"ADULT, OLDER_ADULT",31,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2000-10,2009-03,"West LA VAHCS, Los Angeles, California, 90073, United States|University Missouri, Kansas City, Missouri, 64108, United States|Mental Health Center of Greater Manchester, Manchester, New Hampshire, 03101, United States|University South Carolina, Columbia, South Carolina, 29203, United States"
NCT06660381,Psilocybin-assisted Treatment for Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT06660381,RECRUITING,NO,Cannabis Use Disorder,DRUG: Psilocybin,Johns Hopkins University,Center for Psychedelic and Consciousness Research,ALL,"ADULT, OLDER_ADULT",12,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-11-08,2026-09,"Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, 21224, United States"
NCT01467999,Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence,https://clinicaltrials.gov/study/NCT01467999,COMPLETED,YES,Cannabis Dependence,DRUG: Guanfacine,New York State Psychiatric Institute,,ALL,ADULT,22,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-02,2016-10,"STARS, New York, New York, 10032, United States"
NCT03055377,N-Acetylcysteine for Youth Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT03055377,COMPLETED,YES,Cannabis Use Disorder,DRUG: N-acetyl cysteine|DRUG: Placebo oral capsule,Medical University of South Carolina,,ALL,"CHILD, ADULT",192,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-08-03,2024-02-26,"Medical University of South Carolina, Charleston, South Carolina, 29403, United States"
NCT06124846,Determining the Effect of Six Weeks of Cannabis Abstinence on Fronto- Striatal fMRI Markers in Adolescents With Cannabis Use Disorder (ABSCAN),https://clinicaltrials.gov/study/NCT06124846,RECRUITING,NO,Cannabis Use Disorder,BEHAVIORAL: CB-Abst|BEHAVIORAL: CB-Mon,University of Minnesota,,ALL,"CHILD, ADULT",64,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2024-04-01,2028-04-15,"University of Minnesota, Minneapolis, Minnesota, 55414, United States"
NCT02277665,Clinical Trial Tobacco Marijuana,https://clinicaltrials.gov/study/NCT02277665,COMPLETED,YES,Cannabis Use Disorder|Tobacco Use Disorder,BEHAVIORAL: CUD Treatment|BEHAVIORAL: Tobacco Treatment,Dartmouth-Hitchcock Medical Center,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",67,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-12-18,2017-01-18,"Geisel School of Medicine at Dartmouth; State Building Site, Concord, New Hampshire, 03301, United States|Geisel School of Medicine at Dartmouth; Rivermill Complex Site, Lebanon, New Hampshire, 03766, United States|University of Washington School of Social Work, Seattle, Washington, 98105, United States"
NCT05261321,Cannabis and Polysubstance Use: Response Inhibition and Stress Exposure,https://clinicaltrials.gov/study/NCT05261321,RECRUITING,NO,Healthy,DRUG: Cannabis oil with a high ratio of THC to CBD|DRUG: Cannabis oil with a high ratio of CBD to THC|DRUG: Placebo,University of British Columbia,,ALL,ADULT,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2022-10-15,2024-12,"B.R.A.I.N. Lab, Institute of Mental Health, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, V6T 1Z3, Canada"
NCT00131456,Free Venlafaxine Treatment for Marijuana Addiction and Depression - 1,https://clinicaltrials.gov/study/NCT00131456,COMPLETED,YES,Depression|Marijuana Abuse,DRUG: Venlafaxine|DRUG: Placebo,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,ADULT,123,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2004-03,2010-12,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT00248378,Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis,https://clinicaltrials.gov/study/NCT00248378,COMPLETED,NO,Multiple Sclerosis,DRUG: Smoked Cannabis,Center for Medicinal Cannabis Research,,ALL,"ADULT, OLDER_ADULT",30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT,2001-09,2005-03,"UC San Diego Medical Center, San Diego, California, 92093, United States"
NCT01874886,Cannabis Effects on Brain Morphology in Aging,https://clinicaltrials.gov/study/NCT01874886,COMPLETED,NO,Study Focuses on Brain Morphology and Cognition in Older Subjects,,"University of California, Los Angeles",National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-01,2019-04,"UCLA Semel/Resnick Neuropsychiatric Institute, Los Angeles, California, 90095, United States"
NCT00149617,Effectiveness of Buspirone and Motivational Enhancement Therapy for the Treatment of Marijuana Dependence - 1,https://clinicaltrials.gov/study/NCT00149617,COMPLETED,NO,Marijuana Abuse|Mood Disorders,DRUG: Buspirone,Medical University of South Carolina,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",81,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2004-04,2007-12,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT01538225,Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity,https://clinicaltrials.gov/study/NCT01538225,COMPLETED,NO,Multiple Sclerosis,DRUG: Sativex®|DRUG: Placebo,"Almirall, S.A.",,ALL,"ADULT, OLDER_ADULT",45,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-04,2013-11,"Institute of Experimental Neurology, Milan, 20132, Italy"
NCT02892591,Cannabis Versus Oxycodone for Pain Relief,https://clinicaltrials.gov/study/NCT02892591,COMPLETED,NO,Back Pain|Neck Pain,DRUG: Cannabis|DRUG: Oxycodone|DRUG: Placebo for Cannabis|DRUG: Placebo for Oxycodone,"University of Colorado, Denver",,ALL,"ADULT, OLDER_ADULT",33,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-06-01,2023-06-07,"University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, United States"
NCT00543036,Efficacy and Safety of the Hcoil Deep TMS for the Treatment of Cannabis Addiction,https://clinicaltrials.gov/study/NCT00543036,UNKNOWN,NO,Marijuana Abuse,DEVICE: H-Coil deep TMS,Shalvata Mental Health Center,,ALL,"ADULT, OLDER_ADULT",,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",,,"Shalvata Mental Health Center, Hod-HaSharon, 45100, Israel"
NCT05720312,Investigating Two rTMS Strategies to Treat Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT05720312,COMPLETED,NO,Cannabis Use Disorder,DEVICE: Repetitive Transcranial Magnetic Stimulation (rTMS),Stanford University,,ALL,ADULT,22,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07-01,2024-07-01,"Stanford University, Palo Alto, California, 94304, United States"
NCT01031290,Pilot Study Repetitive Transcranial Magnetic Stimulation (rTMS) in Cannabis Craving,https://clinicaltrials.gov/study/NCT01031290,WITHDRAWN,NO,Cannabis Use,DEVICE: Repetitive Transcranial Magnetic Stimulation,National Institute on Drug Abuse (NIDA),University of Maryland,ALL,"ADULT, OLDER_ADULT",0,NIH,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2009-08-19,2012-02-27,"Maryland Psychiatric Research Center (MPRC) 55 Wade Avenue, Catonsville, Maryland, 21228, United States"
NCT03485274,Substance Misuse To Psychiatric Disorders for Cannabis,https://clinicaltrials.gov/study/NCT03485274,COMPLETED,NO,Cannabis Use Disorder|Depressive State|Anxiety State|Depression|Anxiety Disorders|Pharmacotherapy,DRUG: Vortioxetine|OTHER: Treatment as Usual,The University of Hong Kong,"Queen Mary Hospital, Hong Kong",ALL,"CHILD, ADULT",37,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-07-25,2023-04-30,"Queen Mary Hospital, Hong Kong, 000000, Hong Kong"
NCT06747039,Cannabis Extract in Fibromyalgia Syndrome - the SUNRISE Study,https://clinicaltrials.gov/study/NCT06747039,RECRUITING,NO,Fibromyalgia (FM),,I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio,,ALL,"ADULT, OLDER_ADULT",38,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-12-05,2025-12,"IRCCS Ospedale Galeazzi-Sant'Ambrogio, Milano, 20157, Italy"
NCT04847388,Prevalence of Substance Abuse Among Anti-retroviral Treatment Naive Patients Positive for HIV Antibodies,https://clinicaltrials.gov/study/NCT04847388,COMPLETED,NO,HIV Infections,"DRUG: Substance like alcohol, marijuana, etc.","Singh, Ranjan Kumar, M.D.",,ALL,"CHILD, ADULT, OLDER_ADULT",210,INDIV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-04-01,2022-03-15,"ART centre, Sadar Hospital, Khagaria, Bihar, 851204, India"
NCT02801214,Emotional Brain Processes in Recreational Cannabis Users,https://clinicaltrials.gov/study/NCT02801214,COMPLETED,NO,Recreational Cannabis Use,OTHER: fMRI,University of Electronic Science and Technology of China,"German Research Foundation|University Hospital, Bonn",MALE,ADULT,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-05,2016-12,
NCT01511640,Behavioral Effects of Pregabalin and Cannabis,https://clinicaltrials.gov/study/NCT01511640,COMPLETED,YES,Cannabis-use Disorders,DRUG: Pregabalin|DRUG: Placebo,"Joshua A. Lile, Ph.D.",,ALL,ADULT,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2017-02-01,2020-03-15,"Laboratory of Human Behavioral Pharmacology, Lexington, Kentucky, 40536-0086, United States"
NCT05494437,Effect of PP-01 on Cannabis Withdrawal Syndrome,https://clinicaltrials.gov/study/NCT05494437,COMPLETED,NO,Cannabis Withdrawal,COMBINATION_PRODUCT: PP-01 High Dose|COMBINATION_PRODUCT: PP-01 Low Dose|DRUG: Placebo|DRUG: Nabilone|DRUG: Gabapentin,"PleoPharma, Inc.",,ALL,ADULT,234,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-10-27,2023-08-21,"Behavioral Research Specialists, LLC, Glendale, California, 91206, United States|Synergy San Diego, Lemon Grove, California, 91945, United States|Neuropsychiatric Research Institute, Orange, California, 92868, United States|CNS Clinical Research Group, Coral Springs, Florida, 33067, United States|Gulf Coast Clinical Research, Fort Myers, Florida, 33912, United States|Innovative Clinical Research Inc., Lauderhill, Florida, 33319, United States|CenExel iResearch Atlanta, LLC, Decatur, Georgia, 30030, United States|CenExel iResearch Savannah, LLC, Savannah, Georgia, 31405, United States|Pillar Clinical Research, LLC, Chicago, Illinois, 60641, United States|Otrimed Research Center, Edgewood, Kentucky, 41017, United States|Tandem Clinical Research, Marrero, Louisiana, 70072, United States|Benchmark Research, Shreveport, Louisiana, 71101, United States|Hassman Research Institute, Berlin, New Jersey, 08009, United States|North Star Medical Research, Middleburg Heights, Ohio, 44130, United States|Pahl Pharmaceutical Professionals LLC, Oklahoma City, Oklahoma, 73112, United States|Medical University of South Carolina, Charleston, South Carolina, 29403, United States|Austin Clinical Trials, Austin, Texas, 78744, United States|Cedar Clinical Research, Draper, Utah, 84020, United States"
NCT03233633,Marijuana in Combination With Opioids in Palliative and Hospice Patients,https://clinicaltrials.gov/study/NCT03233633,COMPLETED,YES,Pain,DRUG: Medical Marijuana,The Connecticut Hospice Inc.,,ALL,"ADULT, OLDER_ADULT",66,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2017-05-10,2022-08-05,"The Connecticut Hospice Inc., Branford, Connecticut, 06405, United States"
NCT05292547,Repetitive Transcranial Magnetic Stimulation to People With Cannabis Use Disorder (SToP-C-rTMS x CUD),https://clinicaltrials.gov/study/NCT05292547,RECRUITING,NO,Cannabis Use Disorder|Repetitive Transcranial Magnetic Stimulation,DEVICE: Repetitive Transcranial Magnetic Stimulation,The University of Hong Kong,,ALL,"ADULT, OLDER_ADULT",18,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-01,2026-01-01,"Queen Mary Hospital, Hong Kong, 000000, Hong Kong"
NCT05554926,Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects,https://clinicaltrials.gov/study/NCT05554926,COMPLETED,NO,Marijuana Abuse,DRUG: AEF0117,Aelis Farma,,MALE,"ADULT, OLDER_ADULT",8,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-12-16,2023-02-24,"Labcorp Clinical Research Unit Inc., Madison, Wisconsin, 53704, United States"
NCT04114903,Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity,https://clinicaltrials.gov/study/NCT04114903,COMPLETED,NO,Type 2 Diabetes|Obesity|Cannabis Use|Insulin Sensitivity,OTHER: Study A: Single use of cannabis flower product|OTHER: Study B: Ad libitum cannabis use for four weeks or no cannabis use,"University of Colorado, Boulder","University of Colorado, Denver",ALL,ADULT,255,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-11-08,2024-12-01,"Center for Innovation and Creativity, Boulder, Colorado, 80301, United States"
NCT05726617,Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders,https://clinicaltrials.gov/study/NCT05726617,ACTIVE_NOT_RECRUITING,NO,Psychotic Disorders|Cannabis Use Disorder|Mental Health Disorder,BEHAVIORAL: Avatar Intervention,Ciusss de L'Est de l'Île de Montréal,,ALL,"ADULT, OLDER_ADULT",32,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-09-24,2024-12-31,"Research center of the Institut universitaire en santé mentale de Montréal, Montréal, Quebec, H1N 3M5, Canada"
NCT05873465,Cannabis Use on Sedation for Oral Surgery Procedures,https://clinicaltrials.gov/study/NCT05873465,RECRUITING,NO,Cannabis Use,"DRUG: Sedation with Midazolam, Fentanyl, and Propofol|PROCEDURE: Extraction of teeth",University of Oklahoma,,ALL,"ADULT, OLDER_ADULT",60,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-03-14,2025-06-30,"College of Dentistry, Oklahoma City, Oklahoma, 73117, United States"
NCT05432284,Behavioral Pharmacology of THC and Beta-Myrcene,https://clinicaltrials.gov/study/NCT05432284,NOT_YET_RECRUITING,NO,Cannabis Use,DRUG: Placebo|DRUG: THC|DRUG: Beta-Myrcene,Johns Hopkins University,National Institute on Drug Abuse (NIDA),ALL,ADULT,32,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2025-04,2025-11,"Johns Hopkins School of Medicine Behavioral Pharmacology Research Unit, Baltimore, Maryland, 21224, United States"
NCT05859347,Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT05859347,RECRUITING,NO,Cannabis Use Disorder,DEVICE: Repetitive Transcranial Magnetic Stimulation,Centre for Addiction and Mental Health,Brain & Behavior Research Foundation,ALL,"ADULT, OLDER_ADULT",46,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-05-15,2025-06-15,"Centre for Addiction and Mental Health, Toronto, Ontario, M6J 1H4, Canada"
NCT04595318,Varenicline for Co-occurring Cannabis and Tobacco Use,https://clinicaltrials.gov/study/NCT04595318,COMPLETED,YES,Cannabis Dependence|Tobacco Dependence,"DRUG: Standard clinical care first, followed by standard clinical care and varenicline|DRUG: Standard clinical care and varenicline first, followed by standard clinical care",Albert Einstein College of Medicine,National Institute on Drug Abuse (NIDA)|National Institute of General Medical Sciences (NIGMS),ALL,"ADULT, OLDER_ADULT",7,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2015-01,2015-07,
NCT06239350,Young Adult Tobacco/Nicotine and Cannabis Co-use,https://clinicaltrials.gov/study/NCT06239350,RECRUITING,NO,Tobacco Use Disorder|Nicotine Dependence,BEHAVIORAL: Counseling|BEHAVIORAL: Contingency management|BEHAVIORAL: Text-based support,Medical University of South Carolina,National Cancer Institute (NCI),ALL,ADULT,350,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-05-13,2029-01-01,"Medical University of South Carolina - Charleston, Charleston, South Carolina, 29403, United States"
NCT01212081,Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality,https://clinicaltrials.gov/study/NCT01212081,COMPLETED,NO,Cannabis Use,,National Institute on Drug Abuse (NIDA),,ALL,ADULT,17,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-09-26,2012-11-26,"Maryland Psychiatric Research Center (MPRC) 55 Wade Avenue, Catonsville, Maryland, 21228, United States"
NCT02955329,Vaping THC From Electronic Cigarettes,https://clinicaltrials.gov/study/NCT02955329,COMPLETED,YES,Marijuana Dependence,DRUG: Nicotine|DRUG: Cannabis|DEVICE: PAX Loose Leaf Vaporizer,"University of California, San Francisco",National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",8,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2019-03-20,2019-11-30,"Zuckerberg San Francisco General Hospital, San Francisco, California, 94110, United States"
NCT05273567,A Trial of Guanfacine-er for Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT05273567,COMPLETED,NO,Cannabis Use,DRUG: guanfacine-ER|OTHER: Placebo,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",22,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-06-01,2024-07-31,"STARS Clinic at Columbia and NYSPI Department of Psychiatry, New York, New York, 10017, United States"
NCT02460692,Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain,https://clinicaltrials.gov/study/NCT02460692,COMPLETED,YES,Cannabis|Low Back Pain|Neuropathic Pain,DRUG: Placebos|DRUG: dronabinol|DRUG: Vaporized Cannabis 3.7% THC/5.6% CBD,"University of California, San Diego",National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",131,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-12,2020-03-25,"UC Center for Medicinal Cannabis Research, UC San Diego, San Diego, California, 92103, United States"
NCT06601218,Impact of Daily Oral Cannabis Doses in Patients With Cancer,https://clinicaltrials.gov/study/NCT06601218,NOT_YET_RECRUITING,NO,"Cancer|Cancers, Pain",DRUG: Oral cannabis low THC|DRUG: Placebo Comparator|DRUG: Oral cannabis high THC|DRUG: Oral cannabis THC/CBD,"Shanna Babalonis, PhD",,ALL,"ADULT, OLDER_ADULT",80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2025-03-24,2029-06-01,"University of Kentucky, Lexington, Kentucky, 40508, United States"
NCT05396638,Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT05396638,RECRUITING,NO,Cannabis Use,BEHAVIORAL: Contingency Management,"University of Colorado, Denver",Colorado Clinical & Translational Sciences Institute,ALL,"CHILD, ADULT",30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-10-13,2025-12,"University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, United States"
NCT01793961,Effects of Chronic Intake of Cannabis on Contrast Sensitivity,https://clinicaltrials.gov/study/NCT01793961,COMPLETED,NO,Cannabis Dependence,OTHER: electroretinogram|OTHER: contrast sensitivity tests,"University Hospital, Strasbourg, France",,ALL,ADULT,95,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2013-03-22,2018-09-10,
NCT05328362,CanCope: Digital Intervention for Coping With Cannabis Craving,https://clinicaltrials.gov/study/NCT05328362,COMPLETED,YES,Cannabis Use,BEHAVIORAL: CanCope,Trustees of Dartmouth College,University of Michigan,ALL,ADULT,53,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-08-27,2021-12-16,"Center for Technology and Behavioral Health, Lebanon, New Hampshire, 03766, United States"
NCT02801422,Neural Indices Associated With Relapse in Cannabis Dependence,https://clinicaltrials.gov/study/NCT02801422,UNKNOWN,NO,Cannabis Dependence,OTHER: fMRI,University of Electronic Science and Technology of China,"German Research Foundation|University Hospital, Bonn",ALL,ADULT,75,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-02,2019-03,"University of Bonn, Bonn, North Rhine Westfalia, 53127, Germany"
NCT02088177,Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence,https://clinicaltrials.gov/study/NCT02088177,COMPLETED,YES,Cannabis Dependence,DRUG: Long-acting injectable naltrexone,New York State Psychiatric Institute,,ALL,ADULT,12,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-10,2016-03,"STARS Downtown, Columbia-Presbyterian and New York State Psychiatric Institute, New York, New York, 10019, United States|STARS clinic, Columbia-New York Presbyterian and New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT05368129,Safety and Efficacy of POT PTCA Balloon Dilatation Catheter for the Optimal Dilation After DES Implantation,https://clinicaltrials.gov/study/NCT05368129,COMPLETED,NO,Coronary Artery Disease,PROCEDURE: Balloon dilation,"Nanjing First Hospital, Nanjing Medical University","BrosMed Medical Co., Ltd",ALL,"ADULT, OLDER_ADULT",48,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-06-08,2023-12-30,"Nanjing First Hospital, Nanjing, Jiangsu, 210006, China"
NCT04860089,"Pain, Inflammation, and Cannabis in HIV",https://clinicaltrials.gov/study/NCT04860089,WITHDRAWN,NO,HIV Infections|Neuropathic Pain|Cannabis,,Montefiore Medical Center,"National Institute on Drug Abuse (NIDA)|University of Colorado, Boulder|University of Pittsburgh|Vireo Health",ALL,"ADULT, OLDER_ADULT",0,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-08,2025-06-30,
NCT05114460,Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal,https://clinicaltrials.gov/study/NCT05114460,TERMINATED,NO,Opioid Overdose,DRUG: Naloxone|DRUG: Marijuana,New York State Psychiatric Institute,,ALL,ADULT,2,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2021-11-01,2024-10-29,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT00142870,Effectiveness of Bupropion in Treating Marijuana Dependent Individuals,https://clinicaltrials.gov/study/NCT00142870,COMPLETED,NO,Marijuana Abuse|Substance-Related Disorders,DRUG: Bupropion,National Institute on Drug Abuse (NIDA),,ALL,ADULT,30,NIH,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-03,2006-05,"McLean Hospital, Dept. of Psychiatry, Belmont, Massachusetts, 02478 9106, United States"
NCT05512091,Characterization of the Pattern of Consumption and Withdrawal Syndrome From Dual Cannabis and Tobacco Use,https://clinicaltrials.gov/study/NCT05512091,NOT_YET_RECRUITING,NO,Cannabis Dependence|Tobacco Use|Withdrawal Syndrome|Substance Abuse,,Cristina Martínez Martínez,Hospital Clinic of Barcelona|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|University of Barcelona|Public Health Agency of Barcelona,ALL,"ADULT, OLDER_ADULT",282,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-07,2025-12,
NCT03172741,The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis,https://clinicaltrials.gov/study/NCT03172741,WITHDRAWN,NO,Multiple Sclerosis,DRUG: Medical Marijuana|DRUG: Placebo,Colorado State University,,ALL,"ADULT, OLDER_ADULT",0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2017-01,2018-01,
NCT03334721,Gabapentin for Bipolar & Cannabis Use Disorders,https://clinicaltrials.gov/study/NCT03334721,COMPLETED,YES,Bipolar I Disorder|Bipolar II Disorder|Cannabis Use Disorder|Substance Use Disorders,DRUG: Gabapentin|DRUG: Placebo Oral Capsule,Medical University of South Carolina,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",23,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2017-10-01,2019-07-01,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT01335789,Effect of Oxytocin on Stress in Marijuana Users,https://clinicaltrials.gov/study/NCT01335789,COMPLETED,YES,Marijuana Dependence,DRUG: Oxytocin|DRUG: Saline,Medical University of South Carolina,,ALL,"ADULT, OLDER_ADULT",16,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-03,2012-07,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT06037681,Cannabis Use and Outcomes in Black and White Patients With Cancer,https://clinicaltrials.gov/study/NCT06037681,RECRUITING,NO,Cancer,,State University of New York at Buffalo,University of Pennsylvania|Thomas Jefferson University,ALL,"ADULT, OLDER_ADULT",600,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-03-30,2027-03-30,"University at Buffalo, Buffalo, New York, 14214, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19144, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19176, United States"
NCT06597097,Evaluation of Interprofessional Relations Between Primary Care and Hospital Centers in the Experimentation of Medical Cannabis in France Carried Out by the ANSM (ECIPCanna),https://clinicaltrials.gov/study/NCT06597097,ENROLLING_BY_INVITATION,NO,Medical Cannabis,,"University Hospital, Brest",,ALL,"ADULT, OLDER_ADULT",108,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-10-01,2026-12-31,"Chu Brest, Brest, 29609, France"
NCT05824754,An App to Reduce Cannabis Use Among Emerging Adults,https://clinicaltrials.gov/study/NCT05824754,COMPLETED,NO,Cannabis Use,OTHER: Just-In-Time-Adaptive-Intervention (JITAI),University of Michigan,National Institute on Drug Abuse (NIDA),ALL,ADULT,122,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2024-02-21,2024-05-28,"University of Michigan, Ann Arbor, Michigan, 48109, United States"
NCT04517474,"Comparing the Spanish Version of CANreduce With or Without Psychological Support and Treatment as Usual, Reducing Cannabis Use.",https://clinicaltrials.gov/study/NCT04517474,UNKNOWN,NO,Cannabis Use Disorder,BEHAVIORAL: CANreduce|BEHAVIORAL: psychological support,Parc de Salut Mar,"Research Institute for Public Health and Addiction, Switzerland",ALL,"ADULT, OLDER_ADULT",300,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-11-10,2022-12-01,"Juan-Ignacio Mestre-Pinto, Barcelona, Catalunya, 08003, Spain"
NCT01037608,"Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation",https://clinicaltrials.gov/study/NCT01037608,COMPLETED,NO,Cannabis|Dependence|Cannabis Abuse|Pharmacokinetics|fMRI,DRUG: Sativex(Registered Trademark)|DRUG: THC,National Institute on Drug Abuse (NIDA),,ALL,ADULT,108,NIH,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: OTHER,2007-05-08,2011-12-12,"National Institute on Drug Abuse, Biomedical Research Center (BRC), Baltimore, Maryland, 21224, United States"
NCT04373525,Prospective Evaluation on Cognitive Function and Its Associated Genetic Vulnerability in Cannabis Users,https://clinicaltrials.gov/study/NCT04373525,ENROLLING_BY_INVITATION,NO,Cannabis Use|Neurocognitive Dysfunction|Genetic Predisposition,OTHER: Genome analysis,The University of Hong Kong,,ALL,"CHILD, ADULT",136,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-11-01,2025-08-31,"Queen Mary Hospital, Hong Kong, 000000, Hong Kong"
NCT04935619,Extended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression,https://clinicaltrials.gov/study/NCT04935619,RECRUITING,NO,Cannabis Use|Major Depressive Disorder|Cognitive Impairment,BEHAVIORAL: Contingency Reinforcement|BEHAVIORAL: Non-Contingency Reinforcement,Centre for Addiction and Mental Health,,ALL,ADULT,52,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-07-21,2025-08-31,"Centre for Addiction and Mental Health, Toronto, Ontario, M5T 1R8, Canada"
NCT06490445,A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP),https://clinicaltrials.gov/study/NCT06490445,NOT_YET_RECRUITING,NO,Diabetic Peripheral Neuropathic Pain,DRUG: Medical Cannabis|DRUG: Placebo,Syqe Medical,,ALL,"ADULT, OLDER_ADULT",192,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-07-18,2025-11-08,"Clinical Republican Hospital \""Timofei Mosneaga\"", ARENSIA E.M., Chisinau, 2025, Moldova, Republic of"
NCT04055662,A Comparison of Post-Operative Analgesia Requirements In Recreational Cannabis Users Versus Cannabis Naïve Inflammatory Bowel Disease Patients,https://clinicaltrials.gov/study/NCT04055662,COMPLETED,NO,"Cannabis Use, Opioid Consumption",,"Mount Sinai Hospital, Canada",,ALL,"ADULT, OLDER_ADULT",100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-08-01,2020-03-30,"Sinai Health System, Toronto, Ontario, M5G1X2, Canada"
NCT06206941,IMmunotherapy: Prospective Assessment of Cannabis Treatment in Cancer,https://clinicaltrials.gov/study/NCT06206941,NOT_YET_RECRUITING,NO,Cancer,,State University of New York at Buffalo,Thomas Jefferson University|Oregon Health and Science University,ALL,"ADULT, OLDER_ADULT",450,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-12-30,2027-12-31,"Oregon Health and Science University, Portland, Oregon, 97239, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States"
NCT00202423,Use of Cannabinoids in Patients With Multiple Sclerosis,https://clinicaltrials.gov/study/NCT00202423,UNKNOWN,NO,Multiple Sclerosis,DRUG: Sativex,S. Andrea Hospital,University of Roma La Sapienza,ALL,ADULT,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT,2005-07,,"Department of Neurology- University of Rome la Sapienza, Rome, 00185, Italy"
NCT06055309,Behavioral Pharmacology of Cannabis in Older Adults,https://clinicaltrials.gov/study/NCT06055309,NOT_YET_RECRUITING,NO,Health Services for the Aged,DRUG: Cannabis (up to three doses),University of Arkansas,,ALL,"ADULT, OLDER_ADULT",5,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2025-03-31,2025-06-30,"University of Arkansas for Medical Science, Little Rock, Arkansas, 72205, United States"
NCT05663346,"Cannabis and Cancer, an Online Training for Oncology Nurses",https://clinicaltrials.gov/study/NCT05663346,ACTIVE_NOT_RECRUITING,NO,"Cannabis Use|Cannabis Use, Unspecified|Nurse's Role|Oncology Pain|Symptoms and Signs",OTHER: Cannabis & Cancer digital educational intervention|OTHER: Standard information regarding cannabis use in oncology,Ciusss de L'Est de l'Île de Montréal,,ALL,"ADULT, OLDER_ADULT",70,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2024-01-04,2024-11,"Hôpital Maisonneuve-Rosemont, Montréal, Quebec, H1T 2M4, Canada"
NCT06114212,Deep Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT06114212,RECRUITING,NO,Cannabis Use Disorder,DEVICE: dTMS stimulation via the H4 coil,St. Joseph's Healthcare Hamilton,,ALL,"ADULT, OLDER_ADULT",10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2024-03-26,2025-12,"St. Joseph's Healthcare Hamilton, Hamilton, Ontario, L8N 3K7, Canada"
NCT00954681,Study of Quetiapine Treatment for Cannabis Dependence,https://clinicaltrials.gov/study/NCT00954681,COMPLETED,YES,Cannabis Dependence,DRUG: quetiapine,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-08,2010-08,"Substance Treatment Research Service (STARS) of Columbia University, New York, New York, 10032, United States"
NCT00225407,Processing and Effects of Cannabis,https://clinicaltrials.gov/study/NCT00225407,UNKNOWN,NO,Hypotension|Tachycardia,DRUG: Smoking of cannabis cigarettes (different strength),UMC Utrecht,"Netherlands: Ministry of Health, Welfare and Sports",MALE,ADULT,27,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: PREVENTION,2005-07,2005-12,"University Medical Center Utrecht, Utrecht, Netherlands"
NCT01834794,Targeting Tobacco Cessation During Treatment for Cannabis Use Disorders,https://clinicaltrials.gov/study/NCT01834794,COMPLETED,NO,Cannabis Dependence,BEHAVIORAL: MET/CBT/CM plus NRT,Dartmouth-Hitchcock Medical Center,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",33,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-03,2015-01,"Geisel School of Medicine at Dartmouth; State Building Site, Concord, New Hampshire, 03301, United States|Geisel School of Medicine at Dartmouth; Rivermill Complex Site, Lebanon, New Hampshire, 03766, United States"
NCT01844687,Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana,https://clinicaltrials.gov/study/NCT01844687,COMPLETED,YES,"Smoking, Marijuana",DRUG: CBD,National Institute on Drug Abuse (NIDA),,ALL,ADULT,50,NIH,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2013-05,2014-10,"University of Kentucky, Straus Behavioral Research Bldg., 515 Oldham Ct., Lexington, Kentucky, 40513, United States|Marijuana Outpatient Lab 1051 Riverside Dr. Unit #120, New York, New York, 10032, United States|Center for Drug and Alcohol Programs, Room 459 North, 67 President St., Charleston, South Carolina, 29425, United States"
NCT02898974,Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis,https://clinicaltrials.gov/study/NCT02898974,COMPLETED,YES,Multiple Sclerosis,BEHAVIORAL: Medical Marijuana,Colorado State University,"William R. Shaffer, M.D.",ALL,ADULT,22,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-09,2017-10,"Department of Health and Exercise Science, Fort Collins, Colorado, 80523, United States"
NCT03431363,Medical Cannabis During Chemoradiation for Head and Neck Cancer,https://clinicaltrials.gov/study/NCT03431363,ACTIVE_NOT_RECRUITING,NO,Head and Neck Cancer,,Albert Einstein College of Medicine,,ALL,"ADULT, OLDER_ADULT",30,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-05-18,2026-01,"Montefiore Medical Center, Bronx, New York, 10467, United States"
NCT06395688,Drug-Drug Interaction Between THC and AEF0117,https://clinicaltrials.gov/study/NCT06395688,NOT_YET_RECRUITING,NO,Cannabis Abuse,DRUG: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one|DRUG: Placebo,Aelis Farma,National Institute on Drug Abuse (NIDA),ALL,ADULT,24,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2025-02,2025-06,
NCT05566730,Culturally Tailored Cannabis Use Disorder App,https://clinicaltrials.gov/study/NCT05566730,COMPLETED,NO,Cannabis Use,BEHAVIORAL: CT-MICART App|BEHAVIORAL: Control,University of Houston,National Institute on Minority Health and Health Disparities (NIMHD)|Louisiana State University Health Sciences Center in New Orleans|University of Oklahoma,ALL,"ADULT, OLDER_ADULT",50,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-06-14,2024-01-31,"University of Houston, Houston, Texas, 77004, United States"
NCT02011516,Baclofen Effects on Marijuana Dependence,https://clinicaltrials.gov/study/NCT02011516,COMPLETED,YES,Marijuana Dependence,DRUG: Baclofen|BEHAVIORAL: Psychosocial|DRUG: Placebo,University of Pennsylvania,Pennsylvania Department of Health,ALL,ADULT,47,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-12,2015-06,"University of Pennsylvania Center for Studies of Addiction, Philadelphia, Pennsylvania, 19104, United States"
NCT05337033,Cannabis for Chronic Headaches in Adolescents: the CAN-CHA Trial,https://clinicaltrials.gov/study/NCT05337033,RECRUITING,NO,Chronic Migraine,DRUG: MPL-001,University of Manitoba,SickKids Foundation|The Canadian Collaborative for Childhood Cannabinoid Therapeutics (C4T),ALL,CHILD,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11-27,2025-12-31,"University of British Columbia, Vancouver, British Columbia, V6T1Z4, Canada|Dalhousie University-, Halifax, Nova Scotia, B3K 6R8, Canada|Neurology Centre of Toronto, Toronto, Ontario, Canada"
NCT00678795,A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis,https://clinicaltrials.gov/study/NCT00678795,COMPLETED,YES,Detrusor Overactivity|Multiple Sclerosis,DRUG: Sativex®|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",135,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2002-08,2005-10,"Division of Clinical Neurology, Queen's Medical Centre, Nottingham, Notts, NG7 2UH, United Kingdom"
NCT00149643,Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence,https://clinicaltrials.gov/study/NCT00149643,COMPLETED,YES,"Depressive Disorder, Major|Cannabis Abuse",DRUG: Fluoxetine|OTHER: Placebo,University of Pittsburgh,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",70,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2004-09,2012-12,"Department of Psychiatry, Pittsburgh, Pennsylvania, 15213, United States"
NCT02319746,COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE,https://clinicaltrials.gov/study/NCT02319746,COMPLETED,NO,First-episode Psychosis|Cannabis Abuse,BEHAVIORAL: Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse|BEHAVIORAL: Psychoeducation,Basque Health Service,,ALL,"CHILD, ADULT",88,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-09,2019-09,"Araba University Hospital, Vitoria, Alava, 01002, Spain"
NCT04820361,Effect of Cannabinoids on Pain in Fabry Disease Patients,https://clinicaltrials.gov/study/NCT04820361,RECRUITING,NO,"Pain, Neuropathic","DRUG: Cannabis sativa L., folium cum flore|DRUG: Placebo","Albina Nowak, MD",Swiss National Science Foundation,ALL,"ADULT, OLDER_ADULT",22,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-07-07,2023-12-29,"University Hospital Zürich USZ, Zürich, Switzerland"
NCT00702468,Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis,https://clinicaltrials.gov/study/NCT00702468,COMPLETED,YES,Spasticity|Multiple Sclerosis,DRUG: Sativex|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",36,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2007-11,2009-01,"James Paget University Hospital NHS Foundation Trust, Gorleston on Sea, Norfolk, NR31 6LA, United Kingdom"
NCT04228965,Cannabis and Tobacco Co-use Study,https://clinicaltrials.gov/study/NCT04228965,COMPLETED,NO,Tobacco Use Disorder,DRUG: Varenicline|BEHAVIORAL: Contingency Management|BEHAVIORAL: Counseling,Medical University of South Carolina,National Cancer Institute (NCI)|National Institutes of Health (NIH),ALL,ADULT,181,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-01-28,2024-09-13,"Medical University of South Carolina - Charleston, Charleston, South Carolina, 29403, United States|Medical University of South Carolina - Florence, Florence, South Carolina, 29505, United States|Behavioral Health Services of Pickens County, Pickens, South Carolina, 29671, United States"
NCT04565028,Functional Outcomes of Cannabis Use (FOCUS) in Veterans With Posttraumatic Stress Disorder,https://clinicaltrials.gov/study/NCT04565028,RECRUITING,NO,PTSD|Cannabis-Related Disorder,BEHAVIORAL: Contingency Management (CM),VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",40,FED,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-01-26,2025-12-30,"Durham VA Medical Center, Durham, NC, Durham, North Carolina, 27705-3875, United States"
NCT05170217,Reducing the Harmful Effects of Cannabis Use: Finding the Optimal CBD:THC Ratio,https://clinicaltrials.gov/study/NCT05170217,COMPLETED,NO,Cannabis Use,DRUG: THC|DRUG: Cannabidiol|DRUG: Cannabidiol|DRUG: Cannabidiol,King's College London,,ALL,ADULT,46,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2017-11-08,2019-06-09,"Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 8AF, United Kingdom"
NCT02470325,The Effects of Cannabis on Dystonia and Spasticity on Pediatric Patients,https://clinicaltrials.gov/study/NCT02470325,UNKNOWN,NO,Spasticity|Dystonia,DRUG: Avidekel oil|DRUG: Enriched Avidekel oil,Wolfson Medical Center,,ALL,"CHILD, ADULT",40,OTHER_GOV,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-07,2017-12,"Dr. Lubov Blumkin, Holon, Israel"
NCT02246140,Intracranial Arterial Stenosis and Resin of Cannabis Use,https://clinicaltrials.gov/study/NCT02246140,RECRUITING,NO,Cannabis Users,OTHER: Cerebral MRI and MRA,"University Hospital, Strasbourg, France",,ALL,ADULT,60,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2014-07,2026-08,"Hôpitaux Universitaires de Strasbourg, Strasbourg,, 67091, France"
NCT05192239,Influence of Edible Marijuana on Endurance Exercise Performance,https://clinicaltrials.gov/study/NCT05192239,COMPLETED,YES,Endurance Exercise,DRUG: THC 5|DRUG: Placebo,Christopher Bell,,ALL,ADULT,17,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,2021-12-09,2022-07-19,"Colorado State University, Dept. of Health and Exercise Science, Fort Collins, Colorado, 80523-1582, United States"
NCT04174963,An Electronic Intervention to Reduce Cannabis Among Young Adults in Psychiatric Care,https://clinicaltrials.gov/study/NCT04174963,TERMINATED,NO,Cannabis Use|Psychiatric Disorder,BEHAVIORAL: eToke + TPsy,Rhode Island Hospital,,ALL,ADULT,12,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2019-11-01,2022-05-24,"Rhode Island Hospital, Providence, Rhode Island, 02903, United States"
NCT03246113,Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma,https://clinicaltrials.gov/study/NCT03246113,TERMINATED,NO,Glioblastoma,DRUG: Cannabis|DRUG: Temozolomide|RADIATION: Radiation Therapy,New York State Psychiatric Institute,,ALL,"ADULT, OLDER_ADULT",1,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-03-19,2019-05-09,"Columbia University Medical Center- Department of Radiation Oncology, New York, New York, 10032, United States|New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT06266611,Cannabis for Palliative Care in Cancer,https://clinicaltrials.gov/study/NCT06266611,RECRUITING,NO,Sleep|Anxiety|Depression|Pain,DRUG: fsCBD Cannabidiol|DRUG: Placebo|DRUG: bsCBD Cannabidiol,"University of Colorado, Boulder",,ALL,"ADULT, OLDER_ADULT",185,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-07-15,2028-07-31,"Anschutz Health Sciences Building, Aurora, Colorado, 80045, United States"
NCT02837315,Improving Brief Marijuana Interventions With a Behavioral Economic Supplement,https://clinicaltrials.gov/study/NCT02837315,COMPLETED,NO,Marijuana Use,BEHAVIORAL: Brief Motivational Intervention (BMI)|BEHAVIORAL: Substance-Free Activity Session (SFAS)|BEHAVIORAL: Relaxation Session,University of Memphis,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"ADULT, OLDER_ADULT",133,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-10-23,2016-11-30,"University of Memphis, Memphis, Tennessee, 38152, United States"
NCT02560545,Cannabinoids Effects on the Pain Modulation System,https://clinicaltrials.gov/study/NCT02560545,UNKNOWN,NO,Neuropathic Pain,DRUG: Cannabis oil,Tel-Aviv Sourasky Medical Center,,MALE,"ADULT, OLDER_ADULT",40,OTHER_GOV,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: DIAGNOSTIC",2015-09,2019-09,"Pain Institute, Tel Aviv Medical Center, Tel Aviv, Israel"
NCT01604265,A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis,https://clinicaltrials.gov/study/NCT01604265,COMPLETED,YES,Multiple Sclerosis|Neuropathic Pain,DRUG: Placebo|DRUG: Sativex,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",66,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2002-03,2002-08,"Walton Centre for Neurology and Neurosurgery, Liverpool, L9 7LJ, United Kingdom"
NCT00542750,An Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents,https://clinicaltrials.gov/study/NCT00542750,COMPLETED,YES,Cannabis Dependence,DRUG: N-Acetylcysteine,Medical University of South Carolina,National Institute on Drug Abuse (NIDA)|American Academy of Child Adolescent Psychiatry.,ALL,"CHILD, ADULT",24,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-01,2008-12,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT02864680,Electrophysiological Study of the Functioning of Magnocellular Visual Pathway in Regular Cannabis Users,https://clinicaltrials.gov/study/NCT02864680,COMPLETED,NO,Cannabis Use,OTHER: Electroretinography|OTHER: Contrast sensitivity test during Electroencephalography|OTHER: Visual simultaneity test during Electroencephalography|OTHER: Face perception test during Electroencephalography|OTHER: CAST (cannabis abuse screening test)|OTHER: PANSS (Positive And Negative Symptoms Scale) test|OTHER: Delayed Matching to Sample (DMS) test|OTHER: Spatial Working Memory (SWM) test|OTHER: Rapid Visual Information Processing (RVP) test|OTHER: Test for attentional performance (TAP) / Divided Attention|OTHER: Collection of saliva sample,"Central Hospital, Nancy, France",,ALL,ADULT,163,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2014-02,2019-06,"Maison des Addictions - CHU de Nancy, Hôpital St Julien, Nancy, France"
NCT02132832,"Buspirone, Stress, and Attentional Bias to Marijuana Cues",https://clinicaltrials.gov/study/NCT02132832,COMPLETED,YES,Cannabis Use Disorder,DRUG: Buspirone|DRUG: Placebo,"The University of Texas Health Science Center, Houston",National Institute on Drug Abuse (NIDA),ALL,ADULT,45,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2013-06,2016-03,"University of Texas Health Science Center - Houston, Houston, Texas, 77030, United States"
NCT03909477,Longitudinal Study of Xenon-129 MRI Imaging Effects of Cannabis Smoking,https://clinicaltrials.gov/study/NCT03909477,RECRUITING,NO,Cannabis Use|Cannabis Smoking|Marijuana Smoking|Marijuana Usage,DIAGNOSTIC_TEST: Hyperpolarized Xenon-129 MRI of the lungs|DIAGNOSTIC_TEST: Computed Tomography (CT)|DIAGNOSTIC_TEST: Pulmonary Function Tests (PFTs)|DIAGNOSTIC_TEST: Six Minute Walk Test (6MWT)|DIAGNOSTIC_TEST: Cardiopulmonary exercise testing (CPET)|DIAGNOSTIC_TEST: Sputum analysis|DIAGNOSTIC_TEST: Blood analysis,"Western University, Canada",,ALL,"ADULT, OLDER_ADULT",200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-06-01,2030-12-01,"Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre, London, Ontario, N6A 5B7, Canada"
NCT01153490,Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine,https://clinicaltrials.gov/study/NCT01153490,COMPLETED,NO,Cannabis Dependence,BEHAVIORAL: Behavioral Intervention,Northwell Health,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",124,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-10-22,2012-08-06,"The Zucker Hillside Hospital, Glen Oaks, New York, 11004, United States|General Clinical Research Center, Manhasset, New York, 11030, United States"
NCT01812616,A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients,https://clinicaltrials.gov/study/NCT01812616,COMPLETED,NO,Cancer,DRUG: Sativex|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",21,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-09,2016-06,"Klinik für Onkologie, Hämatologie und Stammzelltransplantation, Universitätsklinikum Aachen RWTH, Aachen, 52074, Germany|Neurologie des Klinikums Altenburger Land, Altenburg, 04600, Germany|Zentrum für Neuroonkologie der Universität Duesseldorf, Duesseldorf, 40225, Germany|Strahlenklinik der Universität Erlangen, Erlangen, 91054, Germany|The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, CH63 4JY, United Kingdom|St James's Institute of Oncology, St James's University Hospital, Leeds, Yorkshire, LS9 7TF, United Kingdom|Bristol Haematology & Oncology Centre, Bristol, BS2 8ED, United Kingdom|Queen's Centre for Haematology & Oncology, Castle Hill Hospital, Cottingham, HU16 5JQ, United Kingdom|West of Scotland Beatson Cancer Centre, Glasgow, G12 0YN, United Kingdom|Guy's & St Thomas' NHS Foundation Trust, of St Thomas' Hospital, London, SE1 7EH, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom"
NCT05132842,Cannabis Use Patterns Among Cancer Patients,https://clinicaltrials.gov/study/NCT05132842,COMPLETED,NO,Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm,OTHER: Survey Administration,Thomas Jefferson University,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",1568,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-02-25,2022-10-29,"Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, 19107, United States"
NCT04964739,Gender/Sex & CUD Remission,https://clinicaltrials.gov/study/NCT04964739,RECRUITING,NO,"Cannabis Use Disorder, Mild|Cannabis Use Disorder, Moderate|Cannabis Use Disorder, Severe",BEHAVIORAL: Cognitive Behavioral Therapy (CBT4CBT),Medical University of South Carolina,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",224,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-11-15,2025-03-31,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT00360269,Atomoxetine Treatment for ADHD and Marijuana Dependence,https://clinicaltrials.gov/study/NCT00360269,COMPLETED,YES,Marijuana Abuse|Attention Deficit Disorder With Hyperactivity,DRUG: Atomoxetine|PROCEDURE: Motivational enhancement therapy|DRUG: Placebo,Medical University of South Carolina,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",38,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-11,2008-06,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT01179425,Sex Differences in Attentional Bias in Marijuana-dependent Individuals,https://clinicaltrials.gov/study/NCT01179425,COMPLETED,NO,Marijuana Dependence,OTHER: Cognitive stressor,Medical University of South Carolina,,ALL,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2009-08,2011-02,"Medical University of South Carolina, Dept. of Psychiatry/Clinical Neuroscience Division, Charleston, South Carolina, 29425, United States"
NCT03555968,Effects of THC and Alcohol on Driving Performance,https://clinicaltrials.gov/study/NCT03555968,WITHDRAWN,NO,"Cannabis|Alcohol Drinking|Accident, Traffic",DRUG: THC 0|DRUG: THC 5|DRUG: THC 10|OTHER: BAC 0|OTHER: BAC .025|OTHER: BAC .049,Lakehead University,,ALL,ADULT,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2021-07,2021-12,
NCT00613405,Stress and Marijuana Cue-elicited Craving and Reactivity,https://clinicaltrials.gov/study/NCT00613405,COMPLETED,YES,Cannabis Use Disorders,OTHER: Stress + cue exposure|OTHER: No stress + cue exposure,Medical University of South Carolina,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",87,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2008-01,2009-05,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT01656707,Adaptive Treatment for Adolescent Cannabis Use Disorders,https://clinicaltrials.gov/study/NCT01656707,COMPLETED,NO,Mental Disorders|Addictive Behaviors|Cannabis Use Disorder,BEHAVIORAL: ACRA|BEHAVIORAL: CBT,UConn Health,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",172,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-09,2016-07,"University of Connecticut Health Center, Farmington, Connecticut, 06030-2103, United States"
NCT00227864,A Brief Marijuana Intervention for Adolescent Women - 1,https://clinicaltrials.gov/study/NCT00227864,COMPLETED,NO,Marijuana Abuse|Sexual Risk Behaviors,BEHAVIORAL: Behavior Therapy|OTHER: Treatment as Usual,Butler Hospital,National Institute on Drug Abuse (NIDA),FEMALE,"CHILD, ADULT",326,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2004-09,2009-12,"Rhode Island Hospital, Providence, Rhode Island, 02903, United States"
NCT04998006,Alcohol and Cannabis Co-Use and the Gut-Brain Axis,https://clinicaltrials.gov/study/NCT04998006,COMPLETED,NO,Cannabis Use|Alcohol Use|Inflammation,DRUG: Alcohol and Cannabis vs. Alcohol only,Colorado State University,"University of Colorado, Boulder",ALL,ADULT,62,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-02-25,2024-12-23,"CU Anschutz School of Medicine, Aurora, Colorado, 80045, United States"
NCT02480283,"Chronic Cannabis Smoking, Oxidative Stress and the Pulmonary Innate Immune Response",https://clinicaltrials.gov/study/NCT02480283,RECRUITING,NO,Cannabis Smoking|Oxidative Stress,PROCEDURE: Bronchoscopy|RADIATION: Chest X-ray|PROCEDURE: Venipuncture|PROCEDURE: Intravenous Catheter,"University of Colorado, Denver",National Center for Advancing Translational Sciences (NCATS),ALL,ADULT,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-11-11,2027-07,"University of Colorado, Denver, Aurora, Colorado, 80045, United States"
NCT02063984,Behavioral Treatment of Adolescent Substance Use,https://clinicaltrials.gov/study/NCT02063984,COMPLETED,YES,Substance Use Disorders,BEHAVIORAL: Intensive Outpatient Treatment (IOP) + Contingency Management (CM)|BEHAVIORAL: Working Memory Training,Dartmouth-Hitchcock Medical Center,National Institute on Drug Abuse (NIDA)|Mountain Manor Treatment Center|University of Pennsylvania|Johns Hopkins University|Spectrum Youth and Family Services,ALL,"CHILD, ADULT",59,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-11,2018-08-14,"Mountain Manor Treatment Center, Baltimore, Maryland, 21229, United States"
NCT05944705,Commercially Available Cannabis Products for Immune Support,https://clinicaltrials.gov/study/NCT05944705,RECRUITING,NO,Influenza|COVID-19|Common Cold,DIETARY_SUPPLEMENT: Immune Support Supplement,Center For Interventional Pain and Spine,Agronomed LLC,ALL,"ADULT, OLDER_ADULT",200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-11-01,2024-12-01,"Center for Interventional Pain and Spine, Bryn Mawr, Pennsylvania, 19010, United States"
NCT01606137,A Study of the Long-term Safety of Sativex Use,https://clinicaltrials.gov/study/NCT01606137,COMPLETED,YES,Multiple Sclerosis|Spasticity|Pain,DRUG: GW-1000-02,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",507,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2002-02,2004-12,"Gartnavel General Hospital, Glasgow, G12 0YN, United Kingdom"
NCT03268551,MEMO-Medical Marijuana and Opioids Study,https://clinicaltrials.gov/study/NCT03268551,COMPLETED,NO,Opioid Use|Marijuana|Chronic Pain|HIV/AIDS,,Albert Einstein College of Medicine,Fordham University|Columbia University|National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",257,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-09-04,2023-07-14,"Montefiore Health System, Bronx, New York, 10451, United States|Vireo Health, White Plains, New York, 10601, United States"
NCT00167297,Atomoxetine for the Treatment of Cannabis Dependence,https://clinicaltrials.gov/study/NCT00167297,COMPLETED,NO,Cannabis Dependence,DRUG: Atomoxetine,National Institute on Drug Abuse (NIDA),University of Pennsylvania,ALL,"ADULT, OLDER_ADULT",16,NIH,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-11,2005-07,"University of Pennsylvania Treatment Rersearch Center, Philadelphia, Pennsylvania, 19104, United States"
NCT06081218,Effect of Acute Exercise on Cognitive Functions and Blood Markers of Brain Plasticity in Regular Chronic Cannabis Users,https://clinicaltrials.gov/study/NCT06081218,RECRUITING,NO,Cannabis User,OTHER: activity test,"University Hospital, Lille",,ALL,ADULT,60,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2024-05-07,2029-12-31,"CHU Lille, Lille, 59000, France"
NCT02874898,Short-Term Exposure for PTSD,https://clinicaltrials.gov/study/NCT02874898,COMPLETED,NO,Chronic Post-Traumatic Stress Disorder|Marijuana Abuse,BEHAVIORAL: Brief Imaginal Exposure,University of Washington,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",46,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-06,2022-08-15,"University of Washington, Seattle, Washington, 98105, United States"
NCT03659942,Study of the Cannabis Use of Minors Imprisoned in the PACA Region,https://clinicaltrials.gov/study/NCT03659942,UNKNOWN,NO,Cannabis Use,OTHER: CAST questionnaire,Assistance Publique Hopitaux De Marseille,,ALL,"CHILD, ADULT",500,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-01,2020-06,"Assistance Publique Des Hopitaux de Marseille, Marseille, Paca, 13354, France"
NCT02675842,Investigation of Cannabis for Pain and Inflammation in Lung Cancer,https://clinicaltrials.gov/study/NCT02675842,WITHDRAWN,NO,Lung Cancer,DRUG: Smoked Cannabis High CBD/low THC|DRUG: Smoked Placebo Cannabis Low CBD/low THC,New York State Psychiatric Institute,,ALL,ADULT,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",,2021-10-28,
NCT00681538,"A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)",https://clinicaltrials.gov/study/NCT00681538,COMPLETED,YES,Spasticity|Multiple Sclerosis,DRUG: Sativex®|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",572,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2008-01,2009-01,"Department of Neurology, Northampton General Hospital, Cliftonville, Northampton, NN1 5BD, United Kingdom"
NCT06569394,A Study of Cannabidiol in Young Adult Cannabis Users,https://clinicaltrials.gov/study/NCT06569394,RECRUITING,NO,Cannabis Use Disorder,DRUG: Broad Spectrum Cannabidiol (bsCBD) 400 mg|DRUG: Placebo,"University of Colorado, Denver",National Institute on Drug Abuse (NIDA),ALL,ADULT,200,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2024-12-09,2028-06-30,"University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, United States"
NCT06077292,"Cannabis THC Potency, Metabolism, and Cognitive Impairment in Young Adults",https://clinicaltrials.gov/study/NCT06077292,NOT_YET_RECRUITING,NO,Cannabis Use|THC|Marijuana Use|Cognitive Impairment|THC Vaping,BEHAVIORAL: 15% THC Potency Reduction|BEHAVIORAL: 35% THC Potency Reduction,"University of California, San Francisco",Cannabis Public Policy Consulting,ALL,ADULT,110,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: OTHER,2024-01-01,2024-06-30,"University of California San Francisco, San Francisco, California, 94143, United States"
NCT04513756,Efficacy of Community Reinforcement Approach (CRA) in the Treatment of Cannabis Users,https://clinicaltrials.gov/study/NCT04513756,UNKNOWN,NO,Cannabis Dependence,BEHAVIORAL: Community Reinforcement Approach,"International Islamic University, Islamabad",Pakistan Institute of Living and Learning,ALL,ADULT,120,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-08-18,2021-12-21,"Psychological Services Clinic, Medical Center, International Islamic University, Islamabad, Federal Capital, 44000, Pakistan|Research Office, Department of Psychology, International Islamic University Islamabad, Islamabad, Federal, 46000, Pakistan"
NCT04269993,Impact of Cannabis on Pain and Inflammation Among Patients With Rheumatoid or Psoriatic Arthritis,https://clinicaltrials.gov/study/NCT04269993,TERMINATED,NO,Rheumatoid Arthritis|Psoriatic Arthritis,DRUG: Cannabis: placebo and medium THC/medium CBD,Brown University,,ALL,"ADULT, OLDER_ADULT",4,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: BASIC_SCIENCE",2022-05-18,2023-07-31,"Brown University School of Public Health, Providence, Rhode Island, 02903, United States"
NCT01115023,Effect of Consuming Food Cooked in Iron Utensils on Iron Status in Children With Iron Deficiency Anemia (IDA),https://clinicaltrials.gov/study/NCT01115023,COMPLETED,NO,Iron Deficiency Anemia,OTHER: iron cooking pot,"Dhande, Leena Ajay, M.D.",Sir Gangadharrao Chitnavis Memorial Medical Research Trust Nagpur,ALL,CHILD,36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2003-10,2004-11,"Government Medical College, Nagpur, Maharashtra, 440003, India"
NCT03221231,N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms,https://clinicaltrials.gov/study/NCT03221231,UNKNOWN,NO,Cannabis Use Disorder|Cannabis Dependence,DRUG: N-acetylcysteine|DRUG: Placebo Oral Tablet|OTHER: Magnetic Resonance Imaging|OTHER: Neurocognitive measures|OTHER: Neuro-inflammatory measures,Universitair Ziekenhuis Brussel,,MALE,ADULT,75,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: BASIC_SCIENCE",2016-05-15,2023-02-01,"University Hospital Brussels, Brussels, 1090, Belgium"
NCT06688539,E-cigarette Cessation in Adults Who Co-use Cannabis,https://clinicaltrials.gov/study/NCT06688539,NOT_YET_RECRUITING,NO,Nicotine Dependence|Tobacco Use Disorder,DRUG: Varenicline Pill|BEHAVIORAL: Contingency management|BEHAVIORAL: Counseling,Medical University of South Carolina,National Cancer Institute (NCI),ALL,ADULT,105,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2025-02-10,2026-10-01,"MUSC Charleston, Charleston, South Carolina, 29425, United States|MUSC Lancaster, Lancaster, South Carolina, 29720, United States|Behavioral Health Services of Pickens County, Pickens, South Carolina, 29671, United States"
NCT01606202,A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury,https://clinicaltrials.gov/study/NCT01606202,COMPLETED,YES,Pain,DRUG: GW-1000-02|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",116,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2002-07,2005-01,"The Royal National Orthopaedic Hospital, Middlesex, HA7 4LP, United Kingdom"
NCT00530764,A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.,https://clinicaltrials.gov/study/NCT00530764,COMPLETED,YES,Palliative Care|Pain|Cancer,DRUG: Sativex Low Dose|DRUG: Sativex Medium Dose|DRUG: Sativex High Dose,GW Pharmaceuticals Ltd,"Quintiles, Inc.",ALL,"ADULT, OLDER_ADULT",360,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2007-11,2010-01,"Cancer Care Center of Tuscaloosa, Tuscaloosa, Alabama, 35406, United States|Desert Oasis Cancer Center, Casa Grande, Arizona, 85222, United States|Pacific Coast Hematology/Oncology Medical Group, Inc., Fountain Valley, California, 92708, United States|Office of Dr. Ronald Yanagihara, Gilroy, California, 95020, United States|University of California San Diego, La Jolla, California, 92037, United States|Loma Linda University, Loma Linda, California, 92354, United States|Florida Institute of Medical Research, Jacksonville, Florida, 32257, United States|Clinical Pharmacology Services, Tampa, Florida, 33617, United States|Center of Hope for Cancer and Blood Disorders, Riverdale, Georgia, 30274, United States|Louisiana Research Associates, New Orleans, Louisiana, 70114, United States|The Center for Clinical Research - Washington County Hospital, Hagerstown, Maryland, 21740, United States|Capital Comprehensive Cancer Care Clinic, Jefferson City, Missouri, 65109, United States|A & A Pain Institute of St. Louis, St. Louis, Missouri, 63141, United States|Office of Donald H. Berdeaux MD, Great Falls, Montana, 59405, United States|Summit Medical Group, Berkeley Heights, New Jersey, 07922, United States|Beth Israel Medical Center, New York, New York, 10003, United States|Metropolitan Hospital Center, New York, New York, 10029, United States|Four Seasons Hospice & Pallative Care, Flat Rock, North Carolina, 28731, United States|Center for Clinical Research, Winston-Salem, North Carolina, 27103, United States|Gabrail Cancer Center, Canton, Ohio, 44718, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, 37232, United States|Lone Star Oncology, Austin, Texas, 78759, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|Jules Bordet Institute, Bruxelles, 1000, Belgium|CHU Charleroi (Hôpital civil de Charleroi), Charleroi, 6000, Belgium|UZ Leuven - Algologisch Centrum Anesthesiologie, Pellenberg, 3212, Belgium|Vancouver Health Research Center, Victoria, British Columbia, V8V 1R2, Canada|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|Instituto Radio-oncológico Santiago (INRAD), Santiago, Chile|Clínica Ciudad del Mar, Viña del Mar, Chile|Ambulance pro lécbu bolesti, ARO, Benešov, 25601, Czech Republic|Ambulance pro lécbu bolesti, Ceské Budejovice, 370 01, Czech Republic|Nemocnice Ceské Budejovice, Ceské Budejovice, 370 87, Czech Republic|FN Hradec Králové - Klinika onkologie a radioterapie, Hradec Králové, 500 05, Czech Republic|Nemocnice Jihlava, Jihlava, 58633, Czech Republic|FN a LF UP Olomouc - Ambulance pro lécbu bolesti, Olomouc, 775 20, Czech Republic|AR klinika FN Plzen -Ambulance pro lécbu bolesti, Plzen, 304 60, Czech Republic|Fakultní nemocnice Na Bulovce, Praha 8 - Liben, 180 81, Czech Republic|ARO, Krajská zdravotni, K.Z. a.s, Nemocnice, Teplice, 41501, Czech Republic|Docrates Clinic, Helsinki, 00150, Finland|Centre hospitalier Lyon Sud, Pierre-Benite, 69495, France|Praticien hospitalier, Tarbes, 65000, France|RWTH Aachen Universität, Aachen, 52074, Germany|Schmerz- und Palliativzentrum Göppingen, Göppingen, 73033, Germany|St.-Marien-Hospital Lunen, Lunen, 44534, Germany|Schmeiz - u Pallielivzendium Wiesbaden, Wiesbaden, 65189, Germany|Yashoda Hospital, Andhra Pradesh, 500 082, India|Bangalore Institute of Oncology, Bangalore,, 560027, India|CBCC- Apollo Hospital, Gandhinagar, India|Apollo Hospital, Hyderabaad, 500033, India|Indo-American Cancer Institute and Research Center, Hyderabaad, 500034, India|Bhagwaan Mahaveer Cancer Hospital and Research Centre, Jaipur, 302017, India|CHL - Apollo Hospitals, Madhya Pradesh, 452 008, India|Jawaharlal Nehru Cancer Hospital, Madhya Pradesh, 462 001, India|Meenakshi Mission Hospital & Research Centre, Madurai, 625107, India|All India Institute of Medical Sciences, New Delhi, 110 029, India|Jehangir Clinical Development Centre Pvt. Ltd., Pune, 411001, India|Deenanath Mangeshkar Hospital and Research Center, Pune, India|Seroc Cancer Center, Rajasthan, 302 013, India|Regina Elana Cancer Institute, Rom, 00144, Italy|Dir. S.C.D.U. Psicologia Clinica ed Oncologica, Turin, 10128, Italy|Hospital Aranda de la Parra, Leon, 37000, Mexico|Htal Ángeles de Pedregal, Mexico DF, 10700, Mexico|Beskidzkie Centrum Onkologii im. Jana Pawla, Bielsko-Biala, 43-300, Poland|Poradnia Leczenia Bolu, Edyty Jakubow, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Gdansk, 80-803, Poland|NZOZ Hospicjum Milosierdzia Bozego, Gliwice, 44-101, Poland|Szpital Uniwersytecki w Krakowie, Krakow, 31-631, Poland|Wielkopolskie Centrum Onkologii, Poznan, 61-866, Poland|Niepubliczny Zaklad Opieki Zdrowotnej, Tychy, 43-100, Poland|Centrum Onkologii - Instytut im. M. Sklodowskiej - Curie, Warszawa, 02-781, Poland|Spitalul Judetean de Urgenta ""Constantin Opris"", Baia Mare, Maramures, 430031, Romania|Spitalul Judetean de Urgenta Braila, Braila, Jud. Braila, 810325, Romania|Hospice ""Casa Sperantei"", Brasov, 500074, Romania|Spitalul Universitar de Urgenta Elias, Bucuresti, 011461, Romania|S.C. IanuliMed S.R.L. Oncologie Medicala, Bucuresti, 020962, Romania|Policnica Orizont-Oncologie Medicala, Craiova, 200535, Romania|District Hospital Dr. Alexandru Simionescu, Hunedoara, 331057, Romania|Centrul de Oncologie Medicala, Iasi, 700106, Romania|Spitalul Municipal Onesti, Onesti, Jud. Bacau, 601048, Romania|Spitalul Municipal Ploiesti, Ploiesti, 100337, Romania|Spitalul Clinic Judetean Sibiu Oncologie, Sibiu, 550245, Romania|Spitalul Judetean de Urgenta ""Sf. Ioan cel Nou"", Suceava, 720237, Romania|Dr. Pirjol & Szpak Inc., Amanzimtoti, 4126, South Africa|Medi Clinic, Bloemfontein, 9301, South Africa|Pain Clinic, Cape Town, 8001, South Africa|Pretoria Urology Research Unit, Hatfield, Pretoria, 0083, South Africa|Trialtech Research - Embassy Drive Medical Centre, Hatfield, Pretoria, 0083, South Africa|Oncology/Haematology Dept Research Unit, Kimberley, 8301, South Africa|Eastleigh Breast Cancer Center, Lynnwood, 0041, South Africa|Hospital Virgen del Mar, Almeria, 04003, Spain|Hospital Universitario Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clinic i Provincial, Barcelona, 08036, Spain|HU Puerta del Mar, Oncologia, Cadiz, 11009, Spain|Hospital Universitario de Bellvitge, Feixa, Llarga, sn, 08907, Spain|Hospital Univ. Virgen de las Nieves, Granada, 180114, Spain|Hospital de la Rioja, Logrono, 26001, Spain|Hospital Los Montalvos, Salamanca, 37192, Spain|Basingstoke & North Hampshire NHS Foundation Trust, Basingstoke, RG24 9NA, United Kingdom|West Suffolk Hospital, Bury St Edmunds, IP33 2QZ, United Kingdom|Fairfield General Hospital, Bury, Lancashire, BL9 7TD, United Kingdom|Edinburgh Cancer Research Centre (CRUK), Edinburgh, EH4 2XR, United Kingdom|James Paget Hospital, Gorleston on Sea, Norfolk, NR31 6LA, United Kingdom|International Observatory on End of Life Care, Lancaster, LA1 4YT, United Kingdom|St Bartholomew's Hospital, London, EC1A 7BE, United Kingdom|The Royal Marsden NHS Foundation Trust, London, SW3 6LL, United Kingdom|Marie Curie Hospice Holme Tower, Penarth, CF64 3YR, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, SM2 5PT, United Kingdom|Weston Area Health Trust, Weston super Mare, BS23 4TQ, United Kingdom|New Cross Hospital, Wolverhampton, WV10 0QP, United Kingdom"
NCT04836611,Cannabinoides Concentrations and Hyperemesis Syndrom Occurrence in Regular Cannabis Consumer (CANEMESE),https://clinicaltrials.gov/study/NCT04836611,UNKNOWN,NO,Chronic Consumption of Cannabis,PROCEDURE: 1 blood sample,Poitiers University Hospital,,ALL,"ADULT, OLDER_ADULT",200,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-07-01,2023-06-30,"CHU, Poitiers, 86000, France"
NCT03727659,CONNECT for Depressed Cannabis Users Trial,https://clinicaltrials.gov/study/NCT03727659,COMPLETED,NO,Substance Abuse|Depression,BEHAVIORAL: SHADE therapy + CONNECT FaceBook support,"University of California, Los Angeles",,ALL,"ADULT, OLDER_ADULT",39,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-03-22,2018-12-01,"UCLA Integrated Substance Abuse Programs, Los Angeles, California, 90025, United States"
NCT03056482,Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC),https://clinicaltrials.gov/study/NCT03056482,COMPLETED,NO,Cannabis Use Disorder,DRUG: Ondansetron 8mg|DRUG: Haloperidol 0.05mg/kg|DRUG: Haloperidol 0.1mg/kg,Dr. Marco L.A. Sivilotti,,ALL,"ADULT, OLDER_ADULT",33,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-05-21,2019-07-07,"Hotel Dieu Hospital, Kingston, Ontario, K7L 2V7, Canada|Kingston General Hospital, Kingston, Ontario, K7L 2V7, Canada|Queen's University, Kingston, Ontario, K7L 3N6, Canada"
NCT03337503,Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients with Chronic Pain,https://clinicaltrials.gov/study/NCT03337503,TERMINATED,NO,Chronic Pain,DRUG: THC and CDB in a 1 to 1 ratio|DRUG: Experimental: THC and CBD in a 1 to 2 ratio|DRUG: High CBD with trace THC oil|OTHER: placebo,Santé Cannabis,Tetra Bio-Pharma,ALL,"ADULT, OLDER_ADULT",161,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-01-29,2019-02-15,"Santé Cannabis, Montréal, Quebec, H2L 3K9, Canada"
NCT04627922,N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use,https://clinicaltrials.gov/study/NCT04627922,RECRUITING,NO,Cannabis Use|Tobacco Use Disorder|Drug Use Disorder,DRUG: N-Acetyl cysteine|OTHER: Placebo comparator|BEHAVIORAL: Cognitive behavioral therapy (CBT),Ellen Herbst,Tobacco Related Disease Research Program,ALL,"ADULT, OLDER_ADULT",60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-08-25,2025-06-30,"San Francisco Veterans Affairs Medical Center, San Francisco, California, 94121, United States"
NCT04116619,Investigating Stress-related Mechanisms in the Laboratory and Real World in Individuals With Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT04116619,COMPLETED,NO,Cannabis Use Disorder,OTHER: Guided Imagery Laboratory Session,Yale University,National Institutes of Health (NIH)|National Center for Advancing Translational Sciences (NCATS),ALL,ADULT,39,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-02-01,2022-02-01,"Yale Stress Center, New Haven, Connecticut, 06519, United States"
NCT01675661,Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment,https://clinicaltrials.gov/study/NCT01675661,COMPLETED,YES,Cannabis Dependence,DRUG: N-Acetylcysteine|DRUG: Placebo,Medical University of South Carolina,National Institute on Drug Abuse (NIDA),ALL,ADULT,302,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-01,2015-08,"UCLA Integrated Substance Abuse Programs, Los Angeles, California, 90025, United States|APT Foundation, Inc., New Haven, Connecticut, 06511, United States|University of Kentucky, Lexington, Kentucky, 40502, United States|CODA, Inc., Portland, Oregon, 97214, United States|Behavioral Health Services of Pickens County, Pickens, South Carolina, 29671, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78229, United States"
NCT05162651,Effect of Extended Cannabis Abstinence on PTSD Symptoms,https://clinicaltrials.gov/study/NCT05162651,RECRUITING,NO,PTSD|Cannabis Use|Cognitive Symptom|Comorbidities and Coexisting Conditions,BEHAVIORAL: Contingency-management|OTHER: Enhanced usual care,Centre for Addiction and Mental Health,,ALL,ADULT,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-02-02,2024-09-01,"Centre for Addiction and Mental Health, Toronto, Ontario, M5S 2S1, Canada"
NCT00079560,Comparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDS,https://clinicaltrials.gov/study/NCT00079560,COMPLETED,NO,HIV Infections,DRUG: dronabinol,National Institute on Drug Abuse (NIDA),,ALL,ADULT,30,NIH,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2001-12,2005-08,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT00391079,Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS,https://clinicaltrials.gov/study/NCT00391079,COMPLETED,YES,Multiple Sclerosis,DRUG: Sativex|DRUG: Placebo,GW Pharmaceuticals Ltd,,ALL,"ADULT, OLDER_ADULT",339,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-09,2008-09,"Multiple Sclerosis Program, Foothills Hospital SSB, Calgary, Alberta, T2N 2T9, Canada|MS Clinic, UBC Purdy Pavilion, Vancouver, British Columbia, V6T 2B5, Canada|Dalhousie MS Research Clinic, Halifax, Nova Scotia, B3H 1V8, Canada|London Health Sciences Centre / University Hospital, London, Ontario, N6A 5A5, Canada|Ottawa Hospital General Campus, Ottawa, Ontario, K1H 8L6, Canada|Montreal Neurological Institute, Montreal, Quebec, H3 A 2B4, Canada"
NCT05629702,ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids,https://clinicaltrials.gov/study/NCT05629702,RECRUITING,NO,"Glioblastoma|Brain Tumor|Cannabis|Brain Tumor, Recurrent",DRUG: Nabiximols|DRUG: Temozolomide|DRUG: Nabiximols-matched placebo,University of Birmingham,University of Leeds|The Brain Tumour Charity|Jazz Pharmaceuticals,ALL,"CHILD, ADULT, OLDER_ADULT",234,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-02-03,2027-02,"Mount Vernon Hospital, The Hillingdon Hospitals NHS Foundation Trust, Northwood, Middlesex, HA6 2RN, United Kingdom|Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, AB25 2ZN, United Kingdom|Belfast City Hospital, Belfast Health and Social Care Trust, Belfast, BT9 7AB, United Kingdom|Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2TH, United Kingdom|Bristol Haematology & Oncology Centre, University Hospitals Bristol & Weston NHS Foundation Trust, Bristol, BS2 8ED, United Kingdom|Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, United Kingdom|Velindre Cancer Centre, Velindre University NHS Trust, Cardiff, CF15 7QZ, United Kingdom|Western General Hospital, NHS Lothian, Edinburgh, EH4 2XU, United Kingdom|Beatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde, Glasgow, G12 0YN, United Kingdom|Castle Hill Hospital, Hull University Teaching Hospitals NHS Trust, Hull, HU16 5JQ, United Kingdom|St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, United Kingdom|St Bartholomew's Hospital, Barts Health NHS Trust, London, EC1A 7BE, United Kingdom|Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, SE1 9RT, United Kingdom|Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, W6 8RF, United Kingdom|Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust, Maidstone, ME16 9QQ, United Kingdom|The Christie Hospital, The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom|City Hospital, Nottingham University Hospitals NHS Trust, Nottingham, NG5 1PB, United Kingdom|Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, United Kingdom|Derriford Hospital, University Hospitals Plymouth NHS Trust, Plymouth, PL6 8DH, United Kingdom|Southampton General Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, United Kingdom|Clatterbridge Cancer Centre, The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, CH63 4JY, United Kingdom"
NCT03808935,Cannabis Extract in Refractory Epilepsy Study,https://clinicaltrials.gov/study/NCT03808935,TERMINATED,NO,Drug Resistant Epilepsy,DRUG: Medical Cannabis|DRUG: Placebo,The Epilepsy Research Program of the Ontario Brain Institute,"Ontario Brain Institute|University of Toronto|University Health Network, Toronto|London Health Sciences Centre|MedReleaf",ALL,"ADULT, OLDER_ADULT",17,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-01-10,2020-03-15,"University Hospital Campus, London Health Sciences Centre, London, Ontario, Canada|University Health Network - Toronto Western Hospital, Toronto, Ontario, Canada"
NCT04737772,Project CheckUP: A Brief Behavioral Intervention for Quitline Callers Who Use Marijuana (MJ) and Tobacco,https://clinicaltrials.gov/study/NCT04737772,UNKNOWN,NO,Smoking Cessation|Marijuana Use,BEHAVIORAL: Behavioral: Quitline treatment as usual|BEHAVIORAL: QL Marijuana Check-Up intervention (QL-MJCU),Consumer Wellness Solutions,University of Washington|SRI International,ALL,"ADULT, OLDER_ADULT",136,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-13,2022-12-01,"Optum, Seattle, Washington, 98104, United States"
NCT04871048,Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia,https://clinicaltrials.gov/study/NCT04871048,RECRUITING,NO,Schizophrenia|Cannabis-Induced Disorder,DEVICE: Transcranial direct current stimulation (tDCS) active|DEVICE: Transcranial direct current stimulation (tDCS) non active,Centre Hospitalier Universitaire de Saint Etienne,Direction Générale de l'Offre de Soins,ALL,ADULT,110,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2023-02-15,2026-03-01,"CH Le Vinatier Service universitaire d'addictologie de Lyon, Bron, 69678, France|Centre Hospitalier Universitaire Service d'Addictologie et Pathologies Duelles, Clermont-Ferrand, 63000, France|CHU de Clermont-Ferrand Service de Psychiatrie, Clermont-Ferrand, 63000, France|Service Hospitalo-Universitaire d'Addictologie CHU de Dijon, Dijon, 21079, France|CHU Pôle de Psychiatrie Neurologie et Rééducation, La Tronche, 38700, France|CH Saint-Cyr-au-Mont-d'Or service de psychiatrie, Saint-Cyr-au-Mont-d'Or, 69450, France|CHU de Saint-Etienne, Saint-Priest-en-Jarez, France|Centre Hospitalier Alpes Isère, Saint-Égrève, 38120, France"
NCT02210195,Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence,https://clinicaltrials.gov/study/NCT02210195,COMPLETED,YES,Cannabis Dependence|Alcohol Dependence|Cannabis Use Disorder|Alcohol Use Disorder,DRUG: aprepitant|DRUG: Placebo|BEHAVIORAL: Manual-guided behavioral counseling,The Scripps Research Institute,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-09-04,2016-12-19,"The Scripps Research Institute, La Jolla, California, 92037, United States"
NCT03334279,Effect of Cannabis and Cigarette Smoking on Oral Mucosa,https://clinicaltrials.gov/study/NCT03334279,UNKNOWN,NO,Field Cancerization for Cannabis Smokers,OTHER: Cigarette smokers|OTHER: Simultaneous cigarette and cannabis smokers,Cairo University,,ALL,"CHILD, ADULT, OLDER_ADULT",20,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-01,2020-03,
NCT00594659,Development and Efficacy Test of Computerized Treatment for Marijuana Dependence,https://clinicaltrials.gov/study/NCT00594659,COMPLETED,YES,Marijuana Abuse and Dependence,BEHAVIORAL: Psychotherapy|BEHAVIORAL: Computerized Psychotherapy|BEHAVIORAL: Motivational enhancement therapy,Dartmouth-Hitchcock Medical Center,,ALL,"ADULT, OLDER_ADULT",75,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-11,2012-07,"Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, 03756, United States"
NCT06629389,Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms,https://clinicaltrials.gov/study/NCT06629389,RECRUITING,NO,Parkinson Disease,DRUG: Cannabidiol 100 mg/ml|DRUG: cannabidiol 300 mg/ml|DRUG: Cannabidiol 400 mg/ml|DRUG: Placebo,Laboratorio Elea Phoenix S.A.,,ALL,"ADULT, OLDER_ADULT",88,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-11-28,2026-11,"Hospital Español de Mendoza, Mendoza, 5501, Argentina"
NCT01964547,A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients,https://clinicaltrials.gov/study/NCT01964547,COMPLETED,YES,Multiple Sclerosis|Spasticity,DRUG: Sativex|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",121,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-01,2013-05,"MS Centre, Charles University, Prague, 128 08, Czechia"
NCT01599234,A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis,https://clinicaltrials.gov/study/NCT01599234,COMPLETED,YES,Multiple Sclerosis,DRUG: Sativex|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",337,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-03,2005-12,"The Royal Berkshire and Battle Hospitals NHS Trust, Reading, RG1 5AN, United Kingdom"
NCT01337089,Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain,https://clinicaltrials.gov/study/NCT01337089,COMPLETED,YES,Pain|Advanced Cancer,DRUG: Nabiximols,Jazz Pharmaceuticals,"Otsuka Pharmaceutical Development & Commercialization, Inc.",ALL,"ADULT, OLDER_ADULT",660,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-01-19,2016-01-27,"Phoenix, Arizona, 85018, United States|Phoenix, Arizona, 85028, United States|El Cajon, California, 92020, United States|Gilroy, California, 95020, United States|Glendale, California, 91204, United States|Santa Rosa, California, 95403, United States|Clearwater, Florida, 33756, United States|Daytona Beach, Florida, 32117, United States|Holiday, Florida, 34691, United States|Jacksonville, Florida, 32257, United States|Lynn Haven, Florida, 32444, United States|Miami, Florida, 33136, United States|Stuart, Florida, 34994, United States|Tampa, Florida, 33609, United States|Winter Park, Florida, 32789, United States|Marietta, Georgia, 30060, United States|Newnan, Georgia, 30265, United States|Stockbridge, Georgia, 30281, United States|Woodlawn, Illinois, 62898, United States|Ashland, Kentucky, 41101, United States|Bossier City, Louisiana, 71111, United States|Shreveport, Louisiana, 71105, United States|Saint Louis Park, Minnesota, 55426, United States|Kansas City, Missouri, 64132, United States|Missoula, Montana, 59802, United States|Berlin, New Jersey, 08009, United States|New York, New York, 10003, United States|New York, New York, 10010, United States|Flat Rock, North Carolina, 28731, United States|Winston-Salem, North Carolina, 27103, United States|Cleveland, Ohio, 44119, United States|Philadelphia, Pennsylvania, 19146, United States|Houston, Texas, 77089, United States|Laredo, Texas, 78041, United States|Salt Lake City, Utah, 84112, United States|Salt Lake City, Utah, 84124, United States|Lacey, Washington, 98503, United States|Parkville, 3050, Australia|Bruxelles, 1000, Belgium|Gabrovo, 5300, Bulgaria|Varna, 9010, Bulgaria|Vratsa, 3000, Bulgaria|Benešov, 25601, Czechia|Jablonec Nad Nisou, 46601, Czechia|Most, 434 64, Czechia|Nová Ves Pod Pleší, 262 04, Czechia|Ostrava, 708 52, Czechia|Plzen, 304 60, Czechia|Sokolov, 356 01, Czechia|Teplice, 415 01, Czechia|České Budějovice, 370 01, Czechia|České Budějovice, 370 87, Czechia|Berlin, 10435, Germany|Frankfurt, 60311, Germany|Jena, 07747, Germany|Lunen, 44534, Germany|Stadtroda, 07646, Germany|Wetzlar, 35578, Germany|Wiesbaden, 65189, Germany|Deszk, 6772, Hungary|Komarom, 2900, Hungary|Miskolc, 3501, Hungary|Nyíregyháza, 4412, Hungary|Szekszard, 7100, Hungary|Szikszo, 3800, Hungary|Beer Sheva, 84101, Israel|Haifa, 31096, Israel|Ramat Gan, 52621, Israel|Zerifin, 60930, Israel|Garbagnate Milanese, 20024, Italy|Piacenza, 29100, Italy|Torino, 10126, Italy|Riga, 1038, Latvia|Rēzekne, 4600, Latvia|Klaipeda, 92288, Lithuania|Siauliai, 76307, Lithuania|Vilnius, 08660, Lithuania|Chihuahua, 31238, Mexico|Distrito Federal, 10700, Mexico|Białystok, 15-250, Poland|Bielsko-Biala, 43-300, Poland|Bydgoszcz, 85-796, Poland|Czeladz, 41-250, Poland|Częstochowa, 42-200, Poland|Częstochowa, 42-217, Poland|Działdowo, 13-200, Poland|Gdansk, 80-208, Poland|Gliwice, 44-101, Poland|Klodzko, 57-300, Poland|Opole, 45-272, Poland|Ostrowiec Swietokrzyski, 27-400, Poland|Poznan, 61-245, Poland|Warszawa, 02-781, Poland|Warszawa, 02-793, Poland|Wloclawek, 87-800, Poland|Ponce, 00717, Puerto Rico|San Juan, 00927, Puerto Rico|Baia Mare, 430031, Romania|Baia Mare, 430241, Romania|Braila, 810325, Romania|Bucuresti, 010976, Romania|Bucuresti, 011461, Romania|Cluj-Napoca, 400015, Romania|Constanţa, 900591, Romania|Craiova, 200385, Romania|Focsani, 620165, Romania|Iaşi, 700106, Romania|Oradea, 410469, Romania|Satu Mare, 440055, Romania|Sibiu, 550245, Romania|Suceava, 720237, Romania|Târgovişte, 130095, Romania|Granada, 18014, Spain|Taichung, 404, Taiwan|Tainan City, 73657, Taiwan|Bury Saint Edmunds, IP33 2QZ, United Kingdom|Bury, BL9 7TD, United Kingdom|Cheltenham, GL53 0QJ, United Kingdom|Crumpsall, M8 5RB, United Kingdom|Edinburgh, EH4 2XR, United Kingdom|Edinburgh, United Kingdom|Gorleston-on-Sea, NR31 6LA, United Kingdom|Leeds, LS17 6QD, United Kingdom|Manchester, M20 4BX, United Kingdom|Norwich, NR4 7UY, United Kingdom|Plymouth, PL6 8DH, United Kingdom|Weston-super-Mare, BS23 4TQ, United Kingdom|Withington, M20 4BX, United Kingdom"
NCT06218550,Delta-8-THC vs. Delta-9-THC on Simulated Driving Performance,https://clinicaltrials.gov/study/NCT06218550,RECRUITING,NO,Cannabis,DRUG: Delta-9-THC|DRUG: Delta-8-THC|DRUG: Placebo,Johns Hopkins University,Substance Abuse and Mental Health Services Administration (SAMHSA),ALL,ADULT,45,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2024-07-01,2025-12,"Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland, 21224, United States"
NCT00893269,"The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep",https://clinicaltrials.gov/study/NCT00893269,COMPLETED,NO,Marijuana Dependence,DRUG: eszopiclone|DRUG: Placebo|DRUG: ramelteon|DRUG: zolpidem,Johns Hopkins University,Food and Drug Administration (FDA)|National Institute on Drug Abuse (NIDA),ALL,ADULT,36,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2008-10,2010-10,"Johns Hopkins University, Baltimore, Maryland, 21224, United States"
NCT02523183,The Use of Medicinal Cannabinoids as Adjunctive Treatment for Medically Refractory Epilepsy,https://clinicaltrials.gov/study/NCT02523183,UNKNOWN,NO,"Epilepsy, Unspecified, Refractory (Medically)",DRUG: Medical Cannabis,"University of Colorado, Denver",Colorado Department of Public Health and Environment,ALL,"CHILD, ADULT",150,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-07,2020-11,"Children's Hospital Colorado, Aurora, Colorado, 80045, United States"
NCT01685073,The Role of Sleep in the Treatment of Cannabis Use Disorders,https://clinicaltrials.gov/study/NCT01685073,COMPLETED,YES,Drug Addiction,DRUG: Zolpidem extended-release|BEHAVIORAL: MET/CBT,Johns Hopkins University,National Institute on Drug Abuse (NIDA),ALL,ADULT,127,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-09,2018-07,"Johns Hopkins University, Baltimore, Maryland, 21224, United States"
NCT06588582,Perceptual Influences from Smoking Cannabis: an Experimental Study,https://clinicaltrials.gov/study/NCT06588582,RECRUITING,NO,Cannabis Use|Stress,OTHER: Water Temperature Variation - WW|OTHER: Water Temperature Variation - CW,"University of Colorado, Boulder",National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",166,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2025-01-02,2029-07-31,"University of Colorado at Boulder, Boulder, Colorado, 80309, United States"
NCT04308148,Does Medical Cannabis Reduce Opioid Use in Adults With Pain,https://clinicaltrials.gov/study/NCT04308148,COMPLETED,NO,Opioid Use|Marijuana|Chronic Pain,,Albert Einstein College of Medicine,Laura and John Arnold Foundation|Vireo Health,ALL,"ADULT, OLDER_ADULT",217,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-10-06,2024-03-13,"Montefiore Health System, Bronx, New York, 10451, United States"
NCT01473719,Emerging Adults Who Use Alcohol and Marijuana,https://clinicaltrials.gov/study/NCT01473719,COMPLETED,NO,Alcohol Use|Marijuana Use|Sexually Transmitted Infections,BEHAVIORAL: motivational intervention|BEHAVIORAL: health education,Butler Hospital,,ALL,ADULT,566,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2012-01,2017-08,"Butler Hospital, Providence, Rhode Island, 02906, United States"
NCT06609083,Effect of Cannabis on Cigarette Use Behavior,https://clinicaltrials.gov/study/NCT06609083,RECRUITING,NO,Cannabis Use|Tobacco Use|Cigarette Smoking,DRUG: THC 30mg|DRUG: THC 5mg|DRUG: THC 0mg|DRUG: Cigarette Full Nicotine|DRUG: Cigarette Reduced Nicotine,Johns Hopkins University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2025-01-22,2029-10-01,"Johns Hopkins University Behavioral Pharmacology Research Unit, Baltimore, Maryland, 21224, United States"
NCT04624074,Pilot Testing the Check Up,https://clinicaltrials.gov/study/NCT04624074,RECRUITING,NO,Cannabis Use Disorder,BEHAVIORAL: Teen Marijuana Check Up,"University of Maryland, Baltimore",,ALL,"CHILD, ADULT",40,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-01-01,2025-06-30,"University of Maryland School of Medicine, Baltimore, Maryland, 21021, United States"
NCT00710424,A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy,https://clinicaltrials.gov/study/NCT00710424,COMPLETED,YES,Pain|Diabetic Neuropathy,DRUG: Sativex|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",297,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2005-07,2006-06,"Royal Hallamshire Hospital, Sheffield, Yorkshire, S10 2JF, United Kingdom"
NCT00490269,Ph1 Marinol Interaction Study - Part 2 - 1,https://clinicaltrials.gov/study/NCT00490269,COMPLETED,YES,Marijuana Dependence,DRUG: Placebo|DRUG: Dronabinol,National Institute on Drug Abuse (NIDA),,ALL,ADULT,12,NIH,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: ",2006-10,2007-12,"Uniformed Services University of Health Science, Bethesda, Maryland, 20814 4799, United States"
NCT04436055,Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC),https://clinicaltrials.gov/study/NCT04436055,TERMINATED,NO,"Cannabis Use|Drug Use|Development, Infant",OTHER: No Intervention will be used,Duke University,John Templeton Foundation,ALL,ADULT,92,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-10-26,2022-07-01,"Duke Child and Family Study Center, Durham, North Carolina, 27705, United States"
NCT05465538,SV2A in Older Adults,https://clinicaltrials.gov/study/NCT05465538,RECRUITING,NO,Cannabis Use,DRUG: [11C]UCB-J PET,Yale University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",24,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-07-06,2025-09-30,"Connecticut Mental Health Center, New Haven, Connecticut, 06519, United States"
NCT01542762,Pot-Cast: Thrombosis Prophylaxis During Plaster Cast Lower Leg Immobilisation,https://clinicaltrials.gov/study/NCT01542762,COMPLETED,NO,Deep Venous Thrombosis|Pulmonary Embolism,DRUG: LMWH,"Suzanne C. Cannegieter, MD PhD",ZonMw: The Netherlands Organisation for Health Research and Development,ALL,"ADULT, OLDER_ADULT",1500,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2012-03,2016-09,"De Isala Klinieken, Zwolle, Overijssel, 8000 GK, Netherlands|Bronovo Ziekenhuis, Den Haag, Zuid Holland, 2597 AX, Netherlands|Reinier de Graaf Gasthuis, Delft, Zuid-Holland, 2625 AD, Netherlands|Medisch Centrum Haaglanden, Den Haag, Zuid-Holland, 2512 VA, Netherlands|HagaZiekenhuis, Den Haag, Zuid-Holland, 2566 MJ, Netherlands|Groene Hart Ziekenhuis, Gouda, Zuid-Holland, 2803 HH, Netherlands|Leiden University Medical Center, Leiden, Zuid-Holland, 2333 ZA, Netherlands|Rijnland Ziekenhuis, Leiderdorp, Zuid-Holland, 2353 GA, Netherlands"
NCT04105231,Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use,https://clinicaltrials.gov/study/NCT04105231,RECRUITING,NO,Dual Diagnosis,DRUG: Cannabidiol|DRUG: Risperidone,Lone Baandrup,"Danish Center for Sleep Medicine|Copenhagen University Hospital, Denmark|Glostrup University Hospital, Copenhagen|University of Copenhagen",ALL,ADULT,64,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-06-01,2025-06,"Center for Neuropsychiatric Schizophrenia Research, Glostrup, 2600, Denmark"
NCT01361607,Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT01361607,COMPLETED,YES,Pain|Advanced Cancer,DRUG: Nabiximols|DRUG: Placebo (GA-0034),Jazz Pharmaceuticals,"Otsuka Pharmaceutical Development & Commercialization, Inc.",ALL,"ADULT, OLDER_ADULT",399,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-05-27,2014-11-24,"Glendale, California, 91204, United States|Santa Rosa, California, 95403, United States|Clearwater, Florida, 33756, United States|Holiday, Florida, 34691, United States|Miami, Florida, 33136, United States|Stuart, Florida, 34994, United States|Marietta, Georgia, 30060, United States|Newnan, Georgia, 30265, United States|Stockbridge, Georgia, 30281, United States|Gurnee, Illinois, 60031, United States|Mount Vernon, Illinois, 62864, United States|Ashland, Kentucky, 41101, United States|Bossier City, Louisiana, 71111, United States|Shreveport, Louisiana, 71105, United States|Missoula, Montana, 59802, United States|Berlin, New Jersey, 08009, United States|New York, New York, 10003, United States|New York, New York, 10010-4086, United States|Cleveland, Ohio, 44119, United States|Lacey, Washington, 98503-1010, United States|Vratsa, 3000, Bulgaria|Benešov, 256 01, Czechia|Jablonec Nad Nisou, 466 01, Czechia|Plzen, 304 60, Czechia|Sokolov, 356 01, Czechia|Teplice, 415 01, Czechia|České Budějovice, 370 01, Czechia|České Budějovice, 370 87, Czechia|Berlin, 10435, Germany|Frankfurt, 60311, Germany|Fulda, 36039, Germany|Hannover, 30625, Germany|Jena, 07747, Germany|Wiesbaden, 65189, Germany|Komarom, 2900, Hungary|Nyíregyháza, 4412, Hungary|Mexico, DF, 10700, Mexico|Chihuahua, 31238, Mexico|Monterrey, 64710, Mexico|Bydgoszcz, 85-796, Poland|Czestochowa, 42-200, Poland|Czestochowa, 42-217, Poland|Dzialdowo, 13-200, Poland|Gdansk, 80-208, Poland|Klodzko, 57-300, Poland|Ostrowiec Swietokrzyski, 27-400, Poland|Poznan, 61-245, Poland|Warszawa, 02-781, Poland|Ponce, 00717, Puerto Rico|Targoviste, Dambovita, 130095, Romania|Baia Mare, 430031, Romania|Braila, 810325, Romania|Brasov, 500366, Romania|Bucuresti, 011461, Romania|Cluj-Napoca, 400015, Romania|Constanta, 900591, Romania|Focșani, 620165, Romania|Iasi, 700503, Romania|Sibiu, 550245, Romania|Suceava, 720237, Romania|Cheltenham, Gloucestershire, GL53 0QJ, United Kingdom|Withington, Manchester, M20 4BX, United Kingdom|Great Yarmouth, Norfolk, NR31 6LA, United Kingdom|Coventry, CV2 2HJ, United Kingdom|Glasgow, G12 0YN, United Kingdom|Manchester, M8 5RB, United Kingdom|Norwich, NR4 7UY, United Kingdom|Plymouth, PL6 8DH, United Kingdom"
NCT04389528,Evaluation of the Effect of tDCS on Cannabis Craving,https://clinicaltrials.gov/study/NCT04389528,UNKNOWN,NO,Addiction to Cannabis,OTHER: Neuromodulation by tDCS,Januel,,ALL,ADULT,78,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2018-09-17,2021-12-17,"Youcef BENCHERIF, Maisons Alfort, Île De France, 94700, France"
NCT01262651,Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer,https://clinicaltrials.gov/study/NCT01262651,COMPLETED,YES,Pain|Advanced Cancer,DRUG: Nabiximols|DRUG: Placebo (GA-0034),GW Pharmaceuticals Ltd,"Otsuka Pharmaceutical Development & Commercialization, Inc.",ALL,"ADULT, OLDER_ADULT",397,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-11-25,2015-07-02,"Phoenix, Arizona, 85027, United States|Phoenix, Arizona, 85028, United States|El Cajon, California, 92020, United States|Gilroy, California, 95020, United States|Brandon, Florida, 33511, United States|Daytona Beach, Florida, 32117, United States|Holiday, Florida, 34691, United States|Jacksonville, Florida, 32257, United States|Lynn Haven, Florida, 32444, United States|Stuart, Florida, 34994, United States|Winter Park, Florida, 32789, United States|Newnan, Georgia, 30265, United States|Stockbridge, Georgia, 30281, United States|Shreveport, Louisiana, 71105, United States|Saint Louis Park, Minnesota, 55426, United States|Kansas City, Missouri, 64132, United States|Berlin, New Jersey, 08009, United States|Hendersonville, North Carolina, 28739, United States|Winston-Salem, North Carolina, 27103, United States|Philadelphia, Pennsylvania, 19146, United States|Houston, Texas, 77024, United States|Houston, Texas, 77089, United States|Laredo, Texas, 78041, United States|Salt Lake City, Utah, 84112, United States|Salt Lake City, Utah, 84124, United States|Bruxelles, 1000, Belgium|Gabrovo, 5300, Bulgaria|Shumen, 9700, Bulgaria|Varna, 9010, Bulgaria|Ceske Budejovice, 370 01, Czechia|Ceske Budejovice, 370 87, Czechia|Hradec Kralove, 500 05, Czechia|Most, 434 64, Czechia|Nová Ves Pod Pleší, 262 04, Czechia|Ostrava-Poruba, 708 52, Czechia|Plzen, 304 60, Czechia|Lunen, 44534, Germany|Stadtroda, 07646, Germany|Wetzlar, 35578, Germany|Deszk, H-6772, Hungary|Kecskemét, H-6000, Hungary|Komarom, H-2900, Hungary|Miskolc, H-3501, Hungary|Nyíregyháza, H-4412, Hungary|Szekszard, H-7100, Hungary|Rezekne, LV-4600, Latvia|Riga, LV-1079, Latvia|Klaipeda, LT-92288, Lithuania|Siauliai, LT-76307, Lithuania|Vilnius, LT-08660, Lithuania|Bialystok, 15-250, Poland|Bielsko-Biala, 43-300, Poland|Gliwice, 44-101, Poland|Poznan, 61-245, Poland|Warszawa, 02-781, Poland|Ponce, 00717, Puerto Rico|San Juan, 00927, Puerto Rico|Baia Mare, 430031, Romania|Braila, 810325, Romania|Bucuresti, 010976, Romania|Craiova, 200385, Romania|Oradea, 410469, Romania|Satu Mare, 440055, Romania|Suceava, 720237, Romania|Bury Saint Edmunds, IP33 2QZ, United Kingdom|Bury, BL9 7TD, United Kingdom|Edinburgh, EH4 2XR, United Kingdom|Glasgow, G12 0YN, United Kingdom|Manchester, M8 5RB, United Kingdom|Norwich, NR4 7UY, United Kingdom|Weston Super Mare, BS23 4TQ, United Kingdom|Wolverhampton, WV10 0QP, United Kingdom"
NCT05324813,Examining Effects of Domain Specific Episodic Future Thinking on Cannabis Use,https://clinicaltrials.gov/study/NCT05324813,UNKNOWN,NO,"Marijuana Use|Marijuana Dependence|Tobacco Use|Alcohol Use, Unspecified",BEHAVIORAL: Domain-Specific Episodic Future Thinking,Michael Sofis,Dartmouth College,ALL,"ADULT, OLDER_ADULT",50,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-04,2022-07,"AHP Corporate Office, Sudbury, Massachusetts, 01776, United States"
NCT01606189,A Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to Treat Brachial Plexus Injury Pain,https://clinicaltrials.gov/study/NCT01606189,COMPLETED,YES,Pain,DRUG: GW-1000-02|DRUG: GW-2000-02|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",48,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2001-12,2002-09,"The Royal National Orthopaedic Hospital, Middlesex, HA7 4LP, United Kingdom"
NCT06058702,Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans,https://clinicaltrials.gov/study/NCT06058702,RECRUITING,NO,Schizophrenia|Cannabis Use Disorder,DRUG: Delta-9-THC|DRUG: Placebo,Yale University,National Institute on Drug Abuse (NIDA),ALL,ADULT,215,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2024-09-16,2028-12-31,"West Haven Veterans Affairs Medical Center, West Haven, Connecticut, 06516, United States"
NCT04239469,"Phase II Clinical Trial, Use of KL16-012 in Women With Fibromyalgia Refractary to Conventional Treatment.",https://clinicaltrials.gov/study/NCT04239469,UNKNOWN,NO,Fibromyalgia|Cannabis,DRUG: KL16-012|DRUG: Placebo,Knop Laboratorios,,FEMALE,"ADULT, OLDER_ADULT",44,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-01-15,2020-09-15,
NCT00798109,Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse,https://clinicaltrials.gov/study/NCT00798109,COMPLETED,NO,"Schizophrenia|Cannabis Dependence, Continuous",BEHAVIORAL: Motivational therapy|BEHAVIORAL: Usual care,Assistance Publique - Hôpitaux de Paris,,ALL,"ADULT, OLDER_ADULT",97,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-11,2013-04,"Service de psychiatrie (Pr Adès), Colombes, 92700, France"
NCT05855668,Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment,https://clinicaltrials.gov/study/NCT05855668,RECRUITING,NO,Alcohol Use Disorder|Cannabis Use Disorder,BEHAVIORAL: CBT,Centre for Addiction and Mental Health,Canadian Institutes of Health Research (CIHR)|AFP Innovation Fund,ALL,"ADULT, OLDER_ADULT",400,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11-10,2027-12,"Centre for Addiction and Mental Health, Toronto, Ontario, M6J 1H4, Canada"
NCT04495725,Do Discounted Vouchers for Medical Cannabis Reduce Opioid Use in Adults With Pain,https://clinicaltrials.gov/study/NCT04495725,COMPLETED,NO,Opioid Use|Marijuana|Chronic Pain,OTHER: Discounted Vouchers for Medical Cannabis Soft-Gel Capsule Products,Vireo Health,,ALL,"ADULT, OLDER_ADULT",270,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-06,2024-03-13,"Vireo Health of New York, Queens, New York, 11373, United States"
NCT00711646,A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.,https://clinicaltrials.gov/study/NCT00711646,COMPLETED,YES,Spasticity|Multiple Sclerosis,DRUG: Sativex®|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",189,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2002-06,2004-03,"Royal Berkshire Hospital, Reading, Oxfordshire, RG1 5AN, United Kingdom"
NCT05119244,Environment and Lung Cancer,https://clinicaltrials.gov/study/NCT05119244,UNKNOWN,NO,Cannabis Use,OTHER: blood and hair sampling,Centre Chirurgical Marie Lannelongue,,ALL,ADULT,150,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-10-01,2023-10-01,"Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, 92350, France|Institut Gustave Roussy, Villejuif, France"
NCT04791917,"Marijuana Use, Strength Training, and Alcohol Consumption (MUSTAC) Study",https://clinicaltrials.gov/study/NCT04791917,COMPLETED,YES,Chronic Pain,BEHAVIORAL: Eccentric Biceps Flexion|BEHAVIORAL: Concentric Biceps Flexion,University of Florida,National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Research Society on Alcohol,ALL,"ADULT, OLDER_ADULT",51,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-10-28,2022-05-10,"University of Florida Center for Pain Research and Behavioral Health, Gainesville, Florida, 32610, United States"
NCT03276221,Cognitive Recovery With Cannabis Abstinence Among High School-Aged Adolescents,https://clinicaltrials.gov/study/NCT03276221,COMPLETED,YES,Cannabis Use|Cognitive Change|Adolescent Behavior,BEHAVIORAL: Abstinence,Massachusetts General Hospital,,ALL,"CHILD, ADULT",201,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2017-08-07,2022-11-09,"Massachusetts General Hospital, Boston, Massachusetts, 02114, United States"
NCT01827332,Effect of Oxytocin on Craving and Therapy Response,https://clinicaltrials.gov/study/NCT01827332,COMPLETED,YES,Marijuana Dependence,DRUG: Oxytocin|DRUG: Saline,Medical University of South Carolina,,ALL,"ADULT, OLDER_ADULT",16,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-03,2016-07,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT00710554,"A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia",https://clinicaltrials.gov/study/NCT00710554,COMPLETED,YES,Pain|Peripheral Neuropathy,DRUG: Sativex|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",246,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2005-08,2006-10,"Pain Clinic Office, Gartnavel General Hospital,, Glasgow, West Lothain, G12 0YN, United Kingdom"
NCT02913924,Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients,https://clinicaltrials.gov/study/NCT02913924,COMPLETED,YES,Cannabis Use Disorder,DRUG: Clonazepam|DRUG: Placebo,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",68,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-12,2020-06,"Substance Treatment Research Service (STARS) of Columbia University, New York, New York, 10032, United States"
NCT00552604,MUltiple Sclerosis and Extract of Cannabis (MUSEC) Study,https://clinicaltrials.gov/study/NCT00552604,TERMINATED,NO,Muscle Spasticity,DRUG: standardized cannabis extract|DRUG: Placebo,"Institut fur Klinische Forschung, Germany",Weleda AG,ALL,ADULT,279,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-06,2008-11,"Peninsula Medical School, Plymouth, PL6 8BX, United Kingdom"
NCT00713817,A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain,https://clinicaltrials.gov/study/NCT00713817,COMPLETED,YES,Pain|Peripheral Neuropathy,DRUG: Sativex®|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",19,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2007-03,2007-07,"Pain Management Research, Clinical Trials Unit, Netherwood House, Solihull Hospital, Solihull, West Midlands, B91 2JL,, United Kingdom"
NCT03929835,Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa,https://clinicaltrials.gov/study/NCT03929835,WITHDRAWN,NO,Hidradenitis Suppurativa,DRUG: Cannabis oil|DRUG: Placebo,TO Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-09-01,2022-09-01,"Haemek Hospital, Afula, Israel"
NCT06149988,Comparative PK Study Of THC/CBD Formulations,https://clinicaltrials.gov/study/NCT06149988,RECRUITING,NO,Cannabis,DRUG: THC/CBD S.E powder|DRUG: THC/CBD oil,CapSoil,,ALL,"ADULT, OLDER_ADULT",14,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2023-08-27,2024-02-01,"Laniado Hospital, Netanya, 42150, Israel"
NCT01005810,A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana,https://clinicaltrials.gov/study/NCT01005810,COMPLETED,YES,Cannabis Dependence,DRUG: N-Acetylcysteine|DRUG: placebo|BEHAVIORAL: Contingency Management,Medical University of South Carolina,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",116,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-09,2011-08,"Medical University of South Carolina, Charleston, South Carolina, 29403, United States"
NCT03245658,The Effect of Cannabis in Pancreatic Cancer,https://clinicaltrials.gov/study/NCT03245658,WITHDRAWN,NO,Neoplasms Pancreatic|Cachexia; Cancer|Cannabis|Appetite Loss|Palliative Medicine|Morbidity|Mortality,DRUG: THC and CBD Mixture,Jens Rikardt Andersen,,ALL,"ADULT, OLDER_ADULT",0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2017-10-06,2018-10-06,"Department of clinical oncology, Næstved-Roskilde Hospital, Naestved, 4700, Denmark"
NCT03805750,Trial of Cannabis for Essential Tremor,https://clinicaltrials.gov/study/NCT03805750,COMPLETED,YES,Essential Tremor,DRUG: CBD/THC|DRUG: Placebo oral capsule,"University of California, San Diego",International Essential Tremor Foundation|Tilray|Center for Medicinal Cannabis Research,ALL,"ADULT, OLDER_ADULT",7,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-01-22,2020-11-30,"University of California San Diego, La Jolla, California, 92093, United States"
NCT00142961,Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder,https://clinicaltrials.gov/study/NCT00142961,COMPLETED,NO,Attention Deficit Disorder With Hyperactivity|Marijuana Abuse,DRUG: Atomoxetine|OTHER: placebo,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",2,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-10,2007-01,"Phoenix House, New York, New York, 10032, United States"
NCT02044809,Cannabidiol: a Novel Intervention for Cannabis Use Problems?,https://clinicaltrials.gov/study/NCT02044809,COMPLETED,NO,Cannabis Use Disorder,DRUG: Cannabidiol|DRUG: Placebo,"University College, London",,ALL,"CHILD, ADULT",82,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2014-03,2017-06-05,"Clinical Psychopharmacology Unit, London, United Kingdom"
NCT01565174,The Pharmaco-genetic and Brain Mechanisms Associated With Cannabis- Induced Psychosis,https://clinicaltrials.gov/study/NCT01565174,UNKNOWN,NO,Cannabis Dependence|Psychosis,,Hadassah Medical Organization,,MALE,ADULT,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-10,2014-10,"Hadassah Medical Organization, Jerusalem, Israel, Jerusalem, 91120, Israel"
NCT03328676,The Effect of Cannabis on Dementia Related Agitation and Aggression,https://clinicaltrials.gov/study/NCT03328676,COMPLETED,NO,Agitation Related to Dementia,DRUG: Cannabis|DRUG: Placebo oil,TO Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",64,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-12-07,2019-08-18,"Laniado Hospital, Netanya, Israel"
NCT04266314,Maternal Marijuana Use and Fetal and Infant Outcome,https://clinicaltrials.gov/study/NCT04266314,WITHDRAWN,NO,Cannabis Use Disorder|Pregnancy Related,DEVICE: Maternal-fetal monitoring|OTHER: NICU Network Neurobehavioral Scale,Johns Hopkins University,National Institute on Drug Abuse (NIDA),FEMALE,ADULT,0,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-04-10,2021-02-15,"Johns Hopkins Bayview Medical Center, Baltimore, Maryland, 21224, United States"
NCT01424566,A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT01424566,COMPLETED,YES,Pain|Advanced Cancer,DRUG: Nabiximols|DRUG: Placebo (GA-0034),Jazz Pharmaceuticals,"Otsuka Pharmaceutical Development & Commercialization, Inc.",ALL,"ADULT, OLDER_ADULT",406,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-06-29,2015-12-28,"East Melbourne, 3002, Australia|Parkville, 3050, Australia|Shumen, 9700, Bulgaria|Varna, 9010, Bulgaria|Vratsa, 3000, Bulgaria|Lunen, 44534, Germany|Stadtroda, 07646, Germany|Wetzlar, 35578, Germany|Budapest, 1135, Hungary|Deszk, 6772, Hungary|Komárom, 2900, Hungary|Nyíregyháza, 4412, Hungary|Szikszó, 3800, Hungary|Bangalore, 560034, India|Jaipur, 302017, India|Pune, 411004, India|Ashkelon, 78306, Israel|Beer Sheva, 84101, Israel|Haifa, 31096, Israel|Jerusalem, 91120, Israel|Ramat Gan, 52621, Israel|Zerifin, 60930, Israel|Garbagnate Milanese, 20024, Italy|Piacenza, 29100, Italy|Torino, 10126, Italy|Klaipeda, 92288, Lithuania|Siauliai, 76307, Lithuania|Vilnius, 08660, Lithuania|Bydgoszcz, 85-796, Poland|Czeladź, 41-250, Poland|Gdansk, 80-208, Poland|Gliwice, 44-101, Poland|Klodzko, 57-300, Poland|Opole, 45-272, Poland|Ostrowiec Swietokrzyski, 27-400, Poland|Poznan, 61-245, Poland|Warszawa, 02-781, Poland|Warszawa, 02-793, Poland|Wloclawek, 87-800, Poland|Alba Iulia, 510077, Romania|Baia Mare, 430241, Romania|Braila, 810325, Romania|Bucuresti, 010976, Romania|Focșani, 620165, Romania|Oradea, 410469, Romania|Satu Mare, 440055, Romania|Sibiu, 550245, Romania|Suceava, 720237, Romania|Cadiz, 11009, Spain|Granada, 18014, Spain|Madrid, 28050, Spain|Salamanca, 37129, Spain|Sevilla, 41013, Spain|Changhua City, 500, Taiwan|Taichung, 404, Taiwan|Tainan City, 73657, Taiwan|Taipei, 10002, Taiwan|Taipei, 10099, Taiwan|Taipei, 11213, Taiwan|Taipei, 11490, Taiwan|Bury Saint Edmunds, IP33 2QZ, United Kingdom|Edinburgh, EH4 2XR, United Kingdom|Glasgow, G12 0YN, United Kingdom|Manchester, M20 4BX, United Kingdom|Norwich, NR4 7UY, United Kingdom"
NCT00711880,A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.,https://clinicaltrials.gov/study/NCT00711880,COMPLETED,YES,Pain|Peripheral Neuropathy,DRUG: Sativex®|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",125,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2002-05,2004-03,"Clinical Trials Unit, The Walton Centre, Fazakerley, Liverpool, L9 7LJ, United Kingdom"
NCT01898520,"A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years",https://clinicaltrials.gov/study/NCT01898520,COMPLETED,NO,Cerebral Palsy,DRUG: Sativex|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"CHILD, ADULT",72,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-12,2017-03,"Center 14, Prague, Czechia|Center 7, Tel Aviv, Israel|Center 8, Tel Hashomer, Israel|Center 2, Bristol, United Kingdom|Center 6, Cambridge, United Kingdom|Center 10, Exeter, United Kingdom|Center 13, Glasgow, United Kingdom|Center 3, Liverpool, United Kingdom|Center 1, London, United Kingdom|Center 5, London, United Kingdom|Center 12, Norwich, United Kingdom|Center 9, Nottingham, United Kingdom|Center 11, Salisbury, United Kingdom|Center 4, Sheffield, United Kingdom"
NCT02932527,Effect of Cannabis Consumption on Sperm Nuclear Quality in Infertile Men,https://clinicaltrials.gov/study/NCT02932527,UNKNOWN,NO,Teratozoospermia,BEHAVIORAL: Questionnaire about cannabis consumption|PROCEDURE: blood intake|PROCEDURE: Semen samples collection,"University Hospital, Rouen",,MALE,ADULT,200,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2017-08-29,2020-08,"Caen University Hospital, Caen, France|Lille University Hospital, Lille, France|Rouen University Hospital, Rouen, France"
NCT00598052,Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy,https://clinicaltrials.gov/study/NCT00598052,UNKNOWN,NO,Marijuana Dependence,DRUG: Escitalopram,Tel-Aviv Sourasky Medical Center,,ALL,ADULT,40,OTHER_GOV,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-12,2008-10,"Sourasky Medical Center, Tel Aviv, 64239, Israel"
NCT05099016,Joint Effort Study,https://clinicaltrials.gov/study/NCT05099016,COMPLETED,NO,Cannabis Use,OTHER: Joint Effort|OTHER: Brief normative feedback and standard information,Centre hospitalier de l'Université de Montréal (CHUM),,ALL,ADULT,99,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-11-15,2022-07-31,"Université de Montréal, Montréal, Canada"
NCT05345951,Project e-PBI+ - Parent Intervention to Reduce College Student Drinking and Cannabis Use,https://clinicaltrials.gov/study/NCT05345951,RECRUITING,NO,"Underage Drinking|Cannabis Use|Drinking, Teen|Drinking, College|College Drinking|Teen Drinking",BEHAVIORAL: e-PBI+|BEHAVIORAL: e-PBI,Penn State University,,ALL,ADULT,2425,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION,2023-07-13,2026-07,"Penn State University, University Park, Pennsylvania, 16802, United States"
NCT05037487,Evaluation of Smoked THC and CBD in Men and Women,https://clinicaltrials.gov/study/NCT05037487,RECRUITING,NO,Drug Abuse|Intoxication by Drug|Impairment,DRUG: Placebo Cannabis|DRUG: 20 mg CBD Cannabis|DRUG: 20 mg CBD + 20 mg THC Cannabis|DRUG: 20 mg THC Cannabis,"University of California, Los Angeles",,ALL,ADULT,22,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2022-09-01,2026-03-01,"University of California, Los Angeles, Los Angeles, California, 90095, United States"
NCT06320470,MIVetsCan: Can-Coach Trial (Phase 1),https://clinicaltrials.gov/study/NCT06320470,COMPLETED,NO,Chronic Pain,BEHAVIORAL: Educational Session,University of Michigan,"Michigan, State of, Licensing and Regulatory Affairs",ALL,"ADULT, OLDER_ADULT",22,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-08-07,2023-12-11,"The University of Michigan, Ann Arbor, Michigan, 48109, United States"
NCT05979272,TECH App Marijuana Use Intervention for Court-Involved Adolescents,https://clinicaltrials.gov/study/NCT05979272,RECRUITING,NO,Cannabis Use|Adolescent,BEHAVIORAL: Treatment as usual|BEHAVIORAL: Teen Empowerment through Computerized Health (TECH) app,Northwestern University,Brown University|Rhode Island Hospital|National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-21,2025-03,"Northwestern University Feinberg School of Medicine, Chicago, Illinois, 60614, United States|Rhode Island Hospital, Chicago, Illinois, 60614, United States|Rhode Island Family Court, Providence, Rhode Island, 02903, United States|Brown University, Providence, Rhode Island, 02912, United States"
NCT05049733,The Pharmacokinetics and Pharmacodynamics of a Single Acute Dose of a Hemp-derived Oral Product With a 1:1 Ratio of CBD:CBD-A,https://clinicaltrials.gov/study/NCT05049733,COMPLETED,NO,Cannabis,DRUG: CBD 1mg/Kg|DRUG: CBD 2mg/Kg|DRUG: CBD 4mg/Kg|DRUG: Placebo CBD,Johns Hopkins University,Cultivate Biologics,ALL,ADULT,21,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2022-03-07,2023-06-01,"Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland, 21224, United States"
NCT04883255,"Cannabis Use, Cognition, and the Endocannabinoid System in HIV",https://clinicaltrials.gov/study/NCT04883255,RECRUITING,NO,HIV-1-infection,DRUG: 10 mg Δ9-tetrahydrocannabinol (THC)|DRUG: 600 mg cannabidiol (CBD)|DRUG: Placebo,"University of California, San Diego",National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",138,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2023-05-03,2026-01-31,"UC San Diego Medical Center-Hillcrest, San Diego, California, 92103-8620, United States"
NCT03624933,Effects of Cannabis Abstinence on Symptoms and Cognition in Depression,https://clinicaltrials.gov/study/NCT03624933,COMPLETED,NO,Cannabis Use Disorder|Major Depressive Disorder|Cognition,BEHAVIORAL: Weekly Behavioral Coaching Session|BEHAVIORAL: Contingency Management,Centre for Addiction and Mental Health,,ALL,ADULT,19,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-11-06,2019-12-30,"Centre for Addiction and Mental Health, Toronto, Ontario, M6J1H4, Canada"
NCT05633043,Validation of the Cannabis Abuse Screening Test in General Practice(GP-CAST),https://clinicaltrials.gov/study/NCT05633043,UNKNOWN,NO,Cannabis|Addictive Behavior|General Practice|Primary Care|Substance-Related Disorders|Questionnaires,,"University Hospital, Clermont-Ferrand",,ALL,"CHILD, ADULT",660,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-01-01,2024-06-01,"Département de Médecine Générale de Clermont-Ferrand, Clermont-Ferrand, France|Département de Médecine Générale de Grenoble, Grenoble, France|Département Universitaire de Médecine Générale, Lyon, Lyon, France|Département de Médecine Générale de Saint-Etienne, Saint-Étienne, France|Département Universitaire de Médecine Générale, Toulouse, Toulouse, France"
NCT03936907,"Comparison of Safety, Tolerability and Pharmacokinetics of Medical Grade Cannabis (MGC) Orally Disintegrating Tablets With Buccal Sativex®, in Healthy Adult Volunteers",https://clinicaltrials.gov/study/NCT03936907,COMPLETED,NO,Healthy Subjects,DRUG: OWCP Orally Disintegrating Tablet|DRUG: Sativex,One World Cannabis Ltd.,,MALE,ADULT,16,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2019-04-15,2019-07-18,"Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (isr), 6423906, Israel"
NCT01606176,A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin,https://clinicaltrials.gov/study/NCT01606176,COMPLETED,YES,Pain|Multiple Sclerosis,DRUG: GW-1000-02|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",70,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2002-03,2002-08,"James Paget Hospital, Norfolk, NR31 6LA, United Kingdom"
NCT04704271,Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II,https://clinicaltrials.gov/study/NCT04704271,RECRUITING,NO,Cannabis,DRUG: Inhaled THC|DRUG: Placebo,Yale University,,ALL,ADULT,100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2019-10-09,2024-12-01,"Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut, 06516, United States"
NCT05065567,"Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis",https://clinicaltrials.gov/study/NCT05065567,TERMINATED,NO,Cyclic Vomiting Syndrome,DRUG: Droperidol|DRUG: Haloperidol|DRUG: Ondansetron 8mg,Spectrum Health - Lakeland,,ALL,"ADULT, OLDER_ADULT",38,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-08-30,2023-11-20,"Lakeland Regional Healthcare, Saint Joseph, Michigan, 49085, United States"
NCT01071135,Quetiapine XR in Schizophrenic Patients,https://clinicaltrials.gov/study/NCT01071135,TERMINATED,NO,Schizophrenia,DRUG: Quetiapine XR,Hannover Medical School,AstraZeneca,ALL,ADULT,5,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-09,2010-08,"Hannover Medical School, Hannover, 30625, Germany|Krankenhaus Lübbecke, Lübbecke, 32312, Germany|Klinikum Wahrendorff, Sehnde, 31319, Germany"
NCT06085222,Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users,https://clinicaltrials.gov/study/NCT06085222,RECRUITING,NO,Cannabis Use Disorder,BEHAVIORAL: Emotional Engagement Distress Tolerance Intervention|BEHAVIORAL: Health Education Intervention,Auburn University,Northwestern University|Duke University|National Institute on Drug Abuse (NIDA),ALL,ADULT,80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-06-25,2026-11-30,"Auburn University, Auburn, Alabama, 36849, United States"
NCT03069612,rTMS Treatment for Cannabis Use Disorders in Psychosis,https://clinicaltrials.gov/study/NCT03069612,TERMINATED,NO,Cannabis Use Disorder|Psychosis,DEVICE: Repetitive Transcranial Magnetic Stimulation (rTMS),Centre for Addiction and Mental Health,,ALL,"CHILD, ADULT",4,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2016-12-01,2017-08-28,"Centre for Addiction and Mental Health, Toronto, Ontario, M5S2S1, Canada"
NCT04816994,Effect of Cannabis Extract on Acute Radicular Pain and on Analgesic Requirement,https://clinicaltrials.gov/study/NCT04816994,RECRUITING,NO,Acute Radicular Back Pain|Cannabis,DRUG: Single-dose of cannabis oil|DRUG: Control,Hadassah Medical Organization,,ALL,"ADULT, OLDER_ADULT",200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2018-01-07,2024-12-31,"Hadassah Medical Center, Jerusalem, Israel"
NCT01292577,Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia,https://clinicaltrials.gov/study/NCT01292577,COMPLETED,NO,Schizophrenia|Schizoaffective Disorder,BEHAVIORAL: CET/PT|BEHAVIORAL: Treatment as Usual,University of Pittsburgh,National Institute on Drug Abuse (NIDA),ALL,ADULT,33,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2010-09,2014-09,"University of Pittsburgh, Pittsburgh, Pennsylvania, 15213, United States"
NCT03379857,Prevalence of Strokes Secondary to a Reversible Cerebral Vasoconstriction Attributable to Cannabis Consumption in Young Subjects (≤ 45 Years) Hospitalized for an Ischaemic Stroke,https://clinicaltrials.gov/study/NCT03379857,ACTIVE_NOT_RECRUITING,NO,Stroke|Cannabis Use,OTHER: Drug urinal test,"University Hospital, Strasbourg, France",,ALL,ADULT,300,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2018-01-11,2025-01-11,"Chu Jean Minjoz, Besancon, 25030, France|Unite Neuro-Vasculaire, Colmar, 68024, France|Chu Bocage, Dijon, 21079, France|C.H. G. Muller, Mulhouse, 68070, France|Hopital Central, Nancy, 54035, France|Les Hôpitaux Universitaires de Strasbourg, Strasbourg, 67098, France"
NCT03144232,A Preliminary Investigation of Pre-Frontal Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT03144232,COMPLETED,YES,Cannabis Use Disorder,DEVICE: Active rTMS|DEVICE: Sham rTMS,Stanford University,National Institute on Drug Abuse (NIDA),ALL,ADULT,72,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-08-01,2022-07-30,"Stanford University, Palo Alto, California, 94304, United States"
NCT02865096,The Correlation of Women's Sexual Health and Marijuana Use,https://clinicaltrials.gov/study/NCT02865096,COMPLETED,NO,Women's Sexual Health,,St. Louis University,,FEMALE,"ADULT, OLDER_ADULT",373,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-03-01,2017-02-01,"St. Mary's Health Center, Saint Louis, Missouri, 63117, United States"
NCT06225232,Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study,https://clinicaltrials.gov/study/NCT06225232,NOT_YET_RECRUITING,NO,"Cannabis Use Disorder, Moderate|Cannabis Use Disorder, Severe",DRUG: Psilocybin combined with Psychotherapy,McMaster University,Center for Medicinal Cannabis Research,ALL,"ADULT, OLDER_ADULT",16,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-03,2026-06,
NCT03522103,"Cannabis Observational Study on Mood, Inflammation, and Cognition",https://clinicaltrials.gov/study/NCT03522103,COMPLETED,NO,Inflammation|Inflammatory Response|Mood|Cognitive Change,,"University of Colorado, Denver","University of Colorado, Boulder",ALL,"ADULT, OLDER_ADULT",421,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-07-01,2020-12-15,"University of Colorado Denver, Aurora, Colorado, 80045, United States"
NCT06607835,Cannabis Suppositories and Mindful Compassion Online Groups for Sexual Functioning,https://clinicaltrials.gov/study/NCT06607835,COMPLETED,NO,Sexual Pain Disorders,BEHAVIORAL: Mindful- compassion|BEHAVIORAL: Mindful-compassion and cannabis suppositories,London Metropolitan University,,FEMALE,"ADULT, OLDER_ADULT",83,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-07-02,2024-04-04,"School of Social Sciences and Professions, London, N7 8DB, United Kingdom"
NCT02083874,Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study,https://clinicaltrials.gov/study/NCT02083874,UNKNOWN,NO,Cannabis Use Disorder,DRUG: CBD,The University of New South Wales,,ALL,"ADULT, OLDER_ADULT",5,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-03,2014-12,
NCT00480441,Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal,https://clinicaltrials.gov/study/NCT00480441,COMPLETED,YES,Marijuana Dependence,DRUG: Dronabinol|BEHAVIORAL: BRENDA therapy|DRUG: Placebo,University of Pennsylvania,National Institute on Drug Abuse (NIDA),ALL,ADULT,61,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-08,2009-07,"Treatment Research Center at the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States"
NCT01868048,"Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.",https://clinicaltrials.gov/study/NCT01868048,WITHDRAWN,NO,Spasticity|Multiple Sclerosis,DRUG: Sativex|DRUG: Placebo,GW Research Ltd,,ALL,"ADULT, OLDER_ADULT",0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",,,
NCT02517424,Evaluating Safety and Efficacy of Cannabis in Participants With Chronic Posttraumatic Stress Disorder,https://clinicaltrials.gov/study/NCT02517424,COMPLETED,NO,Posttraumatic Stress Disorder,DRUG: High THC/Low CBD Cannabis|DRUG: High THC/High CBD Cannabis|DRUG: Low THC/Low CBD Cannabis,Tilray,University of British Columbia,ALL,"ADULT, OLDER_ADULT",6,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-02-07,2019-03-22,"University of British Columbia, Kelowna, British Columbia, V1V 1V7, Canada"
NCT00438139,Ph1 Marinol Interaction Study - Part 1 - 1,https://clinicaltrials.gov/study/NCT00438139,TERMINATED,NO,Marijuana Dependence,DRUG: Dronabinol,National Institute on Drug Abuse (NIDA),,ALL,ADULT,6,NIH,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-03,2007-03,"Uniformed Services University of Health Science, Bethesda, Maryland, 20814 4799, United States"
NCT04799093,Eye Movement Tracking to Detect Impairment Due to Acute Cannabis Intoxication,https://clinicaltrials.gov/study/NCT04799093,COMPLETED,NO,Impairment|Cannabis Intoxication,DIAGNOSTIC_TEST: EyeBOX,"Oculogica, Inc.",,ALL,"ADULT, OLDER_ADULT",225,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-02-01,2021-09-07,"Integrated Medicine LLC, Westport, Connecticut, 06880, United States"
NCT02191605,Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy,https://clinicaltrials.gov/study/NCT02191605,COMPLETED,YES,Marijuana Use|Pregnancy,BEHAVIORAL: eSBIRT|BEHAVIORAL: Tailored texting,Wayne State University,National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA),FEMALE,ADULT,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-09-30,2017-10-27,"Wayne State University, Detroit, Michigan, 48202, United States"
NCT03786224,Pilot Trial of Contingency Management for Long-Term Cannabis Abstinence,https://clinicaltrials.gov/study/NCT03786224,COMPLETED,YES,Cannabis Use|Adolescent Behavior,BEHAVIORAL: Contingency Management,Massachusetts General Hospital,,ALL,"CHILD, ADULT",6,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2019-07-01,2019-12-06,"Massachusetts General Hospital, Boston, Massachusetts, 02114, United States"
NCT02811510,Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I,https://clinicaltrials.gov/study/NCT02811510,RECRUITING,NO,Cannabis,DRUG: Placebo|DRUG: Dronabinol,Yale University,,ALL,ADULT,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2016-06,2025-12,"Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut, 06516, United States"
NCT02781519,Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans,https://clinicaltrials.gov/study/NCT02781519,RECRUITING,NO,Cannabis,DRUG: THC|DRUG: Placebo,Yale University,,ALL,ADULT,100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2015-06,2025-12,"Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut, 06516, United States"
NCT03763851,Cannabis Oil and Radiation Therapy for the Management of Pain,https://clinicaltrials.gov/study/NCT03763851,TERMINATED,NO,Metastatic Prostate Cancer|Lung Cancer|Breast Cancer,RADIATION: Active PPP005|RADIATION: Radiotherapy,Tetra Bio-Pharma,Santé Cannabis|McGill University,ALL,"ADULT, OLDER_ADULT",100,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-03-14,2018-11-30,"Sante Cannabis, Montreal, Quebec, Canada"
NCT00393978,Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania,https://clinicaltrials.gov/study/NCT00393978,COMPLETED,YES,Bipolar Disorder|Cannabis-Related Disorder,DRUG: Quetiapine and placebo|DRUG: Quetiapine and Topiramate,University of Cincinnati,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",75,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-11,2014-03,"University of Cincinnati Medical Center, Cincinnati, Ohio, 45219-0516, United States"
NCT03662737,VRT as a Biomarker of Cerebellar Dysfunction in Chronic Cannabis Use,https://clinicaltrials.gov/study/NCT03662737,COMPLETED,NO,Cannabis Use|Alcohol Use Disorder|Healthy,DIAGNOSTIC_TEST: Visuomotor adaptation task,Hospital Clinic of Barcelona,,ALL,ADULT,61,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-09-01,2021-12-31,"Hospital Clínic, Barcelona, Catalonia, 08036, Spain"
NCT01167556,Family Motivational Intervention in Schizophrenia,https://clinicaltrials.gov/study/NCT01167556,UNKNOWN,NO,Cannabis|Schizophrenia,BEHAVIORAL: Family Motivational Intervention,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),,ALL,"CHILD, ADULT",147,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2006-03,2011-02,"Academic Medical Center, Amsterdam, North Holland, 1066 DP, Netherlands"
NCT06055231,PK/PD of Vaping THC-containing Liquids vs. Smoked Cannabis,https://clinicaltrials.gov/study/NCT06055231,NOT_YET_RECRUITING,NO,Cigarette Smoking-Related Carcinoma,BEHAVIORAL: Vape device|BEHAVIORAL: Joint|DRUG: Marijuana via vape device|DRUG: Marijuana via joint,Roswell Park Cancer Institute,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2025-03-01,2026-06-15,
NCT01292642,Cognitive Behavioral Therapy and the Nicotine Transdermal Patch for Cannabis Dependence and Nicotine Dependence,https://clinicaltrials.gov/study/NCT01292642,COMPLETED,YES,Cannabis Dependence|Nicotine Dependence,BEHAVIORAL: Cognitive Behavioral Therapy|DRUG: Nicotine Replacement Therapy,Mclean Hospital,Harvard Medical School (HMS and HSDM),ALL,"ADULT, OLDER_ADULT",12,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-08,2011-06,"McLean Hospital, Belmont, Massachusetts, 02478, United States"
NCT05765409,Assessment of the Effectiveness of an Integrative Therapy for Cannabis Misuse in Adolescents,https://clinicaltrials.gov/study/NCT05765409,RECRUITING,NO,Cannabis Use Disorder,OTHER: TIMCA|OTHER: Treatment as Usual,Centre Hospitalier St Anne,,ALL,"CHILD, ADULT",100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-02-15,2025-06-09,"GHU Paris Psychiatrie & Neurosciences, Paris, 75014, France"
NCT06609109,Effect of Cannabis on E-Cigarette Use Behavior,https://clinicaltrials.gov/study/NCT06609109,NOT_YET_RECRUITING,NO,Cannabis Use|Tobacco Use|Electronic Cigarette Use,DRUG: THC High Dose|DRUG: THC Low Dose|DRUG: THC 0mg|DRUG: E-Cigarette Full Nicotine|DRUG: E-Cigarette Placebo Nicotine,Johns Hopkins University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2025-03-15,2029-10-01,"Johns Hopkins University Behavioral Pharmacology Research Unit, Baltimore, Maryland, 21224, United States"
NCT05899101,The Impact of Opioid and Cannabis Exposure on Fetal Growth,https://clinicaltrials.gov/study/NCT05899101,RECRUITING,NO,Pregnancy Related|Substance Use|Fetal Growth Retardation|Placenta Diseases,,Dr. Laura Gaudet,University of Ottawa,FEMALE,"CHILD, ADULT, OLDER_ADULT",546,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-09-23,2026-12-31,"Hamilton Health Sciences, Hamilton, Ontario, L8N 3Z5, Canada|Kingston Health Sciences Centre, Kingston, Ontario, K7L2V7, Canada|London Health Sciences Centre, London, Ontario, N6A 5A5, Canada|The Ottawa Hospital, Ottawa, Ontario, K1H8L6, Canada|St. Michael's Hospital, Toronto, Ontario, M5B 1W8, Canada"
NCT06217146,A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.,https://clinicaltrials.gov/study/NCT06217146,TERMINATED,NO,"Agitation,Psychomotor|Disruptive Behavior|Dementia|Alzheimer Disease",DRUG: Medical Cannabis|DRUG: Placebo Oil,M. H MediCane Ltd.,,ALL,"ADULT, OLDER_ADULT",24,INDUSTRY,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-10-12,2024-03-10,"Laniado Hospital, Netanya, Israel|Sheba Medical Center, Ramat-Gan, Israel|Tel-Aviv Sourasky Medical Center Ichilov, Tel Aviv, Israel"
NCT06239701,Development of a Lifestyle Physical Activity Intervention to Reduce Risk for Perinatal Cannabis Use - RCT,https://clinicaltrials.gov/study/NCT06239701,RECRUITING,NO,Pregnancy,BEHAVIORAL: LPA+Fitbit Intervention|BEHAVIORAL: Fitbit Only,Butler Hospital,,FEMALE,"ADULT, OLDER_ADULT",50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2024-01-22,2025-05-30,"Butler Hospital, Providence, Rhode Island, 02906, United States"
NCT04841655,Tobacco Cessation Among Smokers Under Alcohol and/or Cannabis Treatment,https://clinicaltrials.gov/study/NCT04841655,UNKNOWN,NO,Mental Health Disorder|Substance Abuse Drug|Alcohol Abuse|Cannabis Use|Tobacco Use|Smoking Cessation,,Institut Català d'Oncologia,Hospital Clinic of Barcelona|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Althaia Xarxa Assistencial Universitària de Manresa|University of Barcelona|Public Health Agency of Barcelona,ALL,"ADULT, OLDER_ADULT",1625,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-10-01,2022-10,"Hospital Bellvitge, L'Hospitalet de Llobregat, Barcelona, 08908, Spain|Hospital Clinic, Barcelona, Spain"
NCT03734731,Cannabis Vs Opioids Pain Management Objective Testing Comparisons,https://clinicaltrials.gov/study/NCT03734731,NOT_YET_RECRUITING,NO,Chronic Pain|Circulatory Disorders,DEVICE: Monochromatic Infrared Photo Energy (MIRE)|DEVICE: Transcutaneous Electrical Nerve Stimulation|DRUG: Opioids|DRUG: Cannabis,American Association of Sensory Electrodiagnostic Medicine,,ALL,"CHILD, ADULT, OLDER_ADULT",1000,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2025-02-03,2026-01-03,
NCT01382433,Chronic Cannabis Users: A Model for Negative Symptoms in Schizophrenia,https://clinicaltrials.gov/study/NCT01382433,UNKNOWN,NO,Chronic Cannabis Users|Healthy Subjects,PROCEDURE: Magnetoencephalograph (MEG)|BEHAVIORAL: Cambridge Neuropsychological Test Automated Battery (CANTAB).|BEHAVIORAL: Experimental: Scale for the Assessment of Negative Symptoms (SANS) and the Positive and Negative Syndrome Scale (PANSS),Shalvata Mental Health Center,,ALL,"ADULT, OLDER_ADULT",115,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2011-07,,"Bar-Ilan University, Givat Shmuel, Israel"
NCT05751369,"Addressing Tobacco, E-Cigarette, and Cannabis Waste",https://clinicaltrials.gov/study/NCT05751369,RECRUITING,NO,"Knowledge, Attitudes, Practice",BEHAVIORAL: Education plus Support,"California State University, San Marcos","University of California, Davis",ALL,ADULT,400,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-03-01,2025-06-30,"University of California, Davis, Davis, California, 95616, United States|California State University San Marcos, San Marcos, California, 92096, United States"
NCT01329315,Project Chill: Tailored Youth Drug Intervention In Primary Care,https://clinicaltrials.gov/study/NCT01329315,COMPLETED,NO,Marijuana Use,BEHAVIORAL: BMI-T|BEHAVIORAL: BMI-C,University of Michigan,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",1141,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2005-09,2012-11,
NCT03718520,The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity,https://clinicaltrials.gov/study/NCT03718520,COMPLETED,NO,Cannabis Use Disorder|PREG1|Drug Use|Fetal Exposure During Pregnancy|Neurodevelopmental Abnormality,"OTHER: no intervention, this is a purely observational study","University of Colorado, Denver",National Institute on Drug Abuse (NIDA),FEMALE,"ADULT, OLDER_ADULT",168,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-11-07,2020-03-31,"University of Colorado Hospital, Aurora, Colorado, 80045, United States|Denver Health Medical Center, Denver, Colorado, 80204, United States"
NCT04316741,Brief Intervention Combined With Health Coaching Via Social Media for Cannabis Use,https://clinicaltrials.gov/study/NCT04316741,COMPLETED,YES,Cannabis Use,BEHAVIORAL: Snapcoach,University of Michigan,National Institute on Drug Abuse (NIDA),ALL,ADULT,63,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2020-10-19,2022-02-21,"Hurley Medical Center, Flint, Michigan, 48503, United States"
NCT04970342,Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim,https://clinicaltrials.gov/study/NCT04970342,COMPLETED,YES,Driving Behavior|Driving Under the Influence,DRUG: Placebo (Lactose) Capsule|DRUG: 0.75 mg Alprazolam Capsule|DRUG: Cannabis (6.18% THC / <0.025% CBD)|DRUG: Cannabis (0%/ THC / 0% CBD),Timothy L. Brown,"National Highway Traffic Safety Administration (NHTSA)|Acclaro Research Solutions, Inc.|Cognitive Research Corporation",ALL,ADULT,13,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2021-07-16,2021-08-21,"National Advanced Driving Simulator, Iowa City, Iowa, 52242, United States"
NCT05974293,A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders,https://clinicaltrials.gov/study/NCT05974293,NOT_YET_RECRUITING,NO,"NMO Spectrum Disorder|Spasticity, Muscle",DRUG: Nabiximols|DRUG: Placebo,"Michael, Levy M.D.,Ph.D.",Jazz Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",44,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2025-01,2026-09,"Massachusetts General Hospital, Boston, Massachusetts, 02114, United States"
NCT03386487,Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD),https://clinicaltrials.gov/study/NCT03386487,COMPLETED,YES,Cannabis Use Disorder,DRUG: PF 04457845|DRUG: Placebo Oral Tablet,Yale University,Columbia University|Johns Hopkins University|Medical University of South Carolina|National Institute on Drug Abuse (NIDA),ALL,ADULT,228,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-01-14,2022-07-25,"Connecticut Mental Health Center, New Haven, Connecticut, 06519, United States|Johns Hopkins University, Baltimore, Maryland, 21224, United States|Columbia University Medical College / New York State Psychiatric Institute, New York, New York, 10032, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT06099379,Modulation of THC Effects by CBD: a Dose-ranging Study,https://clinicaltrials.gov/study/NCT06099379,RECRUITING,NO,Cannabis|THC,DRUG: ∆9-tetrahydrocannabinol,Centre hospitalier de l'Université de Montréal (CHUM),,ALL,ADULT,100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2024-06-27,2025-12-31,"Centre de recherche du Centre Hospitalier Universitaire de Montréal, Montréal, Quebec, H2X0A9, Canada"
NCT04810858,Modeling the Effects of Chronic Marijuana Use on Neuroinflammation and HIV-related Neuronal Injury,https://clinicaltrials.gov/study/NCT04810858,RECRUITING,NO,Cannabis|HIV|Inflammation|Cognition|Neuroimaging,"OTHER: Multimodal, multi-parametric MRI|OTHER: Immune and cytokine profiling|BEHAVIORAL: Neuropsychological testing",Wake Forest University Health Sciences,National Institute on Drug Abuse (NIDA),ALL,ADULT,220,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-08-18,2025-05-31,"Biotech Place, Winston-Salem, North Carolina, 27101, United States"
NCT05052541,Safety and Efficacy of Oral Cannabis in Chronic Spine Pain,https://clinicaltrials.gov/study/NCT05052541,UNKNOWN,NO,Back Pain|Neck Pain,DRUG: THC/CBD|DRUG: THC|DRUG: Placebo,"University of Colorado, Denver",Colorado Department of Public Health and Environment,ALL,"ADULT, OLDER_ADULT",157,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-02,2024-06,"University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, United States"
NCT05908552,Topical Cannabis for Chronic Musculoskeletal Pain,https://clinicaltrials.gov/study/NCT05908552,NOT_YET_RECRUITING,NO,Chronic Pain|Musculoskeletal Pain|Joint Pain,,"University of Colorado, Denver",,ALL,"ADULT, OLDER_ADULT",77,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-07-01,2024-08-31,
NCT00674609,A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy,https://clinicaltrials.gov/study/NCT00674609,COMPLETED,YES,Palliative Care|Pain|Cancer,DRUG: Placebo|DRUG: Sativex®|DRUG: THC Alone,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",177,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2002-02,2004-03,"Shropshire and Mid-Wales Hospice, Shrewsbury, SY3 8HS, United Kingdom"
NCT02803229,Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder,https://clinicaltrials.gov/study/NCT02803229,COMPLETED,YES,Cannabis Use Disorder|Attention-deficit/Hyperactivity Disorder,DRUG: Adderall-XR|DRUG: Matched placebo,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",33,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-07,2020-06,"New York Psychiatric Institute, New York, New York, 10032, United States"
NCT01088542,The Community Youth Development Study: A Test of Communities That Care,https://clinicaltrials.gov/study/NCT01088542,ACTIVE_NOT_RECRUITING,NO,Substance Abuse|Juvenile Delinquency|Sexual Behavior|Criminal Behavior|Violence|Depression|Anxiety|Suicide|Sexually Transmitted Infection|Educational Attainment,BEHAVIORAL: Communities That Care,University of Washington,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT, OLDER_ADULT",52323,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2003-10-01,2025-06-30,"University of Washington, Seattle, Washington, 98115, United States"
NCT03675971,COPE: Cannabinoids to Obviate Pain Experiment After Knee Replacement,https://clinicaltrials.gov/study/NCT03675971,UNKNOWN,NO,"Arthroplasty, Replacement, Knee",DRUG: Cannabinol|DRUG: Placebo oral capsule,Unity Health Toronto,,ALL,"ADULT, OLDER_ADULT",220,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-05-01,2022-05,"St. Michael's Hospital, Toronto, Ontario, M5B 1W8, Canada"
NCT00969696,Galantamine Effects on Cognitive Function in Marijuana Users,https://clinicaltrials.gov/study/NCT00969696,COMPLETED,NO,Memory,DRUG: Placebo|DRUG: Galantamine,Yale University,National Institute on Drug Abuse (NIDA)|US Department of Veterans Affairs,ALL,ADULT,29,OTHER,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SCREENING",2009-08,2011-07,"Department of Veterans Affairs, West Haven, Connecticut, 06516, United States"
NCT05453513,The Neural Underpinnings of Depression and Cannabis Use in Young People Living With HIV,https://clinicaltrials.gov/study/NCT05453513,RECRUITING,NO,Hiv|Depression|Cannabis Use Disorder,,University of Miami,National Institute on Drug Abuse (NIDA),ALL,ADULT,280,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-04-01,2027-07-30,"University of Miami, Miami, Florida, 33136, United States"
NCT04864860,Effect of Sea Weed (Ecklonia Cava Extract) on Blood Glucose and Insulin Level on Pre-diabetic Patients,https://clinicaltrials.gov/study/NCT04864860,UNKNOWN,NO,PreDiabetes,DIETARY_SUPPLEMENT: brown seaweed (ecklonia cava),King Saud University,Dr. Khalid ALdybayan|Ms. Haneen Molla|Dr. Abdullah Alquwaihes,ALL,"ADULT, OLDER_ADULT",30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-03-01,2021-12-30,"clinical Trial Unit, Riyadh, 11362, Saudi Arabia"
NCT06322303,Effect of Cannabidiol (CBD) on Vision and Driving,https://clinicaltrials.gov/study/NCT06322303,ACTIVE_NOT_RECRUITING,NO,Cannabis Use,OTHER: Placebo (CBD 0%)|OTHER: CBD 15%|OTHER: CBD 30%,Universidad de Granada,,ALL,ADULT,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2023-02-01,2025-12-31,"University of Granada, Granada, 18071, Spain"
NCT06435299,"Efficacy and Tolerance of Cannabidiol in Patients with Severe Pruritus: a Multicenter, Double-blind, Randomized, Placebo-controlled Study",https://clinicaltrials.gov/study/NCT06435299,NOT_YET_RECRUITING,NO,Pruritus,DRUG: Cannabis oil|DRUG: Placebo,"University Hospital, Brest",,ALL,"ADULT, OLDER_ADULT",218,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2025-05-01,2027-07-01,"CHU Angers, Angers, 49000, France|CHD Vendée, La Roche Sur Yon, 85925, France|Groupe Hospitalier La Rochelle, La Rochelle, 17300, France|CHU de Nantes, Nantes, 44093, France|CHU de Poitiers, Poitiers, 86000, France|CHU de Rennes, Rennes, 35033, France|CHRU de Tours, Tours, 37044, France"
NCT06314204,"Impact of Cannabis Consumption on the Course, Modalities of Hospitalization and the Short-term Prognosis of Inpatients Suffering From Psychotic Symptoms",https://clinicaltrials.gov/study/NCT06314204,RECRUITING,NO,"Psychotic; Disorder, Cannabis",,"Centre hospitalier de Ville-Evrard, France",,ALL,"ADULT, OLDER_ADULT",200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-09-20,2026-09-06,"unité de recherche clinique de l'E.P.S de Ville Evrard, Neuilly Sur Marne, 93332, France"
NCT01170260,"Alcohol, Marijuana, and Risky Sex: Group Interventions With Detained Adolescents",https://clinicaltrials.gov/study/NCT01170260,COMPLETED,YES,Risk Reduction Behavior|Health Behavior|Sexual Behavior|Adolescent Behavior|Cannabis,BEHAVIORAL: INFORMATION-ONLY SEXUAL RISK REDUCTION (INFO-ONLY)|BEHAVIORAL: SEXUAL PLUS ALCOHOL RISK REDUCTION (SRRI+ETOH)|BEHAVIORAL: SEXUAL + ALCOHOL + MARIJUANA RISK REDUCTION,University of New Mexico,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"CHILD, ADULT",460,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2010-08,2014-06,"Juvenile Detention Center (JDC), Albuquerque, New Mexico, 87107, United States"
NCT05704582,RCT Comparing Avatar Intervention to Supportive Intervention to Reduce Cannabis Use in Patients With Psychotic Disorders,https://clinicaltrials.gov/study/NCT05704582,RECRUITING,NO,Psychotic Disorders|Cannabis Use Disorder|Mental Health Disorder,OTHER: Avatar Intervention|OTHER: Addiction supportive intervention,Ciusss de L'Est de l'Île de Montréal,Canadian Institutes of Health Research (CIHR),ALL,"ADULT, OLDER_ADULT",150,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-02-01,2028-01,"Research center of the Institut universitaire en santé mentale de Montréal, Montreal, Quebec, H1N 3M5, Canada"
NCT04763252,Canadian Registry for the Use of Spectrum Therapeutics Cannabis Products in Subjects With Chronic Pain,https://clinicaltrials.gov/study/NCT04763252,UNKNOWN,NO,Chronic Pain,OTHER: Spectrum Therapeutics cannabis products,Canopy Growth Corporation,,ALL,"ADULT, OLDER_ADULT",500,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-01-25,2023-07-30,"Burrard Pain Doctors, Vancouver, British Columbia, V6Z 2C7, Canada"
NCT06584942,Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients with Cannabis Use Disorder (Pilot Study),https://clinicaltrials.gov/study/NCT06584942,NOT_YET_RECRUITING,NO,Cue-reactivity|Cannabis Use Disorder|Functional MRI|Orexin Antagonist,DRUG: Suvorexant,Massachusetts General Hospital,,ALL,ADULT,10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2025-01,2025-10,"Center for Addiction Medicine, Massachusetts General Hospital, Boston, Massachusetts, 02114, United States"
NCT03189810,Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Cannabis Use and Cognitive Outcomes in Schizophrenia,https://clinicaltrials.gov/study/NCT03189810,COMPLETED,NO,Repetitive Transcranial Magnetic Stimulation (rTMS)|Schizophrenia|Cannabis Use Disorder|Cognition,DEVICE: Repetitive Transcranial Magnetic Stimulation (rTMS)|DEVICE: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|BEHAVIORAL: Weekly Counselling Session,Centre for Addiction and Mental Health,,ALL,ADULT,24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-06-01,2021-06-30,"Centre for Addiction and Mental Health, Toronto, Ontario, M6J1H4, Canada"
NCT05244460,Droperidol on Prevention of Cannabis Hyperemesis Syndrome,https://clinicaltrials.gov/study/NCT05244460,UNKNOWN,NO,Cannabis Hyperemesis Syndrome,DRUG: Droperidol Injectable Product|DRUG: Diphenhydramine,Mercy Health Ohio,Lake Erie College of Osteopathic Medicine,ALL,"ADULT, OLDER_ADULT",45,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-12-02,2023-01-31,"Mercy Health - Austintown, Austintown, Ohio, 44515, United States|St Elizabeth Boardman Hospital, Boardman, Ohio, 44512, United States|St. Joseph-Warren Hospital, Warren, Ohio, 44484, United States|St Elizabeth Youngstown Hospital, Youngstown, Ohio, 44501, United States"
NCT03972124,Cannabis for the Prophylactic Treatment of Migraine,https://clinicaltrials.gov/study/NCT03972124,NOT_YET_RECRUITING,NO,Chronic Migraine,DRUG: CBD 100 mg OD|DRUG: CBD 200 mg OD|DRUG: Placebo,University of Calgary,,ALL,"ADULT, OLDER_ADULT",120,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2024-06,2026-06,
NCT06098573,Development and Evaluation of HighAlert,https://clinicaltrials.gov/study/NCT06098573,COMPLETED,NO,Cannabis|Youth Drinking,BEHAVIORAL: High Alert|BEHAVIORAL: Information condition|BEHAVIORAL: No contact,"Western University, Canada",,ALL,ADULT,103,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-11-01,2024-09-10,"Western University, London, Ontario, N6G 1G9, Canada"
NCT05386862,Warrior CARE: Naturalistic Observation and Harm Reduction,https://clinicaltrials.gov/study/NCT05386862,WITHDRAWN,NO,Post Traumatic Stress Disorder|Cannabis Use|Suicide,BEHAVIORAL: Reduce THC Use,Wayne State University,,ALL,"ADULT, OLDER_ADULT",0,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-13,2024-01-25,"Tolan Park Medical Building, Detroit, Michigan, 48201, United States"
NCT01610687,A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis,https://clinicaltrials.gov/study/NCT01610687,COMPLETED,YES,Multiple Sclerosis|Spasticity,DRUG: GW-1000-02,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",137,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2001-07,2005-02,"Rivermead Rehabilitation Centre, Oxford, OX3 7LD, United Kingdom"
NCT05814822,Targeting Insomnia to Improve Outcomes in Adults with Problematic Cannabis Use,https://clinicaltrials.gov/study/NCT05814822,RECRUITING,NO,Insomnia,BEHAVIORAL: Cognitive Behavioral Therapy for insomnia (CBTi-CB-TM)|BEHAVIORAL: Sleep Hygiene Education (SHE-TM),University of Michigan,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",200,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2023-06-01,2027-08-31,"University of Michigan, Ann Arbor, Michigan, 48109, United States"
NCT06457841,Black Adult Resilience Study,https://clinicaltrials.gov/study/NCT06457841,RECRUITING,NO,Alcohol Use|Cannabis Use,BEHAVIORAL: Direct Discrimination|BEHAVIORAL: Vicarious Discrimination|BEHAVIORAL: Daily Hassles,University of Washington,National Institute on Drug Abuse (NIDA),ALL,ADULT,456,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,2024-05-09,2027-07,"Southern Methodist University, Dallas, Texas, 75204, United States|University of Washington, Seattle, Washington, 98195, United States"
NCT01610713,An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis,https://clinicaltrials.gov/study/NCT01610713,COMPLETED,YES,Multiple Sclerosis,DRUG: GW-1000-02,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",154,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2001-05,2002-07,"Rivermead Rehabilitation Centre, Oxford, United Kingdom"
NCT01610700,An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients,https://clinicaltrials.gov/study/NCT01610700,COMPLETED,YES,Multiple Sclerosis,DRUG: GW-1000-02|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",160,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2001-05,2002-07,"Rivermead Rehabilitation Centre, Oxford, OX3 7LD, United Kingdom"
NCT05324982,Pharmacokinetics and Pharmacodynamics of CHI-914 in Healthy Participants,https://clinicaltrials.gov/study/NCT05324982,RECRUITING,NO,Behavioral Pharmacology of Cannabis,DRUG: Oral Placebo|DRUG: Oral CBG Cannabis,Johns Hopkins University,Canopy Growth Corporation,ALL,ADULT,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: BASIC_SCIENCE",2022-08-09,2025-06,"Behavioral Pharmacology Research Unit, Baltimore, Maryland, 21224, United States"
NCT03635593,Cannabis Oil for Chronic Non-Cancer Pain Treatment,https://clinicaltrials.gov/study/NCT03635593,UNKNOWN,NO,Chronic Non-cancer Pain,DRUG: CBD|DRUG: CBD+THC|OTHER: Placebo,Hamilton Health Sciences Corporation,,ALL,"ADULT, OLDER_ADULT",309,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-01-01,2021-01-30,"Michael G. DeGroote Pain Clinic, Hamilton, Ontario, L8N 3Z5, Canada|Toronto Poly Clinic, Toronto, Ontario, Canada"
NCT03162640,Impulsivity and Time Perception,https://clinicaltrials.gov/study/NCT03162640,COMPLETED,NO,Cannabis Use,,"University Hospital, Strasbourg, France",,ALL,ADULT,38,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-05-05,2020-03-12,"Les Hôpitaux Universitaires de Strasbourg, Strasbourg, Alsace, 67091, France"
NCT02028858,Cannabis and Parkinson's Disease Tremor: A Natural History Study,https://clinicaltrials.gov/study/NCT02028858,COMPLETED,NO,Parkinson's Disease,,Bastyr University,,ALL,"ADULT, OLDER_ADULT",11,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-11,2015-10,"Bastyr University, Kenmore, Washington, 98028, United States"
NCT06261489,Cannabis (THC vs. CBD) in Multiple Sclerosis,https://clinicaltrials.gov/study/NCT06261489,NOT_YET_RECRUITING,NO,Multiple Sclerosis,DRUG: THC|DRUG: CBD,University of Calgary,Multiple Sclerosis Society of Canada,ALL,ADULT,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-03,2025-12,
NCT05092191,Cannabis as a Complementary Treatment in Multiple Sclerosis,https://clinicaltrials.gov/study/NCT05092191,RECRUITING,NO,Multiple Sclerosis,DRUG: Cannabis oil vs placebo,Centre hospitalier de l'Université de Montréal (CHUM),Canadian Institutes of Health Research (CIHR)|Multiple Sclerosis Society of Canada,ALL,"ADULT, OLDER_ADULT",250,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-11-10,2025-05-10,"CRCHUM, Montreal, Quebec, H2X 0A9, Canada"
NCT04173078,Computerized Intervention for Distress Intolerance,https://clinicaltrials.gov/study/NCT04173078,COMPLETED,NO,Cannabis Use Disorder,BEHAVIORAL: Computerized Distress Intolerance Intervention|BEHAVIORAL: Computerized Healthy Behaviors Intervention,Auburn University,National Institute on Drug Abuse (NIDA)|Florida State University,ALL,ADULT,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-06-01,2017-10-30,
NCT05351801,Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain,https://clinicaltrials.gov/study/NCT05351801,RECRUITING,NO,Diabetic Neuropathic Pain|Peripheral Neuropathic Pain,DRUG: THC (Syndros)|DRUG: CBD (Epidolex)|DRUG: THC + CBD (Nabiximols)|DRUG: Placebo,VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",320,FED,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-06-21,2027-06-30,"VA San Diego Healthcare System, San Diego, CA, San Diego, California, 92161-0002, United States|VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, 06516-2770, United States|Providence VA Medical Center, Providence, RI, Providence, Rhode Island, 02908-4734, United States|South Texas Health Care System, San Antonio, TX, San Antonio, Texas, 78229-4404, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, 98108-1532, United States"
NCT03987347,Health Condition of Cannabis Consumers in the Canadian Population,https://clinicaltrials.gov/study/NCT03987347,WITHDRAWN,NO,Cannabis Use|Old Age|Health Risk,OTHER: Observational,Jewish General Hospital,,ALL,"ADULT, OLDER_ADULT",0,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-12-01,2020-12-01,"Jewish General Hospital, Montréal, Quebec, H3T 1E2, Canada"
NCT06736444,Efficacy of Brief Interventions to Reduce Comorbid Alcohol and Cannabis Misuse and Sleep Impairment in Young Adults (Rest-Up RCT),https://clinicaltrials.gov/study/NCT06736444,NOT_YET_RECRUITING,NO,Insomnia|Alcohol Use|Marijuana Use,BEHAVIORAL: Brief Behavioral Therapy for Insomnia (BBTI)|BEHAVIORAL: Brief Alcohol Screening and Intervention for College Students (BASICS)|BEHAVIORAL: Attention Control,University of Washington,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,ADULT,800,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2025-04-01,2029-04-01,
NCT06283862,MIVetsCan: Can-Coach Trial (Phase 2),https://clinicaltrials.gov/study/NCT06283862,RECRUITING,NO,Chronic Pain,BEHAVIORAL: Educational Session,University of Michigan,"Michigan, State of, Licensing and Regulatory Affairs",ALL,"ADULT, OLDER_ADULT",468,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2024-04-04,2027-02,"University of Michigan, Ann Arbor, Michigan, 48105, United States"
NCT01560013,The Effects of Treatment With Naltrexone in Alcohol and Cannabis-dependent Patients,https://clinicaltrials.gov/study/NCT01560013,UNKNOWN,NO,Alcohol-dependence,DRUG: Naltrexone,Tel-Aviv Sourasky Medical Center,"Ministry of Health, Israel",ALL,ADULT,24,OTHER_GOV,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-10,2014-10,"Dept. of Nuclear Medicine, TASMC, Tel Aviv, 64239, Israel"
NCT02729623,"The Pharmacokinetics, Safety, and Ease of Use of a Portable Metered-Dose Cannabis Inhaler",https://clinicaltrials.gov/study/NCT02729623,UNKNOWN,NO,Healthy,DRUG: Kite Systems cannaHALER cannabis Inhaler.,Kite Systems,Rambam Health Care Campus,ALL,"ADULT, OLDER_ADULT",12,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2016-08,2017-08,
NCT02061020,Study of the Relationship Between Dose-concentration-effect of Delta-9-tetrahydrocannabinol (THC) and the Ability to Drive in Chronic or Occasional Cannabis Users,https://clinicaltrials.gov/study/NCT02061020,COMPLETED,NO,Occasional (1-2 Joints Per Week) and Chronic (1-2 Joints Per Day) Cannabis Users,"DRUG: Cannabis (THC) in cigarettes of 30mg, 10mg and placebo",Assistance Publique - Hôpitaux de Paris,,MALE,ADULT,37,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-01,2016-03,"Raymond Poincare Hospital, Garches, 92380, France"
NCT05210660,Medical Cannabis Against Chronic Musculoskeletal Pain: a Mixed Methods Study.,https://clinicaltrials.gov/study/NCT05210660,UNKNOWN,NO,Musculoskeletal Pain|Cannabis Use,,CHU de Quebec-Universite Laval,McGill University|Université de Sherbrooke,ALL,"ADULT, OLDER_ADULT",45,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-01-21,2022-07-31,"Hôpital du St-Sacrement, Québec, G1S 4L8, Canada"
NCT01252550,Effects of Activia in IBS,https://clinicaltrials.gov/study/NCT01252550,COMPLETED,NO,Irritable Bowel Syndrome,DIETARY_SUPPLEMENT: Activia® (125g/pot)|DIETARY_SUPPLEMENT: Acidified non-fermented dairy product,Sahlgrenska University Hospital,Danone Global Research & Innovation Center,ALL,"ADULT, OLDER_ADULT",100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-05,2014-08,"Sahlgrenska University Hospital, Gothenburg, Västra Götaland, 41345, Sweden|Dept of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, 41345, Sweden|Dept of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, S413-45, Sweden"
NCT03801096,Project RAD: A Brief Intervention for Young Adult Alcohol or Marijuana Users,https://clinicaltrials.gov/study/NCT03801096,UNKNOWN,NO,"Alcohol; Use, Problem|Marijuana Usage",BEHAVIORAL: Narrative Based Therapuetic Assessment (NbTa)|BEHAVIORAL: Health Education Control Condition (HE),University of Houston,,ALL,ADULT,44,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-01,2020-10,
NCT04901910,Social Media Intervention - Physical Activity,https://clinicaltrials.gov/study/NCT04901910,COMPLETED,NO,Cannabis Use,BEHAVIORAL: Physical Activity (PA) Social Media Group|BEHAVIORAL: Verdi plus PA Social Media Group,University of Michigan,,ALL,ADULT,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-05-18,2021-12-25,"University of Michigan, Ann Arbor, Michigan, 48109, United States"
NCT00783185,Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment,https://clinicaltrials.gov/study/NCT00783185,COMPLETED,NO,Psychotic Disorders|Marijuana Abuse|Intervention,BEHAVIORAL: Cannabis-Consumption-Reduction-Training|BEHAVIORAL: Social competence Training,University of Konstanz,,ALL,"ADULT, OLDER_ADULT",50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2006-01,2010-01,"University of Konstanz, Konstanz, Baden-Württemberg, 78462, Germany"
NCT00695487,Does Intravenous Cannabis Reduce Postoperative Nausea and Vomiting (PONV)?,https://clinicaltrials.gov/study/NCT00695487,TERMINATED,NO,Nausea|Vomiting,DRUG: THC 9-d-tetra hydro cannabinol,"Insel Gruppe AG, University Hospital Bern",,ALL,"ADULT, OLDER_ADULT",320,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-07,2011-12,"Inselspital, Bern University Hospital, Bern, 3010, Switzerland"
NCT02112123,Icariin to Prevent Corticosteroid-related Memory Changes,https://clinicaltrials.gov/study/NCT02112123,COMPLETED,NO,the Pharmacokinetic Profile of Icariin in Humans,DRUG: Icariin|DIETARY_SUPPLEMENT: Matching placebo,University of Texas Southwestern Medical Center,National Center for Complementary and Integrative Health (NCCIH),ALL,ADULT,24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2014-04,2016-12,"UT Southwestern Medical Center, Dallas, Texas, 75390, United States"
NCT05865470,Age-dependent Effects of Smoked and Oral Delta-9-THC,https://clinicaltrials.gov/study/NCT05865470,NOT_YET_RECRUITING,NO,"Pain|Abuse, Drug|Intoxication; Cannabinoids",DRUG: Cannabis|DRUG: Dronabinol|DRUG: Smoked Placebo|DRUG: Oral Placebo,"University of California, Los Angeles",National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",103,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2025-02-01,2029-02-01,
NCT06034314,Oral Dronabinol-HIV,https://clinicaltrials.gov/study/NCT06034314,RECRUITING,NO,HIV,DRUG: Dronabinol Capsules,Yale University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",160,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-09-21,2027-10-01,"Connecticut Mental Health Center, New Haven, Connecticut, 06511, United States"
NCT03360799,Questionnaires in Assessing Attitudes About Legalization of Marijuana Use in Participants With Cancer,https://clinicaltrials.gov/study/NCT03360799,COMPLETED,NO,Malignant Neoplasm,OTHER: Questionnaire Administration,M.D. Anderson Cancer Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",103,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-11-17,2019-08-26,"Banner MD Anderson Cancer Center, Gilbert, Arizona, 85234, United States|M D Anderson Cancer Center, Houston, Texas, 77030, United States"
NCT00573287,First Episode Schizophrenia and Cannabis-Related Disorder Study,https://clinicaltrials.gov/study/NCT00573287,COMPLETED,YES,Cannabis-Related Disorder|Substance-Related Disorders|Schizophrenia|Psychotic Disorders,DRUG: clozapine|DRUG: risperidone,Dartmouth-Hitchcock Medical Center,National Institute of Mental Health (NIMH),ALL,"CHILD, ADULT",14,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2006-06,2011-12,"New Hampshire Hospital, Concord, New Hampshire, 03301, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|West Central Behavioral Health, Lebanon, New Hampshire, 03766, United States|Mental Health Center of Greater Manchester, Manchester, New Hampshire, 03101, United States|Center for Psychiatric Advancement & Community Council of Nashua, Nashua, New Hampshire, 03060, United States"
NCT03024827,Cannabidiol in Children With Refractory Epileptic Encephalopathy,https://clinicaltrials.gov/study/NCT03024827,ACTIVE_NOT_RECRUITING,NO,Epileptic Encephalopathy,DRUG: CanniMed® 1:20,University of Saskatchewan,,ALL,CHILD,20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-04-26,2023-12-31,"University of British Columbia, Vancouver, British Columbia, V6T1Z4, Canada|University of Manitoba, Winnipeg, Manitoba, R3T 2N2, Canada|Universite de Montreal, Montreal, Quebec, H3T1J4, Canada|University of Saskatchewan, Saskatoon, Saskatchewan, S7N5C5, Canada"
NCT04314804,Safety and Pharmacokinetics of Smoked Cannabis in Healthy Patients,https://clinicaltrials.gov/study/NCT04314804,COMPLETED,NO,Healthy Volunteers,COMBINATION_PRODUCT: PPP001|COMBINATION_PRODUCT: Placebo,Tetra Bio-Pharma,,ALL,"ADULT, OLDER_ADULT",48,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-03-01,2017-11-16,"Algorithme Pharma., Montréal, Quebec, H2L 3K9, Canada"
NCT04083261,Pharmacogenetic Variation: Factors That May Affect the Efficacy and Safety of Medical Marijuana,https://clinicaltrials.gov/study/NCT04083261,COMPLETED,NO,New York Medical Marijuana Program Qualifying Conditions,OTHER: DNA Genotek Oragene 600,Columbia Care Inc.,,ALL,"ADULT, OLDER_ADULT",157,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-07-11,2020-03-30,"Columbia Care New York Dispensary, New York, New York, 10003, United States"
NCT03664141,Impact of Cannabis Oil on Nutrition in Hemodialysis Patients Study (ICON-HP Study),https://clinicaltrials.gov/study/NCT03664141,WITHDRAWN,NO,Protein-Energy Malnutrition|Hemodialysis|Appetite Disorders,DRUG: Cannabis oil|DRUG: Placebo/ Regular Oil,Assaf-Harofeh Medical Center,Tikun Olam,ALL,"ADULT, OLDER_ADULT",0,OTHER_GOV,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-09-15,2019-10-15,"Asaf ha Rofeh, MC, Zrifin, 70300, Israel"
NCT01302340,Delta-THC in Behavioral Disturbances in Dementia,https://clinicaltrials.gov/study/NCT01302340,COMPLETED,NO,Dementia,DRUG: Delta-THC|DRUG: placebo|DRUG: Delta-THC,Radboud University Medical Center,European Union,ALL,"ADULT, OLDER_ADULT",22,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-09,2013-12,"Radboud university medical center, Nijmegen, Gelderland, 6525EX, Netherlands|Vincent van Gogh Institute for Psychiatry, department of Elderly, Venray, Limburg, 5803, Netherlands"
NCT04988490,Quantification of Cannabinoids and Comparison to Post-Surgical Pain Medication Requirements and Surgical Outcomes,https://clinicaltrials.gov/study/NCT04988490,RECRUITING,NO,Post-Surgical Pain|Post-Surgical Complication|Cancer|Cannabis Use,,"University of Colorado, Denver",National Cancer Institute (NCI)|Institute of Cannabis Research,ALL,"ADULT, OLDER_ADULT",80,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-10-11,2026-02,"University of Colorado Hospital, Denver, Colorado, 80045, United States"
NCT04902092,Brain Exercise and Addiction Trial,https://clinicaltrials.gov/study/NCT04902092,COMPLETED,NO,"Cannabis Use Disorder, Moderate|Cannabis Use Disorder, Severe",BEHAVIORAL: High Intensity Interval Training|BEHAVIORAL: Strength and Resistance Training,Monash University,Turning Point,ALL,ADULT,65,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2019-01-23,2022-11-21,"Monash University, BrainPark, Melbourne, Victoria, 3800, Australia"
NCT05598216,Assessment of Different Equations to Accurately Calculate LDL Cholesterol,https://clinicaltrials.gov/study/NCT05598216,ACTIVE_NOT_RECRUITING,NO,Dyslipidemias|Lipid Disorder,"DIAGNOSTIC_TEST: no intervention, Serum LDL cholesterol calculation",Hospices Civils de Lyon,,ALL,"CHILD, ADULT, OLDER_ADULT",160000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-11-01,2025-12,"Laboratoire de Biologie Médicale Multi Sites, Centre de Biologie et de Pathologie Est, Bron, 69677, France"
NCT01351207,The Effect of Eggs on Postprandial Metabolism,https://clinicaltrials.gov/study/NCT01351207,COMPLETED,NO,Healthy,OTHER: Eggs,Tufts University,American Egg Board,ALL,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2011-04,2014-08,"Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, 02111, United States"
NCT04199468,THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis,https://clinicaltrials.gov/study/NCT04199468,COMPLETED,NO,Cannabis|Ketamine,DRUG: Active Delta-9-THC|DRUG: Placebo Delta-9-THC|DRUG: Active Ketamine|DRUG: Placebo Ketamine,Yale University,Brain & Behavior Research Foundation,ALL,ADULT,22,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2019-09-24,2022-06-21,"VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT02932215,Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder,https://clinicaltrials.gov/study/NCT02932215,COMPLETED,NO,Cannabis Use Disorder,DRUG: lorcaserin|OTHER: Fitbit Charge HR,New York State Psychiatric Institute,,ALL,ADULT,17,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-10,2019-01-17,"Columbia Substance Treatment and Research Service, New York, New York, 10019, United States"
NCT03560934,Tetrahydrocannabinol (THC) and Sleep,https://clinicaltrials.gov/study/NCT03560934,ACTIVE_NOT_RECRUITING,NO,Sleep|THC|Marijuana|Cannabis,DRUG: Dronabinol,Oregon Health and Science University,,ALL,ADULT,18,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2018-09-01,2025-04,"Oregon Health & Science University, Portland, Oregon, 97239, United States"
NCT00687609,Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE,https://clinicaltrials.gov/study/NCT00687609,TERMINATED,YES,Attention Deficit Hyperactivity Disorder|Cannabis Abuse,DRUG: Atomoxetine,Eli Lilly and Company,,ALL,CHILD,7,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-09,2009-06,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Den Haag, 2566 ER, Netherlands"
NCT05613608,Alcohol Use Disorder and Cannabidiol,https://clinicaltrials.gov/study/NCT05613608,RECRUITING,NO,Alcohol Use Disorder,DRUG: Cannabidiol|DRUG: Placebo,"University of Colorado, Denver",National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"ADULT, OLDER_ADULT",180,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-04-30,2027-04,"University of Colorado Anschutz, Aurora, Colorado, 80045, United States"
NCT03886753,Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products,https://clinicaltrials.gov/study/NCT03886753,TERMINATED,NO,"ALS|Autism Spectrum Disorder|Cancer|Spasticity, Muscle|Dyskinetic Syndrome|Epilepsy|Glaucoma|Huntington Disease|Inflammatory Bowel Disease (IBD)|Multiple Sclerosis|Neuropathy|Opioid Use|Parkinson Disease|HIV/AIDS|Ptsd|Intractable Pain|Sickle Cell Disease|Terminal Illness",OTHER: Registry|OTHER: PK microsampling of blood,Children's Hospital of Philadelphia,Ilera Healthcare,ALL,"CHILD, ADULT, OLDER_ADULT",10,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-05-15,2020-06-30,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States"
NCT05547620,Modulating Cerebellar Activity With Low-intensity Focused Ultrasound Stimulation for Primary Orthostatic Tremor,https://clinicaltrials.gov/study/NCT05547620,RECRUITING,NO,Orthostatic Tremor,DEVICE: LIFUS Online Real|DEVICE: LIFUS Online Sham|DEVICE: LIFUS Offline,"University Health Network, Toronto",National Organization for Rare Disorders,ALL,"ADULT, OLDER_ADULT",15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-03-08,2024-09-08,"Toronto Western Hospital, Toronto, Ontario, M5T 2S8, Canada"
NCT06418204,Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics,https://clinicaltrials.gov/study/NCT06418204,RECRUITING,NO,Breast Carcinoma|Colorectal Carcinoma|Lung Non-Small Cell Carcinoma|Melanoma|Non-Hodgkin Lymphoma,OTHER: Non-interventional Study,Wake Forest University Health Sciences,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",2000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2025-01-30,2028-08,"Mercy Hospital Fort Smith, Fort Smith, Arkansas, 72903, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, 83706, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, 83605, United States|Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho, 83814, United States|Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho, 83687, United States|Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, 83854, United States|Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho, 83864, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, 61704, United States|Illinois CancerCare-Canton, Canton, Illinois, 61520, United States|Illinois CancerCare-Carthage, Carthage, Illinois, 62321, United States|Centralia Oncology Clinic, Centralia, Illinois, 62801, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, 62526, United States|Decatur Memorial Hospital, Decatur, Illinois, 62526, United States|Illinois CancerCare-Dixon, Dixon, Illinois, 61021, United States|Crossroads Cancer Center, Effingham, Illinois, 62401, United States|Illinois CancerCare-Eureka, Eureka, Illinois, 61530, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, 61401, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, 61443, United States|Illinois CancerCare-Macomb, Macomb, Illinois, 61455, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, 62269, United States|HSHS Saint Elizabeth's Hospital, O'Fallon, Illinois, 62269, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, 61350, United States|Illinois CancerCare-Pekin, Pekin, Illinois, 61554, United States|Illinois CancerCare-Peru, Peru, Illinois, 61354, United States|Illinois CancerCare-Princeton, Princeton, Illinois, 61356, United States|Southern Illinois University School of Medicine, Springfield, Illinois, 62702, United States|Springfield Clinic, Springfield, Illinois, 62702, United States|Springfield Memorial Hospital, Springfield, Illinois, 62781, United States|Illinois CancerCare - Washington, Washington, Illinois, 61571, United States|Flaget Memorial Hospital, Bardstown, Kentucky, 40004, United States|Saint Joseph Hospital East, Lexington, Kentucky, 40509, United States|1001 Saint Joseph Lane, London, Kentucky, 40741, United States|Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor, Michigan, 48106, United States|OSF Saint Francis Hospital and Medical Group, Escanaba, Michigan, 49829, United States|Marshfield Medical Center Dickinson, Iron Mountain, Michigan, 49801, United States|Parkland Health Center - Farmington, Farmington, Missouri, 63640, United States|Mercy Hospital Joplin, Joplin, Missouri, 64804, United States|Mercy Hospital South, Saint Louis, Missouri, 63128, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, 63131, United States|Missouri Baptist Sullivan Hospital, Sainte Genevieve, Missouri, 63670, United States|Mercy Hospital Springfield, Springfield, Missouri, 65804, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, 63080, United States|BJC Outpatient Center at Sunset Hills, Sunset Hills, Missouri, 63127, United States|Community Hospital of Anaconda, Anaconda, Montana, 59711, United States|Billings Clinic Cancer Center, Billings, Montana, 59101, United States|Montana Cancer Consortium NCORP, Billings, Montana, 59102, United States|Bozeman Health Deaconess Hospital, Bozeman, Montana, 59715, United States|Benefis Sletten Cancer Institute, Great Falls, Montana, 59405, United States|Hi-Line Sletten Cancer Center, Havre, Montana, 59501, United States|Logan Health Medical Center, Kalispell, Montana, 59901, United States|Community Medical Center, Missoula, Montana, 59804, United States|Wake Forest NCORP Research Base, Winston-Salem, North Carolina, 27157, United States|Licking Memorial Hospital, Newark, Ohio, 43055, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, 73120, United States|Saint Alphonsus Cancer Care Center-Ontario, Ontario, Oregon, 97914, United States|Aspirus Langlade Hospital, Antigo, Wisconsin, 54409, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, 54729, United States|Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin, 54701, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, 54301, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, 54303, United States|Marshfield Medical Center - Ladysmith, Ladysmith, Wisconsin, 54848, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, 54449, United States|Aspirus Medford Hospital, Medford, Wisconsin, 54451, United States|Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, 54548, United States|Marshfield Medical Center - Neillsville, Neillsville, Wisconsin, 54456, United States|Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls, Wisconsin, 54154, United States|Aspirus Cancer Care - James Beck Cancer Center, Rhinelander, Wisconsin, 54501, United States|Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, 54868, United States|Saint Vincent Hospital Cancer Center at Sheboygan, Sheboygan, Wisconsin, 53081, United States|Sheboygan Physicians Group, Sheboygan, Wisconsin, 53081, United States|Aspirus Cancer Care - Stevens Point, Stevens Point, Wisconsin, 54481, United States|Marshfield Medical Center-River Region at Stevens Point, Stevens Point, Wisconsin, 54482, United States|Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, 54235, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, 54401, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, 54401, United States|Marshfield Medical Center - Weston, Weston, Wisconsin, 54476, United States|Aspirus Cancer Care - Wisconsin Rapids, Wisconsin Rapids, Wisconsin, 54494, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, 54494, United States"
NCT04641832,The Combined Effect of Chronic Cannabis Use and Subconcussive Head Impacts on Brain Health,https://clinicaltrials.gov/study/NCT04641832,COMPLETED,NO,"Concussion, Mild",OTHER: Soccer heading,Indiana University,,ALL,ADULT,70,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC,2020-10-30,2021-12-01,"Indiana University School of Public Health, Bloomington, Indiana, 47405, United States"
NCT01863095,An Exercise App to Reduce Young Adults' MJ Use,https://clinicaltrials.gov/study/NCT01863095,COMPLETED,NO,Marijuana Smoking,BEHAVIORAL: Personalized Feedback and Exercise,State University of New York at Buffalo,,ALL,ADULT,36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2014-10,2015-06,"Center for Health Research, Buffalo, New York, 14214, United States"
NCT03339622,Safety and Efficacy of Smoked Cannabis for Improving Quality of Life in Advanced Cancer Patients,https://clinicaltrials.gov/study/NCT03339622,TERMINATED,NO,Cancer|Chronic Pain Due to Malignancy (Finding),COMBINATION_PRODUCT: PPP001|COMBINATION_PRODUCT: placebo,Tetra Bio-Pharma,,ALL,"ADULT, OLDER_ADULT",8,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-03-29,2019-02-08,"Sante Cannabis, Montréal, Quebec, H2L 3K9, Canada"
NCT04201197,Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs,https://clinicaltrials.gov/study/NCT04201197,COMPLETED,YES,Drug-Interactions,DRUG: Inje cocktail|DRUG: THC Cannabis extract|DRUG: THC/CBD Cannabis Extract,Johns Hopkins University,Washington State University|National Center for Complementary and Integrative Health (NCCIH),ALL,ADULT,22,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2020-11-10,2022-07-28,"Johns Hopkins University, Baltimore, Maryland, 21224, United States"
NCT03927053,Consequences of Marijuana Use in HIV-infected Youth,https://clinicaltrials.gov/study/NCT03927053,COMPLETED,NO,Youth With HIV,,Duke University,"University of North Carolina, Chapel Hill",ALL,ADULT,21,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-10-31,2021-10-15,"Duke UMC, Durham, North Carolina, 27710, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States"
NCT05414344,A Brief Intervention for Alcohol Users With Interpersonal Trauma,https://clinicaltrials.gov/study/NCT05414344,RECRUITING,NO,Heavy Drinking|Alcohol Drinking|Substance Use|Drinking Behavior,BEHAVIORAL: Standard Brief Intervention|BEHAVIORAL: Trauma-Informed and Peer-Supported Brief Intervention|BEHAVIORAL: Assessment only,Western Kentucky University,,ALL,ADULT,165,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-29,2025-08-31,"Western Kentucky University, Bowling Green, Kentucky, 42101, United States"
NCT06430580,Cannabinoids and Biological Reactivity to Stress,https://clinicaltrials.gov/study/NCT06430580,RECRUITING,NO,Cannabis Use Disorder,DRUG: Hydrocortisone Oral|DRUG: Yohimbine Hydrochloride|DRUG: Cornstarch Placebo 20mg|DRUG: Cornstarch Placebo 54mg,Auburn University,Wayne State University|National Institute on Drug Abuse (NIDA),ALL,ADULT,36,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2024-09-30,2026-09-30,"Auburn University BRAINS Lab, Auburn, Alabama, 36832, United States"
NCT02961309,A Laboratory Model of Increasing Delta-9-tetrahydrocannabinol (THC) Potency on Cigarette Smoking,https://clinicaltrials.gov/study/NCT02961309,COMPLETED,NO,Tobacco Use,DRUG: THC,Battelle Memorial Institute,,ALL,"ADULT, OLDER_ADULT",9,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,2018-05-07,2019-09-30,"Battelle Memorial Institute, Baltimore, Maryland, 21209, United States"
NCT04726254,The JULI Registry--Hemp and Cannabis Observational Registry,https://clinicaltrials.gov/study/NCT04726254,RECRUITING,NO,Chronic Pain|Appetite Disorders|Neuropathy|Menopausal Syndrome|Anxiety|Sleep Disturbance|Nausea,,Juva Life,Targeted Medical Education,ALL,"ADULT, OLDER_ADULT",2000,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-08-01,2025-02-15,"Precision Cancer Specialists, Los Gatos, California, 95032, United States|Justin Lo MD, San Jose, California, 95128, United States|Nashville Breast Center, Nashville, Tennessee, 37203, United States|Dallas Surgical Group, Dallas, Texas, 75231, United States"
NCT01536899,Medical Marijuana Use in HIV+ Patients Prospective Cohort Study,https://clinicaltrials.gov/study/NCT01536899,COMPLETED,NO,HIV Positive|Marijuana Smoking,,Wayne State University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",119,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-02,2017-06,"Wayne State University (HIV clinic, Tolan Park Medical Buiding), Detroit, Michigan, 48201, United States"
NCT06435650,The Use of Mindful Compassion and Cannabis Suppositories for Anal Pain Among Men Who Have Sex With Men,https://clinicaltrials.gov/study/NCT06435650,COMPLETED,NO,Pain;Sexual Intercourse;M,COMBINATION_PRODUCT: Cannabis suppositories and mindful-compassion for anal pain|BEHAVIORAL: Mindful-compassion,London Metropolitan University,,MALE,"ADULT, OLDER_ADULT",52,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-07-01,2024-04-24,"Samantha Banbury, London, N7 8DB, United Kingdom"
NCT00227916,Motivational Interviews for Incarcerated Teens - 1,https://clinicaltrials.gov/study/NCT00227916,COMPLETED,NO,Alcoholic Intoxication|Marijuana Abuse,BEHAVIORAL: Behavior Therapy,Brown University,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",200,OTHER,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,2000-11,2004-07,"Brown University, Providence, Rhode Island, 02912, United States"
NCT03401333,Brief Interventions With Text Messaging to Reduce Adolescent Alcohol and Marijuana Use,https://clinicaltrials.gov/study/NCT03401333,COMPLETED,NO,Alcohol Drinking|Marijuana,BEHAVIORAL: Text Messaging and Brief Negotiation Interview,Yale University,,ALL,"CHILD, ADULT",10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2017-11-14,2018-06-06,"Yale New Haven Hospital, New Haven, Connecticut, 06520, United States"
NCT01832766,"The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes",https://clinicaltrials.gov/study/NCT01832766,TERMINATED,YES,Schizophrenia,DRUG: Dronabinol|OTHER: Placebo Comparator,"University of Colorado, Denver",National Alliance for Research on Schizophrenia and Depression,ALL,ADULT,13,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: ",2005-06,2011-05,"University of Colorado Denver, Aurora, Colorado, 80045, United States"
NCT01180374,The Effects of Cannabidiol and ∆-9-THC in Humans,https://clinicaltrials.gov/study/NCT01180374,COMPLETED,NO,Healthy,DRUG: Cannabidiol|DRUG: Delta-9-THC|DRUG: Placebo|DRUG: Placebo,Yale University,,ALL,ADULT,27,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2010-02-01,2014-10-06,"VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT05742724,The Pharmacokinetics of Single Dose Oral Tetrahydrocannabinol and Cannabidiol,https://clinicaltrials.gov/study/NCT05742724,ACTIVE_NOT_RECRUITING,NO,Cannabis|Chronic Kidney Diseases|Dialysis,DRUG: Tetrahydrocannabinol-Cannabidiol Combination,McMaster University,Center for Medicinal Cannabis Research,ALL,"ADULT, OLDER_ADULT",24,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2024-01-11,2025-03-01,"St. Joseph's Healthcare Hamilton, Hamilton, Ontario, L8S 4A6, Canada"
NCT03601026,Genetic Counselling in the Prevention of Mental Health Consequences of Cannabis Use,https://clinicaltrials.gov/study/NCT03601026,RECRUITING,NO,Mental Illness|Schizophrenia|Bipolar Disorder|Major Depressive Disorder|Cannabis Use|Psychosis,BEHAVIORAL: Genetic counselling,Nova Scotia Health Authority,,ALL,"CHILD, ADULT",120,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2019-11-01,2025-09-01,"Nova Scotia Health Authority, Halifax, Nova Scotia, B3H 2E2, Canada"
NCT04176055,Treatment Strategies in CHS,https://clinicaltrials.gov/study/NCT04176055,COMPLETED,NO,Cannabis Hyperemesis Syndrome,DRUG: Haloperidol,University of Calgary,Canadian Institutes of Health Research (CIHR),ALL,"ADULT, OLDER_ADULT",4,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-13,2022-06-01,"University of Calgary, Calgary, Alberta, T2N 4N1, Canada"
NCT05040828,Early Intervention in Allergic Patients,https://clinicaltrials.gov/study/NCT05040828,COMPLETED,NO,Allergic Rhinitis Due to Weed Pollen|Montelukast,BEHAVIORAL: Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.|BEHAVIORAL: Montelukast Sodium Tablets 10mg quaque die orally was administered after peak pollen count.|DRUG: No oral drug therapy throughout the pollen period,Beijing Tongren Hospital,,ALL,ADULT,59,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-07-01,2020-11-10,"Beijing Tongren Hospital, Beijing, Beijing, 100730, China"
NCT03491384,"Anxiety, Inflammation, and Stress",https://clinicaltrials.gov/study/NCT03491384,COMPLETED,YES,Anxiety|Anxiety Disorders|Anxiety Generalized|Anxiety Chronic|Inflammation|Inflammatory Response,"DRUG: Cannabis (smoked flower, ingested edible)","University of Colorado, Boulder","University of Colorado, Denver",ALL,"ADULT, OLDER_ADULT",361,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-04-01,2023-05-17,"Center for Innovation and Creativity, Boulder, Colorado, 80304, United States"
NCT05537116,Evaluation of an Interactive Mobile Phone-Based Brief Intervention to Reduce Substance-Impaired Driving,https://clinicaltrials.gov/study/NCT05537116,ENROLLING_BY_INVITATION,NO,Driving Impaired,BEHAVIORAL: Personalized feedback|BEHAVIORAL: Personalized feedback and text messages|BEHAVIORAL: Information Only,Western Kentucky University,,ALL,ADULT,240,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-18,2026-03-31,"Kelly Thompson Hall, Bowling Green, Kentucky, 42101, United States"
NCT03107117,Computer-Assisted Brief Intervention,https://clinicaltrials.gov/study/NCT03107117,COMPLETED,NO,Substance Abuse,BEHAVIORAL: Computer Counseling|BEHAVIORAL: Standard Care,Brown University,,ALL,CHILD,83,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2017-10-01,2022-12-30,"Rhode Island Family Court, Providence, Rhode Island, 02903, United States"
NCT05184478,Is Medicinal Cannabis an Effective Treatment for Tourette Syndrome in Adolescents? a Pilot Study,https://clinicaltrials.gov/study/NCT05184478,COMPLETED,NO,Tourette Syndrome in Adolescence,"DRUG: Medicinal cannabis (MC): THC 10mg/mL : CBD 15mg/mL, manufactured by Cann Group Ltd.|DRUG: Placebo",Murdoch Childrens Research Institute,,ALL,"CHILD, ADULT",10,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-05-16,2024-01-04,"Royal Children's Hospital / Murdoch Children's Research Institute, Parkville, Victoria, 3052, Australia"
NCT06446479,Effects of THC on Alcohol Consumption and Neural Correlates of Reward,https://clinicaltrials.gov/study/NCT06446479,RECRUITING,NO,Cannabis Use Disorder,DRUG: Dronabinol Pill|DRUG: Placebo,"University of Colorado, Denver",National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Colorado State University,ALL,ADULT,28,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2024-07-01,2026-06-30,"University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, United States"
NCT04971629,"The Relationship Between Cannabis Use, Biomarkers, Tissue Cannabinoid Levels and Clinical Outcomes in Patients With OA",https://clinicaltrials.gov/study/NCT04971629,RECRUITING,NO,Osteo Arthritis Knee,,"University Health Network, Toronto",,ALL,"ADULT, OLDER_ADULT",1200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-07-13,2025-06-30,"Toronto Western Hospital, Toronto, Ontario, M5T 2S8, Canada"
NCT04783519,Research Evaluating Sleep & Trends for Universal Prevention,https://clinicaltrials.gov/study/NCT04783519,COMPLETED,YES,"Insomnia|Alcohol Use, Unspecified|Marijuana Use",BEHAVIORAL: Brief Behavioral Therapy for Insomnia (BBTI)|BEHAVIORAL: Brief Alcohol Screening and Intervention for College Students (BASICS),University of Washington,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,ADULT,150,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-08-17,2023-07-31,"The Center for the Study of Health and Risk Behaviors, Seattle, Washington, 98105, United States"
NCT03052738,Medical Marijuana in the Pediatric Central Nervous System Tumor Population,https://clinicaltrials.gov/study/NCT03052738,COMPLETED,NO,Central Nervous System Tumor|Brain Tumor|Spinal Tumor,,"University of Colorado, Denver",,ALL,"CHILD, ADULT",19,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-01-15,2020-06-30,"Chilsdren's Hospital Colorado, Aurora, Colorado, 80045, United States"
NCT00376233,Niacin Flushing as Marker of Cannabis Effects on Arachidonic Acid Pathways in Schizophrenia,https://clinicaltrials.gov/study/NCT00376233,COMPLETED,NO,Schizophrenia|Cannabis Abuse,,University of Jena,,ALL,ADULT,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2004-02,2005-06,"University of Jena, Department of Psychiatry, Jena, Thueringen, D-07743, Germany"
NCT04707911,Social Media Intervention to Stop Nicotine and Cannabis Vaping Among Adolescents,https://clinicaltrials.gov/study/NCT04707911,COMPLETED,NO,Vaping,BEHAVIORAL: Social Media Intervention,"University of California, San Francisco",Tobacco Related Disease Research Program|HopeLab Foundation|Rescue Agency,ALL,"CHILD, ADULT",500,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-11-18,2024-06-18,"University of California, San Francisco, San Francisco, California, 94143, United States"
NCT05991882,Mobile Intervention for Simultaneous Alcohol and Marijuana Use in Young Adults,https://clinicaltrials.gov/study/NCT05991882,RECRUITING,NO,Alcohol Drinking|Cannabis Use,BEHAVIORAL: Condition 1: Craving daily+PBS daily|BEHAVIORAL: Condition 2: Craving daily+PBS trigger|BEHAVIORAL: Condition 3: Craving trigger+PBS daily|BEHAVIORAL: Condition 4: Craving trigger+PBS trigger|BEHAVIORAL: Condition 5: PBS daily+ PBS trigger|BEHAVIORAL: Condition 6: Craving daily+Craving trigger|BEHAVIORAL: Condition 7: Craving daily+Craving trigger+PBS daily+PBS trigger|BEHAVIORAL: Condition 8: No daily or trigger craving or PBS,Kaiser Permanente,National Institute on Drug Abuse (NIDA),ALL,ADULT,136,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2024-04-01,2025-01-01,"Kaiser Permanente Hawaii, Center for Integrated Health Care Research, Honolulu, Hawaii, 96815, United States"
NCT04984278,Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis,https://clinicaltrials.gov/study/NCT04984278,TERMINATED,YES,Spasticity With Multiple Sclerosis,DRUG: Nabiximols|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",56,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-16,2022-11-11,"Mountain View Clinical Research, Denver, Colorado, 80209, United States|Collier Neurologic Specialists, Naples, Florida, 34105, United States|University of South Florida, Tampa, Florida, 33613, United States|Consultants in Neurology - Northbrook, Chicago, Illinois, 60062, United States|Premier Neurology Research, PC, Greer, South Carolina, 29650, United States|Neurology Clinic-Cordova, Cordova, Tennessee, 38018, United States|NeuropsychiatrieHK, Choceň, 565 01, Czechia|NeuropsychiatrieHK, Hradec Králové, 503 41, Czechia|Krajská Zdravotní - Nemocnice Teplice, Teplice, 415 29, Czechia|Centrum Medyczne Neuromed - Ośrodek Badań Klinicznych, Bydgoszcz, Kujawsko-Pomorskie, 85-163, Poland|Indywidualna Praktyka Lekarska Dr Hab Konrad Rejdak, Lublin, Lubelskie, 20-016, Poland|Małopolskie Centrum Kliniczne, Kraków, Malopolskie, 30-149, Poland|Instytut Zdrowia dr Boczarska-Jedynak, Oświęcim, Malopolskie, 32-600, Poland|Centrum Medyczne Pratia - Warszawa, Warszawa, Mazowieckie, 01-868, Poland|Szpital Wolski im dr. Anny Gostyńskiej Samodzielny Publiczny Zakład Opieki Zdrowotnej, Warszawa, Mazowieckie, Poland|MA-LEK A.M. Maciejowscy S.C. Centrum Terapii SM, Katowice, Slaskie, 40-571, Poland|DENDRYT Centrum Medyczne, Katowice, Slaskie, 40-684, Poland|Neuro-Medic Janusz Zbrojkiewicz, Katowice, Slaskie, 40-686, Poland|Wielospecjalistyczne Centrum Medyczne Ibismed, Zabrze, Slaskie, 41-800, Poland|RESMEDICA Poradnia Neurologiczna, Kielce, Swietokrzyskie, 25-726, Poland|Niepubliczny Zakład Opieki Zdrowotnej NEURO - KARD, Poznań, Wielkopolskie, 61-853, Poland|Hospital Universitario de Getafe, Getafe, Madrid, 289005, Spain|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, 8003, Spain|Hospital Universitario Ramón y Cajal, Madrid, 28034, Spain|Hospital Vithas Nisa Sevilla, Sevilla, 41009, Spain|Panthera Biopartners - North London, North London, England, EN1 1LJ, United Kingdom|ReCognition Health - Plymouth, Plymouth, England, PL6 8BT, United Kingdom|Panthera Biopartners - Preston, Preston, England, PR2 9QB, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England, S10 2JF, United Kingdom|NHS Highland, Inverness, Scotland, IV2 3UJ, United Kingdom"
NCT03804840,Developing a Mobile Method to Measure THC-induced Impairment,https://clinicaltrials.gov/study/NCT03804840,COMPLETED,YES,Measuring THC-induced Cognitive Impairment Using a Mobile Application,DRUG: Dronabinol|DRUG: Placebo,University of Chicago,,ALL,ADULT,72,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2017-03-01,2018-12-01,"University of Chicago, Chicago, Illinois, 60615, United States"
NCT06204003,Cannabinoids for Pain Management and Neuroprotection From Concussion,https://clinicaltrials.gov/study/NCT06204003,RECRUITING,NO,Healthy,DRUG: Cannabis/Hemp Isolate Extract,University of Regina,National Football League (NFL)|My Next Health Inc.,MALE,ADULT,35,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-02-15,2026-12,"University of Regina, Regina, Saskatchewan, S4S 0A2, Canada|Pasqua Hospital, Regina, Saskatchewan, S4T 7T1, Canada"
NCT06526208,Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults,https://clinicaltrials.gov/study/NCT06526208,NOT_YET_RECRUITING,NO,Autism Spectrum Disorder|Anxiety,DRUG: MB-IMP|OTHER: Placebo,Southwest Autism Research & Resource Center,,ALL,ADULT,108,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-10-01,2027-09-30,"Southwest Autism Research and Resource Center, Phoenix, Arizona, 85006, United States"
NCT00673647,CANDIS-II: Evaluation of the Cognitive-behavioral Treatment Programme CANDIS,https://clinicaltrials.gov/study/NCT00673647,UNKNOWN,NO,Cannabis Use Disorders,BEHAVIORAL: Cognitive-behavioral treatment,Technische Universität Dresden,Federal Ministry of Health,ALL,"CHILD, ADULT, OLDER_ADULT",450,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2008-05,2009-10,"Psychosoziale Beratungs- und Behandlungsstelle für Suchtgefährdete und -kranke, Bautzen, 02625, Germany|LogIn Jugend- und Suchtberatung, Berlin, 10585, Germany|Therapieladen e.V., Berlin, 10783, Germany|Jugend- und Drogenberatung Braunschweig, Braunschweig, 38102, Germany|Jugend- und Drogenberatung Dresden, Dresden, 01219, Germany|Die Boje - Suchtberatung und Behandlung, Hamburg, 20146, Germany|Drobs Hannover, Hannover, 30159, Germany|Caritas-Fachambulanz für junge Suchtkranke, Muenchen, 80335, Germany|Suchtambulanz der LWL-Klinik Münster, Muenster, 48147, Germany|Caritas Fachambulanz für Suchtprävention und Rehabilitation Osnabrück, Osnabrueck, 49074, Germany|Release Stuttgart e.V. & Ambulante Beratungs- und Behandlungsstelle Klinikum Stuttgart, Stuttgart, 70190, Germany"
NCT04841954,Hemp Seed Awareness,https://clinicaltrials.gov/study/NCT04841954,RECRUITING,NO,Allergy,DIAGNOSTIC_TEST: hemp prick-test,"University Hospital, Angers",,ALL,"ADULT, OLDER_ADULT",600,OTHER_GOV,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-06-01,2025-05-31,"MORISSET Martine, Angers, France"
NCT06699251,Effectiveness of Brief Intervention in Primary Care for Diverse Young People (Chat),https://clinicaltrials.gov/study/NCT06699251,RECRUITING,NO,Adolescent Drinking|Cannabis Use,BEHAVIORAL: Chat|BEHAVIORAL: Enhanced Usual Care,RAND,AltaMed Health Services Corporation|University of Pittsburgh Medical Center|Patient-Centered Outcomes Research Institute,ALL,CHILD,500,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2025-03-15,2029-02-28,"AltaMed Health Services, Commerce, California, 90022, United States|University of Pittsburgh Medical Center Children's Hospital, Pittsburgh, Pennsylvania, 15213, United States"
NCT01591629,The Effects of ∆-9-THC and Naloxone in Humans,https://clinicaltrials.gov/study/NCT01591629,COMPLETED,NO,Healthy,DRUG: Naloxone|DRUG: Delta-9-THC|DRUG: Placebo,Yale University,,ALL,ADULT,6,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2011-11-04,2012-06-01,"VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT04592159,Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder,https://clinicaltrials.gov/study/NCT04592159,WITHDRAWN,NO,Post-Traumatic Stress Disorder,DRUG: Nabiximols|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02-01,2023-03,
NCT00350649,Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management,https://clinicaltrials.gov/study/NCT00350649,COMPLETED,NO,Marijuana Dependence,BEHAVIORAL: Standard CBT|BEHAVIORAL: CBT+CM/adherence|BEHAVIORAL: CM/abstinence|BEHAVIORAL: CM/abstinence+CBT,Yale University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",205,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-12,2010-09,"ASAP/1 Long Wharf, New Haven, Connecticut, 06512, United States"
NCT04657666,Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis,https://clinicaltrials.gov/study/NCT04657666,COMPLETED,YES,Spasticity in Participants With Multiple Sclerosis,DRUG: Nabiximols|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",68,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-21,2022-05-10,"Clinical Trial Site, Choceň, 565 01, Czechia|Clinical Trial Site, Bydgoszcz, Kujawsko-Pomorskie, 85-163, Poland|Clinical Trial Site 1, Kraków, Malopolskie, 30-539, Poland|Clinical Trial Site, Oswiecim, Malopolskie, 32-600, Poland|Clinical Trial Site 2, Warszawa, Mazowieckie, 01-211, Poland|Clinical Trial Site 1, Warszawa, Mazowieckie, 01-868, Poland|Clinical Trial Site, Gdansk, Pomorskie, 80-803, Poland|Clinical Trial Site, Chorzow, Slaskie, 41-500, Poland|Clinical Trial Site 3, Katowice, Slaskie, 40-123, Poland|Clinical Trial Site 1, Katowice, Slaskie, 40-571, Poland|Clinical Trial Site 2, Katowice, Slaskie, 40-684, Poland|Clinical Trial Site, Kielce, Swietokrzyskie, 25-726, Poland|Clinical Trial Site 2, Poznan, Wielkopolskie, 61-853, Poland|Clinical Trial Site 1, Poznan, Wielkopolskie, 62-064, Poland|Clinical Trial Site, Kraków, 30-149, Poland|Clinical Trial Site, Zabrze, 41-800, Poland"
NCT03782402,Cannabinoids for Taxane Induced Peripheral Neuropathy,https://clinicaltrials.gov/study/NCT03782402,TERMINATED,YES,Chemotherapy-induced Peripheral Neuropathy,DRUG: Cannabinoids,New York State Psychiatric Institute,,FEMALE,ADULT,12,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-09-01,2021-08-30,"1051 Riverside Drive, New York, New York, 10032, United States"
NCT06523725,Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy,https://clinicaltrials.gov/study/NCT06523725,RECRUITING,NO,Post-traumatic Epilepsy,DRUG: PO BRC-003 (High Cannabidiol Cannabis Extract)|DRUG: Placebo,Dr. Paul Lyons,Biopharmaceutical Research Company,ALL,"ADULT, OLDER_ADULT",50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-11,2026-08,"Winchester Medical Center, Winchester, Virginia, 22601, United States"
NCT04203498,Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis,https://clinicaltrials.gov/study/NCT04203498,TERMINATED,YES,Multiple Sclerosis (MS),DRUG: Nabiximols|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",139,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-10-01,2023-02-28,"University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, 35233, United States|Neurostudies - Port Charlotte, Port Charlotte, Florida, 33952, United States|University of South Florida, Tampa, Florida, 33613, United States|Accel Research Sites - Enterprise, Tampa, Florida, 33634, United States|Shepherd Center, Atlanta, Georgia, 30309, United States|Consultants in Neurology - Northbrook, Northbrook, Illinois, 60062, United States|American Health Network of Indiana, Avon, Indiana, 46123, United States|Ochsner Medical Center, New Orleans, Louisiana, 70121, United States|The Multiple Sclerosis Center For Innovations In Care, Saint Louis, Missouri, 63131, United States|Raleigh Neurology Associates - Raleigh Location, Raleigh, North Carolina, 27607, United States|University of Cincinnati (UC) Health, Dayton, Ohio, 45417, United States|Neurology Clinic - Cordova, Cordova, Tennessee, 38018, United States|Hope Neurology, Knoxville, Tennessee, 37922, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|Central Texas Neurology Consultants, Round Rock, Texas, 78681, United States|Poliklinika Choceň, Choceň, Pardubice, 565 01, Czechia|Neurologie Taláb Radomír Doc. MUDr., CSc, Hradec Králové, 500 03, Czechia|Nemocnice Jihlava, Jihlava, 586 01, Czechia|Fakultní Nemocnice Královské Vinohrady, Praha 10, 100 34, Czechia|Krajská Zdravotní - Nemocnice Teplice, Teplice, 415 29, Czechia|Wromedica Centrum Zdrowia, Wrocław, Dolnoslaskie, 51-685, Poland|Centrum Medyczne Neuromed - Ośrodek Badań Klinicznych, Bydgoszcz, Kujawsko-Pomorskie, 85-163, Poland|Centrum Medyczne Neuroprotect, Warszawa, Mazowieckie, 01-684, Poland|Centrum Medyczne Pratia - Warszawa, Warszawa, Mazowieckie, 01-868, Poland|Neuro-Medic Janusz Zbrojkiewicz, Katowice, Slaskie, 40-555, Poland|Wielospecjalistyczne Centrum Medyczne Ibismed, Zabrze, Slaskie, 41-800, Poland|RESMEDICA Poradnia Neurologiczna, Kielce, Swietokrzyskie, 25-726, Poland|Niepubliczny Zakład Opieki Zdrowotnej NEURO - KARD, Poznań, Wielkopolskie, 61-853, Poland|Centrum Medyczne Oporów, Lublin, 20-855, Poland|Neurologiczny NZOZ Centrum Leczenia SM Ośrodek Badań Klinicznych im. dr n. med. Hanki Hertmanowskiej Witosław Cieślak, Plewiska, 62-064, Poland|Wromedica Centrum Zdrowia, Wrocław, 51-685, Poland|SP ZOZ Uniwersytecki Szpital Kliniczny Nr 1 im. Norberta Barlickiego w Łodzi, Łódź, 90-001, Poland|Spitalul Municipal Caracal, Caracal, 235200, Romania|Spitalul Clinic Cai Ferate Constanta, Constanţa, 900123, Romania|Centrul Medical Clubul Sanatatii, Câmpulung, 115100, Romania|Spitalul Municipal Sf. Dr. Cosma si Damian Radauti, Rădăuți, 725400, Romania|Barts Health NHS Trust, London, England, E1 1BB, United Kingdom"
NCT01536912,Medical Marijuana Use in HIV+ Patients: Probability Survey,https://clinicaltrials.gov/study/NCT01536912,COMPLETED,NO,HIV Positive,,Wayne State University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",218,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-02,2014-12,"Wayne State University (HIV clinic, Tolan Park Medical Building), Detroit, Michigan, 48201, United States"
NCT06379971,Maternal Choline Supplementation and Cannabis Use During Pregnancy: Impact on Early Brain Development,https://clinicaltrials.gov/study/NCT06379971,RECRUITING,NO,Child Development|Cannabis Use,DRUG: Placebo|DRUG: Choline,"University of Colorado, Denver",,FEMALE,ADULT,140,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2024-11-25,2029-04-30,"UC Health, Aurora, Colorado, 80045, United States"
NCT06003725,Cultural Adaptation of Drug Treatment for DJJ Youth,https://clinicaltrials.gov/study/NCT06003725,RECRUITING,NO,Substance Use,BEHAVIORAL: Culturally Adapted Adolescent Substance Use Treatment,"University of California, San Francisco",National Institute on Drug Abuse (NIDA),ALL,CHILD,55,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2024-05-15,2027-05-30,"University of California, San Francisco, San Francisco, California, 94110, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT04461756,Safety and Pharmacokinetics of Vaped Cannabis in Healthy Volunteers,https://clinicaltrials.gov/study/NCT04461756,COMPLETED,NO,Healthy Volonteers,DRUG: PPP001,Tetra Bio-Pharma,Algorithme Pharma Inc,ALL,"ADULT, OLDER_ADULT",12,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-11-01,2018-11-24,"Alta sciences, Montreal, Quebec, Canada"
NCT03483220,"Emotional Regulation, Impulsivity in Cannabis Its Relation to MRI Brain Structure",https://clinicaltrials.gov/study/NCT03483220,COMPLETED,NO,Addiction,DIAGNOSTIC_TEST: MRI brain,Assiut University,,MALE,ADULT,66,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-03-01,2021-12-20,"Assiut University, Assiut, 71111, Egypt"
NCT04605393,"Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study",https://clinicaltrials.gov/study/NCT04605393,COMPLETED,NO,Schizophrenia|Cannabis Use,DRUG: Cannabidiol|DRUG: Placebo|DRUG: Delta-9-THC,King's College London,,ALL,"ADULT, OLDER_ADULT",36,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2021-01-01,2023-07-07,"South London and Maudsley NHS Foundation Trust, London, SE58AZ, United Kingdom"
NCT02983773,Marijuana's Impact on Alcohol Motivation and Consumption,https://clinicaltrials.gov/study/NCT02983773,COMPLETED,NO,Alcohol Drinking|Marijuana,DRUG: THC 7.2%|DRUG: THC 3.0%|DRUG: Placebo,Brown University,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,ADULT,131,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2017-01-23,2021-07-21,"Brown University, Providence, Rhode Island, 02912, United States"
NCT06422299,Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Young Adult Couples,https://clinicaltrials.gov/study/NCT06422299,NOT_YET_RECRUITING,NO,Alcohol Drinking|Cannabis Use|Couples,"BEHAVIORAL: Online, couples-based intervention",University of Washington,National Institutes of Health (NIH)|National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,ADULT,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2026-07-15,2027-08-01,
NCT06513819,HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention),https://clinicaltrials.gov/study/NCT06513819,RECRUITING,NO,Hiv|Alcohol Drinking|Fall|Cannabis Use,BEHAVIORAL: Information Motivation Behavioral and Motivational Interviewing (IMB-MI) technique,Yale University,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"ADULT, OLDER_ADULT",100,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2025-01-15,2025-12,"VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT01433692,"CANABIC : CANnabis and Adolescents, a Brief Intervention (BI) to Reduce Their Consumption",https://clinicaltrials.gov/study/NCT01433692,UNKNOWN,NO,Addictions|Adolescents|Primary Health Care|Brief Intervention,BEHAVIORAL: Brief Intervention,"University Hospital, Clermont-Ferrand",,ALL,"CHILD, ADULT",750,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: ",2012-03,2014-07,"CHU Clermont-Ferrand, Clermont-Ferrand, 63003, France"
NCT02828748,Cytokine Production of Colonic Tissue From IBD Patients,https://clinicaltrials.gov/study/NCT02828748,UNKNOWN,NO,Inflammatory Bowel Disease,"OTHER: no intervention in patients treatment, only biopsy taken",Meir Medical Center,,ALL,"ADULT, OLDER_ADULT",50,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2016-12,2018-09,"Gastroenterology institute Meir Hospital, Kfar Saba, Israel"
NCT06038279,Trial of INI-2004 in Healthy Volunteers and Participants With Allergic Rhinitis.,https://clinicaltrials.gov/study/NCT06038279,RECRUITING,NO,Allergic Rhinitis Due to Weed Pollen|Allergic Rhinitis,DRUG: INI-2004|DRUG: Placebo,Inimmune Corporation,Avance Clinical Pty Ltd.,ALL,ADULT,68,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-07-04,2024-11-01,"Nucleus Network Pty Ltd, Melbourne, Victoria, 3004, Australia"
NCT01510015,Evaluation of the Effects of Treatment of Psycho-stimulant and Cannabis-dependent Users in Israel,https://clinicaltrials.gov/study/NCT01510015,UNKNOWN,NO,Cannabis Dependence|Psychostimulant Dependence,DRUG: Risperidone,Tel-Aviv Sourasky Medical Center,,ALL,ADULT,100,OTHER_GOV,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-01,2013-11,"Sourasky Medical center, Tel Aviv, 64239, Israel"
NCT06473701,Reducing Breathlessness With Dronabinol in COPD Patients,https://clinicaltrials.gov/study/NCT06473701,NOT_YET_RECRUITING,NO,COPD|Breathlessness|Cannabis,DRUG: Dronabinol 2.5mg Capsule|DRUG: Placebo,Vejle Hospital,Region of Southern Denmark|Odense Patient Data Explorative Network|University of Southern Denmark|University of Aarhus,ALL,"ADULT, OLDER_ADULT",30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2025-02,2026-07,
NCT05180968,DIalysis Symptom COntrol-Pruritus Outcome Trial,https://clinicaltrials.gov/study/NCT05180968,COMPLETED,NO,End Stage Renal Disease|Pruritus,DRUG: Nabilone 0.5 MG Oral Capsule|DRUG: Placebo Nabilone,University of Manitoba,Population Health Research Institute,ALL,"ADULT, OLDER_ADULT",14,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-08-02,2023-08-11,"University of Alberta Hospital, Edmonton, Alberta, T6G2P4, Canada|Seven Oaks General Hospital, Winnipeg, Manitoba, R2V 3M3, Canada"
NCT00218114,Divalproex Sodium (Depakote) for Explosive Tempers in Adolescents and Adults,https://clinicaltrials.gov/study/NCT00218114,COMPLETED,NO,Attention Deficit and Disruptive Behavior Disorders|Marijuana Abuse,DRUG: Divalproex Sodium|DRUG: Placebo,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",25,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2000-02,2005-02-18,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT01720433,Reduction of Pain Following Laparoscopic Surgery: A Double Blind Prospective Randomized Controlled Trial,https://clinicaltrials.gov/study/NCT01720433,COMPLETED,NO,Post-operative Pain,PROCEDURE: intervention,Northampton General Hospital NHS Trust,,ALL,"ADULT, OLDER_ADULT",127,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2010-08,2012-02,"Northampton General Hopsital, Northampton, Northamptonshire, NN15BD, United Kingdom"
NCT04231643,Effects of Cannabis on Cognition and Endocannabinoid Levels in Bipolar Disorder Patients and Healthy Volunteers,https://clinicaltrials.gov/study/NCT04231643,TERMINATED,NO,Bipolar Disorder,DRUG: Dronabinol|DRUG: Epidiolex|DRUG: Placebos,"University of California, San Diego",National Institute on Drug Abuse (NIDA),ALL,ADULT,19,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2021-09-01,2023-11-28,"UC San Diego Medical Center, San Diego, California, 92103, United States"
NCT04406948,Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies,https://clinicaltrials.gov/study/NCT04406948,WITHDRAWN,NO,"Resistant Epilepsy, Drug|Adolescent Epilepsy|Children Epilepsy|Children and Adolescents With Resistant Epilepsies",DRUG: MGCND00EP1|DRUG: Placebo|DIAGNOSTIC_TEST: ECG|DIAGNOSTIC_TEST: EEG|DIAGNOSTIC_TEST: Blood and urine collection,MGC Pharmaceuticals d.o.o,,ALL,"CHILD, ADULT",0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-05-30,2024-05-30,"Schneider Children's Medical Center of Israel, Petach Tikvah, Central District, 4920235, Israel|University Children's Hospital Ljubljana University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia"
NCT05235503,Influence of Δ9-tetrahydrocannabinol (THC) on Oxycodone Induced Ventilatory Depression in Healthy Volunteers,https://clinicaltrials.gov/study/NCT05235503,UNKNOWN,NO,Respiratory Depression|Cannabis Use|Opioid Use,DRUG: Medicinal cannabis in combination with oxycodon|DRUG: Medicinal cannabis in combination with placebo oxycodon,Leiden University Medical Center,,ALL,ADULT,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2021-12-09,2023-06,"Leiden University Medical Center, Leiden, Zuid Holland, 2333 ZA, Netherlands"
NCT00708994,"Cannabinoids, Neural Synchrony, and Information Processing",https://clinicaltrials.gov/study/NCT00708994,COMPLETED,NO,Cannabis|Psychotic Disorders,DRUG: THC|DRUG: Placebo,Yale University,National Institute on Drug Abuse (NIDA),ALL,ADULT,42,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2008-02-25,2012-12-03,"VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT05247411,Nurse Educational Intervention to Improve Symptoms in Fibromyalgia Patients,https://clinicaltrials.gov/study/NCT05247411,COMPLETED,NO,Fibromyalgia,OTHER: Educational intervention,University of Milano Bicocca,,ALL,"CHILD, ADULT, OLDER_ADULT",30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-07-15,2021-03-01,"School of Medicine, University of Milano-Bicocca, Monza, 20900, Italy"
NCT04512365,Reward and Drug Effects on Mood and Brain Response,https://clinicaltrials.gov/study/NCT04512365,RECRUITING,NO,Cannabis Use|Healthy,DRUG: Placebo oral capsule|DRUG: THC,University of Illinois at Chicago,National Institute on Drug Abuse (NIDA),ALL,ADULT,80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2021-03-16,2025-06-30,"University of Illinois at Chicago, Chicago, Illinois, 60612, United States"
NCT04226690,Safety and Effects on Responses to Stress and Pain of Natural Medical Marijuana Products,https://clinicaltrials.gov/study/NCT04226690,COMPLETED,NO,Pain,DRUG: Active CBD/THC Dose 1|DRUG: Active CBD/THC Dose 2|DRUG: matched placebo comparator,Yale University,Connecticut Pharmaceutical Solutions,ALL,"ADULT, OLDER_ADULT",24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-11-15,2023-12-15,"The Yale Stress Center: Yale University, New Haven, Connecticut, 06519, United States"
NCT06448923,Cannabidiol After Multi-Trauma for Pain and Opioid Therapy,https://clinicaltrials.gov/study/NCT06448923,NOT_YET_RECRUITING,NO,Fracture,DRUG: Cannabidiol|DRUG: Cannabidiol|DRUG: Placebo,Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal,,ALL,"ADULT, OLDER_ADULT",168,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-09,2026-09,
NCT04030442,"Cannabidiol, Morphine, Pain",https://clinicaltrials.gov/study/NCT04030442,RECRUITING,NO,CBD|Chronic Pain,DRUG: Immediate-release Oral Morphine Sulfate Tablets|OTHER: Thermal and Pressure Nociceptive Sensitivity,Wayne State University,,ALL,ADULT,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2019-05-01,2025-01-26,"Tolan Park Medical Building, Detroit, Michigan, 48201, United States"
NCT01608217,Delta-THC in Dementia,https://clinicaltrials.gov/study/NCT01608217,COMPLETED,NO,Behavioural Disturbances|Pain|Dementia|Alzheimer's Dementia|Vascular Dementia,DRUG: delta-9-tetrahydrocannabinol (delta-THC)|DRUG: Placebo|DRUG: Acetaminophen|DRUG: Acetaminophen,Radboud University Medical Center,"Health Valley, Netherlands",ALL,"ADULT, OLDER_ADULT",50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-06,2014-06,"Radboud university medical center, department of Geriatrics, Nijmegen, Gelderland, 6525, Netherlands|Vincent van Gogh Institute for Psychiatry, department of Elderly, Venlo, Limburg, 5912, Netherlands"
NCT02290938,Motivational Interviewing and Culture for Urban Native American Youth (MICUNAY),https://clinicaltrials.gov/study/NCT02290938,COMPLETED,YES,Alcohol Use|Marijuana Use,BEHAVIORAL: MICUNAY|OTHER: Community Wellness Gathering,RAND,"National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institute on Drug Abuse (NIDA)|University of California, Los Angeles|Sacred Path Indigenous Wellness Center",ALL,"CHILD, ADULT",185,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2014-07,2018-06,"United American Indian Involvement, Inc, Los Angeles, California, 90017, United States|American Indian Child Resource Center, Oakland, California, 94610, United States"
NCT01893424,Bioequivalence Assessment of Oral Administration Vs. Oral Spray of a Cannabinoids (Tetrahydrocannabinol and Cannabidiol),https://clinicaltrials.gov/study/NCT01893424,COMPLETED,NO,Pain,DRUG: Sativex buccal spray|DRUG: CBD-THC-Piperine-PNL capsule,Hadassah Medical Organization,,MALE,ADULT,12,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2013-08,2015-01,"Hadassah medical organization, Jerusalem, Israel"
NCT05064319,Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders,https://clinicaltrials.gov/study/NCT05064319,RECRUITING,NO,"Bipolar Disorder|Cannabis Use|Schizoaffective Disorder, Bipolar Type|Bipolar I Disorder|Bipolar II Disorder|Cannabis Use Disorder, Mild|Cannabis Use Disorder, Moderate|Cannabis Use Disorder, Severe",DRUG: Gabapentin|DRUG: Placebo,Medical University of South Carolina,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",68,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-02-24,2026-06-30,"Medical University Of South Carolina, Charleston, South Carolina, 29425, United States"
NCT05670353,Cannabidiol for the Treatment of Pelvic Pain in Endometriosis (DREAMLAND),https://clinicaltrials.gov/study/NCT05670353,RECRUITING,NO,Endometriosis|Pelvic Pain,DRUG: Cannabis Derivatives|DRUG: Placebo|DRUG: Hormonal Contraceptive Agents,University of Sao Paulo,,FEMALE,"ADULT, OLDER_ADULT",102,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-01-03,2024-08-20,"Center of Chronic Pelvic Pain and Gynecologic Endoscopy of Ribeirao Preto Medical School, University of Sao Paulo, Ribeirão Preto, Sao Paulo, 14049-900, Brazil"
NCT04124146,Long-term Evolution of Patients Suffering From Lumbar Canal Stenosis and Supported by Minimally Invasive Surgery: SUIVISTENO,https://clinicaltrials.gov/study/NCT04124146,UNKNOWN,NO,Lumbar Spinal Stenosis,RADIATION: MRI for some patients according functionnal tests results,Centre Medico-Chirurgicale et Obstetrique Cote d'Opale,,ALL,"ADULT, OLDER_ADULT",100,NETWORK,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-12-01,2021-05-01,
NCT01853020,Cannabinoids and Cerebellar-Motor Functioning,https://clinicaltrials.gov/study/NCT01853020,COMPLETED,NO,Cannabis|Psychotic Disorders,DRUG: THC|DRUG: Placebo,Yale University,,ALL,ADULT,57,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2012-12,2015-04-07,"VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT04374773,Effects of Pregnancy-associated Hormones on THC Metabolism in Women,https://clinicaltrials.gov/study/NCT04374773,ACTIVE_NOT_RECRUITING,NO,Pregnancy Related|Cannabis Use,DRUG: Dronabinol,University of Washington,National Institute on Drug Abuse (NIDA),FEMALE,ADULT,12,OTHER,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2020-10-19,2025-08-31,"Nina Isoherranen, Seattle, Washington, 98125, United States"
NCT05687812,"Effects of Cephalaria Syriaca Flour-added Bread on Glucose Metabolism and Appetite Parameters in Individuals With Obesity, Diabetes, and Healthy Controls.",https://clinicaltrials.gov/study/NCT05687812,COMPLETED,NO,"Nutrition, Healthy",DIETARY_SUPPLEMENT: Cephalaria Syriaca flour-added bread,Istanbul University,,ALL,"ADULT, OLDER_ADULT",60,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-01-01,2022-12-31,"Istanbul University, Faculty of Medicine, Department of Endocrinology and Metabolism, Istanbul, Capa, 34093, Turkey"
NCT02388217,The Effect of Cannabis on Pain and Related Quality Of Life Outcomes In Chronic Pain: A Prospective Open-Label Study,https://clinicaltrials.gov/study/NCT02388217,COMPLETED,NO,Chronic Pain,,Hadassah Medical Organization,,ALL,"ADULT, OLDER_ADULT",400,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-04,2020-11-01,"Hadassah Medical Center, Jerusalem, Israel"
NCT00547963,Brief Counseling to Reduce Injuries Among Emergency Department Patients Who Report Alcohol and Substance Use,https://clinicaltrials.gov/study/NCT00547963,UNKNOWN,NO,Alcohol Drinking|Marijuana Smoking,BEHAVIORAL: brief counseling,National Institute on Alcohol Abuse and Alcoholism (NIAAA),,ALL,"ADULT, OLDER_ADULT",554,NIH,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2003-12,2008-12,"Injury Prevention Center, Rhode Island Hospital, Brown University, Providence, Rhode Island, 02903, United States"
NCT03201835,"5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers",https://clinicaltrials.gov/study/NCT03201835,COMPLETED,NO,Healthy Volunteers,DRUG: PNL-THC:CBD soft gelatin capsule|DRUG: Sativex|DRUG: CBD hard capsule dose 1|DRUG: P-PNL-THC:CBD soft gelatin capsule|DRUG: CBD hard capsule dose 2,"PhytoTech Therapeutics, Ltd.",,MALE,ADULT,15,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2015-09-24,2016-06-06,"Clinical Research Center (CRC)- Souraskey Medical center, Tel Aviv, Israel"
NCT00227903,Therapeutic Substance Abuse Treatment in Pregnancy - 1,https://clinicaltrials.gov/study/NCT00227903,COMPLETED,YES,Alcohol Abuse|Cocaine Abuse|Marijuana Abuse,BEHAVIORAL: MI-CBT|BEHAVIORAL: Brief Advice,Yale University,National Institute on Drug Abuse (NIDA),FEMALE,"CHILD, ADULT",168,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2004-09,2010-08,"Bridgeport Hospital, Bridgeport, Connecticut, 06106, United States|Yale-New Haven Hospital, New Haven, Connecticut, 06510, United States"
NCT00227890,Skills and Motivation at the Rhode Island Training School (Project SMART) - 1,https://clinicaltrials.gov/study/NCT00227890,COMPLETED,NO,"Alcoholic, Marijuana Misuse",BEHAVIORAL: MI/CBT|BEHAVIORAL: RT/TU,University of Rhode Island,National Institute on Drug Abuse (NIDA)|National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"CHILD, ADULT",205,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2005-03,2011-09,"Rhode Island Training School, Cranston, Rhode Island, 02920, United States|University of Rhode Island, Social Sciences Research Center, Kingston, Rhode Island, 02881, United States"
NCT04911127,Therapeutic Response of Cannabidiol in Rheumatoid Arthritis,https://clinicaltrials.gov/study/NCT04911127,COMPLETED,NO,Rheumatoid Arthritis|Cannabis,DRUG: 200mg Cannabidiol by capsules twice daily|DRUG: 400mg Cannabidiol by capsules twice daily|DRUG: Placebo capsules,"University of California, Los Angeles",,ALL,"ADULT, OLDER_ADULT",67,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-10-05,2023-12-31,"UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, California, 90095, United States"
NCT04741477,The Pharmacokinetics and Pharmacodynamics of Hemp-based Topical Cannabinoid Products,https://clinicaltrials.gov/study/NCT04741477,COMPLETED,NO,Cannabis|Drug Effect,DRUG: CBD|DRUG: THC|DRUG: Placebo,Johns Hopkins University,Substance Abuse and Mental Health Services Administration (SAMHSA),ALL,ADULT,47,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2021-07-14,2022-09-16,"Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland, 21224, United States"
NCT05520294,Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant Melanoma,https://clinicaltrials.gov/study/NCT05520294,ACTIVE_NOT_RECRUITING,NO,Melanoma,OTHER: High-performance liquid chromatography-tandem mass spectrometry assays,"University of Colorado, Denver",Cancer League of Colorado,ALL,"ADULT, OLDER_ADULT",90,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-09-01,2024-08-31,"University of Colorado Denver, Aurora, Colorado, 80045, United States"
NCT04283019,The Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabidiol (CBD) Under Acute and Chronic Exposure Conditions,https://clinicaltrials.gov/study/NCT04283019,COMPLETED,NO,"Cannabis, Drug Effects",DRUG: CBD|DRUG: THC,Johns Hopkins University,Substance Abuse And Mental Health Administration|Canopy Growth Corporation,ALL,ADULT,75,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2021-08-15,2024-06-17,"Johns Hopkins University, Baltimore, Maryland, 21224, United States"
NCT04566627,"Acceptability and Feasibility Study of the Program ""Yo Se Lo Que Quiero"" (Unplugged)",https://clinicaltrials.gov/study/NCT04566627,COMPLETED,NO,Substance Use|Adolescent Behavior,"BEHAVIORAL: ""Yo Sé Lo Que Quiero"" programl","Universidad de los Andes, Chile",Comisión Nacional de Investigación Científica y Tecnológica,ALL,CHILD,1214,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2019-03-01,2019-12-30,"Universidad de los Andes, Santiago, 7620060, Chile"
NCT03604341,Cannabinoids for Pain Control During Medical Abortion,https://clinicaltrials.gov/study/NCT03604341,COMPLETED,YES,Medical Abortion|Pain,DRUG: Dronabinol 5mg Cap|OTHER: Placebo,Oregon Health and Science University,Society of Family Planning,FEMALE,"ADULT, OLDER_ADULT",72,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-11-01,2019-05-28,"Oregon Health & Science University, Portland, Oregon, 97239, United States"
NCT05832281,Role of CBD in Improving Alexithymia,https://clinicaltrials.gov/study/NCT05832281,RECRUITING,NO,Alexithymia|HIV,DRUG: Purysis CBD|DRUG: Placebo,"University of California, San Diego",California Department of Cannabis Control (DCC)|Center for Medicinal Cannabis Research,ALL,"ADULT, OLDER_ADULT",30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11-28,2024-07-01,"HIV Neurobehavioral Research Center/Center for Medicinal Cannabis Research, San Diego, California, 92103, United States"
NCT02441985,rTMS Therapy for Primary Orthostatic Tremor,https://clinicaltrials.gov/study/NCT02441985,COMPLETED,NO,Primary Orthostatic Tremor,"DEVICE: Magstim RapidStim2|DEVICE: Sham Magstim RapidStim2|OTHER: Fahn-Tolosa-Marin Tremor Rating Scale (TRS)|OTHER: Timed ""Up & Go"" Test (TUG) test|OTHER: 10m walk test|OTHER: Tremor electrophysiology|OTHER: Cerebellar-brain Inhibition (CBI)",University of Florida,National Organization for Rare Disorders|Neuronetics,ALL,"ADULT, OLDER_ADULT",11,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-08,2019-01-08,"Center for Movement Disorders and Neurorestoration, Gainesville, Florida, 32607, United States"
NCT02534064,Effect of Consumption of Yogurt Fortified in Calcium and Vit. D on Circulating Levels of 25OHD in Postmenopausal Women,https://clinicaltrials.gov/study/NCT02534064,COMPLETED,NO,Menopause|Vitamin D Deficiency,DIETARY_SUPPLEMENT: CALIN+|DIETARY_SUPPLEMENT: CALIN+,Yoplait France SAS,Eurofins Optimed,FEMALE,"ADULT, OLDER_ADULT",140,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2014-10,2015-10,"Eurofins Optimed, Gières, 38610, France"
NCT03398083,Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam,https://clinicaltrials.gov/study/NCT03398083,COMPLETED,NO,Cannabis Use Disorder,DRUG: THC|DRUG: Alprazolam|DRUG: Placebo oral capsule|DRUG: CBD,National Institute on Drug Abuse (NIDA),,ALL,ADULT,42,NIH,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: DIAGNOSTIC",2017-12-04,2018-05-30,"Debra Kelsh, MD, Overland Park, Kansas, 66212, United States"
NCT03676049,Cannabidiol for Drug Resistant Pediatric Epilepsy (Expanded Access Use),https://clinicaltrials.gov/study/NCT03676049,AVAILABLE,NO,Drug Resistant Epilepsy,DRUG: Cannabidiol,John,,ALL,"CHILD, ADULT",,OTHER,EXPANDED_ACCESS,,,,"University of Mississippi Medical Center, Jackson, Mississippi, 39216, United States"
NCT06249542,Implementing Screening for Cannabis and Other Drug Use Disorders in Primary Care: Impact on Diagnosis and Treatment,https://clinicaltrials.gov/study/NCT06249542,COMPLETED,NO,Cannabis-Related Disorder|Cannabis Abuse|Drug Abuse|Drug Use Disorders|Opioid Use Disorder|Opioid Abuse|Substance Abuse|Substance Use Disorders,OTHER: Care Delivery Improvement Intervention,Kaiser Permanente,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",363936,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2015-01,2024-07-31,
NCT03508895,Hemp Seed Protein and Bioactive Peptides Consumption for Hypertension,https://clinicaltrials.gov/study/NCT03508895,COMPLETED,NO,Hypertension,OTHER: Whole hemp seed protein|OTHER: Whole hemp seed protein plus bioactive peptides|OTHER: Casein protein,University of Manitoba,Heart and Stroke Foundation of Canada|Manitoba Harvest,ALL,"ADULT, OLDER_ADULT",35,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-07-16,2019-11-15,"Richardson Centre for Food Technology and Research, Winnipeg, Manitoba, R3T 6C5, Canada"
NCT02407808,"Cannabinoids, Learning, and Memory",https://clinicaltrials.gov/study/NCT02407808,ACTIVE_NOT_RECRUITING,NO,Cannabis|Psychotic Disorders,DRUG: THC|DRUG: Placebo,Yale University,,ALL,ADULT,80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2015-02,2025-08,"VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT02387489,A Clinical Trial of SBIRT Services in School-based Health Centers,https://clinicaltrials.gov/study/NCT02387489,COMPLETED,NO,Marijuana Use|Alcohol Consumption|Unsafe Sex|Risk Behavior,BEHAVIORAL: Brief in-person motivational intervention|BEHAVIORAL: Computerized Brief Intervention,"Friends Research Institute, Inc.",National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",300,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2015-10-02,2018-09-11,
NCT03722888,"Development of a Videogame Prototype Targeting Cigarette and Marijuana Smoking, and Tobacco Product Prevention Among Young Adolescents (smokeScreen)",https://clinicaltrials.gov/study/NCT03722888,COMPLETED,NO,Smoking,DEVICE: smokeSCREEN video game,Yale University,,ALL,CHILD,40,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2017-10-25,2018-09-28,"Hamden Youth Center, Hamden, Connecticut, 06517, United States|Leadership, Education, and Athletics Partnership (LEAP) Inc., New Haven, Connecticut, 06511, United States|Farnam Neighborhood House, New Haven, Connecticut, 06513, United States"
NCT01979133,Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders,https://clinicaltrials.gov/study/NCT01979133,COMPLETED,YES,Bipolar Disorder|Substance Use Disorder,DRUG: Icariin,University of Texas Southwestern Medical Center,,ALL,"ADULT, OLDER_ADULT",10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-10,2015-06,"The University of Texas Southwestern Medical Center, Dallas, Texas, 75390-8849, United States"
NCT03107936,"Development of a Videogame Prototype Targeting Cigarette and Marijuana Smoking, and Tobacco Product Prevention Among Young Adolescents",https://clinicaltrials.gov/study/NCT03107936,COMPLETED,NO,Smoking,BEHAVIORAL: smokeSCREEN game,Yale University,,ALL,CHILD,40,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2017-01,2018-03,"Hamden Youth Center, Hamden, Connecticut, 06517, United States|Leadership, Education, and Athletics Partnership (LEAP) Inc., New Haven, Connecticut, 06511, United States|Yale New Haven Hospital, New Haven, Connecticut, 06511, United States|Farnam Neighborhood House, New Haven, Connecticut, 06513, United States"
NCT06621888,Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS),https://clinicaltrials.gov/study/NCT06621888,ACTIVE_NOT_RECRUITING,NO,PANS Pediatric Acute-Onset Neuropsychiatric Syndrome,DRUG: NTI164,Fenix Innovation Group,Neurotech International,ALL,CHILD,18,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-06-02,2025-12,"The Childrens Hospital at Westmead, Sydney, New South Wales, 2145, Australia|Monash Children&#39;s Hospital, Melbourne, Victoria, Australia"
NCT04422600,"Fetal Exposure to Cannabinoids: Exposure, Methylation and Neurodevelopmental Effects",https://clinicaltrials.gov/study/NCT04422600,COMPLETED,NO,Fetal Exposure Timing Unspecified,"OTHER: There is no other intervention, only clinical treatment.",University of Arkansas,,FEMALE,"ADULT, OLDER_ADULT",72,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-02-26,2023-08-01,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States"
NCT03066713,Post-prandial Glucose Response From Phytochemical Rich Potato Products,https://clinicaltrials.gov/study/NCT03066713,COMPLETED,NO,Glycemic Response|Appetitive Behavior,OTHER: Skin Off French Fry|OTHER: Skin On French Fry|OTHER: Hash brown|OTHER: Carbohydrate control,Purdue University,USDA Beltsville Human Nutrition Research Center,ALL,ADULT,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2017-01-31,2017-06-25,"Purdue University, West Lafayette, Indiana, 47906, United States"
NCT00982982,Effects of Delta-9-THC and Iomazenil in Healthy Humans,https://clinicaltrials.gov/study/NCT00982982,COMPLETED,NO,Schizophrenia|Mental Disorders|Psychotic Disorders,DRUG: THC and Iomazenil|DRUG: Placebo (control),Yale University,,MALE,ADULT,17,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2009-02-11,2013-02-22,"VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT04634136,Full-spectrum Medical Cannabis for Treatment of Spasticity in Patients With Severe Forms of Cerebral Palsy,https://clinicaltrials.gov/study/NCT04634136,COMPLETED,NO,"Children, Adult|Spastic Cerebral Palsy|Quality of Life|Cannabis|Physical Disability",DIAGNOSTIC_TEST: Lab tests|DIAGNOSTIC_TEST: ECG|DIAGNOSTIC_TEST: Cannabinoid Levels|DRUG: Full-spectrum Medical Canabis Product (HemPhar)|DRUG: Placebo|DIAGNOSTIC_TEST: Spasticity level according to modified Ashworth scale (Bohannon)|DIAGNOSTIC_TEST: Gross Motor Function Measure|DIAGNOSTIC_TEST: Borg rating of perceived exertion scale|DIAGNOSTIC_TEST: Edmonton symptom assessment system,University Medical Centre Ljubljana,"PharmaHemp|University of Ljubljana, Faculty of Medicine",ALL,"CHILD, ADULT",55,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-15,2024-02-29,"PharmaHemp, Ljubljana, 1000, Slovenia|University Medical Centre Ljubljana, Ljubljana, Slovenia"
NCT04978129,Enhancing Quality in Protective Strategies,https://clinicaltrials.gov/study/NCT04978129,ACTIVE_NOT_RECRUITING,NO,Health Risk Behaviors|Risk Reduction Behavior,BEHAVIORAL: Online and Text Messaging Intervention,University of North Texas Health Science Center,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,ADULT,162,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-08-15,2025-03-01,"University of North Texas Health Science Center, Fort Worth, Texas, 76107, United States"
NCT04031313,Effectiveness and Safety of Oil Extracts Medical Cannabis Treatment for Patients With Chronic Pain,https://clinicaltrials.gov/study/NCT04031313,UNKNOWN,NO,Chronic Pain,,Dorit Pud,Rambam Health Care Campus|Sheba Medical Center,ALL,"ADULT, OLDER_ADULT",600,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-08-01,2021-07,"Rambam Health Care Campus, Haifa, Israel"
NCT05516407,Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder.,https://clinicaltrials.gov/study/NCT05516407,UNKNOWN,NO,Autism Spectrum Disorder,DRUG: FEN164,Fenix Innovation Group,Neurotech International|Monash Health,ALL,CHILD,18,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-04-01,2022-09-02,"Monash Children's Hospital, Clayton, Victoria, 3168, Australia"
NCT04339114,Reason to Season; Flavors to Increase Vascular Health,https://clinicaltrials.gov/study/NCT04339114,COMPLETED,NO,Overweight and Obesity|Healthy,OTHER: Breakfast: control meal|OTHER: Breakfast: Cinnamon meal|OTHER: Breakfast: Italian herbs meal|OTHER: Breakfast: pumpkin spice,"Clinical Nutrition Research Center, Illinois Institute of Technology",McCormick Science Institute,ALL,"ADULT, OLDER_ADULT",28,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2019-04-18,2021-02-01,"Clinical Nutrition Research Center, Chicago, Illinois, 60616, United States"
NCT05747599,Adapting and Testing a Behavioural Intervention to Prevent FASD and Adverse Infant Outcomes,https://clinicaltrials.gov/study/NCT05747599,COMPLETED,YES,Maternal Behavior|Alcohol Drinking|Fetal Conditions,BEHAVIORAL: Intervention with contingent incentives and text-based support,RTI International,"Medical Research Council, South Africa",FEMALE,"ADULT, OLDER_ADULT",48,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-04-01,2024-10-31,"South African Medical Research Council, Cape Town, South Africa"
NCT00484367,A Comparison of Adolescent Group Therapy and Transitional Family Therapy for Adolescent Alcohol and Drug Abusers,https://clinicaltrials.gov/study/NCT00484367,UNKNOWN,NO,Alcohol Abuse|Alcohol Dependence|Cannabis Abuse|Cannabis Dependence|Other Substance Abuse,BEHAVIORAL: Adolescent group therapy|BEHAVIORAL: Transitional family therapy,"The Morton Center, Inc.",National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,CHILD,120,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,1999-07,2012-08,"The Morton Center, Louisville, Kentucky, 40204, United States"
NCT05267769,Clinical Trial on Pharmacokinetics and Tolerability of AP707,https://clinicaltrials.gov/study/NCT05267769,COMPLETED,NO,Pharmacokinetics|Tolerability|Safety,DRUG: AP707,CannaXan GmbH,,MALE,ADULT,12,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-03-02,2022-04-03,"Phase I Unit of CannaXan GmbH, Warngau, Bavaria, 83627, Germany"
NCT02820805,Dietary Carbohydrate Consumption on Memory Performance and Mood in Children,https://clinicaltrials.gov/study/NCT02820805,COMPLETED,NO,"Cognitive Ability, General",OTHER: Meal Skipping|OTHER: French fries|OTHER: Mashed potatoes|OTHER: Hash browns|OTHER: Rice|OTHER: Beans,Toronto Metropolitan University,,ALL,CHILD,22,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2016-04,2016-10,"School of Nutrition, Ryerson University, Toronto, Ontario, Canada"
NCT04875286,Patient Reported Symptom Control with THC or CBD Use,https://clinicaltrials.gov/study/NCT04875286,ACTIVE_NOT_RECRUITING,NO,Cancer-Associated Pain|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm,OTHER: Electronic Health Record Review|OTHER: Questionnaire Administration,M.D. Anderson Cancer Center,,ALL,"ADULT, OLDER_ADULT",200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-02-03,2027-02-02,"Banner MD Anderson Cancer Center, Gilbert, Arizona, 85234, United States|M D Anderson Cancer Center, Houston, Texas, 77030, United States"
NCT06713447,NTI164 Human PK Study,https://clinicaltrials.gov/study/NCT06713447,NOT_YET_RECRUITING,NO,Healthy|Healthy Volunteer,DRUG: NTI164,Fenix Innovation Group,CMAX Clinical Research Pty Ltd|Neurotech International,ALL,"ADULT, OLDER_ADULT",12,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2024-12-01,2025-06-01,"CMAX Clinical Research Pty Ltd, Adelaide, South Australia, 5000, Australia"
NCT04708795,Clinical Trial on Pharmacokinetic and Tolerability of AP701,https://clinicaltrials.gov/study/NCT04708795,COMPLETED,NO,Pharmacokinetic|Tolerability|Safety,DRUG: AP701,CannaXan GmbH,,MALE,ADULT,15,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-01-11,2021-03-07,"Phase I Unit of CannaXan GmbH, Warngau, Bavaria, D-83627, Germany"
NCT02710578,Alcohol Effects on Driving-related Skills of Young Drivers,https://clinicaltrials.gov/study/NCT02710578,COMPLETED,NO,Psychomotor Impairment,DRUG: Alcohol|DRUG: Placebo,Centre for Addiction and Mental Health,Ontario Ministry of Transportation,ALL,ADULT,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2016-03,2017-07-18,"Centre for Addiction and Mental Health, Toronto, Ontario, M5S 2S1, Canada"
NCT01730781,Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning,https://clinicaltrials.gov/study/NCT01730781,RECRUITING,NO,Schizophrenia|Cannabis Dependence|Prodromal for Psychotic Illness|Family History of Alcoholism|Healthy Control|Opioid-use Disorder|Post Traumatic Stress Disorder,RADIATION: [11-C]OMAR,Yale University,National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH),MALE,ADULT,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-07,2024-12,"Connecticut Mental Health Center, Clinical Neuroscience Research Unit, New Haven, Connecticut, 06519, United States"
NCT01554384,Trial of Point-of-treatment Xpert MTB/RIF Assay,https://clinicaltrials.gov/study/NCT01554384,COMPLETED,NO,Tuberculosis,PROCEDURE: Xpert MTB/RIF assay|PROCEDURE: Smear microscopy,University of Cape Town,"Biomedical Research and Training Institute|University of Zimbabwe|University of Zambia|Medical Research Council, South Africa|Mbeya medical research program|McGill University|Radboud University Medical Center|University of Cape Town Lung Institute",ALL,"ADULT, OLDER_ADULT",1472,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2010-10,2012-07,"Medical Research Council, Durban, Kwazulu-Natal, South Africa|University of Cape Town, Cape Town, Western Cape, 7945, South Africa|University Teaching Hospital of Zambia, Lusaka, Zambia|University of Zimbabwe, Harare, Zimbabwe"
NCT04603781,CBD Oil for Reducing Emotional Impact of COVID-19,https://clinicaltrials.gov/study/NCT04603781,SUSPENDED,NO,Anxiety Depression|Alcohol Abuse|Substance Abuse|Anger|Sleep Disturbance|Stress Reaction,DIETARY_SUPPLEMENT: CBD Isolate|DIETARY_SUPPLEMENT: Full Spectrum CBD Oil|DIETARY_SUPPLEMENT: Broad-Spectrum CBD Oil|DIETARY_SUPPLEMENT: Placebo Oil,University of Texas at Austin,Way West Wellness|SunFlora.Inc,ALL,"ADULT, OLDER_ADULT",200,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-04,2023-12-31,"University of Texas at Austin, Laboratory for the Study of Anxiety Disorders, Austin, Texas, 78712, United States"
NCT05626959,Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder,https://clinicaltrials.gov/study/NCT05626959,UNKNOWN,NO,Autism Spectrum Disorder,DRUG: NTI164,Fenix Innovation Group,Neurotech International|Monash Health,ALL,CHILD,54,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-11-30,2023-11-30,"Monash Children's Hospital, Clayton, Victoria, 3168, Australia"
NCT03995121,SV2 PET Imaging With [11C]APP311,https://clinicaltrials.gov/study/NCT03995121,RECRUITING,NO,Schizophrenia and Other Psychotic Disorders|Cannabis Use Disorder|Healthy,RADIATION: [11C]APP311,Yale University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",120,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-12-01,2025-12,"Conneticut Mental Health Center, New Haven, Connecticut, 06519, United States"
NCT06621043,Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT),https://clinicaltrials.gov/study/NCT06621043,ACTIVE_NOT_RECRUITING,NO,Rett Syndrome,DRUG: NTI164,Fenix Innovation Group,Neurotech International,FEMALE,"CHILD, ADULT",14,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-09-20,2025-12,"The Childrens Hospital at Westmead, Sydney, New South Wales, 2145, Australia"
NCT02710019,Good Shepherd: Back to Reality Series,https://clinicaltrials.gov/study/NCT02710019,COMPLETED,NO,Knowledge,OTHER: Back to Reality Series Video Games|OTHER: Control Video Game,McMaster University,Good Shepherd Health Centre,ALL,"CHILD, ADULT",55,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2016-05-05,2017-04-18,"Good Shepherd, Hamilton, Ontario, L8R 2B3, Canada"
NCT00238550,Study of CBME in the Relief of Painful Diabetic Neuropathy,https://clinicaltrials.gov/study/NCT00238550,COMPLETED,NO,Diabetic Neuropathy|Painful,DRUG: Cannabis based medicine extract (CBME),Sheffield Teaching Hospitals NHS Foundation Trust,Diabetes UK,ALL,"ADULT, OLDER_ADULT",36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2003-10,2006-03,"Royal Hallamshire Hospital, Sheffield, South Yorkshire, S10 2JF, United Kingdom"
NCT04110626,"Realistic Evaluation of Expériences Animées, a School-based Intervention in Nouvelle Aquitaine",https://clinicaltrials.gov/study/NCT04110626,COMPLETED,NO,Addiction,OTHER: Questionnaires|OTHER: Non-directive Interviews,"University Hospital, Bordeaux",CMG-EC U1219 Inserm,ALL,"CHILD, ADULT, OLDER_ADULT",1026,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-09-30,2022-06-16,"CIC1401-EC - CHU de Bordeaux Centre Inserm U1219, Bordeaux, 33000, France"
NCT04261166,A Phase I Open Label Study to Assess PK and Safety of Plant Cannabis Extract,https://clinicaltrials.gov/study/NCT04261166,COMPLETED,NO,Healthy,DRUG: A1|DRUG: A2|DRUG: A3|DRUG: A4|DRUG: A5|DRUG: B1|DRUG: B2|DRUG: B3|DRUG: B4,Breath of Life International Pharma Ltd,,ALL,ADULT,76,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2019-07-24,2022-10-24,"Ziv Medical Center, Zefat, 13100, Israel"
NCT00506753,Motivation and Skills for Delta-9-tetrahydrocannabinol/Ethanol (THC/ETOH+) Teens in Jail,https://clinicaltrials.gov/study/NCT00506753,COMPLETED,YES,Alcohol Drinking|Marijuana Smoking,BEHAVIORAL: MI/CBT|BEHAVIORAL: RT/SU,University of Rhode Island,National Institute on Drug Abuse (NIDA)|National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"CHILD, ADULT",205,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2004-09,2011-09,"Rhode Island Training School, Cranston, Rhode Island, 02920, United States"
NCT00936299,Bupropion for ADHD in Adolescents With Substance Use Disorder,https://clinicaltrials.gov/study/NCT00936299,COMPLETED,YES,Attention Deficit Hyperactivity Disorder|Nicotine Dependence|Cannabis Use Disorder,DRUG: Bupropion|OTHER: Placebo,"University of Colorado, Denver",National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",105,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-01,2013-05,"University of Colorado Denver, Adolescent Clinical Research, Denver, Colorado, 80210, United States"
NCT04236999,"Unplugged, a Drug Use Prevention Program: Adaptation and Evaluation of Effectiveness Among Students in Chile",https://clinicaltrials.gov/study/NCT04236999,UNKNOWN,NO,Substance Use,BEHAVIORAL: Yo Sé Lo Que Quiero (YSLQQ),"Universidad de los Andes, Chile",Comisión Nacional de Investigación Científica y Tecnológica,ALL,CHILD,8880,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-09-01,2023-03-31,"Universidad de los Andes, Santiago, Chile"
NCT04042545,Safety and Efficacy of Inhaled Cannabis For the Uncontrolled Pain Relief in Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT04042545,UNKNOWN,NO,"Cancer Pain|Quality of Life|Pain, Acute|Cannabis Use",DRUG: PPP001|DRUG: Placebo,Tetra Bio-Pharma,,ALL,"ADULT, OLDER_ADULT",78,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-30,2022-09,"Scottsdale Research Institute, Cave Creek, Arizona, 85331, United States"
NCT02983695,Cannabinoid Therapy for Pediatric Epilepsy,https://clinicaltrials.gov/study/NCT02983695,COMPLETED,NO,Epilepsy,DRUG: TIL-TC150,The Hospital for Sick Children,Tilray,ALL,"CHILD, ADULT",20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-02-02,2021-07-20,"The Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada"
NCT03655574,Substance Use Interventions for Truant Adolescents,https://clinicaltrials.gov/study/NCT03655574,COMPLETED,NO,Adolescent Problem Behavior|Truancy; Unsocialized|Marijuana Abuse|Truancy; Socialized|Substance Abuse|Alcohol Abuse,BEHAVIORAL: Motivational + Family Check-up (MET+FCU)|OTHER: Psychoeducation,Brown University,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",110,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-01-01,2024-04-30,"Rhode Island Family Court, Providence, Rhode Island, 02903, United States|Brown Univerity, Providence, Rhode Island, 02912, United States"
NCT05075213,QuitBet Phase II: A Digital Social Game That Pays You to Stop Smoking,https://clinicaltrials.gov/study/NCT05075213,COMPLETED,NO,Smoking Cessation,BEHAVIORAL: contingency management (deposit contract)|BEHAVIORAL: leaderboard and social feed|BEHAVIORAL: smoking cessation resource list,"WayBetter, Inc.",Hennepin Healthcare Research Institute,ALL,"ADULT, OLDER_ADULT",246,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-11-01,2024-07-27,"WayBetter, Wilmington, Delaware, 19807, United States"
NCT02696850,"The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis",https://clinicaltrials.gov/study/NCT02696850,COMPLETED,YES,Rhinosinusitis|Chronic Eosinophilic Rhinosinusitis|Allergic Rhinosinusitis,DRUG: Budesonide|DRUG: Saline alone,Washington University School of Medicine,,ALL,"ADULT, OLDER_ADULT",80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2016-01-01,2017-04-13,"Washington University School of Medicine, Saint Louis, Missouri, 63110, United States"
NCT05167097,Mindsets and the Effectiveness of a Brief Intervention - Replication,https://clinicaltrials.gov/study/NCT05167097,COMPLETED,NO,Alcohol Drinking|Cannabis Use,OTHER: ASSIST-linked Brief Intervention|OTHER: Mindset Intervention,University of Konstanz,,ALL,ADULT,125,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2021-11-08,2023-03-02,"University of Konstanz, Konstanz, Baden-Württemberg, 78462, Germany"
NCT05989841,Mitigating PTSD-CUD After Sexual Assault,https://clinicaltrials.gov/study/NCT05989841,RECRUITING,NO,Posttraumatic Stress Disorder|Cannabis Use Disorder,BEHAVIORAL: RISE Guide|BEHAVIORAL: Relaxation Control,"University of Nevada, Las Vegas","University of North Carolina, Chapel Hill",FEMALE,"ADULT, OLDER_ADULT",100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-12-15,2028-02-29,"Hennepin Assault Response Team, Minneapolis, Minnesota, 55415, United States|University Medical Center, Las Vegas, Nevada, 89102, United States|UNC Chapel Hill, Chapel Hill, North Carolina, 27599, United States|Harbor Shelter, Smithfield, North Carolina, 27577, United States|Tulsa Forensic Nursing, Tulsa, Oklahoma, 74103, United States|SAFE Austin, Austin, Texas, 74103, United States"
NCT00957775,Computer-delivered Psychosocial Intervention for Adolescent Substance Use Disorders,https://clinicaltrials.gov/study/NCT00957775,UNKNOWN,NO,Substance-Related Disorders|Alcohol-Related Disorders|Marijuana Abuse,BEHAVIORAL: Usual care|BEHAVIORAL: Computer-delivered ACRA,"National Development and Research Institutes, Inc.",St. Luke's-Roosevelt Hospital Center,ALL,"CHILD, ADULT",84,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2009-08,2011-07,"National Development and Research Institutes, Inc.; St. Luke's-Roosevelt Hospital Center, New York, New York, 10010; 10025, United States"
NCT01529047,Web-based vs In-person Personalized Feedback Intervention for Comorbid Substance Use and Disordered Gambling,https://clinicaltrials.gov/study/NCT01529047,COMPLETED,NO,Gambling|Alcohol Consumption|Cannabis,BEHAVIORAL: Personalized Feedback Intervention,University of Washington,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",361,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2010-02,2015-01,"University of Washington, Seattle, Washington, 98195, United States"
NCT02229032,Genetic Analysis Between Charlotte's Web Responders Versus Non- Responders in a Dravet Population,https://clinicaltrials.gov/study/NCT02229032,COMPLETED,NO,Dravet Syndrome,,"University of Colorado, Denver",Denver Health Medical Center,ALL,"CHILD, ADULT",19,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-08,2017-07,"Denver Health Medical Center, Denver, Colorado, 80204, United States"
NCT04036968,Enhancing Medication-based Analgesia in Humans- STUDY 2,https://clinicaltrials.gov/study/NCT04036968,COMPLETED,YES,Pain|Cannabis|Opioid Use,DRUG: Within-subject test of blinded study medications,Johns Hopkins University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",31,OTHER,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2020-02-01,2022-11-01,"Johns Hopkins University Bayview Medical Campus, Baltimore, Maryland, 21224, United States"
NCT00650585,An Effectiveness Trial of Project ALERT,https://clinicaltrials.gov/study/NCT00650585,COMPLETED,YES,Alcohol Drinking|Smoking|Marijuana Smoking,BEHAVIORAL: Project ALERT,Pacific Institute for Research and Evaluation,,ALL,"CHILD, ADULT, OLDER_ADULT",8338,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2004-05,2008-06,"Pacific Institute for Research & Evaluation, Chapel Hill, North Carolina, 27514, United States"
NCT03550196,Coronary Revascularisation by rePOT,https://clinicaltrials.gov/study/NCT03550196,COMPLETED,NO,Coronary Disease,OTHER: Provisional stenting with rePOT technique,Hospices Civils de Lyon,,ALL,"ADULT, OLDER_ADULT",500,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-05-14,2022-06-23,"Département de cardiologie Clinique Axium, Aix-en-Provence, 13090, France|Fédération de cardiologie médicale - Hôpital Cardiologique Louis Pradel - Hospices civils de Lyon, Bron, 69500, France|Département de cardiologie Hôpital Gabriel Montpied CHU de Clermont Ferrand, Clermont-Ferrand, 63003, France|Département de cardiologie CHU de Nimes, Nîmes, 30029, France"
NCT04975191,Personalized Feedback Programs for College Students,https://clinicaltrials.gov/study/NCT04975191,COMPLETED,YES,"Alcohol Use, Unspecified",BEHAVIORAL: Resources|BEHAVIORAL: Personalized Feedback Program (PFP)|BEHAVIORAL: Substance Use Feedback Program (BMI),Virginia Commonwealth University,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"ADULT, OLDER_ADULT",252,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-08-29,2022-03-23,"Virginia Commonwealth University, Richmond, Virginia, 23298, United States"
NCT03295903,Cannabinoid Supplementation on Vascular and Cognitive Function,https://clinicaltrials.gov/study/NCT03295903,UNKNOWN,NO,Diet Modification,DIETARY_SUPPLEMENT: Cannabidiol supplement,University of British Columbia,Lexaria Bioscience Corp.,ALL,"ADULT, OLDER_ADULT",24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2018-01-01,2021-10-01,"University of British Columbia, Kelowna, Ontario, V1V 1V7, Canada"
NCT01815645,Contingency Management Treatment for Crack Addiction - Study With Brazilian Population,https://clinicaltrials.gov/study/NCT01815645,COMPLETED,YES,Cocaine Related Disorders,BEHAVIORAL: ST+CM|BEHAVIORAL: standard treatment,Federal University of São Paulo,Fundação de Amparo à Pesquisa do Estado de São Paulo,ALL,"ADULT, OLDER_ADULT",65,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-05,2015-06,"Ambulatorio Medico de Especialidades (AME) da Vila Maria, Sao Paulo, SP, Brazil"
NCT04931927,Impact of Telehealth on Engagement in Psychotherapy and/or Medication Treatment,https://clinicaltrials.gov/study/NCT04931927,TERMINATED,NO,Psychiatric Diagnosis,BEHAVIORAL: Making Connections Intervention-Telehealth (MCI-T)|BEHAVIORAL: Treatment as usual (TAU),New York State Psychiatric Institute,,ALL,"CHILD, ADULT",14,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-11-08,2022-07-12,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT00624715,Cannabinoid Receptor Function & Alcoholism,https://clinicaltrials.gov/study/NCT00624715,COMPLETED,NO,Alcoholism,DRUG: THC|DRUG: Placebo,Yale University,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,ADULT,29,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2007-08-09,2010-06-22,"VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT03957798,Evaluation of a Motion-Activated Refusal-Skills Training Video Game for Prevention of Substance Use Disorder Relapse,https://clinicaltrials.gov/study/NCT03957798,COMPLETED,NO,Relapse|Opioid Use|Marijuana Usage,BEHAVIORAL: RecoveryWarrior 2.0,George Washington University,Maryland Treatment Centers,ALL,"CHILD, ADULT",80,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2016-02-05,2016-10-31,
NCT05020028,Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis,https://clinicaltrials.gov/study/NCT05020028,RECRUITING,NO,Knee Arthritis,DRUG: Cannabidiol (CBD)|DRUG: Placebo,NYU Langone Health,Orcosa Inc.,ALL,"ADULT, OLDER_ADULT",100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-06-22,2025-09,"NYU Langone Health, New York, New York, 10016, United States"
NCT01721473,Brain Nicotine Receptor Density in Veteran Smokers,https://clinicaltrials.gov/study/NCT01721473,COMPLETED,YES,Positron Emission Tomography,OTHER: positron emission tomography scan,VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",184,FED,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-01-01,2016-06-30,"VA San Diego Healthcare System, San Diego, CA, San Diego, California, 92161, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, 90073, United States"
NCT05478863,The Pharmacodynamics of Cannabinoid-Caffeine Combinations,https://clinicaltrials.gov/study/NCT05478863,COMPLETED,NO,Behavioral Pharmacology of Cannabinoids,DRUG: Oral Placebo|DRUG: Oral THC|DRUG: Oral CBD|DRUG: Oral Caffeine,Johns Hopkins University,Canopy Growth Corporation,ALL,ADULT,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: BASIC_SCIENCE",2023-01-20,2024-10-02,"Johns Hopkins University School of Medicine BPRU, Baltimore, Maryland, 21224, United States"
NCT02102113,Probing the Cannabinoid System in Individuals With a Family History of Psychosis,https://clinicaltrials.gov/study/NCT02102113,ACTIVE_NOT_RECRUITING,NO,Psychosis|Cannabis Use|THC|Marijuana|Schizophrenia,DRUG: Placebo|DRUG: Very Low Dose THC|DRUG: Low Dose THC,Yale University,,ALL,ADULT,21,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: OTHER",2014-01,2025-12,"VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT03138460,Analysis of Orthopedic Patients Response to New Pain Modulating Substances and Drugs,https://clinicaltrials.gov/study/NCT03138460,COMPLETED,NO,Low Back Pain,OTHER: standard medications crossed over to cannabis,Rabin Medical Center,,ALL,"ADULT, OLDER_ADULT",100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-01-01,2018-08-01,"Hasharon Hospital, Petaẖ Tiqwa, Israel"
NCT01081119,Brief Voluntary Alcohol and Drug Intervention for Middle School Youth,https://clinicaltrials.gov/study/NCT01081119,COMPLETED,NO,Alcohol Drinking|Cigarette Smoking|Marijuana Smoking,BEHAVIORAL: Project CHOICE,RAND,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,CHILD,6455,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2008-09,2014-06,"16 middle schools in Torrance, Santa Monica, and Los Angeles, Los Angeles, California, United States"
NCT05985850,Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy,https://clinicaltrials.gov/study/NCT05985850,ACTIVE_NOT_RECRUITING,NO,Opioid Use Disorder|Methadone|Cannabis|Fentanyl,DRUG: Aurora 1:1 Drops (Indica)|DRUG: Placebo,BC Centre on Substance Use,Canadian Institutes of Health Research (CIHR),ALL,"ADULT, OLDER_ADULT",24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-05-23,2027-03,"Rapid Access Addiction Clinic (RAAC), St. Paul's Hospital, Vancouver, British Columbia, V6Z 1Y6, Canada"
NCT04011046,Register of Patients Benefiting From a Coronary Bifurcation Angioplasty at the University Hospital of Nîmes and Montpellier in 2017,https://clinicaltrials.gov/study/NCT04011046,COMPLETED,NO,Stent Thrombosis,DEVICE: Stent,Centre Hospitalier Universitaire de Nīmes,,ALL,"ADULT, OLDER_ADULT",143,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-01-01,2017-12-31,"CHU de Nîmes, Nîmes, 30029, France"
NCT01878929,The Effect of Pollen Season on Subcutaneous Allergen Immunotherapy Reactions,https://clinicaltrials.gov/study/NCT01878929,UNKNOWN,NO,Allergic Rhinitis|Asthma|Allergic Conjunctivitis,"DRUG: Allergen(Tree, Grass, Weeds)",University Hospitals Cleveland Medical Center,,ALL,"CHILD, ADULT, OLDER_ADULT",245,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-04,2014-04,"Allergy/Immunology Associates Inc., South Euclid, Ohio, 44121, United States"
NCT02362009,South Miami Hospital Fibroid Registry,https://clinicaltrials.gov/study/NCT02362009,TERMINATED,NO,"Uterine Myomas, Leiomyomas, or Fibromas",,Baptist Health South Florida,,FEMALE,"ADULT, OLDER_ADULT",52,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-02,2015-12,"South Miami Hospital, Miami, Florida, 33143, United States"
NCT02530645,Development and Testing of a Smartphone Application to Reduce Substance Use and Sexual Risk Among Homeless Young Adults,https://clinicaltrials.gov/study/NCT02530645,COMPLETED,NO,Alcohol Use|Marijuana Use|Sexual Behavior,BEHAVIORAL: OnTrack|BEHAVIORAL: Treatment as Usual|BEHAVIORAL: Brief Motivational Interviewing,New York State Psychiatric Institute,,ALL,ADULT,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-11,2016-08,"Covenant House New York, New York, New York, United States"
NCT06821035,The THRIVE Study: Teaching Healthy Regulation in Individuals & Vulnerable Environments,https://clinicaltrials.gov/study/NCT06821035,NOT_YET_RECRUITING,NO,Adverse Childhood Experiences|Family Functioning,BEHAVIORAL: Garnering Resilience in Traumatized youth and families (GRIT)|BEHAVIORAL: Digital Citizenship Curriculum (DCC),"University of California, Irvine","University of California, Los Angeles|University of Illinois at Chicago|National Institute on Drug Abuse (NIDA)",ALL,CHILD,420,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2025-03,2028-10,"The Regents of the University of California, Irvine, Irvine, California, 92697-7600, United States"
NCT03806296,Delayed Sleep Timing in Teens Study,https://clinicaltrials.gov/study/NCT03806296,COMPLETED,NO,Delayed Sleep Phase,"OTHER: Increase morning bright light|OTHER: Decrease evening blue light|BEHAVIORAL: Sleep scheduling|BEHAVIORAL: Monitor sleep, mood, and substance use",University of Pittsburgh,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",148,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2018-12-03,2024-11-30,"Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, 15213, United States"
NCT01595620,Cannabinoid Modulation of Pain,https://clinicaltrials.gov/study/NCT01595620,COMPLETED,NO,Pain,OTHER: Thermal|OTHER: Electrical|OTHER: Capsaicin|DRUG: THC|DRUG: THC|DRUG: Placebo,Yale University,,ALL,ADULT,6,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2011-11-09,2012-04-19,"VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT00176085,Pharmacokinetics of THCCOOH and Its Acyl-glucuronide After Intravenous Administration of THCCOOH,https://clinicaltrials.gov/study/NCT00176085,COMPLETED,NO,THCCOOH|Pharmacokinetics|Metabolism|Cannabis,,Heidelberg University,,MALE,ADULT,10,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2004-10,2005-03,"Clinical Research Center, Department of Internal Medicine VI, Heidelberg, 69120, Germany"
NCT03944954,Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults,https://clinicaltrials.gov/study/NCT03944954,COMPLETED,YES,Neurosciences|Substance-Related Disorders|Behavior Problem,DEVICE: Placebo TMS Sham|DRUG: Marinol 10Mg Capsule TMS Sham|DRUG: Marinol 30Mg Capsule TMS Sham|DEVICE: Placebo TMS Real|OTHER: Marinol 10Mg Capsule TMS Real|OTHER: Marinol 30Mg Capsule TMS Real,"Michael J. Wesley, PhD",National Institute on Drug Abuse (NIDA),ALL,ADULT,66,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE,2017-07-15,2023-12-13,"Neurobehavioral Systems Lab of the University of Kentucky College of Medicine, Lexington, Kentucky, 40507, United States"
NCT05950074,It´s Up To You: Update and Digitalization of a Universal School-based Prevention Intervention for Drug Initiation and Use,https://clinicaltrials.gov/study/NCT05950074,ACTIVE_NOT_RECRUITING,NO,"Substance Use|Behavior, Addictive|Smoking Behaviors|Alcohol Drinking|Illicit Drug Use","BEHAVIORAL: ""It´s Up To You"" program",Instituto Europeo de Estudios en Prevención,University of Santiago de Compostela|University of Oviedo|University of the Balearic Islands,ALL,CHILD,1000,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2023-10-01,2024-07-31,"Instituto Europeo de Estudios en Prevención, Palma De Mallorca, Spain"
NCT05041647,Cannabinoids As a Treatment for Insomnia in Major Depression,https://clinicaltrials.gov/study/NCT05041647,ACTIVE_NOT_RECRUITING,NO,"Insomnia|Depressive Disorder, Major|Sleep Disorder|Depression|Insomnia Chronic",DRUG: 25:1 CBD/THC|DRUG: 5:1 CBD/THC|OTHER: Placebo,St. Joseph's Healthcare Hamilton,McMaster University,ALL,"ADULT, OLDER_ADULT",60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-08-28,2025-02,"St. Joseph's Healthcare Hamilton, Hamilton, Ontario, L9C 0E3, Canada"
NCT04617938,TACUNA (Traditions and Connections for Urban Native Americans),https://clinicaltrials.gov/study/NCT04617938,ACTIVE_NOT_RECRUITING,NO,Opioid Use|Alcohol Drinking|Marijuana Use,BEHAVIORAL: TACUNA plus Wellness Circle|BEHAVIORAL: Opioid Education Workshop,RAND,"University of California, Los Angeles|Sacred Path Indigenous Wellness Center",ALL,ADULT,541,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-11-23,2025-07-28,"United American Indian Involvement, Inc, Los Angeles, California, 90017, United States|UCLA, Los Angeles, California, 90095, United States|RAND Corporation, Santa Monica, California, 90401, United States"
NCT06457555,Knowledge Levels and Experiences of Intensive Care Nurses on the Prevention of Pressure Sores: Mixed Method,https://clinicaltrials.gov/study/NCT06457555,NOT_YET_RECRUITING,NO,Nurses|Pressure Ulcer|Critical Care,OTHER: type of parallel data in a convergent parallel hash pattern (near time),Burdur Mehmet Akif Ersoy University,,ALL,"CHILD, ADULT, OLDER_ADULT",60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-07-01,2024-12-31,
NCT06475001,Dose-Response Characterization of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain,https://clinicaltrials.gov/study/NCT06475001,RECRUITING,NO,Chronic Non-specific Low Back Pain,DRUG: VER-01|DRUG: Placebo,Vertanical GmbH,,ALL,"ADULT, OLDER_ADULT",800,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-06-28,2025-07,"St Pancras Clinical Research, London, United Kingdom"
NCT00247221,Brief Intervention for Families of Teens Treated in the Emergency Department for an Alcohol-Related Event,https://clinicaltrials.gov/study/NCT00247221,COMPLETED,NO,Alcohol Abuse,BEHAVIORAL: MI/Family Check-up|BEHAVIORAL: MI only,Brown University,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,CHILD,208,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2002-10,2008-07,"Rhode Island Hospital/Lifespan Corporation and Brown University, Providence, Rhode Island, 02903, United States"
NCT05351905,Improving Pain Disability With the Use of Oral Cannabinoids,https://clinicaltrials.gov/study/NCT05351905,RECRUITING,NO,Chronic Pain|Opioid Use|Cannabis,DRUG: CBD oil ( MPL-001)|DRUG: CDB+THC oil (MPL-005)|DRUG: Placebo oil,"University Health Network, Toronto",,ALL,"ADULT, OLDER_ADULT",51,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-11-22,2024-12,"University Health Network, Toronto, Ontario, M5G 2C4, Canada"
NCT05066308,Cannabidiol for Reduction of Brain Neuroinflammation,https://clinicaltrials.gov/study/NCT05066308,RECRUITING,NO,Back Pain|Depressive Symptoms,DRUG: CBD|OTHER: Placebo,Massachusetts General Hospital,,ALL,"ADULT, OLDER_ADULT",80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2022-01-04,2026-12-15,"Massachusetts General Hospital, Boston, Massachusetts, 02114, United States"
NCT06650059,Cohort Study of Sickle Cell Patients Evaluating Analgesic Strategies and Their Consequences,https://clinicaltrials.gov/study/NCT06650059,RECRUITING,NO,Sickle Cell Disease,OTHER: Questionnaire,Assistance Publique - Hôpitaux de Paris,,ALL,"ADULT, OLDER_ADULT",600,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-12-01,2025-06-01,"Hôpital Henri Mondor, Créteil, 94010, France|Hôpital européen Georges-Pompidou, Paris, 75015, France|Hôpital Necker-Enfants Malades, Paris, 75015, France"
NCT02710097,Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II,https://clinicaltrials.gov/study/NCT02710097,ACTIVE_NOT_RECRUITING,NO,Cannabis|Alcohol Effect|Driving Under the Influence of Alcohol and Other Drugs,DRUG: Active inhaled cannabis|DRUG: Placebo|DRUG: Active Oral Ethanol|DRUG: Placebo,Yale University,,ALL,ADULT,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2016-03,2024-12,"Biological Studies Unit, VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT04261504,Brain Mechanisms of Reducing Polysubstance Use Following a Novel Body-mind Intervention,https://clinicaltrials.gov/study/NCT04261504,COMPLETED,YES,Multiple Drug Use,BEHAVIORAL: IBMT|BEHAVIORAL: RT,Texas Tech University,National Center for Complementary and Integrative Health (NCCIH),ALL,ADULT,70,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2019-04-19,2023-02-28,"TTU/UT, Lubbock, Texas, 79409, United States"
NCT03633149,Choices4Health: Intervention to Prevent Substance-exposed Pregnancy,https://clinicaltrials.gov/study/NCT03633149,COMPLETED,NO,Prenatal Alcohol Exposure|Prenatal Tobacco Exposure|Prenatal Marijuana Exposure,BEHAVIORAL: Computer tablet-delivered C4H|BEHAVIORAL: Person-delivered C4H|BEHAVIORAL: Brief Advice,University of Texas at Austin,"Baylor College of Medicine|The University of Texas Health Science Center, Houston|University of Houston",FEMALE,ADULT,219,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2018-06-28,2020-12-31,"University of Texas at Austin, Austin, Texas, 78713, United States"
NCT01037322,Cannabidiol for Inflammatory Bowel Disease,https://clinicaltrials.gov/study/NCT01037322,COMPLETED,NO,Crohn's Disease|Ulcerative Colitis,DRUG: cannabidiol|DRUG: placebo in drops,Meir Medical Center,,ALL,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-01,2012-09,"Sapir Medical center Meir Hospital, Kefar Saba, 44281, Israel"
NCT05491629,Competencies of Operating Room Nurses and Influencing Factors,https://clinicaltrials.gov/study/NCT05491629,COMPLETED,NO,Competence|Nurse's Role,OTHER: type of parallel data in a convergent parallel hash pattern (near time),Burdur Mehmet Akif Ersoy University,Akdeniz University,ALL,"CHILD, ADULT, OLDER_ADULT",224,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-03-01,2022-06-20,"Fatma Cebeci, Muratpaşa, 07160, Turkey"
NCT06044415,Brain Activity Under the Influence of JWH,https://clinicaltrials.gov/study/NCT06044415,NOT_YET_RECRUITING,NO,Neurotransmission During JWH Intoxication,DRUG: JWH018|OTHER: non-active control (no substance),Maastricht University,,ALL,ADULT,24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2023-10,2024-10,
NCT05754840,CANnabinoids in Pediatric ONCology,https://clinicaltrials.gov/study/NCT05754840,NOT_YET_RECRUITING,NO,Childhood Cancer|Cancer,DRUG: MPL-001|DRUG: MPL-005|DRUG: MPL-009,University of Manitoba,The Canadian Collaborative for Childhood Cannabinoid Therapeutics|Canadian Cancer Society (CCS)|Canadian Institutes of Health Research (CIHR),ALL,"CHILD, ADULT",60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2024-03,2025-12,
NCT04801641,A Pilot Trial of Nabilone for the Treatment of Obesity,https://clinicaltrials.gov/study/NCT04801641,TERMINATED,NO,Obesity,DRUG: Placebo|DRUG: Nabilone,Centre for Addiction and Mental Health,,ALL,ADULT,24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-09-17,2023-08-14,"Center for Addiction and Mental Health, Toronto, Ontario, M5S 2S1, Canada"
NCT06822569,Teen Health Choices & Wellness,https://clinicaltrials.gov/study/NCT06822569,RECRUITING,NO,"Health Behavior|Wellness, Psychological|Substance Use",OTHER: Cue reactivity paradigm,Brown University,National Institute on Drug Abuse (NIDA),ALL,CHILD,224,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-12-27,2028-02,"Brown University School of Public Health, Providence, Rhode Island, 02903, United States"
NCT03721822,Imaging Sex Differences in Smoking-Induced Pulmonary Inflammation,https://clinicaltrials.gov/study/NCT03721822,RECRUITING,NO,"Smoking, Cigarette|Smoking E-cigarette|Healthy Volunteer",DRUG: [18F]NOS,University of Pennsylvania,,ALL,ADULT,100,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2018-10-23,2026-10-23,"University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States"
NCT00397605,Cannabinoids in Bipolar Affective Disorder,https://clinicaltrials.gov/study/NCT00397605,WITHDRAWN,NO,Bipolar Affective Disorder,DRUG: Synthetic cannabinoids (1:1 ratio of THC % CBD),University of British Columbia,Vancouver General Hospital,ALL,ADULT,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-11,2013-12,"Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, V6T 2A1, Canada"
NCT01031563,Risk Perception in Drug-Dependent Adults With and Without Schizophrenia,https://clinicaltrials.gov/study/NCT01031563,COMPLETED,NO,Cocaine Dependence|Cannabis Dependence|Schizophrenia,,National Institute on Drug Abuse (NIDA),University of Maryland,ALL,ADULT,120,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-08-18,2012-05-03,"Maryland Psychiatric Research Center (MPRC) 55 Wade Avenue, Catonsville, Maryland, 21228, United States"
NCT01826188,Combined THC and CBD Drops for Treatment of Crohn's Disease,https://clinicaltrials.gov/study/NCT01826188,COMPLETED,NO,Crohn's Disease,DRUG: THC 5mg/ml and CBS 50mg/ml|DRUG: Placebo,Meir Medical Center,,ALL,"ADULT, OLDER_ADULT",50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-03,2018-06,"Meir Hospital, Kfar Saba, Israel"
NCT04086342,CHI-902 for Treatment of Social Anxiety Disorder,https://clinicaltrials.gov/study/NCT04086342,WITHDRAWN,NO,Social Anxiety Disorder,DRUG: CHI-902|DRUG: Placebo,Canopy Growth Corporation,Centre for Addiction and Mental Health|McMaster University,ALL,"ADULT, OLDER_ADULT",0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-01-24,2021-01-26,"MacAnxiety Research Center, McMaster University, Hamilton, Ontario, L8S 1B8, Canada|Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada"
NCT03549819,Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study,https://clinicaltrials.gov/study/NCT03549819,UNKNOWN,NO,Generalized Anxiety Disorder|Social Anxiety Disorder|Panic Disorder|Agoraphobia,DRUG: Cannabidiol (CBD) Oil Capsules|DRUG: Sunflower Lecithin Oil in Capsule,McMaster University,Tilray,ALL,"ADULT, OLDER_ADULT",50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-12-15,2024-02,"MacAnxiety Research Centre, Hamilton, Ontario, L8S 1B7, Canada"
NCT05888415,WELL-being Improvement Following Sophrology Practice,https://clinicaltrials.gov/study/NCT05888415,RECRUITING,NO,Well-being,,"University Hospital, Clermont-Ferrand",,ALL,"CHILD, ADULT, OLDER_ADULT",60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-06-19,2025-12,"CHU Clemront-Ferrand, Clermont-Ferrand, France"
NCT06022120,Health Literacy Among Youth,https://clinicaltrials.gov/study/NCT06022120,RECRUITING,NO,"Health Knowledge, Attitudes, Practice|Health Behavior|Health Literacy|Health-Related Behavior",BEHAVIORAL: An integrated health literacy intervention,Holbaek Sygehus,,ALL,"CHILD, ADULT",160,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2023-07-01,2026-12,"Department of Occupational and Social Medicine, Holbaek Hospital, Holbaek, Region Sjælland, 4300, Denmark"
NCT05146167,Testing a Meditation App With Justice-Involved Youth on Probation,https://clinicaltrials.gov/study/NCT05146167,RECRUITING,NO,Emotion Regulation|Alcohol Use|Cannabis Use|Sexual Behavior|Aggression,BEHAVIORAL: Bodhi AIM (intervention group)|BEHAVIORAL: HIB (control group),University of Illinois at Chicago,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2022-04-05,2025-02-28,"University of Illinois at Chicago, Chicago, Illinois, 60612, United States"
NCT03566706,Parents' View About Discussing Health Behaviors,https://clinicaltrials.gov/study/NCT03566706,COMPLETED,NO,Parents of Children Ages 10 to 17 Years Old,BEHAVIORAL: Discussion Tool: Unhealthy Eating|BEHAVIORAL: Discussion Tool: Marijuana Use|BEHAVIORAL: Discussion Tool: Sedentary Behavior,"University of California, Merced",,ALL,"CHILD, ADULT, OLDER_ADULT",318,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2018-08-20,2018-09-10,"UC Merced, Merced, California, 95343, United States"
NCT04959461,Preventing Impaired Driving Among Adolescents,https://clinicaltrials.gov/study/NCT04959461,RECRUITING,NO,Substance-Related Disorders,BEHAVIORAL: webCHAT|BEHAVIORAL: Usual Care,Stanford University,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,CHILD,150,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-01-01,2024-06-30,"DriveSafe Driving School, Denver, Colorado, 80220, United States|DriveSafe Driving School, Dearborn, Michigan, 48126, United States"
NCT00628706,Investigating the Acute Effects of THC on Functional Brain Systems,https://clinicaltrials.gov/study/NCT00628706,COMPLETED,NO,Reward|Tetrahydrocannabinol|Endocannabinoids|Memory|Magnetic Resonance Imaging,DRUG: Delta9-tetrahydrocannabinol (THC),UMC Utrecht,Center for Human Drug Research|Leiden University Medical Center|TI Pharma,MALE,ADULT,12,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2008-04,2008-09,"University Medical Center Utrecht, Utrecht, 3584CX, Netherlands"
NCT02976779,"A Phase I, Double Blind, Randomized, Placebo Controlled, Maximal Dose Study to Determine the Safety, Tolerability of Topical Cream Containing MGC (Medical Grade Cannabis) in Healthy Volunteers",https://clinicaltrials.gov/study/NCT02976779,COMPLETED,NO,Safety Study for Future Treatment of Psoriasis,DRUG: OWC MGC cream|DRUG: OWC Control Cream,One World Cannabis Ltd.,,ALL,ADULT,26,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2017-02-03,2019-01-25,"Sheba Medical Center, Ramat Gan, Israel"
NCT00061113,Substance Dependent Teens - Impact of Treating Depression Study 1 - 1,https://clinicaltrials.gov/study/NCT00061113,COMPLETED,NO,Alcohol-Related Disorders|Marijuana Abuse|Substance-Related Disorders,DRUG: Fluoxetine + outpatient cognitive behavioral therapy|DRUG: fluoxetine|DRUG: placebo + CBT,National Institute on Drug Abuse (NIDA),,ALL,"CHILD, ADULT",126,NIH,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2001-02,2006-08,"University of Colorado Denver, Aurora, Colorado, 80045, United States|1611 South Federal Blvd., Denver, Colorado, 80219, United States"
NCT03758131,Peer MI in FQHCs for Substance-using Emerging Adults,https://clinicaltrials.gov/study/NCT03758131,UNKNOWN,NO,Substance Use Disorders,BEHAVIORAL: Peer-enhanced Motivational Interviewing|BEHAVIORAL: Motivational Interviewing|OTHER: Waitlist Control,University of Illinois at Urbana-Champaign,University of Washington,ALL,ADULT,150,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-08,2024-02,"School of Social Work, Urbana, Illinois, 61801, United States"
NCT04040153,Guiding Good Choices for Health,https://clinicaltrials.gov/study/NCT04040153,ACTIVE_NOT_RECRUITING,NO,Adolescent Substance Use,BEHAVIORAL: Guiding Good Choices,University of Washington,Kaiser Permanente|Henry Ford Health System|National Center for Complementary and Integrative Health (NCCIH),ALL,CHILD,3636,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2019-09-30,2025-05-31,"Kaiser Permanente Northern California, Oakland, California, 94612, United States|Kaiser Permanente Colorado, Aurora, Colorado, 80014, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States"
NCT03809546,Individual Differences in Drug Response,https://clinicaltrials.gov/study/NCT03809546,COMPLETED,YES,Differential Female Response to Δ9-tetrahydrocannabinol (THC),DRUG: Dronabinol|DRUG: dextrose,University of Chicago,,FEMALE,ADULT,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2018-11-06,2021-06-01,"University of Chicago, Chicago, Illinois, 60615, United States"
NCT05906511,PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults,https://clinicaltrials.gov/study/NCT05906511,RECRUITING,NO,"Pain, Tolerance|Oral vs Vaporized THC|Abuse Liability",DRUG: Dronabinol 5 MG|DRUG: Dronabinol 10 MG|DRUG: 2mg Purified THC in an ethanolic solution|DRUG: 4mg Purified THC in an ethanolic solution|DRUG: Placebo,Yale University,VA Connecticut Healthcare System|National Institute on Drug Abuse (NIDA),ALL,OLDER_ADULT,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2023-10-17,2025-08-31,"VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT01784627,Trial of Computerized SBI to Reduce Teen Alcohol Use,https://clinicaltrials.gov/study/NCT01784627,WITHDRAWN,NO,Alcohol Abuse|Cannabis Abuse|Nicotine Dependence,BEHAVIORAL: c-ASBI,Boston Children's Hospital,,ALL,"CHILD, ADULT",0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2015-01,2017-10,"Tufts Medical Center, Boston, Massachusetts, 02111, United States|Boston Children's Hospital, Boston, Massachusetts, 02115, United States|Longwood Pediatrics, Boston, Massachusetts, 02115, United States|East Boston Neighborhood Health Center, Boston, Massachusetts, 02128, United States|Cambridge Pediatrics, Cambridge, Massachusetts, 02139, United States|Lexington Pediatrics, Lexington, Massachusetts, 02421, United States"
NCT06393101,The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome,https://clinicaltrials.gov/study/NCT06393101,RECRUITING,NO,Complex Regional Pain Syndrome,DRUG: BRC-002|DRUG: BRC-002 Placebo,"University of California, San Diego",,ALL,"ADULT, OLDER_ADULT",52,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-06-01,2029-06-01,"Altman Clinical and Translational Research Institute, La Jolla, California, 92093, United States|University of California, San Diego, San Diego, California, 92093, United States"
NCT03582137,A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease,https://clinicaltrials.gov/study/NCT03582137,COMPLETED,YES,Parkinson Disease,DRUG: Cannabidiol|OTHER: Placebo,"University of Colorado, Denver",Colorado Department of Public Health and Environment,ALL,"ADULT, OLDER_ADULT",74,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-09-05,2022-01-04,"University of Colorado hospital, Aurora, Colorado, 80045, United States"
NCT00925340,Family Check-Up for Adolescents and Siblings,https://clinicaltrials.gov/study/NCT00925340,COMPLETED,NO,Alcohol Abuse,BEHAVIORAL: Family Check Up|BEHAVIORAL: Psychoeducation,Brown University,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"CHILD, ADULT",104,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-09,2014-07,"Brown University, Providence, Rhode Island, 02906, United States"
NCT04516057,Nabilone for Agitation Blinded Intervention Trial,https://clinicaltrials.gov/study/NCT04516057,RECRUITING,NO,Alzheimer Disease|Agitation,DRUG: Nabilone|OTHER: Placebo,Sunnybrook Health Sciences Centre,Alzheimer's Drug Discovery Foundation|Weston Brain Institute,ALL,"ADULT, OLDER_ADULT",112,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02-01,2025-10,"University of Calgary, Calgary, Alberta, T2N 4N1, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|Centre for Addiction and Mental Health, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Ontario Shores Centre for Mental Health Sciences, Whitby, Ontario, L1N 5S9, Canada"
NCT01740960,Safety and Tolerability of Namisol in the Elderly,https://clinicaltrials.gov/study/NCT01740960,COMPLETED,NO,Drug Safety,DRUG: delta-9-tetrahydrocannabinol|DRUG: Placebo,Radboud University Medical Center,,ALL,OLDER_ADULT,12,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-08,2012-12,"Radboud University Medical Centre, department of Geriatrics, Nijmegen, Gelderland, Netherlands"
NCT03005119,"Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms",https://clinicaltrials.gov/study/NCT03005119,UNKNOWN,NO,Multiple Sclerosis,DRUG: PTL201|DRUG: Placebo Oral Capsule,"PhytoTech Therapeutics, Ltd.",,ALL,"ADULT, OLDER_ADULT",70,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-03-01,2018-12,"Sheba medical center, Tel Hashomer, Ramat gan, Israel"
NCT05730504,Evaluating the Effectiveness of Mobile Self-guided Psychological Interventions to Reduce Relapse in Substance Use Disorder,https://clinicaltrials.gov/study/NCT05730504,RECRUITING,NO,"Substance Use Disorders|Addiction, Alcohol|Addiction, Substance",OTHER: Mobile app-based self-guided interventions,PredictWatch,,ALL,"ADULT, OLDER_ADULT",400,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-03-05,2023-06,"PredictWatch, Białystok, 15-668, Poland"
NCT00907309,"Dental and Medical Office iMET to Reduce Teen Tobacco, Alcohol, and Drug Use",https://clinicaltrials.gov/study/NCT00907309,COMPLETED,NO,"Use; Tobacco, Harmful|Alcohol Abuse|Drug Abuse",BEHAVIORAL: iMET|BEHAVIORAL: iMET/TE,Boston Children's Hospital,Cambridge Health Alliance|Tufts Medical Center|Harvard School of Dental Medicine|Fallon Clinic,ALL,"CHILD, ADULT",121,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2010-09,2012-09,"Children's Hospital Boston, Boston, Massachusetts, 02115, United States"
NCT02359123,Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients,https://clinicaltrials.gov/study/NCT02359123,COMPLETED,NO,Cancer Cachexia|Atypical Anorexia Nervosa,OTHER: Cannabics capsules,Cannabics Pharmaceuticals Inc.,,ALL,"ADULT, OLDER_ADULT",24,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-11,2018-04-01,"Rambam MC, Haifa, Israel"
NCT04976738,A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain,https://clinicaltrials.gov/study/NCT04976738,COMPLETED,NO,"Chronic Pain|Neck Pain|Back Pain|Pain|Pain, Chronic|Pain, Back|Pain, Neck|CBD|THC",DRUG: Cybis™ 10:25 THC:CBD oil,Cymra Life Sciences,,ALL,"ADULT, OLDER_ADULT",28,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-09-20,2022-06-21,"ACRN - Australian Clinical Research Network, Maroubra, New South Wales, 2035, Australia|Holdsworth House Medical Practice, Sydney, New South Wales, 2000, Australia"
NCT06647524,Pilot fMRI Studies of Aging-Related Effects of THC,https://clinicaltrials.gov/study/NCT06647524,NOT_YET_RECRUITING,NO,THC,DRUG: THC|DRUG: Placebo,Yale University,Biopharmaceutical Research Company|Bloom Labs Cannabis Solutions,ALL,"ADULT, OLDER_ADULT",10,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2025-02,2025-12,"Olin Neuropsychiatric Research Center at Hartford Healthcare, Hartford, Connecticut, 06106, United States"
NCT04569760,Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study,https://clinicaltrials.gov/study/NCT04569760,WITHDRAWN,NO,Generalized Anxiety Disorder|Social Anxiety Disorder|Panic Disorder|Agoraphobia,DRUG: 50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose)|DRUG: Placebo Oil,McMaster University,MediPharm Labs Corp,ALL,"ADULT, OLDER_ADULT",0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04,2023-06,"MacAnxiety Research Centre, Hamilton, Ontario, L8S 1B7, Canada"
NCT06395467,12-Step Facilitation/MET/CBT (InTEGRA) vs. MET/CBT for Youth With Alcohol and Other Drug Use Disorder,https://clinicaltrials.gov/study/NCT06395467,NOT_YET_RECRUITING,NO,Alcohol Use Disorder|Cannabis Use Disorder,BEHAVIORAL: InTEGRA|BEHAVIORAL: MET/CBT,Massachusetts General Hospital,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"CHILD, ADULT",294,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2024-06-01,2027-04-30,"UConn Health, Farmington, Connecticut, 06032, United States|MGH Department of Psychiatry, Boston, Massachusetts, 02114, United States"
NCT05840822,Evaluating Efficacy and Safety of CBD TPM Capsules for Use in Insomnia,https://clinicaltrials.gov/study/NCT05840822,NOT_YET_RECRUITING,NO,Insomnia,DRUG: Cannabidiol,Avecho Biotechnology,,ALL,"ADULT, OLDER_ADULT",540,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-06,2024-05,
NCT03932097,REAL Parenting Alcohol and Substance Use App,https://clinicaltrials.gov/study/NCT03932097,COMPLETED,NO,"Underage Drinking|Alcohol Use, Underage",BEHAVIORAL: REAL Parenting|OTHER: Active Control Materials,"Real Prevention, LLC",,ALL,"CHILD, ADULT",306,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION,2021-01-15,2022-05-31,"REAL Prevention, LLC, Clifton, New Jersey, 07013, United States"
NCT06660901,Cannabinoid Hyperemesis Syndrome. Prospective Multicenter Study of Patients Admitted to Adult Emergency Departments in Maine-et-Loire.,https://clinicaltrials.gov/study/NCT06660901,NOT_YET_RECRUITING,NO,D000096704|Cannabinoid Hyperemesis Syndrome,,"University Hospital, Angers",,ALL,"ADULT, OLDER_ADULT",3000,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2025-01-20,2026-05,
NCT02901275,Enhancing Medication-based Analgesia in Humans,https://clinicaltrials.gov/study/NCT02901275,COMPLETED,YES,"Pain|Cannabis|Opioid Use, Unspecified",DRUG: Within-subject test of blinded study medications,Johns Hopkins University,,ALL,"ADULT, OLDER_ADULT",29,OTHER,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2016-12,2020-03-23,"Johns Hopkins University, Baltimore, Maryland, 21224, United States"
NCT01170013,Substance Use Prevention in Teen Psychiatric Patients,https://clinicaltrials.gov/study/NCT01170013,COMPLETED,NO,Adolescent Substance Use,BEHAVIORAL: Family Check-up|BEHAVIORAL: Parent psychoeducation,Brown University,,ALL,CHILD,68,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2008-08,2011-12,"Brown University, Providence, Rhode Island, 02912, United States"
NCT05610813,Comparison of VER-01 to Opioids in Patients With Chronic Non-specific Low Back Pain,https://clinicaltrials.gov/study/NCT05610813,COMPLETED,NO,Chronic Non-specific Low Back Pain,DRUG: VER-01|DRUG: Opioid therapy,Vertanical GmbH,,ALL,"ADULT, OLDER_ADULT",384,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-06-08,2024-10-18,"Rheumazentrum Prof. Dr. med. Gunther Neeck, Bad Doberan, 18209, Germany|Medizinische Hochschule Hannover (MHH), Hannover, 30625, Germany"
NCT03164512,The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol,https://clinicaltrials.gov/study/NCT03164512,COMPLETED,NO,Cannabidiol Pharmacokinetics,DRUG: Oral or vaporized cannabidiol|DRUG: Placebo,Johns Hopkins University,,ALL,ADULT,19,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2018-06-01,2020-01-22,"Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland, 21224, United States"
NCT02392780,Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease,https://clinicaltrials.gov/study/NCT02392780,UNKNOWN,NO,Acute-graft-versus-host Disease,DRUG: Cannabidiol|DRUG: Methylprednisolone|DRUG: Calcineurin inhibitor,moshe yeshurun,,ALL,"ADULT, OLDER_ADULT",10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-04,,"Davidof Cancer Center, Beilinson hospital, Rabin medical center, Petach Tikva, Israel"
NCT01700725,Gulf War Illness Nasal Irrigation Study,https://clinicaltrials.gov/study/NCT01700725,COMPLETED,YES,Persian Gulf Syndrome|Chronic Sinusitis|Fatigue|Acute Sinusitis,OTHER: Nasal Irrigation - Saline|DRUG: Nasal Irrigation - Xylitol,"University of Wisconsin, Madison",,ALL,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-10,2017-05,"University of Wisconsin General Clinical Research Center, Madison, Wisconsin, 53792, United States"
NCT02110693,"The Tobacco, Alcohol, Prescription Medication and Other Substances Tool",https://clinicaltrials.gov/study/NCT02110693,COMPLETED,YES,Substance Use Disorder,OTHER: Interviewer and tablet administration of the TAPS Tool,"Friends Research Institute, Inc.",National Institute on Drug Abuse (NIDA)|Johns Hopkins University|Virginia Commonwealth University|NYU Langone Health|Duke University,ALL,"ADULT, OLDER_ADULT",2057,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2014-03,2015-04,"Chase Brexton Health Services, Baltimore, Maryland, 21201, United States|Bellevue Hospital, New York, New York, 10016, United States|MURDOCK Study, Kannapolis, North Carolina, 28081, United States|Virginia Commonwealth University Health System Ambulatory Care Center, Richmond, Virginia, 23284, United States"
NCT04001010,Safety and Efficacy of Inhaled Synthetic THC/CBD for Improving Physical Functioning and for Modulating Cachexia Progression in Patients With Advanced Cancer and Associated Cachexia,https://clinicaltrials.gov/study/NCT04001010,SUSPENDED,NO,Cannabis Use|Cachexia; Cancer|Advanced Cancer,DRUG: PPP011|DRUG: Placebo,Tetra Bio-Pharma,,ALL,"ADULT, OLDER_ADULT",334,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-07,2023-12,"William Osler Health Service Brampton, Brampton, Ontario, Canada"
NCT06640712,Oral and Dental Health in Substance Dependent Individuals,https://clinicaltrials.gov/study/NCT06640712,COMPLETED,NO,Substance Use Disorder (SUD)|Decayed Teeth|Teeth Loss|Teeth Missing,"DIAGNOSTIC_TEST: Dental caries was assessed using the DMFT index (Decayed, Missing, and Filled Teeth) according to the World Health Organization's caries diagnostic criteria.|DIAGNOSTIC_TEST: Substance Use Disorder Diagnosis",Izmir Democracy University,,MALE,ADULT,281,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2024-04-25,2024-08-25,"İzmir Demokrasi Üniversitesi, İzmir, Konak, Turkey"
NCT06353828,Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients,https://clinicaltrials.gov/study/NCT06353828,ACTIVE_NOT_RECRUITING,NO,Ulcerative Colitis,"DRUG: CBD, synthetic form|DRUG: Placebo",CannaMore Biotechs,,ALL,"ADULT, OLDER_ADULT",45,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-03-01,2025-04-01,"Meir Medical Center, Kfar Saba, Israel"
NCT02781350,Anti-inflammatory Effects of Fiber,https://clinicaltrials.gov/study/NCT02781350,COMPLETED,NO,Postprandial Inflammation,OTHER: HFHC meal|DIETARY_SUPPLEMENT: HFHC MEAL plus Fiber,University at Buffalo,,ALL,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2010-11,2013-05,"ECMC Ambulatory Center, 3rd Floor, Buffalo, New York, 14215, United States"
NCT04571463,Ethyl Glucuronide in Urine Samples of Pregnant Women Within the HUS ja PHHYKY Area,https://clinicaltrials.gov/study/NCT04571463,COMPLETED,NO,Fetal Alcohol Spectrum Disorders,,Hanna Kahila,Finnish Pediatric Neurology Association|Finnish Foundation for Alcohol Studies|Päijänne Tavastia Central Hospital|Helsinki University Central Hospital|Seinajoki Central Hospital,FEMALE,"CHILD, ADULT, OLDER_ADULT",505,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-10-01,2021-07-30,"HALSO-poliklinikka, Lahti, Päijät-Häme, 715850, Finland|Äitiyspoliklinikka/neuvola, Lahti, Päijät-Häme, 715850, Finland|HAL-poliklinikka, Helsinki, Uusimaa, 00029, Finland|Äitiyspoliklinikka/neuvola, Helsinki, Uusimaa, 00120, Finland"
NCT05469477,Increasing Seat Belt Wearing and Decreasing Handheld Phone Use While Driving,https://clinicaltrials.gov/study/NCT05469477,COMPLETED,NO,Distracted Driving|Impaired Driving|Driving Behaviors,"BEHAVIORAL: Persuasive education|BEHAVIORAL: WOOP (aka, mental contrasting with implementation intentions., Wish, Outcome, Obstacle, Plan)|BEHAVIORAL: Customized Habit Tips|BEHAVIORAL: Raffle Financial Incentive|BEHAVIORAL: Shared Pot Financial Incentive|BEHAVIORAL: Weekly SMS Support text|BEHAVIORAL: Weekly SMS Encouragement",University of Pennsylvania,General Motors (GM),ALL,"ADULT, OLDER_ADULT",1139,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-12,2023-06-29,"University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States"
NCT06784908,Stress and Pain in People Living With HIV,https://clinicaltrials.gov/study/NCT06784908,NOT_YET_RECRUITING,NO,HIV|Depression|Cannabis Use Disorder|Stress|Pain,OTHER: Yale Pain Stress Task (YPST),Yale University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",120,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2025-01-16,2030-01-31,"The Yale Stress Center, New Haven, Connecticut, 06519, United States"
NCT00107562,Adolescent Safer Sex Social Network Intervention,https://clinicaltrials.gov/study/NCT00107562,COMPLETED,NO,Sexual Behavior|Alcohol Drinking|Marijuana Smoking,BEHAVIORAL: Adolescent Safer Sex Social Network Intervention,"University of North Carolina, Chapel Hill",National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)|National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"CHILD, ADULT",200,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-02,2006-03,"University of South Florida College of Medicine, Tampa, Florida, 33606, United States|Children's Hospital of Boston, Boston, Massachusetts, 02115, United States"
NCT04764344,Haloperidol for the Treatment of Nausea and Vomiting in the ED,https://clinicaltrials.gov/study/NCT04764344,COMPLETED,NO,Vomiting|Nausea|Abdominal Pain|Cannabis Use,DRUG: Haloperidol|DRUG: Ondansetron,Western Michigan University School of Medicine,,ALL,ADULT,60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-04-01,2023-05-22,"Bronson Methodist Hospital, Kalamazoo, Michigan, 49007, United States"
NCT01454206,Integration of (iSBIRT) for Teen Drug Use Into a Pediatric Network,https://clinicaltrials.gov/study/NCT01454206,WITHDRAWN,NO,Substance Use,BEHAVIORAL: iSBIRT,Boston Children's Hospital,,ALL,"CHILD, ADULT",0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2012-07,2016-12,"Children's Hospital Boston, Boston, Massachusetts, 02115, United States"
NCT05380765,Developing a Positive Approach to Substance Use Prevention in North American Indian Adolescents,https://clinicaltrials.gov/study/NCT05380765,RECRUITING,NO,Alcohol Drinking|Tobacco Use|Drug Use,BEHAVIORAL: Native PATHS,University of Rhode Island,,ALL,CHILD,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2024-06-17,2025-05-31,"University of Rhode Island, Kingston, Rhode Island, 02881-1967, United States"
NCT03467620,Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease,https://clinicaltrials.gov/study/NCT03467620,WITHDRAWN,NO,Crohn Disease|Inflammatory Bowel Diseases|Cannabis,DRUG: Cannabidiol|DRUG: Placebo oral capsule,University of Illinois at Chicago,,ALL,"ADULT, OLDER_ADULT",0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-07,2019-07,
NCT03090620,Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome,https://clinicaltrials.gov/study/NCT03090620,COMPLETED,YES,Anticholinergics Toxicity,DRUG: Physostigmine|DRUG: Lorazepam,"University of Colorado, Denver",American Academy of Clinical Toxicology,ALL,CHILD,19,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-03-30,2020-08-31,"University of Colorado Anschutz Medical Campus, Children's Hospital Colorado, Aurora, Colorado, 80045, United States"
NCT01064206,ADDICTAO: Psychological and Addictive Profile of Patients With Buerger's Disease,https://clinicaltrials.gov/study/NCT01064206,COMPLETED,NO,Thromboangiitis Obliterans|Atheromatous Arteritis,,"University Hospital, Lille",,ALL,"ADULT, OLDER_ADULT",224,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-09,2016-09,"University Hospital, Bordeaux, Bordeaux, France|University Hospital, Brest, Brest, France|University Hospital, Caen, Caen, France|University Hospital, Lille, Lille, France|University Hospital, Marseille, Marseille, France|University Hospital, Montpellier, Montpellier, France|University Hospital, Nancy, Nancy, France|University Hospital, Nantes, Nantes, France|Georges Pompidou European Hospital, Paris, Paris, France|Tenon Hospital, Paris, Paris, France|University Hospital, Rouen, Rouen, France|University Hospital, Strasbourg, Strasbourg, France|University Hospital, Toulouse, Toulouse, France|University Hospital, Tours, Tours, France|General Hospital, Valenciennes, Valenciennes, France|Paul Brousse Hospital, Villejuif, Villejuif, France"
NCT04340700,Characterization of the Pharmacodynamic Response to Vaped THC,https://clinicaltrials.gov/study/NCT04340700,WITHDRAWN,NO,Vaping|THC,DRUG: THC or Placebo,Massachusetts General Hospital,,ALL,ADULT,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2022-11-01,2025-10-01,
NCT02576912,Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone,https://clinicaltrials.gov/study/NCT02576912,COMPLETED,NO,Healthy,DRUG: Active Delta-9-THC|DRUG: Active Pregnenolone|DRUG: Placebo|DRUG: Placebo,Yale University,,ALL,ADULT,38,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2015-02,2019-06-24,"Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut, 06516, United States"
NCT03984604,Investigation of the Efficacy and Safety of CHI-921 in Insomnia.,https://clinicaltrials.gov/study/NCT03984604,TERMINATED,NO,Insomnia,DRUG: CHI-921|DRUG: Placebo,Canopy Growth Corporation,Galenova Inc|Algorithme Pharma Inc|Hopital du Sacre-Coeur de Montreal|McGill University Health Centre/Research Institute of the McGill University Health Centre|Centre hospitalier de l'Université de Montréal (CHUM),ALL,"ADULT, OLDER_ADULT",21,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-03-21,2020-06-17,"Algorithme Pharma Inc., Montréal, Quebec, H3B 1P5, Canada"
NCT03386110,Couples Health Project: Couples-based Intervention to Reduce Drug Use and HIV Transmission Risk,https://clinicaltrials.gov/study/NCT03386110,COMPLETED,YES,"Risk Behavior|Drug Use|Sex, Anal",BEHAVIORAL: Couples Health Project (CHP)|BEHAVIORAL: Education,Hunter College of City University of New York,National Institute on Drug Abuse (NIDA),MALE,ADULT,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2018-03-06,2020-09-14,"Center for HIV Educational Studies and Training, New York, New York, 10018, United States"
NCT03825965,Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following TKA: A Pilot RCT,https://clinicaltrials.gov/study/NCT03825965,RECRUITING,NO,Knee Osteoarthritis,DRUG: MPL-001 (CBD: THC 25:1)|DRUG: Placebo oil for oral use,McMaster University,St. Joseph's Healthcare Hamilton|Hamilton Health Sciences Corporation,ALL,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-05-03,2024-08,"St. Joseph's Healthcare Hamilton, Hamilton, Ontario, L8N 4A6, Canada|St. Michael's Hospital, Toronto, Ontario, M5B 1W8, Canada"
NCT02802540,"Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients",https://clinicaltrials.gov/study/NCT02802540,UNKNOWN,NO,Non-Small Cell Lung Cancer|Anorexia|Cachexia|Weight Lose,DRUG: Nabilone|DRUG: Placebo,Instituto Nacional de Cancerologia de Mexico,,ALL,"ADULT, OLDER_ADULT",78,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2014-12,2017-07,"Instituto Nacional de Cancerologia, Mexico City, 14080, Mexico"
NCT03693833,CBD Treatment in Hand Osteoarthritis and Psoriatic Arthritis.,https://clinicaltrials.gov/study/NCT03693833,COMPLETED,NO,Psoriatic Arthritis|Hand Osteoarthritis,DRUG: Cannabidiol|DRUG: Placebo Oral Tablet,Aalborg University Hospital,Aalborg University,ALL,"ADULT, OLDER_ADULT",136,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-11-28,2021-06-01,"Department of Rheumatology Aalborg Universityhospital North, Aalborg, 9000, Denmark"
NCT03928756,Adaptive Interventions for Prevention/Intervention for Youth Substance Abuse,https://clinicaltrials.gov/study/NCT03928756,COMPLETED,NO,Substance Use,"BEHAVIORAL: Push Notifications with Tailored Intervention Content|BEHAVIORAL: Push Notifications with Engaging, Non-therapeutic Content|BEHAVIORAL: No Push Notifications",University of Michigan,,ALL,"CHILD, ADULT",39,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2019-08-12,2019-10-17,"University of Michigan, Ann Arbor, Michigan, 48108, United States"
NCT05543681,Clinical Trial on Agitation in Alzheimer's Dementia,https://clinicaltrials.gov/study/NCT05543681,RECRUITING,NO,"Alzheimer Disease|Agitation,Psychomotor|Care Giving Burden|NPS|Aggression",DRUG: IGC-AD1-Active|DRUG: IGC-AD1-Placebo,"IGC Pharma, LLC",,ALL,"ADULT, OLDER_ADULT",164,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-10-11,2025-06-30,"ClinCloud, LLC, Maitland, Florida, 32751, United States|ClinCloud, LLC, Melbourne, Florida, 32940, United States|Global Medical Institutes Florida, LLC, Miami, Florida, 33125, United States|Miami Jewish Health, Miami, Florida, 33137, United States|Neurostudies Inc., Port Charlotte, Florida, 33952, United States|BayCare Health System Inc., Saint Petersburg, Florida, 33705, United States|MedStar Franklin Square Medical Center Neurology, Baltimore, Maryland, 21237, United States|Medstar Georgetown University Hospital Neurology, Clinton, Maryland, 20735, United States|Medstar Montgomery Medical Center, Olney, Maryland, 20832, United States|Site 800, Newton, Massachusetts, 02459, United States|Dent Neurosciences Research Center, Amherst, New York, 02459, United States|Lynn Health Science Institute (LHSI), Oklahoma City, Oklahoma, 73112, United States|Senior Adults Specialty Research, Austin, Texas, 78757, United States|Baycrest Academy, University of Toronto, Toronto, Ontario, ON M6A 2E1, Canada|Site 300, Montréal, Quebec, H3Z 2Y5, Canada|Douglas Hospital Research Center, McGill university, Montréal, Quebec, H4H 1R3, Canada|Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellín, Antioquia, Colombia|Instituto Sanacoop, Bayamón, 00961, Puerto Rico|SCB Research Center, Bayamón, 00961, Puerto Rico|University of Puerto Rico, Rio Piedras, 00935, Puerto Rico"
NCT03051633,Substance Use Prevention Campaign for American Indian Youth,https://clinicaltrials.gov/study/NCT03051633,COMPLETED,YES,Adolescent Substance Use,BEHAVIORAL: Be Under Your Own Influence,Colorado State University,,ALL,CHILD,528,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2014-04-15,2018-05-16,
NCT02391220,Assessment of the Symbiotic Fermented Milk in Patients With Irritable Bowel Syndrome,https://clinicaltrials.gov/study/NCT02391220,COMPLETED,NO,Irritable Bowel Syndrome,OTHER: LCA symbiotic fermented milk|OTHER: heat-treated fermented milk,Clinres Farmacija d.o.o.,"Competence Centre for Biotechnology Research and Innovation|European Regional Development Fund|Ministry of Education, Science and Sport of the Republic of Slovenia|Institute of Dairy Science and probiotics, Biotechnical Faculty, UL|Dairy Celeia",ALL,"ADULT, OLDER_ADULT",76,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-02,2013-01,
NCT04572646,Benefit of Systematic Proposition of Nicotine Substitution for Patients Undergoing Surgery,https://clinicaltrials.gov/study/NCT04572646,TERMINATED,NO,Smoking Cessation,OTHER: NRT proposition and exhaled CO measurement,Groupe Hospitalier Mutualiste de Grenoble,,ALL,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-08-24,2022-05-31,"Groupe hospitalier Mutualiste de Grenoble, Grenoble, 38028, France"
NCT05434429,Mobile Health for Problematic Behaviors and Substance Use,https://clinicaltrials.gov/study/NCT05434429,UNKNOWN,NO,Addiction|Behavioral Addiction|Nicotine Addiction|Nicotine Dependence|Cannabis Dependence,OTHER: mobile application,PredictWatch,,ALL,"ADULT, OLDER_ADULT",600,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-06-21,2023-02,"PredictWatch, Białystok, 15-668, Poland"
NCT00245531,Effects of Endocrine Health on Mental Performance of Men and Women Using Drugs,https://clinicaltrials.gov/study/NCT00245531,COMPLETED,NO,Human Immunodeficiency Virus Positive or Negative,,Johns Hopkins University,National Institutes of Health (NIH),ALL,ADULT,300,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2004-08,2010-12,"Johns Hopkins University, The Clinical Trials Unit, Baltimore, Maryland, 21205, United States"
NCT04251013,"Multicenter RCT for BIliary Brushing: RX Cytology, BOSTON vs. Infinity®, US Endoscopy",https://clinicaltrials.gov/study/NCT04251013,COMPLETED,NO,"Biliary Stricture|Jaundice, Obstructive","DEVICE: Biliary brushing with the RX Cytology brush, Boston Scientific|DEVICE: Biliary brushing with the Infinity® brush, US Endoscopy",Société Française d'Endoscopie Digestive,,ALL,"ADULT, OLDER_ADULT",51,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-07-01,2022-03-01,"Clinique Paris Bercy, Charenton-le-Pont, F-94220, France"
NCT04771494,Effect of Instability on Power and Speed in Bench Press,https://clinicaltrials.gov/study/NCT04771494,COMPLETED,NO,"Instability, Joint",OTHER: Power and execution speed as a function of instability experience,Universidad Politecnica de Madrid,,MALE,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2019-09-01,2020-05-17,"Facultad Ciencias de la Actividad Física y del Deporte, Madrid, 28040, Spain"
NCT03677583,Duckweed Intake Study,https://clinicaltrials.gov/study/NCT03677583,COMPLETED,NO,Gastrointestinal Complication,OTHER: Duckweed|OTHER: Spinach,Wageningen University and Research,,ALL,ADULT,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2018-10-01,2018-10-15,"Stichting Wageningen Research, Wageningen, Gelderland, 6708 WG, Netherlands"
NCT02811939,Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I,https://clinicaltrials.gov/study/NCT02811939,COMPLETED,NO,Healthy,DRUG: Active Dronabinol|DRUG: Active Pregnenolone|DRUG: Placebo Dronabinol|DRUG: Placebo Pregnenolone,Yale University,,ALL,ADULT,13,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2016-04-07,2017-06-09,"Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut, 06516, United States"
NCT04113512,Yoga Nasal Irrigation in the Treatment of Chronic Tension Type Headache,https://clinicaltrials.gov/study/NCT04113512,COMPLETED,NO,Chronic Tension-Type Headache,OTHER: Jalaneti,NMP Medical Research Institute,University of Rajasthan|Yog-Kulam,ALL,ADULT,98,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-03-15,2019-07-26,"Yoga Bhavan, Jaipur, Rajasthan, India"
NCT06157112,Students' Lifestyle Behaviour and Later Health Care Utilization Due to Musculoskeletal Pain,https://clinicaltrials.gov/study/NCT06157112,COMPLETED,NO,Musculoskeletal Pain,OTHER: Lifestyle behaviour (exposure in a observational study),Oslo Metropolitan University,,ALL,ADULT,50054,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-02-06,2021-04-05,"Oslo Metropolitan University, Oslo, 0130, Norway"
NCT05467904,Double-Blind Randomized Placebo-Controlled Trial of a Proprietary Full Hemp Flower Formulation for Long COVID,https://clinicaltrials.gov/study/NCT05467904,NOT_YET_RECRUITING,NO,Post-acute COVID-19 Syndrome,"OTHER: Xltranplus, Xltran","LUCINDA BATEMAN, MD","Endourage, LLC",ALL,"ADULT, OLDER_ADULT",111,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2024-06,2025-12,"Bateman Horne Center, Salt Lake City, Utah, 84102, United States"
NCT04901312,Preventing OUD in Justice-Involved Youth,https://clinicaltrials.gov/study/NCT04901312,UNKNOWN,NO,Substance Use Disorders|Recidivism,BEHAVIORAL: Adolescent Community Reinforcement Approach|BEHAVIORAL: Assertive Continuing Care|BEHAVIORAL: Trauma Affect Regulation Guide for Education and Therapy|BEHAVIORAL: Motivational Interviewing|OTHER: Opioid Education Workbook,Seattle Children's Hospital,"University of Washington|Washington State Department of Children, Youth and Families|Michigan State University|RTI International|National Institute on Drug Abuse (NIDA)",ALL,"CHILD, ADULT",215,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-01-20,2024-08-31,"Washington State Department of Children, Youth and Families, Olympia, Washington, 98504, United States"
NCT06275698,HONEY for the Treatment of POst-Tonsillectomy Pain,https://clinicaltrials.gov/study/NCT06275698,RECRUITING,NO,Post Surgical Pain|Analgesia,"DIETARY_SUPPLEMENT: Manuka honey MGO 1000|DIETARY_SUPPLEMENT: Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring",East and North Hertfordshire NHS Trust,"Manuka Doctor UK Ltd|National Institute for Health Research, United Kingdom",ALL,"ADULT, OLDER_ADULT",100,OTHER_GOV,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-09-04,2025-09-04,"Lister Hospital, Stevenage, SG1 4AB, United Kingdom"
NCT04775030,Methodology for Developing an Occlusal Appliance With CBD Active Carrier,https://clinicaltrials.gov/study/NCT04775030,UNKNOWN,NO,Temporomandibular Disorder|Myofascial Pain|Cannabis|Electromyography|Occlusal Appliance|CBD,DRUG: CBD occlusal appliance|DEVICE: Acrylic resin occlusal appliance,Medical University of Silesia,,ALL,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2021-01-01,2023-01-01,"Department of TMD Silesian Medical University, Zabrze, 41-800, Poland"
NCT04749628,Cannabidiol for Bilateral Total Knee Arthroplasty,https://clinicaltrials.gov/study/NCT04749628,COMPLETED,NO,"Pain, Postoperative|Opioid Use|Knee Osteoarthritis",DRUG: cannabidiol|OTHER: Ora-sweet SF,"Hospital for Special Surgery, New York",,ALL,"ADULT, OLDER_ADULT",37,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-11-02,2025-01-08,"Hospital for Special Surgery, New York, New York, 10021, United States"
NCT01841892,The Therapeutic Workplace Intervention in Community Settings,https://clinicaltrials.gov/study/NCT01841892,WITHDRAWN,NO,Drug Abuse|Alcohol Abuse,BEHAVIORAL: Community Therapeutic Workplace,"University of Maryland, Baltimore County",Johns Hopkins University,ALL,"ADULT, OLDER_ADULT",0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-04,2015-03,"Center for Learning and Health, Johns Hopkins University School of Medicince, Department of Psychiatry and Behavioral Sciences, Baltimore, Maryland, 21224, United States"
NCT03590132,Strong African American Families STEPS Project,https://clinicaltrials.gov/study/NCT03590132,COMPLETED,NO,Adolescent Alcohol Use,BEHAVIORAL: Strong African American Families Program|BEHAVIORAL: Strong African American Families--Teen Program,University of Georgia,,ALL,CHILD,472,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2012-12-10,2018-11-30,
NCT05990881,Injection of Botulinum Toxin for Thumb Carpometacarpal Arthritis,https://clinicaltrials.gov/study/NCT05990881,RECRUITING,NO,Carpometacarpal Sprain|Thumb Sprain|Clostridium; Botulinum,DRUG: Botulinum toxin|DRUG: Standard-of-care corticosteroid injections,Rhode Island Hospital,,ALL,"ADULT, OLDER_ADULT",50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-08-27,2026-07,"235 Plain Street, Providence, Rhode Island, 02905, United States"
NCT01134770,Prenatal Exposure Effects Psychophysiology Study,https://clinicaltrials.gov/study/NCT01134770,ENROLLING_BY_INVITATION,NO,Pregnancy,,"University of North Carolina, Chapel Hill",,FEMALE,ADULT,150,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-07,2025-06,"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States"
NCT06163690,Symptom Tracking in Long COVID Patients Using Formula C™ Sublingual Drops,https://clinicaltrials.gov/study/NCT06163690,ACTIVE_NOT_RECRUITING,NO,Long COVID|Long Covid19|Post-Acute COVID-19|Post-Acute COVID-19 Syndrome|Long Haul COVID|Long-Haul COVID-19,"COMBINATION_PRODUCT: Endourage Targeted Wellness Formula C™, a full hemp flower extract","Endourage, LLC",,ALL,"ADULT, OLDER_ADULT",20,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-12-13,2025-03,"Endourage, LLC, Denver, Colorado, 80033, United States"
NCT03984565,PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product,https://clinicaltrials.gov/study/NCT03984565,RECRUITING,NO,Chronic Pain,DRUG: Cannabidiol|DRUG: Placebo,"Staci Gruber, Ph.D.",Etheridge Foundation,ALL,"ADULT, OLDER_ADULT",25,OTHER,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2024-06-27,2026-09,"McLean Hospital, Belmont, Massachusetts, 02478, United States"
NCT03488914,Examining Community-based Effectiveness of a Substance Use and HIV Risk Reduction Intervention for Young Men of Color,https://clinicaltrials.gov/study/NCT03488914,COMPLETED,YES,Substance Use|Sexual Risk,BEHAVIORAL: YMHP Intervention|BEHAVIORAL: Enhanced Treatment as Usual,Hunter College of City University of New York,National Institute on Drug Abuse (NIDA),MALE,"CHILD, ADULT",86,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2016-06-15,2021-04-30,"BOOM!Health, Bronx, New York, 10458, United States|Bridging Access to Care, Brooklyn, New York, 11226, United States"
NCT06758596,Research Investigating Drug Effects-2 (RiDE-2),https://clinicaltrials.gov/study/NCT06758596,NOT_YET_RECRUITING,NO,Cannabis Use|Substance Use Disorder (SUD)|Healthy,DRUG: Placebo Oral Capsule|DRUG: THC,University of Illinois at Chicago,,ALL,ADULT,144,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2025-07-15,2030-03,"University of Illinois at Chicago, Chicago, Illinois, 60612, United States"
NCT02227589,Treatment for Teens With Alcohol Abuse and Depression,https://clinicaltrials.gov/study/NCT02227589,COMPLETED,NO,"AOD Use, Abuse, and Dependence|Depression",BEHAVIORAL: MET/CBT-12|BEHAVIORAL: CBT-D|OTHER: D-TAU,Duke University,UConn Health|National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"CHILD, ADULT",103,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2015-01-16,2020-01-03,"University of Connecticut Health Center, Farmington, Connecticut, 06030-3926, United States|Duke Child and Family Study Center, Durham, North Carolina, 27705, United States"
NCT01539525,Screening to Augment Referral to Treatment- Project START,https://clinicaltrials.gov/study/NCT01539525,COMPLETED,YES,Alcohol Abuse|Tobacco Use Disorder|Marijuana Abuse|Substance-Related Disorders,BEHAVIORAL: Motivational Interview|OTHER: Treatment as Usual,Yale University,National Institute on Drug Abuse (NIDA),FEMALE,ADULT,439,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-09-05,2015-01-28,"Yale-New Haven Hospital- York St Campus, New Haven, Connecticut, 06510, United States|Yale-New Haven Hospital-Chapel St Campus, New Haven, Connecticut, 06519, United States"
NCT05705362,Simple Crossover Versus Side Branch Opening in Patients With Non-Left Main Bifurcation Lesion,https://clinicaltrials.gov/study/NCT05705362,NOT_YET_RECRUITING,NO,Coronary Artery Disease,PROCEDURE: Simple Crossover|PROCEDURE: Side branch opening,Keimyung University Dongsan Medical Center,,ALL,"ADULT, OLDER_ADULT",1000,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-01,2029-12-31,
NCT05159830,Cannabidiol for Reducing Drinking in Alcohol Use Disorder,https://clinicaltrials.gov/study/NCT05159830,NOT_YET_RECRUITING,NO,Alcohol Use Disorder,DRUG: Cannabidiol oral oil|DRUG: Placebo oral oil,Hôpital le Vinatier,,ALL,"ADULT, OLDER_ADULT",76,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-10-31,2026-12-31,"Centre Hospitalier Le Vinatier, Bron, Auvergne Rhone Alpes, 69678 cedex, France"
NCT01403298,Project RAP: Family-based HIV Prevention in the Juvenile Drug Court,https://clinicaltrials.gov/study/NCT01403298,COMPLETED,NO,HIV/AIDS,BEHAVIORAL: Family-Based HIV prevention|OTHER: Adolescent Only Health Promotion,"University of California, San Francisco",,ALL,"CHILD, ADULT",120,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2009-12,2013-06,"Rhode Island Hospital, Providence, Rhode Island, 02903, United States"
NCT03967262,Secondary Prevention and Recidivism Reduction in Trauma Patients,https://clinicaltrials.gov/study/NCT03967262,UNKNOWN,NO,"Trauma|Alcohol Use, Unspecified|Drug Use",BEHAVIORAL: Brief Motivational Intervention,Corporacion Parc Tauli,,ALL,"ADULT, OLDER_ADULT",102,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-09-01,2022-10-01,"Corporacion Sanitaria Parc Taulí, Sabadell, Barcelona, 08208, Spain"
NCT03690791,Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease,https://clinicaltrials.gov/study/NCT03690791,ACTIVE_NOT_RECRUITING,NO,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,DRUG: MediCabilis CBD Oil|DRUG: Placebo Oil,Gold Coast Hospital and Health Service,Bod Australia,ALL,"ADULT, OLDER_ADULT",17,OTHER_GOV,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-01-09,2024-01-30,"Gold Coast Hospital and Health Service, Gold Coast, Queensland, 4215, Australia"
NCT06213233,MIVetsCan: Cannabidiol (CBD)-Care Trial,https://clinicaltrials.gov/study/NCT06213233,RECRUITING,NO,"Pain, Chronic",DRUG: Placebo|DRUG: Cannabidiol,Kevin Boehnke,"Michigan, State of, Licensing and Regulatory Affairs",ALL,"ADULT, OLDER_ADULT",468,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-02-12,2026-12,"University of Michigan, Ann Arbor, Michigan, 48109, United States"
NCT02334956,"Linking fMRI to Mobile Technologies in Addiction Research: Pathophysiology of Executive Deficits, Craving and Substance Use",https://clinicaltrials.gov/study/NCT02334956,COMPLETED,NO,Addiction,OTHER: Brain MRI,"University Hospital, Bordeaux",Fondation pour la Recherche Médicale,ALL,ADULT,107,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2015-03,2018-01-10,"CHU de Bordeaux, Bordeaux, 33000, France|Hôpital Charles Perrens, Bordeaux, 33076, France"
NCT05282797,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test",https://clinicaltrials.gov/study/NCT05282797,COMPLETED,NO,Acute Cannabinoid Intoxication,DRUG: ANEB-001|DRUG: Placebo,Anebulo Pharmaceuticals,,ALL,ADULT,154,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-12-15,2023-08-26,"Centre for Human Drug Research (CHDR), Leiden, ZH, 2333, Netherlands"
NCT06701487,Role of Pavlovian Mechanisms for Control Over Substance Use,https://clinicaltrials.gov/study/NCT06701487,RECRUITING,NO,Alcohol Use Disorder (AUD)|Alcoholism|Substance Use Disorders|Cannabis Use Disorder|Methamphetamine-dependence|Amphetamine Use Disorder|Cocaine Use Disorder,BIOLOGICAL: fMRI imaging (BOLD)|BIOLOGICAL: sMRI (structure)|BEHAVIORAL: Pavlovian-to-instrumental transfer (PIT) paradigm|DIAGNOSTIC_TEST: Basic psychological assessment (interview)|DIAGNOSTIC_TEST: Basic psychological assessment (questionnaires)|BEHAVIORAL: Neuropsychological tests,Technische Universität Dresden,"Charite University, Berlin, Germany|Central Institute of Mental Health, Mannheim",ALL,"ADULT, OLDER_ADULT",200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-08-05,2027-06-30,"Department of Psychiatry and Psychotherapy, Technische Universität Dresden, Dresden, Germany"
NCT01343420,Dog Hair Extract Study,https://clinicaltrials.gov/study/NCT01343420,COMPLETED,NO,Potency of Dog Hair Extract,"BIOLOGICAL: Dog Hair Extract, ALK-Abelló, Inc.",National Jewish Health,ALK-Abelló A/S,ALL,ADULT,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2010-11,2011-10,"National Jewish Health, Denver, Colorado, 80206, United States"
NCT06213064,"A Direct-to-Consumer Study Investigating the Effect of Specific Cannabinoid Products on Motivation, Energy Level, Focus, and Appetite in Healthy Adults",https://clinicaltrials.gov/study/NCT06213064,RECRUITING,NO,Motivation,"BEHAVIORAL: Study Product, THC Product, Placebo","Phylos Bioscience, Inc.","People Science, Inc.",ALL,"ADULT, OLDER_ADULT",58,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-08-14,2024-06-01,"People Science, Inc., Los Angeles, California, 90034, United States"
NCT05672342,Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors,https://clinicaltrials.gov/study/NCT05672342,WITHDRAWN,NO,Breast Carcinoma|Chemotherapy-Induced Peripheral Neuropathy|Colon Carcinoma,DRUG: Cannabidiol|DRUG: Delta-8-Tetrahydrocannabinol|DRUG: Placebo Administration|OTHER: Questionnaire Administration,City of Hope Medical Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2024-07-06,2025-10-31,"City of Hope Medical Center, Duarte, California, 91010, United States"
NCT06578455,A Pharmacokinetic Study to Compare CBD-NE to Epidyolex in Healthy Adult Volunteers Under Both Fed and Fasted Conditions,https://clinicaltrials.gov/study/NCT06578455,COMPLETED,NO,CBD Pharmacokinetics|Healthy Participants,DRUG: Cannabidiol (CBD) Powder|DRUG: Cannabidiol 100 MG/ML [Epidiolex],"DSM Nutritional Products, Inc.","Nutrasource Pharmaceutical and Nutraceutical Services, Inc.",ALL,ADULT,32,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2024-08-30,2024-12-16,"Nutrasource Site (Apex Trials), Guelph, Ontario, N1G0B4, Canada"
NCT06111911,Detection of High-Risk HPV in Urine and Cervical Swab Specimen Using HPV Diagnostic Kit (Bio Farma),https://clinicaltrials.gov/study/NCT06111911,COMPLETED,NO,Human Papilloma Virus Infection,DIAGNOSTIC_TEST: HPV Diagnostic Kit (Bio Farma),PT Bio Farma,,FEMALE,ADULT,900,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-04-01,2022-10-29,"Cipto Mangunkusumo Hospital, Jakarta, DKI Jakarta, 10430, Indonesia"
NCT02751359,"Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers",https://clinicaltrials.gov/study/NCT02751359,COMPLETED,YES,Pain,DRUG: Cannabidiol|DRUG: Placebo,"University of California, Los Angeles",INSYS Therapeutics Inc,ALL,ADULT,18,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2016-07,2020-04,"Cooper, New York, New York, 10013, United States"
NCT05935891,A Feasibility Study of Topical Cannabinoids for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in Adults With Hormone Receptor-Positive Breast Cancer (CanAroma),https://clinicaltrials.gov/study/NCT05935891,ACTIVE_NOT_RECRUITING,NO,Musculoskeletal Syndrome,DRUG: CBD-dominant|DRUG: THC dominant,University of Minnesota,,ALL,"ADULT, OLDER_ADULT",24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2023-02-09,2024-12-31,"University of Minnesota, Minneapolis, Minnesota, 55455, United States"
NCT03461614,"Effects of Core Stabilization Exercises on Pulmonary Functions, Respiratory Muscle Strength and Functional Capacity",https://clinicaltrials.gov/study/NCT03461614,COMPLETED,NO,Substance Use Disorders|Substance Abuse|Substance Use,OTHER: Exercise group|OTHER: Control group,Istanbul University,,MALE,"CHILD, ADULT",49,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-02-01,2018-04-05,"Rustem Mustafaoğlu, Istanbul, Turkey"
NCT04920539,In Vivo Study of THC-induced Immune-genome Changes at Single Cell Solution in HIV-infected Humans,https://clinicaltrials.gov/study/NCT04920539,RECRUITING,NO,HIV Infections|Healthy,DRUG: Active Delta-9-THC,Yale University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-02-08,2025-06-30,"VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT04729179,Cannabidiol for Fibromyalgia (The CANNFIB Trial),https://clinicaltrials.gov/study/NCT04729179,COMPLETED,NO,Fibromyalgia,DRUG: Cannabidiol|DRUG: Placebo,Marius Henriksen,,ALL,"ADULT, OLDER_ADULT",200,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-03-01,2024-02-14,"The Parker Institute, Frederiksberg Hospital, Copenhagen, 2000, Denmark"
NCT04070521,EEG Monitoring in the Emergency Department,https://clinicaltrials.gov/study/NCT04070521,ACTIVE_NOT_RECRUITING,NO,Drug Overdose|Substance Abuse|Alcohol Abuse,OTHER: Observational EEG Monitoring,Massachusetts General Hospital,Brigham and Women's Hospital,ALL,"ADULT, OLDER_ADULT",10,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-09-06,2024-10-31,"Massachusetts General Hospital, Boston, Massachusetts, 02114, United States"
NCT03928015,Evaluation of Dronabinol For Acute Pain Following Traumatic Injury,https://clinicaltrials.gov/study/NCT03928015,WITHDRAWN,NO,"Traumatic Injury|Pain, Acute",DRUG: Adjunctive dronabinol|DRUG: Systemic analgesics,CommonSpirit Health,,ALL,"ADULT, OLDER_ADULT",0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2019-10-01,2021-06-29,"St. Anthony Hospital, Lakewood, Colorado, 80228, United States"
NCT01551511,Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain,https://clinicaltrials.gov/study/NCT01551511,COMPLETED,NO,"Pancreatitis, Chronic|Abdominal Pain|Chronic Pain",DRUG: Tetrahydrocannabinol|DRUG: Placebo,Radboud University Medical Center,European Union,ALL,"ADULT, OLDER_ADULT",29,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-10,2014-06,"Radboud University Nijmegen Medical Centre, Nijmegen, 6500 HB, Netherlands"
NCT03422861,Nabilone Use For Acute Pain in Inflammatory Bowel Disease Patients,https://clinicaltrials.gov/study/NCT03422861,NOT_YET_RECRUITING,NO,Inflammatory Bowel Diseases,DRUG: Nabilone|DRUG: Placebos,"Samuel Lunenfeld Research Institute, Mount Sinai Hospital",,ALL,"ADULT, OLDER_ADULT",80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2023-12,2024-12,"Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada"
NCT03539575,CB1R in Synthetic Psychoactive Cannabinoids,https://clinicaltrials.gov/study/NCT03539575,ACTIVE_NOT_RECRUITING,NO,Drug Dependence,OTHER: [11-C]OMAR,Yale University,National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA),ALL,ADULT,15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2018-05-01,2024-12,"Connecticut Mental Health Center, New Haven, Connecticut, 06519, United States"
NCT03556618,A Pilot Trial of a Network Intervention for Youth After Incarceration,https://clinicaltrials.gov/study/NCT03556618,TERMINATED,YES,Youth Incarceration|Health Care Utilization,BEHAVIORAL: Whole Person Care (WPC) Reentry Program - Pre & Post Release services,"University of California, Los Angeles",,ALL,ADULT,19,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-03-02,2023-10-31,"Los Angeles County Jails, Los Angeles, California, 90012, United States"
NCT03495869,Feasibility and Validation of a Standard Phenotyping Assessment Battery,https://clinicaltrials.gov/study/NCT03495869,COMPLETED,YES,Opioid-use Disorder|Cocaine Use Disorder|Marijuana Use Disorder|Healthy Controls,,Virginia Commonwealth University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",368,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-06-21,2020-03-16,"VCU Institute for Drug and Alcohol Studies, Richmond, Virginia, 23219, United States"
NCT04731779,Cannabidiol and Autonomic Function at Rest,https://clinicaltrials.gov/study/NCT04731779,COMPLETED,NO,Healthy,DRUG: cannabidiol|DRUG: Placebo,Castleton University,,ALL,ADULT,18,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2021-08-30,2021-11-29,"Castleton University, Jeffords Science Building, Castleton, Vermont, 05735, United States"
NCT02447198,Cannabidiol (CBD) and Pediatric Epilepsy,https://clinicaltrials.gov/study/NCT02447198,COMPLETED,NO,Epilepsy,,"University of Colorado, Denver",,ALL,CHILD,42,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-11-02,2018-09-11,"Children's Hospital Colorado, Aurora, Colorado, 80045, United States"
NCT04997954,EMERALD TRIAL Open Label Extension Study,https://clinicaltrials.gov/study/NCT04997954,ACTIVE_NOT_RECRUITING,NO,Amyotrophic Lateral Sclerosis|Cannabis|CBD|Motor Neuron Disease,DRUG: MediCabilis CBD oil,Gold Coast Hospital and Health Service,Bod Australia,ALL,"ADULT, OLDER_ADULT",7,OTHER_GOV,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-05-17,2024-01,"Gold Coast Hospital and Health Service, Gold Coast, Queensland, 4215, Australia"
NCT03087201,CANNAbinoids in the Treatment of TICS (CANNA-TICS),https://clinicaltrials.gov/study/NCT03087201,COMPLETED,NO,Tourette Syndrome|Tic Disorders,DRUG: nabiximols|DRUG: placebo,Hannover Medical School,German Research Foundation,ALL,"ADULT, OLDER_ADULT",98,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-04-05,2020-11-20,"Uniklinik RWTH Aachen, Psychiatry and Psychotherapy, Aachen, Germany|University Hospital Cologne, Psychiatry and Psychotherapy, Cologne, Germany|University of Freiburg, Psychiatry and Psychotherapy, Freiburg, Germany|Hannover Medical School, Clinic of Psychiatry, Socialpsychiatry and Psychotherapy, Hannover, Germany|University Hospital Schleswig-Holstein, Institute of Neurogenetics, Department of Pediatric and Adult Movement Disorders and Neuropsychiatrics, Luebeck, Germany|LMU Munich, Psychiatry and Psychotherapy, Munich, Germany"
NCT01797835,Alcohol Screening in an Ethnically Diverse Sample of Adolescents in Primary Care,https://clinicaltrials.gov/study/NCT01797835,COMPLETED,YES,Alcohol Use|Drug Use,BEHAVIORAL: CHAT brief MI intervention|BEHAVIORAL: usual care,RAND,Valley Community Clinic|University of Pittsburgh,ALL,"CHILD, ADULT",294,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2013-03,2018-08,"Valley Community Clinic, North Hollywood, California, 91605, United States|UPMC St. Margaret, Pittsburgh, Pennsylvania, 15215, United States"
NCT02293057,Gender-Responsive Drug Use Treatment for Juvenile Justice Girls,https://clinicaltrials.gov/study/NCT02293057,COMPLETED,NO,Drug Use,BEHAVIORAL: VOICES Group|BEHAVIORAL: Girl Health Group,"University of California, San Francisco",,FEMALE,"CHILD, ADULT",132,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-09,2020-09,"UCSF Zuckerberg San Francisco General Hospital, San Francisco, California, 94131, United States"
NCT05329909,Epidemiology of Neurological Complications to Nitrous Oxide Poisoning,https://clinicaltrials.gov/study/NCT05329909,UNKNOWN,NO,Neurology Department,,Centre Hospitalier de Saint-Denis,,ALL,"CHILD, ADULT, OLDER_ADULT",135,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-04-10,2022-08-31,"Hôpital DELAFONTAINE, Saint-denis, ILE DE France, 93200, France"
NCT05299944,Reducing Pain and Opioid Use With CBD,https://clinicaltrials.gov/study/NCT05299944,RECRUITING,NO,Opioid Use Disorder,DRUG: Cannabidiol|DRUG: Placebo,"University of Colorado, Denver",,ALL,"ADULT, OLDER_ADULT",150,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-03-08,2027-02-28,"University of Colorado - Anschutz Medical Campus, Aurora, Colorado, 80045, United States|University of Colorado Denver, Aurora, Colorado, 80045, United States"
NCT04301024,Nitrous Oxyde Misuse Among Teenagers Consulting in an Addictology Center Dedicated to Young Drug Users in Montpellier,https://clinicaltrials.gov/study/NCT04301024,COMPLETED,NO,Nitrous Oxide|Drug Abuse,OTHER: assessing the nitrous oxide misuse,"University Hospital, Montpellier",,ALL,"CHILD, ADULT",60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-03-30,2020-09-30,"Uhmontpellier, Montpellier, 34295, France"
NCT00589641,Relapse Prevention for Suicidal Dually Diagnosed Youths,https://clinicaltrials.gov/study/NCT00589641,COMPLETED,NO,"Suicide, Attempted|Suicide, Ideation|Depression|Substance Abuse",BEHAVIORAL: CBT-RP (relapse prevention) + Enhanced TAU|BEHAVIORAL: Enhanced TAU Alone,Duke University,"UConn Health|University of North Carolina, Chapel Hill|University of North Carolina, Greensboro",ALL,"CHILD, ADULT",13,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2005-07,2010-10,"Duke Child and Family Study Center, Durham, North Carolina, 27705, United States"
NCT04878068,Study to Evaluate the Performance of the Therma COVID-19 Rapid Antigen Test for Detection of SARS-CoV-2,https://clinicaltrials.gov/study/NCT04878068,UNKNOWN,NO,Covid19,DEVICE: Theram COVID-19 Rapid Antigen Test,Cannabis Research Associates,,ALL,"CHILD, ADULT, OLDER_ADULT",300,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-05-15,2021-06-30,
NCT04349930,The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Urinary SymptOms in INterstitial Cystitis (CHRONIC),https://clinicaltrials.gov/study/NCT04349930,WITHDRAWN,NO,Interstitial Cystitis|Bladder Pain Syndrome,DRUG: Cannabidiol vaginal suppository|DRUG: Placebo vaginal suppository,University of New Mexico,,FEMALE,"ADULT, OLDER_ADULT",0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01,2022-09,"University of New Mexico, Albuquerque, New Mexico, 87131, United States"
NCT00239837,Prevention Program for Problem Behaviors in Girls in Foster Care,https://clinicaltrials.gov/study/NCT00239837,COMPLETED,YES,Juvenile Justice Involvement|Drug Abuse,BEHAVIORAL: Middle School Success Intervention (MSS),Oregon Social Learning Center,National Institute of Mental Health (NIMH)|National Institute on Drug Abuse (NIDA),FEMALE,CHILD,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2003-12,2013-04,"Oregon Social Learning Center, Eugene, Oregon, 97401, United States"
NCT01427465,Brief Integrative Alcohol Interventions for Adolescents,https://clinicaltrials.gov/study/NCT01427465,WITHDRAWN,NO,Alcohol Abuse|Drug Abuse,BEHAVIORAL: Brief Prevention Program Using Positive Image|BEHAVIORAL: Brief Prevention Program Using Positive Image|BEHAVIORAL: Brief Prevention Program Using Positive Image|BEHAVIORAL: Brief Prevention Program Using Positive Image,University of Florida,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"CHILD, ADULT, OLDER_ADULT",0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: PREVENTION,2007-09,2010-09,"Addictive & Health Behaviors Research Institute, University of Florida, Jacksonville, Florida, 32256, United States"
NCT01502046,Neuroprotection by Cannabinoids in Huntington's Disease,https://clinicaltrials.gov/study/NCT01502046,COMPLETED,NO,Huntington's Disease,DRUG: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)|DRUG: Placebo,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,GW Pharmaceuticals Ltd,ALL,"ADULT, OLDER_ADULT",25,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-09,2012-06,"Hospital Universitario Ramón y Cajal, Madrid, 28034, Spain"
NCT03642106,Unidos Against ATOD Use Intervention Trial,https://clinicaltrials.gov/study/NCT03642106,UNKNOWN,NO,Substance Use,BEHAVIORAL: Unidos Se Puede,Oklahoma State University,National Institute of General Medical Sciences (NIGMS)|National Institute on Drug Abuse (NIDA),ALL,CHILD,240,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-01-01,2023-08-31,"Oklahoma State University-Tulsa, Tulsa, Oklahoma, 74106, United States"
NCT05959408,Bacterial Sexually Transmitted Infections (STIs) Viability by Polymerase Chain Reaction (PCR),https://clinicaltrials.gov/study/NCT05959408,RECRUITING,NO,Men Who Have Sex With Men,PROCEDURE: Collection of throat swab|PROCEDURE: Collection of anal swab|PROCEDURE: Collection of first void urine,"University Hospital, Bordeaux",,MALE,"ADULT, OLDER_ADULT",600,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-04-18,2024-04-30,"Service des Maladies Infectieuses et Tropicales, Hôpital Pellegrin, Bordeaux, France"
NCT06553196,MATAspire: Mental Health Awareness Tailored App for Substance Prevention and Integrated Resilience Education,https://clinicaltrials.gov/study/NCT06553196,NOT_YET_RECRUITING,NO,Alcohol Use|Cannabis Use|Nicotine Use|Illicit Drug Use|Prescription Opioid Misuse,BEHAVIORAL: MATAspire Web-app,"California State University, Northridge",,ALL,"ADULT, OLDER_ADULT",1000,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2024-08-24,2028-12-31,
NCT00108407,Study Comparing Two Types of Psychotherapy for Treating Depression and Substance Abuse,https://clinicaltrials.gov/study/NCT00108407,COMPLETED,NO,Alcohol Abuse|Cannabis Abuse|Major Depressive Disorder|Substance-Related Disorders,BEHAVIORAL: Integrated Cognitive Behavioral Therapy|BEHAVIORAL: Twelve Step Facilitation Therapy,US Department of Veterans Affairs,,ALL,"ADULT, OLDER_ADULT",,FED,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2004-10,,"VA San Diego Healthcare System, San Diego, San Diego, California, 92161, United States"
NCT03848481,CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS),https://clinicaltrials.gov/study/NCT03848481,COMPLETED,NO,Prader-Willi Syndrome,DRUG: CBDV Compound|DRUG: Placebo,Montefiore Medical Center,Foundation for Prader-Willi Research|GW Pharmaceuticals Ltd,ALL,"CHILD, ADULT",14,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-11-23,2024-10-31,"Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, 10467, United States"
NCT02233946,Computerized Alcohol Screening for Children and Adolescents (cASCA) in Primary Care,https://clinicaltrials.gov/study/NCT02233946,COMPLETED,YES,Prevention Harmful Effects,BEHAVIORAL: computer-facilitated brief intervention,Boston Children's Hospital,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"CHILD, ADULT",871,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2015-01,2018-05-31,"Tufts Medical Center, Boston, Massachusetts, 02111, United States|Boston Childrens Primary Care Center, Boston, Massachusetts, 02115, United States|Longwood Pediatrics, Boston, Massachusetts, 02115, United States|East Boston Neighborhood Health Center, East Boston, Massachusetts, 02128, United States|Lexington Pediatrics, Lexington, Massachusetts, 02421, United States"
NCT05514899,Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV,https://clinicaltrials.gov/study/NCT05514899,RECRUITING,NO,HIV|Cannabis|THC|Neuroinflammatory Disease|Neuroinflammatory Response|Microbiome,DRUG: THC|DRUG: CBD,"University of California, San Diego",,ALL,"ADULT, OLDER_ADULT",90,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-04-01,2027-07-31,"HIV Neurobehavioral Research Program (HNRP), San Diego, California, 92103, United States"
NCT04294966,Age-Related Effects of THC,https://clinicaltrials.gov/study/NCT04294966,COMPLETED,YES,Tolerance|Adolescent Behavior|THC,DRUG: Dextrose|DRUG: Dronabinol|DRUG: Dronabinol,University of Chicago,,ALL,ADULT,24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2020-03-10,2021-05-01,"University of Chicago Hospital, Chicago, Illinois, 60637, United States|University of Chicago, Chicago, Illinois, 60637, United States"
NCT03866941,Acute and Chronic Toxicity of Some Synthetic Cannabinoids in Assiut Psychiatric Hospitals,https://clinicaltrials.gov/study/NCT03866941,UNKNOWN,NO,"Epidemiologic Data of Some Synthetic Cannibinoids Toxicity in Patients Presenting at Assiut University Hospital, Psychiatric Hospital of Ministry of Health)|Proportion of Acute and Chronic Abusers of Synthetic Cannibinoids Among Cases of Illicit Drugs Abuser in Studied Sites",BEHAVIORAL: causes of abuse synthetic cannibinoids,Assiut University,,ALL,"CHILD, ADULT, OLDER_ADULT",100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-01-01,2021-12-30,"Egypt, Assiut, 71515, Egypt"
NCT04275258,Collaborative Opioid Taper After Trauma: Preventing Opioid Misuse and Opioid Use Disorder,https://clinicaltrials.gov/study/NCT04275258,UNKNOWN,NO,"Opioid Use|Pain, Postoperative|Opioid Use, Unspecified|Trauma|Opioid-use Disorder",OTHER: Provide assistance to subject's rural PCP pertaining to subject/patient pain management goals and opioid taper plan,University of Washington,Centers for Disease Control and Prevention|Harborview Injury Prevention and Research Center,ALL,"ADULT, OLDER_ADULT",100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2020-06-01,2022-01-31,"Harborview Medical Center, Seattle, Washington, 98195, United States"
NCT05002114,Evaluation of a Specific Transdermal Cannabidiol Product for Chronic Musculoskeletal Joint Pain.,https://clinicaltrials.gov/study/NCT05002114,WITHDRAWN,NO,Musculoskeletal Joint Pain,DRUG: Cannabidiol|OTHER: Placebo,Louisiana State University Health Sciences Center Shreveport,,ALL,"ADULT, OLDER_ADULT",0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-01,2023-01,
NCT00916201,Evaluation Study of New Compounds With Potential Use in Schizophrenia,https://clinicaltrials.gov/study/NCT00916201,UNKNOWN,NO,Schizophrenia,DRUG: URB597|DRUG: intranasal Insulin|DRUG: Cannabidiol CR,"Central Institute of Mental Health, Mannheim",Max Planck Institute for Metabolism Research,ALL,"ADULT, OLDER_ADULT",86,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06,2022-12,"Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, BW, 68159, Germany"
NCT06286839,Study of Cannabidiol (CBD) in Healthy Volunteers,https://clinicaltrials.gov/study/NCT06286839,COMPLETED,NO,Immune System and Related Disorders|Immune System Diseases,DIETARY_SUPPLEMENT: Cannabidiol (CBD),NextEvo Inc.,Atlantia Food Clinical Trials,ALL,ADULT,26,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-12,2022-12-14,"Altantia Clinical Trials, Chicago, Illinois, 60611, United States"
NCT04420819,Effects of Ischemic Preconditioning on Muscle Damage Induced by Excentric Exercise,https://clinicaltrials.gov/study/NCT04420819,COMPLETED,NO,Healthy,DEVICE: Ischemic Preconditioning,Paulista University,,MALE,ADULT,80,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION,2021-04-01,2022-04-01,"Franciele Marques Vanderlei, Presidente Prudente, SP, 55, Brazil"
NCT03206463,Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder,https://clinicaltrials.gov/study/NCT03206463,TERMINATED,NO,Delta-9-Tetrahydroncannabinol|Bipolar Disorder|Healthy Controls,DRUG: 4 mg Delta-9-THC|DRUG: Placebo|DRUG: 2 mg Delta-9-THC,Yale University,,ALL,ADULT,2,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2017-08-01,2017-09-29,"Biological Studies Unit, VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT04146714,Substance Use Screening to Encourage Behavior Change Among Young People in Primary Care,https://clinicaltrials.gov/study/NCT04146714,NOT_YET_RECRUITING,NO,Substance Use|Binge Drinking|Cannabis Use|Adolescent Behavior,OTHER: Substance use questionnaire|OTHER: Physical activity questionnaire,Prof. Dagmar M. Haller,,ALL,"CHILD, ADULT",840,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2025-01,2027-12,"University Institute for Primary Care, Faculty of Medicine, University of Geneva, Geneva, Switzerland"
NCT02504151,Cannabidiol Treatment in Patients With Early Psychosis,https://clinicaltrials.gov/study/NCT02504151,COMPLETED,YES,Schizophrenia|Schizoaffective Disorder,DRUG: Cannabidiol|DRUG: Placebo,Yale University,,ALL,"ADULT, OLDER_ADULT",18,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-01-28,2018-03-09,"Connecticut Mental Health Center, New Haven, Connecticut, 06519, United States|VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT05879198,Train Your Brain: A Pilot Project to Improve Memory and Decision Making,https://clinicaltrials.gov/study/NCT05879198,COMPLETED,NO,"Behavior, Health",BEHAVIORAL: Computer-based Intervention,Henry Ford Health System,National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT, OLDER_ADULT",24,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-06-15,2023-09-07,"Downtown Boxing Gym, Detroit, Michigan, 48207, United States|Freedom Schools Collaborative, Flint, Michigan, 48504, United States"
NCT06444295,Testing the Impact of Thrive App Versions on Alcohol Use and Posttraumatic Stress After Recent Sexual Assault,https://clinicaltrials.gov/study/NCT06444295,RECRUITING,NO,Posttraumatic Stress Symptom|Alcohol Drinking|Alcohol Problem,BEHAVIORAL: Activity scheduling|BEHAVIORAL: Cognitive restructuring|BEHAVIORAL: Coaching calls|BEHAVIORAL: Non-core intervention components,University of Washington,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"ADULT, OLDER_ADULT",464,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: PREVENTION,2024-07-29,2027-07-15,"University of Washington, Seattle, Washington, 98195, United States"
NCT04419831,Characterizing Subjective and Physiological Responses to Stress and Pain and Cognitive Learning and Executive Function,https://clinicaltrials.gov/study/NCT04419831,COMPLETED,NO,"Pain Response, Stress, Trauma",DIAGNOSTIC_TEST: Yale Stress Pain Test (YSPT),Yale University,,ALL,ADULT,81,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-04-14,2023-12-30,"Yale Stress Center, New Haven, Connecticut, 06519, United States"
NCT05353036,Survey to Identify Substance Use in Teenagers and Adolescents,https://clinicaltrials.gov/study/NCT05353036,COMPLETED,YES,Anesthesia,OTHER: Survey,Nationwide Children's Hospital,,ALL,"CHILD, ADULT",250,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-05-27,2022-07-15,"Nationwide Children's Hospital, Columbus, Ohio, 43205, United States"
NCT03264872,Peer MI for Substance-using Emerging Adults,https://clinicaltrials.gov/study/NCT03264872,UNKNOWN,NO,Substance-Related Disorders,BEHAVIORAL: Peer-Enhanced Motivational Interviewing|OTHER: Waitlist Control,University of Illinois at Urbana-Champaign,,ALL,ADULT,180,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-03-08,2021-10-31,"School of Social Work, Urbana, Illinois, 61801, United States"
NCT04527003,Cannabidiol and Management of Endometriosis Pain,https://clinicaltrials.gov/study/NCT04527003,TERMINATED,NO,Endometriosis|CBD|Pelvic Pain,DRUG: Cannabidiol (CBD) Extract|DRUG: Norethindrone Acetate|OTHER: Placebo,Milton S. Hershey Medical Center,,FEMALE,ADULT,10,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-04,2024-06-26,"Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033, United States"
NCT05368571,CHOICES-TEEN Randomized Controlled Trial,https://clinicaltrials.gov/study/NCT05368571,RECRUITING,NO,Risk for an Alcohol-Exposed Pregnancy|Risk for Marijuana-Exposed Pregnancy|Risk for Substance-Exposed Pregnancy|HIV Risk|Sexually Transmitted Infection Risk,OTHER: CHOICES-TEEN|OTHER: Health and Life Skills Education,Baylor University,University of Texas at Austin|Wayne State University,FEMALE,"CHILD, ADULT",400,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-04-08,2026-03,"Baylor University, Houston, Texas, 77002, United States"
NCT04301401,Assessment of Changes in Vaginal Microbiota Profiles Before and After Vaginal Urogynecologic Surgery,https://clinicaltrials.gov/study/NCT04301401,COMPLETED,NO,Gynecological Surgery,OTHER: Vaginal swabs|OTHER: Stool samples|OTHER: Urine samples,Centre Hospitalier Universitaire de Nīmes,Nantes University Hospital,FEMALE,"ADULT, OLDER_ADULT",60,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-03-01,2023-10-10,"Centre Hospitalier Universitaire, Nîmes, Gard, 30000, France"
NCT05793411,Risk Behaviors in Adolescents With Chronic Diseases,https://clinicaltrials.gov/study/NCT05793411,RECRUITING,NO,Chronic Disease|Somatic Disorders,OTHER: Questionnaire risk behaviors in adolescents with chronic diseases,Assistance Publique - Hôpitaux de Paris,,ALL,"CHILD, ADULT",500,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-01-01,2023-12-01,"Robert Debre Hospital, Paris, 75019, France"
NCT05445804,Oral Cannabidiol for Tobacco Cessation,https://clinicaltrials.gov/study/NCT05445804,RECRUITING,NO,Tobacco Use|Tobacco Smoking|Tobacco Dependence|Tobacco Use Disorder|Tobacco Use Cessation,DRUG: 300 mg Cannabidiol|DRUG: 600 mg Cannabidiol|DRUG: Placebo,Johns Hopkins University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2022-11-01,2025-07-01,"Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland, 21224, United States"
NCT05872074,Immediate and Short Term Outcomes for Using Drug Coated Balloons in Treating Coronary Bifurcation Lesions,https://clinicaltrials.gov/study/NCT05872074,RECRUITING,NO,Ischemia; Heart|Stents,DIAGNOSTIC_TEST: Coronary angiography plus percutenous coronary intervention,Ain Shams University,,ALL,"ADULT, OLDER_ADULT",50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: DIAGNOSTIC,2023-10-04,2023-10-11,"Ainshams university , Faculty of Medicine, Cairo, 002, Egypt"
NCT04794205,Acute Changes In Thermal Pain Response Following Single Oral Dose of Beta-Cary,https://clinicaltrials.gov/study/NCT04794205,WITHDRAWN,NO,Beta-Caryophyllene,DRUG: Low Dose Beta-Caryophyllene|DRUG: Medium Dose Beta-Caryophyllene|DRUG: High Dose Beta-Caryophyllene|DRUG: Placebo,Hartford Hospital,,ALL,ADULT,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2021-09,2022-04,"Hartford Hospital, Hartford, Connecticut, 06106, United States"
NCT05933473,Clinical and Procedural Outcomes of Ostial Left Anterior Descending Artery Intervention With or Without Crossover to Left-main,https://clinicaltrials.gov/study/NCT05933473,NOT_YET_RECRUITING,NO,Coronary Artery Disease,PROCEDURE: Percutaneous coronary intervention,Assiut University,,ALL,"CHILD, ADULT, OLDER_ADULT",72,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-07,2025-07,
NCT04100759,A Comparative Pharmacokinetic and Pharmacodynamic Study of Sildenafil in Adult Smokers and Non Smokers,https://clinicaltrials.gov/study/NCT04100759,COMPLETED,NO,Erectile Dysfunction|Smoking|Pharmacokinetics|Pharmacodynamics,DRUG: Sildenafil 50 mg Oral Tablet,Ain Shams University,"Drug Research Centre, Cairo, Egypt",MALE,"ADULT, OLDER_ADULT",36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-06-11,2019-07-08,"Drug Research Centre, Cairo, Sheraton Heliopolis, Egypt"
NCT04451863,Analgesic and Subjective Effects of Terpenes,https://clinicaltrials.gov/study/NCT04451863,RECRUITING,NO,"Pain|Abuse, Drug",DRUG: Low THC|DRUG: High THC|DRUG: Low Myrcene|DRUG: High Myrcene|DRUG: Low Beta-Caryophyllene|DRUG: High Beta-Caryophyllene|DRUG: Placebo,"University of California, Los Angeles",National Center for Complementary and Integrative Health (NCCIH),ALL,ADULT,45,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2021-12-15,2025-11-30,"University of California, Los Angeles, Los Angeles, California, 90095, United States"
NCT03296384,Influence of Environmental Factors and Schizophrenia,https://clinicaltrials.gov/study/NCT03296384,UNKNOWN,NO,Patients With Schizophrenia|Relatives,OTHER: Clinical and environmental evaluation,Assistance Publique - Hôpitaux de Paris,"Institut national d'étude démographique (INED)|CPN (INSERM U894) CH Sainte-Anne - Paris|Institut National de la Santé Et de la Recherche Médicale, France|Fondation FondaMental|University Hospital, Clermont-Ferrand",ALL,"ADULT, OLDER_ADULT",600,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2014-03,2018-11,"Henri Mondor Hospital, Creteil, 94010, France"
NCT06226818,"Evaluation of the Impact on Mental and Physical Health of Caring for Women Who Are Victims of Sexual and Gender-based Violence, Using a Coordinated Multidisciplinary Approach in Women's Centres or Traditional Health Centres.",https://clinicaltrials.gov/study/NCT06226818,RECRUITING,NO,Domestic And/or Sexual Violence,OTHER: completion of scales and questionnaires,Centre Hospitalier Universitaire Dijon,,FEMALE,"ADULT, OLDER_ADULT",360,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-08-08,2026-02,"Chu Dijon Bourgogne, Dijon, 21000, France"
NCT05308459,Data Health VET - Data-driven Health Promotion at Vocational Education and Training Schools,https://clinicaltrials.gov/study/NCT05308459,ACTIVE_NOT_RECRUITING,NO,Food Habits|Physical Inactivity|Smoking Behaviors|Drug Use|Alcohol Consumption|Wellbeing,BEHAVIORAL: Data-driven health promotion at Vocational Education and Training schools (Data Health VET),Steno Diabetes Center Copenhagen,Steno Diabetes Center Sjaelland|University of Southern Denmark,ALL,"CHILD, ADULT, OLDER_ADULT",1370,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2022-01-19,2025-06-30,"Steno Diabetes Center Copenhagen, Herlev, 2730, Denmark|Steno Diabetes Center Zealand, Holbæk, 4300, Denmark"
NCT05155176,Novel Real-world Methods in Social Drinkers and AUD,https://clinicaltrials.gov/study/NCT05155176,COMPLETED,NO,Alcohol Drinking|Alcohol Abuse|Alcohol Use Disorder,BEHAVIORAL: Intensive Day Monitoring,Yale University,Peter McManus Charitable Trust,ALL,"ADULT, OLDER_ADULT",54,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-05-01,2023-12-31,"Yale Stress Center, New Haven, Connecticut, 06519, United States"
NCT06100575,Tool for Sibling and Children of Someone With Suicidal Thoughts,https://clinicaltrials.gov/study/NCT06100575,COMPLETED,NO,Suicide,BEHAVIORAL: Website (www.mee-leven.be),University Ghent,,ALL,"CHILD, ADULT",29,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-10-16,2024-01-29,"Flemish Centre of Expertise in Suicide Prevention, Ghent University, Ghent, 9000, Belgium"
NCT01575457,Harriet Lane Healthy Futures Program,https://clinicaltrials.gov/study/NCT01575457,COMPLETED,NO,Youth Coaching|Future Planning,BEHAVIORAL: Career Counseling and Motivational Interviewing,Johns Hopkins University,Zanvyl and Isabelle Krieger Fund,ALL,"CHILD, ADULT",202,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: ",2009-06,2014-12,"Harriet Lane Clinic, Baltimore, Maryland, 21287, United States"
NCT03533491,The Rewire Study (Mindfulness Mobile App to Reduce Adolescent Substance Use),https://clinicaltrials.gov/study/NCT03533491,COMPLETED,YES,Adolescent Substance Use,BEHAVIORAL: Rewire App,"Oregon Research Behavioral Intervention Strategies, Inc.",National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",60,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-03-30,2018-10-31,"Oregon Research Behavioral Intervention Strategies, Inc./Oregon Research Institute, Eugene, Oregon, 97403, United States"
NCT04794543,Effects of Using E-Cigarettes on Lungs in People With HIV (HBS Ancillary),https://clinicaltrials.gov/study/NCT04794543,COMPLETED,NO,Hiv|Lung Injury,,Pennington Biomedical Research Center,National Institute of General Medical Sciences (NIGMS),ALL,"ADULT, OLDER_ADULT",23,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-04-01,2023-12-04,"Pennington Biomedical Research Center, Baton Rouge, Louisiana, 70808, United States|Lsuhsc-No, New Orleans, Louisiana, 70112, United States"
NCT04778644,Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task,https://clinicaltrials.gov/study/NCT04778644,ACTIVE_NOT_RECRUITING,NO,CBD,DRUG: CBD|DRUG: Placebo,Hartford Hospital,Yale University,ALL,ADULT,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2021-12-15,2025-12-15,"Hartford Hospital, Hartford, Connecticut, 06106, United States"
NCT01573416,"""Effectiveness of a Brief Intervention for Substances Consumption Linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): A Randomized Control Trial in Chilean Primary Care.""",https://clinicaltrials.gov/study/NCT01573416,COMPLETED,NO,Alcohol-Related Disorders|Substance-Related Disorders|Substance Abuse,OTHER: ASSIST-linked brief intervention for hazardous and harmful substance use.|OTHER: Observation,Pontificia Universidad Catolica de Chile,Servicio Nacional para la Prevención y Rehabilitación del Consumo de Drogas y Alcohol (SENDA),ALL,ADULT,400,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2011-12,2013-04,"CESFAM Dr. Sergio Aguilar, Coquimbo, IV, Chile|CESFAM San Juan, Coquimbo, IV, Chile|CESFAM Santa Cecilia, Coquimbo, IV, Chile|CESFAM Tierras Blancas, Coquimbo, IV, Chile|SAPU Dr. Sergio Aguilar, Coquimbo, IV, Chile|SAPU Tierras Blancas, Coquimbo, IV, Chile|5ta. Comisaría Conchalí, Conchalí, RM, Chile|CS Alberto Bachelet, Conchalí, RM, Chile|CS José Symon Ojeda, Conchalí, RM, Chile|CS Juanita Aguirre, Conchalí, RM, Chile|CS Lucas Sierra, Conchalí, RM, Chile|SAPU Lucas Sierra, Conchalí, RM, Chile|43va. Comisaría Peñalolén, Peñalolén, RM, Chile|CESFAM Lo Hermida, Peñalolén, RM, Chile|CESFAM Padre Gerardo Whelan, Peñalolén, RM, Chile|CS Carol Urzúa Ibañez, Peñalolén, RM, Chile|CS La Faena, Peñalolén, RM, Chile|SAPU Lo Hermida, Peñalolén, RM, Chile|26va. Comisaría Pudahuel, Pudahuel, RM, Chile|CESFAM Gustavo Molina, Pudahuel, RM, Chile|CESFAM RAúl Silva Henríquez, Pudahuel, RM, Chile|CESFAM Violeta Parra, Pudahuel, RM, Chile|Consultorio Estrella, Pudahuel, RM, Chile|SAPU La Estrella, Pudahuel, RM, Chile|14va. Comisaría San Bernardo, San Bernardo, RM, Chile|APS Carol Urzúa, San Bernardo, RM, Chile|APS Confraternidad, San Bernardo, RM, Chile|APS El Manzano, San Bernardo, RM, Chile|APS Raúl Cuevas, San Bernardo, RM, Chile|SAPU Raúl Brañes, San Bernardo, RM, Chile"
NCT06477406,Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis,https://clinicaltrials.gov/study/NCT06477406,RECRUITING,NO,Endometriosis,DRUG: Cannabidiol|DRUG: Placebo,Mclean Hospital,Massachusetts Life Sciences Center,FEMALE,"ADULT, OLDER_ADULT",30,OTHER,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2024-12,2026-06,"McLean Hospital, Belmont, Massachusetts, 02478, United States"
NCT03526354,Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder,https://clinicaltrials.gov/study/NCT03526354,COMPLETED,NO,Schizophrenia|Schizoaffective Disorder|Substance Use Disorders,DRUG: Brexpiprazole|OTHER: Treatment as Usual,"University of Massachusetts, Worcester","Massachusetts General Hospital|University of North Carolina, Chapel Hill|Otsuka Pharmaceutical Co., Ltd.|Augusta University",ALL,"ADULT, OLDER_ADULT",52,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-03-19,2024-02-29,"Augusta University, Augusta, Georgia, 30912, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|UMass Medical School, Worcester, Massachusetts, 01655, United States|University of North Carolina, Chapel Hill, North Carolina, 27599, United States"
NCT04322929,Roflumilast in Non-CF Bronchiectasis Study (2019),https://clinicaltrials.gov/study/NCT04322929,COMPLETED,NO,Non-cystic Fibrosis Bronchiectasis,DRUG: Roflumilast Oral Tablet,The University of Hong Kong,,ALL,"ADULT, OLDER_ADULT",42,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-11-12,2024-11-30,"Queen Mary Hospital, Hong Kong, Hong Kong"
NCT03776422,Homeless Youth Study - Stepping Stone 2.0,https://clinicaltrials.gov/study/NCT03776422,COMPLETED,NO,"Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse)",BEHAVIORAL: Mobile self-help intervention,Rush University Medical Center,Illinois Department of Human Services|Sparrow Mobile,ALL,"CHILD, ADULT",100,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-12-21,2019-07-08,"Rush University Medical Center, Chicago, Illinois, 60612, United States"
NCT03577301,Young Men's Health Project Targeting HIV Risk Reduction and Substance Abuse,https://clinicaltrials.gov/study/NCT03577301,COMPLETED,YES,HIV Infections,BEHAVIORAL: Clinic-based Delivery|BEHAVIORAL: Remote Delivery|BEHAVIORAL: Multi-modal Delivery,Florida State University,,MALE,"CHILD, ADULT",83,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2018-10-04,2022-05-31,"University of Miami Miller School of Medicine, Miami, Florida, 33136, United States|Wayne State University, Detroit, Michigan, 48202, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States"
NCT06278246,Investigating the Muscarinic System in Schizophrenia Using Positron Emission Tomography,https://clinicaltrials.gov/study/NCT06278246,NOT_YET_RECRUITING,NO,Schizophrenia|Schizophreniform Disorders,RADIATION: PET Scan,Centre for Addiction and Mental Health,,ALL,"ADULT, OLDER_ADULT",58,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-02,2029-02,"Centre for Addiction and Mental Health, Toronto, Ontario, M5T1R8, Canada"
NCT03268980,Smoking Prevalence at a University Hospital,https://clinicaltrials.gov/study/NCT03268980,COMPLETED,NO,Tobacco Smoking,OTHER: Questionnaire Hospital Staff group|OTHER: Questionnaire students and patients group,Hospices Civils de Lyon,,ALL,"ADULT, OLDER_ADULT",11276,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-11-23,2017-11-23,"Service de Pneumologie Aigue Spécialisée et Cancérologie Thoracique - Hôpital Lyon-Sud, Pierre-Bénite, 69495, France"
NCT03227809,First Years Away From Home: Letting Go and Staying Connected,https://clinicaltrials.gov/study/NCT03227809,UNKNOWN,NO,Substance Abuse|Risk Reduction|RIsky Sexual Behavior,BEHAVIORAL: Handbook condition|BEHAVIORAL: Handbook plus condition,Washington State University,,ALL,"CHILD, ADULT",910,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2017-04-01,2021-09-14,"Washington State University, Pullman, Washington, 99164, United States"
NCT02915120,Ultrasound-Guided Pulsed Radiofrequency In The Treatment Of Patients With Osteoarthritis Knee (USPRFGENOAK),https://clinicaltrials.gov/study/NCT02915120,RECRUITING,NO,"Osteoarthritis, Knee",PROCEDURE: Real Pulsed Radiofrequency|PROCEDURE: Sham Pulsed Radiofrequency,Hospital Son Llatzer,,ALL,"ADULT, OLDER_ADULT",142,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2017-03-27,2024-12,"Son Llatzer University Hospital, Palma, Balear Islands, 07198, Spain"
NCT02503618,Understanding Substance Use and Incident HIV/STI Among Young Black MSM,https://clinicaltrials.gov/study/NCT02503618,COMPLETED,NO,HIV|Substance Abuse,,Emory University,National Institute on Drug Abuse (NIDA),MALE,ADULT,469,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-07,2019-03-18,"Grady Health System, Atlanta, Georgia, 30303, United States|Grady Infectious Diseases Clinic (Ponce Clinic), Atlanta, Georgia, 30308, United States|The Ponce de Leon Center of the Grady Health System, Atlanta, Georgia, 30308, United States|AID Atlanta, Atlanta, Georgia, 30309, United States|Southside Medical Center, Atlanta, Georgia, 30315, United States|Rollins School of Public Health, Atlanta, Georgia, 30322, United States|SisterLove, Inc, Atlanta, Georgia, 30331, United States"
NCT06097533,Improvement of Quality of Life by Cannabinoids in Oncologic Patients,https://clinicaltrials.gov/study/NCT06097533,RECRUITING,NO,Medical Oncology|Palliative Care|Quality of Life|Cannabinoids,DRUG: Cannabisextrakt Avextra 10/10 Lösung,University Hospital Schleswig-Holstein,Avextra Pharma GmbH|SocraMetrics GmbH,ALL,"ADULT, OLDER_ADULT",170,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-04-08,2026-11-30,"University Hospital Schleswig-Holstein, Kiel, Schleswig-Holstein, 24105, Germany|University Hospital Schleswig-Holstein, Kiel, Schleswig-Holstein, 24105, Germany|University Hospital Schleswig-Holstein, Lübeck, Schleswig-Holstein, Germany|Hubertus Wald Tumorzentrum Universitäres Cancer Center Hamburg (UCCH), Hamburg, 20246, Germany"
NCT01253408,Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS),https://clinicaltrials.gov/study/NCT01253408,COMPLETED,YES,Irritable Bowel Syndrome,DRUG: Dronabinol|DRUG: Placebo,Mayo Clinic,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Center for Research Resources (NCRR),ALL,"ADULT, OLDER_ADULT",36,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: ",2009-09,2011-12,"Mayo Clinic, Rochester, Minnesota, 55905, United States"
NCT05317676,Effect of Palmitoylethanolamide on Reducing Opioid Consumption for Below Knee Fracture Fixation,https://clinicaltrials.gov/study/NCT05317676,WITHDRAWN,NO,Tibial Fractures|Fibula Fracture|Knee Fracture,DRUG: Palmitoylethanolamide|DRUG: Placebo,"University of California, Irvine",GE Nutrients Inc. (Gencor),ALL,"ADULT, OLDER_ADULT",0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2023-05,2025-12,"UC Irvine Medical Center, Orange, California, 92868, United States"
NCT04565470,Strategies of Self-management of Endometriosis Symptoms,https://clinicaltrials.gov/study/NCT04565470,COMPLETED,NO,Endometriosis,OTHER: online questionnaire,Benno Rehberg-Klug,,FEMALE,"ADULT, OLDER_ADULT",165,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-09-21,2024-06-01,"Hôpitaux Universitaires de Genève HUG, Geneva, 1211, Switzerland"
NCT02300324,The Bioavailability Of Sulforaphane From Broccoli Soups Study (BOBS),https://clinicaltrials.gov/study/NCT02300324,COMPLETED,NO,Healthy,DIETARY_SUPPLEMENT: Standard broccoli and stilton soup|DIETARY_SUPPLEMENT: Beneforte broccoli and stilton soup|DIETARY_SUPPLEMENT: Beneforte Extra broccoli and stilton soup,Quadram Institute Bioscience,Biotechnology and Biological Sciences Research Council|Prostate Cancer Foundation,ALL,"ADULT, OLDER_ADULT",11,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2014-10,2015-08,"Institute of Food Research, Norwich, Norfolk, NR4 7UY, United Kingdom"
NCT04770025,A Pilot Study of Non-invasive Brain Stimulation to Boost the Efficacy of Psychotherapy in a Community Sample of People Who Drink Alcohol,https://clinicaltrials.gov/study/NCT04770025,RECRUITING,NO,Alcohol Use Disorder,DEVICE: High-density transcranial alternating current stimulation|DEVICE: Sham stimulation|BEHAVIORAL: Motivational interviewing,The Mind Research Network,National Institute of General Medical Sciences (NIGMS),ALL,ADULT,75,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: OTHER",2020-09-01,2025-02-28,"The Mind Research Network, Albuquerque, New Mexico, 87106, United States"
NCT05225441,National Investigation in College and High School Among Adolescents on Health and Substances at the FSEF,https://clinicaltrials.gov/study/NCT05225441,COMPLETED,NO,Psychiatric Disorder|Somatic Symptom|Traumatic Injury,,Fondation Santé des Étudiants de France,,ALL,"CHILD, ADULT",598,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-03-01,2022-06-24,"Godart Nathalie, Paris, 75014, France"
NCT04935606,MHealth to Enhance & Sustain Drug Use Reduction of the QUIT BI in Primary Care,https://clinicaltrials.gov/study/NCT04935606,RECRUITING,NO,Drug Use,"BEHAVIORAL: Usual Care|BEHAVIORAL: QUIT Intervention (doctor brief advice, video doctor, health coaching sessions at 2- and 6-weeks)|BEHAVIORAL: QUIT-Mobile (QUIT Intervention plus weekly mobile-web app or text message weekly self-monitoring, automated feedback over 12 months)","University of California, Los Angeles",National Institute on Drug Abuse (NIDA)|University of Arkansas|Medical University of South Carolina,ALL,"ADULT, OLDER_ADULT",600,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2021-06-01,2026-03-31,"The Children's Clinic (TCC) Family Health, Long Beach, California, 90806, United States|South Central Family Health Clinic, Los Angeles, California, 90011, United States|Wesley Health Centers, Los Angeles, California, 90013, United States|Saban Community Clinic, Los Angeles, California, 90038, United States|UMMA Community Clinic, Los Angeles, California, 90044, United States"
NCT06108349,Topical Cannabidiol for Treating Carpal Tunnel Syndrome,https://clinicaltrials.gov/study/NCT06108349,NOT_YET_RECRUITING,NO,Carpal Tunnel Syndrome,DRUG: Cannabidiol,University of Virginia,,ALL,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-11-01,2024-12-01,
NCT05823753,Cannabidiol to Reduce Anxiety Reactivity,https://clinicaltrials.gov/study/NCT05823753,COMPLETED,NO,Social Anxiety|Social Anxiety Disorder,DRUG: Cannabidiol|DRUG: Placebo,"University of California, San Diego",,ALL,"ADULT, OLDER_ADULT",63,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-04-19,2024-08-20,"University of California, San Deigo, San Diego, California, 92093, United States"
NCT03627117,Influence of CBD on Episodic Memory in Healthy Subjects,https://clinicaltrials.gov/study/NCT03627117,COMPLETED,NO,Healthy,DRUG: Verum|DRUG: Placebo,"Prof. Dominique de Quervain, MD",,ALL,ADULT,39,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2018-08-13,2018-12-08,"University of Basel, Division of Cognitive Neuroscience, Basel, 4055, Switzerland"
NCT05362357,iSTART: A Campus & Community Initiative for Services in Tec-health,https://clinicaltrials.gov/study/NCT05362357,COMPLETED,NO,Substance Use|Binge Drinking|Marijuana Use|Alcohol Drinking|Prescription Opioid Misuse|Illicit Drug Use,BEHAVIORAL: iSTART Web-app,"California State University, Northridge",,ALL,ADULT,1100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-02-20,2023-12-04,"California State University, Northridge, Northridge, California, 91330, United States"
NCT03310593,Cannabidiol as an Adjunctive Treatment for Bipolar Depression,https://clinicaltrials.gov/study/NCT03310593,TERMINATED,NO,Bipolar Disorder|Bipolar Depression|Bipolar Affective Disorder,DRUG: Cannabidiol|DRUG: Placebo,Hospital de Clinicas de Porto Alegre,Federal University of Rio Grande do Sul|University of Sao Paulo,ALL,"ADULT, OLDER_ADULT",36,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-11-01,2020-03-24,"Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, 90035-903, Brazil"
NCT06590480,An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma,https://clinicaltrials.gov/study/NCT06590480,AVAILABLE,NO,Advanced Melanoma,BIOLOGICAL: RP1|BIOLOGICAL: Nivolumab,Replimune Inc.,,ALL,"ADULT, OLDER_ADULT",,INDUSTRY,EXPANDED_ACCESS,,,,
NCT05687773,The Effect of Immersion in Virtual Reality on Upper Limb Functionality in Subjects With Parkinson's Disease: Randomized Clinical Trial,https://clinicaltrials.gov/study/NCT05687773,UNKNOWN,NO,Parkinson Disease,DEVICE: Leap Motion Controller on flat display|DEVICE: Leap Motion Controller in Head-Mounted Display,Fernanda Cechetti,,ALL,"ADULT, OLDER_ADULT",30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-09-01,2023-09-14,"Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, 90050-170, Brazil"
NCT05509166,Affirmative Psychotherapy for Sexual Minority Women's Mental and Behavioral Health,https://clinicaltrials.gov/study/NCT05509166,RECRUITING,NO,Heavy Drinking|Mental Health Issue,BEHAVIORAL: LGBTQ-affirmative Cognitive Behavioral Therapy|BEHAVIORAL: LGBTQ-affirmative Treatment-As-Usual,Yale University,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"ADULT, OLDER_ADULT",450,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-02-01,2027-06-01,"Yale LGBTQ Mental Health Initiative with the Yale School of Public Office, New York, New York, 10001, United States"
NCT00794222,A Mobile Phone Self-Monitoring Tool to Increase Emotional Self-Awareness and Reduce Depression in Young People,https://clinicaltrials.gov/study/NCT00794222,COMPLETED,NO,Depression,DEVICE: Mobile Tracking Young People's Experiences (mobiletype),Murdoch Childrens Research Institute,,ALL,"CHILD, ADULT",118,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2009-04,2011-01,"Clifton Hill Medical Centre, Melbourne, Victoria, 3068, Australia"
NCT05641766,Multimodal Magnetoencephalography and Electroencephalography Exploration of the Acute Effects of THC Exposure on Neural Noise and Information Transmission Within Working Memory Networks,https://clinicaltrials.gov/study/NCT05641766,NOT_YET_RECRUITING,NO,THC,DRUG: THC|OTHER: Placebo,Yale University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2024-12-31,2025-12-01,"VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut, 06516, United States"
NCT03916276,Living in Full Even With Pain Study,https://clinicaltrials.gov/study/NCT03916276,COMPLETED,NO,Musculoskeletal Pain|Chronic Pain,BEHAVIORAL: Cognitive Therapy (CT)|BEHAVIORAL: Mindfulness Meditation (MM)|BEHAVIORAL: Activation Skills (AS),University of Washington,National Center for Complementary and Integrative Health (NCCIH)|The University of Queensland|Medical University of South Carolina|Rush University,ALL,"ADULT, OLDER_ADULT",115,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-06-16,2023-01-25,"University of Washington, Ninth and Jefferson Building, Seattle, Washington, 98104, United States"
NCT00780442,D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals,https://clinicaltrials.gov/study/NCT00780442,COMPLETED,YES,Cocaine Use Disorders,DRUG: D-cycloserine|DRUG: Placebo,Medical University of South Carolina,,ALL,"ADULT, OLDER_ADULT",27,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2006-09,2008-07,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT02309021,PHAST: Physical Activity in Substitution Therapy,https://clinicaltrials.gov/study/NCT02309021,COMPLETED,NO,Substance-related Disorders,OTHER: Sport|OTHER: Non-sport activities,"University Hospital, Basel, Switzerland",Psychiatric Hospital of the University of Basel,ALL,"ADULT, OLDER_ADULT",28,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2014-11,2015-11,"Department for Sport, Exercise and Health, Basel, 4052, Switzerland"
NCT06731894,Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors,https://clinicaltrials.gov/study/NCT06731894,NOT_YET_RECRUITING,NO,Breast Carcinoma|Chemotherapy-Induced Peripheral Neuropathy|Colon Carcinoma,PROCEDURE: Biospecimen Collection|DRUG: Cannabidiol|DRUG: Dronabinol|DRUG: Placebo Administration|OTHER: Survey Administration,City of Hope Medical Center,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",120,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2025-10-27,2026-10-27,"City of Hope Medical Center, Duarte, California, 91010, United States|City of Hope at Irvine Lennar, Irvine, California, 92618, United States"
NCT04071002,Patients With Distal Radius Fracture,https://clinicaltrials.gov/study/NCT04071002,COMPLETED,NO,Physical Disability,OTHER: 12 weeks physical therapy programme,Pamukkale University,,ALL,ADULT,53,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-01-21,2016-09-01,"Pamukkale University, Denizli, Kinikli, 20000, Turkey"
NCT01170026,Individual and Family Motivational Interviews for Substance Using Truant Teens,https://clinicaltrials.gov/study/NCT01170026,COMPLETED,YES,Substance Use,BEHAVIORAL: Family Check-up/ Individual MI|BEHAVIORAL: Individual and family psychoeducation,Brown University,,ALL,CHILD,69,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2010-08,2013-07,"Brown University, Providence, Rhode Island, 02912, United States"
NCT02335060,N-acetylcysteine Effects on Tetrahydrocannabinol,https://clinicaltrials.gov/study/NCT02335060,TERMINATED,NO,Healthy,DRUG: Delta-9-THC|DRUG: N-acetylcysteine|DRUG: Placebo|DRUG: Placebo,Yale University,,ALL,ADULT,5,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2014-05-02,2014-09-16,"VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT05088018,Swallowable Cannabigerol Tablets for Sleep Quality In Veterans (Veterans Exploring Cannabigerol for Sleep),https://clinicaltrials.gov/study/NCT05088018,COMPLETED,NO,Sleep,OTHER: Cannabigerol|OTHER: Placebo,Chris Emerson,Veterans Cannabis Group|Curebase Inc.|Santa Cruz Veterans Alliance,ALL,"ADULT, OLDER_ADULT",68,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-10-11,2022-05-11,"Virtual Site, Walnut, California, 91789, United States"
NCT04517279,Peer Approaches to Substances in Early Psychosis Programs: A Pilot Study of a Peer-Led Intervention,https://clinicaltrials.gov/study/NCT04517279,NOT_YET_RECRUITING,NO,Psychotic Disorders|Substance Use,BEHAVIORAL: Invest in My Recovery Bank|BEHAVIORAL: Usual Care Peer Services,University of Texas at Austin,Southern Methodist University|Thresholds Inc.|Indiana University,ALL,"CHILD, ADULT",140,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-08-01,2025-01-31,
NCT03695419,Prevalence of New Psychoactive Substances Use,https://clinicaltrials.gov/study/NCT03695419,UNKNOWN,NO,Addiction,,Assiut University,,ALL,ADULT,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-01-01,2021-12-30,
NCT03655717,Using Imaging to Assess Effects of THC on Brain Activity,https://clinicaltrials.gov/study/NCT03655717,COMPLETED,YES,Intoxication Alcohol|Intoxication THC|Intoxication Combined Alcohol THC,DRUG: Dronabinol|DRUG: Ethanol|DRUG: Placebo dronabinol|DRUG: Placebo ethanol,Massachusetts General Hospital,National Institute on Drug Abuse (NIDA),ALL,ADULT,316,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2018-11-05,2021-01-21,"Center for Addiction Medicine, Massachusetts General Hospital, Dept. of Psychiatry, Boston, Massachusetts, 02114, United States"
NCT04592120,Randomized Trial of a Data-driven Technical Assistance System for Drug Prevention Coalitions,https://clinicaltrials.gov/study/NCT04592120,COMPLETED,NO,Substance Use|Adolescent Problem Behavior,BEHAVIORAL: Coalition Check-Up,"The University of Texas Health Science Center, Houston",National Institute on Drug Abuse (NIDA)|Penn State University,ALL,"CHILD, ADULT, OLDER_ADULT",68,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2020-10-20,2024-05-15,"Prevention Research Center, University Park, Pennsylvania, 16802, United States"
NCT02478424,Extended Use of Cannabidiol for the Prevention of Graft-versus-host-disease,https://clinicaltrials.gov/study/NCT02478424,UNKNOWN,NO,Graft vs Host Disease,DRUG: Cannabidiol|DRUG: cyclosporine|DRUG: Methotrexate,Rabin Medical Center,,ALL,"ADULT, OLDER_ADULT",10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2015-07,2017-06,
NCT05272865,Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC,https://clinicaltrials.gov/study/NCT05272865,UNKNOWN,NO,Nausea Post Chemotherapy|Vomiting|Cancer Pain|Cancer Related Pain|Neoplasms,DRUG: Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator,LaSanta S A S,,ALL,"ADULT, OLDER_ADULT",334,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-08-15,2024-10-17,"Lasanta S A S, Bogotá, 110231, Colombia"
NCT05114304,Prevalence of Mood and Anxiety Disorders in Adult Patients With Pulmonary Langerhans Cell Histiocytosis,https://clinicaltrials.gov/study/NCT05114304,UNKNOWN,NO,Pulmonary Langerhans Cell Histiocytosis,OTHER: Evaluation of co-morbid psychiatric disorders,Assistance Publique - Hôpitaux de Paris,,ALL,"ADULT, OLDER_ADULT",100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-11,2022-11,"Hôpital Saint-Louis, Centre de référence national des histiocytoses, Service de Pneumologie, Paris, France"
NCT05166590,Sleep and Social Experiences Study 2,https://clinicaltrials.gov/study/NCT05166590,ACTIVE_NOT_RECRUITING,NO,Sleep|Blood Pressure,BEHAVIORAL: Sleep Restriction,"University of California, San Francisco","National Heart, Lung, and Blood Institute (NHLBI)",ALL,ADULT,77,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,2021-06-01,2025-12,"University of California, San Francisco, San Francisco, California, 94118, United States"
NCT02584621,Web-Based Adolescent Motivational Enhancement Study,https://clinicaltrials.gov/study/NCT02584621,COMPLETED,NO,Alcohol Risk Behaviors|Health Care Services Quality of Care,BEHAVIORAL: Check Yourself App with Feedback,Seattle Children's Hospital,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"CHILD, ADULT",148,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2015-11,2017-04,"Interagency Teen Health Center, Seattle, Washington, 98118, United States|Garfield Teen Health Center, Seattle, Washington, 98122, United States|Nathan Hale Teen Health Center, Seattle, Washington, 98125, United States"
NCT04700930,CBD Cigarettes Instead of Normal Cigarettes as Innovative Treatment for Schizophrenia,https://clinicaltrials.gov/study/NCT04700930,UNKNOWN,NO,Schizophrenia and Other Psychotic Disorders|Harm Reduction,OTHER: CBD-Cigarettes,Psychiatric Hospital of the University of Basel,,ALL,"ADULT, OLDER_ADULT",31,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-10-04,2021-10-31,"Universitäre Psychiatrische Kliniken, Basel, 4002, Switzerland"
NCT03955523,Single Exercise Session or Meal vs Control in SCI: Case Series,https://clinicaltrials.gov/study/NCT03955523,COMPLETED,NO,Spinal Cord Injuries,OTHER: Single exercise bout trial|DIETARY_SUPPLEMENT: Single diet trial,University of British Columbia,,ALL,"ADULT, OLDER_ADULT",10,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2019-01-06,2019-11-29,"University of British Columbia Okanagan, Kelowna, British Columbia, V1V 1V7, Canada"
NCT06115603,The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder,https://clinicaltrials.gov/study/NCT06115603,RECRUITING,NO,Attention-Deficit/Hyperactivity Disorder,DRUG: Cannabigerol|OTHER: Placebo,"University of Arkansas, Fayetteville",,ALL,ADULT,76,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-11-14,2025-12,"University of Arkansas, Fayetteville, Arkansas, 72703, United States"
NCT04125303,The Effectiveness of a Brief Motivational Nursing Intervention,https://clinicaltrials.gov/study/NCT04125303,COMPLETED,NO,"Behavior, Addictive",BEHAVIORAL: brief motivational psychoeducational therapy,Cardenal Herrera University,,ALL,"ADULT, OLDER_ADULT",50,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2016-05-01,2016-10-31,"University CEU Cardenal Herrera, Castellón De La Plana, Castellón, 12006, Spain"
NCT04398446,Effect of Hemp-CBD on Patients With CIPN,https://clinicaltrials.gov/study/NCT04398446,UNKNOWN,NO,Chemotherapy-induced Peripheral Neuropathy|Colorectal Cancer Stage II|Colorectal Cancer Stage III|Breast Cancer|Ovarian Cancer|Uterine Cancer|Pancreatic Cancer,DRUG: Hemp-based CBD|OTHER: Placebo oral tablet,Main Line Health,"Ananda Hemp, Inc.",ALL,"ADULT, OLDER_ADULT",56,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-05-27,2023-04-01,"Lankenau Medical Center, Wynnewood, Pennsylvania, 19096, United States"
NCT03687762,Back on Track to Healthy Living Study,https://clinicaltrials.gov/study/NCT03687762,COMPLETED,NO,Chronic Pain,BEHAVIORAL: Cognitive Therapy (CT)|BEHAVIORAL: Mindfulness Meditation (MM)|BEHAVIORAL: Activation Skills (AS),University of Washington,Rush University|Medical University of South Carolina|The University of Queensland|National Center for Complementary and Integrative Health (NCCIH),ALL,"ADULT, OLDER_ADULT",397,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-09-07,2023-01-25,"University of Washington, Ninth and Jefferson Building, Seattle, Washington, 98104, United States"
NCT01063335,Imaging Cannabinoid CB1 Receptors in Schizophrenia,https://clinicaltrials.gov/study/NCT01063335,TERMINATED,NO,Schizophrenia,,National Institute of Mental Health (NIMH),,ALL,ADULT,1,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-02-01,2012-09-20,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT03037476,Personalized Health Assessment Related to Medications (Project PHARM),https://clinicaltrials.gov/study/NCT03037476,COMPLETED,YES,"Feedback, Psychological|Clinical Trial|Substance Abuse",BEHAVIORAL: Web-based PFI|BEHAVIORAL: Assessment Only,University of Washington,National Institute on Drug Abuse (NIDA),ALL,ADULT,843,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2017-03-30,2021-12-15,"University of Washington, Seattle, Washington, 98105, United States"
NCT01010620,Screening Protocol for Research Participants,https://clinicaltrials.gov/study/NCT01010620,COMPLETED,NO,Schizophrenia|Substance Abuse|Cocaine Abuse|Tobacco Use Disorder,BEHAVIORAL: Various Screening psychiatric and medical assessments,"University of Maryland, Baltimore",,ALL,ADULT,523,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-12,2019-06-01,"Maryland Psychiatric Research Center, Catonsville, Maryland, 21228, United States"
NCT02135991,Preparing to Run Effective Prevention,https://clinicaltrials.gov/study/NCT02135991,COMPLETED,NO,Implementation of Evidence Based Programs,BEHAVIORAL: Getting To Outcomes|BEHAVIORAL: Project CHOICE,RAND,,ALL,CHILD,990,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2013-09,2018-09,"BGC of Buena Park, Buena Park, California, 90620, United States|BGC of Burbank and Greater E Valley, Burbank, California, 91504, United States|BGC of Carson, Carson, California, 90810, United States|BGC of South Bay, Harbor City, California, 90710, United States|BGC of East LA, Los Angeles, California, 90022, United States|Challengers Boys and Girls Club, Los Angeles, California, 90037, United States|Salesian BGC, Los Angeles, California, 90063, United States|BGC of Santa Monica, Los Angeles, California, 90401, United States|BGC of West Valley, Los Angeles, California, 91303, United States|East Valley Boys and Girls Club, Los Angeles, California, 91744, United States|BGC of Santa Ana, Los Angeles, California, 92703, United States|BGC of LA Harbor, San Pedro, California, 90731, United States|BGC Stanton, Stanton, California, 90680, United States|BGC of Westminster, Westminster, California, 92683, United States|BGC of Whittier, Whittier, California, 90602, United States"
NCT05822362,CBD for Individuals at Risk for Alzheimer's Disease,https://clinicaltrials.gov/study/NCT05822362,RECRUITING,NO,Mild Cognitive Impairment,DRUG: Cannabidiol|OTHER: Placebo,"University of Colorado, Denver",,ALL,"ADULT, OLDER_ADULT",236,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-01-19,2029-04,"University of Colorado - Anschutz Medical Campus, Aurora, Colorado, 80045, United States"
NCT05023759,"Anxiety Symptoms in Relation to Use of Hemp-derived, Full Spectrum Cannabidiol (CBD)",https://clinicaltrials.gov/study/NCT05023759,COMPLETED,NO,Generalized Anxiety Disorder,DIETARY_SUPPLEMENT: Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules,Formula30A LLC,,ALL,"ADULT, OLDER_ADULT",30,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-06-01,2020-10-31,"NP Care Clinic, Denton, Texas, 76201, United States|Dr. Michael Jelinek, MD, Edinburg, Texas, 78539, United States|Modern Medicine, Forney, Texas, 75126, United States|Destination Health, Southlake, Texas, 76092, United States|Melville Medicine, Southlake, Texas, 76092, United States|Dr. Jenaro Velez, MD, Ceiba, 00735, Puerto Rico"
NCT06754527,Options for Navigating Talking About Risk and Adolescent Choices,https://clinicaltrials.gov/study/NCT06754527,NOT_YET_RECRUITING,NO,"Substance Use (Drugs, Alcohol)|Substance Use Risk|Substance Use|Emotion Regulation|Risk Reduction Behavior|Risk Reduction",BEHAVIORAL: ON-TRAC,Rhode Island Hospital,,ALL,CHILD,200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2026-03-01,2029-02-01,
NCT02715206,Adaptation Processes in School-based Substance Abuse Prevention,https://clinicaltrials.gov/study/NCT02715206,COMPLETED,NO,Substance Abuse Problem,BEHAVIORAL: keepin' it REAL classic|BEHAVIORAL: keepin' it REAL rural|BEHAVIORAL: control,Penn State University,,ALL,CHILD,2827,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2006-07,2015-01,"The Ohio State University, Columbus, Ohio, 43210, United States|The Pennsylvania State University, University Park, Pennsylvania, 16802, United States"
NCT05885685,Investigating the Effects of Nabilone on Endocannabinoid Metabolism,https://clinicaltrials.gov/study/NCT05885685,RECRUITING,NO,Healthy,DRUG: Nabilone Oral Capsule,Centre for Addiction and Mental Health,,ALL,"ADULT, OLDER_ADULT",30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-10-31,2026-10,"Centre for Addiction and Mental Health, Toronto, Ontario, M5T 1R8, Canada"
NCT04613791,Situation and Evolution of the Misuse of Alcohol and Other Addictive Behaviors in Obese Patients Being Managed at Nîmes University Hospital,https://clinicaltrials.gov/study/NCT04613791,UNKNOWN,NO,Obesity,BIOLOGICAL: Blood test,Centre Hospitalier Universitaire de Nīmes,,ALL,"ADULT, OLDER_ADULT",800,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-02-16,2023-12-15,"CHU de Nimes, Nîmes, France"
NCT00847873,Treatment of Intimate Partner Violence and Substance Abuse in a Substance Abuse Treatment Facility,https://clinicaltrials.gov/study/NCT00847873,COMPLETED,NO,Domestic Violence|Substance Abuse,BEHAVIORAL: substance abuse/domestic violence treatment|BEHAVIORAL: Cognitive behavioral therapy addressing substance abuse,VU University of Amsterdam,,ALL,"ADULT, OLDER_ADULT",100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2009-10,2013-06,"JellinekMentrum, Amsterdam, Netherlands"
NCT03079856,Drug Use and Sexual Risk Behaviors Among Emerging Adults in the ER,https://clinicaltrials.gov/study/NCT03079856,COMPLETED,NO,Drug Use|Sex Behavior,BEHAVIORAL: Brief Intervention,University of Michigan,National Institute on Drug Abuse (NIDA),ALL,ADULT,63,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2017-10-09,2018-08-13,"Hurley Medical Center, Flint, Michigan, 48503, United States"
NCT03962491,Mobile-Based Contingency Management to Promote Daily Self-monitoring in Primary Care Patients,https://clinicaltrials.gov/study/NCT03962491,COMPLETED,YES,"Pain, Chronic",BEHAVIORAL: Daily Self-Monitoring Surveys + Contingency Management|BEHAVIORAL: Daily Self-Monitoring Surveys,Virginia Commonwealth University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",81,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-24,2021-04-14,"Virginia Commonwealth University, Richmond, Virginia, 23298, United States"
NCT03471585,Effects of THC on Emotional Memory Retrieval,https://clinicaltrials.gov/study/NCT03471585,COMPLETED,NO,Healthy,DRUG: THC|DRUG: Placebo oral capsule,University of Chicago,,ALL,ADULT,24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2017-02-15,2017-10-04,"University of Chicago, Chicago, Illinois, 60637, United States"
NCT04930796,Food Effect Study of VER-01 in Healthy Volunteers,https://clinicaltrials.gov/study/NCT04930796,COMPLETED,NO,Healthy,DRUG: VER-01,Vertanical GmbH,,MALE,ADULT,18,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2022-08-10,2022-11-24,"University of Medicine in Vienna - Department of Clinical Pharmacology, Vienna, 1090, Austria"
NCT00251173,Project Health Link: Connecting Patients With Services,https://clinicaltrials.gov/study/NCT00251173,COMPLETED,NO,Drug Abuse,BEHAVIORAL: Strengths Based Case Management (SBCM)|BEHAVIORAL: Motivational Enhancement Therapy (MET)|BEHAVIORAL: Brief Informational Feedback (BIF) session,University of Michigan,,ALL,ADULT,755,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2005-11,2009-12,"Hurley Medical Center, Flint, Michigan, 48503, United States"
NCT04236947,Effectiveness of the Social Competence Promotion Program for Young Adolescents for Substance Use Prevention in Chile,https://clinicaltrials.gov/study/NCT04236947,UNKNOWN,NO,Substance Use,BEHAVIORAL: SCPP-YA,"Universidad de los Andes, Chile",Comisión Nacional de Investigación Científica y Tecnológica|University of Talca,ALL,CHILD,600,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2022-03-01,2023-05-30,"Universidad de los Andes, Santiago, Chile"
NCT06206161,Optimizing and Advancing SBIRT in Schools,https://clinicaltrials.gov/study/NCT06206161,ENROLLING_BY_INVITATION,NO,"Adolescent Drinking|Adolescent Substance Use|Risk Behavior, Health","BEHAVIORAL: Indicated Prevention, Clinical Staff|BEHAVIORAL: Selective Prevention|BEHAVIORAL: Expanded Paraprofessional Workforce",Massachusetts General Hospital,"C4 Innovations, LLC|Harvard University|Patient-Centered Outcomes Research Institute",ALL,"CHILD, ADULT",18000,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-10-11,2027-11-11,"Massachusetts General Hopsital, Boston, Massachusetts, 02114, United States"
NCT04242134,Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions,https://clinicaltrials.gov/study/NCT04242134,ACTIVE_NOT_RECRUITING,NO,Coronary Artery Disease,DEVICE: Drug-coating balloon,"Nanjing First Hospital, Nanjing Medical University",,ALL,"ADULT, OLDER_ADULT",784,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-09-08,2026-06-30,"Nanjing First Hospital, Nanjing, Jiangsu, 210006, China"
NCT04808531,NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers,https://clinicaltrials.gov/study/NCT04808531,UNKNOWN,NO,Cancer Related Pain,DRUG: NanaBis™|DRUG: Oxycodone CR|DRUG: Placebo Spray|DRUG: Placebo Tablet|DRUG: Oxycodone IR,Medlab Clinical,George Clinical Pty Ltd|WriteSource Medical Pty Ltd,ALL,"ADULT, OLDER_ADULT",360,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11,2024-06,
NCT04930809,Single and Multiple Dose Study of VER-01 in Healthy Volunteers,https://clinicaltrials.gov/study/NCT04930809,COMPLETED,NO,Healthy,DRUG: VER-01,Vertanical GmbH,,MALE,ADULT,42,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-11-25,2022-07-11,"University of Medicine in Vienna - Department of Clinical Pharmacology, Vienna, 1090, Austria"
NCT01883791,"Screening, Brief Intervention and Referral to Treatment for Substance Abuse in Mental Health Treatment Settings",https://clinicaltrials.gov/study/NCT01883791,COMPLETED,NO,Substance Use Disorders|Mental Illness,BEHAVIORAL: SBIRT|BEHAVIORAL: Health Education,"University of California, Los Angeles",National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",1080,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2013-03,2018-06-30,"UCLA Inpatient and Outpatient Psychiatric Units, Los Angeles, California, 90025, United States|Ventura County Behavioral Health, Oxnard, California, 93036, United States"
NCT02435589,The Effects of a Systematic Pain Assessment Approach on Critically Ill Patients Outcomes in ICU,https://clinicaltrials.gov/study/NCT02435589,UNKNOWN,NO,Pain,OTHER: Systematic pain assessment|OTHER: Notification of results of assessments,Cyprus University of Technology,Nicosia General Hospital,ALL,"ADULT, OLDER_ADULT",120,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2015-03,2016-05,"Nicosia General Hospital, Nicosia, Cyprus"
NCT02129153,Linking Families Together Study- A Randomized Trial to Raise Parental Monitoring,https://clinicaltrials.gov/study/NCT02129153,COMPLETED,NO,Adolescent Behaviors|Substance Abuse,BEHAVIORAL: LIFT (Parent Information),"University of California, Los Angeles",,ALL,CHILD,318,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2014-09-01,2016-08-01,"UCLA, Los Angeles, California, 90095, United States"
NCT00321945,A Retrospective Analysis of the Use of ACE-inhibitors and Angiotensin Receptor Blockers,https://clinicaltrials.gov/study/NCT00321945,COMPLETED,NO,Atrial Fibrillation|Atrial Flutter,PROCEDURE: ACE-Inhibitors and Angiotensin Receptor Blockers,Emory University,,ALL,"ADULT, OLDER_ADULT",546,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2005-12,2009-10,"Emory University Hospital, Atlanta, Georgia, 30322, United States|Crawford Long Hospital, Atlanta, Georgia, 30365, United States|Veterans Administration Medical Center, Decatur, Georgia, 30033, United States"
NCT04764552,Yeahhh Baby! Ointment on Hip and/or Knee Pain in Men and Women,https://clinicaltrials.gov/study/NCT04764552,COMPLETED,NO,Joint Pain,DIETARY_SUPPLEMENT: Yeahhh Baby Ointment|OTHER: Coconut oil ointment,University of Memphis,YEAHHH! BABY LLC,ALL,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2021-02-09,2021-06-07,"Center for Nutraceutical and Dietary Supplement Reseach, Memphis, Tennessee, 38152, United States"
NCT02803567,Trial of a Novel Brief Intervention on Health Behaviors for Youth With Chronic Medical Conditions,https://clinicaltrials.gov/study/NCT02803567,COMPLETED,NO,Substance Use,BEHAVIORAL: Brief psycho-educational intervention,Boston Children's Hospital,Conrad N. Hilton Foundation,ALL,CHILD,460,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2017-04-01,2019-11-26,"Boston Children's Hospital, Boston, Massachusetts, 02115, United States"
NCT05239390,SCI-110 for Alzheimer Disease and Agitation,https://clinicaltrials.gov/study/NCT05239390,UNKNOWN,NO,Alzheimer Disease,DRUG: SCI -110,The Israeli Medical Center for Alzheimer's,,ALL,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-12-29,2023-06-29,"The Israeli Medical Center for Alzheimer's, Ramat Gan, 56621, Israel"
NCT05173116,Evaluation of the API-VIGIE Monitoring System: Program to Reduce Emergency Visits for Severe Paroxysmal Alcoholism,https://clinicaltrials.gov/study/NCT05173116,WITHDRAWN,NO,Intoxication;Alcohol;Acute|Emergencies,OTHER: Medical Outcomes Study Short Form 36 (SF 36)|OTHER: observationnal study,Centre Hospitalier Arras,F2RSM Psy (Hauts-de-France Regional Federation for Research in Psychiatry and Mental Health),ALL,"ADULT, OLDER_ADULT",0,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-02,2023-08,"Dominique LEJEUNE, Arras, France"
NCT04585841,The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy,https://clinicaltrials.gov/study/NCT04585841,COMPLETED,NO,Lean Body Mass|Cannabis|Cancer|Nausea|Cachexia|Emesis|Appetitive Behavior,DRUG: Cannabidiol,University of Copenhagen,Zealand University Hospital,ALL,"ADULT, OLDER_ADULT",32,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-12-01,2022-11-01,"Zealand University Hospital, Roskilde, 4000, Denmark"
NCT04970524,Comparison of Conventional Free Gingival Grafts With Partially De-epithelized Free Gingival Grafts,https://clinicaltrials.gov/study/NCT04970524,COMPLETED,NO,Gingival Recession,PROCEDURE: Comparison of conventional free gingival graft versus partial free gingival graft|PROCEDURE: Comparison of conventional free gingival graft versus partial free gingival graft,Yonca Naziker,,ALL,"ADULT, OLDER_ADULT",15,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-05-05,2021-02-04,"İzmir Katip Çelebi University Faculty of dentistry, Periodontology department, Izmir, Turkey"
NCT00723918,Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy,https://clinicaltrials.gov/study/NCT00723918,WITHDRAWN,NO,HIV-associated Neuropathy|Polyneuropathy,DRUG: SAB378|DRUG: methadone|DRUG: SAB placebo|DRUG: Methadone placebo,Washington University School of Medicine,National Institute of Neurological Disorders and Stroke (NINDS),ALL,"ADULT, OLDER_ADULT",0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-04,2010-01,"University of California, San Diego, San Diego, California, 92093, United States|University of New York Downstate Medical Center, Brooklyn, New York, 11208, United States|University of Rochester, Rochester, New York, 14620, United States"
NCT04699526,Evaluation of Universal Prevention Curriculum for Schools in Peru,https://clinicaltrials.gov/study/NCT04699526,COMPLETED,NO,Substance Use,OTHER: Universal Prevention Curriculum Training for Schools,HBSA,,ALL,"CHILD, ADULT",27012,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2018-05-01,2019-11-30,"Prevention Research Center, Berkeley, California, 94704, United States"
NCT05679830,The Effects of CBD Isolate on Menstrual-Related Symptoms,https://clinicaltrials.gov/study/NCT05679830,COMPLETED,NO,Menstrual Discomfort,DRUG: Cannabidiol,Canopy Growth Corporation,James Madison University,FEMALE,ADULT,33,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-09-23,2021-09-23,"James Madison University, Harrisonburg, Virginia, 22801, United States"
NCT04504981,"Y2Prevent: Preventing Drug Use and HIV Through Empowerment, Social Support and Mentorship (Y2P)",https://clinicaltrials.gov/study/NCT04504981,COMPLETED,NO,HIV|Drug Use,BEHAVIORAL: Y2Prevent,Children's Hospital Los Angeles,National Institute on Drug Abuse (NIDA),MALE,ADULT,27,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-01-22,2023-03-01,"Children's Hospital Los Angeles, Los Angeles, California, 90027, United States"
NCT04847570,The Effect of Music on Patients in Critical Care,https://clinicaltrials.gov/study/NCT04847570,UNKNOWN,NO,Intensive Care,OTHER: Music session,Chelsea and Westminster NHS Foundation Trust,CW+ Charity|Imperial College London,ALL,"ADULT, OLDER_ADULT",30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2021-04-13,2021-10-04,"Chelsea and Westminster Hospital NHS Foundation Trust, London, SW10 9NH, United Kingdom"
NCT04831294,Effects of Cannabidiol (CBD) on the Brain,https://clinicaltrials.gov/study/NCT04831294,ACTIVE_NOT_RECRUITING,NO,CBD|Fear|Inhibition,DRUG: Cannabidiol|DRUG: Placebo,Auburn University,Folium Biosciences|FutureCeuticals,ALL,ADULT,15,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2021-07-15,2023-12-31,"Auburn University MRI Research Center, Auburn, Alabama, 36849, United States"
NCT03332966,Youth Experiences and Health Study,https://clinicaltrials.gov/study/NCT03332966,RECRUITING,NO,"Psychotic Disorders|Psychiatric Hospitalization|Prodromal Symptoms|Cannabis Use|Trauma, Psychological",DIAGNOSTIC_TEST: Psychiatric questionnaires|DIAGNOSTIC_TEST: Semi-structured psychiatric interview,Finnish Institute for Health and Welfare,Hospital District of Helsinki and Uusimaa|Pirkanmaa Hospital District|Northern Ostrobothnia Hospital District,ALL,"CHILD, ADULT",1000,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-12-01,2024-12-31,"HUS Helsinki University Hospital, adolescent psychiatry clinics, Helsinki, 00029, Finland|Northern Ostrobothnia Hospital District, Adolescent Mental Health Clinic, Oulu, 90230, Finland|Pirkanmaa Hospital District, Tays Central Hospital, Adolescent psychiatry clinic, Tampere, 33521, Finland"
NCT05121428,Patients' Attitudes Toward and Experiences With Buprenorphine Treatment,https://clinicaltrials.gov/study/NCT05121428,RECRUITING,NO,Opioid-use Disorder|Acceptability of Health Care|Opioid-Related Disorders,,Cambridge Health Alliance,National Cancer Institute (NCI)|National Center for Complementary and Integrative Health (NCCIH),ALL,"ADULT, OLDER_ADULT",1000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-11-20,2025-03-20,"CHA Center for Mindfulness and Compassion, Cambridge, Massachusetts, 02141, United States"
NCT01647425,Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer,https://clinicaltrials.gov/study/NCT01647425,COMPLETED,NO,Head and Neck Cancer|Lung Cancer,BEHAVIORAL: physician assessment,Centre Oscar Lambret,"Centre Régional de Référence en Cancérologie|National Cancer Institute, France",ALL,"ADULT, OLDER_ADULT",385,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-04,2014-09,"Centre Hospitalier Régional et Universitaire - Hopital CALMETTE, Lille, 59 037, France|Centre Hospitalier Régional et Universitaire - Hopital HURIEZ, Lille, 59 037, France|Oscar Lambret Center, Lille, 59020, France"
NCT04298554,Comparison of Cannabinoids to Placebo in Management of TMJ Pain and Myofascial Pain in the TMJ Region,https://clinicaltrials.gov/study/NCT04298554,COMPLETED,NO,TMJ Disorder|Myofacial Pain|TMD,OTHER: CBD Oil|OTHER: Hemp Oil,Weill Medical College of Cornell University,,ALL,"ADULT, OLDER_ADULT",59,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-08-06,2022-05-29,"Weill Cornell Medicine, New York, New York, 10028, United States"
NCT00136279,Linking Lives: Building Quality Parent Components for School-Based Health Programs in Middle Schools,https://clinicaltrials.gov/study/NCT00136279,COMPLETED,NO,Smoking|Sexual Behavior,BEHAVIORAL: Linking Lives parent-based intervention,Centers for Disease Control and Prevention,Columbia University,ALL,"CHILD, ADULT, OLDER_ADULT",9510,FED,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2004-01,2007-09,"Columbia University School of Social Work, New York, New York, 10027, United States"
NCT06432400,Identification of Post-Traumatic Stress Disorder in Adult Patients With Substance Use Disorders,https://clinicaltrials.gov/study/NCT06432400,NOT_YET_RECRUITING,NO,Trauma,OTHER: Patient questionnaires,Hôpital NOVO,,ALL,"ADULT, OLDER_ADULT",120,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2024-12,2025-12,"Medical and Psychological Centre - Novo Hospital - Site Beaumont-sur-Oise, Beaumont-sur-Oise, 95260, France|Medical and Psychological Centre - Isarien Hospital Centre, Clermont, 60600, France"
NCT04421313,Fibres Supplementation in Rheumatoid Arthritis,https://clinicaltrials.gov/study/NCT04421313,UNKNOWN,NO,Rheumatoid Arthritis,DRUG: Dietary Fiber Supplementation,"University Hospital, Montpellier",University of Sydney|Institut de Génétique Moléculaire de Montpellier,ALL,"ADULT, OLDER_ADULT",87,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-09-02,2024-10,"UH Montpellier, Montpellier, France"
NCT03773796,Nabilone for Non-motor Symptoms in Parkinson's Disease,https://clinicaltrials.gov/study/NCT03773796,COMPLETED,YES,Parkinson Disease,DRUG: Nabilone 0.25 mg,Medical University Innsbruck,,ALL,"ADULT, OLDER_ADULT",22,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-08-06,2020-01-31,"Department of Neurology - Medical University Innsbruck, Innsbruck, Tyrol, 6020, Austria"
NCT04873453,CBD for the Treatment of Alcohol Use Disorder,https://clinicaltrials.gov/study/NCT04873453,COMPLETED,NO,Alcohol Use Disorder,DRUG: Cannabidiol|DRUG: Placebo,"University of Colorado, Denver",,ALL,ADULT,45,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-30,2023-05-31,"University of Colorado Denver, Aurora, Colorado, 80045, United States"
NCT03744091,Evaluation of the Pharmacokinetics of Prana P1 Capsules,https://clinicaltrials.gov/study/NCT03744091,UNKNOWN,NO,Healthy,DRUG: P1,The University of The West Indies,,MALE,ADULT,13,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2018-07-16,2019-08-23,"Tropical Metabolism Research Unit, Caribbean Institute for Health Reserach, University of the West Indies, Mona, Kingston, 7, Jamaica"
NCT05685225,Single-Site Study of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Phase 2 Randomized Trial,https://clinicaltrials.gov/study/NCT05685225,RECRUITING,NO,Migraine,DRUG: Stage 1: Naltrexone/Acetaminophen|DRUG: Stage 1: Naltrexone|DRUG: Stage 1: Acetaminophen|DRUG: Stage1: Placebo|DRUG: Stage 2: Naltrxone/Acetaminophen high dose|DRUG: Stage 2: Naltrexone/Acetaminophen medium dose|DRUG: Stage 2: Naltrxone/Acetaminophen low dose|DRUG: Stage 2: Placebo,"Allodynic Therapeutics, Inc",,ALL,"ADULT, OLDER_ADULT",300,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2025-01-31,2026-12-31,"Keystone Clinical Research, North Miami, Florida, 33181, United States"
NCT06273241,Impact of Food Intake on Berberine Kinetics,https://clinicaltrials.gov/study/NCT06273241,COMPLETED,NO,Pharmacokinetic Study in Healthy Volunteers,OTHER: food intake,University Medicine Greifswald,,ALL,ADULT,12,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2024-03-04,2024-05-11,"University Medicine Greifswald, Institute of Pharmacology, Greifswald, Mecklenburg-Vorpommern, 17487, Germany"
NCT02229513,Uterine Cooling During Cesarean Delivery to Reduce Blood Loss and Incidence of Postpartum Hemorrhage,https://clinicaltrials.gov/study/NCT02229513,COMPLETED,YES,Postpartum Hemorrhage|Uterine Atony,PROCEDURE: Uterine Cooling,Baylor Research Institute,,FEMALE,"ADULT, OLDER_ADULT",200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2013-07,2014-08,"Baylor University Medical Center, Dallas, Texas, 75246, United States"
NCT02383225,Culturally Grounded Early Substance Use Prevention for American Indian Families,https://clinicaltrials.gov/study/NCT02383225,COMPLETED,NO,Substance Use,BEHAVIORAL: Lakota Language enhancement|BEHAVIORAL: Facebook Supplement|BEHAVIORAL: Substance Use Resistance Skills,"University of Colorado, Denver",,ALL,"CHILD, ADULT, OLDER_ADULT",449,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2013-06-15,2018-01-04,"University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, United States"
NCT04599270,Efficiency of Prevention Program Dedicated to Addictive Behaviors (PREVENTURE) of Vulnerable Teenagers,https://clinicaltrials.gov/study/NCT04599270,RECRUITING,NO,"Addiction, Alcohol|Addiction, Substance",OTHER: PREVENTURE Program|OTHER: Routine care,"University Hospital, Brest",,ALL,CHILD,700,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-10-01,2027-10-01,"Loik JOUSNI, Brest, France|Morgane GUILLOU - LANDREAT, Brest, France|Pascale ROZEC, Landerneau, France|Catherine SIMON, Morlaix, France|Benoit SCHRECK, Nantes, France"
NCT06740422,Xuanhuang Runtong Tablet in the Treatment of Constipation (Yin-deficiency Type),https://clinicaltrials.gov/study/NCT06740422,NOT_YET_RECRUITING,NO,Constipation,DRUG: Xuanhuang Runtong Tablet|DRUG: Xuanhuang Runtong Tablet Simulator,Beijing Hospital of Traditional Chinese Medicine,,ALL,"ADULT, OLDER_ADULT",300,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-12-15,2027-06-15,
NCT04158089,Holistic Assessment of Tulsa Children's Health,https://clinicaltrials.gov/study/NCT04158089,COMPLETED,NO,Pregnancy,"BEHAVIORAL: Babies and Moms connected through Love, Openness, and Opportunity (BLOOM)",University of Oklahoma,Oklahoma Center for the Advancement of Science and Technology,FEMALE,"ADULT, OLDER_ADULT",129,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-12-20,2023-07-18,"OU Women's Health and Specialty Clinic, Oklahoma City, Oklahoma, 73104, United States"
NCT05923697,Addiction-focused EMDR in Inpatients Who Use Non-opioid Drugs: a Multiple Baseline Study,https://clinicaltrials.gov/study/NCT05923697,RECRUITING,NO,Substance Use Disorders,BEHAVIORAL: AF-EMDR,IrisZorg,Radboud University Medical Center,ALL,"ADULT, OLDER_ADULT",9,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11-06,2024-12-31,"Addiction clinic 'Tiel' IrisZorg, Tiel, Gelderland, 4001 AG, Netherlands"
NCT03444974,Addiction in Adolescence - Pathomechanisms and Treatment Evaluation,https://clinicaltrials.gov/study/NCT03444974,UNKNOWN,NO,Substance Use Disorders|Adolescent Behavior,OTHER: adapted treatment according to the MATRIX-A therapy,Technische Universität Dresden,,ALL,CHILD,450,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-08-01,2021-12-31,"Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital C.G.Carus, Dresden, Saxony, 01307, Germany"
NCT06278922,Evaluating Signs of Safety: A Deaf-Accessible Therapy Toolkit for AUD and Trauma,https://clinicaltrials.gov/study/NCT06278922,RECRUITING,NO,"PTSD|Alcohol; Use, Problem",BEHAVIORAL: Seeking Safety + Signs of Safety toolkit|BEHAVIORAL: Treatment as usual,"University of Massachusetts, Worcester",National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"ADULT, OLDER_ADULT",144,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-12-02,2028-11-30,"University of Massachusetts Medical School, Worcester, Massachusetts, 01655, United States"
NCT01571752,Health Outcomes by Neighborhood - Baltimore,https://clinicaltrials.gov/study/NCT01571752,COMPLETED,NO,Stigma|Activity Space|Social Networks|HIV Status|Drug Abuse/Dependence,,National Institute on Drug Abuse (NIDA),,ALL,"ADULT, OLDER_ADULT",1651,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-07-17,,"National Institute on Drug Abuse, Baltimore, Maryland, 21224, United States"
NCT00965809,Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD),https://clinicaltrials.gov/study/NCT00965809,UNKNOWN,NO,Posttraumatic Stress Disorders,DRUG: Tetrahydrocannabinol|OTHER: Placebo,Hadassah Medical Organization,,ALL,ADULT,70,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-10,2013-04,"Hadassah Medical Organization, Jerusalem, 91120, Israel"
NCT04026594,Mindfulness-based Therapy Versus Relaxation in Prevention of Burnout in Medical Students,https://clinicaltrials.gov/study/NCT04026594,UNKNOWN,NO,Burnout|Emotional Disturbances|Depression,OTHER: Mindfulness Based Stress Reduction|OTHER: Relaxation group,"University Hospital, Montpellier","Centre Hospitalier Universitaire de Nīmes|University Hospital, Paris|University Hospital, Angers|University Hospital, Clermont-Ferrand|University Hospital of Saint-Etienne|University Hospital, Tours|University Hospital, Marseille|University Hospital, Strasbourg|INSERM U1061 Montpellier|University Hospital, Toulouse|Hospices Civils de Lyon",ALL,"ADULT, OLDER_ADULT",612,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2019-10-04,2024-09-04,"CHU Montpellier, Montpellier, 34295, France"
NCT03538197,"Suicide Re Attempts in Young Adults After First Suicide Attempt : Socio-demographic, Clinical and Biological Correlates",https://clinicaltrials.gov/study/NCT03538197,COMPLETED,NO,Suicide,OTHER: clinical and biological correlates,Hôpital le Vinatier,,ALL,ADULT,200,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2018-05-22,2022-06-29,"Centre Hospitalier Le Vinatier, Bron, Aura, 69678 CEDEX, France"
NCT04374084,Moxibustion Plus Cupping in Convalescent Patients With COVID-19,https://clinicaltrials.gov/study/NCT04374084,UNKNOWN,NO,COVID-19|Convalescence,OTHER: Moxibustion plus Cupping,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,Hubei Hospital of Traditional Chinese Medicine|Hubei Provincial Hospital of Integrated Chinese & Western Medicine|Wuhan Hospital of Traditional Chinese Medicine|Wuhan Third Hospital|Huangshi Hospital of Traditional Chinese Medicine|Yichang Hospital of Traditional Chinese Medicine|Ezhou Hospital of Traditional Chinese Medicine|The First Hospital of Hunan University of Chinese Medicine|The Hospital of Jiangxi University of Chinese Medicine,ALL,"ADULT, OLDER_ADULT",60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-05-10,2021-12,"Hubei Province Hospital, Wuhan, Hubei, China"
NCT04400526,Development of a Community-based Network for Drug Abusers,https://clinicaltrials.gov/study/NCT04400526,UNKNOWN,NO,Adolescent,BEHAVIORAL: A video competition|BEHAVIORAL: A training workshop|BEHAVIORAL: A mass promotional campaign,The Hong Kong Polytechnic University,,ALL,"CHILD, ADULT",250,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-09-01,2023-09-30,"Ka Yan HO, Hong Kong, Hong Kong, China, 0000, Hong Kong"
NCT02709954,Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I,https://clinicaltrials.gov/study/NCT02709954,ACTIVE_NOT_RECRUITING,NO,Cannabis|Alcohol Effect|Driving Under the Influence of Alcohol and Other Drugs,DRUG: Active inhaled delta-9-THC|DRUG: Placebo|DRUG: Placebo|DRUG: Active Oral Ethanol,Yale University,,ALL,ADULT,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2016-03,2024-12,"Biological Studies Unit, VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT05063097,Addiction in Intensive Cardiac Care Units,https://clinicaltrials.gov/study/NCT05063097,ACTIVE_NOT_RECRUITING,NO,Intensive Care Unit Syndrome|Drug Abuse|Substance-Related Disorders|Cardiovascular Events|Cardiac Disease,OTHER: urine test|OTHER: Fagerström questionnaire|OTHER: Exhaled carbon monoxide (CO) measurement,Assistance Publique - Hôpitaux de Paris,Fondation Coeur et Recherche,ALL,"ADULT, OLDER_ADULT",1500,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-04-06,2023-04,"CHU Lariboisière, APHP, Cardiology, Paris, Ile De France, 75010, France"
NCT02404688,Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition,https://clinicaltrials.gov/study/NCT02404688,ACTIVE_NOT_RECRUITING,NO,Cannabis|Alcohol Effect|Driving Under the Influence of Alcohol and Other Drugs,DRUG: Active delta-9-THC|DRUG: Placebo|DRUG: Active Ethanol|DRUG: Placebo,Yale University,,ALL,ADULT,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2015-12,2024-12,"Biological Studies Unit, VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT02602418,Neural Correlates of Working Memory Training for HIV Patients,https://clinicaltrials.gov/study/NCT02602418,UNKNOWN,NO,HIV Infection,OTHER: Adaptive WM CogMed Training|OTHER: Nonadaptive WM CogMed Training,University of Hawaii,"National Institute on Drug Abuse (NIDA)|University of Maryland, Baltimore",ALL,"ADULT, OLDER_ADULT",180,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-09,2020-05,"University of Maryland School of Medicine, Baltimore, Maryland, 21201, United States"
NCT06599372,Evaluation of the Efficacy of Transcranial Magnetic Stimulation on Resistant Auditory Hallucinations in Schizophrenia,https://clinicaltrials.gov/study/NCT06599372,RECRUITING,NO,"Schizophrenia|Transcranial Magnetic Stimulation|Hallucinations, Verbal Auditory",OTHER: The rTMS method|OTHER: The cTBS method,Dominique JANUEL,,ALL,"ADULT, OLDER_ADULT",30,OTHER,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-07-11,2027-11,"Etablissement Public de Santé de Ville-Evrard, Neuilly-sur-Marne, 93330, France"
NCT04027075,Mindfulness Mobile App to Reduce Adolescent Substance Use,https://clinicaltrials.gov/study/NCT04027075,COMPLETED,YES,Adolescent Drinking|Adolescent Problem Behavior,BEHAVIORAL: Qlarity app users,"Oregon Research Behavioral Intervention Strategies, Inc.",,ALL,"CHILD, ADULT",257,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-02-10,2023-04-30,"Oregon Research Behavioral Intervention Strategies, Inc., Springfield, Oregon, 97477, United States"
NCT01169922,HIV Prevention With Adolescents: Neurocognitive Deficits and Treatment Response,https://clinicaltrials.gov/study/NCT01169922,WITHDRAWN,NO,Risk Reduction Behavior|Sexual Behavior|Health Behavior|Drinking Behavior|Adolescent Behavior,BEHAVIORAL: SEXUAL RISK REDUCTION + ALCOHOL RISK REDUCTION|BEHAVIORAL: INFORMATION-ONLY SEXUAL RISK REDUCTION,University of New Mexico,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"CHILD, ADULT",0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2007-10,2007-10,"Diversion Meetings (Youth Services Center), Albuquerque, New Mexico, 87107, United States|Youth Reporting Center (Youth Services Center), Albuquerque, New Mexico, 87107, United States|Albuquerque Academy, Albuquerque, New Mexico, 87109, United States|Sandia Preparatory School, Albuquerque, New Mexico, 87113, United States"
NCT00787735,Improving Delivery of Mental Health Services for Patients With Drug Use and Other Behavioral and Emotional Problems,https://clinicaltrials.gov/study/NCT00787735,COMPLETED,NO,Study Focusing on Integrated Versus Non-integrated Psychiatric Care in|Opioid-dependent and Methadone Treated Patients With Other Psychiatric|Diagnoses,BEHAVIORAL: Counseling compliance,Johns Hopkins University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",380,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2004-01,2009-06,"Addiction Treatment Services, Baltimore, Maryland, 21224, United States"
NCT03194295,Activating Community Support for Substance Users,https://clinicaltrials.gov/study/NCT03194295,COMPLETED,NO,Substance Use Disorders,BEHAVIORAL: Community Support Intervention Group|BEHAVIORAL: Substance Use Disorder Educational Group,Johns Hopkins University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",49,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-01-10,2020-03-16,"Johns Hopkins Bayview Medical Center, Baltimore, Maryland, 21224, United States"
NCT05416697,Effectiveness of Cannabinoids on Appetite in Scleroderma,https://clinicaltrials.gov/study/NCT05416697,RECRUITING,NO,Systemic Sclerosis|Malnutrition|Loss of Appetite,DRUG: CBD oil|DRUG: Placebo,Khon Kaen University,,ALL,"ADULT, OLDER_ADULT",30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-11-09,2024-12,"Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand|Scleroderma Clinic, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand"
NCT06036316,Study of Language Disorders and Interactions Between Mnesic Capabilities and Semantic Competencies in Patients With Psychosis,https://clinicaltrials.gov/study/NCT06036316,RECRUITING,NO,Psychosis|Schizophrenia|At-risk Mental State|Language Disorders,"BEHAVIORAL: Language assessment|BEHAVIORAL: TLC - Scale for the Assessment of Thought, Language, and Communication|BEHAVIORAL: MINI - Mini International Neuropsychiatric Interview|COMBINATION_PRODUCT: CAST - Cannabis Abuse Screening Test",Centre Psychothérapique de Nancy,,ALL,"CHILD, ADULT",90,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2024-01-23,2026-01-23,"Centre Psychothérapeutique de Nancy, Laxou, 54520, France"
NCT03157700,Interactive Technology for Media Literacy Drug Prevention in Community Groups,https://clinicaltrials.gov/study/NCT03157700,COMPLETED,NO,Substance Use,BEHAVIORAL: REAL media curriculum,"Real Prevention, LLC",Rutgers University|University of Missouri-Columbia,ALL,"CHILD, ADULT, OLDER_ADULT",642,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: PREVENTION,2018-08-08,2019-08-22,"Rutgers, The State University of New Jersey, New Brunswick, New Jersey, 08901, United States"
NCT02111772,Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic,https://clinicaltrials.gov/study/NCT02111772,COMPLETED,YES,Asthma,BIOLOGICAL: Rhinovirus,University of Virginia,National Institute of Allergy and Infectious Diseases (NIAID),ALL,ADULT,26,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2013-09-01,2017-04-27,"University of Virginia, Charlottesville, Virginia, 22908, United States"
NCT05684939,"Relation Between Substance Use and Pain, in Patients Suffering or Surviving From Cancer and Followed in France",https://clinicaltrials.gov/study/NCT05684939,COMPLETED,NO,Cancer|Pain|Substance Use,BEHAVIORAL: Questionnaire (patient reported outcome),"University Hospital, Clermont-Ferrand",,ALL,"ADULT, OLDER_ADULT",2010,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-01-27,2023-03-20,"CHU Clermont-Ferrand, Clermont-Ferrand, France"
NCT04637815,A Social Network AOD Intervention for Homeless Youth Transitioning to Housing,https://clinicaltrials.gov/study/NCT04637815,COMPLETED,YES,Substance Use,BEHAVIORAL: Motivational Network Intervention|OTHER: Usual Care,RAND,National Institute on Drug Abuse (NIDA),ALL,ADULT,39,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-02-09,2023-09-01,"The Village Family Services, Burbank, California, 90512, United States"
NCT01464554,Brief Substance Use Intervention for Youth in Teen Court,https://clinicaltrials.gov/study/NCT01464554,COMPLETED,NO,Alcohol or Other Drugs Use,BEHAVIORAL: Usual care|BEHAVIORAL: Project Free Talk,RAND,,ALL,"CHILD, ADULT",193,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2009-01,2014-08,"The Council on Drug and Alcohol Abuse, Santa Barbara, California, 93101, United States"
NCT03119415,Enlisting Peer Cooperation and Prosociality in the Service of Substance Use Prevention in Middle School,https://clinicaltrials.gov/study/NCT03119415,COMPLETED,NO,Social Behavior,BEHAVIORAL: Cooperative Learning,Oregon Research Institute,Michigan State University,ALL,"CHILD, ADULT, OLDER_ADULT",2064,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2016-07-01,2020-06-30,"Oregon Research Insititute, Eugene, Oregon, 97403, United States"
NCT04731116,Cannabidiol Treatment for Severe and Critical Coronavirus (COVID-19) Pulmonary Infection,https://clinicaltrials.gov/study/NCT04731116,UNKNOWN,NO,COVID-19,DRUG: Cannabidiol,Rabin Medical Center,,ALL,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-10,2022-04-30,"Rabin Medical Center, Petach Tikva, Israel"
NCT02188797,Substance Use and Sexual Risk Reduction Intervention for Homeless Youth,https://clinicaltrials.gov/study/NCT02188797,COMPLETED,NO,Substance Use|Sexual Risk Behavior,BEHAVIORAL: Group MI risk reduction program,RAND,,ALL,ADULT,200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2014-01,2015-08,"My Friend's Place, Hollywood, California, United States|Safe Place for Youth, Venice Beach, California, 90291, United States"
NCT06542445,The Safety and Efficacy of Terpene-enriched Cannabidiol (CBD) Oil in ADHD,https://clinicaltrials.gov/study/NCT06542445,RECRUITING,NO,Attention Deficit Hyperactivity Disorder (ADHD),DRUG: Oral CBD oil enriched with terpenes|DRUG: Oral Placebo,Bazelet Nehushtan LtD.,,ALL,"CHILD, ADULT",120,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-08-22,2026-09-22,"Shamir Medical Center, Zerifin, Israel"
NCT06593470,Mindfulness-Based Substance Use Prevention (MINDS-UP),https://clinicaltrials.gov/study/NCT06593470,NOT_YET_RECRUITING,NO,Substance Use,BEHAVIORAL: MINDS-UP|BEHAVIORAL: Prevention Plus Wellness|DIAGNOSTIC_TEST: fMRI,New York State Psychiatric Institute,National Institute on Drug Abuse (NIDA),ALL,CHILD,45,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2025-07-01,2027-01-01,
NCT05383989,The UniVenture Program,https://clinicaltrials.gov/study/NCT05383989,UNKNOWN,NO,Anxiety Sensitivity|Hopelessness|Sensation Seeking|Impulsivity,BEHAVIORAL: UniVenture Hopelessness manual|BEHAVIORAL: UniVenture Anxiety Sensitivity manual|BEHAVIORAL: UniVenture Sensation Seeking manual|BEHAVIORAL: UniVenture Impulsivity manual|BEHAVIORAL: Service as usual provided by the University,Sherry Stewart,Dalhousie University|St. Francis Xavier University|Université de Montréal|York University|University of British Columbia|University of Victoria|Canadian Centre on Substance Use and Addiction (CCSA)|Canadian Research Initiative in Substance Misuse|Injury Free Nova Scotia (IFNS)|Mental Health Commission of Canada (MHCC)|Postsecondary Education Partnership - Alcohol Harms (PEP-AH)|Strategy for Patient Orientated Research|SHARP- Students for Healthy Alternatives & Risk Prevention|Nova Scotia Health Authority,ALL,ADULT,1000,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-09-11,2024-07-01,"University of British Columbia-Okanagan campus, Kelowna, British Columbia, Canada|St. Francis Xavier University, Antigonish, Nova Scotia, Canada|Dalhousie University, Halifax, Nova Scotia, Canada|York University, Toronto, Ontario, Canada|Université de Montréal, Montréal, Quebec, Canada"
NCT05344170,Cannabinol Use in Patients With Insomnia Disorder,https://clinicaltrials.gov/study/NCT05344170,COMPLETED,NO,Insomnia Disorder,DRUG: 30 mg Cannabinol (CBN)|DRUG: 300 mg Cannabinol (CBN)|DRUG: Placebo,Woolcock Institute of Medical Research,University of Sydney,ALL,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-08-24,2023-09-05,"Woolcock Institute of Medical Research, Glebe, New South Wales, 2095, Australia"
NCT04532619,A Substance Use Adaptation of Fathering Through Change,https://clinicaltrials.gov/study/NCT04532619,COMPLETED,YES,Parenting|Substance Use,BEHAVIORAL: Fathering Through Change,University of Oregon,,MALE,"ADULT, OLDER_ADULT",41,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-07-01,2021-12-31,"Willamette Family Treatment Center, Eugene, Oregon, 97402, United States"
NCT03793153,A Novel Technique Of Uterine Cooling During Repeated Cesarean Section For Reducing Blood Loss,https://clinicaltrials.gov/study/NCT03793153,COMPLETED,NO,"Cesarean Section Complications|Intrapartum Hemorrhage|Postpartum Hemorrhage|Atony, Uterine",PROCEDURE: Uterine Cooling Technique,Al-Azhar University,,FEMALE,ADULT,99,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2018-12-19,2019-03-25,"OB/GYN Departments, Al-Hussein University Hospital, Al-Azhar University, Cairo, Egypt"
NCT02921841,Digital Star: HIV Prevention for Youth in Mental Health Treatment,https://clinicaltrials.gov/study/NCT02921841,COMPLETED,YES,Human Immunodeficiency Virus|Mental Health,BEHAVIORAL: D*STAR|BEHAVIORAL: D*HEALTH,Rhode Island Hospital,"Virtually Better, Inc.",ALL,"CHILD, ADULT",125,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2016-11,2019-07,"Rhode Island Hospital, Providence, Rhode Island, 02903, United States"
NCT04940741,Efficacy and Safety of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain,https://clinicaltrials.gov/study/NCT04940741,COMPLETED,NO,Chronic Non-specific Low Back Pain,DRUG: VER-01|OTHER: Placebo,Vertanical GmbH,,ALL,"ADULT, OLDER_ADULT",820,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-07-07,2024-03-26,"Emovis GmbH, Berlin, 10629, Germany"
NCT01598207,The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain,https://clinicaltrials.gov/study/NCT01598207,COMPLETED,YES,Chest Pain,DRUG: Marinol|DRUG: Placebo,Yehudith Assouline-Dayan,,ALL,"ADULT, OLDER_ADULT",13,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-02,2014-05,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, 52242, United States"
NCT03394261,Pilot Test of Patient Decision Aid for Opioid Use Disorder,https://clinicaltrials.gov/study/NCT03394261,COMPLETED,NO,Opioid Use Disorder,BEHAVIORAL: Patient Decision Aid,"University of California, Los Angeles",,ALL,"ADULT, OLDER_ADULT",72,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-06-14,2018-12-21,"Tarzana Treatment Centers, Inc., Tarzana, California, 91356, United States"
NCT05516823,Personality and Drug Use,https://clinicaltrials.gov/study/NCT05516823,UNKNOWN,NO,No Conditions Study Focus on Substance Use and Personality,OTHER: Usage of drugs,Psychedelic Data Society,Maastricht University|Quantified Citizen Technologies Inc.,ALL,"ADULT, OLDER_ADULT",1000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-11,2023-11,
NCT01511380,Targeting HIV Risk Behaviors in Juvenile Drug Court-Involved Youth,https://clinicaltrials.gov/study/NCT01511380,COMPLETED,NO,Substance Use|Sexual Risk Behaviors,BEHAVIORAL: Risk Reduction Therapy for Adolescents|BEHAVIORAL: Usual services,Medical University of South Carolina,,ALL,CHILD,120,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-09,2013-06,"Medical University of South Carolina, Charleston, South Carolina, 29401, United States"
NCT03662529,Neurobehavioral Measurement of Substance Users in Outpatient Treatment Setting,https://clinicaltrials.gov/study/NCT03662529,COMPLETED,NO,Cocaine Dependence|Cocaine Use Disorder|Opiate Dependence|Opioid-use Disorder|Cannabis Dependence,BEHAVIORAL: Four-Session Mind Freedom Plan|BEHAVIORAL: Treatment as usual therapy,Hunter Holmes Mcguire Veteran Affairs Medical Center,"VA Mental Illness Research, Education and Clinical Centers",ALL,"ADULT, OLDER_ADULT",35,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-06-05,2018-02-01,"Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, 23249, United States"
NCT05180149,Personality and Drug Use (PDU),https://clinicaltrials.gov/study/NCT05180149,WITHDRAWN,NO,Personality,,Quantified Citizen Technologies Inc.,Maastricht University|Psychedelic Data Society,ALL,"ADULT, OLDER_ADULT",0,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-04,2023-04,
NCT04402099,Study KBP-2020-CPHG Documenting New Cases of Primary Lung Cancer (PLC) Diagnosed in Respiratory Medicine Departments and Lung Cancer Units at General Hospitals From January 1st to December 31st 2020,https://clinicaltrials.gov/study/NCT04402099,RECRUITING,NO,Lung Cancer,,Collège des Pneumologues des Hôpitaux Généraux,,ALL,"ADULT, OLDER_ADULT",10000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-01-01,2026-01-01,"Collège des Pneumologues des Hôpitaux Généraux (CPHG) (General Hospital Pulmonologists College), Paris, 75006, France"
NCT05301439,Use Of Hall Technique In Deciduous Molars Affected By Extensive Caries Lesions,https://clinicaltrials.gov/study/NCT05301439,NOT_YET_RECRUITING,NO,Caries,PROCEDURE: Restoration with Resin|PROCEDURE: Hall Technique|PROCEDURE: Conventional Steel Crown,University of Nove de Julho,Universidade Metropolitana de Santos,ALL,CHILD,90,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-06-20,2024-06-20,
NCT02710331,Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III,https://clinicaltrials.gov/study/NCT02710331,ACTIVE_NOT_RECRUITING,NO,Cannabis|Alcohol Effect|Driving Under the Influence of Alcohol and Other Drugs,DRUG: Active Dronabinol|DRUG: Placebo|DRUG: Placebo|DRUG: Active Ethanol,Yale University,,ALL,ADULT,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2016-03,2024-12,"Biological Studies Unit, VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States"
NCT05274217,Journey of Transformation Curriculum for Native American Adolescents,https://clinicaltrials.gov/study/NCT05274217,TERMINATED,YES,Alcohol Use|Tobacco Use|Substance Use|Sexual Health,BEHAVIORAL: Journey of Transformation-Native Youth Health Leadership Program curriculum,University of Washington,National Institute on Drug Abuse (NIDA),ALL,CHILD,33,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-09-13,2022-09-21,"University of Washington, Seattle, Washington, 98105, United States"
NCT04390347,The Effect of Probiotic Supplementation,https://clinicaltrials.gov/study/NCT04390347,ACTIVE_NOT_RECRUITING,NO,End Stage Renal Disease,DIETARY_SUPPLEMENT: Yakult|DIETARY_SUPPLEMENT: Placebo,University of Leicester,"Loughborough University|Yakult Honsha Co., LTD|Chinese University of Hong Kong|Universitaire Ziekenhuizen KU Leuven|Yakult Honsha European Research Center, ESV",ALL,"ADULT, OLDER_ADULT",50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-20,2024-12-31,"University Hospitals of Leicester, Leicester, Leicestershire, United Kingdom"
NCT00891631,Primary Care iSBIRT to Reduce Serious Teen Health Risks,https://clinicaltrials.gov/study/NCT00891631,WITHDRAWN,NO,Substance-related Disorders|Depression|High-risk Sex,BEHAVIORAL: iSBIRT|BEHAVIORAL: iSBIRT/TE,Boston Children's Hospital,,ALL,"CHILD, ADULT",0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2009-09,2011-09,"Children's Hospital Boston, Boston, Massachusetts, 02115, United States"
NCT02291536,Processing of Salient Emotional Stimuli as a Function of Tetrahydrocannabinol (THC) and Cannabidiol (CBD),https://clinicaltrials.gov/study/NCT02291536,COMPLETED,NO,Healthy Humans,DRUG: tetrahydrocannabinol|DRUG: cannabidiol|OTHER: placebo,"Central Institute of Mental Health, Mannheim",,MALE,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2014-02,2014-12,"Central Institute of Mental Health, Mannheim, 68159, Germany"
NCT04501471,The Rural African American's Health Project,https://clinicaltrials.gov/study/NCT04501471,COMPLETED,NO,SAAF-T|FUEL for Families,BEHAVIORAL: SAAF-T|BEHAVIORAL: Fuel for Families,University of Georgia,,ALL,CHILD,502,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: PREVENTION",2005-09,2010-09,
NCT05824117,Enhancing Educational and Vocational Recovery in Adolescents and Young Adults With Early Psychosis Through Supported Employment and Education.,https://clinicaltrials.gov/study/NCT05824117,RECRUITING,NO,"Persistent Delusional Disorder|Acute and Transient Psychotic Disorder, Unspecified|Schizophrenia|Schizoaffective Disorder|Other Nonorganic Psychotic Disorders|Unspecified Nonorganic Psychosis",OTHER: Individual Placement and Support (IPS),"Charite University, Berlin, Germany",,ALL,"CHILD, ADULT",184,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-10-18,2025-03-31,"Klinik für Sozialpsychiatrie, Zentrum für Psychiatrie Reichenau, Reichenau, Baden Württemberg, Germany|Klinik für Psychiatrie und Psychotherapie, LMU Klinikum, München, Bayern, Germany|Klinik für Psychiatrie, Psychotherapie und Psychosomatik II, Günzburg, Ulm, Bayern, Germany|Klinik für Psychiatrie und Psychotherapie Charité Campus Mitte, Berlin, 10117, Germany|Klinik für Psychiatrie, Psychotherapie und Psychosomatik Vivantes Klinikum am Urban, Berlin, 10967, Germany|Klinik für Psychiatrie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany"
NCT04773535,Validation of the DyCare® Lynx System for Motion Analysis of the Wrist,https://clinicaltrials.gov/study/NCT04773535,COMPLETED,NO,Healthy Volunteers,DEVICE: 3D Motion analysis,University of Zurich,,ALL,"ADULT, OLDER_ADULT",10,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-03-01,2019-12-31,"University Hospital Zurich, Clinic of Reconstructive Surgery, Zurich, ZH, 8091, Switzerland"
NCT05839080,"FoodACT: Investigating the Impact of a School Garden Intervention on Children's Food Literacy, Climate Literacy, School Motivation and Physical Activity",https://clinicaltrials.gov/study/NCT05839080,ACTIVE_NOT_RECRUITING,NO,Physical Inactivity|Literacy|Motivation,BEHAVIORAL: Gardens to Bellis|BEHAVIORAL: No intervention,Center for Clinical Research and Prevention,University of Copenhagen|Haver til Maver,ALL,CHILD,990,NETWORK,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-09-01,2026-12-31,"Center for Clinical Research and Prevention, Frederiksberg, Capital Region, 2000, Denmark"
NCT02205437,Novel Candidate Genes for Treatment Response to Antipsychotics in Schizophrenia,https://clinicaltrials.gov/study/NCT02205437,UNKNOWN,NO,Schizophrenia,,Fundación Marques de Valdecilla,Centro de Investigación Biomédica en Red de Salud Mental|Instituto de Investigación Marqués de Valdecilla,ALL,"CHILD, ADULT",200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-01,2020-12,"University Hospital Marques de Valdecilla, Santander, Cantabria, 39008, Spain"
NCT05870098,Meatal Swab Yourself With Testing for Infections Collectively,https://clinicaltrials.gov/study/NCT05870098,RECRUITING,NO,Chlamydia|Gonorrhea,DIAGNOSTIC_TEST: All participants,The Leeds Teaching Hospitals NHS Trust,,MALE,"ADULT, OLDER_ADULT",1250,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-07-18,2024-08-30,"Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, LS1 3EX, United Kingdom"
NCT02094599,A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users,https://clinicaltrials.gov/study/NCT02094599,COMPLETED,NO,"Drug Abuse, Medication",DRUG: Dronabinol 10 mg|DRUG: Dronabinol 30 mg|DRUG: Placebo,INSYS Therapeutics Inc,,ALL,ADULT,43,INDUSTRY,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: ",2014-02,2014-05,"INC Research Toronto, Inc., Toronto, Ontario, M5V 2T3, Canada"
NCT01430624,Prevention of Post Sexual Assault Stress,https://clinicaltrials.gov/study/NCT01430624,COMPLETED,YES,Drug Use|Drug Abuse|Posttraumatic Stress Disorder,BEHAVIORAL: PPRS|BEHAVIORAL: PIRI,Medical University of South Carolina,National Institute on Drug Abuse (NIDA),FEMALE,"CHILD, ADULT, OLDER_ADULT",245,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2009-05,2013-12,"Hennepin County Medical Center, Minneapolis, Minnesota, 55404, United States|North Memorial Medical Center, Minneapolis, Minnesota, 55422, United States"
NCT05442294,"""Juego de LLaves"": Study Protocol of a Universal School-based Drug Use Prevention Program (PSIDUP)",https://clinicaltrials.gov/study/NCT05442294,NOT_YET_RECRUITING,NO,"Behavior, Addictive|Adolescent - Emotional Problem|Alcohol Abuse|Smoking Behaviors|Adolescent Behavior|Psychological",BEHAVIORAL: Juego de Llaves,Susana Al-Halabí,United Nations Office on Drugs and Crime (UNODC)|Asociación Proyecto Hombre,ALL,CHILD,2500,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2022-09-01,2025-12-30,"Grupo de Conductas Adictivas, University of Oviedo, Oviedo, Asturias, 33006, Spain"
NCT05843474,Effectiveness of Take it Personal!,https://clinicaltrials.gov/study/NCT05843474,RECRUITING,NO,"Alcohol Use|Drug Use|Mild Intellectual Disability, IQ 50-70|Borderline Intellectual Disabilities (Intelligence Quotient 70-85)|Personality|Adolescent Behavior",BEHAVIORAL: Take it Personal!,Behavioural Science Institute,Pluryn,ALL,"CHILD, ADULT",15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-08-01,2024-08-01,"Behavioural Science Institute, Radboud University, Nijmegen, 6525 GD, Netherlands"
NCT05579717,Examining EAL for PTSD,https://clinicaltrials.gov/study/NCT05579717,RECRUITING,NO,Posttraumatic Stress Disorder,BEHAVIORAL: Equine Assisted Learning,McMaster University,University of Saskatchewan|University of Regina,ALL,"ADULT, OLDER_ADULT",80,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2022-03-01,2024-11-30,"McMaster University, Hamilton, Ontario, L9C0E3, Canada"
NCT01439334,"Multiple Behavior Screening, Brief Intervention and Referral to Treatment (SBIRT) Model of Drug Abuse in Primary Care",https://clinicaltrials.gov/study/NCT01439334,WITHDRAWN,NO,Drug Abuse,"BEHAVIORAL: MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Brief|BEHAVIORAL: MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Extended Length|BEHAVIORAL: MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Control",University of Florida,National Institute on Drug Abuse (NIDA),ALL,ADULT,0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: PREVENTION,2009-12,2011-07,"Addictive & Health Behaviors Research Institute, University of Florida, Jacksonville, Florida, 32256, United States"
NCT04050176,Use of Blinded Tapering for Hypnotic Discontinuation,https://clinicaltrials.gov/study/NCT04050176,ACTIVE_NOT_RECRUITING,NO,Hypnotic Dependence Among Those With Insomnia,BEHAVIORAL: Hypnotic Medication Open-Label Taper|BEHAVIORAL: Hypnotic Medication Blinded Taper,National Jewish Health,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",260,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-12-16,2026-06,"National Jewish Health, Denver, Colorado, 80206, United States"
NCT02780245,Role of Tranexamic Acid Versus Uterine Cooling at Caesarean Section,https://clinicaltrials.gov/study/NCT02780245,COMPLETED,NO,Hemorrhage of Cesarean Section and/or Perineal Wound|Postpartum Hemorrhage|Uterine Atony,DRUG: Tranexamic Acid|PROCEDURE: Intraoperative Uterine Cooling,Talkha Central Hospital,,FEMALE,ADULT,100,OTHER_GOV,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2016-06,2016-09,"Talkha Central Hospital, Mansoura, Al-Dakahliya, 35511, Egypt"
NCT02324725,Biomarkers of Injectable Extended Release Naltrexone Treatment,https://clinicaltrials.gov/study/NCT02324725,COMPLETED,NO,Heroin Dependence|Opioid Dependence,DRUG: Naltrexone,University of Pennsylvania,,ALL,ADULT,32,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-10,2021-12,"Center for the Studies of Addiction, Philadelphia, Pennsylvania, 19104, United States"
NCT00221975,Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling,https://clinicaltrials.gov/study/NCT00221975,COMPLETED,NO,Bipolar Disorder,DRUG: Divalproex|DRUG: Lamotrigine|DRUG: Lithium,University Hospitals Cleveland Medical Center,,ALL,"CHILD, ADULT, OLDER_ADULT",98,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2002-07,2007-12,"University Hospitals of Cleveland, Cleveland, Ohio, 44106, United States"
NCT03813095,Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction,https://clinicaltrials.gov/study/NCT03813095,NOT_YET_RECRUITING,NO,Addiction|Opioid Dependence|Opioid Withdrawal,DRUG: APH-1501|DRUG: Placebo,Aphios,,ALL,ADULT,32,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-10,2025-12,
NCT03226132,Improving Sleep to Reduce Risk for Substance Use Disorder,https://clinicaltrials.gov/study/NCT03226132,COMPLETED,NO,Substance Use Disorders|Insomnia|Posttraumatic Stress Disorder,BEHAVIORAL: Brief Behavioral Therapy for Insomnia|BEHAVIORAL: Repeated Contact,Florida State University,National Institute on Drug Abuse (NIDA),ALL,ADULT,73,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2017-08-20,2018-09-01,"Anxiety and Behavioral Health Clinic, Tallahassee, Florida, 32306, United States"
NCT04908410,"The Norwegian Addiction, Pain and Trauma Study",https://clinicaltrials.gov/study/NCT04908410,ACTIVE_NOT_RECRUITING,NO,Chronic Pain|Post-traumatic Stress Disorder|Substance Use Disorders,,"University Hospital, Akershus",Oslo University Hospital|Norwegian Center for Violence and Traumatic Stress Studies|The Hospital of Vestfold|Sykehuset Telemark,ALL,"ADULT, OLDER_ADULT",1650,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-03-23,2030-12-31,"Akershus University Hospital, Lørenskog, 0192, Norway|Oslo University Hospital, Oslo, Norway|Telemark Hospital, Skien, Norway|The Hospital in Vestfold, Tønsberg, Norway"
NCT04198974,The Canadian Underage Substance Use Prevention Trial,https://clinicaltrials.gov/study/NCT04198974,UNKNOWN,NO,Substance Use Disorders|Adolescent Behavior|Adolescent Development,BEHAVIORAL: PreVenture Training (PTtT)|BEHAVIORAL: PreVenture Training+Implementation Facilitation,St. Justine's Hospital,University of British Columbia|Center for Addiction and Mental Health|Dalhousie University|Canadian Institutes of Health Research (CIHR),ALL,CHILD,12500,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2019-12-01,2022-06,"University of British Columbia Okanagan Campus, Kelowna, British Columbia, Canada|Dalhousie University, Halifax, Nova Scotia, Canada|Center for Mental Health and Addicitions, Toronto, Ontario, Canada|CHU Sainte-Justine Research Center, Montreal, Quebec, H3T 1C5, Canada"
NCT06678672,Contingency Management for Veteran Smokers Undergoing Major Elective Surgery,https://clinicaltrials.gov/study/NCT06678672,NOT_YET_RECRUITING,NO,Tobacco Use Disorder|Substance Use Disorder (SUD),BEHAVIORAL: Contingency Management (CM)|BEHAVIORAL: Treatment as Usual (TAU),"University of California, San Francisco",Tobacco Related Disease Research Program,ALL,"ADULT, OLDER_ADULT",36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2024-12-01,2026-07-01,"San Francisco VA Health Care System, San Francisco, California, 94121, United States"
NCT00843635,Tadalafil in Treating Patients Undergoing Surgery for Cancer of the Oral Cavity or Oropharynx,https://clinicaltrials.gov/study/NCT00843635,COMPLETED,YES,Head and Neck Cancer,DRUG: Tadalafil|OTHER: Placebo,Donald T. Weed,,ALL,"ADULT, OLDER_ADULT",35,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-09,2015-04,"University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, 33136, United States"
NCT03568552,Patient Decision Aid for Opioid Use Disorder,https://clinicaltrials.gov/study/NCT03568552,RECRUITING,NO,Opioid Use Disorder,BEHAVIORAL: Patient Decision Aid,"University of California, Los Angeles",,ALL,"ADULT, OLDER_ADULT",5400,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-03,2024-08,"UCLA Integrated Substance Abuse Programs, Los Angeles, California, 90049, United States"
NCT05606601,An Online Intervention Addressing Mental Health and Substance Use in University Students,https://clinicaltrials.gov/study/NCT05606601,COMPLETED,NO,Anxiety|Depression|Alcohol Use|Substance Use,BEHAVIORAL: Minder,University of British Columbia,,ALL,"CHILD, ADULT, OLDER_ADULT",1489,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2022-09-28,2023-07-21,"University of British Columbia, Vancouver, British Columbia, V6T 2A1, Canada"
NCT06691386,Nicotine Pharmacokinetics and Subjective Effects of Oral Nicotine Products Relative to Smokeless Tobacco in Adult Users,https://clinicaltrials.gov/study/NCT06691386,COMPLETED,NO,Tobacco Use,OTHER: Test Product A|OTHER: Test Product B|OTHER: Test Product C|OTHER: Test Product D|OTHER: Test Product E|OTHER: Reference Product F: Subjects' OBMST,Altria Client Services LLC,Celerion,ALL,"ADULT, OLDER_ADULT",64,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2023-02-06,2024-02-08,"Pillar Clinical Research LLC, Bentonville, Arkansas, 72712, United States|QPS Bio-Kinetic, Springfield, Missouri, 65802, United States"
NCT06581978,Early Warning and Intervention Mechanism of Foot Health Risk in Children and Adolescents,https://clinicaltrials.gov/study/NCT06581978,RECRUITING,NO,Flexible Flatfoot,PROCEDURE: Whole-Body Vibration Intervention|PROCEDURE: Exercise Intervention Group,"Nanfang Hospital, Southern Medical University",,ALL,"CHILD, ADULT",120,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2024-01-01,2027-12-31,"Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China"
NCT04587115,Reducing the Abuse Liability of Prescription Opioids,https://clinicaltrials.gov/study/NCT04587115,COMPLETED,NO,Addiction,DRUG: Risperidone|DRUG: Ziprasidone|DRUG: Oxycodone,The University of Texas Health Science Center at San Antonio,,ALL,"ADULT, OLDER_ADULT",15,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-06-16,2020-01-01,"Westgate Pain Clinic, San Antonio, Texas, 78229, United States"
NCT02628964,Electronic Cigarettes (E-cigarettes) as a Harm Reduction Strategy,https://clinicaltrials.gov/study/NCT02628964,COMPLETED,YES,Tobacco Use Disorder|Smoking,DEVICE: e-cigarettes,NYU Langone Health,,ALL,ADULT,100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2015-05,2018-03-26,"New York University School of Medicine, New York, New York, 10016, United States"
NCT04145791,Ice Application for Postoperative Pain,https://clinicaltrials.gov/study/NCT04145791,COMPLETED,NO,Postoperative Pain,OTHER: Ice,University of Texas Southwestern Medical Center,,FEMALE,"ADULT, OLDER_ADULT",74,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2019-02-15,2021-02-03,"Parkland Health and Hospital System, Dallas, Texas, 75235, United States|Clements University Hospital, Dallas, Texas, 75390, United States"
NCT05731713,Journey of Transformation Curriculum for Native American Youth,https://clinicaltrials.gov/study/NCT05731713,RECRUITING,NO,Alcohol Drinking|Tobacco Use|Substance Use|Sexual Behavior,BEHAVIORAL: Journey of Transformation-Native Youth Health Leadership Program curriculum,University of Washington,National Institute on Drug Abuse (NIDA),ALL,CHILD,255,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-12-11,2027-02-28,"University of Washington, Seattle, Washington, 98105, United States"
NCT05867849,Cannabidiol for Bipolar Depression (CBD-BD),https://clinicaltrials.gov/study/NCT05867849,RECRUITING,NO,Bipolar Disorder,DRUG: Cannabidiol|OTHER: Placebo,University of British Columbia,,ALL,"ADULT, OLDER_ADULT",360,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-10-15,2030-12,"UBC Mood Disorders Centre, Vancouver, British Columbia, V6T 1Z3, Canada|St. Joseph's Healthcare, Hamilton, Ontario, L8N 3K7, Canada|Providence Care Hospital, Kingston, Ontario, K7L 4X3, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, M6J1H4, Canada|Douglas Mental Health University Institute, Montreal, Quebec, H4H 1R3, Canada"
NCT03769896,Nabilone for Non-motor Symptoms in Parkinson's Disease,https://clinicaltrials.gov/study/NCT03769896,COMPLETED,YES,Parkinson Disease,DRUG: Nabilone 0.25 mg|DRUG: Placebo,Medical University Innsbruck,,ALL,"ADULT, OLDER_ADULT",48,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-10-03,2019-07-15,"Department of Neurology - Medical University Innsbruck, Innsbruck, Tyrol, 6020, Austria"
NCT00812851,Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS),https://clinicaltrials.gov/study/NCT00812851,COMPLETED,NO,Cramps|Amyotrophic Lateral Sclerosis,DRUG: Dronabinol,Cantonal Hospital of St. Gallen,ALS Association,ALL,"ADULT, OLDER_ADULT",24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-04,2008-04,"Kantonsspital St.Gallen, St.Gallen, 9007, Switzerland"
NCT04839978,Community Trial in the Cherokee Nation,https://clinicaltrials.gov/study/NCT04839978,ACTIVE_NOT_RECRUITING,NO,Opioid Abuse,BEHAVIORAL: Connect Program|BEHAVIORAL: Communities Mobilizing for Change and Action (CMCA),Emory University,National Institute on Drug Abuse (NIDA),ALL,CHILD,1152,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-09-29,2025-08,"Cherokee Nation Reservation, Tahlequah, Oklahoma, 74464, United States"
NCT01969305,Youth Drug Abuse Prevention in Kazakhstan,https://clinicaltrials.gov/study/NCT01969305,COMPLETED,NO,Drug Use,BEHAVIORAL: Kazakhstani Family Together|BEHAVIORAL: Usual Care Alone,University of Chicago,National Institute on Drug Abuse (NIDA)|Columbia University,ALL,CHILD,181,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2014-01,2016-05,"Columbia University Global Heath Research Center of Central Asia, Almaty, Kazakhstan"
NCT05731687,Bifurcation PCI With a Hybrid Strategy With Drug Eluting Balloons Versus a Stepwise Provisional Two-stent Strategy,https://clinicaltrials.gov/study/NCT05731687,RECRUITING,NO,Coronary Artery Disease|Coronary Bifurcation Lesion,OTHER: Hybrid DEB approach with drug-eluting balloon|OTHER: Two-stent strategy,Cathreine BV,Catharina Ziekenhuis Eindhoven|Albert Schweitzer Hospital|Onze Lieve Vrouwe Gasthuis|Maasstad Hospital|The Elisabeth-TweeSteden Hospital|St. Antonius Hospital|Medical Centre Leeuwarden|Meander Medical Center|VieCuri Medical Centre|Haga Hospital|Rijnstate Hospital|Jeroen Bosch Ziekenhuis,ALL,"ADULT, OLDER_ADULT",500,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-03-21,2030-03,"Catharina Hospital, Eindhoven, North- Brabant, 5623 EJ, Netherlands"
NCT04659278,Endourage Complete Spectrum Oral Mucosal Drops (OMD) in Adults Desiring a Reduction in Ethanol Use,https://clinicaltrials.gov/study/NCT04659278,WITHDRAWN,NO,"Alcohol Drinking|Alcohol Use, Unspecified|Alcohol Abstinence|Alcohol-Related Disorders","DIETARY_SUPPLEMENT: Endourage 1200 mg OMD ™ Oral Mucosal Drops|DIETARY_SUPPLEMENT: Isolate|OTHER: Placebo|DIETARY_SUPPLEMENT: Peppermint Oil, masking flavor","Endourage, LLC",,ALL,"ADULT, OLDER_ADULT",0,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-09,2022-01-31,"Thomas P Young, PhD, NP, Novato, California, 94947, United States"
NCT05109923,Onnit Labs New Mood Supplementation in Healthy College Students,https://clinicaltrials.gov/study/NCT05109923,COMPLETED,NO,Mental Health Wellness 1,DIETARY_SUPPLEMENT: Multi-Ingredient Herbal Supplement|DIETARY_SUPPLEMENT: Placebo Supplement,University of Idaho,,ALL,ADULT,56,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2018-09-10,2019-08-02,"University of Idaho, Moscow, Idaho, 83844, United States"
NCT05017272,Technology for MAT in Primary Care - Phase 2,https://clinicaltrials.gov/study/NCT05017272,ENROLLING_BY_INVITATION,NO,Opioid-use Disorder,OTHER: Opioid Addiction Recovery Support Software Platform,"Q2i, LLC","University of California, Los Angeles|National Institute on Drug Abuse (NIDA)",ALL,"ADULT, OLDER_ADULT",200,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-05-01,2023-08-31,"UCLA Center for Behavioral and Addiction Medicine, Los Angeles, California, 90024, United States"
NCT05490589,Evaluation of the Implementation of a Parenting Program in Parents With Children Aged 4 to 12 Years and One Parent With an Alcohol Use Disorders,https://clinicaltrials.gov/study/NCT05490589,RECRUITING,NO,"Addiction, Alcohol",OTHER: EQUIPE Program,"University Hospital, Brest",,ALL,"ADULT, OLDER_ADULT",90,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2024-02-22,2027-08-22,"CHU de Brest, Brest, 29609, France"
NCT06455397,Building Emotional Awareness and Mental Health (BEAM) 2024-2027,https://clinicaltrials.gov/study/NCT06455397,RECRUITING,NO,"Depression, Anxiety|Anger|Parenting|Stress, Psychological|Parent-Child Relations|Child Development",BEHAVIORAL: The Building Emotional Awareness and Mental Health (BEAM) Program,Leslie E. Roos,"Canadian Institutes of Health Research (CIHR)|Manitoba Centre for Health Policy|George & Fay Yee Centre for Healthcare Innovation|Children's Hospital Research Institute of Manitoba|Family Dynamics, Manitoba, Canada",ALL,"ADULT, OLDER_ADULT",400,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-03-11,2027-06,"University of Manitoba - Department of Psychology & Pediatrics, Winnipeg, Manitoba, R3T 2N2, Canada"
NCT06665308,"Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)",https://clinicaltrials.gov/study/NCT06665308,RECRUITING,NO,Chronic Immune Thrombocytopenia|Primary Immune Thrombocytopenia|Adult Immune Thrombocytopenia,OTHER: No intervention,Sanofi,,ALL,"ADULT, OLDER_ADULT",110,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2025-01-13,2025-05-23,"University of Washington-Fred Hutchinson Cancer Center_Site Number: 8400003, Seattle, Washington, 98109, United States|Imperial College Healthcare NHS Trust,Hammersmith Hospital, Gary Weston Centre_Site Number: 8260001, London, City Of London, W120 HS, United Kingdom"
NCT04878627,Role of CBD in Regulating Meal Time Anxiety in Anorexia Nervosa,https://clinicaltrials.gov/study/NCT04878627,ACTIVE_NOT_RECRUITING,NO,Anorexia Nervosa,DRUG: Cannabidiol|DRUG: Placebo,"University of California, San Diego",,FEMALE,ADULT,40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-01-20,2025-06,"University of California San Diego, San Diego, California, 92121, United States"
NCT05464160,Focal Muscular Vibration in Patients With Severe Acquired Brain Injury,https://clinicaltrials.gov/study/NCT05464160,RECRUITING,NO,"Brain Injuries|Spasticity, Muscle","DEVICE: Focal Muscular Vibration using the EVM EVO medical device (Endomedica, Italy)|OTHER: Conventional Rehabilitation",Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,ALL,"ADULT, OLDER_ADULT",24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2021-10-15,2024-10-31,"UOC Neuroriabilitazione ad Alta Intensità, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, 00168, Italy"
NCT03256357,Constraint-Induced Movement Therapy and Action Observation Training in Children With Unilateral Cerebral Palsy,https://clinicaltrials.gov/study/NCT03256357,COMPLETED,NO,Cerebral Palsy,BEHAVIORAL: Constraint-induced movement therapy|BEHAVIORAL: Action observation training|BEHAVIORAL: Placebo observation training,KU Leuven,"ETH Zurich (Switzerland)|University of Pisa, Italy",ALL,CHILD,44,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-01-01,2018-02-28,"KU Leuven, Leuven, 3000, Belgium"
NCT01186315,"Post-traumatic Stress Disorder (PTSD), Addiction, and Virtual Reality",https://clinicaltrials.gov/study/NCT01186315,COMPLETED,NO,Substance Use Disorders|Posttraumatic Stress Disorder,BEHAVIORAL: Prolonged Exposure Therapy|BEHAVIORAL: Prolonged Exposure therapy + VR/ER,Duke University,United States Department of Defense|Telemedicine & Advanced Technology Research Center,ALL,"ADULT, OLDER_ADULT",38,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2008-12,2013-12,"Duke University Medical Center, Durham, North Carolina, 27710, United States"
NCT06538389,High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer,https://clinicaltrials.gov/study/NCT06538389,RECRUITING,NO,Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Breast Adenocarcinoma|Breast Ductal Carcinoma In Situ|Estrogen Receptor-Positive Breast Carcinoma|Progesterone Receptor-Positive Breast Carcinoma,PROCEDURE: Biospecimen Collection|DRUG: BRC-001|DRUG: Placebo Administration|OTHER: Questionnaire Administration,City of Hope Medical Center,National Cancer Institute (NCI)|Biopharmaceutical Research Company,FEMALE,"ADULT, OLDER_ADULT",36,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2025-08-15,2026-08-15,"City of Hope Medical Center, Duarte, California, 91010, United States"
NCT04405414,EffectS of CAnnabidiol in Patients: Evaluation,https://clinicaltrials.gov/study/NCT04405414,COMPLETED,NO,Substance-Related Disorders,OTHER: Form,Nantes University Hospital,,ALL,"ADULT, OLDER_ADULT",746,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-05-06,2021-07-26,"Nantes University Hospital, Nantes, Loire-Atlantique, 44093, France"
NCT05384223,Evaluation of RRFT for Co-occurring SUD and PTSD Among Teens,https://clinicaltrials.gov/study/NCT05384223,RECRUITING,NO,Substance Use Disorders|PTSD,BEHAVIORAL: RRFT (Risk Reduction through Family Therapy)|BEHAVIORAL: ENCOMPASS (Integrated Treatment for Adolescents and Young Adults),Medical University of South Carolina,"University of Colorado, Denver|Indiana University School of Medicine|Oregon Social Learning Center",ALL,"CHILD, ADULT",212,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-10-26,2026-06,"CU Medicine Psychiatry - Outpatient Clinic, Aurora, Colorado, 80045, United States|ARTS - Synergy Outpatient Services, Denver, Colorado, 80236, United States"
NCT05764213,Improving Maternal Mental Health & SUD Screening and Treatment,https://clinicaltrials.gov/study/NCT05764213,ENROLLING_BY_INVITATION,NO,Mental Health Issue|Substance Use Disorders|Postpartum Depression|Postpartum Anxiety,BEHAVIORAL: Listening to Women & Pregnant and Postpartum People,Medical University of South Carolina,Patient-Centered Outcomes Research Institute,FEMALE,ADULT,9444,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2023-04-03,2027-10-01,"Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT06484647,Comparing T-stenting And Minimal Protrusion With External Minicrush for Treatment of Complex Coronary Bifurcation,https://clinicaltrials.gov/study/NCT06484647,RECRUITING,NO,Coronary Artery Disease|Ischemic Heart Disease|Chronic Coronary Syndrome|Acute Coronary Syndrome,PROCEDURE: Percutaneous Coronary Intervention,San Luigi Gonzaga Hospital,,ALL,"ADULT, OLDER_ADULT",382,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-06-01,2024-10-01,"Rivoli Hospital, Rivoli, Turin, 10098, Italy"
NCT00218426,Addiction Treatment in Russia: Oral vs. Naltrexone Implant,https://clinicaltrials.gov/study/NCT00218426,COMPLETED,YES,Heroin Dependence|Opioid-Related Disorders,DRUG: naltrexone implant|DRUG: oral naltrexone|DRUG: oral placebo naltrexone|DRUG: placebo implant,University of Pennsylvania,National Institute on Drug Abuse (NIDA)|St. Petersburg State Pavlov Medical University,ALL,ADULT,306,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-07,2010-11-04,"University of Pennsylvania, Philadelphia, Pennsylvania, 19104 6178, United States|Pavlov Medical University, St. Petersburg, 197022, Russian Federation"
NCT04465318,Electronic Cigarettes as a Harm Reduction Strategy Among Patients With COPD,https://clinicaltrials.gov/study/NCT04465318,COMPLETED,NO,COPD,OTHER: E-cigarette (EC)|OTHER: Nicotine Replacement Therapy (NRT)|BEHAVIORAL: Smoking Harm Reduction Counseling Sessions,NYU Langone Health,,ALL,"ADULT, OLDER_ADULT",146,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-11-09,2023-03-09,"NYU Langone Health, New York, New York, 10016, United States"
NCT05699252,Matching Adults to Treatments for Chronic Pain (MATCH) Study,https://clinicaltrials.gov/study/NCT05699252,RECRUITING,NO,Chronic Pain,BEHAVIORAL: Cognitive Behavioral Therapy (CBT)|BEHAVIORAL: Hypnotic Cognitive Therapy (HYP-CT)|BEHAVIORAL: Mindfulness-Based Cognitive Therapy (MBCT),University of Washington,National Center for Complementary and Integrative Health (NCCIH)|VA Puget Sound Health Care System,ALL,"ADULT, OLDER_ADULT",330,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2023-04-26,2026-03-31,"University of Washington, Ninth and Jefferson Building, Seattle, Washington, 98104, United States|VA Puget Sound Health Care System, Seattle Division, Seattle, Washington, 98108, United States|VA Puget Sound Health Care System, American Lake, Tacoma, Washington, 98493, United States"
NCT03276819,A Clinical and Biological Umbrella Protocol for Smoker or Non-smoker Patients With OPML or HNSCC,https://clinicaltrials.gov/study/NCT03276819,TERMINATED,NO,Premalignant Lesion|Head and Neck Squamous Cell Carcinoma (HNSCC),PROCEDURE: Samples collection|BEHAVIORAL: Psychological and Sociological evaluation|BEHAVIORAL: Intensive and sustained smoking cessation program|BEHAVIORAL: Tobacco and alcohol status follow-up,Centre Leon Berard,,ALL,"ADULT, OLDER_ADULT",53,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2018-02-01,2020-07-31,"Centre Hospitalier Annecy genevois, Annecy, 74374, France|CHU de Clermont-Ferrand, Clermont-Ferrand, 63003, France|CHU de Grenoble, Grenoble, 38043, France|Centre Léon Bérard, Lyon, 69373, France|CHU de Montpellier, Hôpital Gui De Chauliac, Montpellier, 34295, France|AP-HP, Hôpital de la Pitié Salpêtrière, Paris, 75013, France|Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, 69495, France|CHU de Nancy, Vandœuvre-lès-Nancy, 54511, France|Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, 54511, France|Institut Gustave Roussy, Villejuif, 94805, France"
NCT02119949,Working Memory Training for Substance Dependent Individuals,https://clinicaltrials.gov/study/NCT02119949,COMPLETED,NO,Substance Dependency|Addiction|Anxiety|Depression,BEHAVIORAL: Working memory training|BEHAVIORAL: Placebo training,Erasmus Medical Center,,ALL,"CHILD, ADULT, OLDER_ADULT",180,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-05,2014-06,"Bouman Clinic, Rotterdam, Zuid Holland, 3084 LD, Netherlands"
NCT01285856,Hair Testing to Assess Consumption of Illicit Psychotropic Agents and Alcohol by Patients Treated With High-dose Buprenorphine and Methadone. Search for a Pharmacogenetic Contribution to Low Efficacy of Substitution Medications,https://clinicaltrials.gov/study/NCT01285856,UNKNOWN,NO,Substance Abuse,OTHER: hair and saliva samples,Assistance Publique Hopitaux De Marseille,,ALL,"ADULT, OLDER_ADULT",220,OTHER,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2010-08,2015-08,"APHM, Marseille, 13005, France"
NCT02535858,Virtual Environment With Biofeedback to Promote Awareness of Relapse Risk Among Chemically Dependent Individuals,https://clinicaltrials.gov/study/NCT02535858,COMPLETED,NO,Anxiety,DEVICE: Heart and respiratory rate and VE|DEVICE: Heart and respiratory rate and video,University of Mogi das Cruzes,,MALE,ADULT,80,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2007-11,2008-05,"University of Mogi das Cruzes, Mogi das Cruzes, São Paulo, 08780911, Brazil"
NCT02872454,Psychotherapeutic Text Messaging for Depression Pilot Study,https://clinicaltrials.gov/study/NCT02872454,COMPLETED,NO,Major Depression,BEHAVIORAL: Text Messaging,University of Michigan,,ALL,"ADULT, OLDER_ADULT",190,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2015-04,2016-04,"University of Michigan Inpatient Psychiatry Unit, Ann Arbor, Michigan, 48109, United States"
NCT03119129,The Development and Evaluation of the Ho'Ouna Pono Drug Prevention Curriculum,https://clinicaltrials.gov/study/NCT03119129,UNKNOWN,NO,Substance-Related Disorders,BEHAVIORAL: Ho'ouna Pono Drug Prevention Curriculum,Hawaii Pacific University,University of Hawaii|Arizona State University,ALL,CHILD,486,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2016-09-01,2018-04-15,
NCT01639274,Human Immunodeficiency Virus (HIV)and Chronic Obstructive Pulmonary Disease (COPD),https://clinicaltrials.gov/study/NCT01639274,COMPLETED,NO,Chronic Obstructive Pulmonary Disease,OTHER: COPD prevalence,Centre Hospitalier Universitaire de Nice,,ALL,"ADULT, OLDER_ADULT",639,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2012-01,2013-11,"Service d'Infectiologie - Hôpital de l'Archet, Nice, 06000, France"
NCT01713517,Impact of Insecticide Resistance on Vector Control,https://clinicaltrials.gov/study/NCT01713517,UNKNOWN,NO,"Malaria, Falciparum",OTHER: Indoor residual insecticide spraying (IRS)|DEVICE: Long Lasting Insecticidal Nets (LLIN),London School of Hygiene and Tropical Medicine,"Federal Ministry of Health, Sudan|World Health Organization|Liverpool School of Tropical Medicine",ALL,CHILD,28000,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2011-04,2014-10,"Malaria Control Programme, Gedarif, Gedarif State, Sudan|Malaria Control Programme, Wad Medani, Gezira State, Sudan|Malaria Control Programme, Kassala, Kassala State, Sudan"
NCT02088060,A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients,https://clinicaltrials.gov/study/NCT02088060,TERMINATED,NO,Schizophrenia,DRUG: Cannabidiol|DRUG: Olanzapine|DRUG: Placebo Cannabidiol|DRUG: Placebo Olanzapine,"Central Institute of Mental Health, Mannheim","Martin-Luther-Universität Halle-Wittenberg|Heidelberg University|Technical University of Munich|Ludwig-Maximilians - University of Munich|Glostrup University Hospital, Copenhagen",ALL,"ADULT, OLDER_ADULT",150,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-12-08,2024-09-16,"Psychiatric Centre Glostrup, Glostrup, 2600, Denmark|Department of General Psychiatry, Heidelberg University, Heidelberg, BW, 68115, Germany|Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, BW, 68159, Germany|Dept. of Psychiatry and Psychotherapy, Ludwig-Maximillians-University Munich, Munich, BY, 80336, Germany|Dept. of Psychiatry and Psychotherapy, Technical University Munich, Munich, BY, 81675, Germany|Dept. of Psychiatry and Psychotherapy, Martin-Luther-University, Halle/Wittenberg, Halle, ST, 06112, Germany"
NCT04550715,Prevention Interventions for Opioid Misuse,https://clinicaltrials.gov/study/NCT04550715,ACTIVE_NOT_RECRUITING,NO,Opioid Use,BEHAVIORAL: Brief intervention (BI)|BEHAVIORAL: Portal|BEHAVIORAL: Enhanced Usual Care (EUC),University of Michigan,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",1155,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: PREVENTION,2021-01-04,2025-03-30,"University of Michigan, Ann Arbor, Michigan, 48109, United States"
NCT06787118,"Randomized, Double-blind, Placebo-controlled, 2x2 Cross Over Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer",https://clinicaltrials.gov/study/NCT06787118,NOT_YET_RECRUITING,NO,Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III|HR+ Breast Cancer|AI-related Musculoskeletal Pain,DRUG: CBD oil|DRUG: Placebo,"Gustave Roussy, Cancer Campus, Grand Paris",,FEMALE,"ADULT, OLDER_ADULT",130,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2025-02,2027-05,"Gustave Roussy, Villejuif, 94805, France"
NCT05306626,Building Emotion Awareness and Mental Health (BEAM): Mothers of Toddlers,https://clinicaltrials.gov/study/NCT05306626,COMPLETED,NO,"Depression, Anxiety",BEHAVIORAL: Building Emotion Awareness and Mental Health (BEAM),University of Manitoba,University of Calgary|Tactica Interactive|Centre for Healthcare Innovation|Research Manitoba,ALL,"ADULT, OLDER_ADULT",140,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-01,2022-11-01,"The University of Manitoba - Department of Psychology, Winnipeg, Manitoba, R3T 2N2, Canada"
NCT02544880,PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC,https://clinicaltrials.gov/study/NCT02544880,COMPLETED,NO,Head and Neck Squamous Cell Carcinoma|Head and Neck Cancer,DRUG: Tadalafil|BIOLOGICAL: Anti-MUC1 Vaccine|BIOLOGICAL: Anti-Influenza Vaccine|OTHER: Tadalafil Placebo|OTHER: Anti-MUC1 Vaccine Placebo|OTHER: Standard of Care Treatment|OTHER: Anti-Influenza Vaccine Placebo,"Donald T. Weed, MD, FACS",,ALL,"ADULT, OLDER_ADULT",16,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2016-04-25,2021-06-08,"University of Miami, Miami, Florida, 33136, United States"
NCT05398107,Building Emotion Awareness and Mental Health (BEAM): Community Partnership With Family Dynamics,https://clinicaltrials.gov/study/NCT05398107,COMPLETED,NO,"Depression, Anxiety",BEHAVIORAL: Experimental: Building Emotion Awareness and Mental Health (BEAM)|BEHAVIORAL: Control: MoodMission,University of Manitoba,University of Calgary|Tactica Interactive|Canadian Institutes of Health Research (CIHR),ALL,"ADULT, OLDER_ADULT",80,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-28,2022-12-30,"University of Manitoba - Department of Psychology, Winnipeg, Manitoba, R3T 2N2, Canada"
NCT03485183,The Effect of White and Pink Noise on Hospitalized Older Adults,https://clinicaltrials.gov/study/NCT03485183,COMPLETED,NO,Delirium in Old Age,DEVICE: White/Pink Noise|OTHER: Control Group,University of Alabama at Birmingham,,ALL,OLDER_ADULT,50,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2018-10-01,2018-12-08,"UAB Highlands Hospital, Birmingham, Alabama, 35205, United States"
NCT01143961,Bedside Measurement of Ventilation With or Without a One-way Valve During Lung Lavage,https://clinicaltrials.gov/study/NCT01143961,COMPLETED,NO,Intensive Care,DEVICE: CSC100 - Verso airway access adapter CareFusion,Cardiff and Vale University Health Board,,ALL,"ADULT, OLDER_ADULT",50,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2010-06,2011-01,"Adult Critical Care, University Hospital of Wales, Cardiff, South Glamorgan, CF14 4XW, United Kingdom"
NCT06595654,Treatment of Negative Symptoms of Schizophrenia by rTMS,https://clinicaltrials.gov/study/NCT06595654,RECRUITING,NO,Schizophrenia|Negative Symptoms in Schizophrenia,OTHER: repetitive Transcranial Magnetic Stimulation,"Centre hospitalier de Ville-Evrard, France",,ALL,"ADULT, OLDER_ADULT",124,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-06-09,2028-03,"Etablissement Public de Santé de Ville-Evrard, Neuilly-sur-Marne, 93330, France"
NCT05380583,Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) and Substance Use: a Pilot Study,https://clinicaltrials.gov/study/NCT05380583,RECRUITING,NO,Psychosis|Substance Use|Substance Use Disorders|Family|Cannabis|Marijuana|Alcohol|Schizophrenia|Schizoaffective Disorder|Bipolar Disorder|Mental Disorder,BEHAVIORAL: CRAFT-EP|BEHAVIORAL: TAU,Mclean Hospital,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",80,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-19,2025-06-30,"McLean Hospital, Belmont, Massachusetts, 02478, United States"
NCT04880278,Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder,https://clinicaltrials.gov/study/NCT04880278,WITHDRAWN,NO,Obsessive-Compulsive Disorder,DRUG: Nabilone|DRUG: Placebo,New York State Psychiatric Institute,National Institute of Mental Health (NIMH),ALL,ADULT,0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2022-03-01,2024-05-08,"New York State Psychiatric Institute, New York, New York, 10032, United States"
NCT01334164,Recovery Management Checkups for Women Offenders,https://clinicaltrials.gov/study/NCT01334164,COMPLETED,NO,Recovery Management Checkup (RMC)|Outcome Monitoring,BEHAVIORAL: Recovery Management Checkups|OTHER: Outcome Monitoring,Chestnut Health Systems,Haymarket Center|Cook County Sheriff's Women's Justice Services,FEMALE,"ADULT, OLDER_ADULT",480,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2007-07,2015-06,"Chestnut Health Systems-Lighthouse Institute, Chicago, Illinois, 60610, United States|Chestnut Health Systems, Normal, Illinois, 61761, United States"
NCT05321563,Evaluating the Effectiveness of a Drug Education and Diversion Program for Middle and High School Students,https://clinicaltrials.gov/study/NCT05321563,TERMINATED,NO,Adolescent Behavior|Substance Use|Youth|Health Risk Behaviors,"BEHAVIORAL: iDECIDE (Drug Education Curriculum: Intervention, Diversion, and Empowerment)",Massachusetts General Hospital,Massachusetts Department of Health,ALL,"CHILD, ADULT",132,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2022-02-04,2023-09-14,"Massachusetts General Hospital, Boston, Massachusetts, 02114, United States"
NCT02228044,"Alcohol, Suicide and HIV Prevention for Teens in Mental Health Treatment",https://clinicaltrials.gov/study/NCT02228044,COMPLETED,NO,Suicide|Alcohol Abuse|Drug Abuse|HIV,BEHAVIORAL: Prevention program,George Mason University,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"CHILD, ADULT",81,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2008-09,2014-03,"George Mason University, Fairfax, Virginia, 22030, United States"
NCT04403048,Drug Coated Balloon for Side Branch Treatment vs. Conventional Approach in True Bifurcation Coronary Disease: PRO-DAVID,https://clinicaltrials.gov/study/NCT04403048,UNKNOWN,NO,Stable Angina|Ischemic Heart Disease|Coronary Artery Disease|Unstable Angina|NSTEMI - Non-ST Segment Elevation MI,PROCEDURE: Provisional DCB approach PCI procedure|PROCEDURE: Standard provisional approach PCI procedure,Clinical Hospital Center Rijeka,,ALL,"ADULT, OLDER_ADULT",800,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-10,2024-04,
NCT02359396,"A Randomized, Open-label, Three-arm Study of MZRW on Tolerability, Exposure and Pharmacokinetics",https://clinicaltrials.gov/study/NCT02359396,COMPLETED,NO,Functional Constipation|Gastrointestinal Disorders,DRUG: MZRW,Hong Kong Baptist University,,ALL,"ADULT, OLDER_ADULT",23,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-11,2015-08,"School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong, China"
NCT06242704,Train Your Brain 2.0 - Improving Memory and Decision Making Among Youth,https://clinicaltrials.gov/study/NCT06242704,RECRUITING,NO,"Behavior, Health",BEHAVIORAL: Working Memory Training|BEHAVIORAL: Working Memory,Henry Ford Health System,,ALL,"CHILD, ADULT, OLDER_ADULT",72,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2024-06-25,2026-08-01,"Freedom Schools Collaborative, Flint, Michigan, 48504, United States|Ernest T. Ford Recreation Center, Highland Park, Michigan, 48203, United States"
NCT05121194,Evaluation of Virtual CBTm for Public Safety Personnel,https://clinicaltrials.gov/study/NCT05121194,ACTIVE_NOT_RECRUITING,NO,Cognitive Behaviour Therapy,BEHAVIORAL: Cognitive Behaviour Therapy,University of Manitoba,,ALL,"ADULT, OLDER_ADULT",168,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-01-15,2024-09,"University of Manitoba, Winnipeg, Manitoba, R3E 3N4, Canada"
NCT06585631,The Collaborative Care PrTNER Study,https://clinicaltrials.gov/study/NCT06585631,RECRUITING,NO,HIV|Substance Use Disorders|Substance Use|AIDS,BEHAVIORAL: CC PrTNER,Children's Hospital of Philadelphia,Johns Hopkins University|Baltimore City Health Department|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA),MALE,"CHILD, ADULT",275,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2025-01-02,2028-06,"Johns Hopkins Center for Adolescent and Young Adult Health, Baltimore, Maryland, 21205, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19146, United States"
NCT00194129,Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder,https://clinicaltrials.gov/study/NCT00194129,COMPLETED,YES,Bipolar Disorder,DRUG: Lithium|DRUG: Divalproex|DRUG: Placebo,University Hospitals Cleveland Medical Center,National Institute of Mental Health (NIMH)|Abbott,ALL,"CHILD, ADULT, OLDER_ADULT",31,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",1997-11,2006-09,"University Hospitals of Cleveland, Cleveland, Ohio, 44106, United States"
NCT02677025,Young Women's Health CoOp (Cooperative) in Cape Town,https://clinicaltrials.gov/study/NCT02677025,COMPLETED,NO,HIV|Substance Abuse,BEHAVIORAL: Young Women's Health CoOp (YWHC)|BEHAVIORAL: HIV Counseling/Testing,RTI International,"Medical Research Council, South Africa",FEMALE,"CHILD, ADULT",100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2014-05,2016-04,"RTI International, Research Triangle Park, North Carolina, 27709, United States"
NCT02902081,Cannabidiol and Emotional Stimuli,https://clinicaltrials.gov/study/NCT02902081,COMPLETED,YES,Drug Addiction,DRUG: Cannabidiol|DRUG: Placebo,University of Chicago,INSYS Therapeutics Inc,ALL,ADULT,38,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2013-02,2017-03,"University of Chicago, Chicago, Illinois, 60637, United States"
NCT01652456,Alcohol and Tobacco Consumption in Patients With Head and Neck Cancer : Interest of an Addiction Support,https://clinicaltrials.gov/study/NCT01652456,WITHDRAWN,NO,Head and Neck Cancer|Lung Cancer,OTHER: Addiction support,Centre Oscar Lambret,,ALL,ADULT,0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2012-10,2017-11,"Oscar Lambret Center, Lille, 59 020, France|Centre Hospitalier Régional et Universitaire - Hopital CALMETTE, Lille, 59 037, France|Centre Hospitalier Régional et Universitaire - Hopital HURIEZ, Lille, 59 037, France"
NCT02051387,Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study,https://clinicaltrials.gov/study/NCT02051387,COMPLETED,NO,Schizophrenia,DRUG: Cannabidiol CR|DRUG: Cannabidiol|DRUG: Amisulpride|DRUG: Olanzapine|DRUG: Quetiapine|DRUG: Risperidone|DRUG: Placebo,"Central Institute of Mental Health, Mannheim",University of Cologne,ALL,ADULT,74,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-01,2017-08,"Central Institute of Mental Health, Mannheim, BW, 68159, Germany|Dept. of Pharmacology, University of Cologne, Cologne, NRW, 50931, Germany"
NCT04041414,Feasibility of a Multi-Level School Intervention for LGBTQ Youth,https://clinicaltrials.gov/study/NCT04041414,COMPLETED,YES,Sexual Minority Stress Experiences Among LGBTQ Youth,OTHER: Proud & Empowered!,University of Southern California,,ALL,"CHILD, ADULT",47,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2019-09-04,2020-04-30,"John Muir High School, Pasadena, California, 91103, United States|Marshall Fundamental High School, Pasadena, California, 91104, United States|Blair High School, Pasadena, California, 91106, United States|Pasadena High School, Pasadena, California, 91107, United States"
NCT02347345,Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs,https://clinicaltrials.gov/study/NCT02347345,COMPLETED,YES,Hepatitis C,DRUG: Harvoni (Fixed dose combination ledipasvir/sofosbuvir),Rockefeller University,National Institute on Drug Abuse (NIDA),ALL,ADULT,34,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-11-15,2016-11-15,"Rockefeller University Hospital, New York, New York, 10021, United States"
NCT03301012,Smartphone Addiction Recovery Coach for Young Adults (SARC-YA) Experiment,https://clinicaltrials.gov/study/NCT03301012,COMPLETED,NO,Substance Use Disorders,OTHER: Recovery support as usual|OTHER: Smartphone assisted relapse prevention,Chestnut Health Systems,,ALL,ADULT,237,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-10-30,2024-05-31,"Chestnut Health Systems, Bloomington, Illinois, 61701, United States|Chestnut Health Systems, Chicago, Illinois, 60610, United States"
NCT01751672,Integrating Substance Abuse Assessment & Intervention in Primary Care Settings,https://clinicaltrials.gov/study/NCT01751672,COMPLETED,NO,Drug Use|Alcohol Use,BEHAVIORAL: SBIRT|BEHAVIORAL: SBIRT+,Treatment Research Institute,Pennsylvania Department of Health,ALL,"ADULT, OLDER_ADULT",600,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-06,2015-05,"Eleventh Street Family Health Services of Drexel University, Philadelphia, Pennsylvania, 19123, United States|Public Health Management Corporation's Care Clinic, Philadelphia, Pennsylvania, 19123, United States|Abbottsford-Falls Family Practice, Resources for Human Development, Inc., Philadelphia, Pennsylvania, 19144, United States"
NCT00198939,Neurological Influences on Drug Prevention Intervention,https://clinicaltrials.gov/study/NCT00198939,COMPLETED,NO,Youths At-risk for Drug Use/Abuse,BEHAVIORAL: Integrated Family and Cognitive-Behavioral Drug Prevention Intervention|OTHER: Psychoeducation,University of Florida,National Institutes of Health (NIH)|Johns Hopkins University,ALL,CHILD,330,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: PREVENTION,2005-01,2011-12,"Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205, United States"
NCT00198874,Youth Drug Abuse Family and Cognitive-Behavioral Therapy,https://clinicaltrials.gov/study/NCT00198874,COMPLETED,NO,Drug Abuse,BEHAVIORAL: Integrated Family and Cognitive-Behavioral Therapy|OTHER: Education,University of Florida,National Institutes of Health (NIH),ALL,"CHILD, ADULT",296,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2005-01,2011-12,"Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205, United States"
NCT05818384,Wakaya: Rising Up for Choctaw Youth Health,https://clinicaltrials.gov/study/NCT05818384,RECRUITING,NO,"Obesity, Adolescent|Healthy Nutrition|Sedentary Behavior|Drug Abuse",BEHAVIORAL: Wakaya: Rising Up for Choctaw Youth Curriculum,University of Washington,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",176,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2023-04-28,2027-04-30,"Choctaw Nation of Oklahoma, Talihina, Oklahoma, 74571, United States|University of Washington, IWRI, School of Social Work, Seattle, Washington, 98105, United States"
NCT01155544,Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole,https://clinicaltrials.gov/study/NCT01155544,WITHDRAWN,NO,Substance Abuse|Substance Dependence,BEHAVIORAL: Behavioral Intervention,Northwell Health,National Institute of Mental Health (NIMH),ALL,"CHILD, ADULT",0,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-06,2014-06,"The Zucker Hillside Hospital, Glen Oaks, New York, 11004, United States|North Shore Hospital, Manhasset, New York, 11030, United States"
NCT06274827,Electromyographic Analysis of Scapular Muscles During Closed Kinetic Chain Exercises,https://clinicaltrials.gov/study/NCT06274827,COMPLETED,NO,"Shoulder Pain|Shoulder Injuries|Activation, Patient",DIAGNOSTIC_TEST: Superficial Electromyography,Hacettepe University,,MALE,ADULT,22,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-09-25,2023-06-20,"Hacettepe University, Ankara, 06430, Turkey"
NCT03804242,Black Youth M.A.T.T.E.R: Positive Youth Development Group Intervention,https://clinicaltrials.gov/study/NCT03804242,UNKNOWN,NO,"Depression, Anxiety",BEHAVIORAL: Black Youth M.A.T.T.E.R.: Molding Young Advocates While Transforming the School to Prison Pipeline Through Psychological Services Education and Resilience,Children's Hospital Los Angeles,,ALL,"CHILD, ADULT",20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2019-04,2020-08,
NCT00683033,Contingency Management for Smoking in Substance Abusers,https://clinicaltrials.gov/study/NCT00683033,COMPLETED,NO,Cigarette Smoking,BEHAVIORAL: Contingency Management|BEHAVIORAL: Brief smoking cessation counseling,UConn Health,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",51,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-05,2010-10,"University of Connecticut Health Center, Farmington, Connecticut, 06030, United States"
NCT02733003,Implementation Research for Vulnerable Women in South Africa,https://clinicaltrials.gov/study/NCT02733003,COMPLETED,NO,HIV|Substance Abuse,BEHAVIORAL: Women's Health CoOp (WHC),RTI International,Kheth'Impilo,FEMALE,ADULT,564,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2015-09,2018-12-04,"RTI International, Research Triangle Park, North Carolina, 27709, United States|Kheth'Impilo, Cape Town, 8001, South Africa"
NCT05109065,Peripheral Immune System in Individuals With Schizophrenia,https://clinicaltrials.gov/study/NCT05109065,RECRUITING,NO,Schizophrenia|Schizo Affective Disorder|Schizophreniform Disorders,DIAGNOSTIC_TEST: SCID (Standardized Clinical Interview for DSM-V)|DIAGNOSTIC_TEST: PSS (Perceived Stress Score)|DIAGNOSTIC_TEST: Urine Toxicology Screen|DIAGNOSTIC_TEST: Vitals|DIAGNOSTIC_TEST: Blood Work|DIAGNOSTIC_TEST: PQ-B|DIAGNOSTIC_TEST: COVID Screening|DIAGNOSTIC_TEST: Positive and Negative Syndrome Scale (PANSS),Stanford University,,ALL,ADULT,100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-03-01,2025-06-01,"Stanford University School of Medicine, Stanford, California, 94704, United States"
NCT05988931,Technology Interventions for Youth Alcohol Use,https://clinicaltrials.gov/study/NCT05988931,RECRUITING,NO,Alcohol Drinking,BEHAVIORAL: Web Program + App|BEHAVIORAL: Web Program + App + Text Messages,University of Michigan,Patient-Centered Outcomes Research Institute,ALL,CHILD,1400,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-10-25,2027-09,"University of Michigan, Ann Arbor, Michigan, 48109, United States"
NCT04998045,Feasibility and Acceptability of a Substance Use Screening and Brief Intervention for Youth Living With HIV in Kenya,https://clinicaltrials.gov/study/NCT04998045,COMPLETED,NO,Substance Use|Substance Use Disorders,BEHAVIORAL: Screening and brief intervention for substance use,Moi University,Indiana University|Duke University|Moi Teaching and Referral Hospital|Fogarty International Center of the National Institute of Health,ALL,"CHILD, ADULT",106,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2021-07-01,2022-06-30,"Florence Jaguga, Eldoret, RIFT Valley, 30100, Kenya"
NCT03294148,Mind-body Treatments for Chronic Back Pain,https://clinicaltrials.gov/study/NCT03294148,COMPLETED,YES,"Chronic Pain|Back Pain Lower Back Chronic|Back Pain, Low",OTHER: Open-Label Placebo Treatment for Chronic Back Pain|BEHAVIORAL: Psychotherapy Treatment for Chronic Back Pain,"University of Colorado, Boulder",Radiological Society of North America|National Institutes of Health (NIH)|Psychophysiologic Disorders Society|Foundation for the Science of Therapeutic Encounter,ALL,"ADULT, OLDER_ADULT",151,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2017-08-07,2019-11-26,"University of Colorado Boulder, Boulder, Colorado, 80309, United States"
NCT05219422,Testing ALERT With GTO in Middle Schools,https://clinicaltrials.gov/study/NCT05219422,RECRUITING,NO,Substance Abuse,BEHAVIORAL: Project ALERT|BEHAVIORAL: Getting to Outcomes,RAND,University of Southern California,ALL,"CHILD, ADULT, OLDER_ADULT",42,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2020-05-01,2025-03-31,"Los Angeles Unified School District, Los Angeles, California, 90017, United States"
NCT02655354,A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity,https://clinicaltrials.gov/study/NCT02655354,COMPLETED,YES,Posttraumatic Stress Disorder|Depression|Alcohol-Related Disorders|Suicidal Ideation|Substance-Related Disorders|Mild Cognitive Impairment|Quality of Life|Pain|Wounds and Injury|Brain Injuries|Chronic Disease,BEHAVIORAL: Motivational Interviewing|BEHAVIORAL: Cognitive Behavioral Therapy Elements|BEHAVIORAL: Care Management|DRUG: Fluoxetine|DRUG: Fluvoxamine|DRUG: Paroxetine|DRUG: Sertraline|DRUG: Citalopram|DRUG: Venlafaxine|DRUG: Duloxetine|DRUG: Mirtazapine|DRUG: Diphenhydramine|DRUG: Trazodone|DRUG: Prazosin,University of Washington,National Institutes of Health (NIH)|National Institute of Mental Health (NIMH)|National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"ADULT, OLDER_ADULT",635,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2015-10,2019-11,"Honor Health, Scottsdale, Arizona, 85251, United States|Cedars Sinai, Beverly Hills, California, 90211, United States|U.C. Davis, Sacramento, California, 95816, United States|Santa Clara Valley Medical Center, San Jose, California, 95128, United States|U.C.L.A. Harbor, Torrance, California, 90509, United States|Hartford Hospital, Hartford, Connecticut, 06102, United States|Georgia Regents, Augusta, Georgia, 30912, United States|Eskenazi Health, Indianapolis, Indiana, 46202, United States|University of Iowa, Iowa City, Iowa, 52242, United States|University of Kentucky, Lexington, Kentucky, 40536, United States|Louisiana State University, New Orleans, Louisiana, 70112, United States|Regions Hospital, Saint Paul, Minnesota, 55101, United States|Jacobi Medical Center, Bronx, New York, 10461, United States|University of Rochester, Rochester, New York, 14642, United States|Wake Forest, Winston-Salem, North Carolina, 27157, United States|University of Cincinnati, Cincinnati, Ohio, 45267, United States|Ohio State University, Columbus, Ohio, 43210, United States|Baylor Health Care System, Dallas, Texas, 75204, United States|UT Southwestern Medical Center, Dallas, Texas, 75390, United States|University of Texas Medical Branch at Galveston, Galveston, Texas, 77555, United States|The University of Utah, Salt Lake City, Utah, 84132, United States|The University of Vermont, Burlington, Vermont, 05405, United States|Inova Trauma Center, Falls Church, Virginia, 22042, United States|The University of Wisconsin Madison, Madison, Wisconsin, 53715, United States"
NCT01386138,Treating South African Pregnant Women for Methamphetamine,https://clinicaltrials.gov/study/NCT01386138,COMPLETED,NO,HIV|Drug Addiction,BEHAVIORAL: Psycho-education|BEHAVIORAL: Experimental,RTI International,University of Cape Town,FEMALE,"ADULT, OLDER_ADULT",60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION,2011-07,2013-06,"Medical Research Council, Tygerberg, Western Cape, 7505, South Africa"
NCT04267679,Cannabidiol for Anxiety,https://clinicaltrials.gov/study/NCT04267679,WITHDRAWN,NO,Anxiety,DRUG: Cannabidiol,CB2 Insights,Green Lotus Hemp,ALL,"ADULT, OLDER_ADULT",0,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-03-01,2020-12-01,
NCT02818777,A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease,https://clinicaltrials.gov/study/NCT02818777,COMPLETED,YES,Parkinson's Disease,DRUG: cannabidiol,"University of Colorado, Denver",Colorado Department of Public Health and Environment|GW Research Ltd,ALL,"ADULT, OLDER_ADULT",13,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-10,2017-11,"University of Colorado School of Medicine, Aurora, Colorado, 80045, United States"
NCT05026099,"Boxing Training for Upper Limb Functions, Balance, and Quality of Life in Stroke",https://clinicaltrials.gov/study/NCT05026099,COMPLETED,NO,Stroke,OTHER: Boxing training|OTHER: Task Oriented Training,Riphah International University,,ALL,ADULT,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-08-15,2022-08-20,"Iradah Rehabilitation Center Kalar Kahar, Chakwal, Punjab, Pakistan"
NCT01751217,Family Therapy Via Video Teleconference for Substance-Abusing Rural Adolescents,https://clinicaltrials.gov/study/NCT01751217,COMPLETED,NO,Substance-Related Disorders,BEHAVIORAL: Functional Family Tx|BEHAVIORAL: Services as Usual,Oregon Research Institute,,ALL,"CHILD, ADULT",90,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-02,2016-11-30,"Oregon Research Institute Center for Family and Adolescent Research, Albuquerque, New Mexico, 87102, United States"
NCT05461885,Value of Gym-based Exercise Training for Young Adults Receiving Antipsychotic Medication: The Vega Trial,https://clinicaltrials.gov/study/NCT05461885,RECRUITING,NO,Affective Disorder|Psychosis,BEHAVIORAL: Supervised exercise,"Rigshospitalet, Denmark",Aarhus University Hospital|Aalborg University Hospital,ALL,ADULT,400,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-10-25,2025-10,"Aalborg University Hospital, Aalborg, 9220, Denmark|Aarhus University Hospital, Aarhus, 8200, Denmark|Mental Health Centre Copenhagen, Copenhagen, 2100, Denmark|Mental Health Centre Glostrup, Glostrup, 2600, Denmark"
NCT06808984,"Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease",https://clinicaltrials.gov/study/NCT06808984,NOT_YET_RECRUITING,NO,Agitation|Alzheimer Disease,DRUG: BMS-986368|DRUG: Placebo,Celgene,,ALL,"ADULT, OLDER_ADULT",120,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2025-04-15,2027-05-31,"Local Institution - 0001, Tampa, Florida, 33607, United States"
NCT05053503,Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder,https://clinicaltrials.gov/study/NCT05053503,RECRUITING,NO,Opioid-use Disorder|Opioid Withdrawal,DEVICE: Sparrow Ascent Therapy System|DRUG: Lofexidine|DRUG: Extended-release injectable naltrexone,"Spark Biomedical, Inc.","Hazelden Betty Ford Foundation|Gaudenzia, Inc.",ALL,"ADULT, OLDER_ADULT",168,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2022-05-27,2025-05,"Hazelden Betty Ford Foundation, Rancho Mirage, California, 92270, United States|Gaudenzia, Inc., Crownsville, Maryland, 21032, United States|Hazelden Betty Ford Foundation, Center City, Minnesota, 55012, United States|Hazelden Betty Ford Foundation, Plymouth, Minnesota, 55441, United States"
NCT04405960,Role of Alphacalcidol Supplement to Reduce Pain and COMP in Geriatric Knee Osteoarthritis Patients,https://clinicaltrials.gov/study/NCT04405960,COMPLETED,NO,"Osteoarthritis, Knee|Aged",DRUG: Alfacalcidol 1 MCG Oral Capsule|DRUG: Sugar pill,Syarif Hidayatullah State Islamic University Jakarta,,ALL,"ADULT, OLDER_ADULT",146,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-07-01,2017-12-31,"Public Health Service Clinic Reni Jaya, South Tangerang, Banten, 15417, Indonesia"
NCT04192760,Culotte Versus DK-CRUSH Technique in Non-left Main Coronary Bifurcation Lesions,https://clinicaltrials.gov/study/NCT04192760,UNKNOWN,NO,Coronary Stenosis|Stent Stenosis,PROCEDURE: Stenting,University Heart Center Freiburg - Bad Krozingen,,ALL,"ADULT, OLDER_ADULT",400,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-12-01,2023-12-31,"University Heart Center Freiburg • Bad Krozingen, Bad Krozingen, Suedring 15, 79189, Germany|Herz-u. Diabeteszentrum, Bad Oeynhausen, 32545, Germany|Herz-und Gefäßzentrum, Bad Segeberg, 23795, Germany|St. Johannes-Hospital, Dortmund, 44137, Germany|Herzzentrum Dresden an der Technischen Universität, Dresden, 01307, Germany|Elisabeth Krankenhaus, Essen, 45138, Germany|Universitätsklinikum Gießen, Gießen, 35392, Germany|Universitätsklinikum Leipzig, Leipzig, 04103, Germany|Universitätsklinik Mannheim, Mannheim, 68167, Germany|Deutsches Herzzentrum, München, 80636, Germany|Klinikum Oldenburg, Oldenburg, 26133, Germany|Herzzentrum Trier, Trier, 54292, Germany|Universitätsklinikum Ulm, Ulm, 89070, Germany"
NCT05964010,Primary Connections for Youth and Families,https://clinicaltrials.gov/study/NCT05964010,RECRUITING,NO,Substance Use,BEHAVIORAL: Standard Screening|BEHAVIORAL: Standard Psychoeducation|BEHAVIORAL: Standard Brief Negotiated Interview (BNI)|BEHAVIORAL: Standard Referral to Treatment (RT)|BEHAVIORAL: Family Screening|BEHAVIORAL: Family Psychoeducation|BEHAVIORAL: Family Brief Negotiated Interview (BNI)|BEHAVIORAL: Family Facilitated Conversation (FC) & Referral to Treatment (RT),The National Center on Addiction and Substance Abuse at Columbia University,Abt Associates|Northwestern University Feinberg School of Medicine|UConn Health|Massachusetts General Hospital|Boston Medical Center|Boston Children's Hospital|Columbia University|Patient-Centered Outcomes Research Institute,ALL,CHILD,2300,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING,2024-03-01,2027-11,"Columbia University Medical Center, New York, New York, 10013, United States"
NCT04812613,Tobacco-Concurrent Addictions in At-Risk Youth in Ottawa,https://clinicaltrials.gov/study/NCT04812613,ACTIVE_NOT_RECRUITING,NO,Tobacco Use|Substance Use,,Ottawa Hospital Research Institute,Operation Come Home,ALL,"CHILD, ADULT, OLDER_ADULT",173,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-03-01,2023-12-01,"The Bridge Engagement Centre, Ottawa, Ontario, K1G 5T2, Canada"
NCT05305235,RCT for Innovating Stress-related eHealth,https://clinicaltrials.gov/study/NCT05305235,COMPLETED,NO,Posttraumatic Stress Disorder|Sexual Assault|Pain,DEVICE: RISE Guide|DEVICE: Relaxation Control,"University of North Carolina, Chapel Hill",Mayday Fund,FEMALE,"ADULT, OLDER_ADULT",60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-12-01,2024-02-24,"University of North Carolina at Chapel Hill, SANE Program, Chapel Hill, North Carolina, 27599, United States|Austin Stop Abuse for Everyone (SAFE), Austin, Texas, 78760, United States"
NCT04155008,Nutrition and Pharmacological Algorithm for Oncology Patients Study,https://clinicaltrials.gov/study/NCT04155008,TERMINATED,YES,Oncologic Complications|Quality of Life|Nutrition Poor|Head and Neck Cancer|Lung Cancer|Pancreatic Cancer,DRUG: Dexamethasone|DRUG: Dronabinol|DRUG: Mirtazapine|BEHAVIORAL: Nutrition Intervention,Montefiore Medical Center,,ALL,"ADULT, OLDER_ADULT",1,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2021-03-01,2021-04-05,"Montefiore Hospital, Bronx, New York, 10467, United States"
NCT05753683,Gathering Online for Dialogue and Discussion to Enhance Social Support,https://clinicaltrials.gov/study/NCT05753683,NOT_YET_RECRUITING,NO,Alcohol Misuse|HIV|Sexually Transmitted Infections|Pre-exposure Prophylaxis,BEHAVIORAL: mHealth-Women's CoOp|BEHAVIORAL: Virtual Group,RTI International,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,ADULT,500,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2025-02,2027-04,"RTI International, Durham, North Carolina, 27707, United States"
NCT00706901,Impact of Group Motivational Interviewing and In-Home-Messaging-Devices for Dually Diagnosed Veterans,https://clinicaltrials.gov/study/NCT00706901,COMPLETED,YES,Alcohol Dependence|Dual Diagnosis|Drug Dependence,BEHAVIORAL: Arm 1 GMI|BEHAVIORAL: Arm 2 IHMD|BEHAVIORAL: Arm 3 TCC,VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",180,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2010-05-03,2013-09-30,"Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, 29401-5799, United States"
NCT02059005,Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions,https://clinicaltrials.gov/study/NCT02059005,COMPLETED,YES,Drug Use|Alcohol Use|Congestive Heart Failure|Pneumonia|Acute Myocardial Infarction|Diabetes Mellitus|Chronic Obstructive Pulmonary Disease|End-Stage Renal Disease,BEHAVIORAL: Specialized Community Disease Management|BEHAVIORAL: Treatment As Usual,Treatment Research Institute,Patient-Centered Outcomes Research Institute,ALL,"ADULT, OLDER_ADULT",97,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-11-18,2017-02-28,"Temple University Hospital, Philadelphia, Pennsylvania, 19140, United States"
NCT06074172,The Effect of Cannabidiol in Learning and Memory of Adults,https://clinicaltrials.gov/study/NCT06074172,COMPLETED,NO,Memory,DRUG: Cannabidiol in Oral Dose Form|DRUG: Placebo in Oral Dose Form,Colorado State University,Institute of Cannabis Research,ALL,"ADULT, OLDER_ADULT",57,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-03-14,2020-11-06,"Colorado State University Pueblo, Pueblo, Colorado, 81001, United States"
NCT02791399,A Patient-Centered Intervention to Improve Opioid Safety,https://clinicaltrials.gov/study/NCT02791399,COMPLETED,YES,Opioid Safety|Prescription Opioid Misuse|Chronic Pain,BEHAVIORAL: ISOP Intervention with the Nurse Care Manager,VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",286,FED,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-03-23,2020-10-31,"VA Portland Health Care System, Portland, OR, Portland, Oregon, 97207-2964, United States"
NCT02764190,I-ACT With Check Yourself,https://clinicaltrials.gov/study/NCT02764190,COMPLETED,YES,Adolescent Behavior,BEHAVIORAL: I-ACT with Check Yourself,Seattle Children's Hospital,Patient-Centered Outcomes Research Institute,ALL,"CHILD, ADULT",302,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2016-10,2018-11,"University of Washington, Seattle, Washington, 98105, United States"
NCT04859972,"How Well do Primary Care Doctors in Region Örebro County, Sweden Follow Diagnostic Guidelines of IBS?",https://clinicaltrials.gov/study/NCT04859972,UNKNOWN,NO,Irritable Bowel Syndrome,DIAGNOSTIC_TEST: Diagnosis of IBS,Region Örebro County,,ALL,"ADULT, OLDER_ADULT",3000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-11-22,2023-05,
NCT04587999,Quick-Wee Versus Bladder Stimulation System to Collect Midstream Urine From Pre-continent Infants,https://clinicaltrials.gov/study/NCT04587999,COMPLETED,NO,Urinary Tract Infections,OTHER: bladder stimulation|OTHER: Quick wee,Fondation Lenval,,ALL,CHILD,230,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-01-29,2022-11-17,"Centre Hospitalier Universitaire de Sainte-Justine, Montréal, Canada|Centre Hospitalier Antibes Juan les Pins, Antibes, France|Hôpitaux Pédiatriques de Nice CHU-Lenval, Nice, France"
NCT05760404,Modulatory Effects of Active Drugs on the Endocannabinoid System on Spontaneous and Induced Contractility of the Colon,https://clinicaltrials.gov/study/NCT05760404,UNKNOWN,NO,Colorectal Cancer,PROCEDURE: Surgery for colorectal cancer|OTHER: in vitro study,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,ALL,"CHILD, ADULT, OLDER_ADULT",60,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-12-19,2024-12,"Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy"
NCT00713479,An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers,https://clinicaltrials.gov/study/NCT00713479,COMPLETED,YES,Methamphetamine Addiction|Crystal Meth Addiction|Amphetamine Addiction,"DRUG: Varenicline, then placebo|DRUG: Placebo, then varenicline","University of California, Los Angeles",National Institute on Drug Abuse (NIDA),ALL,ADULT,8,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-07,2009-09,"UCLA NPI, Los Angeles, California, 90095, United States"
NCT05259592,Modular Patient Centred CBT for Danish Veterans With Complex PTSD,https://clinicaltrials.gov/study/NCT05259592,RECRUITING,NO,Complex Post-Traumatic Stress Disorder,BEHAVIORAL: Psychotherapy,Danish Veterans Centre,University of Copenhagen|Edinburgh Napier University,ALL,"ADULT, OLDER_ADULT",60,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-17,2026-12,"Danish Veterans Centre, Aalborg Kaserner, Aalborg, 9400, Denmark|Danish Veterans Centre, Garderkasernen, Birkerød, 3460, Denmark|Danish Veterans Centre, Svanemoellen Kaserne, Copenhagen Ø, 2100, Denmark|Danish Veterans Centre, Ryes Kaserne, Fredericia, 7000, Denmark|Danish Veterans Centre; Ringsted Kaserne, Ringsted, 4100, Denmark"
NCT05541406,Efficacy of a Multi-level School Intervention for LGBTQ Youth,https://clinicaltrials.gov/study/NCT05541406,RECRUITING,NO,Depression|Anxiety|Post Traumatic Stress Disorder|Coping Behavior|Sexual Minority Stress|Suicidality|Substance Use|Bullying|Harassment,BEHAVIORAL: Proud & Empowered,Washington University School of Medicine,National Institute on Minority Health and Health Disparities (NIMHD)|University of Southern California,ALL,"CHILD, ADULT",450,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-09-14,2025-12-01,"El Monte High School, El Monte, California, 91731, United States|Arroyo High School, El Monte, California, 91732, United States|Fernando R Ledesma High School, El Monte, California, 91732, United States|Mountain View High School, El Monte, California, 91732, United States|South El Monte High School, El Monte, California, 91733, United States|Anderson W. Clark Magnet High School, Glendale, California, 91214, United States|Animo Leadership High School, Inglewood, California, 90304, United States|Crescenta Valley High School, La Crescenta-Montrose, California, 91214, United States|Millikan High School, Long Beach, California, 90815, United States|Animo Pat Brown Charter High School, Los Angeles, California, 90001, United States|USC Hybrid High School, Los Angeles, California, 90037, United States|South LA College Prep, Los Angeles, California, 90044, United States|Larchmont Charter School, Los Angeles, California, 90057, United States|Brio College Prep, Los Angeles, California, 90071, United States|Lynwood High School, Lynwood, California, 90262, United States|Marco Antonio Firebaugh High School, Lynwood, California, 90262, United States|Vista High School, Lynwood, California, 90262, United States|Marshall Fundamental Secondary School, Pasadena, California, 91104, United States|Blair High School, Pasadena, California, 91106, United States|Pasadena High School, Pasadena, California, 91107, United States|Rosemead High School, Rosemead, California, 91770, United States"
NCT04499781,"Adherence Connection for Counseling, Education, and Support (ACCESS) II",https://clinicaltrials.gov/study/NCT04499781,COMPLETED,NO,HIV Infections,BEHAVIORAL: ACCESS II mHealth Intervention|BEHAVIORAL: ACCESS II control condition,NYU Langone Health,Jacobi Medical Center,ALL,ADULT,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-02-14,2024-07-25,"Jacobi Medical Center, Bronx, New York, 10461, United States"
NCT04135404,Factors That Impact the Relationship Between Pulmonary Status and Actual Electronic Cigarette Use,https://clinicaltrials.gov/study/NCT04135404,COMPLETED,NO,Electronic Cigarette Use|Pulmonary Disease,OTHER: health-related telephone surveys,University of Alabama at Birmingham,,ALL,"ADULT, OLDER_ADULT",400000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-01-01,2017-12-30,
NCT03859778,Evaluation of Pharmacy Students' Perception of Opioid / Opiate Dependence,https://clinicaltrials.gov/study/NCT03859778,COMPLETED,NO,Opioid-Related Disorders,OTHER: survey,"University Hospital, Clermont-Ferrand",UFR Pharmacie (Clermont-Ferrand),ALL,"ADULT, OLDER_ADULT",2034,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-01-14,2019-03-31,"Chu Clermont-Ferrand, Clermont-Ferrand, 63003, France"
NCT06084520,Translation and Validation of the COMM and ASI-SR,https://clinicaltrials.gov/study/NCT06084520,RECRUITING,NO,"Opioid Use|Opioid Use Disorder|Alcohol Use Disorder|Pain, Chronic",DIAGNOSTIC_TEST: Current Opioid Misuse Measure (COMM)-SWE|DIAGNOSTIC_TEST: Oral fluid drug test|DIAGNOSTIC_TEST: PETh|DIAGNOSTIC_TEST: ASI-SR|DIAGNOSTIC_TEST: AUDIT|DIAGNOSTIC_TEST: DUDIT|DIAGNOSTIC_TEST: Brief Pain Inventory - BPI|DIAGNOSTIC_TEST: Patient Global Impression of Change PGIC|DIAGNOSTIC_TEST: GAD-7|DIAGNOSTIC_TEST: Patient Health questionnaire (PHQ9)|DIAGNOSTIC_TEST: DBS - cannabis test|OTHER: Sample of Blood for later DNA and immunological analysis in future studies,Uppsala University,"The Kamprad Family Foundation for Entrepreneurship, Research & Charity",ALL,"ADULT, OLDER_ADULT",400,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-12-01,2026-12-31,"Multidisciplinary Pain Center, Uppsala, Uppland, 75185, Sweden"
NCT06381219,Pediatric Eosinophilic Esophagitis (pedEoE): Effect of Allergen Heat Denaturation on EoE Remission: a Pilot Trial,https://clinicaltrials.gov/study/NCT06381219,RECRUITING,NO,Eosinophilic Esophagitis,OTHER: Implementation of cow's milk in decreasingly heated forms|OTHER: Implementation of hen's egg in decreasingly heated forms,Universitaire Ziekenhuizen KU Leuven,,ALL,"CHILD, ADULT",36,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-12-19,2028-12-31,"UZ Leuven Gasthuisberg, Leuven, Vlaams-Brabant, 3000, Belgium"
NCT01895426,ArcadiusXP L Post Market Clinical Follow-Up,https://clinicaltrials.gov/study/NCT01895426,COMPLETED,NO,Degenerative Disc Disease,,Aesculap AG,,ALL,ADULT,32,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-04,2017-02,"Sana Kliniken Sommerfeld, Kremmen, 16766, Germany|St. Bonifatius Hospital Lingen, Lingen, 49808, Germany"
NCT01944748,Family Mediation Program For At-Risk Youth,https://clinicaltrials.gov/study/NCT01944748,COMPLETED,NO,Family Functioning,BEHAVIORAL: Families Able To Resolve Situations (FARS),RAND,,ALL,"CHILD, ADULT",111,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2011-07,2016-04,"Centinela Youth Services, Hawthorne, California, 90250, United States"
NCT04173546,Identification of Psychoactive Substance Users in Young Adults (16 to 25 Years Old) Visiting the Emergency Department,https://clinicaltrials.gov/study/NCT04173546,COMPLETED,NO,Psychiatric Emergency|Drug Use,,Hospices Civils de Lyon,,ALL,"CHILD, ADULT",459,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-02-11,2021-04-15,"Hôpital Edouard Herriot, Lyon, 69003, France"
NCT06234722,Modeling Tobacco Regulatory Impacts in Appalachia Using the Experimental Tobacco Marketplace,https://clinicaltrials.gov/study/NCT06234722,ENROLLING_BY_INVITATION,NO,Tobacco Use|Cigarette Use,DRUG: Very Low Nicotine Cigarette|BEHAVIORAL: Reduced nicotine regulatory environment|BEHAVIORAL: Restriction on characterizing flavors in combustible nicotine products|BEHAVIORAL: Restriction on characterizing flavors in noncombustible nicotine products,Mikhail N Koffarnus,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",473,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2024-08-16,2028-08,"University of Kentucky, Lexington, Kentucky, 40504, United States"
NCT04678960,Preventing Opioid Use Among Justice-involved Youth As They Transition to Adulthood Leveraging Safe Adults (LeSA),https://clinicaltrials.gov/study/NCT04678960,ACTIVE_NOT_RECRUITING,NO,Opioid Use|Substance Use,BEHAVIORAL: Trust-based Relational Intervention Training|BEHAVIORAL: Trust-based Relational Intervention In-Home Structured Coaching|BEHAVIORAL: Trust-based Relational Intervention In-Home Responsive Coaching,Texas Christian University,,ALL,"CHILD, ADULT",360,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-02-15,2025-08-31,"Illinois Youth Center - Chicago, Chicago, Illinois, 60612, United States|Illinois Youth Center - Pere Marquette, Grafton, Illinois, 62037, United States|Illinois Youth Center- Harrisburg, Harrisburg, Illinois, 62946, United States|Illinois Youth Center- Warrenville, Naperville, Illinois, 60563, United States|Illinois Youth Center - St. Charles, St. Charles, Illinois, 60175, United States|Grayson County Juvenile Center/Boot Camp, Denison, Texas, 75020, United States|Texas Monarch Academy for Girls/Rite of Passage, Denison, Texas, 75020, United States|Williamson County Juvenile Services, Georgetown, Texas, 78626, United States|Lake Granbury Youth Services/Rite of Passage, Granbury, Texas, 76048, United States|Harris County Youth Village, Houston, Texas, 77586, United States|Collin County Juvenile Probation Services, McKinney, Texas, 75071, United States"
NCT02926859,Enhancing Recovery in Early Schizophrenia,https://clinicaltrials.gov/study/NCT02926859,RECRUITING,NO,Schizophrenia,DRUG: Cannabidiol as add-on|DRUG: Placebo as add-on,"Central Institute of Mental Health, Mannheim",,ALL,"ADULT, OLDER_ADULT",180,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-04-08,2026-06,"Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, BW, 68159, Germany|Dept. of Psychiatry and Psychotherapy, Ludwig-Maximillians-University Munich, Munich, BY, 80336, Germany|Dept. of Psychiatry and Psychotherapy, Charité, Campus Charité-Mitte, Berlin, B, 10117, Germany|Department of Psychiatry, Psychotherapy, and Psychosomatics, RWTH Aachen, Aachen, NRW, 52074, Germany|Dept. of Psychiatry and Psychotherapy, University Hospital of Cologne, Cologne, NRW, 50924, Germany|Department of Psychiatry und Psychotherapy, University Hospital Hamburg-Eppendorf, Hamburg, 20246, Germany"
NCT04218201,Subthreshold Opioid Use Disorder Prevention (STOP) Trial,https://clinicaltrials.gov/study/NCT04218201,COMPLETED,NO,Opioid-use Disorder,BEHAVIORAL: PCP brief advice|BEHAVIORAL: Video doctor|BEHAVIORAL: Telephone health coaching|BEHAVIORAL: Nurse Care Manager (NCM) intervention,NYU Langone Health,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",202,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2020-03-25,2024-05-17,"NYU Langone Health, New York, New York, 10016, United States"
NCT03284541,Online HIV Prevention for Young Male Couples,https://clinicaltrials.gov/study/NCT03284541,COMPLETED,NO,Hiv|Chlamydia|Gonorrhea,BEHAVIORAL: 2GETHER|BEHAVIORAL: Existing Public Health Practice,Northwestern University,,MALE,"ADULT, OLDER_ADULT",400,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2018-04-05,2022-04-01,"Northwestern University-Feinberg School of Medicine, Chicago, Illinois, 60611, United States"
NCT03260647,Risk Stratified Multidisciplinary Ambulatory Management of Malignant Bowel Obstruction in Gynecological Cancers,https://clinicaltrials.gov/study/NCT03260647,RECRUITING,NO,Gynecologic Cancer,OTHER: Management algorithm for Malignant Bowel Obstruction,"University Health Network, Toronto",,FEMALE,"ADULT, OLDER_ADULT",150,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-08-04,2024-12,"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"
NCT03885349,Motivational Strategies in Batterer Intervention Programs for Offenders With Alcohol/Drug Abuse Problems (IMP-ADAPs),https://clinicaltrials.gov/study/NCT03885349,RECRUITING,NO,Intimate Partner Violence Against Women|Alcohol Abuse|Drug Abuse,BEHAVIORAL: SBIP+ ADAPs-IMP|BEHAVIORAL: SBIP+IMP,University of Valencia,"Ministerio de Sanidad, Servicios Sociales e Igualdad",MALE,"ADULT, OLDER_ADULT",80,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2019-03-04,2025-12-30,"Faculty of Psychology, Valencia, 46010, Spain"
NCT05283161,CBD (Cannabidiol)/THC (Tetrahydrocannabinol) Solution as a Pharmacological Strategy for Patients With Fibromyalgia (FibroCann),https://clinicaltrials.gov/study/NCT05283161,UNKNOWN,NO,Fibromyalgia,DRUG: cannabidiol and tetrahydrocannabinol|DRUG: Placebo,FG Brasil LTDA,3F Clinical Trials LTDA,ALL,"ADULT, OLDER_ADULT",40,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-04-15,2022-11-20,
NCT05014074,The Dreamer Girls Project: Adaptation of SISTA/SIHLE for HIV/AIDS and Substance Abuse Prevention Among Black Adolescent Girls,https://clinicaltrials.gov/study/NCT05014074,NOT_YET_RECRUITING,NO,HIV/AIDS,OTHER: Theater/Pilot Testing,Yale University,National Institute of Mental Health (NIMH),FEMALE,"CHILD, ADULT",10,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2024-07,2025-08,"Paterson Youth Services Bureau, Paterson, New Jersey, 07522, United States"
NCT03377296,Study of Controlled Human Plasmodium Vivax Infection,https://clinicaltrials.gov/study/NCT03377296,COMPLETED,NO,"Malaria, Vivax",OTHER: Plasmodium vivax infection|PROCEDURE: Collection of 250mL blood from each volunteer (N=2),University of Oxford,,ALL,ADULT,2,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2018-03-03,2023-04-13,"Centre for Clinical Vaccinology & Tropical Medicine, Oxford, Oxfordshire, OX3 7LE, United Kingdom|John Warin Ward, Oxford University NHS Foundation Trust, Oxford, Oxfordshire, OX3 7LE, United Kingdom"
NCT05814575,NEXUS - Next Generation Health Through 2D & 3D Fetal UltraSound; Building Connections to Support Maternal-fetal Health,https://clinicaltrials.gov/study/NCT05814575,RECRUITING,NO,Pregnancy Related|Substance Use|Mental Health Issue,BEHAVIORAL: NEXUS intervention|BEHAVIORAL: Standardized Non-Medical fetal ultrasound,Virginia Commonwealth University,,ALL,ADULT,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2023-06-08,2025-10,"Virginia Commonwealth University, Richmond, Virginia, 23298, United States"
NCT02718352,A Naturalistic Study of Adolescents and Young Adults in Treatment for Opioid Dependence,https://clinicaltrials.gov/study/NCT02718352,COMPLETED,NO,Opioid Dependence,OTHER: Naturalistic Prospective Cohort,Yale University,,ALL,"CHILD, ADULT",8,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-03,2018-03,"APT Foundation, New Haven, Connecticut, 06511, United States"
NCT05905250,mHealth for Young Adult Cancer Survivors,https://clinicaltrials.gov/study/NCT05905250,RECRUITING,NO,Survivorship|Cancer|Psychological Well-Being,"BEHAVIORAL: an empirically supported protocol, further refined with evidence-based strategies|BEHAVIORAL: Health education",George Washington University,National Cancer Institute (NCI),ALL,ADULT,200,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2024-03-15,2024-12-31,"George Washington University, Washington, District of Columbia, 20052, United States"
NCT05973838,Peer Recovery to Improve Polysubstance Use and Mobile Telemedicine Retention,https://clinicaltrials.gov/study/NCT05973838,RECRUITING,NO,Polysubstance Addiction|Opioid Medication Assisted Treatment|Treatment Adherence|Retention in Care|Substance-Related Disorders,"BEHAVIORAL: Peer-Delivered Behavioral Activation (""Peer Activate"")","University of Maryland, College Park","University of Maryland, Baltimore|Weill Medical College of Cornell University|National Institute on Drug Abuse (NIDA)",ALL,"ADULT, OLDER_ADULT",180,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-06-15,2027-09-01,"University of Maryland Baltimore (UMD Drug Treatment Center), Baltimore, Maryland, 21223, United States|University of Maryland, College Park, College Park, Maryland, 20742, United States|Caroline County Behavioral Health, Denton, Maryland, 21629, United States"
NCT05585203,Contingency Management for Recovery Oriented Activities at Recovery Houses,https://clinicaltrials.gov/study/NCT05585203,RECRUITING,NO,Substance Use Disorders,BEHAVIORAL: Contingency management|BEHAVIORAL: Usual Care,Wayne State University,,ALL,"ADULT, OLDER_ADULT",120,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-01,2024-09-20,"Wayne State University School of Medicine, Detroit, Michigan, 48201, United States"
NCT01554423,Four-Arm Randomized Control Trial of Brief MI Versus Couples-Based HIV/STI Prevention in South Africa,https://clinicaltrials.gov/study/NCT01554423,COMPLETED,NO,HIV Prevention,OTHER: Testing and Counseling|BEHAVIORAL: Brief Motivational Interview (BMI)|BEHAVIORAL: Integrated Family and Cognitive Behavioral Therapy,The City College of New York,National Institute on Drug Abuse (NIDA),ALL,ADULT,464,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2010-07,2017-06-30,"Louis Pasteur Medical Centre, Pretoria, Gauteng, 0002, South Africa"
NCT02755103,Mindfulness Meditation for the Treatment of Women With Comorbid PTSD and SUD,https://clinicaltrials.gov/study/NCT02755103,COMPLETED,YES,"Stress Disorders, Post-Traumatic|Substance-Related Disorders",BEHAVIORAL: Mindfulness Based Relapse Prevention (MBRP),Medical University of South Carolina,National Institute on Drug Abuse (NIDA)|National Institutes of Health (NIH),FEMALE,"ADULT, OLDER_ADULT",90,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-06-01,2021-10-01,"The Charleston Center, Charleston, South Carolina, 29401, United States"
NCT05560737,ODYSSEE-vCHAT Mental Health Program for Heart Failure and Kidney Disease Patients,https://clinicaltrials.gov/study/NCT05560737,ACTIVE_NOT_RECRUITING,NO,Chronic Heart Failure|Chronic Kidney Diseases,BEHAVIORAL: ODYSSEE-vCHAT,"University Health Network, Toronto","Sunnybrook Health Sciences Centre|Mount Sinai Hospital, Canada|The Ottawa Hospital",ALL,"ADULT, OLDER_ADULT",215,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-09-14,2023-12-31,"The Ottawa Hospital, Ottawa, Ontario, K1H 7W9, Canada|University Health Network, Toronto, Ontario, M2N 7A2, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada"
NCT04025697,Complete Denture Tooth Movement in Digital Light Processing Versus Conventional Fabrication Techniques,https://clinicaltrials.gov/study/NCT04025697,UNKNOWN,NO,Rapid Prototyping in Dentures,OTHER: Complete Denture|OTHER: Rapid prototyped denture,Cairo University,,ALL,ADULT,14,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2019-10-01,2021-10-30,
NCT05860257,"Transforming Adolescent Mental Health Through Accessible, Scalable, Technology-supported Small-group Instruction",https://clinicaltrials.gov/study/NCT05860257,RECRUITING,NO,Anxiety Depression|Suicidal Ideation,BEHAVIORAL: PeerLearning.net,University of Oregon,"Arizona State University|University of Wisconsin, Madison|Oregon Research Institute",ALL,"CHILD, ADULT, OLDER_ADULT",1200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2023-09-01,2027-06-15,"Arizona State University, Tempe, Arizona, 85281, United States|U of Oregon, Eugene, Oregon, 97401, United States|U of Wisconsin, Madison, Wisconsin, 53706, United States"
NCT05555264,Enhancing Internet-delivered Cognitive Behaviour Therapy for Alcohol Misuse,https://clinicaltrials.gov/study/NCT05555264,ACTIVE_NOT_RECRUITING,NO,Alcohol Misuse,BEHAVIORAL: Self-Guided|BEHAVIORAL: Therapist-Guided,University of Regina,Saskatchewan Health Research Foundation|Saskatchewan Centre for Patient-Oriented Research,ALL,"ADULT, OLDER_ADULT",205,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-09-16,2025-03-31,"Online Therapy Unit, University of Regina, Regina, Saskatchewan, S4S 0A2, Canada"
NCT02065349,A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety,https://clinicaltrials.gov/study/NCT02065349,COMPLETED,NO,Post-Herpetic Neuralgia (PHN)|Neuropathic Pain|Painful Diabetic Peripheral Neuropathy (PDPN),DRUG: ASP8477|DRUG: Placebo,Astellas Pharma Europe B.V.,,ALL,"ADULT, OLDER_ADULT",132,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2014-02-24,2015-02-13,"Site: CZ42003, Chocen, 561 01, Czechia|Site: CZ42004, Litomysl, 517 14, Czechia|Site: CZ42011, Olomouc, 77900, Czechia|Site: CZ42014, Praha 2, 12000, Czechia|Site: CZ42001, Rychnov nad Kneznou, 516 01, Czechia|Site: CZ42002, Slezska Ostrava, 710 00, Czechia|Site: DE49003, Koeln, 50937, Germany|Site: DE49005, Neuss, 41460, Germany|Site: PL48003, Bialystok, 15-950, Poland|Site: PL48004, Poznan, 60-773, Poland|Site: PL48001, Poznan, 61-655, Poland|Site: PL48002, Torun, 87-100, Poland|Site: PL48005, Warszawa, 00-465, Poland|Site: GB44001, Glasgow, Scotland, G12OYN, United Kingdom|Site: GB44003, Ipswich, IP45PD, United Kingdom|Site: GB44006, London, SE17EH, United Kingdom|Site: GB44002, Manchester, M320UT, United Kingdom"
NCT03624075,Effect of Kinesio Taping in Women With Knee Osteoarthritis,https://clinicaltrials.gov/study/NCT03624075,COMPLETED,NO,Kinesio Taping|Knee Osteoarthritis,OTHER: application of kinesio taping,Universidade Federal do Rio Grande do Norte,,FEMALE,"ADULT, OLDER_ADULT",45,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-06-11,2019-06-11,"Faculdade de ciências da saúde do trairi - FACISA/UFRN, Santa Cruz, Brazil"
NCT06488612,Evaluation of the Use of Minced Skin Grafts for Promoting Donor Site Wound Healing After Split-Thickness Skin Grafting,https://clinicaltrials.gov/study/NCT06488612,RECRUITING,NO,"Traumatic Skin Loss, 2nd and 3rd Degree Burn, Post Tumour Excision - Raw Areas Undergoes Split- Thickness Skin Grafts",PROCEDURE: Minced skin grafts for donor site,Sohag University,,ALL,"CHILD, ADULT",20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-12-01,2024-12-01,"Plastic surgery department, Faculty of medicine, Sohag university, Sohag, 02093, Egypt"
NCT06218056,Cannabidiol for Reducing Cigarette Use,https://clinicaltrials.gov/study/NCT06218056,RECRUITING,NO,Tobacco Use Disorder|Tobacco Smoking|Tobacco Dependence,DRUG: Cannabidiol (CBD) 800 mg|DRUG: Placebo,"University of California, Los Angeles",,ALL,"ADULT, OLDER_ADULT",120,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-10-31,2026-12-31,"CRI-Help, Inc., North Hollywood, California, 91601, United States"
NCT03506880,Project MADD - NIH Underage DUI and Ride,https://clinicaltrials.gov/study/NCT03506880,COMPLETED,YES,"Underage Drinking|Driving Under the Influence|Drinking, Teen",BEHAVIORAL: MADD Materials|BEHAVIORAL: Surgeon General Materials,Penn State University,National Institutes of Health (NIH)|National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"CHILD, ADULT",2352,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2017-11-17,2022-04-30,"Penn State University, University Park, Pennsylvania, 16802, United States"
NCT00586534,Developing Computer Based Treatments for Addiction,https://clinicaltrials.gov/study/NCT00586534,COMPLETED,NO,Cocaine Addiction,BEHAVIORAL: I/GDC + VR/CER|BEHAVIORAL: I/GDC,Duke University,National Institute on Drug Abuse (NIDA),ALL,ADULT,216,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2007-01,2014-12,"Duke University Medical Center, Durham, North Carolina, 27710, United States"
NCT01695850,"A Double-blinded,Double-dummy Clinical Trial of Chinese Herbal Medicine (MaZiRenWan) for Functional Constipation",https://clinicaltrials.gov/study/NCT01695850,COMPLETED,NO,Functional Constipation|Gastrointestinal Disorders,DRUG: MZRW|DRUG: Senna|DRUG: placebo,Hong Kong Baptist University,"Queen Elizabeth Hospital, Hong Kong|Prince of Wales Hospital, Shatin, Hong Kong",ALL,"ADULT, OLDER_ADULT",291,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-06,2015-08,"School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong, China"
NCT02573194,The Effect of Breakfasts Varying in Protein Source on Appetite and Energy Intake,https://clinicaltrials.gov/study/NCT02573194,COMPLETED,NO,Obesity,DIETARY_SUPPLEMENT: Breakfasts varying in protein source content on appetite,Lund University,,MALE,ADULT,28,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2015-08,2015-11,"Food for Health Science Center, Lund, Scania, 223 81, Sweden"
NCT06187025,Addiction & Stroke,https://clinicaltrials.gov/study/NCT06187025,RECRUITING,NO,Stroke,"OTHER: Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)|OTHER: Ecological Momentary Assessment (EMA)","University Hospital, Bordeaux",,ALL,"ADULT, OLDER_ADULT",300,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2024-02-07,2027-08-07,"CHU de Bordeaux, Bordeaux, 33076, France"
NCT05143424,Evaluation of the Interactions of Cannabidiol (CBD) With Morphine,https://clinicaltrials.gov/study/NCT05143424,RECRUITING,NO,Opioid Use Disorder,DRUG: Morphine Sulfate,National Institute on Drug Abuse (NIDA),,ALL,ADULT,60,NIH,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC,2021-11-04,2024-12-01,"AltaSciences, Overland Park, Kansas, 66212, United States"
NCT05201196,Task Oriented Training in Post Stroke Patients,https://clinicaltrials.gov/study/NCT05201196,COMPLETED,NO,Stroke,OTHER: Conventional physical therapy|OTHER: Task Oriented Training,Riphah International University,,ALL,"ADULT, OLDER_ADULT",70,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-08-15,2022-01-30,"Riphah international university, Lahore, Pakistan(Punjab_, 54000, Pakistan"
NCT04868513,Streptococcus Mutans Reduction Early Mother-infant Transmission,https://clinicaltrials.gov/study/NCT04868513,COMPLETED,NO,Pregnant Women,DRUG: Pregnant women to whom applied silane fluoride|DRUG: Pregnant women to whom applied silane fluoride + 1% chlorhexidine,"Biochemical and Microbiology Laboratory, Faculty of Dentistry, Autonomous University of San Luis Pot",,FEMALE,ADULT,58,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION,2015-01,2017-12,
NCT02326363,Mindfulness-Based Recovery in Veterans,https://clinicaltrials.gov/study/NCT02326363,COMPLETED,YES,Substance Abuse|Depression|Anxiety Disorder,BEHAVIORAL: Mindfulness Based Relapse Prevention (MBRP)|BEHAVIORAL: Twelve-Step Facilitation Intervention (TSF),VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",204,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-03-16,2018-10-29,"Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa, Alabama, 35404, United States|Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, 29401-5799, United States"
NCT03366636,Project Legacy Impact Evaluation Study,https://clinicaltrials.gov/study/NCT03366636,COMPLETED,NO,Pregnancy Prevention|Sexual Behavior|Contraception Behavior|Sexually Transmitted Diseases,BEHAVIORAL: Project Legacy,Children's Hospital Los Angeles,ETR Associates,ALL,"CHILD, ADULT",571,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2017-10-30,2021-03-30,"Five Keys, Boyle Heights, California, 90033, United States|Youth Program, Long Beach, California, 90712, United States|Century Villages at Cabrillo, Long Beach, California, 90810, United States|Da Vinci Rise High, Los Angeles, California, 90011, United States|LA CAUSA Youth Build, Los Angeles, California, 90022, United States|Covenant House, Los Angeles, California, 90027, United States|Los Angeles LGBT Center, Los Angeles, California, 90038, United States|YMCA of San Diego County, Oceanside, California, 92054, United States|San Diego Central Library, San Diego, California, 92101, United States|San Diego Youth Services, San Diego, California, 92110, United States|Monarch School, San Diego, California, 92113, United States|Safe Place for Youth, Venice, California, 90291, United States"
NCT04859296,AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT),https://clinicaltrials.gov/study/NCT04859296,RECRUITING,NO,"Pain|Appetite Loss|Abuse, Drug",DRUG: Placebo|DRUG: Low CBG|DRUG: High CBG|DRUG: Low THC|DRUG: High THC,"University of California, Los Angeles",Center for Medicinal Cannabis Research,ALL,ADULT,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2023-02-15,2026-06-22,"University of California, Los Angeles, Los Angeles, California, 90095, United States"
NCT00591617,Optimizing Outcomes Using Suboxone for Opiate Dependence,https://clinicaltrials.gov/study/NCT00591617,COMPLETED,NO,Opioid Dependency,OTHER: Psychosocial treatment plus Suboxone pharmacotherapy,"University of California, Los Angeles",,ALL,"CHILD, ADULT, OLDER_ADULT",202,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2006-09,2012-12,"UCLA Integrated Substance Abuse Programs Outpatient Clinical Research Center, Los Angeles, California, 90025, United States"
NCT04411225,Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis,https://clinicaltrials.gov/study/NCT04411225,RECRUITING,NO,Early Psychosis,DRUG: Cannabidiol oral solution,"University of California, San Diego",Center for Medicinal Cannabis Research,ALL,"CHILD, ADULT",120,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-06-01,2025-10-30,"UC San Diego, La Jolla, California, 92093, United States|University of California, San Diego, San Diego, California, 92093, United States"
NCT02909686,Effects of Botanical Microglia Modulators in Gulf War Illness,https://clinicaltrials.gov/study/NCT02909686,COMPLETED,YES,Gulf War Illness,DIETARY_SUPPLEMENT: Boswellia Serrata|DIETARY_SUPPLEMENT: Curcumin|DIETARY_SUPPLEMENT: Epimedium|DIETARY_SUPPLEMENT: Fisetin|DIETARY_SUPPLEMENT: Luteolin|DIETARY_SUPPLEMENT: Nettle|DIETARY_SUPPLEMENT: Pycnogenol|DIETARY_SUPPLEMENT: Reishi Mushroom|DIETARY_SUPPLEMENT: Resveratrol|DIETARY_SUPPLEMENT: Placebo,University of Alabama at Birmingham,Congressionally Directed Medical Research Programs,MALE,"ADULT, OLDER_ADULT",36,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2016-07,2022-09,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States"
NCT04941950,A Digital Intervention to Prevent the Initiation of Opioid Misuse in Adolescents in School-based Health Centers,https://clinicaltrials.gov/study/NCT04941950,ACTIVE_NOT_RECRUITING,NO,Opioid Misuse,BEHAVIORAL: PlaySmart|OTHER: Video Game Control,Trustees of Dartmouth College,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",533,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-10-19,2025-03,"Harding High School, Bridgeport, Connecticut, 06610, United States|Coginchaug High School, Durham, Connecticut, 06422, United States|CT River Academy, East Hartford, Connecticut, 06118, United States|Fairfield College Preparatory School, Fairfield, Connecticut, 06824, United States|Fitch High School, Groton, Connecticut, 06340, United States|Hamden High School, Hamden, Connecticut, 06514, United States|Weaver High School, Hartford, Connecticut, 06112, United States|Maloney High School, Meriden, Connecticut, 06450, United States|Platt High School, Meriden, Connecticut, 06450, United States|Hopkins High School, New Haven, Connecticut, 06515, United States|New London High School, New London, Connecticut, 06320, United States|Stamford High School, Stamford, Connecticut, 06902, United States|Westhill High School, Stamford, Connecticut, 06902, United States|Academy of Information, Technology, and Engineering, Stamford, Connecticut, 06905, United States|West Haven High School, West Haven, Connecticut, 06516, United States"
NCT05033821,A Library-based Prevention Intervention for Adolescents Affected by Parental Drug Use,https://clinicaltrials.gov/study/NCT05033821,COMPLETED,NO,Substance Use|Sexual Behavior|Adolescent Behavior,BEHAVIORAL: Adapted FOY+ImPACT,Johns Hopkins Bloomberg School of Public Health,,ALL,CHILD,61,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-07-08,2023-08-11,"Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21212, United States"
NCT01079117,Morphine Slow-release Capsules in Substitution Therapy,https://clinicaltrials.gov/study/NCT01079117,COMPLETED,NO,Opiate Dependent,DRUG: Sevre-Long™|DRUG: Slow release oral morphine|DRUG: Methadone,Mundipharma Medical Company,,ALL,"ADULT, OLDER_ADULT",276,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2006-10,2011-06,"Zurich, Switzerland"
NCT04762537,Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone,https://clinicaltrials.gov/study/NCT04762537,COMPLETED,YES,Opioid-use Disorder,OTHER: Standard Induction Procedure (SP)|OTHER: Rapid Induction Procedure (RP),New York State Psychiatric Institute,"National Institute on Drug Abuse (NIDA)|The Emmes Company, LLC",ALL,"ADULT, OLDER_ADULT",415,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2021-03-16,2022-12-21,"Aspire Health Partners, Orlando, Florida, 32810, United States|Avery Road Treatment Center, Rockville, Maryland, 20853, United States|Gibson Recovery Center, Inc., Cape Girardeau, Missouri, 63703, United States|Stony Brook Eastern Long Island Hospital, Greenport, New York, 11944, United States|Adapt, Roseburg, Oregon, 97470, United States|Nexus Recovery Center, Inc., Dallas, Texas, 75228, United States"
NCT04405362,Consequences of the QUARANTINE Relating to the COvid-19 Epidemic on the Mental Health of the Patients Followed in PSYchiatry,https://clinicaltrials.gov/study/NCT04405362,UNKNOWN,NO,SARS-CoV 2|Traumatic Stress Disorder,,"University Hospital, Lille",,ALL,"ADULT, OLDER_ADULT",753,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-05,2021-05,
NCT03194191,Pregnancy With Insomnia: a Trial of Acupuncture,https://clinicaltrials.gov/study/NCT03194191,UNKNOWN,NO,Insomnia,DEVICE: Acupuncture needles,Assistance Publique - Hôpitaux de Paris,,FEMALE,"ADULT, OLDER_ADULT",60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2017-09,2019-05,
NCT05812339,Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls,https://clinicaltrials.gov/study/NCT05812339,ENROLLING_BY_INVITATION,NO,Motility Disorder|Gastroparesis|Functional Dyspepsia|Cyclical Vomiting|Cannabinoid Hyperemesis Syndrome|Diabetic Gastroparesis,DEVICE: Gastric Alimetry System,University of Calgary,,ALL,"ADULT, OLDER_ADULT",200,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-11-01,2025-12-31,"University of Calgary, Calgary, Alberta, T2N 4Z6, Canada"
NCT06620900,Expanding Access to mTBI Treatment for Veterans and Service Members With Co-occurring Substance Use,https://clinicaltrials.gov/study/NCT06620900,NOT_YET_RECRUITING,NO,"Concussion, Mild Traumatic Brain Injury|Brain Injury|Traumatic Brain Injury|Substance Use|Substance Use Disorder (SUD)",OTHER: Integrated Model of Care,"Shepherd Center, Atlanta GA",,ALL,"ADULT, OLDER_ADULT",360,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2025-02,2028-08,"Shepherd Center, Atlanta, Georgia, 30309, United States"
NCT03125291,Optimizing a Drug Abuse Prevention Program for Dissemination,https://clinicaltrials.gov/study/NCT03125291,UNKNOWN,NO,Substance Abuse|Mental Health|Educational Problems,BEHAVIORAL: Bridges 4-week Program,Arizona State University,National Institute on Drug Abuse (NIDA),ALL,CHILD,664,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2015-07-28,2019-09,"Arizona State University, Tempe, Arizona, 85287-1106, United States"
NCT03003260,The Effect of CanChew® Cannabidiol (CBD) Containing Chewing Gum on Irritable Bowel Syndrome,https://clinicaltrials.gov/study/NCT03003260,UNKNOWN,NO,Irritable Bowel Syndrome,OTHER: CBD chewing gum|OTHER: Placebo,Wageningen University,,ALL,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-12,2017-06,"Wageningen University, Wageningen, Gelderland, 6700 EV, Netherlands"
NCT03134833,Engaging Seronegative Youth to Optimize HIV Prevention Continuum,https://clinicaltrials.gov/study/NCT03134833,COMPLETED,NO,HIV|Mental Health|Substance Use|STI,BEHAVIORAL: Automated Messaging & Monitoring|BEHAVIORAL: Peer Support|BEHAVIORAL: Coaching,"University of California, Los Angeles","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Tulane University Health Sciences Center|University of California, San Francisco|Friends Research Institute, Inc.",ALL,"CHILD, ADULT",1478,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2017-05-06,2022-11-30,"University of California, Los Angeles, Los Angeles, California, 90024, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, 70112, United States"
NCT06320327,Topical CBD's Effects on Soreness and Performance,https://clinicaltrials.gov/study/NCT06320327,COMPLETED,NO,Muscle Soreness,OTHER: Cannabidiol cream|OTHER: Placebo cream,Joseph Pastina,,ALL,ADULT,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2022-08-23,2023-04-30,"Seaton Center Building, Lexington, Kentucky, 40502, United States|Multidisciplinary Science Building, Lexington, Kentucky, 40536, United States"
NCT01813123,A Web-Based Intervention to Prevent Drug Abuse Among Adolescent Girls,https://clinicaltrials.gov/study/NCT01813123,COMPLETED,NO,Drug Abuse Prevention,BEHAVIORAL: RealTeen,Columbia University,National Institute on Drug Abuse (NIDA),FEMALE,CHILD,788,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2013-03,2019-01-30,"Columbia University School of Social Work, New York, New York, 10027, United States"
NCT05793944,SmartMom: Teaching by Texting to Promote Health Behaviours in Pregnancy,https://clinicaltrials.gov/study/NCT05793944,RECRUITING,NO,Pregnancy,BEHAVIORAL: SmartMom text messaging|BEHAVIORAL: Control text messaging,University of British Columbia,Canadian Institutes of Health Research (CIHR),FEMALE,"CHILD, ADULT, OLDER_ADULT",3078,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-11-10,2026-02,"BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada"
NCT04796246,Leap Motion Controller on the Functionality of Upper Limbs in Parkinson's Disease,https://clinicaltrials.gov/study/NCT04796246,COMPLETED,NO,Parkinson Disease|Upper Extremity Dysfunction|Therapy-Related MDS,OTHER: Leap Motion Controller|OTHER: Conventional Physiotherapy,Federal University of Health Science of Porto Alegre,,ALL,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-01-15,2023-08-01,"Philipe Souza Correa, Porto Alegre, RIO Grande DO SUL, 55, Brazil"
NCT05222061,A Study of Drug Coated Balloon For Treating the Side Branch in Complex Bifurcation Lesions,https://clinicaltrials.gov/study/NCT05222061,UNKNOWN,NO,Coronary Artery Disease,DEVICE: Drug coated balloon for the side brunch|DEVICE: Conventional balloon for the side brunch,Meshalkin Research Institute of Pathology of Circulation,,ALL,"ADULT, OLDER_ADULT",80,NETWORK,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-02-15,2023-02-15,"Meshalkin National Medical Research Center, Novosibirsk, Novosibirskaya Oblast, 630055, Russian Federation"
NCT06594835,Test of the Better Together Intervention,https://clinicaltrials.gov/study/NCT06594835,COMPLETED,NO,Substance Use,BEHAVIORAL: Better Together|BEHAVIORAL: Youth In the Media (YM),Johns Hopkins Bloomberg School of Public Health,,ALL,CHILD,54,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-09-01,2024-05-01,"Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205, United States"
NCT05122988,Facing Adverse Childhood Experiences,https://clinicaltrials.gov/study/NCT05122988,ACTIVE_NOT_RECRUITING,NO,Adverse Childhood Experiences,,University of Applied Sciences and Arts Northwestern Switzerland,,ALL,ADULT,2606,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-10-28,2024-11,"University of Applied Science Northwestern Switzerland, Olten, 4600, Switzerland"
NCT04791124,Assessment of Neural Oscillations in Adult Subjects With Down Syndrome and Typically Developing Subjects in Resting State and While Conducting Cognitive Tasks,https://clinicaltrials.gov/study/NCT04791124,UNKNOWN,NO,Down Syndrome,OTHER: Electroencephalography,Parc de Salut Mar,Aelis Farma|Starlab,ALL,ADULT,48,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-01-11,2021-06-01,"IMIM (Hospital del Mar Medical Research Institute), Barcelona, 08003, Spain"
NCT03367234,Patient-Centered Care for Opioid Use Disorders in Federally Qualified Healthcare Centers and Specialty Care Settings,https://clinicaltrials.gov/study/NCT03367234,WITHDRAWN,NO,Opioid-use Disorder|Substance Use Disorders,BEHAVIORAL: Individual Therapy Sessions|BEHAVIORAL: Cognitive Behavioral Therapy (CBT)|BEHAVIORAL: Medication-Assisted Treatment|BEHAVIORAL: Peer Recovery Specialist Support|BEHAVIORAL: Group Therapy Sessions|BEHAVIORAL: Psychiatric Consultation|BEHAVIORAL: Contingency Management,Public Health Management Corporation,Patient-Centered Outcomes Research Institute,ALL,"ADULT, OLDER_ADULT",0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-07,2022-06-30,
NCT02882919,Check Yourself v2.0,https://clinicaltrials.gov/study/NCT02882919,COMPLETED,NO,Adolescent Behavior,BEHAVIORAL: Check Yourself v2.0,Carolyn McCarty,,ALL,"CHILD, ADULT",300,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2016-10,2018-08,"Seattle Children's Hospital, Seattle, Washington, 98105, United States"
NCT03458299,Strategies: Motivational Interviewing/Psychoeducation,https://clinicaltrials.gov/study/NCT03458299,COMPLETED,NO,"Alcohol Use, Underage|Substance Use|Underage Drinking",BEHAVIORAL: Motivational Interviewing|BEHAVIORAL: Psychoeducation,Pacific Institute for Research and Evaluation,National Institute on Alcohol Abuse and Alcoholism (NIAAA)|The Scripps Research Institute,ALL,"CHILD, ADULT",75,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2018-01-23,2022-02-09,"Southern California Tribal Health Center, Valley Center, California, 92082, United States"
NCT05893550,Omega-3 Supplementation to Both Parent and Adolescent,https://clinicaltrials.gov/study/NCT05893550,RECRUITING,NO,Behavior Problems,DIETARY_SUPPLEMENT: Smartfish Omega|DIETARY_SUPPLEMENT: Smartfish Fruit Juice Only,"Joint Child Health Project, Mauritius",University of Pennsylvania,ALL,"CHILD, ADULT",800,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-03-05,2023-07-31,"Joint Child Health Project, Quatre Bornes, Mauritius"
NCT02375516,Preventing Drug Abuse Among Hispanic Adolescents,https://clinicaltrials.gov/study/NCT02375516,COMPLETED,NO,Drug Abuse,BEHAVIORAL: Prevention Program,Columbia University,National Institute on Drug Abuse (NIDA),ALL,CHILD,678,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2012-09,2021-04-07,"Columbia University Irving Medical Center, New York, New York, 10032, United States"
NCT01847768,Human Rhinovirus Infection and Airway Remodeling Mediators,https://clinicaltrials.gov/study/NCT01847768,TERMINATED,NO,Asthma,BIOLOGICAL: GMP-grade HRV-39|PROCEDURE: Bronchoalveolar Lavage|DRUG: Methacholine Inhalation Challenge|PROCEDURE: Nasal Lavage|PROCEDURE: Nasal Scrapings|PROCEDURE: Bronchial Brushings|PROCEDURE: Lung Mucosal Biopsy|PROCEDURE: Allergen Skin Prick Testing|PROCEDURE: Venipuncture|PROCEDURE: Bronchoscopy|PROCEDURE: Spirometry,National Institute of Allergy and Infectious Diseases (NIAID),Asthma and Allergic Diseases Cooperative Research Centers,ALL,ADULT,2,NIH,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2013-04,2015-07,"University of Calgary, Calgary, Alberta, T2N 4Z6, Canada"
NCT06749912,"Effects of a Lower Back Wrap Device on Lower Back Pain, Physical Function, and Quality of Life",https://clinicaltrials.gov/study/NCT06749912,RECRUITING,NO,Lower Back Pain|Lower Back Pain Chronic|Acute Low Back Pain,DEVICE: Low back pain wrap,State University of New York at Buffalo,,ALL,"ADULT, OLDER_ADULT",150,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-12-02,2025-11-01,"University at Buffalo, Buffalo, New York, 14203, United States"
NCT05450146,Trial-based Effectiveness and Cost-effectiveness of the Partner in Balance Intervention,https://clinicaltrials.gov/study/NCT05450146,RECRUITING,NO,"Dementia, Mild",OTHER: Partner in Balance,Maastricht University,VU University of Amsterdam|ZonMw: The Netherlands Organisation for Health Research and Development,ALL,"ADULT, OLDER_ADULT",141,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-04-01,2026-02-28,"Alzheimer Centrum Limburg, Maastricht, Limburg, 6221, Netherlands"
NCT04589455,Pharmacokinetics of CBD From a Hennep Extract,https://clinicaltrials.gov/study/NCT04589455,UNKNOWN,NO,CBD Pharmacokinetics,DIETARY_SUPPLEMENT: Hennep extract,Wageningen University,Becanex,ALL,ADULT,12,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-01-10,2021-03-10,"Wageningen University, Division of Human Nutrition, Wageningen, Netherlands"
NCT03954535,Preventing Drug Abuse Among Sexual Minority Youth,https://clinicaltrials.gov/study/NCT03954535,COMPLETED,NO,Substance Abuse,BEHAVIORAL: Free2b|BEHAVIORAL: Attention-Placebo,Columbia University,National Institute on Drug Abuse (NIDA),ALL,CHILD,1216,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2020-01-15,2024-03-30,"Columbia University Irving Medical Center, New York, New York, 10032, United States"
NCT05006079,Opioid/Benzodiazepine Polydrug Abuse: Aim 3,https://clinicaltrials.gov/study/NCT05006079,RECRUITING,NO,Opioid Abuse|Benzodiazepine Abuse|Polysubstance Abuse,DRUG: Morphine|DRUG: Alprazolam|DRUG: Placebo,Wayne State University,Henry Ford Health System,ALL,"ADULT, OLDER_ADULT",24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2024-03-13,2025-12,"Tolan Park Medical Building, Detroit, Michigan, 48201, United States"
NCT02240485,Integrative Couple Treatment for Pathological Gambling,https://clinicaltrials.gov/study/NCT02240485,COMPLETED,YES,Pathological Gambling,BEHAVIORAL: Integrative Couple Treatment for Pathological Gambling (ICT-PG)|BEHAVIORAL: Usual individual/group treatment,Université du Québec à Trois-Rivières,,ALL,"ADULT, OLDER_ADULT",80,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-03-01,2018-07,"Université du Québec à Trois-Rivières, Québec, G1S2P1, Canada"
NCT04659408,Probiotic and Prebiotic Supplementation in Elite Athletes with Spinal Cord Injury,https://clinicaltrials.gov/study/NCT04659408,COMPLETED,NO,Spinal Cord Injuries,DIETARY_SUPPLEMENT: Multistrain probiotic preparation|DIETARY_SUPPLEMENT: Oat Bran,"Swiss Paraplegic Research, Nottwil",,ALL,"ADULT, OLDER_ADULT",14,NETWORK,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2021-03-01,2021-10-29,"Swiss Paraplegic Centre, Nottwil, Luzern, 6207, Switzerland"
NCT05116956,SKin and Soft Tissue Necrotizing INfections in the Intensive Care Unit: a Prospective Multi-national Cohort Study,https://clinicaltrials.gov/study/NCT05116956,UNKNOWN,NO,Necrotizing Fasciitis|Fournier Gangrene|Necrotizing Soft Tissue Infection,OTHER: non interventional,Henri Mondor University Hospital,European Society of Intensive Care Medicine,ALL,"ADULT, OLDER_ADULT",1033,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-11-08,2023-07-22,"Hopital Henri Mondor, Créteil, 94000, France"
NCT02894229,The Stress Reduction Intervention Study,https://clinicaltrials.gov/study/NCT02894229,UNKNOWN,NO,"Stress, Physiological|Stress, Psychological",BEHAVIORAL: Mindfulness Based Stress Reduction|BEHAVIORAL: Cognitive-Behavioral Therapy (CBT) Group,Ohio University,,ALL,ADULT,150,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-08,2019-07,
NCT03966885,Zambia Common Elements Treatment Approach Pilot Study,https://clinicaltrials.gov/study/NCT03966885,TERMINATED,YES,Alcohol Use Disorder|Depression|Post-traumatic Stress Disorder|HIV/AIDS|Substance Use Disorders,BEHAVIORAL: Brief Intervention|BEHAVIORAL: Common Elements Treatment Approach (CETA),Columbia University,Centre for Infectious Disease Research in Zambia|University of Alabama at Birmingham|National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"ADULT, OLDER_ADULT",160,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-06-24,2020-03-17,"Centre for infectious Disease Research in Zambia, Lusaka, Zambia"
NCT02797990,Conflict Between Maternal Autonomy and Child Health in Substance-use,https://clinicaltrials.gov/study/NCT02797990,COMPLETED,NO,"Substance-Related Disorders|Alcohol-Related Disorders|Amphetamine-Related Disorders|Inhalant Abuse|Cocaine-Related Disorders|Opioid-Related Disorders|Marijuana Abuse|Substance Abuse, Intravenous|Neonatal Abstinence Syndrome|Pregnancy|Pregnancy, High-Risk",,London School of Hygiene and Tropical Medicine,,ALL,"CHILD, ADULT, OLDER_ADULT",6,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-05,2016-09,"Trevor Mann Baby Unit, Royal Sussex County Hospital, Brighton, BN2 5BE, United Kingdom"
NCT03109431,Stepped Care for Youth Living With HIV,https://clinicaltrials.gov/study/NCT03109431,COMPLETED,NO,HIV|Mental Health|Illicit Substance Use|Sexually Transmitted Infections (STI),BEHAVIORAL: Level 1|BEHAVIORAL: Level 2|BEHAVIORAL: Level 3,"University of California, Los Angeles",Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Tulane University Health Sciences Center,ALL,"CHILD, ADULT",170,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2017-05-06,2022-11-30,"University of California, Los Angeles, Los Angeles, California, 90024, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, 70112, United States"
NCT05545904,Feasibility of Peer-mentor Delivered Substance Use Brief Intervention for Adolescents in Kenya,https://clinicaltrials.gov/study/NCT05545904,UNKNOWN,NO,Substance Use,BEHAVIORAL: Substance use brief intervention (BI)|BEHAVIORAL: substance use education intervention,Moi University,Indiana University,ALL,"CHILD, ADULT",60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-01-15,2024-06-30,"Florence Jaguga, Eldoret, RIFT Valley, 30100, Kenya"
NCT01690546,Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence,https://clinicaltrials.gov/study/NCT01690546,COMPLETED,YES,Opiate Dependence,DRUG: very low dose naltrexone|DRUG: extended release naltrexone|DRUG: buprenorphine/naloxone,Paolo Mannelli,"Alkermes, Inc.",ALL,"ADULT, OLDER_ADULT",38,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-09,2015-02,"Duke University Medical Center / Civitan Building, Durham, North Carolina, 27705, United States"
NCT06655961,The Effect of Gardening Activities on Anxiety and Psychosocial Symptoms of Hospitalized Children,https://clinicaltrials.gov/study/NCT06655961,NOT_YET_RECRUITING,NO,Gardening|Pediatric Nursing|Activity|Psychosocial Symptoms|Anxiety|Hospital|Child|Investigation of Anxiety Levels and Psychosocial Symptoms of Children Hospitalized for Acute Diseases During Their Hospital Stay,OTHER: Garden Activities Program|OTHER: Clinical routine treatment and nursing care protocol,Tokat Gaziosmanpasa University,,ALL,CHILD,36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2024-12,2025-09,"Tokat Gaziosmanpasa University, Tokat, Turkey"
NCT02033707,Effects of Hallucinogens and Other Drugs on Mood and Performance,https://clinicaltrials.gov/study/NCT02033707,COMPLETED,NO,Healthy,DRUG: Hallucinogens and psychoactive substances,Johns Hopkins University,,ALL,ADULT,20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2014-04,2019-02,"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, 21224, United States"
NCT06399822,Impact of Capillaroscopy on the Management of Undifferentiated Connective Tissue Disease,https://clinicaltrials.gov/study/NCT06399822,RECRUITING,NO,Undifferentiated Connective Tissue Diseases,DIAGNOSTIC_TEST: Nail capillaroscopy,CHU de Quebec-Universite Laval,,ALL,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2024-05-22,2025-12,"CHU de Quebec-Université Laval, Québec, Quebec, G1V4G2, Canada"
NCT05745480,Natural Language Processing for Screening Opioid Misuse,https://clinicaltrials.gov/study/NCT05745480,COMPLETED,NO,Opioid Use Disorder|Opioid Misuse,OTHER: Opioid Misuse Screening with an Addiction Consult Service,"University of Wisconsin, Madison",,ALL,"ADULT, OLDER_ADULT",47502,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-03-06,2023-12-31,"University of Wisconsin Hospital (UW Health), Madison, Wisconsin, 53792, United States"
NCT06300957,Help Wanted: Evaluating a Prevention Intervention for People With Sexual Interest in Children,https://clinicaltrials.gov/study/NCT06300957,RECRUITING,NO,Program Evaluation|Child Sexual Abuse|Perpetration of Child Sexual Abuse|Prevention Intervention,OTHER: Help Wanted Prevention Intervention|OTHER: Waitlist Control,Johns Hopkins Bloomberg School of Public Health,"Barry University|University of Massachusetts, Lowell",MALE,"ADULT, OLDER_ADULT",310,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-10-24,2026-10-31,"Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21231, United States"
NCT06769282,Trauma-Informed Peer Aggression and Dating Violence Prevention for Preteens Receiving Intensive Mental Health Services,https://clinicaltrials.gov/study/NCT06769282,RECRUITING,NO,Aggression Childhood|Teen Dating Violence,BEHAVIORAL: Experimental: Intervention (SPARE) plus Treatment as Usual|BEHAVIORAL: Treatment as Usual (TAU),Rhode Island Hospital,Centers for Disease Control and Prevention,ALL,CHILD,88,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2024-10-25,2027-03-30,"Rhode Island Hospital, Providence, Rhode Island, 02906, United States"
NCT06580457,Understanding and Treating Substance Use Disorder and Comorbid Conditions in Veterans' Real-Life Settings,https://clinicaltrials.gov/study/NCT06580457,NOT_YET_RECRUITING,NO,Substance Use Disorder,BEHAVIORAL: Personal Causal Model + Personalized Feedback,VA Office of Research and Development,Emory University|University of Minnesota,ALL,"ADULT, OLDER_ADULT",74,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-05-01,2029-12-01,"Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, 55417-2309, United States"
NCT06018389,Prevention of Hazardous Use of Alcohol with Danish High School Students (Our Choice),https://clinicaltrials.gov/study/NCT06018389,ENROLLING_BY_INVITATION,NO,Healthy Participants,BEHAVIORAL: Structural only|BEHAVIORAL: Structural+Group MI,University of Aarhus,,ALL,"CHILD, ADULT, OLDER_ADULT",3100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-08-09,2027-01,"Centre for Alcohol and Drug Research, Aarhus BSS, Aarhus University, Aarhus, Denmark"
NCT05933226,Project Khanya: Peer-Delivered Intervention to Improve HIV Medication Adherence and Substance Use in South Africa,https://clinicaltrials.gov/study/NCT05933226,RECRUITING,NO,Human Immunodeficiency Virus|Alcohol-Related Disorders|Drug Use|Substance Use,BEHAVIORAL: Khanya,"University of Maryland, College Park",University of Cape Town|National Institute on Drug Abuse (NIDA)|Weill Medical College of Cornell University|University of Miami,ALL,"ADULT, OLDER_ADULT",160,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-06-21,2026-12,"University of Cape Town, Cape Town, Western Cape, South Africa"
NCT03472937,Outpatient Foley For Starting Induction of Labor at Term in Nulliparous Women,https://clinicaltrials.gov/study/NCT03472937,COMPLETED,NO,Pregnancy Related,PROCEDURE: Transcervical Foley catheter placement for cervical ripening,University of Alabama at Birmingham,,FEMALE,"ADULT, OLDER_ADULT",126,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-05-04,2019-12-13,"University of Alabama at Birmingham, Birmingham, Alabama, 35233, United States"
NCT01142986,Evaluating Three Methods for Helping Syringe Exchangers Begin Methadone Maintenance,https://clinicaltrials.gov/study/NCT01142986,COMPLETED,NO,Substance Abuse Disorder,BEHAVIORAL: Low intensity care|BEHAVIORAL: Voucher reinforcement,Johns Hopkins University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",223,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2010-07,2015-10,"Addiction Treatment Services, Baltimore, Maryland, 21224, United States"
NCT06072560,Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain,https://clinicaltrials.gov/study/NCT06072560,RECRUITING,NO,"Pain|Pain Syndrome|Pain, Chronic|Chronic Pain|Chronic Pain Syndrome|Back Pain|Lower Back Pain|Lower Back Pain Chronic",DRUG: Adezunap (AP707)|DRUG: Placebo,Apurano Pharmaceuticals GmbH,,ALL,"ADULT, OLDER_ADULT",558,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11-02,2024-12-31,"Klinikum Rechts der Isar (Zentrum für Interdisziplinäre Schmerztherapie), Munich, Bavaria, 81675, Germany"
NCT06071962,Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain,https://clinicaltrials.gov/study/NCT06071962,RECRUITING,NO,"Pain|Pain Syndrome|Pain, Chronic|Chronic Pain|Chronic Pain Syndrome|Back Pain|Lower Back Pain|Lower Back Pain Chronic",DRUG: Adezunap (AP707)|DRUG: Placebo,Apurano Pharmaceuticals GmbH,,ALL,"ADULT, OLDER_ADULT",558,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11-02,2024-12-31,"Klinikum Rechts der Isar (Zentrum für Interdisziplinäre Schmerztherapie), Munich, Bavaria, 81675, Germany"
NCT06508411,Exploration of the Relationship Between Sexual Health and Pain in the Context of Cancer in France,https://clinicaltrials.gov/study/NCT06508411,NOT_YET_RECRUITING,NO,Pain|Cancer|Survivorship,OTHER: Pain screening,"University Hospital, Clermont-Ferrand",,ALL,"ADULT, OLDER_ADULT",1000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-09-13,2025-01-31,"CHU Clermont-Ferrand, Clermont-Ferrand, France"
NCT02239250,Water Filters and Improved Cookstoves in Western Rwanda,https://clinicaltrials.gov/study/NCT02239250,COMPLETED,NO,Diarrhoeal Disease|Respiratory Infection|Pneumonia,DEVICE: Water filter and cookstove,London School of Hygiene and Tropical Medicine,"DelAgua|Emory University|Portland State University|University of Colorado, Boulder|Oregon Health and Science University|Ministry of Health, Rwanda|National University, Rwanda",ALL,CHILD,1582,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2014-08,2016-03,"Manna Energy Ltd., Kigali, PO Box 1594, Rwanda"
NCT04966104,ODYSSEE-vCHAT Pilot Trial for Heart Failure,https://clinicaltrials.gov/study/NCT04966104,COMPLETED,NO,Heart Failure,BEHAVIORAL: ODYSSEE-vCHAT,"University Health Network, Toronto","Sunnybrook Health Sciences Centre|Mount Sinai Hospital, Canada",ALL,"ADULT, OLDER_ADULT",61,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE,2021-10-25,2023-01-16,"University Health Network, Toronto, Ontario, M2N 7A2, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada"
NCT03014687,Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions,https://clinicaltrials.gov/study/NCT03014687,RECRUITING,NO,Antibiotics|Pituitary Adenoma,DRUG: Placebo|DRUG: Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole,"St. Joseph's Hospital and Medical Center, Phoenix",Thomas Jefferson University|The Cleveland Clinic,ALL,"ADULT, OLDER_ADULT",116,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-07-01,2019-07,"Barrow Brain and Spine, Phoenix, Arizona, 85013, United States"
NCT02358226,HIV & Drug Abuse Prevention for South African Men,https://clinicaltrials.gov/study/NCT02358226,COMPLETED,NO,Substance-Related Disorders|Human Immunodeficiency Virus|Alcoholism,BEHAVIORAL: Soccer League (SL)|BEHAVIORAL: Soccer League/Vocational Training (SL-V),"University of California, Los Angeles",National Institute on Drug Abuse (NIDA),MALE,ADULT,1211,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2016-05,2020-01,"Stellenbosch University, Stellenbosch, South Africa"
NCT03592186,Adolescents With Substance Use Disorders Transitioníng From Residential Treatment to the Community,https://clinicaltrials.gov/study/NCT03592186,COMPLETED,YES,Substance Use|Adolescent Behavior,BEHAVIORAL: Parenting Wisely+|BEHAVIORAL: Treatment as Usual,Brown University,Rhode Island Hospital|National Institute on Drug Abuse (NIDA),ALL,CHILD,122,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2017-04-01,2020-02-28,"Rosecrance Health Network, Rockford, Illinois, 61107, United States|Caritas ARTS Program, Cranston, Rhode Island, 02920, United States"
NCT05665179,Removing Barriers: Community Partnering for Innovative Solutions to the Opioid Crisis,https://clinicaltrials.gov/study/NCT05665179,RECRUITING,NO,Opioid Use Disorder|Alcohol Use Disorder|Health Risk Behaviors|Criminal Behavior|Housing Problems|Overdose of Opiate,BEHAVIORAL: Removing Barriers to Recovery,University of Michigan,U.S. National Science Foundation,ALL,"ADULT, OLDER_ADULT",800,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2021-12-23,2025-07-31,"Home of New Vision, Ann Arbor, Michigan, 48104, United States|Dawn Farm, Ypsilanti, Michigan, 48197, United States"
NCT02718508,An e-Parenting Skills Intervention to Decrease Injured Adolescents' Alcohol Use,https://clinicaltrials.gov/study/NCT02718508,COMPLETED,NO,Parenting|Alcohol Drinking,BEHAVIORAL: eParenting,"Michael J. Mello, MD, MPH",Connecticut Children's Medical Center|University of Pittsburgh,ALL,CHILD,36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-09,2018-02,"Rhode Island Hospital, Providence, Rhode Island, 02903, United States"
NCT04406363,Confinement Effect on Low Back Pain Intensity in Chronic Low Back Pain Patients,https://clinicaltrials.gov/study/NCT04406363,UNKNOWN,NO,Chronic Low-back Pain,OTHER: non interventional,"University Hospital, Angers",,ALL,"ADULT, OLDER_ADULT",300,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-06-02,2020-06-21,"Petit, Angers, 49000, France"
NCT05845164,tDCS and Impulsivity,https://clinicaltrials.gov/study/NCT05845164,RECRUITING,NO,Substance Use Disorders|Substance Abuse|Substance Use,DEVICE: tDCS|DEVICE: tDCS Sham,University of Arizona,,ALL,"ADULT, OLDER_ADULT",30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-06-01,2023-10-11,"Allison J. Huff, Tucson, Arizona, 85711, United States"
NCT02408952,Screening for Youth Alcohol and Drug Use: A Study of Primary Care Providers,https://clinicaltrials.gov/study/NCT02408952,ACTIVE_NOT_RECRUITING,NO,Substance Related Disorders,BEHAVIORAL: Primary Care Physician|BEHAVIORAL: Behavioral Medicine Specialist,Kaiser Permanente,,ALL,"CHILD, ADULT, OLDER_ADULT",9084,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: SCREENING,2011-10,2025-12-31,"Stacy A Sterling, Oakland, California, 94612, United States"
NCT06701500,"Assessing Habitual, Goal-Directed, and Pavlovian Influences in Alcohol Use Disorder",https://clinicaltrials.gov/study/NCT06701500,RECRUITING,NO,Alcohol Use Disorder (AUD)|Alcoholism|Substance Use Disorders,BEHAVIORAL: Pavlovian-to-instrumental transfer (PIT) paradigm|BEHAVIORAL: Action Sequence Task (AST)|DIAGNOSTIC_TEST: Basic psychological assessment (interview)|DIAGNOSTIC_TEST: Basic psychological assessment (questionnaires)|BEHAVIORAL: Neuropsychology tests,Technische Universität Dresden,"Charite University, Berlin, Germany|Central Institute of Mental Health, Mannheim",ALL,"ADULT, OLDER_ADULT",180,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-03-02,2027-06-30,"Department of Psychiatry and Psychotherapy, Technische Universität Dresden, Dresden, Germany"
NCT06125509,SHARE Project Define,https://clinicaltrials.gov/study/NCT06125509,ACTIVE_NOT_RECRUITING,NO,HIV,,Florida State University,"University of California, San Diego|Nova Southeastern University|University of Florida|University of Central Florida",ALL,ADULT,105,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-08-01,2025-06-30,"Florida State University, Center for Translational Behavioral Science, Tallahassee, Florida, 32310, United States"
NCT02153671,Immunogenicity of H5N1 Vaccine Following H5N2,https://clinicaltrials.gov/study/NCT02153671,COMPLETED,YES,Influenza Vaccine,BIOLOGICAL: A(H5N1) inactivated influenza vaccine (IIV)|BIOLOGICAL: A(H5N2) live attenuated influenza vaccine (LAIV),PATH,"Institute of Experimental Medicine, Russia|Research Institute of Influenza, Russia",ALL,ADULT,43,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2014-05,2014-09,"Research Institute of Influenza, St. Petersburg, Russian Federation"
NCT05669716,Adolescent Vaping Characterization and Parent Views on Adolescent Vaping Protocol,https://clinicaltrials.gov/study/NCT05669716,RECRUITING,NO,Healthy Volunteers|Vaping Teens,,National Institute on Drug Abuse (NIDA),,ALL,"CHILD, ADULT, OLDER_ADULT",1600,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-02-03,2025-07-01,"National Institute on Drug Abuse, Baltimore, Maryland, 21224, United States"
NCT04892589,The Role of the Proprioceptive Training in Functional Recovery of Patient With Thumb Base Osteoarthritis,https://clinicaltrials.gov/study/NCT04892589,UNKNOWN,NO,Thumb Osteoarthritis,OTHER: Proprioceptive thumb exercises.,"Clinica Universitaria Reina Fabiola, Universidad Catolica de Cordoba",,ALL,"ADULT, OLDER_ADULT",50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-05-30,2022-02,"Clínica Universitaria Reina Fabiola, Córdoba, 5000, Argentina|Centro TECAN Clinica de la Mano, Málaga, 29002, Spain"
NCT02958813,An Integrated HIV Prevention Model for African American Mothers and Daughters,https://clinicaltrials.gov/study/NCT02958813,COMPLETED,NO,HIV Prevention,BEHAVIORAL: IMARA|BEHAVIORAL: FUEL,University of Illinois at Chicago,Rush University,FEMALE,"CHILD, ADULT, OLDER_ADULT",514,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2012-11-01,2018-01-31,
NCT04955795,Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA,https://clinicaltrials.gov/study/NCT04955795,RECRUITING,NO,Hiv|Alcohol Problem,BEHAVIORAL: Alcohol Brief Intervention (BI)|BEHAVIORAL: Common Elements Treatment Approach (CETA) via Telemedicine,University of Alabama at Birmingham,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"ADULT, OLDER_ADULT",308,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-05-04,2027-09-30,"Health Service Center, Anniston, Alabama, 36201, United States|UAB Family Clinic, Birmingham, Alabama, 35233, United States|Thrive, Huntsville, Alabama, 35801, United States|Five Horizons, Montgomery, Alabama, 36111, United States|Unity Wellness, Opelika, Alabama, 36801, United States"
NCT03745183,Senna Alata Leaf Decoction as a Treatment for Tinea Imbricata,https://clinicaltrials.gov/study/NCT03745183,COMPLETED,NO,Tinea Imbricata,OTHER: Senna alata leaf decoction,Philippine Dermatological Society,,ALL,"ADULT, OLDER_ADULT",20,NETWORK,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-11,2015-01-15,
NCT01723527,Diversion to Treatment for Injection Drug Users Arrested for Possession of Heroin,https://clinicaltrials.gov/study/NCT01723527,COMPLETED,NO,Cocaine-Related Disorders|HIV|Heroin Dependence,DRUG: Methadone|DRUG: Buprenorphine|BEHAVIORAL: Employment-based drug abstinence reinforcement,Johns Hopkins University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",1,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-12,2014-08,"Center for Learning and Health, Baltimore, Maryland, 21224, United States"
NCT00604188,A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED),https://clinicaltrials.gov/study/NCT00604188,COMPLETED,YES,Opiate Dependence|Drug Dependence|Substance Dependence,DRUG: Suboxone (SCH 000484)|DRUG: Subutex (SCH 028444),Merck Sharp & Dohme LLC,,ALL,"CHILD, ADULT, OLDER_ADULT",188,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-02-22,2009-12-10,
NCT06072573,Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy,https://clinicaltrials.gov/study/NCT06072573,RECRUITING,NO,"Pain|Pain Syndrome|Pain, Chronic|Chronic Pain|Chronic Pain Syndrome|Diabetes|Diabetic Neuropathies|Diabetic Polyneuropathy|Peripheral Neuralgia|Peripheral Neuropathy|Peripheral Neuropathy With Type 2 Diabetis",DRUG: Adezunap (AP707)|DRUG: Placebo,Apurano Pharmaceuticals GmbH,,ALL,"ADULT, OLDER_ADULT",558,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11-02,2024-12-31,"Klinikum Rechts der Isar (Zentrum für Interdisziplinäre Schmerztherapie), Munich, Bavaria, 81675, Germany"
NCT06071975,Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy,https://clinicaltrials.gov/study/NCT06071975,RECRUITING,NO,"Pain|Pain Syndrome|Pain, Chronic|Chronic Pain|Chronic Pain Syndrome|Diabetes|Diabetic Neuropathies|Diabetic Polyneuropathy|Peripheral Neuralgia|Peripheral Neuropathy|Peripheral Neuropathy With Type 2 Diabetis",DRUG: Adezunap (AP707)|DRUG: Placebo,Apurano Pharmaceuticals GmbH,,ALL,"ADULT, OLDER_ADULT",558,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11-02,2024-12-31,"Klinikum Rechts der Isar (Zentrum für Interdisziplinäre Schmerztherapie), Munich, Bavaria, 81675, Germany"
NCT05743985,"Efficacy and Safety of Hemp-derived, Full Spectrum Cannabigerol (CBG) in Adults",https://clinicaltrials.gov/study/NCT05743985,COMPLETED,NO,"Health, Subjective|Inflammatory Response|Adverse Effect|Side Effect",OTHER: Cannabigerol,Formula30A LLC,,ALL,"ADULT, OLDER_ADULT",69,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-01,2024-04-30,"Institute for Hormonal Balance, Arlington, Texas, 76016, United States|NP Care Clinic, Denton, Texas, 76201, United States|Infectious Disease Specialists, Edinburg, Texas, 78539, United States|Modern Medicine, Forney, Texas, 75126, United States|Texas Gynecology, Frisco, Texas, 75034, United States|Melville Medicine, Southlake, Texas, 76092, United States|Java Med, Ceiba, 00735, Puerto Rico"
NCT02337361,Computerized Tool for Preventing Prenatal Drinking,https://clinicaltrials.gov/study/NCT02337361,COMPLETED,YES,Foetal Exposure During Pregnancy,BEHAVIORAL: Electronic SBI,"Public Health Institute, California",Sonoma County Department of Health Services|La Clínica de La Raza Inc.,FEMALE,ADULT,185,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2016-02-22,2018-08-31,"La Clinica Women Infants and Children Program Site, Oakland, California, 94601, United States|Sonoma County Department of Health Services, Santa Rosa, California, 95403, United States"
NCT01736995,Family and Adolescent Motivational Incentives for Leveraging Youth,https://clinicaltrials.gov/study/NCT01736995,COMPLETED,NO,Substance-Related Disorders,BEHAVIORAL: Functional Family Therapy|BEHAVIORAL: Motivational Enhancement Tx/Cognitive Behavioral Tx|BEHAVIORAL: Contingency Management,Oregon Research Institute,Dartmouth College,ALL,CHILD,212,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-07,2018-04,"Oregon Research Institute Center for Family and Adolescent Research, Albuquerque, New Mexico, 87102, United States"
NCT05365347,Piloting of an Intervention to Reduce Problematic Alcohol Use in Early Phase Psychosis Patients,https://clinicaltrials.gov/study/NCT05365347,RECRUITING,NO,Psychosis|Alcohol Use Disorder,BEHAVIORAL: Cognitive Enhancement Therapy (CET),Nova Scotia Health Authority,Canadian Institutes of Health Research (CIHR),ALL,"CHILD, ADULT",24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-12-01,2026-12-30,"Nova Scotia Health Authority, Halifax, Nova Scotia, B3S0H6, Canada"
NCT06112912,Components Study of REAL Essentials,https://clinicaltrials.gov/study/NCT06112912,COMPLETED,NO,Components of REAL Essentials,OTHER: REAL Essentials Advance,"Mathematica Policy Research, Inc.","Office of Population Affairs, Department of Health and Human Services",ALL,"CHILD, ADULT",1301,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-01-01,2023-06-30,"Mathematica, Princeton, New Jersey, 08543, United States"
NCT02222389,Contingency Management for the Treatment of Co-Occurring Alcohol and Drug Misuse,https://clinicaltrials.gov/study/NCT02222389,COMPLETED,NO,Co-Occurring Alcohol and Drug Misuse,BEHAVIORAL: CM for Alcohol|BEHAVIORAL: CM for drugs|BEHAVIORAL: CM for both substances|BEHAVIORAL: Non-Contingent group,Washington State University,,ALL,"ADULT, OLDER_ADULT",120,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2015-06-01,2018-09-10,"Washington State University, Spokane, Washington, United States"
NCT06605924,Oral Nicotine Pouch Marketing Features Influence on Perceptions,https://clinicaltrials.gov/study/NCT06605924,NOT_YET_RECRUITING,NO,Tobacco Use,OTHER: Tobacco-free|OTHER: Discrete|OTHER: Convenient,Johns Hopkins Bloomberg School of Public Health,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT, OLDER_ADULT",5000,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2025-03,2025-05,
NCT03891628,Modified ABC: A Home-based Parenting Program for Opioid-dependent Mothers and Their Infants,https://clinicaltrials.gov/study/NCT03891628,COMPLETED,NO,Opioid-Related Disorders|Parent-Child Relations|Infant Development|Parenting,BEHAVIORAL: Modified Attachment and Biobehavioral Catch-up|BEHAVIORAL: Modified Developmental Education for Families,University of Delaware,,FEMALE,"ADULT, OLDER_ADULT",65,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2018-08-13,2021-03-31,"University of Delaware, Newark, Delaware, 19716, United States"
NCT05228964,Focused Ultrasound Amygdala Neuromodulation,https://clinicaltrials.gov/study/NCT05228964,ACTIVE_NOT_RECRUITING,NO,Depression|Anxiety Disorders|Bipolar Depression|Ptsd,DEVICE: Focused ultrasound,University of Texas at Austin,,ALL,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-01-13,2024-12-31,"Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, Austin, Texas, 78712, United States"
NCT04200339,Adolescent SCreening To Help Eliminate Misuse,https://clinicaltrials.gov/study/NCT04200339,COMPLETED,NO,Substance Use,,Boston Children's Hospital,"National Institute on Drug Abuse (NIDA)|The Emmes Company, LLC|Friends Research Institute, Inc.",ALL,CHILD,810,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-07-21,2022-02-25,"Boston Childrens Hopsital - Adolecents Substance Use and Addiction Program, Boston, Massachusetts, 02115, United States"
NCT05949060,Effects of Self-Compassion Practice on Stress Reactivity Among Sexual Minority Women,https://clinicaltrials.gov/study/NCT05949060,COMPLETED,NO,Stress Reaction|Sexuality|Compassion,BEHAVIORAL: Compassion Intervention,Syracuse University,GLMA: Health Professionals Advancing LGBTQ+ Equality,ALL,"ADULT, OLDER_ADULT",39,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-07-17,2024-09-20,"Syracuse University, Syracuse, New York, 13244, United States"
NCT04804579,Boston ARCH 4F Intervention to Reduce Fall Risk in People With HIV and Alcohol Use,https://clinicaltrials.gov/study/NCT04804579,COMPLETED,YES,"HIV Infection|Alcohol Consumption|Falls, Accidental|Falls",BEHAVIORAL: Fall Prevention Intervention,Boston University,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"ADULT, OLDER_ADULT",23,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-10-20,2022-08-01,"Boston University Medical Campus, Boston, Massachusetts, 02118, United States"
NCT02951455,Community Wise: An Innovative Multi-level Intervention to Reduce Alcohol and Illegal Drug Use,https://clinicaltrials.gov/study/NCT02951455,COMPLETED,YES,Substance Use Disorders,BEHAVIORAL: Critical Dialogue|BEHAVIORAL: Capacity Building Project|BEHAVIORAL: Quality of Life Wheel|BEHAVIORAL: PF|BEHAVIORAL: LC,University of Illinois at Urbana-Champaign,"National Development and Research Institutes, Inc.|University of Michigan|National Institute on Minority Health and Health Disparities (NIMHD)|North Jersey Community Research Initiative",MALE,"ADULT, OLDER_ADULT",602,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2017-01-17,2020-01-20,"Integrity House, Newark, New Jersey, 07102, United States"
NCT03215654,"""EspaiJove.Net""- a School-based Intervention Program to Promote Mental Health in Adolescent Population",https://clinicaltrials.gov/study/NCT03215654,COMPLETED,NO,"Mental Health|Stigma, Social","OTHER: ""EspaiJove.net"" mental health literacy program",Centre d'Higiene Mental Les Corts,,ALL,"CHILD, ADULT",432,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2017-10-02,2019-03-22,"Centre Higiene Mental Les Corts, Barcelona, 08029, Spain|Rocio Casañas, Barcelona, 08029, Spain"
NCT06071988,Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy,https://clinicaltrials.gov/study/NCT06071988,RECRUITING,NO,"Pain|Pain Syndrome|Pain, Chronic|Chronic Pain|Chronic Pain Syndrome|Neuropathic Pain|Peripheral Neuropathy|Peripheral Neuralgia|Peripheral Nerve Injury|Post Operative Pain|Post-Traumatic Neuralgia|Plexopathy",DRUG: Adezunap (AP707)|DRUG: Placebo,Apurano Pharmaceuticals GmbH,,ALL,"ADULT, OLDER_ADULT",558,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11-02,2024-12-31,"Klinikum Rechts der Isar (Zentrum für Interdisziplinäre Schmerztherapie), Munich, Bavaria, 81675, Germany"
NCT06298734,High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial,https://clinicaltrials.gov/study/NCT06298734,RECRUITING,NO,Melanoma (Skin)|Skin Cancer|Advanced Melanoma,BEHAVIORAL: Exercise Program|BEHAVIORAL: Diet Program,Dana-Farber Cancer Institute,World Cancer Research Fund International,ALL,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-07-01,2026-03-31,"Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States"
NCT02132481,Using Smartphones to Provide Recovery Support Services,https://clinicaltrials.gov/study/NCT02132481,COMPLETED,NO,Substance Use Disorder (SUD)|Recovery,OTHER: EMA Only|OTHER: EMI Only|OTHER: EMA+EMI|OTHER: Neither - RSAU,Chestnut Health Systems,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",401,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2015-06,2021-02-28,"Haymarket, Chicago, Illinois, 60607, United States|Chestnut Health Systems, Chicago, Illinois, 60610, United States|Chestnut Health Systems, Normal, Illinois, 61761, United States"
NCT05186688,"Braining - Physical Exercise in Psychiatry - Evaluation of Feasibility, and Health Among Patients",https://clinicaltrials.gov/study/NCT05186688,COMPLETED,NO,Mental Disorder,BEHAVIORAL: Braining,Region Stockholm,Karolinska Institutet,ALL,"ADULT, OLDER_ADULT",22,OTHER_GOV,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-03-02,2023-09-30,"Region Stockholm, Liljeholmsberget, Stockholm, Sweden"
NCT05340686,Braining- Aerobic Physical Activity As Add on Treatment in Bipolar Depression,https://clinicaltrials.gov/study/NCT05340686,ACTIVE_NOT_RECRUITING,NO,"Bipolar Disorder|Bipolar Depression|Bipolar I Disorder|Bipolar II Disorder|Bipolar Affective Disorder; Remission in|Bipolar Affective Disorder, Currently Depressed, Moderate",BEHAVIORAL: Aerobic Physical Exercise|BEHAVIORAL: Relaxing Physical Exercise|BEHAVIORAL: Information about physical exercise,Region Stockholm,Karolinska Institutet,ALL,"ADULT, OLDER_ADULT",54,OTHER_GOV,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-10-26,2027-04-20,"Region Stockholm, Psykiatri Sydväst (Psychiatric Clinic Psychiatry Southwest), Stockholm, 14186, Sweden"
NCT01337973,Preventing Violence Among Veterans in Substance Use Disorder Treatment,https://clinicaltrials.gov/study/NCT01337973,COMPLETED,YES,Aggression|Substance-Related Disorders,BEHAVIORAL: MI-CBT|BEHAVIORAL: MI-CBT+CC|BEHAVIORAL: E-TAU,VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",180,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2012-06-20,2017-12-01,"VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, 48105, United States"
NCT04284813,Families With Substance Use and Psychosis: A Pilot Study,https://clinicaltrials.gov/study/NCT04284813,COMPLETED,YES,Psychosis|Substance Use|Substance Use Disorders|Family|Tobacco Use|Nicotine Use Disorder|Cigarette Smoking|Cannabis|Marijuana|Alcohol Use Disorder|Alcohol|Schizophrenia|Schizoaffective Disorder|Bipolar Disorder|Mental Disorder,BEHAVIORAL: CRAFT-FT,Mclean Hospital,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",29,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-24,2022-07-07,"McLean Hospital, Belmont, Massachusetts, 02478, United States"
NCT03529409,Effectiveness & Implementation of a Behavioral Intervention for Adherence and Substance Use in HIV Care in South Africa,https://clinicaltrials.gov/study/NCT03529409,COMPLETED,YES,Human Immunodeficiency Virus|Alcohol-Related Disorders|Drug Use,BEHAVIORAL: Project Khanya,"University of Maryland, College Park",University of Cape Town|National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",66,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-07-30,2020-04-07,"University of Maryland, College Park, Maryland, 20742, United States|University of Cape Town, Cape Town, 7700, South Africa"
NCT05947136,"PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.",https://clinicaltrials.gov/study/NCT05947136,RECRUITING,NO,Multiple Myeloma|Complication,BEHAVIORAL: Interpretation of the results from the detection visit|BEHAVIORAL: Explaining detection results and referrals to the patient|BEHAVIORAL: Early medical care through the network|BEHAVIORAL: Transmission of results from each detection visit to the referring onco-haematologists - Control Group,Centre Leon Berard,"National Cancer Institute, France",ALL,"ADULT, OLDER_ADULT",204,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2024-01-19,2027-09-14,"Centre Léon Bérard, Lyon, 69373, France"
NCT04489394,Quintex® Follow-up After One Year Minimum,https://clinicaltrials.gov/study/NCT04489394,COMPLETED,NO,Degenerative Disc Disease|Spondylolisthesis|Trauma|Spinal Stenosis|Deformity of Spine|Pseudoarthrosis of Spine|Cervical Spondylosis|Instability; Back,,Aesculap AG,,ALL,"CHILD, ADULT, OLDER_ADULT",60,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-11-11,2020-02-18,"Katholisches Klinikum Koblenz, Koblenz, 56073, Germany"
NCT01591759,A Pilot Trial of Citicoline in Individuals With Mild Traumatic Brain Injury (mTBI),https://clinicaltrials.gov/study/NCT01591759,WITHDRAWN,NO,Traumatic Brain Injury,DRUG: Citicoline|DRUG: Placebo,Mclean Hospital,,ALL,ADULT,0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2012-04,2014-04,"McLean Hospital Brain Imaging Center, Belmont, Massachusetts, 02478-9106, United States"
NCT06291597,Vaping Adverse Lung and Heart Events Cohort,https://clinicaltrials.gov/study/NCT06291597,RECRUITING,NO,Vaping|Electronic Cigarette Use,OTHER: Vaping,Laval University,Ministere de la Sante et des Services Sociaux,ALL,"ADULT, OLDER_ADULT",250,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-10-14,2032-06,"IUCPQ-UL, Québec, G1V 4G5, Canada"
NCT00292240,Brief Youth Substance Use Intervention for Primary Care,https://clinicaltrials.gov/study/NCT00292240,COMPLETED,NO,Alcohol Consumption|Drug Abuse,BEHAVIORAL: Brief motivational substance use intervention,RAND,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2004-10,2007-04,"Los Angeles Free Clinic, Los Angeles, California, 90028, United States"
NCT00026728,Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States,https://clinicaltrials.gov/study/NCT00026728,COMPLETED,NO,Kaposi's Sarcoma|Herpesviridae Infection,,National Cancer Institute (NCI),,ALL,"CHILD, ADULT, OLDER_ADULT",20169,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2001-02,2005-12,"National Cancer Institute (NCI), Bethesda, Maryland, 20892, United States"
NCT03817255,Young People's Health Assessment as Treatment and Health Guide,https://clinicaltrials.gov/study/NCT03817255,COMPLETED,NO,Adolescent Behavior|Substance Use,OTHER: Substance use questionnaire|OTHER: Physical activity,"University of Geneva, Switzerland",,ALL,"CHILD, ADULT",29,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2018-09-01,2018-12-04,"Primary Care Unit, University of Geneva, Geneva, 1211, Switzerland"
NCT06782347,Activating SilverSneakers Benefits for Seniors With Osteoarthritis,https://clinicaltrials.gov/study/NCT06782347,NOT_YET_RECRUITING,NO,Osteoarthritis|Physical Inactivity,BEHAVIORAL: Proactive Care,Milton S. Hershey Medical Center,Humana Healthcare Research|Kaiser Permanente|Global Healthy Living Foundation|Patient-Centered Outcomes Research Institute|CVS Healthspire Life Sciences Solutions|Tivity Health,ALL,OLDER_ADULT,1454,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2025-02,2028-07,"Penn State College of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033, United States"
NCT06486688,Centralized Virtual SBIRT for Pediatric Primary Care,https://clinicaltrials.gov/study/NCT06486688,RECRUITING,NO,Adolescent Alcohol Use|Mental Health Issue|Alcohol Related Disorders|Adolescents,BEHAVIORAL: Centralized Virtual SBIRT,Kaiser Permanente,,ALL,CHILD,22320,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2024-02-13,2027-08-31,"Kaiser Permanente Division of Research, Pleasanton, California, 94588, United States"
NCT06072001,Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis,https://clinicaltrials.gov/study/NCT06072001,RECRUITING,NO,"Pain|Pain Syndrome|Pain, Chronic|Chronic Pain|Chronic Pain Syndrome|Neuropathic Pain|Central Neuropathic Pain|Paraplegia|Multiple Sclerosis|Stroke|Phantom Limb Syndrome With Pain|Phantom Pain|Traumatic Brain Injury",DRUG: Adezunap (AP707)|DRUG: Placebo,Apurano Pharmaceuticals GmbH,,ALL,"ADULT, OLDER_ADULT",558,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11-02,2024-12-31,"Klinikum Rechts der Isar (Zentrum für Interdisziplinäre Schmerztherapie), Munich, Bavaria, 81675, Germany"
NCT06071949,Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis,https://clinicaltrials.gov/study/NCT06071949,RECRUITING,NO,"Pain|Pain Syndrome|Pain, Chronic|Chronic Pain|Chronic Pain Syndrome|Neuropathic Pain|Central Neuropathic Pain|Paraplegia|Multiple Sclerosis|Stroke|Phantom Limb Syndrome With Pain|Phantom Pain|Traumatic Brain Injury",DRUG: Adezunap|DRUG: Placebo,Apurano Pharmaceuticals GmbH,,ALL,"ADULT, OLDER_ADULT",558,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11-02,2024-12-31,"Klinikum Rechts der Isar (Zentrum für Interdisziplinäre Schmerztherapie), Munich, Bavaria, 81675, Germany"
NCT06170437,Smoke-free Home Study in Subsidized Housing,https://clinicaltrials.gov/study/NCT06170437,RECRUITING,NO,Tobacco Dependence|Tobacco Smoking,BEHAVIORAL: Smoke-free home resident intervention|BEHAVIORAL: Lay Health Worker coaching,"University of California, San Francisco",National Institute on Minority Health and Health Disparities (NIMHD),ALL,"ADULT, OLDER_ADULT",544,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2024-07-12,2026-12-31,"University of California, San Francisco, San Francisco, California, 94143, United States"
NCT06822322,The European Bifurcation Club Randomized Trial of Stepwise Provisional Stenting Versus Drug Coated Balloon Therapy for Non-left Main True Coronary Bifurcations,https://clinicaltrials.gov/study/NCT06822322,NOT_YET_RECRUITING,NO,Coronary Artery Disease (non-left Main)|Coronary Bifurcation Lesion,PROCEDURE: Percutaneous Coronary Angioplasty|DEVICE: Stepwise Provisional Stent Strategy|DEVICE: Drug Coated Balloon Strategy|DEVICE: Cross-Over Stepwise Provisional Stent Strategy,Ceric Sàrl,European Cardiovascular Research Center,ALL,"ADULT, OLDER_ADULT",750,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2025-05,2035-08,
NCT05753007,"A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients",https://clinicaltrials.gov/study/NCT05753007,RECRUITING,NO,Glioblastoma,DRUG: Cannabidiol (CBD)|DRUG: Placebo,Mclean Hospital,"University of California, San Francisco|Center for Medicinal Cannabis Research",ALL,"ADULT, OLDER_ADULT",36,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-02-15,2025-09,"University of California San Francisco Brain Tumor Center, San Francisco, California, 94143, United States"
NCT04097964,Examining the Effectiveness of the FaCES Adolescent SBIRT Intervention,https://clinicaltrials.gov/study/NCT04097964,COMPLETED,NO,Adolescent Health Services|Adolescent Behavior,BEHAVIORAL: brief intervention|BEHAVIORAL: treatment as usual,"Friends Research Institute, Inc.",Conrad N. Hilton Foundation,ALL,CHILD,1226,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2018-03-15,2021-06-30,"Hidalgo Medical Services, Lordsburg, New Mexico, 88045, United States|Hidalgo Medical Services, Silver City, New Mexico, 88061, United States|Lifespan Health, Adamsville, Tennessee, 33810, United States|Lifespan Health, Savannah, Tennessee, 38372, United States"
NCT05253235,Health and Resilience Projects: Foundations,https://clinicaltrials.gov/study/NCT05253235,RECRUITING,NO,Substance Use,BEHAVIORAL: SAAF|OTHER: Receipt of parenting book,University of Georgia,,ALL,CHILD,650,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2022-01-25,2027-12-31,"Center for Family Research, Athens, Georgia, 30602, United States"
NCT03529448,TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma,https://clinicaltrials.gov/study/NCT03529448,ACTIVE_NOT_RECRUITING,NO,Glioblastoma,DRUG: TN-TC11G|DRUG: Temozolomide Oral Product|RADIATION: Radiotherapy,Grupo Español de Investigación en Neurooncología,Medical Cannabis Bike Tour|Voices Against Brain Cancer|Tilray,ALL,"ADULT, OLDER_ADULT",33,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-08-18,2025-12,"Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, 41013, Spain|Institut Català d'Oncología L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, 08908, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Mallorca, Spain|Hospital del Mar, Barcelona, 08003, Spain|Complejo Hospitalario Regional Virgen de las Nieves, Granada, 18004, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, 37007, Spain"
NCT04391413,Does OCT Optimise Results of Stenting on the Left Main Stem,https://clinicaltrials.gov/study/NCT04391413,UNKNOWN,NO,Myocardial Infarction|Myocardial Ischemia|Non ST Segment Elevation Myocardial Infarction,DEVICE: Use of OCT to guide the angioplasty procedure,Centre Hospitalier Universitaire de Besancon,,ALL,"ADULT, OLDER_ADULT",188,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-07,2023-07-16,"CHU Besancon, Besançon, Please Select, 25000, France|CHRU Lille, Lille, Please Select, France|Hôpital Privé Saint Martin, Caen, France|Centre Hospitalier de Chartres - Hôpital Louis Pasteur, Chartres, France|CHRU Clermont Ferrand, Clermont-Ferrand, France|Institut Cardiovasculaire Paris Sud, Massy, France|CHU Nîmes - Hôpital Carémeau, Nîmes, France|Institut Mutualiste Montsouris, Paris, 75014, France|CHU Poitiers, Poitiers, France|Clinique Saint Hilaire, Rouen, France|Institut Arnault Tzanck, Saint-Laurent-du-Var, France|Hôpital Nord Franche-Comté, Trévenans, France"
NCT06366633,Web-based Mind-body Program for Comorbid Nontraumatic Upper-extremity Condition and Risky Substance Use,https://clinicaltrials.gov/study/NCT06366633,RECRUITING,NO,Orthopedic Disorder|Nontraumatic Injury|Substance Use|Upper Extremity Problem,BEHAVIORAL: Web-TIRELESS,Jafar Bakhshaie,National Center for Complementary and Integrative Health (NCCIH),ALL,"ADULT, OLDER_ADULT",12,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-10-11,2025-07-31,"Massachusetts General Hospital (MGH), Boston, Massachusetts, 02129, United States"
NCT02083523,Project CHOICE: Efficacy Testing of CHOICE and CHOICE+Normative Feedback Interventions,https://clinicaltrials.gov/study/NCT02083523,COMPLETED,NO,Substance-related Disorders,BEHAVIORAL: Motivational Interview with Normative Feedback|BEHAVIORAL: Motivational Interview,University of Illinois at Urbana-Champaign,,ALL,"CHILD, ADULT",48,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2013-03,2013-08,
NCT05860699,Cannabidiol As an Add-on Treatment During Inpatient Alcohol Cessation : CBD-OH,https://clinicaltrials.gov/study/NCT05860699,RECRUITING,NO,Severe Alcohol Use Disorder (DSM 5),DRUG: Placebo|DRUG: Half dose CBD|DRUG: Full dose CBD,Assistance Publique - Hôpitaux de Paris,,ALL,"ADULT, OLDER_ADULT",210,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2024-07-03,2026-08-17,"Hôpital Fernand Widal, Paris, France, France"
NCT01335529,Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin,https://clinicaltrials.gov/study/NCT01335529,COMPLETED,NO,HCV Coinfection|HIV-1 Infection,"DRUG: Boceprevir, Peg-interferon alfa 2b and Ribavirin","ANRS, Emerging Infectious Diseases",Rennes University Hospital|Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",69,OTHER_GOV,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-05,2014-05,"CHU Sainte Marguerite, Marseille, 13009, France"
NCT04283292,Capsaicin for the Treatment of Cannabinoid Hyperemesis Syndrome,https://clinicaltrials.gov/study/NCT04283292,COMPLETED,NO,Cannabinoid Hyperemesis Syndrome,DRUG: Capsaicin|DRUG: Placebo,University of Virginia,,ALL,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-12-01,2022-03-18,"UVA Health System, Charlottesville, Virginia, 22908, United States"
NCT03947177,Culturally Enhancing a Motivational Interviewing Intervention For Latinx Adolescents,https://clinicaltrials.gov/study/NCT03947177,COMPLETED,NO,"Underage Alcohol Use|Smoking, Non-Tobacco Products",BEHAVIORAL: GMIT|BEHAVIORAL: GMIT+,Virginia Commonwealth University,Virginia Foundation of Healthy Youth|Sacred Heart Center|Virginia Polytechnic Institute and State University|The College of William and Mary,ALL,CHILD,59,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2019-09-09,2021-09-21,"Virginia Commonwealth University, Richmond, Virginia, 23298, United States"
NCT03248167,Cannabidiol as a Treatment for AUD Comorbid With PTSD,https://clinicaltrials.gov/study/NCT03248167,COMPLETED,YES,Alcohol Use Disorder|Post Traumatic Stress Disorder,DRUG: Cannabidiol|DRUG: Placebos,NYU Langone Health,National Institutes of Health (NIH)|Tilray,ALL,"ADULT, OLDER_ADULT",95,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-09-16,2022-04-20,"New York University School of Medicine, New York, New York, 10016, United States"
NCT04400227,Preventing Youth Substance Use With Family Talk,https://clinicaltrials.gov/study/NCT04400227,WITHDRAWN,NO,Substance Use Disorders,OTHER: Family Talk,Boston Medical Center,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT, OLDER_ADULT",0,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-07,2023-06,
NCT06381609,Peer Support in Alcohol Dependence,https://clinicaltrials.gov/study/NCT06381609,NOT_YET_RECRUITING,NO,Alcohol Use Disorder,BEHAVIORAL: Quality life questionnaire AQoLS|BEHAVIORAL: Quality life questionnaire Euroqol EQ-5D-5L|OTHER: Peer support consultations,Hospices Civils de Lyon,,ALL,"ADULT, OLDER_ADULT",626,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2024-10-01,2028-04-01,"CH Le Vinatier, Bron, 69500, France|Hôpital Beaujon, Clichy, 92110, France|GH Nord, Hospices Civils de Lyon, Lyon, 69004, France|CHS St Anne, Paris, 75014, France|Bichat Hospital, Paris, 75018, France"
NCT05897580,Impact of Community-Based Biofeedback Program on Drug Use and Mental Health Among People Experiencing Homelessness,https://clinicaltrials.gov/study/NCT05897580,COMPLETED,NO,Heart Rate Variability,BEHAVIORAL: Heart Rate Variability - Biofeedback (HRV-BF)|BEHAVIORAL: Health Promotion (HP),"University of California, Irvine",,ALL,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-22,2022-10-21,"Amity Foundation, Los Angeles, Los Angeles, California, 90007, United States|Downtown Women Center, Los Angeles, Los Angeles, California, 90013, United States|Los Angeles Christian Health Centers (LACHC), Los Angeles, California, 90013, United States"
NCT05870540,BPL-003 Efficacy and Safety in Treatment Resistant Depression,https://clinicaltrials.gov/study/NCT05870540,RECRUITING,NO,Treatment Resistant Depression,DRUG: BPL-003,Beckley Psytech Limited,,ALL,"ADULT, OLDER_ADULT",225,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-09-14,2025-06,"UAB School of Public Health, Department of Health Behavior, Birmingham, Alabama, 35209, United States|Woodland Research Northwest, Rogers, Arkansas, 72758, United States|Kadima Neuropsychiatry Institute, San Diego, California, 92037, United States|San Francisco Insight and Integration Center, San Francisco, California, 94114, United States|Pacific Neuroscience Institute, Treatment and Research in Psychedelics (TRIP) Program, Santa Monica, California, 90404, United States|Wholeness Center, Fort Collins, Colorado, 80525, United States|Segal Trials Center for Psychedelic and Cannabis Research, Lauderhill, Florida, 33319, United States|Emory University, Brain Health Center, Department of Psychiatry and Behavioral Sciences, Atlanta, Georgia, 30329, United States|CenExel ACMR, Atlanta, Georgia, 30331, United States|CenExel iResearch, Decatur, Georgia, 30030, United States|Sunstone Medical PC (Sunstone Therapies / Aquilino Cancer Center), Rockville, Maryland, 20850, United States|Boston Clinical Trials, Boston, Massachusetts, 02131, United States|CenExel HRI, Berlin, New Jersey, 08009, United States|New York State Psychiatric Institute, New York, New York, 10032, United States|Portland Psychotherapy, Portland, Oregon, 97227, United States|Insite clinical research, DeSoto, Texas, 75115, United States|AIM Trials, Plano, Texas, 75093, United States|Cedar Clinical Research, Draper, Utah, 84020, United States|University of Wisconsin, Dept of Family Medicine & Community Health, Madison, Wisconsin, 53705, United States|Royal Prince Alfred Hospital, Sydney, New South Wales, 2050, Australia|Dept. of Psychiatry and School Psychological Sciences, Monash University, Clayton, Victoria, 3168, Australia|NeuroCentrix Research, Melbourne, 3053, Australia|Royal Melbourne Hospital, University of Melbourne, Parkville, 3050, Australia|Charité - Universitätsmedizin Berlin, Berlin, 10117, Germany|OVID Clinic, Augmented Psychotherapy, Berlin, 10247, Germany|Department of Psychiatry, University Hospital Frankfurt, Frankfurt am Main, 60528, Germany|Central Institute of Mental Health, Dept. of Molecular Neuroimaging, Mannheim, 68159, Germany|Universitätsklinik für Psychiatrie und Psychotherapie, Calwerstr. 14, Tubingen, 72076, Germany|Department of Psychiatry, UCK, Gdansk, 80-214, Poland|Centrum Badań Klinicznych PI-House sp. z o.o., Gdansk, 80-546, Poland|SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi, Lodz, 92-216, Poland|Klinika Inventiva, Tuszyn, 95-080, Poland|Department of Pharmacology and Physiology of CNS, Warsaw, 02-957, Poland|Hospital del Mar, Barcelona, 08003, Spain|Parc Sanitari Sant Joan de Deu HD Numancia, Barcelona, 08029, Spain|Hospital Clinic de Barcelona, Psychiatry and Psychology Dept., Barcelona, 08036, Spain|Fundación de Investigación HM Hospital, Madrid, 28050, Spain|Centro de Salud Mental La Corredoria, Oviedo, 33011, Spain|Centro Salud San Juan, Salamanca, 37005, Spain|King's College London - Institute of Psychiatry, Psychology & Neuroscience (IoPPN) - Centre for Affective Disorders (CfAD), London, SE5 8AF, United Kingdom|Clerkenwell Health, London, W1G 8DR, United Kingdom"
NCT04737603,Feasibility of Pediatric Emergency Department-Initiated Treatment for Adolescents With Opioid Use Disorder,https://clinicaltrials.gov/study/NCT04737603,WITHDRAWN,NO,Opioid-use Disorder,DRUG: ED-Initiated treatment with buprenorphine / naloxone,"University of California, Davis",Yale University|University of Utah,ALL,CHILD,0,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2025-07-30,2025-07-30,
NCT06256952,Effect of Social Isolation on the Role of Pavlovian Mechanisms for Control Over Alcohol Use,https://clinicaltrials.gov/study/NCT06256952,NOT_YET_RECRUITING,NO,Alcohol Use Disorder|Alcoholism|Stress Reaction|Ostracism|Substance Use Disorders,BEHAVIORAL: PIT paradigm|BEHAVIORAL: social exclusion (Cyberball task)|DIAGNOSTIC_TEST: Saliva samples|DIAGNOSTIC_TEST: basic psychological assessment|DIAGNOSTIC_TEST: pre and post cyberball task|DIAGNOSTIC_TEST: VAS|DIAGNOSTIC_TEST: after cyberball task|BEHAVIORAL: social inclusion (Cyberball task),"Charite University, Berlin, Germany",Heidelberg University|Zentralinstitut für Seelische Gesundheit Mannheim|Technische Universität Dresden,ALL,"ADULT, OLDER_ADULT",100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2024-10-01,2027-06-30,"Charite - Universitätsmedizin Berlin, Berlin, 10117, Germany"
NCT05095675,Predicting Effective Adaptation to Breast Cancer to Help Women to BOUNCE Back,https://clinicaltrials.gov/study/NCT05095675,RECRUITING,NO,Breast Cancer,BEHAVIORAL: psychological questionnaires,European Institute of Oncology,"Helsinki University Central Hospital|Hebrew University of Jerusalem|Fundacao Champalimaud|Foundation for Research and Technology - Hellas|Institute of Communications and Computer Systems, Athens, Greece|SINGULARLOGIC|NHG CONSULTING OY|Noona Healthcare",FEMALE,"ADULT, OLDER_ADULT",660,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-12-06,2023-12-31,"European Institute of Oncology, Milan, 20141, Italy"
NCT02067299,A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants,https://clinicaltrials.gov/study/NCT02067299,COMPLETED,NO,"Depressive Disorder, Major",DRUG: JNJ-42847922|OTHER: Placebo,"Janssen Research & Development, LLC",,ALL,ADULT,20,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-02,2014-12,"Berlin, Germany|Leiden, Netherlands"
NCT06392542,Online Intervention for Transgender/Nonbinary Young Adults' Experiences With Alcohol and Romantic Relationships,https://clinicaltrials.gov/study/NCT06392542,NOT_YET_RECRUITING,NO,"Alcohol Use, Unspecified|Relationship, Social|Depression, Anxiety|Transgenderism",BEHAVIORAL: Whole Selves,Boston University,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,ADULT,107,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2026-04,2027-04,"Boston University School of Public Health, Boston, Massachusetts, 02118, United States"
NCT05922046,Age Dependents Benefits of Virtual Reality Rehabilitation,https://clinicaltrials.gov/study/NCT05922046,COMPLETED,NO,Parkinson Disease,DEVICE: Leap Motion Controller on flat display,Federal University of Health Science of Porto Alegre,,ALL,"ADULT, OLDER_ADULT",16,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2024-03-01,2024-08-08,"Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, 90050-170, Brazil"
NCT03906500,High Schools- High on Life: an Intervention to Reduce Excessive Drinking in Danish High Schools,https://clinicaltrials.gov/study/NCT03906500,TERMINATED,NO,Alcohol Drinking,BEHAVIORAL: High schools High on Life,University of Southern Denmark,Danish Cancer Society,ALL,"CHILD, ADULT",3682,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2019-04-01,2021-08-30,"National Institute of Public Health, Copenhagen, 1455, Denmark"
NCT03922360,Smartphone-based Financial Incentives,https://clinicaltrials.gov/study/NCT03922360,UNKNOWN,NO,Tobacco Use Disorder,BEHAVIORAL: Smartphone-based Financial Incentives|BEHAVIORAL: Best Practices,University of Vermont,,FEMALE,"ADULT, OLDER_ADULT",150,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-09-01,2021-06,"University of Vermont, Burlington, Vermont, 05401, United States"
NCT02496403,Buprenorphine and Substance Abuse Services for Prescription Opioid Dependence,https://clinicaltrials.gov/study/NCT02496403,COMPLETED,NO,Opiate Substitution Treatment,BEHAVIORAL: Standard Medical Management (SMM),Kaiser Permanente,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",239,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2015-12,2019-05,"Kaiser Sacramento Chemical Dependency Recovery Program, Sacramento, California, 95821, United States"
NCT05829863,A Neuroimaging Approach to Advance Mechanistic Understanding of Tobacco Use Escalation Risk Among Young Adult African American Vapers,https://clinicaltrials.gov/study/NCT05829863,NOT_YET_RECRUITING,NO,Message Exposure,BEHAVIORAL: educational message exposure,University of Georgia,,ALL,ADULT,60,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-05-01,2024-05-31,"UGA Bio-imaging Research Center, Athens, Georgia, 30602, United States"
NCT05015439,Cannabidiol (CBD) in Adults With ASD,https://clinicaltrials.gov/study/NCT05015439,RECRUITING,NO,Autism Spectrum Disorder,DRUG: Cannabidiol|DRUG: Placebo,Johns Hopkins University,"Charlotte's Web, Inc",ALL,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-04-20,2025-12,"JHBMC, Baltimore, Maryland, 21224, United States"
NCT03785223,"A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity",https://clinicaltrials.gov/study/NCT03785223,COMPLETED,NO,Attention Deficit Hyperactivity Disorder|Generalized Anxiety Disorder|Social Anxiety Disorder|Panic Disorder|Agoraphobia,DRUG: Methylphenidate Hydrochloride Controlled-Release Capsules|DRUG: Placebo Capsule,McMaster University,"Purdue Pharma, Canada",ALL,"ADULT, OLDER_ADULT",60,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-04-20,2022-10-31,"MacAnxiety Research Center, Hamilton, Ontario, L8S 1B7, Canada"
NCT05632770,A Deployment Focused Pragmatic Trial of Optimal Stepped Care Intervention Targeting PTSD and Comorbidity for Acutely Hospitalized Injury Survivors Treated in US Trauma Care Systems,https://clinicaltrials.gov/study/NCT05632770,RECRUITING,NO,PTSD|Physical Injury,BEHAVIORAL: Stepped Collaborative Care|BEHAVIORAL: American College of Surgeons (ACS) Required Screening and Referral (Usual Care),University of Washington,National Institute of Mental Health (NIMH),ALL,"ADULT, OLDER_ADULT",424,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-01-09,2027-10-31,"Harborview Medical Center, Seattle, Washington, 98104, United States"
NCT01492842,Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV,https://clinicaltrials.gov/study/NCT01492842,COMPLETED,NO,HIV Infection,,"University of North Carolina, Chapel Hill",National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH),ALL,"CHILD, ADULT",272,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-09,2012-06,"University of Colorado Denver, Aurora, Colorado, 80045, United States|Johns Hopkins University, Baltimore, Maryland, 21287, United States|The Fenway Institute, Boston, Massachusetts, 02215, United States|Children's Hospital of Michigan, Detroit, Michigan, 48201, United States|Baylor College of Medicine, Houston, Texas, 77030, United States"
NCT06132971,Multi-court Trial of NBP to Prevent Substance Abuse and Mental Health Disorders (MTC),https://clinicaltrials.gov/study/NCT06132971,COMPLETED,NO,Divorce|Drug Abuse|Mental Health Disorder,BEHAVIORAL: New Beginnings Program,Arizona State University,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",2415,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2012-07-30,2017-01-31,"Sharlene Wolchik, Tempe, Arizona, 85287, United States"
NCT03409328,Understanding and Reducing HIV Risk Behavior and Substance Use Among Self-identified Bisexual Adolescent Men,https://clinicaltrials.gov/study/NCT03409328,COMPLETED,YES,HIV/AIDS|Substance Use|Bisexuality,BEHAVIORAL: HIV and substance use prevention,Rosalind Franklin University of Medicine and Science,,ALL,CHILD,60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-06-11,2022-01-31,"Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, 60064, United States"
NCT04559893,Collaboration Leading to Addiction Treatment and Recovery From Other Stresses,https://clinicaltrials.gov/study/NCT04559893,COMPLETED,NO,Opioid-use Disorder|Addiction|Depression|Post-traumatic Stress Disorder,BEHAVIORAL: Collaborative Care,RAND,University of New Mexico|Boston Medical Center|First Choice Community Healthcare|Hidalgo Medical Services|National Institute of Mental Health (NIMH)|Stanford University|University of Pittsburgh|Saint John's Cancer Institute|Olive View-UCLA Education & Research Institute,ALL,"ADULT, OLDER_ADULT",729,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-01-08,2024-06-12,"Hubert Humphrey Comprehensive Health Center, Los Angeles, California, 90003, United States|Providence Saint John's Health Center, Santa Monica, California, 90404, United States|First Choice Community Healthcare - South Broadway Medical Center, Albuquerque, New Mexico, 87102, United States|First Choice Community Healthcare - South Valley Medical/Dental Center, Albuquerque, New Mexico, 87105, United States|First Choice - Alameda Medical Center, Albuquerque, New Mexico, 87107, United States|First Choice Community Healthcare - North Valley Medical Center, Albuquerque, New Mexico, 87107, United States|University of New Mexico Family Health Clinic, North Valley, Albuquerque, New Mexico, 87107, United States|University of New Mexico Family Health Clinic, Southeast Heights, Albuquerque, New Mexico, 87108, United States|First Choice Community Healthcare - Alamosa Medical Center, Albuquerque, New Mexico, 87121, United States|University of New Mexico Internal Medicine Clinic, Southwest Mesa, Albuquerque, New Mexico, 87121, United States|First Choice Community Healthcare - Belen Medical Center, Belen, New Mexico, 87002, United States|First Choice Community Healthcare - Edgewood Medical/Dental Center, Edgewood, New Mexico, 87015, United States|Hidalgo Medical Services - Lordsburg Clinic, Lordsburg, New Mexico, 88045, United States|First Choice Community Healthcare - Los Lunas Medical/Dental Center, Los Lunas, New Mexico, 87031, United States|Hidalgo Medical Services - Community Health Center, Silver City, New Mexico, 88061, United States|Hidalgo Medical Services - Med Square Clinic, Silver City, New Mexico, 88061, United States"
NCT04604236,"Family Assessment Motivation, and Linkage Intervention (FAMLI)",https://clinicaltrials.gov/study/NCT04604236,COMPLETED,NO,Mapping Enhanced Counseling (MEC)|Active Linkage (AL),BEHAVIORAL: Mapping Enhanced Counseling|BEHAVIORAL: Active Linkage,Texas Christian University,,ALL,"CHILD, ADULT",150,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-07,2023-04-17,"Texas Christian University, Fort Worth, Texas, 76109, United States"
NCT05012124,"Using Technology to Optimize Collaborative Care Management of Depression in Urban and Rural Cancer Centers, SCOPE",https://clinicaltrials.gov/study/NCT05012124,RECRUITING,NO,Depression|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm,OTHER: Collaborative care|OTHER: Interview or Focus Group|OTHER: Media/technology Intervention with collaborative care|OTHER: Survey Administration,University of Washington,National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",390,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2022-04-15,2026-03-31,"MultiCare Regional Cancer Center - Auburn, Auburn, Washington, 98002, United States|MultiCare Regional Cancer Center - Gig Harbor, Gig Harbor, Washington, 98335, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, 98109, United States|MultiCare Regional Cancer Center - Tacoma, Tacoma, Washington, 98405, United States"
NCT04160754,Mindfulness for at Risk Youth: Understanding Substance Use and Important Mechanisms of Change,https://clinicaltrials.gov/study/NCT04160754,COMPLETED,NO,"Alcohol Use, Underage|Alcohol Problem Drinking|Substance Use",BEHAVIORAL: Mindfulness Based Relapse Prevention|BEHAVIORAL: Control (CTL),University of Southern California,,ALL,ADULT,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2019-03-05,2020-06-30,"University of Southern California, School of Social Work, Los Angeles, California, 90089, United States"
NCT05598905,"Combined Effect of Pregabalin and Oxycodone, and Lacosamide and Oxycodone, on Breathing",https://clinicaltrials.gov/study/NCT05598905,COMPLETED,NO,Opioid-induced Respiratory Depression,DRUG: Pregabalin 150mg|DRUG: Oxycodone 10mg|DRUG: Lacosamide 150 mg,Leiden University Medical Center,,ALL,ADULT,24,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-10-10,2024-01-12,"Leiden University Medical Center, Leiden, ZH, 2333 ZA, Netherlands"
NCT06706037,Effect of Reformer Exercises on Pain Perception in Chronic Musculoskeletal Pain.,https://clinicaltrials.gov/study/NCT06706037,RECRUITING,NO,Musculoskeletal Pain,OTHER: Exercise,Atılım University,Çankırı Karatekin University,ALL,ADULT,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2024-09-27,2024-11-30,"Naime Ulug, Ankara, Select State, 06830, Turkey"
NCT06311838,Building Social and Structural Connections for the Prevention of Opioid Use Disorder Among Youth Experiencing Homelessness,https://clinicaltrials.gov/study/NCT06311838,RECRUITING,NO,Opioid Use Disorder|Dual Diagnosis|Housing Problems|Mental Disorder in Adolescence|Risk Behavior|Homelessness,BEHAVIORAL: Motivational Interviewing/Community Reinforcement Approach (MI/CRA)|BEHAVIORAL: Strengths-Based Outreach and Advocacy (SBOA )|BEHAVIORAL: Services as Usual (SAU),Ohio State University,,ALL,"CHILD, ADULT",300,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2024-05-06,2029-12-01,"Star House, Columbus, Ohio, 43201, United States|Ohio State University, Columbus, Ohio, 43210, United States"
NCT03984214,Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer,https://clinicaltrials.gov/study/NCT03984214,ACTIVE_NOT_RECRUITING,NO,Pancreatic Cancer Non-resectable|Chemotherapy-induced Nausea and Vomiting|Pancreatic Cancer Metastatic,DRUG: Dronabinol in Oral Dosage Form|DRUG: Placebo in Oral Dosage Form,Arbeitsgemeinschaft medikamentoese Tumortherapie,Medical University of Graz|Unidata Geodesign|Bionorica SE,ALL,"ADULT, OLDER_ADULT",109,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-12-16,2024-09-30,"Klinikum Wels-Grieskirchen GmbH, Abteilung für Innere Medizin IV, Wels, Oberösterreich, 4600, Austria|KABEG-Klinikum Klagenfurt am Woerthersee, Abteilung f. Anaesthesie u. Intensivmedizin, Klagenfurt, 9020, Austria|LKH Hochsteiermark - Standort Leoben Abteilung für Innere Medizin und Hämatologie und internistische Onkologie, Leoben, 8700, Austria|IIIrd Medical Department, Private Medical University Hospital Salzburg, Salzburg, 5020, Austria|Krankenhaus d. Barmherzigen Brüder, Abt. f. Innere Medizin, St. Veit an der Glan, 9300, Austria|Pyhrn-Eisenwurzen Klinikum Steyr, Interne Medizin II, Steyr, A-4400, Austria|Medizinische Univ. Wien, Univ.Klinik f. Innere Medizin I, Onkologie, Vienna, 1090, Austria|Hanusch Krankenhaus der Wiener Gebietskrankenkasse, Vienna, 1140, Austria|KH Zams, Innere Medizin, Internistische Onkologie u. Haematologie, Zams, 6511, Austria|Universitätsmedizin Göttingen Abt. f. Gastroenterologie, gastrointestinale Onkologie u. Endokrinologie, Göttingen, 37075, Germany|München Klinik Neuperlach, München, 81737, Germany|Marienhospital Onkologie, Hämatologie, Palliativmedizin, Stuttgart, 07199, Germany"
NCT03940508,Engaging Black Youth in Depression and Suicide Prevention Treatment Within Urban Schools,https://clinicaltrials.gov/study/NCT03940508,COMPLETED,NO,Depression|Suicidal Ideation,BEHAVIORAL: Making Connections Intervention|BEHAVIORAL: IPT-A,New York University,National Institute of Mental Health (NIMH)|Columbia University,ALL,"CHILD, ADULT",29,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-31,2023-12-31,"Columbia University, New York, New York, 10003, United States|McSilver Institute for Poverty Policy and Research, New York, New York, 10003, United States"
NCT00717444,Healthy Activities for Prize Incentives,https://clinicaltrials.gov/study/NCT00717444,COMPLETED,NO,Substance Abuse|HIV Infections,BEHAVIORAL: contingency management|BEHAVIORAL: contingency management,UConn Health,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",75,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2008-09,2013-05,"Connections, Inc., Hartford, Connecticut, 06106, United States"
NCT03523923,TBI Care: Collaborative Care for Pain After Traumatic Brain Injury (TBI),https://clinicaltrials.gov/study/NCT03523923,COMPLETED,NO,"Brain Injuries, Traumatic|Chronic Pain|Post-Traumatic Headache",BEHAVIORAL: Collaborative Care,University of Washington,"National Institute on Disability, Independent Living, and Rehabilitation Research",ALL,"ADULT, OLDER_ADULT",158,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-06-18,2022-09-30,"Harborview Medical Center, TBI Clinic, Seattle, Washington, 98104, United States|University of Washington Medical Center, TBI Clinic, Seattle, Washington, 98195, United States"
NCT05057754,Sonographic Measurement of Intraneural Blood Flow in the Median Nerve,https://clinicaltrials.gov/study/NCT05057754,COMPLETED,NO,Carpal Tunnel Syndrome|Median Nerve Injury,BEHAVIORAL: Cooling|BEHAVIORAL: Heating|BEHAVIORAL: Exercising|BEHAVIORAL: Typing|BEHAVIORAL: Using a mouse|BEHAVIORAL: Cooking,University of Southern California,,ALL,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-12-13,2022-05-30,"USC; Musculoskeletal Sonography & Occupational Performance Laboratory, Los Angeles, California, 90033, United States|Ohio State University; School of Health and Rehabilitation Sciences, Columbus, Ohio, 43210, United States"
NCT02037126,Psilocybin-facilitated Treatment for Cocaine Use,https://clinicaltrials.gov/study/NCT02037126,COMPLETED,NO,Cocaine-Related Disorders,DRUG: Psilocybin|DRUG: Diphenhydramine,University of Alabama at Birmingham,,ALL,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-05,2024-05,"UAB Outpatient Clinical Research Unit, Birmingham, Alabama, 35294, United States"
NCT04242992,Effectiveness of Transdiagnostic Cognitive Behavioral Therapy for Improving HIV Treatment Outcomes in South Africa,https://clinicaltrials.gov/study/NCT04242992,ACTIVE_NOT_RECRUITING,NO,HIV/AIDS|Violence,BEHAVIORAL: CETA|OTHER: Short Message Service (SMS) text reminders,Boston University,National Institute of Mental Health (NIMH),FEMALE,"ADULT, OLDER_ADULT",400,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE,2021-11-12,2026-05,"HIV Clinic, Johannesburg, Gauteng, 02476, South Africa"
NCT02360410,Check Yourself Study,https://clinicaltrials.gov/study/NCT02360410,COMPLETED,NO,Health Risk Behaviors|Health Care Services Quality of Care,BEHAVIORAL: Check Yourself App with Feedback,Laura Richardson,,ALL,"CHILD, ADULT",300,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2015-02,2016-12,"Seattle Children's Hospital, Seattle, Washington, 98105, United States"
NCT05381883,Mental Health of Professionals of the Silver Economy of New Aquitaine : Online Survey of Accommodation Establishments for Old People and Home Assistance Establishments,https://clinicaltrials.gov/study/NCT05381883,NOT_YET_RECRUITING,NO,COVID-19 Pandemic|Professional Stress,OTHER: Questionnaire,"Centre Hospitalier Charles Perrens, Bordeaux",,ALL,"ADULT, OLDER_ADULT",4500,OTHER_GOV,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2024-09-15,2026-11-30,"Centre Hospitalier Charles Perrens, Bordeaux, 33076, France"
NCT02721498,Improving Outcome Measures For Adult CF ACT Trials,https://clinicaltrials.gov/study/NCT02721498,COMPLETED,NO,Cystic Fibrosis,PROCEDURE: Airway clearance session using the Active Cycle of Breathing Techniques (ACBT)|OTHER: Rest period,Royal Brompton & Harefield NHS Foundation Trust,"National Institute for Health Research, United Kingdom",ALL,"CHILD, ADULT, OLDER_ADULT",68,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: OTHER,2016-09,2021-12,"The Royal Brompton Hospital, London, Greater London, SW3 6NP, United Kingdom"
NCT03935646,Acute Effects of Stimulant Medication in College Students With ADHD,https://clinicaltrials.gov/study/NCT03935646,RECRUITING,NO,Attention Deficit Hyperactivity Disorder|Stimulant Use|Working Memory|Change in Sustained Attention|Mood,DRUG: Adderall IR 10mg|DRUG: Placebo,University of Wyoming,,ALL,ADULT,40,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-02-11,2025-06-30,"University of Wyoming, Laramie, Wyoming, 82071, United States"
NCT04700137,"Mental Health Among Patients, Providers, and Staff During the COVID-19 Era",https://clinicaltrials.gov/study/NCT04700137,COMPLETED,YES,Covid19|Mental Health,OTHER: Caring Contacts Plus Introductory Phone Call (CC+)|OTHER: Caring Contacts without an introductory phone call (CC),"St. Luke's Health System, Boise, Idaho",Patient-Centered Outcomes Research Institute|Idaho Crisis & Suicide Hotline|University of Washington,ALL,"CHILD, ADULT, OLDER_ADULT",666,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-01-18,2022-01-06,"St. Luke's Health System, Boise, Idaho, 83712, United States"
NCT03406039,Testing the Efficacy of an Online Integrated Treatment for Comorbid Alcohol Misuse and Emotional Problems,https://clinicaltrials.gov/study/NCT03406039,COMPLETED,NO,Alcohol Use Disorder,BEHAVIORAL: Integrated Online CBT and MI,University of Manitoba,,ALL,ADULT,273,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-09-04,2020-03-17,"University of Manitoba, Winnipeg, Manitoba, R3T 2M8, Canada"
NCT06335329,Point-of-Care Ultrasound (POCUS) Findings and Impact on Vaping,https://clinicaltrials.gov/study/NCT06335329,RECRUITING,NO,Vaping,BEHAVIORAL: Discussion of point-of-care ultrasound lung findings,Medical University of South Carolina,,ALL,"CHILD, ADULT",200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2024-07-17,2025-07,"Medical University of South Carolina, Charleston, South Carolina, 29412, United States"
NCT03155906,Integrated Treatment of Hepatitis C Virus Infection,https://clinicaltrials.gov/study/NCT03155906,ACTIVE_NOT_RECRUITING,NO,"Hepatitis C, Chronic|Opioid Dependence, on Agonist Therapy",OTHER: Health care delivery,Haukeland University Hospital,Helse Stavanger HF|Forskningsrådet|Helse Vest|University of Bergen|Folkehelseinstituttet|Bergen kommune,ALL,"CHILD, ADULT, OLDER_ADULT",240,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2017-05-18,2025-08-08,"Department of Addiction Medicine, Haukeland University Hospital, Bergen, Hordaland, 5020, Norway|LAR Helse Stavanger HF, Stavanger, Rogaland, 4010, Norway"
NCT03925220,Testing a Brief Substance Misuse Preventative Intervention for Parents/Guardians of 5th-7th Grade Students,https://clinicaltrials.gov/study/NCT03925220,ACTIVE_NOT_RECRUITING,NO,Substance-Related Disorders|Underage Drinking|Drug Use,BEHAVIORAL: The SUPPER Project|BEHAVIORAL: Improving nutrition and physical activity among youth,Tufts University,Brown University,ALL,CHILD,1000,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2019-03-06,2025-06-30,"Tufts University School of Medicine, Boston, Massachusetts, 02111, United States"
NCT06782490,"A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity",https://clinicaltrials.gov/study/NCT06782490,NOT_YET_RECRUITING,NO,Multiple Sclerosis Spasticity,DRUG: BMS-986368|DRUG: Placebo,Celgene,,ALL,"ADULT, OLDER_ADULT",200,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2025-03-14,2026-11-02,"Local Institution - 0050, Scottsdale, Arizona, 85253, United States|Local Institution - 0017, Aurora, Colorado, 80045, United States|Local Institution - 0015, Tampa, Florida, 33612, United States|Local Institution - 0016, Kansas City, Kansas, 66160, United States|Local Institution - 0049, Foxboro, Massachusetts, 02035, United States|Local Institution - 0018, Saint Louis, Missouri, 63110, United States|Local Institution - 0002, Cincinnati, Ohio, 45219, United States|Local Institution - 0003, Knoxville, Tennessee, 37922, United States|Local Institution - 0001, Kirkland, Washington, 98034, United States|Local Institution - 0005, Newcastle, New South Wales, 2305, Australia|Local Institution - 0004, Sydney, New South Wales, 2050, Australia|Local Institution - 0030, Kent Town, South Australia, 5067, Australia|Local Institution - 0007, Box Hill, Victoria, 3128, Australia|Local Institution - 0008, Heidelberg, Victoria, 3084, Australia|Local Institution - 0006, Parkville, Victoria, 3050, Australia|Local Institution - 0019, Nedlands, Western Australia, 6009, Australia|Local Institution - 0013, Edmonton, Alberta, T6G 2G3, Canada|Local Institution - 0024, London, Ontario, N6A 5A5, Canada|Local Institution - 0012, Ottawa, Ontario, K1H 8L6, Canada|Local Institution - 0028, Toronto, Ontario, M5B 1W8, Canada|Local Institution - 0014, Lévis, Quebec, G6W0M5, Canada|Local Institution - 0029, Montreal, Quebec, H3A2B4, Canada|Local Institution - 0055, Brno, Brno-město, 656 91, Czechia|Local Institution - 0010, Hradec Kralove, Hradec Králové, 500 05, Czechia|Local Institution - 0054, Prague, Praha 2, 12111, Czechia|Local Institution - 0059, Prague, Praha 4, 14059, Czechia|Local Institution - 0011, Praha, Praha 5, 150 06, Czechia|Local Institution - 0053, Pardubice, 532 03, Czechia|Local Institution - 0009, Teplice, Ústecký Kraj, 415 01, Czechia|Local Institution - 0052, Wuerzburg, Bayern, 97074, Germany|Local Institution - 0022, Kassel, Hessen, 34121, Germany|Local Institution - 0027, Bochum, Nordrhein-Westfalen, 44791, Germany|Local Institution - 0031, Meisenheim, Rheinland-Pfalz, 55590, Germany|Local Institution - 0023, Jena, Thüringen, 07747, Germany|Local Institution - 0051, Bielefeld, 33647, Germany|Local Institution - 0021, Dresden, 01307, Germany|Local Institution - 0020, Essen, 45122, Germany|Local Institution - 0057, Bydgoszcz, Kujawsko-pomorskie, 85-163, Poland|Local Institution - 0044, Bydgoszcz, Kujawsko-pomorskie, 85-796, Poland|Local Institution - 0046, Kraków, Małopolskie, 30-727, Poland|Local Institution - 0056, Kraków, Małopolskie, 31-503, Poland|Local Institution - 0061, Gdańsk, 80-952, Poland|Local Institution - 0045, Katowice, Śląskie, 40-571, Poland|Local Institution - 0058, Caguas, 00725, Puerto Rico"
NCT06558474,Optimization of Percutaenous Coronary Intervention With Liberal Use of Post-dilatation,https://clinicaltrials.gov/study/NCT06558474,RECRUITING,NO,Coronary Artery Disease,BEHAVIORAL: Liberal post-dilatation strategy during PCI,Cathreine BV,Medtronic,ALL,"ADULT, OLDER_ADULT",12000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-09-01,2026-05-01,"Catharina Hospital, Eindhoven, North- Brabant, 5623 EJ, Netherlands"
NCT06417827,Artificial Intelligence for Mental Health Diagnoses and Treatment Plans: A Protocol for Actors and Patients,https://clinicaltrials.gov/study/NCT06417827,RECRUITING,NO,Mental Health Diagnosis,DIAGNOSTIC_TEST: SP patients-actors|DIAGNOSTIC_TEST: Patients|DIAGNOSTIC_TEST: Control group- patients,Sheba Medical Center,,ALL,"ADULT, OLDER_ADULT",220,OTHER_GOV,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-12-12,2024-12-31,"Sheba Medical Center, Psychiatry Department, Ramat Gan, Israel"
NCT04111887,Pilot Study Comparing Two Versions of Group Cognitive-behavioral Indicated Prevention Programs,https://clinicaltrials.gov/study/NCT04111887,COMPLETED,NO,Depressive Symptoms,BEHAVIORAL: Group-based therapy,Oregon Research Institute,,ALL,ADULT,91,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-10-10,2018-12-13,"Oregon Research Institute, Eugene, Oregon, 97401, United States"
NCT06715163,Evaluation of the Safety and Tolerability of Three Doses of Diamine Oxidase (DAO) in Healthy Volunteers,https://clinicaltrials.gov/study/NCT06715163,COMPLETED,NO,Safety and Tolerability in Healthy Volunteers,DIETARY_SUPPLEMENT: Dose 1 (42mg) of DAO|DIETARY_SUPPLEMENT: Placebo|DIETARY_SUPPLEMENT: Dose 2 (84mg) of DAO|DIETARY_SUPPLEMENT: Dose 3 (210mg) of DAO,AB Biotek,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,ALL,ADULT,43,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2024-07-08,2024-07-29,"Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Barcelona, 08041, Spain"
NCT06471335,Fetal Alcohol Spectrum Disorder : Clinical Description and Search for Epigenetic Biomarker (EPI-TSAF),https://clinicaltrials.gov/study/NCT06471335,RECRUITING,NO,Fetal Alcohol Spectrum Disorders,DIAGNOSTIC_TEST: Extraction of microRNAs extracted from plasma (4 ml recovered as part of treatment)|DIAGNOSTIC_TEST: Extraction of microRNAs extracted from bucal swabs (act added for research).,Centre Hospitalier Universitaire de la Réunion,,ALL,"CHILD, ADULT",200,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2024-06-12,2024-12-31,"CHU de la Réunion, St Denis, 97400, France"
NCT05471921,Effectiveness of an Evidence-based Stepped Care System for Alcohol and Other Drug Use Problems Among Congolese Refugees in Zambia,https://clinicaltrials.gov/study/NCT05471921,ACTIVE_NOT_RECRUITING,NO,Alcohol and Substance-Related Mental Disorders,BEHAVIORAL: SBIRT|BEHAVIORAL: Treatment as usual,Columbia University,,ALL,"CHILD, ADULT, OLDER_ADULT",400,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-04-26,2025-06-30,"Mantapala Refugee Settlement, Nchelenge, Luapula, Zambia"
NCT05873933,"An Investigation of a Multi-Function Skincare Product to Improve Aging, Eczema, and Acne Outcomes",https://clinicaltrials.gov/study/NCT05873933,WITHDRAWN,NO,Acne|Eczema|Skin Aging,OTHER: Hemptress Oil,Hemptress,Citruslabs,ALL,"ADULT, OLDER_ADULT",0,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2024-07-01,2024-11-01,"Citruslabs, Santa Monica, California, 09404, United States"
NCT02497014,The European Bifurcation Club Left Main Study,https://clinicaltrials.gov/study/NCT02497014,UNKNOWN,NO,Percutaneous Transluminal Coronary Angioplasty|Coronary Artery Disease,DEVICE: 1 Stent|DEVICE: 2 Stents,European Cardiovascular Research Center,Medtronic,ALL,"ADULT, OLDER_ADULT",450,NETWORK,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-02,2020-08,"Aarhus University Hospital, Aarhus, 8200, Denmark|Rigshospitalet Copenhagen University Hospital, Copenhagen, 2100, Denmark|Clinique de Fontaine, Fontaine-lès-Dijon, 21121, France|HCL CHU Luis Pradel, Lyon, 69500, France|Hopital Jacques Cartier, Massy, 91300, France|Clinique Saint Hilaire, Rouen, 76000, France|Clinique Pasteur, Toulouse, 31076, France|CHU Rangueil, Toulouse, 31403, France|Herzzentrum Bad Krozingen, Bad Krozingen, 79189, Germany|Elisabeth Krankenhaus Essen, Essen, 45138, Germany|University of Catania - Ferrarotto Hospital, Catania, 95124, Italy|Ospedale San Raffaele, Milano, 20132, Italy|Universita Cattolica del Sacre Cuore, Roma, 00168, Italy|Pauls Stradins Clinical University Hospital, Riga, 1002, Latvia|Clinical Center of Serbia, Belgrade, 11000, Serbia|Hospital del Mar, Barcelona, 08003, Spain|Hospital Clinic de Barcelona, Barcelona, 08006, Spain|Hospital Sant Pau i Sant Creu, Barcelona, 08025, Spain|Hospital de la Reina Sofia, Cordoba, 14004, Spain|Belfast City Hospital, Belfast, BT97AB, United Kingdom|Royal Sussex County Hospital, Brighton, United Kingdom|St Thomas Hospital, London, SE1 7EH, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, NE7 7DN, United Kingdom|John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom"
NCT03329573,Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga Sites in Healthy Chinese Subjects,https://clinicaltrials.gov/study/NCT03329573,COMPLETED,YES,Anxiety Disorders,DRUG: Paroxetine IR tablets A|DRUG: Paroxetine IR tablets B,GlaxoSmithKline,,ALL,ADULT,85,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2018-05-30,2018-08-03,"GSK Investigational Site, Shanghai, 201508, China"
NCT02832362,Local Nasal Tolerability and Safety Study of 1146A in Healthy Adult Participants,https://clinicaltrials.gov/study/NCT02832362,COMPLETED,NO,Common Cold,DRUG: Carbomer 980|OTHER: Placebo,GlaxoSmithKline,,ALL,ADULT,30,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2016-06-11,2016-07-18,"GSK Investigational Site, Quebec City, Quebec, G1P 0A2, Canada"
NCT05075629,"Anxiety, Depression and Substance Use in Undergraduate Health Science Students During the Covid-19 Pandemic.",https://clinicaltrials.gov/study/NCT05075629,COMPLETED,NO,Depression|Anxiety|Substance-Related Disorders,,"Universidad Westhill, Facultad de Psicología",,ALL,ADULT,384,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-10-12,2022-03-31,"Alejandro Hernández Posadas, Ciudad de México, Mexico"
NCT05060445,Mental Health in Latin American Countries With Different Economic Incomes During the Covid-19 Pandemic.,https://clinicaltrials.gov/study/NCT05060445,COMPLETED,NO,Depression|Anxiety|Substance-Related Disorders,,"Universidad Westhill, Facultad de Psicología",,ALL,"ADULT, OLDER_ADULT",3022,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-11-22,2022-03-13,"Westhill University, Ciudad de México, 010, Mexico"
NCT00816439,Imaging Cannabinoid CB1 Receptors in Alcohol Dependence,https://clinicaltrials.gov/study/NCT00816439,COMPLETED,NO,Alcoholism,,National Institute of Mental Health (NIMH),,MALE,"ADULT, OLDER_ADULT",101,NIH,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-12-29,2014-08-28,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT04855357,Smoke-free Home Intervention in Permanent Supportive Housing,https://clinicaltrials.gov/study/NCT04855357,RECRUITING,NO,Smoking Cessation|Second Hand Tobacco Smoke,BEHAVIORAL: Resident counselling|BEHAVIORAL: Staff Training,"University of California, San Francisco",National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",400,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2022-01-24,2025-03-31,"University of California, San Francisco, San Francisco, California, 94143, United States"
NCT04989972,Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults,https://clinicaltrials.gov/study/NCT04989972,WITHDRAWN,NO,Anxiety and Depression,DRUG: PSIL428|DIETARY_SUPPLEMENT: Oyster mushroom|DRUG: PSIL428,"Wake Network, Inc.",Professor Roger Gibson Section of Psychiatry Faculty of Medical Sciences UWI,ALL,"ADULT, OLDER_ADULT",0,NETWORK,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-09-15,2023-08-31,"FMS Department of Psychiatry, Kingston, Jamaica"
NCT03682978,Arbaclofen in Children and Adolescents With ASD,https://clinicaltrials.gov/study/NCT03682978,COMPLETED,NO,Autism Spectrum Disorder,DRUG: Arbaclofen|DRUG: Placebo,"Celso Arango, MD, PhD",UMC Utrecht,ALL,CHILD,124,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-09-19,2023-01-27,"Robert Debré Hospital, Paris, 75019, France|Hospital Clínic de Barcelona, Barcelona, 08036, Spain|Servicio de Psiquiatría del Niño y del Adolescente, Hospital General Universitario Gregorio Marañón, SERMAS, Madrid, 28009, Spain|University of Salamanca & Complejo asistencial de Zamora, Salamanca, Spain|University of Glasgow, Glasgow, G78 1SL, United Kingdom|King's College London, London, SE5 8AF, United Kingdom|University of Newcastle upon Tyne, Newcastle, NE1 7RU, United Kingdom"
NCT05382091,Evaluation of the O'Neil Long Acting Naltrexone Implant in Opioid Dependent Persons,https://clinicaltrials.gov/study/NCT05382091,NOT_YET_RECRUITING,NO,Opioid Use Disorder,DRUG: naltrexone implant,Go Medical Industries Pty Ltd,"National Institute on Drug Abuse (NIDA)|New York State Psychiatric Institute|Columbia University|The Emmes Company, LLC|University at Buffalo",ALL,"ADULT, OLDER_ADULT",250,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2025-03-15,2028-03-15,
NCT05900115,Feasibility Study of a Web-based Program to Help Parents of Middle School Students Effectively Communicate With Their Children About Substance Use,https://clinicaltrials.gov/study/NCT05900115,COMPLETED,YES,Substance Use|Parenting|Communication,BEHAVIORAL: Media Ready Parent|BEHAVIORAL: Active Control Program,Innovation Research & Training,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT, OLDER_ADULT",576,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-05-08,2023-11-29,"innovation Research and Training, Durham, North Carolina, 27713, United States"
NCT00321698,Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer,https://clinicaltrials.gov/study/NCT00321698,TERMINATED,YES,Prostate Cancer,RADIATION: Intensity-Modulated Radiation Therapy (IMRT)|DRUG: Docetaxel+IMRT,OHSU Knight Cancer Institute,,MALE,"ADULT, OLDER_ADULT",25,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-04-21,2023-08-18,"Veterans Affairs Medical Center - Portland, Portland, Oregon, 97207, United States|OHSU Knight Cancer Institute, Portland, Oregon, 97239-3098, United States"
NCT03989934,Teenage Health and Wellness Study,https://clinicaltrials.gov/study/NCT03989934,COMPLETED,NO,Stress|Externalizing Symptoms|Depression Symptoms|Anxiety,BEHAVIORAL: The Mind in Action|BEHAVIORAL: Healthy Topics,Penn State University,"Johns Hopkins Bloomberg School of Public Health|University of Cincinnati|University of North Carolina, Chapel Hill",ALL,CHILD,203,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2019-02-05,2022-06-22,"Baltimore City Public Schools, Baltimore, Maryland, 21202, United States"
NCT06236100,Evaluating an Adverse Childhood Experience-Targeting Advocate Model of a Substance Use Prevention Program,https://clinicaltrials.gov/study/NCT06236100,RECRUITING,NO,Substance-Related Disorders|Adverse Childhood Experiences,BEHAVIORAL: Strengthening Families Program + Family Advocate|BEHAVIORAL: Strengthening Families Program,RTI International,New Jersey Prevention Network|RWJBarnabas Health Institute for Prevention and Recovery,ALL,"CHILD, ADULT, OLDER_ADULT",360,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2023-11-29,2027-09-29,"New Jersey Prevention Network, Tinton Falls, New Jersey, 07724, United States"
NCT02140099,Evaluation of the Healthy Relationships Plus Program for Youth,https://clinicaltrials.gov/study/NCT02140099,COMPLETED,NO,Mental Health Wellness 1,BEHAVIORAL: Healthy Relationships Plus Program (HRPP)|BEHAVIORAL: Control Condition (Classroom Activities),Centre for Addiction and Mental Health,CAMH Foundation,ALL,CHILD,238,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2014-03,2015-08,"CAMH Centre for Prevention Science, London, Ontario, N6G4X8, Canada"
NCT05157386,Physical Exercise as Adjunctive Therapy for Affective Disorder and Anxiety,https://clinicaltrials.gov/study/NCT05157386,ACTIVE_NOT_RECRUITING,NO,Depression|Physical Inactivity|Bipolar Disorder|Anxiety Disorders|Anxiety|Posttraumatic Stress Disorder|ADHD|Autism|Social Phobia|Panic Disorder|Generalized Anxiety Disorder|Personality Disorders|Insomnia|Stress,OTHER: Braining,Region Stockholm,Karolinska Institutet,ALL,"ADULT, OLDER_ADULT",50,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-12-20,2024-12,"Region Stockholm, Psykiatri Sydväst (Psychiatric Clinic Psychiatry Southwest), Stockholm, 14186, Sweden"
NCT04478240,Automating Peer Learning to Reduce Alcohol Use and Related Deviant Behavior in Secondary School,https://clinicaltrials.gov/study/NCT04478240,COMPLETED,NO,"Substance Use|Stress|Relation, Interpersonal|Bullying|Victimisation|Mental Health Issue|Sleep, Inadequate|Social Skills",BEHAVIORAL: PeerLearning.net,"Oregon Research Behavioral Intervention Strategies, Inc.",,ALL,"CHILD, ADULT, OLDER_ADULT",924,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2021-09-01,2022-08-31,"Oregon Research Behavioral Intervention Strategies, Inc., Eugene, Oregon, 97403, United States"
NCT02485158,Individual Differences in the Response to Drugs,https://clinicaltrials.gov/study/NCT02485158,COMPLETED,YES,Healthy,DRUG: THC|DRUG: AMP|DRUG: ALC|DRUG: Placebo capsules|DRUG: Placebo beverage,University of Chicago,,ALL,ADULT,28,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2013-07,2013-12,
NCT06005298,"Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT Intervention",https://clinicaltrials.gov/study/NCT06005298,RECRUITING,NO,"Alcohol Use Disorder|Risk Behavior, Health|Dysbiosis|HIV Infections","BEHAVIORAL: Screening, Brief Intervention, Referral to Treatment (SBIRT)",Shirish S Barve,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"ADULT, OLDER_ADULT",120,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-08-01,2027-10-24,"University of Louisville, Louisville, Kentucky, 40202, United States"
NCT05759052,Vincristine-induced Peripheral Neuropathy in Adult Survivors of Childhood and Adolescent Leukemia,https://clinicaltrials.gov/study/NCT05759052,RECRUITING,NO,Chemotherapy-induced Peripheral Neuropathy,BEHAVIORAL: self-administered questionnaire,"University Hospital, Clermont-Ferrand",,ALL,"ADULT, OLDER_ADULT",750,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-05-05,2025-07-31,"CHU Clermont-Ferrand, Clermont-Ferrand, France"
NCT01821950,Evaluation of Yoga for Substance Use Risk Factors in a School Setting,https://clinicaltrials.gov/study/NCT01821950,COMPLETED,NO,Adolescent Development,BEHAVIORAL: Yoga during physical education,Brigham and Women's Hospital,National Institute on Drug Abuse (NIDA)|Kripalu Center for Yoga and Health|Boston University,ALL,CHILD,211,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2013-09,2015-04,"Boston Latin School, Boston, Massachusetts, 02115, United States"
NCT04566926,A Study of JNJ-64140284 in Healthy Male Participants,https://clinicaltrials.gov/study/NCT04566926,TERMINATED,NO,Healthy,DRUG: JNJ-64140284|DRUG: Placebo,"Janssen Pharmaceutica N.V., Belgium",,MALE,ADULT,33,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2020-09-29,2021-04-05,"SGS Life Science Services, Antwerpen, 2060, Belgium"
NCT05798039,ENRICH Nurse-Family Partnership Study,https://clinicaltrials.gov/study/NCT05798039,RECRUITING,NO,Blood Pressure|Body Composition|Blood Sugar|Body Weight|Diet Habit|Physical Inactivity,BEHAVIORAL: ENRICH,"University of Colorado, Denver","Denver Health and Hospital Authority|National Heart, Lung, and Blood Institute (NHLBI)",FEMALE,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-06-19,2024-04-30,"University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, United States"
NCT05743699,Adaptation and Evaluation of Bright Horizons,https://clinicaltrials.gov/study/NCT05743699,NOT_YET_RECRUITING,NO,Alcohol Abuse|Substance Use,BEHAVIORAL: Bright Horizons|BEHAVIORAL: Case Management,Johns Hopkins Bloomberg School of Public Health,Native American Research Centers for Health|White Mountain Apache Tribe,ALL,CHILD,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2025-05,2025-12,"Johns Hopkins Center for Indigenous Health - Whiteriver Site, Whiteriver, Arizona, 85941, United States"
NCT02941809,Harnessing Placebo Effects in Methadone Treatment,https://clinicaltrials.gov/study/NCT02941809,COMPLETED,NO,Opioid-use Disorder|Opioid-Related Disorders,BEHAVIORAL: Open-Label Placebo (OLP),"University of Maryland, Baltimore","University of Maryland, College Park",ALL,"ADULT, OLDER_ADULT",133,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-12-05,2020-07-31,"Maryland Methadone Treatment Center, Baltimore, Maryland, 21201, United States"
NCT00075205,Rimonabant to Reduce Alcohol Consumption,https://clinicaltrials.gov/study/NCT00075205,COMPLETED,NO,Healthy|Alcohol Drinking,DRUG: SR141716 (Rimonabant),National Institute on Alcohol Abuse and Alcoholism (NIAAA),Sanofi-Synthelabo,ALL,ADULT,54,NIH,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,2003-12-31,2007-03-15,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT05533957,Role of Oxygen in the Development of Fatigue in Patients With Chronic Respiratory Failure,https://clinicaltrials.gov/study/NCT05533957,COMPLETED,NO,Failure Pulmonary|COPD,OTHER: Application of different dosages of oxygen therapy,Istituti Clinici Scientifici Maugeri SpA,Universita di Verona,ALL,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-05,2024-07-08,"Istituti Clinici Scientifici Maugeri IRCCS, Lumezzane, Brescia, 25065, Italy"
NCT06554431,Assessing the Efficacy of Self-Driven Repetitive Artmaking Practice,https://clinicaltrials.gov/study/NCT06554431,RECRUITING,NO,Chronic Pain|Opioid Use Disorder|Opioid Misuse|Opioid-Related Disorders,BEHAVIORAL: Self-Driven Repetitive Artmaking,Montefiore Medical Center,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2024-07-02,2025-05,"Montefiore Wellness Center at Waters Place, Bronx, New York, 10461, United States"
NCT05705973,Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients,https://clinicaltrials.gov/study/NCT05705973,RECRUITING,NO,Cardiovascular Disease|Coronary Artery Occlusion|Ischemic Heart Disease,DEVICE: Ultimaster Nagomi™,Terumo Europe N.V.,,ALL,"ADULT, OLDER_ADULT",3000,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-04-25,2027-09,"Imelda Hospital, Bonheiden, Belgium|C.H.U. Charleroi, Charleroi, Belgium|Ziekenhuis Oost-Limburg, Genk, Belgium|CHR Citadelle, Liège, Belgium|Clinique Saint-Luc Bouge, Namur, Belgium|CHU UCL Mont Godinne Namur, Yvoir, Belgium|East Tallinn Central Hospital, Tallin, Estonia|Mater Private Network, Cork, Ireland|Mater Private Hospital, Dublin, Ireland|IRCCS Istituto Auxologico Italiano, Milano, Italy|Rijnstate Ziekenhuis, Arnhem, Netherlands|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Catharina Hospital Eindhoven, Eindhoven, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands|Jeroen Bosch Ziekenhuis, s-Hertogenbosch, Netherlands|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Juan Ramón Jiménez, Huelva, Spain|Salamanca University Hospital, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Universitätsspital Basel, Basel, Switzerland|Istituto Cardiocentro Ticino, Lugano, Switzerland|Royal Sussex County Hospital, Brighton, United Kingdom|Lincolnshire Heart Centre Lincoln County Hospital, Lincoln, United Kingdom|Newcastle Freeman Hospital, Newcastle upon Tyne, United Kingdom|University Hospital Plymouth NHS trust, Plymouth, United Kingdom|University Hospital of North Midlands, Staffordshire, United Kingdom|Worcestershire Royal Hospital, Worcester, United Kingdom"
NCT05228093,A Randomized Controlled Clinical Trial of Surgery Versus Conservative Treatment for Mild and Moderate-grade Nasopharyngeal Necrosis,https://clinicaltrials.gov/study/NCT05228093,UNKNOWN,NO,"Nasopharyngeal Carcinoma, Postradiation, Necrosis, Endoscopy Surgery, Conservative Treatment",PROCEDURE: Curative-intent endoscopic necrectomy followed by reconstruction using the posterior pedicle nasal septum and floor mucoperiosteum flap|PROCEDURE: Conservative treatment,Sun Yat-sen University,,ALL,"ADULT, OLDER_ADULT",216,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-11-01,2024-10-30,"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, China|The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, 510080, China|The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510700, China|The First Hospital of Nanchang, Nanchang, Jiangxi, 330000, China"
NCT04286594,A Clinical Trial of a Hemp-Derived Cannabidiol Product for Anxiety,https://clinicaltrials.gov/study/NCT04286594,TERMINATED,YES,Anxiety,DRUG: CBD,Mclean Hospital,,ALL,"ADULT, OLDER_ADULT",15,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-02-01,2023-08-24,"McLean Hospital, Belmont, Massachusetts, 02478, United States"
NCT04373343,Food Addiction Clinical Treatment Program,https://clinicaltrials.gov/study/NCT04373343,COMPLETED,NO,Food Addiction,BEHAVIORAL: 16-week Food Addiction Clinical Treatment (FACT) Program,Wake Forest University Health Sciences,,ALL,"ADULT, OLDER_ADULT",2,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-03-21,2023-09-07,"Wake Forest Health Sciences, Winston-Salem, North Carolina, 27157, United States"
NCT04803448,Patient Doctor Lies,https://clinicaltrials.gov/study/NCT04803448,COMPLETED,NO,Patient Lying|Privacy Statements|Risk Statements|Benefit Statements|Patient Lie Detection,BEHAVIORAL: Benefit statement|BEHAVIORAL: Risk Statement|BEHAVIORAL: Privacy Statement|BEHAVIORAL: Benefit + Privacy|BEHAVIORAL: Risk + Privacy,University of Utah,,ALL,"ADULT, OLDER_ADULT",619,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2020-02-12,2020-04-19,"Brigham Young University, Provo, Utah, 84602, United States"
NCT03894501,Pilot of Mindfulness Oriented Recovery Enhancement in MethadoneTreatment,https://clinicaltrials.gov/study/NCT03894501,COMPLETED,YES,Opioid Use|Chronic Pain,BEHAVIORAL: Mindfulness Oriented Recovery Enhancement|BEHAVIORAL: Methadone program behavioral treatment as usual,"Rutgers, The State University of New Jersey",University of Utah,ALL,"ADULT, OLDER_ADULT",30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-01-31,2019-06-19,"Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, 08901, United States"
NCT04222556,Evaluation of Thiwáhe Gluwáš'Akapi Substance Use Prevention Program,https://clinicaltrials.gov/study/NCT04222556,ACTIVE_NOT_RECRUITING,NO,Substance Use|Substance Abuse|Suicide,BEHAVIORAL: Thiwáhe Gluwáš'akapi|BEHAVIORAL: Woyute Waśte,"University of Colorado, Denver",National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT, OLDER_ADULT",552,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: PREVENTION,2020-02-26,2025-02-28,"University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, United States"
NCT01733888,Resin Infiltration and Resin Infiltration With Bleaching in Improving the Esthetics for Fluorosis Stains,https://clinicaltrials.gov/study/NCT01733888,COMPLETED,YES,Caries Infiltration|Fluorosis|Dental Care,DEVICE: Office Bleaching|DEVICE: Resin Infiltration|DEVICE: Resin Infiltration twice|DEVICE: Bleaching + Resin Infiltration,DMG Dental Material Gesellschaft mbH,,ALL,CHILD,80,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2013-07,2014-05,"Department of Pediatric and Preventive Dentistry DAV Dental College, Yamuna Nagar, Haryana, 135001, India|Department of Pediatric and Preventive Dentistry DRIDS Dental College, Faridkot, Punjab, India"
NCT05195853,Optimization of Donor-Recipient Matching in Lung Transplantation,https://clinicaltrials.gov/study/NCT05195853,UNKNOWN,NO,Lung Transplant,,Fondation Hôpital Saint-Joseph,,ALL,"ADULT, OLDER_ADULT",500,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-01-15,2023-12-31,"Groupe Hospitalier Paris Saint-Joseph, Paris, 75014, France"
NCT04448808,Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol,https://clinicaltrials.gov/study/NCT04448808,RECRUITING,NO,Posttraumatic Stress Disorder,DRUG: BX-1|DRUG: Placebo,"Charite University, Berlin, Germany",Bionorica SE,ALL,"ADULT, OLDER_ADULT",176,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-10-01,2025-05,"Berlin St. Hedwig, Berlin, 10115, Germany|Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Psychiatrie und Psychotherapie, Berlin, 12203, Germany|Zentralinstitut für Seelische Gesundheit Mannheim, Mannheim, 86159, Germany"
NCT02484170,Mannitol Cream for Post Herpetic Neuralgia,https://clinicaltrials.gov/study/NCT02484170,COMPLETED,NO,"Neuralgia, Postherpetic",DRUG: Mannitol cream|DRUG: Placebo,University of British Columbia,,ALL,"ADULT, OLDER_ADULT",20,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-09-30,2017-04-30,"Dr. Helene Bertrand Inc., North Vancouver, British Columbia, V7M 2K2, Canada"
NCT04409873,Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19),https://clinicaltrials.gov/study/NCT04409873,TERMINATED,YES,COVID-19|SARS-CoV 2|Severe Acute Respiratory Syndrome Coronavirus 2|Virus Disease|Coronavirus Infections|Pharyngeal Diseases,DRUG: Oral-B Mouth Sore mouthwash|DRUG: Crest Pro-Health Multi-Protection mouthwash|DRUG: CloSYS Ultra Sensitive Rinse mouthwash|DRUG: Distilled water|DRUG: Listerine Zero Mouthwash Product,"University of California, San Francisco","Rowpar Pharmaceuticals, Inc.",ALL,"ADULT, OLDER_ADULT",54,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-03-31,2022-09-10,"University Of California, San Francisco, San Francisco, California, 94143, United States"
NCT04989413,Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg vs Placebo as Adjuvant Treatment in Chronic Migraine -,https://clinicaltrials.gov/study/NCT04989413,UNKNOWN,NO,"Chronic Migraine, Headache|Overuse Headache Medication",DRUG: Placebo oral drops|DRUG: Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg,Hospital Israelita Albert Einstein,Industria Farmacêutica Health Meds,ALL,"ADULT, OLDER_ADULT",110,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-10-18,2024-04-19,"Centro de Pesquisa Clinica Hospital Israelita Albert Einstein, São Paulo, 05653120, Brazil"
NCT02999334,HIV With Innovative Group Antenatal Care in Two African Countries,https://clinicaltrials.gov/study/NCT02999334,COMPLETED,NO,Prenatal Care,BEHAVIORAL: Group Antenatal Care,University of Illinois at Chicago,,FEMALE,"CHILD, ADULT, OLDER_ADULT",218,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2013-09,2016-08,
NCT04528615,Testing the Effectiveness of Coping With Cancer in the Kitchen,https://clinicaltrials.gov/study/NCT04528615,COMPLETED,NO,Cancer|Nutrition Aspect of Cancer,BEHAVIORAL: CCK In-Person Sessions|BEHAVIORAL: CCK Printed Materials,American Institute for Cancer Research,,ALL,"ADULT, OLDER_ADULT",53,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2019-04-30,2019-10-08,"Cancer Support Community Los Angeles, Los Angeles, California, 90025, United States"
NCT03953534,Quantity of Opioids for Acute Pain and Limit Unused Medication,https://clinicaltrials.gov/study/NCT03953534,COMPLETED,NO,Acute Pain,,Hopital du Sacre-Coeur de Montreal,Queen's University|Maisonneuve-Rosemont Hospital|Sunnybrook Health Sciences Centre|Hopital de l'Enfant-Jesus,ALL,"ADULT, OLDER_ADULT",2240,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-05-06,2023-06-14,"Kingston General Hospital, Kingston, Ontario, K7L 2V7, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|Hôpital Maisonneuve-Rosemont, Montréal, Quebec, H1T 2M4, Canada|Hôpital du Sacré-Coeur de Montréal, Montréal, Quebec, H4J 1C4, Canada|Hôpital régional de Saint-Jérôme, Saint-Jérôme, Quebec, J7Z 5T3, Canada|Hôpital de l'Enfant-Jésus, Québec, G1J 1Z4, Canada"
NCT01670708,HOPE Demonstration Field Experiment Multisite Evaluation,https://clinicaltrials.gov/study/NCT01670708,COMPLETED,NO,Substance Use|Criminal Recidivism,BEHAVIORAL: HOPE|BEHAVIORAL: Probation as Usual,RTI International,Penn State University|U.S. Department of Justice,ALL,"ADULT, OLDER_ADULT",1504,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2012-08,2015-03-31,"Court and Probation Office, Saline County, Benton, Arkansas, United States|Salem County Probation Office, Massachusetts Salem District Court, Essex County Superior Court, Salem, Massachusetts, United States|Court and Probation Office, Oregon City, Oregon, United States|Court and Probation Office, Tarrant County, Fort Worth, Texas, United States"
NCT05447325,Neuroimaging Approaches to Improve Prediction of Smoking Initiation and Nicotine Use Escalation Among Young Adult Electronic Nicotine Delivery Systems Users,https://clinicaltrials.gov/study/NCT05447325,RECRUITING,NO,Message Exposure (sequence: Regular Then Flavor)|Message Exposure (sequence: Flavor Then Regular)|No Message Exposure (control Condition),BEHAVIORAL: Exposure to Anti-Vaping Messages (generic themes then flavor-specific themes)|BEHAVIORAL: Exposure to Anti-Vaping Messages (flavor-specific themes then generic themes)|BEHAVIORAL: Exposure to Anti-Vaping Messages (no message exposure),University of Georgia,,ALL,ADULT,180,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-07-15,2025-07-31,"UGA Bio-imaging Research Center, Athens, Georgia, 30602, United States"
NCT03668041,National Adaptive Trial for PTSD Related Insomnia,https://clinicaltrials.gov/study/NCT03668041,RECRUITING,NO,Insomnia,DRUG: Trazodone|DRUG: Eszopiclone|OTHER: Placebo,VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",774,FED,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02-25,2026-02-28,"Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, 35233, United States|Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa, Alabama, 35404, United States|Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, 85012, United States|VA Loma Linda Healthcare System, Loma Linda, CA, Loma Linda, California, 92357-1000, United States|VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, 90822, United States|VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, 94304-1207, United States|VA San Diego Healthcare System, San Diego, CA, San Diego, California, 92161, United States|San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, 94121-1563, United States|VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, 06516-2770, United States|CERC (VISN1, West Haven, CT), West Haven, Connecticut, 06516, United States|Bay Pines VA Healthcare System, Pay Pines, FL, Bay Pines, Florida, 33744-0000, United States|Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, 30033, United States|Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois, 60141-3030, United States|Overton Brooks VA Medical Center, Shreveport, LA, Shreveport, Louisiana, 71101, United States|VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, 02130-4817, United States|Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, 55417, United States|New Mexico VA Health Care System, Albuquerque, NM, Albuquerque, New Mexico, 87108-5153, United States|Asheville VA Medical Center, Asheville, NC, Asheville, North Carolina, 28805, United States|Durham VA Medical Center, Durham, NC, Durham, North Carolina, 27705-3875, United States|Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC, Salisbury, North Carolina, 28144, United States|Cincinnati VA Medical Center, Cincinnati, OH, Cincinnati, Ohio, 45220-2213, United States|Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, 44106, United States|Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, 19104, United States|VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania, 15240, United States|Providence VA Medical Center, Providence, RI, Providence, Rhode Island, 02908, United States|Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, 29401-5799, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, 75216-7167, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, 77030-4211, United States|South Texas Health Care System, San Antonio, TX, San Antonio, Texas, 78229, United States|VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, 84148, United States|White River Junction VA Medical Center, White River Junction, VT, White River Junction, Vermont, 05009-0001, United States|Salem VA Medical Center, Salem, VA, Salem, Virginia, 24153, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, 98108, United States|William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, 53705, United States|Clement J. Zablocki VA Medical Center, Milwaukee, WI, Milwaukee, Wisconsin, 53295-0001, United States"
NCT00183157,Project RAP: Reaching Adolescents for Prevention,https://clinicaltrials.gov/study/NCT00183157,UNKNOWN,NO,Alcohol Related Morbidity|Alcohol Dependence,BEHAVIORAL: Brief Motivational Intervention|BEHAVIORAL: Assessment and list of resources|BEHAVIORAL: Referral to Community Resources,National Institute on Alcohol Abuse and Alcoholism (NIAAA),,ALL,"CHILD, ADULT",1400,NIH,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2004-10,2009-12,"Boston Medical Center Pediatric Emergency Department, Boston, Massachusetts, 02118, United States|Boston University School of Public Health - Youth Alcohol Prevention Center, Boston, Massachusetts, 02118, United States"
NCT02555345,"Gene Expression Profile and Inflammation Profile of Classic Asthma, Cough Variant Asthma and Eosinophilic Bronchitis",https://clinicaltrials.gov/study/NCT02555345,UNKNOWN,NO,Asthmatic Bronchitis,,State Key Laboratory of Respiratory Disease,,ALL,"ADULT, OLDER_ADULT",250,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-10,2016-01,"The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China"
NCT05273021,"Validation of the Dutch Translation of the Tobacco, Alcohol, Prescription Medication and Other Substances (TAPS)-Tool",https://clinicaltrials.gov/study/NCT05273021,RECRUITING,NO,"Substance Use|Severe Mental Disorder|Intellectual Disability, Mild",DIAGNOSTIC_TEST: TAPS,Birgit Seelen-de Lang,Ggz Oost Brabant,ALL,"ADULT, OLDER_ADULT",150,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-07-01,2025-07,"GGZ Oost Brabant - FACT, Boekel, Noord Brabant, 5427 ZG, Netherlands|GGZ Oost Brabant - LVB-P, Boekel, Noord Brabant, 5427 ZG, Netherlands|Stichting ORO, Helmond, Noord Brabant, 5709 HL, Netherlands"
NCT04561544,Pilot Test of a Cultural Intervention to Enhance Alaska Native Students' Behavioral Health,https://clinicaltrials.gov/study/NCT04561544,COMPLETED,NO,Depression|Anxiety|Suicidal Ideation|Substance Use,BEHAVIORAL: Knowing Who You Are (Becoming): Cultural Identity Intervention,University of Alaska Anchorage,National Institute of General Medical Sciences (NIGMS),ALL,"ADULT, OLDER_ADULT",44,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2020-08-30,2022-05-31,"University of Alaska Anchorage, Anchorage, Alaska, 99508, United States"
NCT00230009,Brief Intervention in At-Risk First-time Mothers,https://clinicaltrials.gov/study/NCT00230009,COMPLETED,YES,Substance Use,BEHAVIORAL: Brief motivational intervention,Wayne State University,National Institute on Drug Abuse (NIDA),FEMALE,ADULT,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2004-04,2007-03,"Wayne State University, Detroit, Michigan, 48207, United States"
NCT06594263,Validation of the French Version of the Perinatal Assessment of Paternal Affectivity (PAPA),https://clinicaltrials.gov/study/NCT06594263,RECRUITING,NO,Perinatal Depression|Affective Disorder|Fathers,,"University Hospital, Clermont-Ferrand",,ALL,"ADULT, OLDER_ADULT",340,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-10-19,2025-12,"CHU Clermont-Ferrand, Clermont-Ferrand, France"
NCT05457465,Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder,https://clinicaltrials.gov/study/NCT05457465,RECRUITING,NO,Bipolar Disorder,DRUG: Cannabidiol,Mclean Hospital,,ALL,ADULT,25,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-06-01,2025-06,"McLean Hospital, Belmont, Massachusetts, 02478, United States"
NCT05790785,Vascular Complications in Children From T1D Diagnosis,https://clinicaltrials.gov/study/NCT05790785,RECRUITING,NO,Type 1 Diabetes|Cardiovascular Complications|Child|Adolescent,,University of British Columbia,Canadian Institutes of Health Research (CIHR)|BC Children's Hospital Research Institute,ALL,CHILD,150,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-12-01,2026-09-30,"Endocrine and Diabetes Unit, BC Children's Hospital, Vancouver, British Columbia, V5Z4H4, Canada"
NCT04671693,A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.,https://clinicaltrials.gov/study/NCT04671693,RECRUITING,NO,"Late Effects|Testicular Germ Cell Tumor Mixed|Non-Metastatic Breast Carcinoma|Soft Tissue Sarcoma, Adult, Stage IIC|Osteosarcoma|Ewing's Sarcoma|Acute Myeloid Leukemia|Hodgkin Disease|Non Hodgkin Lymphoma",OTHER: PASCA intervention,Centre Leon Berard,Malakoff-Humanis|Fondation Apicil|Fédération Leucémie Espoir|Biogaran|Le défi Anthony|Novartis|Roche Pharma AG,ALL,"ADULT, OLDER_ADULT",858,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2020-12-24,2028-04-24,"Centre Leon Berard, Lyon, 69373, France"
NCT05167695,Maintaining Behavior Change: An Evaluation of a Habit-based Sleep Health Intervention,https://clinicaltrials.gov/study/NCT05167695,RECRUITING,NO,Circadian Dysregulation,BEHAVIORAL: Habit-based Sleep Health Intervention|BEHAVIORAL: Text messaging intervention,"University of California, Berkeley",,ALL,ADULT,160,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-05-04,2026-07-01,"University of California, Berkeley, California, 94703, United States"
NCT05260268,Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant,https://clinicaltrials.gov/study/NCT05260268,RECRUITING,NO,Liver Transplant; Complications|Cirrhosis|End Stage Liver DIsease|Medication Adherence,BEHAVIORAL: TEST Intervention,University of Pennsylvania,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),ALL,"ADULT, OLDER_ADULT",360,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-12-01,2027-01-01,"University of Miami, Miami, Florida, 33146, United States|Northwestern University, Chicago, Illinois, 60208, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States"
NCT05310773,Couples Health CoOp Plus,https://clinicaltrials.gov/study/NCT05310773,RECRUITING,NO,"HIV|Substance Use|Stigma, Social",BEHAVIORAL: Community Stigma Awareness and Education Workshop|BEHAVIORAL: Couples Health CoOp Plus (CHC+),RTI International,"Medical Research Council, South Africa",ALL,"ADULT, OLDER_ADULT",7944,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2022-05-06,2025-05-31,"South African Medical Research Council, Cape Town, Western Cape, 7500, South Africa"
NCT02524171,Justice-Involved Veterans and Moral Reconation Therapy,https://clinicaltrials.gov/study/NCT02524171,COMPLETED,YES,Antisocial Personality Disorder|Substance Use Disorder,BEHAVIORAL: Moral Reconation Therapy (MRT),VA Office of Research and Development,,ALL,"CHILD, ADULT, OLDER_ADULT",344,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-04-04,2021-03-30,"Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR, North Little Rock, Arkansas, 72114-1706, United States|VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, 94304-1207, United States|VA Bedford HealthCare System, Bedford, MA, Bedford, Massachusetts, 01730-1114, United States"
NCT06447701,Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis,https://clinicaltrials.gov/study/NCT06447701,NOT_YET_RECRUITING,NO,"Brain Diseases|Ischemic Stroke|Ischemia|Stroke|Cerebral Infarction|Atherosclerosis of Artery|Atheroscleroses, Intracranial",DRUG: Tocilizumab|DRUG: NaCl 0.9% 100ml,Zhujiang Hospital,"Shenzhen Second People's Hospital|Central People's Hospital of Zhanjiang|Shantou Central Hospital|Eighth Affiliated Hospital, Sun Yat-sen University|Guangzhou First People's Hospital|Peking University Shenzhen Hospital|Guangdong Provincial People's Hospital",ALL,"ADULT, OLDER_ADULT",486,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-06-30,2029-06-30,
NCT06419868,Acceptability and Feasibility of a Universal Preventive Intervention,https://clinicaltrials.gov/study/NCT06419868,NOT_YET_RECRUITING,NO,Depression/Anxiety,"BEHAVIORAL: ""Universal preventive intervention for depression and anxiety for university students""","Universidad de los Andes, Chile",,ALL,"ADULT, OLDER_ADULT",272,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2024-07-01,2025-04-30,
NCT02823535,Iwin: Individual Well-Being Navigator,https://clinicaltrials.gov/study/NCT02823535,COMPLETED,NO,Other Drug Substance Abuse,BEHAVIORAL: Iwin: Individual Well-Being Navigator,Pro-Change Behavior Systems,IMS Health,ALL,ADULT,253,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: PREVENTION,2017-06-17,2019-12-31,"RallyPoint.com, Watertown, Massachusetts, 02472, United States|Military Media Inc., Poughkeepsie, New York, 12601, United States|Pro-Change Behavior Systems, Inc., South Kingstown, Rhode Island, 02879, United States|Pilot Media, Norfolk, Virginia, 23510, United States"
NCT03287180,Adolescent Community Reinforcement Approach in Combination With Buprenorphine/Naloxone for Severe Opioid Use,https://clinicaltrials.gov/study/NCT03287180,WITHDRAWN,NO,"Opioid-Related Disorders|Behavior, Addictive",BEHAVIORAL: Adolescent Community Reinforcement Approach (A-CRA)|OTHER: Combination of buprenorphine/naloxone 4/1,Emory University,National Institute on Drug Abuse (NIDA)|Chestnut Health Systems,ALL,ADULT,0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-01-01,2020-06-09,
NCT06753344,Youth Promotion of Resilience Involving Mental E-health,https://clinicaltrials.gov/study/NCT06753344,NOT_YET_RECRUITING,NO,Mental Well-being|Resilience|Population Study,BEHAVIORAL: Intervention app,University of British Columbia,"St. Francis Xavier University|Institute of Population, Health and Development, Vietnam|Simon Fraser University|University of Melbourne",ALL,CHILD,1800,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2025-01-01,2028-03-31,"Institute of Population, Health, and Development, Vietnam, Hanoi, 117222, Vietnam"
NCT05598996,The YourMove Study: Optimizing Individualized and Adaptive mHealth Interventions Via Control Systems Engineering Methods,https://clinicaltrials.gov/study/NCT05598996,ACTIVE_NOT_RECRUITING,NO,"Inactivity, Physical|Sedentary Behavior",BEHAVIORAL: COT-Based Intervention,"University of California, San Diego","Arizona State University|University of Michigan|National Cancer Institute (NCI)|Small Steps Labs, LLC",ALL,"ADULT, OLDER_ADULT",386,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-10-07,2025-08-09,"University of California San Diego, San Diego, California, 92093, United States"
NCT06785311,Native Spirit: Significant Aim 3: Intervention,https://clinicaltrials.gov/study/NCT06785311,RECRUITING,NO,"Substance Use|Self Esteem|Youth Drinking|Prevention, Suicide",BEHAVIORAL: Native Spirit After-School Program,Arizona State University,,ALL,"CHILD, ADULT",60,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2025-01-09,2026-07,"Way of Life Facility, Scottsdale, Arizona, 85256, United States|Pascua Yaqui Tribe Boys & Girls Club, Tucson, Arizona, 85746, United States"
NCT06460428,Online Interactive Video Developed for Fertility Awareness,https://clinicaltrials.gov/study/NCT06460428,NOT_YET_RECRUITING,NO,Fertility Awareness,BEHAVIORAL: Interactive video usage,Gazi University,,ALL,ADULT,70,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2024-06-24,2025-06-30,
NCT03180762,"A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Participants",https://clinicaltrials.gov/study/NCT03180762,TERMINATED,NO,Healthy,DRUG: JNJ-64140284 0.1 mg|DRUG: JNJ-64140284 0.5 mg|DRUG: JNJ-64140284 2.5 mg|DRUG: JNJ-64140284 10 mg|DRUG: JNJ-64140284 50 mg|DRUG: JNJ-64140284 150 mg|DRUG: JNJ-64140284 (dose to be determined [TBD])|DRUG: Placebo,"Janssen Research & Development, LLC",,ALL,"ADULT, OLDER_ADULT",36,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2017-05-30,2017-09-25,"Clinical Pharmacology Unit, Merksem, 2170, Belgium"
NCT03907462,SMART 2.0: Social Mobile Approaches to Reducing weighT in Young Adults,https://clinicaltrials.gov/study/NCT03907462,COMPLETED,NO,Overweight and Obesity,BEHAVIORAL: SMART 2.0,"University of California, San Diego","National Institutes of Health (NIH)|Small Steps Labs, LLC",ALL,ADULT,638,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-04-01,2024-02-01,"University of California, San Diego, La Jolla, California, 92093, United States"
NCT02578472,"Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Participants",https://clinicaltrials.gov/study/NCT02578472,COMPLETED,NO,Healthy,DRUG: JNJ-42847922|DRUG: Zolpidem|DRUG: Placebo,Janssen-Cilag International NV,,ALL,ADULT,36,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-11,2016-02,"Leiden, Netherlands"
NCT06444087,Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation,https://clinicaltrials.gov/study/NCT06444087,RECRUITING,NO,Hidradenitis Suppurativa,OTHER: secukinumab,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",177,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-06-17,2027-03-30,"Novartis Investigative Site, Antony, 92160, France|Novartis Investigative Site, Bordeaux Cedex, 33075, France|Novartis Investigative Site, Brest, 29609, France|Novartis Investigative Site, Calais, 62100, France|Novartis Investigative Site, Dijon, 21034, France|Novartis Investigative Site, La Rochelle, 17019, France|Novartis Investigative Site, Le Mans, 72000, France|Novartis Investigative Site, Lille, 59037, France|Novartis Investigative Site, Lorient, 56322, France|Novartis Investigative Site, Lyon, 69003, France|Novartis Investigative Site, Montpellier, 34295, France|Novartis Investigative Site, Nantes Cedex 1, 44093, France|Novartis Investigative Site, Nice, 06000, France|Novartis Investigative Site, Paris, 75014, France|Novartis Investigative Site, Rodez, 12000, France|Novartis Investigative Site, Rouen, 76031, France|Novartis Investigative Site, Saint Mande, 94160, France|Novartis Investigative Site, Saint Pierre, 97410, France|Novartis Investigative Site, Toulouse, 31400, France|Novartis Investigative Site, Vannes, 56000, France"
NCT04010019,The Facing Pain Study,https://clinicaltrials.gov/study/NCT04010019,COMPLETED,NO,Chronic Pain,BEHAVIORAL: Enhanced Facebook Condition|BEHAVIORAL: Control Facebook Condition,Wayne State University,,ALL,"ADULT, OLDER_ADULT",119,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-09-27,2020-04-13,"Wayne State University, Detroit, Michigan, 48202, United States"
NCT04797689,Managing Our Relationship With Food and Eating,https://clinicaltrials.gov/study/NCT04797689,COMPLETED,NO,"Mental Health Wellness 1|Eating Behavior|Stress, Psychological|Eating Habit",BEHAVIORAL: Trauma Informed Yoga|BEHAVIORAL: Trauma Informed Psychotherapy,University of Lethbridge,,FEMALE,"ADULT, OLDER_ADULT",158,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-01,2021-07-22,"University of Lethbridge, Lethbridge, Alberta, T1K 3M4, Canada"
NCT06153199,Self-management of Low Back Pain in Horticulture Workers,https://clinicaltrials.gov/study/NCT06153199,RECRUITING,NO,Back Pain,BEHAVIORAL: Self-management videos|BEHAVIORAL: Check lists for ergonomic options|BEHAVIORAL: Text reminders|BEHAVIORAL: Video review,University of Florida,,ALL,"ADULT, OLDER_ADULT",164,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2024-06-06,2028-06-30,"University of Florida, Gainesville, Florida, 32608, United States"
NCT02032433,Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment,https://clinicaltrials.gov/study/NCT02032433,COMPLETED,YES,Opioid Use Disorder,DRUG: Extended-Release Naltrexone|DRUG: Buprenorphine-Naloxone,NYU Langone Health,"National Institute on Drug Abuse (NIDA)|The Emmes Company, LLC",ALL,"ADULT, OLDER_ADULT",570,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-01-29,2017-01-31,"Tarzana Treatment Centers, Tarzana, California, 91356, United States|Gateway Community Services, Inc., Jacksonville, Florida, 32201, United States|Avery Road Treatment Center, Rockville, Maryland, 20853, United States|Stanley Street Treatment and Resources, Fall River, Massachusetts, 02720, United States|Turquoise Lodge Hospital, Albuquerque, New Mexico, 87108, United States|Bellevue Hospital Center, New York, New York, 10016, United States|Maryhaven, Columbus, Ohio, 43207, United States|Evergreen Treatment Services, Seattle, Washington, 98134, United States"
NCT01666496,An Interactive Game for HIV Prevention in Early Adolescents,https://clinicaltrials.gov/study/NCT01666496,COMPLETED,NO,HIV|Risk Reduction,BEHAVIORAL: Experimental Video Game|BEHAVIORAL: Off the Shelf Video Game,Yale University,,ALL,CHILD,333,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2013-01,2016-06-18,"Yale School of Medicine, New Haven, Connecticut, 06510, United States"
NCT01936623,Computerized Brief Intervention vs. Delayed Computerized Brief Intervention,https://clinicaltrials.gov/study/NCT01936623,COMPLETED,YES,Drug Abuse,BEHAVIORAL: Computerized Brief Intervention,"Friends Research Institute, Inc.",,ALL,"ADULT, OLDER_ADULT",80,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2013-08,2014-09,"First Choice Community Healthcare, Edgewood, New Mexico, 87015, United States"
NCT05425511,WELL-being Improvement Following a SOphrology Intervention in Hospital Staff,https://clinicaltrials.gov/study/NCT05425511,RECRUITING,NO,Stress Related Disorder|Sophrology|Neurolinguistic Programming,BEHAVIORAL: sophrology / neurolinguistic programming intervention,"University Hospital, Clermont-Ferrand","University Clermont Auvergne (UCA)|Centre National de la Recherche Scientifique, France",ALL,"ADULT, OLDER_ADULT",200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2023-03-08,2028-03,"CHU clermont-ferrand, Clermont-Ferrand, France"
NCT03132753,"Developing SUPPORT, a Community-Driven, Recovery-Oriented System of Care",https://clinicaltrials.gov/study/NCT03132753,COMPLETED,YES,Substance Use,BEHAVIORAL: SUPPORT,Indiana University,,ALL,"ADULT, OLDER_ADULT",100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2017-10-23,2020-09-30,"Public Advocates in Community Re-Entry (PACE), Indianapolis, Indiana, 46218, United States"
NCT04670640,Mechanistic Interventions and Neuroscience of Dissociation,https://clinicaltrials.gov/study/NCT04670640,RECRUITING,NO,Dissociation,DEVICE: Vibration|BEHAVIORAL: Breath Focus|BEHAVIORAL: No Distractions,Emory University,National Center for Complementary and Integrative Health (NCCIH),ALL,"ADULT, OLDER_ADULT",200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-18,2026-01-31,"Grady Hospital, Atlanta, Georgia, 30303, United States|Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, 15213, United States"
NCT04669249,Reward-Based Recovery Outcomes Management for Opioid Use Disorder,https://clinicaltrials.gov/study/NCT04669249,COMPLETED,YES,Opioid Use Disorder,BEHAVIORAL: PROCare,"Medical Decision Logic, Inc.",PRO Health Group|National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",13,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-03-01,2022-09-29,"South Florida Behavioral Health Network, Inc., Miami, Florida, 33126, United States"
NCT00438516,Follow-up of Families in Early Preventive Intervention,https://clinicaltrials.gov/study/NCT00438516,COMPLETED,NO,Child Rearing|Adolescent Development|Reproductive Behavior|Risk Reduction Behavior,BEHAVIORAL: nurse home visitation,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),"University of Colorado, Denver",FEMALE,"CHILD, ADULT, OLDER_ADULT",627,NIH,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2000-06,2003-03,"University of Rochester School of Nursing, Rochester, New York, 14642, United States"
NCT04642404,CBD for Dental Pain,https://clinicaltrials.gov/study/NCT04642404,COMPLETED,YES,Odontalgia|Toothache,DRUG: Epidiolex 100 mg/mL Oral Solution|DRUG: Placebo,The University of Texas Health Science Center at San Antonio,,ALL,"ADULT, OLDER_ADULT",64,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-03-01,2023-03-13,"The University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78229, United States"
NCT05286879,Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations,https://clinicaltrials.gov/study/NCT05286879,ACTIVE_NOT_RECRUITING,NO,Opioid Use Disorder|Infectious Disease|Risk Reduction Behavior|Substance Use|Substance Abuse|Stimulant Use Disorder,BEHAVIORAL: Patient Navigator|BEHAVIORAL: Mobile Health Unit,Yale University,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",600,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-03-31,2025-07-31,"Yale School of Medicine, New Haven, Connecticut, 06510, United States|UT Southwestern, Dallas, Texas, 75390, United States|Texas Christian University, Fort Worth, Texas, 76129, United States"
NCT05182671,"Relationship Between Pelvic Angle, Femoral Anteversion, and Hip Muscle Strength Ratios in Bladder-bowel Dysfunction",https://clinicaltrials.gov/study/NCT05182671,COMPLETED,NO,"Bladder and Bowel Dysfunction, Femoral Anteversion|Bladder and Bowel Dysfunction, Hip Strength Ratios|Bladder and Bowel Dysfunction, Pelvic Angle","OTHER: Scales and measurements for bladder and bowel dysfunction, pelvic angle, proximal hip strength, femoral hip anteversion",Halil Tugtepe,Bahçeşehir University,ALL,CHILD,50,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-01-15,2024-02-09,"Private Tugtepe Pediatric Urology Clinic, Istanbul, 34353, Turkey"
NCT03065517,VillageWhere: Innovative Mobile Technology for Youth With Conduct Disorder and Their Parents,https://clinicaltrials.gov/study/NCT03065517,COMPLETED,YES,Child Behavior Disorders,DEVICE: VillageWhere App|DEVICE: Attention-Control Placebo App,"Evidence-Based Practice Institute, Seattle, WA","National Institute of Mental Health (NIMH)|University of Maryland, Baltimore",ALL,"CHILD, ADULT, OLDER_ADULT",226,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-07-16,2020-02-28,"Evidence-Based Practice Institute, Seattle, Washington, 98144, United States"
NCT02603471,Cell Phone Technology Targeting ART and Naltrexone Adherence and Alcohol Use,https://clinicaltrials.gov/study/NCT02603471,COMPLETED,NO,HIV Infections|Alcohol Dependence,OTHER: Informational group|BEHAVIORAL: Text Messaging CBT (TXT-CBT),"University of California, Los Angeles",,ALL,"ADULT, OLDER_ADULT",35,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-07,2016-12,"UCLA Integrated Substance Abuse Programs, Los Angeles, California, 90025, United States"
NCT03861013,Reward Under Stress: Effects of a Multidimensional Stress Prevention Program in University Students,https://clinicaltrials.gov/study/NCT03861013,COMPLETED,NO,"Stress, Psychological",BEHAVIORAL: Multidimensional stress prevention program (GeDStress),Chantal Martin Soelch,University of Fribourg|University of Bern,ALL,"ADULT, OLDER_ADULT",64,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2015-03-14,2017-06-04,"University of Fribourg, Fribourg, 1700, Switzerland"
NCT06315218,Examining the Health Effects of iTHRIVE 365 Among Black Same Gender Loving Men,https://clinicaltrials.gov/study/NCT06315218,NOT_YET_RECRUITING,NO,Sexual and Gender Minorities|Social Stigma|Medication Adherence|Depressive Symptoms|Anxiety Symptoms,BEHAVIORAL: iTHRIVE 365 HIV care intervention,"Rutgers, The State University of New Jersey",Positive Impact Health Centers|George Washington University|Carnegie Mellon University|Emory University|Columbia University|Arizona State University|Thrive Social Services,ALL,"ADULT, OLDER_ADULT",350,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2024-05,2028-04,
NCT05836090,Family Spirit Strengths,https://clinicaltrials.gov/study/NCT05836090,RECRUITING,NO,Depressive Symptoms|Anxiety Disorders and Symptoms|Substance Use|Mental Health Issue,BEHAVIORAL: Family Spirit Strengths (FSS)|BEHAVIORAL: Family Spirit Nurture,Johns Hopkins Bloomberg School of Public Health,,FEMALE,"CHILD, ADULT, OLDER_ADULT",188,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-04-20,2028-12,"Johns Hopkins Center for Indigenous Health, Chinle, Arizona, 86503, United States|Pokagon Health Services, Pokagon, Michigan, 49047, United States|Johns Hopkins Center For Indigenous Health, Shiprock, New Mexico, 87420, United States"
NCT06115746,A Randomized Clinical Trial of a Novel Drug Education and Diversion Program (iDECIDE) for Middle and High School Students,https://clinicaltrials.gov/study/NCT06115746,RECRUITING,NO,Substance Use|Harm Reduction|Adolescent Behavior,BEHAVIORAL: iDECIDE,Massachusetts General Hospital,Massachusetts Department of Health,ALL,"CHILD, ADULT",300,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-11-17,2026-07-31,"Massachusetts General Hospital, Boston, Massachusetts, 02114, United States"
NCT06576648,Thailand Transgender Women Stigma Study,https://clinicaltrials.gov/study/NCT06576648,NOT_YET_RECRUITING,NO,Pre-Exposure Prophylaxis,BEHAVIORAL: Mobile Healthy Choices (mHC)|BEHAVIORAL: Finding Respect and Ending Stigma around HIV (FRESH)|BEHAVIORAL: Standard PrEP Counseling,"University of Massachusetts, Worcester","National Institute of Mental Health (NIMH)|Institute of HIV Research and Innovation Foundation, Thailand",MALE,ADULT,154,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: PREVENTION,2025-03-15,2027-08-14,"Institute of HIV Research and Innovation, Bangkok, Thailand|Rainbow Sky Association of Thailand, Bangkok, Thailand|SWING Foundation, Bangkok, Thailand"
NCT05345405,Clinical Trial of a Supporter-Targeted Intervention to Improve Outcomes in Recent Sexual Assault Survivors,https://clinicaltrials.gov/study/NCT05345405,COMPLETED,NO,"Stress Disorders, Post-Traumatic|Helping Behavior|Help-Seeking Behavior|Stress|Relationship, Social|Sexual Assault|Sexual Violence|Social Interaction",BEHAVIORAL: Dyadic CARE|BEHAVIORAL: Supporter-Only CARE,University of Washington,,ALL,"CHILD, ADULT, OLDER_ADULT",126,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-05-18,2024-07-04,"University of Washington School of Medicine, Seattle, Washington, 98195-7238, United States"
NCT04166266,National Cohort of Patients Co-infected with Hepatitis B and Delta Viruses,https://clinicaltrials.gov/study/NCT04166266,RECRUITING,NO,"Hepatitis D, Chronic|Hepatitis B, Chronic",OTHER: Blood draw for the laboratory assessment,"ANRS, Emerging Infectious Diseases",,ALL,"ADULT, OLDER_ADULT",800,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-02-19,2028-06-30,"CHU of Angers, Angers, France|Centre Hospitalier de la région annécienne, Annecy, France|Avicenne Hospital - Hepatology, Bobigny, France|Avicenne Hospital, Bobigny, France|Haut Lévêque Hospital, Bordeaux, France|Estaing Hospital, Clermont-Ferrand, France|Beaujon Hospital, Clichy, France|Centre Hospitalier Intercommunal, Créteil, France|Henri Mondor Hospital, Créteil, France|Bocage Hospital, Dijon, France|Michallon Hospital, Grenoble, France|Claude Huriez Hospital, Lille, France|Dupuytren Hospital, Limoges, France|Croix Rousse Hospital, Lyon, France|Edouard Herriot Hospital, Lyon, France|Hôpital de la Croix Rousse, Lyon, France|SAint Joseph Hospital, Marseille, France|Saint Eloi Hospital, Montpellier, France|Hotel Dieu Hospital, Nantes, France|Hôtel-Dieu Hospital, Nantes, France|l'Archet 2 Hospital, Nice, France|La Source Hospital, Orléans, France|Bichat-Claude Bernard Hospital, Paris, France|Cochin Hospital, Paris, France|Hôpital Tenon, Paris, France|La Pitié Salpêtrière Hospital, Paris, France|Lariboisière Hospital, Paris, France|Pitié-Salpêtrière Hospital, Paris, France|Saint Antoine Hospital, Paris, France|Saint Louis Hospital, Paris, France|Saint-Antoine Hospital, Paris, France|Pontchaillou Hospital, Rennes, France|Charles Nicolle Hospital, Rouen, France|Nouvel Hôpital Civil, Strasbourg, France|Hôpital Rangueil, Toulouse, France|Rangueil Hospital, Toulouse, France|Trousseau Hospital, Tours, France|Paul Brousse Hospital, Villejuif, France"
NCT02498132,Development and Testing of a Behavioral Activation Mobile Therapy for Elevated Depressive Systems,https://clinicaltrials.gov/study/NCT02498132,COMPLETED,YES,Depression,OTHER: Behavioral Activation|OTHER: Cognitvie Based Therapy|OTHER: Treatment as Usual,"University of Maryland, College Park","MOUNTAINPASS TECHNOLOGY, LLC|Medical University of South Carolina",ALL,"ADULT, OLDER_ADULT",52,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-06-01,2016-12-31,
NCT04080427,Effects of Delta9-tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study,https://clinicaltrials.gov/study/NCT04080427,RECRUITING,NO,Posttraumatic Stress Disorder,DRUG: Placebo capsule|DRUG: Dronabinol 7.5 milligram oral capsule,Wayne State University,National Institute of Mental Health (NIMH),ALL,ADULT,100,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2021-04-15,2025-12-31,"Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan, 48201, United States"
NCT06273228,Parenting Young Children in Pediatrics,https://clinicaltrials.gov/study/NCT06273228,RECRUITING,NO,Parenting|Parent-Child Relations|Substance Use Disorders|Stress|Depression|Anxiety|Parenting Self-efficacy|Pediatrics,BEHAVIORAL: Family Check-Up Online,University of Oregon,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT, OLDER_ADULT",36,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-09-27,2024-10-01,"Prevention Science Institute, University of Oregon, Eugene, Oregon, 97403, United States"
NCT01296802,Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging,https://clinicaltrials.gov/study/NCT01296802,COMPLETED,NO,Amphetamine-Related Disorders|Amphetamine Abuse,DRUG: dexfenfluramine,University of Zurich,,MALE,ADULT,50,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2006-04,2008-07,"University Hospital of Psychiatry Zurich, Zurich, ZH, 8032, Switzerland"
NCT05180487,Parenting Young Children Study,https://clinicaltrials.gov/study/NCT05180487,ACTIVE_NOT_RECRUITING,NO,Parenting|Parent-Child Relations|Opioid Misuse|Opioid Use Disorder|Executive Function|Stress|Depression|Parenting Self-efficacy,BEHAVIORAL: Family Check-Up,University of Oregon,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",356,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-01-06,2025-05-31,"University of Oregon Prevention Science Institute, Portland, Oregon, 97209, United States"
NCT00319436,Stage I Randomized Trial of Mentalization-Based Therapy for Substance Using Mothers of Infants and Toddlers,https://clinicaltrials.gov/study/NCT00319436,COMPLETED,YES,Maternal Substance Use|Child Abuse and Neglect,BEHAVIORAL: Mentalizing Therapy for Substance Using Mothers|BEHAVIORAL: Standard Parent Education for Substance Using Mothers,Yale University,National Institute on Drug Abuse (NIDA),FEMALE,"ADULT, OLDER_ADULT",47,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2004-08,2009-03,"The APT Foundation, New Haven, Connecticut, 06519, United States"
NCT01490307,A Family Intervention for Adolescent Problem Behavior (AKA Project Alliance 2),https://clinicaltrials.gov/study/NCT01490307,COMPLETED,NO,Substance Use|Conduct Disorder|Depression|Anxiety,BEHAVIORAL: Family Check-Up,University of Oregon,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT, OLDER_ADULT",593,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2006-02,2011-03,"University of Oregon-Child and Family Center, Portland, Oregon, 97232, United States"
NCT05530538,BrainWeighve Weight Loss App,https://clinicaltrials.gov/study/NCT05530538,RECRUITING,NO,Weight Loss,BEHAVIORAL: BrainWeighve App,"University of California, Los Angeles","Children's Hospital Los Angeles|eHealth International, INC.",ALL,"CHILD, ADULT",46,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-11,2025-07,"UCLA Integrated Substance Abuse Programs, Los Angeles, California, 90025, United States"
NCT02927457,"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects",https://clinicaltrials.gov/study/NCT02927457,COMPLETED,YES,"Lupus Erythematosus, Cutaneous",DRUG: GSK2646264 1%|DRUG: Placebo,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",11,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-01-13,2018-06-12,"GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, 72076, Germany|GSK Investigational Site, Bonn, Nordrhein-Westfalen, 53127, Germany|GSK Investigational Site, Muenster, Nordrhein-Westfalen, 48149, Germany|GSK Investigational Site, Wuppertal, Nordrhein-Westfalen, 42283, Germany|GSK Investigational Site, Berlin, 10117, Germany"
NCT03978247,Signature Diagnostic of Non-alcoholic Steatohepatitis (NASH) by Infrared Light Spectroscopy,https://clinicaltrials.gov/study/NCT03978247,COMPLETED,NO,Obesity,DIAGNOSTIC_TEST: NASHMIR,Diafir,Clinact,ALL,"ADULT, OLDER_ADULT",382,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2019-06-21,2020-10-31,"CHU de Liège, Liège, 4000, Belgium"
NCT02258737,Efficacy of Transitional Case Management Following Psychiatric Hospital Discharge,https://clinicaltrials.gov/study/NCT02258737,COMPLETED,NO,Mental Disorders,BEHAVIORAL: Transitional Case Management|BEHAVIORAL: Standard Care,University of Lausanne Hospitals,Swiss National Science Foundation,ALL,"ADULT, OLDER_ADULT",110,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2007-10,2009-04,"Social Psychiatry Section, Lausanne University Hospital, Prilly, VD, 1008, Switzerland"
NCT03455790,"Relationship Between Muscle Strength,Anaerobic,Aerobic Capacity,and Sportive Performance in WC Basketball Athletes",https://clinicaltrials.gov/study/NCT03455790,COMPLETED,NO,Sports Physical Therapy,DIAGNOSTIC_TEST: Aerobic Capacity,Ankara Yildirim Beyazıt University,,ALL,ADULT,26,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2017-11-25,2018-01-18,"Ankara Yıldırım Beyazıt University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Etlik, 06010, Turkey"
NCT02823756,Short-Term Effects of PT on Physical Activity,https://clinicaltrials.gov/study/NCT02823756,COMPLETED,NO,Low Back Pain|Motor Activity|Chronic Pain,PROCEDURE: Physical Therapy,Texas Woman's University,,ALL,"ADULT, OLDER_ADULT",27,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-03,2016-04,
NCT01899768,GSK2339345 Hypertussive Challenge Study,https://clinicaltrials.gov/study/NCT01899768,COMPLETED,YES,Cough,DRUG: GSK2339345|DRUG: Placebo,GlaxoSmithKline,North West Lung Centre,ALL,"ADULT, OLDER_ADULT",16,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-11,2014-10,"GSK Investigational Site, Manchester, Lancashire, M23 9LT, United Kingdom|GSK Investigational Site, Belfast, BT9 7AB, United Kingdom"
NCT06556251,Effectiveness of a Digital Platform in Engagement and Prognosis of Patients in an Early Intervention Pychosis Programme,https://clinicaltrials.gov/study/NCT06556251,NOT_YET_RECRUITING,NO,Device Adherence,DEVICE: PIPPEP App,Fundació Sant Joan de Déu,Parc Sanitari Sant Joan de Déu,ALL,ADULT,128,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-09-18,2027-12-31,"Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, 08830, Spain"
NCT04851561,Post-coronavirus Disease-2019 Fatigue,https://clinicaltrials.gov/study/NCT04851561,COMPLETED,NO,Covid19|Post-COVID / Long-COVID,DIAGNOSTIC_TEST: Cardiopulmonary stress test (CPET),Rabin Medical Center,,ALL,"ADULT, OLDER_ADULT",144,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-03-02,2021-08-24,"Rabin Medical Center - Beilinson Hospital, Petah Tikva, 49100, Israel"
NCT05114824,Acceptability and Feasibility of an 8-week Online Mindfulness-Based Cognitive Therapy Program Among Undergraduate Students,https://clinicaltrials.gov/study/NCT05114824,UNKNOWN,NO,"Stress, Psychological|Anxiety Disorders|Depression, Unipolar",BEHAVIORAL: Mindfulness-Based Cognitive Therapy,"Universidad de los Andes, Chile","Ministerio de Educación, Chile",ALL,"ADULT, OLDER_ADULT",60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-09-23,2022-03,"Universidad de los Andes, Santiago, Metropolitana, Chile"
NCT04688710,Use of Audio Recordings of Self-Hypnosis and Meditation for Fatigue Management in Multiple Sclerosis,https://clinicaltrials.gov/study/NCT04688710,COMPLETED,NO,Multiple Sclerosis|Fatigue,BEHAVIORAL: Self-Hypnosis (HYP)|BEHAVIORAL: Mindfulness Meditation (MM),University of Washington,National Multiple Sclerosis Society|The University of Queensland,ALL,"ADULT, OLDER_ADULT",333,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-04-30,2023-12-31,"UW Medicine Multiple Sclerosis Center, Seattle, Washington, 98133, United States"
NCT06057623,Neuromuscular Fatigue and Exercise Capacity in Patients With Type 2 Diabetes Mellitus and HFpEF,https://clinicaltrials.gov/study/NCT06057623,ACTIVE_NOT_RECRUITING,NO,"Diabetes Mellitus, Type 2|Heart Failure Preserved Ejection Fraction",OTHER: Evaluation of central and peripheral neuromuscular fatigue,Istituti Clinici Scientifici Maugeri SpA,,ALL,OLDER_ADULT,21,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-06-15,2025-04-30,"Istituti Clinici Scientifici Maugeri IRCCS, Lumezzane, Brescia, 25065, Italy"
NCT05019963,Enhancing COVID Rehabilitation With Technology,https://clinicaltrials.gov/study/NCT05019963,ACTIVE_NOT_RECRUITING,NO,Covid19,BEHAVIORAL: NexJ Connected Wellness|OTHER: Usual Care,University of Ottawa,Canadian Institutes of Health Research (CIHR)|Ottawa Hospital Research Institute,ALL,"ADULT, OLDER_ADULT",106,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-05-02,2024-09,"Ottawa Hospital Research Institute, Ottawa, Ontario, K1H 7W9, Canada"
NCT01884233,Cell Phone Technology Targeting ART Adherence and Drug Use,https://clinicaltrials.gov/study/NCT01884233,COMPLETED,NO,HIV|Opioid Abuse,BEHAVIORAL: Standard Care|BEHAVIORAL: Text Messaging CBT (TXT-CBT),"University of California, Los Angeles",National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",62,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-12,2016-01,"UCLA Isap Ocrc, Los Angeles, California, 90025, United States"
NCT04982445,"Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)",https://clinicaltrials.gov/study/NCT04982445,COMPLETED,NO,HIV Infections,DRUG: CABENUVA,ViiV Healthcare,,ALL,"ADULT, OLDER_ADULT",44,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-18,2024-01-31,"GSK Investigational Site, Evans, Georgia, 30809, United States|GSK Investigational Site, East Lansing, Michigan, 48823, United States|GSK Investigational Site, Novi, Michigan, 48377-2977, United States|GSK Investigational Site, Plymouth, Minnesota, 55446, United States|GSK Investigational Site, Charlotte, North Carolina, 28226, United States|GSK Investigational Site, Greensboro, North Carolina, 27405, United States|GSK Investigational Site, Raleigh, North Carolina, 27612, United States|GSK Investigational Site, Charleston, South Carolina, 29414, United States|GSK Investigational Site, Florence, South Carolina, 29501, United States|GSK Investigational Site, Summerville, South Carolina, 29483, United States|GSK Investigational Site, West Columbia, South Carolina, 29169, United States|GSK Investigational Site, Fort Worth, Texas, 76244-5307, United States|GSK Investigational Site, Kingwood, Texas, 77339, United States|GSK Investigational Site, North Richland Hills, Texas, 76180-7379, United States|GSK Investigational Site, Plano, Texas, 75093, United States"
NCT02588612,Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT02588612,COMPLETED,YES,Neoplasms,DRUG: letetresgene autoleucel (GSK3377794)|DRUG: Cyclophosphamide|DRUG: Fludarabine,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",10,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-02-01,2020-08-10,"GSK Investigational Site, Miami, Florida, 33136, United States|GSK Investigational Site, Tampa, Florida, 33612, United States|GSK Investigational Site, Houston, Texas, 77030, United States"
NCT00529568,Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease,https://clinicaltrials.gov/study/NCT00529568,COMPLETED,YES,"Hepatitis C, Chronic",DRUG: eltrombopag|DRUG: placebo,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",759,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-10,2011-08,"GSK Investigational Site, Birmingham, Alabama, 35294-0005, United States|GSK Investigational Site, Tucson, Arizona, 85750, United States|GSK Investigational Site, Anaheim, California, 92801, United States|GSK Investigational Site, Arcadia, California, 91007, United States|GSK Investigational Site, La Jolla, California, 92037, United States|GSK Investigational Site, Los Angeles, California, 90017, United States|GSK Investigational Site, Los Angeles, California, 90048, United States|GSK Investigational Site, Lynwood, California, 90262, United States|GSK Investigational Site, Sacramento, California, 95817, United States|GSK Investigational Site, San Clemente, California, 92673, United States|GSK Investigational Site, San Diego, California, 92123, United States|GSK Investigational Site, San Mateo, California, 94403, United States|GSK Investigational Site, Aurora, Colorado, 80045, United States|GSK Investigational Site, New Haven, Connecticut, 06510, United States|GSK Investigational Site, Washington, District of Columbia, 20010, United States|GSK Investigational Site, Washington, District of Columbia, 20307, United States|GSK Investigational Site, Bradenton, Florida, 34209, United States|GSK Investigational Site, Jacksonville, Florida, 32207, United States|GSK Investigational Site, Miami, Florida, 33125, United States|GSK Investigational Site, Honolulu, Hawaii, 96817, United States|GSK Investigational Site, Chicago, Illinois, 60612-3824, United States|GSK Investigational Site, Indianapolis, Indiana, 46202, United States|GSK Investigational Site, Lexington, Kentucky, 40536, United States|GSK Investigational Site, New Orleans, Louisiana, 70112, United States|GSK Investigational Site, Boston, Massachusetts, 02215, United States|GSK Investigational Site, Burlington, Massachusetts, 01805, United States|GSK Investigational Site, Worcester, Massachusetts, 01655, United States|GSK Investigational Site, Detroit, Michigan, 48201, United States|GSK Investigational Site, Detroit, Michigan, 48202, United States|GSK Investigational Site, Jackson, Mississippi, 39202, United States|GSK Investigational Site, St. Louis, Missouri, 63104, United States|GSK Investigational Site, St. Louis, Missouri, 63110, United States|GSK Investigational Site, Lebanon, New Hampshire, 03756, United States|GSK Investigational Site, Bronx, New York, 10468, United States|GSK Investigational Site, Manhasset, New York, 11030, United States|GSK Investigational Site, New York, New York, 10016, United States|GSK Investigational Site, New York, New York, 10021, United States|GSK Investigational Site, Rochester, New York, 14642, United States|GSK Investigational Site, Syracuse, New York, 13210, United States|GSK Investigational Site, Asheville, North Carolina, 28801, United States|GSK Investigational Site, Durham, North Carolina, 27710, United States|GSK Investigational Site, Kinston, North Carolina, 28501, United States|GSK Investigational Site, Morganton, North Carolina, 28655, United States|GSK Investigational Site, Tulsa, Oklahoma, 74104, United States|GSK Investigational Site, Portland, Oregon, 97239, United States|GSK Investigational Site, Hershey, Pennsylvania, 17033-0850, United States|GSK Investigational Site, Philadelphia, Pennsylvania, 19104, United States|GSK Investigational Site, Germantown, Tennessee, 38138, United States|GSK Investigational Site, Mountain Home, Tennessee, 37684, United States|GSK Investigational Site, Nashville, Tennessee, 37203, United States|GSK Investigational Site, Nashville, Tennessee, 37205, United States|GSK Investigational Site, Nashville, Tennessee, 37212, United States|GSK Investigational Site, Dallas, Texas, 75203, United States|GSK Investigational Site, Galveston, Texas, 77555-0435, United States|GSK Investigational Site, Houston, Texas, 77030, United States|GSK Investigational Site, San Antonio, Texas, 78215, United States|GSK Investigational Site, Charlottesville, Virginia, 22908, United States|GSK Investigational Site, Richmond, Virginia, 23249, United States|GSK Investigational Site, Seattle, Washington, 98111, United States|GSK Investigational Site, Garran, Australian Capital Territory, 2606, Australia|GSK Investigational Site, Camperdown, New South Wales, 2050, Australia|GSK Investigational Site, Randwick, New South Wales, 2031, Australia|GSK Investigational Site, Cairns, Queensland, 4870, Australia|GSK Investigational Site, Herston, Queensland, 4029, Australia|GSK Investigational Site, Clayton, Victoria, 3168, Australia|GSK Investigational Site, Fitzroy, Victoria, 3065, Australia|GSK Investigational Site, Parkville, Victoria, 3050, Australia|GSK Investigational Site, Prahran, Victoria, 3181, Australia|GSK Investigational Site, Nedlands, Western Australia, 6009, Australia|GSK Investigational Site, Bruxelles, 1200, Belgium|GSK Investigational Site, Edegem, 2650, Belgium|GSK Investigational Site, Gent, 9000, Belgium|GSK Investigational Site, Leuven, 3000, Belgium|GSK Investigational Site, Campinas, São Paulo, 13083-888, Brazil|GSK Investigational Site, São Paulo, 04023900, Brazil|GSK Investigational Site, Edmonton, Alberta, T6G 2C8, Canada|GSK Investigational Site, Victoria, British Columbia, V8V 3P9, Canada|GSK Investigational Site, Winnipeg, Manitoba, R3E 3P4, Canada|GSK Investigational Site, Barrie, Ontario, L4M 7G1, Canada|GSK Investigational Site, Hamilton, Ontario, L8L 2X2, Canada|GSK Investigational Site, Hamilton, Ontario, L8N 4A6, Canada|GSK Investigational Site, London, Ontario, N6A 5A5, Canada|GSK Investigational Site, Ottawa, Ontario, K1H 8L6, Canada|GSK Investigational Site, Toronto, Ontario, M5G 1X5, Canada|GSK Investigational Site, Toronto, Ontario, M5G 2C4, Canada|GSK Investigational Site, Toronto, Ontario, M5T 2S8, Canada|GSK Investigational Site, Toronto, Ontario, M6H 3M1, Canada|GSK Investigational Site, Montreal, Quebec, H2X 3J4, Canada|GSK Investigational Site, Montreal, Quebec, H3T 1E2, Canada|GSK Investigational Site, Hradec Kralove, 500 12, Czech Republic|GSK Investigational Site, Olomouc, 775 20, Czech Republic|GSK Investigational Site, Praha 6, 169 02, Czech Republic|GSK Investigational Site, Cairo, Egypt|GSK Investigational Site, Mansoura, 35516, Egypt|GSK Investigational Site, Shebeen El-Kom, Menoufeya, 35111, Egypt|GSK Investigational Site, Besançon, 25030, France|GSK Investigational Site, Bondy, 93140, France|GSK Investigational Site, Dijon cedex, 21019, France|GSK Investigational Site, Grenoble, 38043, France|GSK Investigational Site, Lille, 59037, France|GSK Investigational Site, Marseille Cedex 08, 13285, France|GSK Investigational Site, Orléans, 45100, France|GSK Investigational Site, Paris Cedex 12, 75571, France|GSK Investigational Site, Paris Cedex 13, 75651, France|GSK Investigational Site, Rouen, 76000, France|GSK Investigational Site, Strasbourg, 67091, France|GSK Investigational Site, Vandoeuvre Les Nancy, 54511, France|GSK Investigational Site, Freiburg, Baden-Wuerttemberg, 79106, Germany|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, 69120, Germany|GSK Investigational Site, Mannheim, Baden-Wuerttemberg, 68167, Germany|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, 70197, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, 89081, Germany|GSK Investigational Site, Deggendorf, Bayern, 94469, Germany|GSK Investigational Site, Hof/Saale, Bayern, 95028, Germany|GSK Investigational Site, Muenchen, Bayern, 81377, Germany|GSK Investigational Site, Muenchen, Bayern, 81675, Germany|GSK Investigational Site, Regensburg, Bayern, 93049, Germany|GSK Investigational Site, Wuerzburg, Bayern, 97080, Germany|GSK Investigational Site, Beeskow, Brandenburg, 15848, Germany|GSK Investigational Site, Frankfurt, Hessen, 60590, Germany|GSK Investigational Site, Frankfurt, Hessen, 60596, Germany|GSK Investigational Site, Kassel, Hessen, 34127, Germany|GSK Investigational Site, Goettingen, Niedersachsen, 37075, Germany|GSK Investigational Site, Hannover, Niedersachsen, 30159, Germany|GSK Investigational Site, Hannover, Niedersachsen, 30625, Germany|GSK Investigational Site, Rotenburg (Wuemme), Niedersachsen, 27356, Germany|GSK Investigational Site, Aachen, Nordrhein-Westfalen, 52074, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, 44787, Germany|GSK Investigational Site, Bonn, Nordrhein-Westfalen, 53127, Germany|GSK Investigational Site, Dortmund, Nordrhein-Westfalen, 44263, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, 40225, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, 45122, Germany|GSK Investigational Site, Herne, Nordrhein-Westfalen, 44623, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, 50937, Germany|GSK Investigational Site, Leverkusen, Nordrhein-Westfalen, 51375, Germany|GSK Investigational Site, Muenster, Nordrhein-Westfalen, 48143, Germany|GSK Investigational Site, Oberhausen, Nordrhein-Westfalen, 46045, Germany|GSK Investigational Site, Siegen, Nordrhein-Westfalen, 57072, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, 55131, Germany|GSK Investigational Site, Halle, Sachsen-Anhalt, 06120, Germany|GSK Investigational Site, Magdeburg, Sachsen-Anhalt, 39120, Germany|GSK Investigational Site, Chemnitz, Sachsen, 09116, Germany|GSK Investigational Site, Leipzig, Sachsen, 04129, Germany|GSK Investigational Site, Berlin, 10439, Germany|GSK Investigational Site, Berlin, 10969, Germany|GSK Investigational Site, Berlin, 12203, Germany|GSK Investigational Site, Berlin, 13353, Germany|GSK Investigational Site, Hamburg, 20099, Germany|GSK Investigational Site, Hamburg, 20246, Germany|GSK Investigational Site, Athens, 10676, Greece|GSK Investigational Site, Athens, 115 27, Greece|GSK Investigational Site, Rio, Patras, 265 04, Greece|GSK Investigational Site, Thessaloniki, 546 42, Greece|GSK Investigational Site, Bangalore, 560054, India|GSK Investigational Site, Chennai, 600 096, India|GSK Investigational Site, Hyderabad, 500082, India|GSK Investigational Site, Mumbai, 400 008, India|GSK Investigational Site, Mumbai, 400 016, India|GSK Investigational Site, Mumbai, 400036, India|GSK Investigational Site, Haifa, 31096, Israel|GSK Investigational Site, Haifa, 34362, Israel|GSK Investigational Site, Jerusalem, 91120, Israel|GSK Investigational Site, Nazareth, 16100, Israel|GSK Investigational Site, Petach Tikva, 49100, Israel|GSK Investigational Site, Rehovot, 76100, Israel|GSK Investigational Site, Safed, 13110, Israel|GSK Investigational Site, Tel Aviv, 64239, Israel|GSK Investigational Site, Catanzaro, Calabria, 88100, Italy|GSK Investigational Site, Avellino, Campania, 83100, Italy|GSK Investigational Site, Bologna, Emilia-Romagna, 40138, Italy|GSK Investigational Site, Roma, Lazio, 00133, Italy|GSK Investigational Site, Genova, Liguria, 16132, Italy|GSK Investigational Site, Brescia, Lombardia, 25123, Italy|GSK Investigational Site, Milano, Lombardia, 20132, Italy|GSK Investigational Site, Milano, Lombardia, 20157, Italy|GSK Investigational Site, Bari, Puglia, 70124, Italy|GSK Investigational Site, San Giovanni Rotondo (FG), Puglia, 71013, Italy|GSK Investigational Site, Palermo, Sicilia, 90127, Italy|GSK Investigational Site, Busan, 614-735, Korea, Republic of|GSK Investigational Site, Daegu, 700-721, Korea, Republic of|GSK Investigational Site, Pusan, 602-739, Korea, Republic of|GSK Investigational Site, Seoul, 120-752, Korea, Republic of|GSK Investigational Site, Seoul, 135-720, Korea, Republic of|GSK Investigational Site, Lahore, 54000, Pakistan|GSK Investigational Site, Lahore, 54600, Pakistan|GSK Investigational Site, Chorzow, 41-500, Poland|GSK Investigational Site, Kielce, 25-317, Poland|GSK Investigational Site, Raciborz, 47-400, Poland|GSK Investigational Site, Szczecin, 71-455, Poland|GSK Investigational Site, Warszawa, 01-201, Poland|GSK Investigational Site, Wroclaw, 51-149, Poland|GSK Investigational Site, Ponce, 00717, Puerto Rico|GSK Investigational Site, San Juan, 00927, Puerto Rico|GSK Investigational Site, Bucharest, 021105, Romania|GSK Investigational Site, Constanta, 900709, Romania|GSK Investigational Site, Moscow, 107014, Russian Federation|GSK Investigational Site, Saint-Petersburg, 191167, Russian Federation|GSK Investigational Site, Samara, 443011, Russian Federation|GSK Investigational Site, St.Peterburg, 190103, Russian Federation|GSK Investigational Site, Bratislava, 811 07, Slovakia|GSK Investigational Site, Bratislava, 833 05, Slovakia|GSK Investigational Site, Kosice, 041 66, Slovakia|GSK Investigational Site, Martin, 036 59, Slovakia|GSK Investigational Site, Alicante, 03010, Spain|GSK Investigational Site, Barcelona, 08003, Spain|GSK Investigational Site, Barcelona, 08035, Spain|GSK Investigational Site, La Coruña, 15006, Spain|GSK Investigational Site, Madrid, 28006, Spain|GSK Investigational Site, Madrid, 28007, Spain|GSK Investigational Site, Madrid, 28034, Spain|GSK Investigational Site, Málaga, 29010, Spain|GSK Investigational Site, Palma de Mallorca, 07010, Spain|GSK Investigational Site, Pontevedra, 36071, Spain|GSK Investigational Site, Sabadell (Barcelona), 08208, Spain|GSK Investigational Site, San Sebastián, 20014, Spain|GSK Investigational Site, Sevilla, 41014, Spain|GSK Investigational Site, Valencia, 46009, Spain|GSK Investigational Site, Valencia, 46010, Spain|GSK Investigational Site, Changhua, 500, Taiwan|GSK Investigational Site, Chia-Yi Hsien, 613, Taiwan|GSK Investigational Site, Kaohsiung, 833, Taiwan|GSK Investigational Site, Taichung, 404, Taiwan|GSK Investigational Site, Taipei, 112, Taiwan|GSK Investigational Site, Taiyuan Hsien, 333, Taiwan|GSK Investigational Site, Donetsk, 83114, Ukraine|GSK Investigational Site, Kiev, 01030, Ukraine|GSK Investigational Site, Vinnitsa, 21021, Ukraine"
NCT02945436,Optimizing HIV Counseling and Testing and Referral Through an Adaptive Drug Use Intervention,https://clinicaltrials.gov/study/NCT02945436,COMPLETED,NO,HIV|Substance Use,BEHAVIORAL: Substance Use Brief Intervention|BEHAVIORAL: Standard of Care (SOC),University of Michigan,National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",258,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: PREVENTION,2017-04-07,2021-06-01,"Center for Sexuality and Health Disparities, Ann Arbor, Michigan, 48109, United States"
NCT03610217,Pragmatic Clinical Trials in Scleroderma,https://clinicaltrials.gov/study/NCT03610217,UNKNOWN,NO,"Scleroderma, Systemic|Sclerosis, Systemic",OTHER: Interstitial lung disease induction algorithm|OTHER: Pulmonary arterial hypertension algorithm|OTHER: Raynaud's phenomenon algorithm|OTHER: Digital ulcer algorithm|OTHER: Inflammatory arthritis algorithm|OTHER: Gastroesophageal reflux algorithm|OTHER: Bacterial overgrowth algorithm|OTHER: Constipation algorithm|OTHER: Skin involvement algorithm|OTHER: Pain algorithm,University of West London,"University of Western Ontario, Canada",ALL,"ADULT, OLDER_ADULT",400,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2018-10,2021-10,"Saint Joseph's Health Care London, London, Ontario, n6a 4v2, Canada"
NCT06414993,Leveraging Parents and Peers to Increase Recovery Capital in Emerging Adults,https://clinicaltrials.gov/study/NCT06414993,RECRUITING,NO,Polysubstance Drug Use (Indiscriminate Drug Use),BEHAVIORAL: Contingency Management for Emerging Adults (CM-EA)|BEHAVIORAL: Standard Peer Recovery Support Services (PRSS) +Vocational/Educational (V/E) Skill Building services,Chestnut Health Systems,National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",48,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2024-06-06,2025-05-30,"Chestnut Health Systems, Eugene, Oregon, 97401, United States"
NCT05959538,Building Regulation in Dual Generations 2022-2025,https://clinicaltrials.gov/study/NCT05959538,RECRUITING,NO,"Maternal Depression|Self-Regulation, Emotion|Child Mental Disorder|Child Development",BEHAVIORAL: Building Regulation in Dual Generations (BRIDGE)|BEHAVIORAL: Dialectical Behavioural Therapy Skill Training,University of Manitoba,Canadian Institutes of Health Research (CIHR),ALL,"ADULT, OLDER_ADULT",180,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-10-28,2024-10-30,"University of Manitoba - Department of Psychology, Winnipeg, Manitoba, R3T 2N2, Canada"
NCT05013346,Characteristics of Young-onset Diabetes in Sub-Saharan Africa (YODA) Study,https://clinicaltrials.gov/study/NCT05013346,UNKNOWN,NO,"Type 1 Diabetes|Diabetes, Autoimmune",OTHER: No intervention needed,Yaounde Central Hospital,University of Yaounde 1|University of Exeter|London School of Hygiene and Tropical Medicine,ALL,"CHILD, ADULT, OLDER_ADULT",1200,OTHER_GOV,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-09-01,2022-03-31,"National Obesity Centre, Yaounde Central Hospital, Yaounde, Centre, Cameroon|School of Pathology, University of Witwatersrand, Johannesburg, Gauteng, South Africa|Muhimbili National Hospital, Dar Es Salaam, Tanzania|Uganda Virus Research Institute, Entebbe, P.O. Box 49, Uganda"
NCT00516321,Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease,https://clinicaltrials.gov/study/NCT00516321,COMPLETED,YES,"Hepatitis C, Chronic",DRUG: eltrombopag|DRUG: placebo,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",687,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-10,2011-05,"GSK Investigational Site, Birmingham, Alabama, 35294-0005, United States|GSK Investigational Site, Tucson, Arizona, 85750, United States|GSK Investigational Site, Little Rock, Arkansas, 72205-7199, United States|GSK Investigational Site, La Jolla, California, 92037, United States|GSK Investigational Site, Los Angeles, California, 90017, United States|GSK Investigational Site, Los Angeles, California, 90048, United States|GSK Investigational Site, San Clemente, California, 92673, United States|GSK Investigational Site, Aurora, Colorado, 80045, United States|GSK Investigational Site, New Haven, Connecticut, 06520, United States|GSK Investigational Site, Washington, District of Columbia, 20010, United States|GSK Investigational Site, Washington, District of Columbia, 20307, United States|GSK Investigational Site, Bradenton, Florida, 34209, United States|GSK Investigational Site, Gainsville, Florida, 32610, United States|GSK Investigational Site, Miami, Florida, 33136, United States|GSK Investigational Site, Orlando, Florida, 32803, United States|GSK Investigational Site, Atlanta, Georgia, 30309, United States|GSK Investigational Site, Honolulu, Hawaii, 96817, United States|GSK Investigational Site, Louisville, Kentucky, 40202, United States|GSK Investigational Site, Baltimore, Maryland, 21202, United States|GSK Investigational Site, Burlington, Massachusetts, 01805, United States|GSK Investigational Site, Worcester, Massachusetts, 01655, United States|GSK Investigational Site, Ann Arbor, Michigan, 48109, United States|GSK Investigational Site, Detroit, Michigan, 48201, United States|GSK Investigational Site, Jackson, Mississippi, 39202, United States|GSK Investigational Site, St. Louis, Missouri, 63110, United States|GSK Investigational Site, Bronx, New York, 10468, United States|GSK Investigational Site, Manhasset, New York, 11030, United States|GSK Investigational Site, New York, New York, 10021, United States|GSK Investigational Site, Rochester, New York, 14642, United States|GSK Investigational Site, Syracuse, New York, 13210, United States|GSK Investigational Site, Valhalla, New York, 10595, United States|GSK Investigational Site, Asheville, North Carolina, 28801, United States|GSK Investigational Site, Durham, North Carolina, 27705, United States|GSK Investigational Site, Tulsa, Oklahoma, 74104, United States|GSK Investigational Site, Portland, Oregon, 97239, United States|GSK Investigational Site, Hershey, Pennsylvania, 17033-0850, United States|GSK Investigational Site, Philadelphia, Pennsylvania, 19104, United States|GSK Investigational Site, Jackson, Tennessee, 38301, United States|GSK Investigational Site, Nashville, Tennessee, 37203, United States|GSK Investigational Site, Nashville, Tennessee, 37205, United States|GSK Investigational Site, Nashville, Tennessee, 37212, United States|GSK Investigational Site, Galveston, Texas, 77555-0435, United States|GSK Investigational Site, Houston, Texas, 77030, United States|GSK Investigational Site, San Antonio, Texas, 78215, United States|GSK Investigational Site, Charlottesville, Virginia, 22908, United States|GSK Investigational Site, Fairfax, Virginia, 22031, United States|GSK Investigational Site, Richmond, Virginia, 23249, United States|GSK Investigational Site, Garran, Australian Capital Territory, 2606, Australia|GSK Investigational Site, Camperdown, New South Wales, 2050, Australia|GSK Investigational Site, Randwick, New South Wales, 2031, Australia|GSK Investigational Site, Fitzroy, Victoria, 3065, Australia|GSK Investigational Site, Heidelberg, Victoria, 3084, Australia|GSK Investigational Site, Melbourne, Victoria, 3168, Australia|GSK Investigational Site, Nedlands, Western Australia, 6009, Australia|GSK Investigational Site, Bruxelles, 1200, Belgium|GSK Investigational Site, Edegem, 2650, Belgium|GSK Investigational Site, Gent, 9000, Belgium|GSK Investigational Site, Leuven, 3000, Belgium|GSK Investigational Site, Campinas, São Paulo, 13083-888, Brazil|GSK Investigational Site, São Paulo, 04023900, Brazil|GSK Investigational Site, Calgary, Alberta, T2N 4Z6, Canada|GSK Investigational Site, Victoria, British Columbia, V8V 3P9, Canada|GSK Investigational Site, Winnipeg, Manitoba, R3E 3P4, Canada|GSK Investigational Site, Barrie, Ontario, L4M 7G1, Canada|GSK Investigational Site, Hamilton, Ontario, L8L 2X2, Canada|GSK Investigational Site, Hamilton, Ontario, L8N 4A6, Canada|GSK Investigational Site, Ottawa, Ontario, K1H 8L6, Canada|GSK Investigational Site, Ottawa, Ontario, K1N 6N5, Canada|GSK Investigational Site, Toronto, Ontario, M5G 1X5, Canada|GSK Investigational Site, Toronto, Ontario, M5G 2C4, Canada|GSK Investigational Site, Toronto, Ontario, M5T 2S8, Canada|GSK Investigational Site, Toronto, Ontario, M6H 3M1, Canada|GSK Investigational Site, Montreal, Quebec, H2X 2P4, Canada|GSK Investigational Site, Montreal, Quebec, H2X 3J4, Canada|GSK Investigational Site, Praha 4, 140 21, Czech Republic|GSK Investigational Site, Praha 6, 169 02, Czech Republic|GSK Investigational Site, Besançon, 25030, France|GSK Investigational Site, Dijon cedex, 21019, France|GSK Investigational Site, Marseille, 13385, France|GSK Investigational Site, Montpellier, 34295, France|GSK Investigational Site, Nice, 06202, France|GSK Investigational Site, Pessac Cedex, 33604, France|GSK Investigational Site, Strasbourg, 67091, France|GSK Investigational Site, Toulouse cedex 9, 31059, France|GSK Investigational Site, Toulouse, 31300, France|GSK Investigational Site, Freiburg, Baden-Wuerttemberg, 79106, Germany|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, 69120, Germany|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, 70197, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, 89081, Germany|GSK Investigational Site, Deggendorf, Bayern, 94469, Germany|GSK Investigational Site, Hof/Saale, Bayern, 95028, Germany|GSK Investigational Site, Muenchen, Bayern, 81377, Germany|GSK Investigational Site, Regensburg, Bayern, 93053, Germany|GSK Investigational Site, Wuerzburg, Bayern, 97080, Germany|GSK Investigational Site, Beeskow, Brandenburg, 15848, Germany|GSK Investigational Site, Frankfurt, Hessen, 60590, Germany|GSK Investigational Site, Kassel, Hessen, 34127, Germany|GSK Investigational Site, Goettingen, Niedersachsen, 37075, Germany|GSK Investigational Site, Hannover, Niedersachsen, 30159, Germany|GSK Investigational Site, Hannover, Niedersachsen, 30625, Germany|GSK Investigational Site, Aachen, Nordrhein-Westfalen, 52074, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, 44787, Germany|GSK Investigational Site, Bonn, Nordrhein-Westfalen, 53127, Germany|GSK Investigational Site, Dortmund, Nordrhein-Westfalen, 44263, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, 40225, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, 45122, Germany|GSK Investigational Site, Herne, Nordrhein-Westfalen, 44623, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, 50937, Germany|GSK Investigational Site, Leverkusen, Nordrhein-Westfalen, 51375, Germany|GSK Investigational Site, Muenster, Nordrhein-Westfalen, 48143, Germany|GSK Investigational Site, Siegen, Nordrhein-Westfalen, 57072, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, 55131, Germany|GSK Investigational Site, Halle, Sachsen-Anhalt, 06120, Germany|GSK Investigational Site, Magdeburg, Sachsen-Anhalt, 39120, Germany|GSK Investigational Site, Leipzig, Sachsen, 04103, Germany|GSK Investigational Site, Leipzig, Sachsen, 04129, Germany|GSK Investigational Site, Berlin, 12203, Germany|GSK Investigational Site, Berlin, 13353, Germany|GSK Investigational Site, Pokfulam, Hong Kong|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Chennai, 600 096, India|GSK Investigational Site, Mumbai, 400036, India|GSK Investigational Site, Haifa, 31096, Israel|GSK Investigational Site, Jerusalem, 91120, Israel|GSK Investigational Site, Petach Tikva, 49100, Israel|GSK Investigational Site, Safed, 13110, Israel|GSK Investigational Site, Tel Aviv, 64239, Israel|GSK Investigational Site, Catanzaro, Calabria, 88100, Italy|GSK Investigational Site, Avellino, Campania, 83100, Italy|GSK Investigational Site, Bologna, Emilia-Romagna, 40138, Italy|GSK Investigational Site, Roma, Lazio, 00133, Italy|GSK Investigational Site, Genova, Liguria, 16132, Italy|GSK Investigational Site, Brescia, Lombardia, 25123, Italy|GSK Investigational Site, Milano, Lombardia, 20132, Italy|GSK Investigational Site, Milano, Lombardia, 20157, Italy|GSK Investigational Site, Bari, Puglia, 70124, Italy|GSK Investigational Site, San Giovanni Rotondo (FG), Puglia, 71013, Italy|GSK Investigational Site, Palermo, Sicilia, 90127, Italy|GSK Investigational Site, Busan, 614-735, Korea, Republic of|GSK Investigational Site, Incheon, 400-711, Korea, Republic of|GSK Investigational Site, Seoul, 135-710, Korea, Republic of|GSK Investigational Site, Amsterdam, 1081 HV, Netherlands|GSK Investigational Site, Nijmegen, 6525 GA, Netherlands|GSK Investigational Site, Rotterdam, 3015 CE, Netherlands|GSK Investigational Site, Lahore, 54000, Pakistan|GSK Investigational Site, Lahore, 54600, Pakistan|GSK Investigational Site, Bydgoszcz, 85-030, Poland|GSK Investigational Site, Chorzow, 41-500, Poland|GSK Investigational Site, Kielce, 25-317, Poland|GSK Investigational Site, Szczecin, 71-455, Poland|GSK Investigational Site, Wroclaw, 51-149, Poland|GSK Investigational Site, Ponce, 00717, Puerto Rico|GSK Investigational Site, San Juan, 00927, Puerto Rico|GSK Investigational Site, Bucharest, 021105, Romania|GSK Investigational Site, Constanta, 900708, Romania|GSK Investigational Site, Moscow, 110020, Russian Federation|GSK Investigational Site, Moscow, 129110, Russian Federation|GSK Investigational Site, Mosocow, 117593, Russian Federation|GSK Investigational Site, Smolensk, 214018, Russian Federation|GSK Investigational Site, Bratislava, 811 07, Slovakia|GSK Investigational Site, Bratislava, 833 05, Slovakia|GSK Investigational Site, Kosice, 041 66, Slovakia|GSK Investigational Site, Martin, 036 59, Slovakia|GSK Investigational Site, Barcelona, 08025, Spain|GSK Investigational Site, Granada, 18012, Spain|GSK Investigational Site, L'Hospitalet de Llobregat. Barcelona, 08907, Spain|GSK Investigational Site, La Coruña, 15006, Spain|GSK Investigational Site, Madrid, 28006, Spain|GSK Investigational Site, Madrid, 28007, Spain|GSK Investigational Site, Madrid, 28029, Spain|GSK Investigational Site, Madrid, 28034, Spain|GSK Investigational Site, San Sebastián, 20014, Spain|GSK Investigational Site, Sevilla, 41014, Spain|GSK Investigational Site, Valencia, 46010, Spain|GSK Investigational Site, Kaohsiung, 80708, Taiwan|GSK Investigational Site, Taichung, 407, Taiwan|GSK Investigational Site, Tainan, 704, Taiwan|GSK Investigational Site, Taipei, 100, Taiwan|GSK Investigational Site, Bangkok, 10330, Thailand|GSK Investigational Site, Bangkok, 10700, Thailand|GSK Investigational Site, Chiangmai, 50200, Thailand|GSK Investigational Site, Khon Kaen, 40002, Thailand|GSK Investigational Site, Songkla, 90110, Thailand|GSK Investigational Site, Donetsk, 83114, Ukraine|GSK Investigational Site, Kyiv, 01030, Ukraine|GSK Investigational Site, Kyiv, 04112, Ukraine|GSK Investigational Site, Vinnytsia, 21021, Ukraine|GSK Investigational Site, Glasgow, Lanarkshire, G12 0YN, United Kingdom|GSK Investigational Site, London, NW3 2QG, United Kingdom|GSK Investigational Site, London, W2 1NY, United Kingdom|GSK Investigational Site, Plymouth, PL6 8DH, United Kingdom"
NCT04075435,Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia,https://clinicaltrials.gov/study/NCT04075435,RECRUITING,NO,"Alzheimer Disease|Anxiety|Agitation,Psychomotor",DRUG: high CBD/low THC sublingual solution,Mclean Hospital,Spier Family Foundation,ALL,"ADULT, OLDER_ADULT",12,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-01-11,2025-07-16,"McLean Hospital, Belmont, Massachusetts, 02478, United States"
NCT01893983,Motivational Coaching to Enhance Mental Health Engagement in Rural Veterans,https://clinicaltrials.gov/study/NCT01893983,COMPLETED,YES,Mental Health|Rural Health|Veterans Health,BEHAVIORAL: Motivational Coaching,VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",418,FED,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2015-10-01,2018-09-30,"Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR, North Little Rock, Arkansas, 72114-1706, United States|San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, 94121, United States"
NCT00965419,A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder,https://clinicaltrials.gov/study/NCT00965419,TERMINATED,YES,Attention Deficit Hyperactivity Disorder,DRUG: Edivoxetine,Eli Lilly and Company,,ALL,"CHILD, ADULT",267,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-09,2015-07,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spring Valley, California, 91978, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gainesville, Florida, 32607, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, 32806, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., University Park, Florida, 34201, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Smyrna, Georgia, 30080, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Libertyville, Illinois, 60048, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, 46202, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester Hills, Michigan, 48307, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, 68198, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Las Vegas, Nevada, 89128, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, 19139, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, 38117, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lake Jackson, Texas, 77566, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lubbock, Texas, 79423, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Herndon, Virginia, 20170, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, 98104, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kelowna, British Columbia, V1Y 1Z9, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santurce, 00912, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuei Shan Hsiang, 33305, Taiwan"
NCT03911882,Efficacy and Tolerability of CELERGEN in Fibromyalgia,https://clinicaltrials.gov/study/NCT03911882,COMPLETED,NO,Fibromyalgia,DIETARY_SUPPLEMENT: Celergen Administration,Celergan SA,,ALL,"ADULT, OLDER_ADULT",90,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-04-29,2016-08-30,"Clinica DFK, Madrid, Spain"
NCT04964843,A Study of NAC for AUD,https://clinicaltrials.gov/study/NCT04964843,WITHDRAWN,NO,Alcohol Use Disorder,DRUG: N-acetylcysteine|DRUG: Placebo,Uniformed Services University of the Health Sciences,,ALL,"ADULT, OLDER_ADULT",0,FED,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-04,2025-01,
NCT04772677,Building Emotional Awareness and Mental Health,https://clinicaltrials.gov/study/NCT04772677,UNKNOWN,NO,Maternal Depression,BEHAVIORAL: BEAM Mental Health and Parenting Program,University of Manitoba,University of Calgary|Tactica Interactive|Centre for Healthcare Innovation|Research Manitoba,FEMALE,"ADULT, OLDER_ADULT",60,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-05,2021-09-01,"The University of Manitoba - Department of Psychology, Winnipeg, Manitoba, R3T 2N2, Canada"
NCT06519487,Social Experiences and Demographic Factors in the Regulation of Immune Cells,https://clinicaltrials.gov/study/NCT06519487,RECRUITING,NO,Perceived Discrimination|RNA|Inflammatory Response,BEHAVIORAL: Cyberball,Morgan State University,"Texas Christian University|University of Maryland, Baltimore|University of Baltimore",ALL,"ADULT, OLDER_ADULT",480,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2025-02-03,2029-02-28,"Morgan State University, Baltimore, Maryland, 21251, United States|Texas Christian University, Fort Worth, Texas, 76129, United States"
NCT01880996,Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies,https://clinicaltrials.gov/study/NCT01880996,WITHDRAWN,NO,Ovarian Cancer|Primary Peritoneal Cancer|Other Gynecological Cancers,OTHER: Tai-chi/Qi-gong,Sheba Medical Center,Tel Aviv University,FEMALE,"ADULT, OLDER_ADULT",0,OTHER_GOV,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-08,2015-08,"Sheba Hospital, Ramat Gan, Israel"
NCT02064387,"Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916",https://clinicaltrials.gov/study/NCT02064387,COMPLETED,YES,Multiple Myeloma,DRUG: GSK2857916,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",79,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-07-29,2019-08-01,"GSK Investigational Site, Boston, Massachusetts, 02215, United States|GSK Investigational Site, New York, New York, 10065, United States|GSK Investigational Site, Chapel Hill, North Carolina, 27599-7600, United States|GSK Investigational Site, Philadelphia, Pennsylvania, 19104, United States|GSK Investigational Site, Dallas, Texas, 75390-8565, United States|GSK Investigational Site, Seattle, Washington, 98109, United States|GSK Investigational Site, Vancouver, British Columbia, V5Z 1M9, Canada|GSK Investigational Site, Toronto, Ontario, M5G 2M9, Canada|GSK Investigational Site, London, NW1 2BU, United Kingdom"
NCT06044675,MDMA-Assisted CBCT for PTSD vs CBCT RCT,https://clinicaltrials.gov/study/NCT06044675,RECRUITING,NO,Post Traumatic Stress Disorder,DRUG: MDMA assisted psychotherapy|BEHAVIORAL: Psychotherapy,Remedy,Remedy Institute,ALL,"ADULT, OLDER_ADULT",60,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2024-11-15,2026-12-31,"Remedy Institute, Toronto, Ontario, M6G 1L5, Canada"
NCT03397641,A Phase 1 Study of HBI-3000,https://clinicaltrials.gov/study/NCT03397641,COMPLETED,NO,Atrial Fibrillation,DRUG: HBI-3000|OTHER: Placebo,"HUYABIO International, LLC.",Quotient Clinical,ALL,ADULT,47,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-10-17,2018-07-10,"Quotient Clinical, Nottingham, NG11 6JS, United Kingdom"
NCT05385289,A Cognitive-behavioral Intervention of Rumination for Perfectionists,https://clinicaltrials.gov/study/NCT05385289,COMPLETED,NO,Perfectionism|Rumination - Thoughts|Anxiety|Depression,BEHAVIORAL: A cognitive-behavioral approach of rumination as intervention for overgeneral mode of processing in perfectionism,Université Catholique de Louvain,,ALL,"ADULT, OLDER_ADULT",13,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-03-14,2022-11-24,"Université catholique de Louvain, Louvain-la-Neuve, Brabant Wallon, 1348, Belgium"
NCT06325345,RCT of Gut-directed Hypnotherapy in Ehlers-Danlos Syndromes and Generalized Hypermobility Spectrum Disorders,https://clinicaltrials.gov/study/NCT06325345,NOT_YET_RECRUITING,NO,Ehlers-Danlos Syndrome|Irritable Bowel Syndrome|Hypermobility Syndrome|Gastrointestinal Dysfunction,BEHAVIORAL: Gut-directed hypnotherapy|OTHER: Standard Medical Therapy,"University Health Network, Toronto",,ALL,"ADULT, OLDER_ADULT",74,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-04-01,2025-04-01,"Toronto General Hospital, Toronto, Ontario, M5G 2C4, Canada"
NCT02939131,IMPAACT 2002: Cognitive Behavioral Therapy and Medication Management for Treatment of Depression in US Youth With HIV,https://clinicaltrials.gov/study/NCT02939131,COMPLETED,YES,HIV|Depression,BEHAVIORAL: Health and Wellness Combined Cognitive Behavioral Therapy and a Medication Management Algorithm|BEHAVIORAL: Enhanced Standard of Care,International Maternal Pediatric Adolescent AIDS Clinical Trials Group,National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH),ALL,"CHILD, ADULT",156,NETWORK,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-03-06,2020-01-21,"University of Southern California - MCA Center (CRS 5048),, Alhambra, California, 91803, United States|University California, San Diego (CRS 4601), La Jolla, California, 92093, United States|David Geffen School of Medicine at UCLA (CRS 5112), Los Angeles, California, 90095, United States|Children's Hospital of Colorado (CRS 5052), Aurora, Colorado, 80045, United States|Children's Diagnostic and Treatment Center (CRS 5055), Fort Lauderdale, Florida, 33316, United States|Emory University School of Medicine (CRS 5030), Atlanta, Georgia, 30308, United States|Rush University Medical Center (CRS 5083), Chicago, Illinois, 60612, United States|Johns Hopkins University School of Medicine (CRS 5092), Baltimore, Maryland, 21287, United States|Bronx-Lebanon Hospital Center (CRS 5114), Bronx, New York, 10457, United States|Jacobi Medical Center (CRS 5013), Bronx, New York, 10461, United States|Stony Brook University Medical Center (CRS 5040), Stony Brook, New York, 11794, United States|St Jude Children's Research Hospital (CRS 6501), Memphis, Tennessee, 38105, United States|Texas Children's/Baylor (CRS 3801), Houston, Texas, 77030, United States"
NCT05397691,Substance Use Prevention for Youth With Parents in Recovery,https://clinicaltrials.gov/study/NCT05397691,RECRUITING,NO,Substance Use Disorders,OTHER: Modified Family Talk|OTHER: Control-like parameter estimation,Brown University,National Institute on Drug Abuse (NIDA)|National Institutes of Health (NIH),ALL,"CHILD, ADULT, OLDER_ADULT",80,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2024-08-29,2026-03-31,"CODAC, Pawtucket, Rhode Island, 02904, United States"
NCT04863729,Evaluation of Asdzáán Be'eená Teen Pregnancy and Substance Use Prevention Program for Native American Youth and Their Caregiver,https://clinicaltrials.gov/study/NCT04863729,ACTIVE_NOT_RECRUITING,NO,Sex Behavior,BEHAVIORAL: Asdzaan Be'eena Program,Johns Hopkins Bloomberg School of Public Health,Children's Bureau - Administration for Children and Families,FEMALE,CHILD,820,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2021-05-20,2025-09,"Center for American Indian Health - Chinle, Chinle, Arizona, 86503, United States|Center for American Indian Health - Tuba City, Tuba City, Arizona, 86045, United States"
NCT04616235,Acute Exercise and NK Cell Regulation in Tissue and Circulation After IL-6R Blockade,https://clinicaltrials.gov/study/NCT04616235,COMPLETED,NO,Interleukin-6 Inhibition|Physical Stress|Appetitive Behavior,DRUG: Tocilizumab Injectable Product|OTHER: Saline 0.9% 100 ml NaCl 0.9% will be infused over 1 hour,"Rigshospitalet, Denmark",,MALE,ADULT,30,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2021-03-15,2021-10-04,"Center For Physical Activity (CFAS), Copenhagen Ø, 2100, Denmark"
NCT02049034,Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes,https://clinicaltrials.gov/study/NCT02049034,COMPLETED,NO,Type 2 Diabetes,OTHER: Lixisenatide|OTHER: Placebo,University of Surrey,Sanofi,MALE,"ADULT, OLDER_ADULT",8,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2014-01,2016-01,"University of Surrey FHMS Diabetes and Metabolic Medicine, Guildford, Surrey, GU2 7WG, United Kingdom"
NCT00290355,Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery,https://clinicaltrials.gov/study/NCT00290355,COMPLETED,YES,"Lung Cancer, Non-Small Cell",BIOLOGICAL: GSK 249553 vaccine|BIOLOGICAL: Placebo,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",182,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2002-05-28,2011-07-19,"GSK Investigational Site, Bruxelles, 1200, Belgium|GSK Investigational Site, Edegem, 2650, Belgium|GSK Investigational Site, Gent, 9000, Belgium|GSK Investigational Site, Leuven, 3000, Belgium|GSK Investigational Site, Tallinn, 13419, Estonia|GSK Investigational Site, Tartu, 51014, Estonia|GSK Investigational Site, Helsinki, 00029, Finland|GSK Investigational Site, Tampere, 33520, Finland|GSK Investigational Site, Pessac, 33600, France|GSK Investigational Site, Rennes Cedex 09, 35033, France|GSK Investigational Site, Freiburg, Baden-Wuerttemberg, 79106, Germany|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, 69126, Germany|GSK Investigational Site, Villingen-Schwenningen, Baden-Wuerttemberg, 78050, Germany|GSK Investigational Site, Ebensfeld, Bayern, 96250, Germany|GSK Investigational Site, Gauting, Bayern, 82131, Germany|GSK Investigational Site, Muenchen, Bayern, 81675, Germany|GSK Investigational Site, Frankfurt, Hessen, 60488, Germany|GSK Investigational Site, Offenbach, Hessen, 63069, Germany|GSK Investigational Site, Delmenhorst, Niedersachsen, 27753, Germany|GSK Investigational Site, Hemer, Nordrhein-Westfalen, 58675, Germany|GSK Investigational Site, Witten, Nordrhein-Westfalen, 58455, Germany|GSK Investigational Site, Kaiserslautern, Rheinland-Pfalz, 67655, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, 55131, Germany|GSK Investigational Site, Halle (Saale), Sachsen-Anhalt, 06114, Germany|GSK Investigational Site, Halle, Sachsen-Anhalt, 06120, Germany|GSK Investigational Site, Leipzig, Sachsen, 04129, Germany|GSK Investigational Site, Grosshansdorf, Schleswig-Holstein, 22927, Germany|GSK Investigational Site, Bad Berka, Thueringen, 99437, Germany|GSK Investigational Site, Berlin, 14109, Germany|GSK Investigational Site, Marousi, 15125, Greece|GSK Investigational Site, Rio-Patras, 26504, Greece|GSK Investigational Site, Thessaloniki, 57010, Greece|GSK Investigational Site, Pordenone, Friuli-Venezia-Giulia, 33170, Italy|GSK Investigational Site, Udine, Friuli-Venezia-Giulia, 33100, Italy|GSK Investigational Site, Genova, Liguria, 16132, Italy|GSK Investigational Site, Perugia, Umbria, 06156, Italy|GSK Investigational Site, Venezia, Veneto, 30122, Italy|GSK Investigational Site, Rigas Rajons, LV 2118, Latvia|GSK Investigational Site, Riga, LV 1002, Latvia|GSK Investigational Site, Vilnius, LT-01102, Lithuania|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Nijmegen, 6525 GA, Netherlands|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Trondheim, 7006, Norway|GSK Investigational Site, Checiny, 26-060, Poland|GSK Investigational Site, Gdansk, 80-211, Poland|GSK Investigational Site, Poznan, 60-569, Poland|GSK Investigational Site, Tuszyn, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Zakopane, 34-500, Poland|GSK Investigational Site, Barcelona, 08036, Spain|GSK Investigational Site, La Coruña, 15006, Spain|GSK Investigational Site, Madrid, 28035, Spain|GSK Investigational Site, Madrid, 28040, Spain|GSK Investigational Site, Madrid, 28047, Spain|GSK Investigational Site, Oviedo, 33006, Spain|GSK Investigational Site, Palma de Mallorca, 07014, Spain|GSK Investigational Site, Santander, 38008, Spain|GSK Investigational Site, Valencia, 46010, Spain|GSK Investigational Site, Hull, HU8 9HE, United Kingdom|GSK Investigational Site, London, SE1 9RS, United Kingdom|GSK Investigational Site"
NCT05517382,A Digital Game Targeting Suicide Prevention in Adolescents Who Report Substance Misuse,https://clinicaltrials.gov/study/NCT05517382,COMPLETED,YES,Substance Misuse|Suicide,OTHER: supportED|OTHER: Control,Yale University,National Center for Advancing Translational Sciences (NCATS),ALL,"CHILD, ADULT",61,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-12-21,2023-05-11,"Yale, New Haven, Connecticut, 06519, United States"
NCT05931406,Effects of a Sedentary Behaviors at Work on Health in Emergency Medical Dispatchers and CODIS Operators (SECODIS),https://clinicaltrials.gov/study/NCT05931406,RECRUITING,NO,Sedentary Behavior|Occupational Stress,BEHAVIORAL: Control|BEHAVIORAL: Sit-and-stand desk|BEHAVIORAL: Cycloergometer,"University Hospital, Clermont-Ferrand",,ALL,"ADULT, OLDER_ADULT",36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2024-03-07,2026-09,"CHU clermont-ferrand, Clermont-Ferrand, France"
NCT06487533,Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder,https://clinicaltrials.gov/study/NCT06487533,RECRUITING,NO,Opioid Withdrawal|Opioid Use Disorder,DEVICE: EmbracePlus Smartwatch|DEVICE: Corti Sensor,"Spark Biomedical, Inc.",Battelle Memorial Institute|Hazelden Betty Ford Foundation|National Institutes of Health (NIH),ALL,ADULT,20,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-11-21,2025-07,"Hazelden Betty Ford Foundation, Center City, Minnesota, 55012, United States|Battelle Memorial Institute, Columbus, Ohio, 43201, United States"
NCT04366544,"Effects of an 8-day Advanced Meditation, Samyama on Physical, Psychological and Spiritual Wellbeing ,and Associated Neural Mechanisms",https://clinicaltrials.gov/study/NCT04366544,COMPLETED,NO,"Mental Health Wellness 1|Happiness|Depression|Consciousness, Level Altered|Ecstasy|Dietary Habits|Stress|Inflammatory Bowel Diseases",OTHER: Part A1: Survey|OTHER: Part A2: Sample collection|OTHER: Part B:,Indiana University,,ALL,"ADULT, OLDER_ADULT",759,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2018-01-19,2018-07-31,"Indiana University, Indianapolis, Indiana, 46202, United States"
NCT04263272,Circuit Training Program for Persons With Spinal Cord Injury,https://clinicaltrials.gov/study/NCT04263272,UNKNOWN,NO,Spinal Cord Injuries,OTHER: Upper Body Circuit Training Program,London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's,,ALL,"ADULT, OLDER_ADULT",16,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-02,2020-07,
NCT05374161,An Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain,https://clinicaltrials.gov/study/NCT05374161,RECRUITING,NO,Female Breast Cancer|Depression|Pain,BEHAVIORAL: Acceptance and Commitment Therapy|OTHER: Waitlist Control Group,University of Cyprus,,FEMALE,"ADULT, OLDER_ADULT",88,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-20,2025-06-30,"University of Cyprus, Nicosia, Non-US/Non-Canadian, 1678, Cyprus"
NCT02754557,Physiological Augmentation of Mindfulness Meditation,https://clinicaltrials.gov/study/NCT02754557,COMPLETED,YES,Post Traumatic Stress Disorder,OTHER: Breath-Focused Meditation|DEVICE: Physiological Feedback,Emory University,University of Pittsburgh,FEMALE,"ADULT, OLDER_ADULT",65,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-03,2021-09-21,"Grady Health System, Atlanta, Georgia, 30303, United States|Wesley Woods Center, Atlanta, Georgia, 30329, United States"
NCT03834779,HIV+ Substance Users Released From Jail,https://clinicaltrials.gov/study/NCT03834779,COMPLETED,YES,HIV/AIDS|Substance Use Disorders,BEHAVIORAL: DOORS-CHW Intervention,University of Texas Southwestern Medical Center,National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",31,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2019-05-29,2021-08-25,"Amelia Court, HIV Research Unit, Dallas, Texas, 75235, United States"
NCT05291481,Implementing a Church-based Parenting Intervention for Hispanics,https://clinicaltrials.gov/study/NCT05291481,RECRUITING,NO,Adolescent Behavior|Parenting,BEHAVIORAL: CAPAS-yOUTH,University of Texas at Austin,,ALL,"CHILD, ADULT, OLDER_ADULT",327,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-04-21,2024-07-30,"Steve Hicks School of Social Work, the University of Texas at Austin, Austin, Texas, 78712, United States"
NCT03323437,Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia,https://clinicaltrials.gov/study/NCT03323437,COMPLETED,YES,Schizophrenia Spectrum and Other Psychotic Disorders,DRUG: Risperidone,Weill Medical College of Cornell University,New York State Psychiatric Institute|Columbia University|National Institute of Mental Health (NIMH),ALL,ADULT,26,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2017-09-15,2023-05-31,"New York State Psychiatric Institute & Columbia University, New York, New York, 10032, United States"
NCT00107042,Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths,https://clinicaltrials.gov/study/NCT00107042,COMPLETED,YES,Hepatitis B,BIOLOGICAL: Recombivax|BIOLOGICAL: Twinrix,"University of North Carolina, Chapel Hill",Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)|National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,CHILD,123,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2004-02,2008-07,"Children's Hospital of Los Angeles, Los Angeles, California, 90027, United States|University of California at San Diego, San Diego, California, 92103, United States|University of California at San Francisco, San Francisco, California, 94118, United States|Children's Hospital National Medical Center, Washington, District of Columbia, 20010, United States|University of Southern Florida College of Medicine, Tampa, Florida, 33606, United States|Ruth M Rothstein CORE Center/ John H Stroger Jr Hospital, Chicago, Illinois, 60612, United States|Tulane Medical Center, New Orleans, Louisiana, 70112, United States|University of Maryland, Baltimore, Maryland, 21201, United States|Montefiore Medical Center, Bronx, New York, 10467, United States|St. Jude Childrens Research Hospital, Memphis, Tennessee, 38105-2794, United States|Unversity of Peurto Rico School of Medicine, San Juan, 00936, Puerto Rico"
NCT04667338,A Study to Collect Information of People With Narcolepsy in Spain,https://clinicaltrials.gov/study/NCT04667338,COMPLETED,YES,Narcolepsy,,Takeda,,ALL,"ADULT, OLDER_ADULT",214,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-02-18,2022-11-04,"Hospital Clinic de Barcelona, Barcelona, Cataluna, 8036, Spain"
NCT03405441,"A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Participants",https://clinicaltrials.gov/study/NCT03405441,COMPLETED,NO,Healthy,DRUG: JNJ-55375515 Dose Level 1|DRUG: JNJ-55375515 Dose Level 2|DRUG: JNJ-55375515 Dose Level 3|DRUG: JNJ-55375515 Dose Level 4|DRUG: JNJ-55375515 Dose Level 5|DRUG: JNJ-55375515 Dose Level 6|DRUG: Placebo|DRUG: JNJ-55375515,"Janssen Research & Development, LLC",,MALE,ADULT,42,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-01-02,2018-09-04,"PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, 9728 NZ, Netherlands"
NCT05639556,Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF,https://clinicaltrials.gov/study/NCT05639556,RECRUITING,NO,Cystic Fibrosis,DIAGNOSTIC_TEST: BMI and lean mass index from DXA|DIAGNOSTIC_TEST: Anthropometric Measurements|DIAGNOSTIC_TEST: Hand-grip strength|DIAGNOSTIC_TEST: Six-minute walk Test|DIAGNOSTIC_TEST: Sit-to-Stand Test|DIAGNOSTIC_TEST: Short physical performance battery (SPPB)|DIAGNOSTIC_TEST: BIA Sub-study|DIAGNOSTIC_TEST: Accelerometry to assess physical activity|OTHER: Gastrointestinal (GI) and nutrition questionnaires:|OTHER: Psychosocial questionnaire: PHQ-8|OTHER: Psychosocial questionnaire: GAD-7|OTHER: Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ)|OTHER: Psychosocial questionnaire: CF Fatalism Scale|OTHER: Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA)|OTHER: 12-month Questionnaire|OTHER: Oral glucose tolerance testing (OGTT)|DEVICE: Continuous glucose monitoring (CGM)|DIAGNOSTIC_TEST: Chest CT scans (When available within the past 6 months in medical records)|DIAGNOSTIC_TEST: Hologic Dual X-Ray Absorptiometry (DXA)|DIAGNOSTIC_TEST: Ultrasound Sub-study of assessment of appendage muscles using ultrasound|DIAGNOSTIC_TEST: Psychosocial questionnaire: Hunger Vital Sign questionnaire|OTHER: Respiratory symptom questionnaire: CRISS|DIAGNOSTIC_TEST: Spirometry|OTHER: Psychosocial questionnaire: Additional Health Questionnaire,Jaeb Center for Health Research,,ALL,"ADULT, OLDER_ADULT",300,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-04-20,2028-12,"University of Arizona, Tucson, Arizona, 85724, United States|University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, 72205, United States|Yale University School of Medicine, New Haven, Connecticut, 06520, United States|Emory, Atlanta, Georgia, 30324, United States|Northwestern University, Chicago, Illinois, 60611, United States|University of Iowa, Iowa City, Iowa, 52242, United States|University of Kentucky, Lexington, Kentucky, 40508, United States|Tulane University, New Orleans, Louisiana, 70112, United States|John Hopkins University, Baltimore, Maryland, 21287, United States|Massachusetts General Hospital (MGH), Boston, Massachusetts, 02114, United States|Boston Children's Hospital and Brigham and Women's CF Center, Boston, Massachusetts, 02120, United States|University of Minnesota, Minneapolis, Minnesota, 55455, United States|Washington University School of Medicine (St. Louis), Saint Louis, Missouri, 63110, United States|New York Medical College (NYMC), Hawthorne, New York, 10532, United States|Northwell LIJ Adult Cystic Fibrosis Center, New Hyde Park, New York, 11040, United States|University of Cincinnati, Cincinnati, Ohio, 45220, United States|University Hospitals, Cleveland, Ohio, 44106, United States|University of Oklahoma Sciences Center, Oklahoma City, Oklahoma, 73104, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15224, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Baylor University, Houston, Texas, 77030, United States|University of Virginia Cystic Fibrosis Center, Charlottesville, Virginia, 22908, United States"
NCT03855410,Preventing Cigarette Use Among Urban Youth Via an M-Health Primary Care Preventive Intervention,https://clinicaltrials.gov/study/NCT03855410,COMPLETED,NO,Tobacco Use|Drug Use|Adolescent Behavior|Alcohol Use|Sexual Risk Behavior,BEHAVIORAL: S4E|BEHAVIORAL: Attention-Matched Control Group,University of Michigan,,ALL,"CHILD, ADULT",50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2016-10-27,2017-08-31,"University of Michigan, Ann Arbor, Michigan, 48109, United States|Corner Health Center, Ypsilanti, Michigan, 48198, United States"
NCT01179191,Conversion to Embeda With Rescue Trial,https://clinicaltrials.gov/study/NCT01179191,TERMINATED,YES,Chronic Disease|Pain,DRUG: morphine sulfate and naltrexone hydrochloride (EMBEDA),Pfizer,,ALL,"ADULT, OLDER_ADULT",684,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2010-08,2011-04,"Adamsville Family Medicine, Adamsville, Alabama, 35005, United States|Office of David McLain, Birmingham, Alabama, 35209, United States|Monte Sano Clinical Research, LLC, Huntsville, Alabama, 35801, United States|Tennessee Valley Pain Consultants Properties, LLC, Huntsville, Alabama, 35801, United States|Sunbelt Research Group, LLC, Mobile, Alabama, 36693, United States|Office of Vaughn H. Mancha, Jr., PC, Montgomery, Alabama, 36117, United States|Dedicated Clinical Research, Goodyear, Arizona, 85395, United States|Dedicated Clinical Research, Inc, Phoenix, Arizona, 85020, United States|Redpoint Research, Phoenix, Arizona, 85029, United States|Anasazi Internal Medicine, PC, Phoenix, Arizona, 85032, United States|Cochise Clinical Research, Sierra Vista, Arizona, 85635, United States|Premiere Phamaceutical Research, LLC, Tempe, Arizona, 85282, United States|Quality of Life Medical and Research Center, LLC, Tucson, Arizona, 85712, United States|Ouachita Regional Pain Management, Hot Springs, Arkansas, 71913, United States|NEA Baptist Clinic, Jonesboro, Arkansas, 72401, United States|Hollis Family Medical Clinic, PLC, Paragould, Arkansas, 72450, United States|CSI Clinical Trials, Costa Mesa, California, 92626, United States|Global Wellness Medical Corporation, Foothill Ranch, California, 92610, United States|Chrishard Medical Group, Inglewood, California, 90301, United States|Triwest Research Associates LLC, La Mesa, California, 91942, United States|Pacific Coast Pain Management Center, Laguna Hills, California, 92637, United States|Valerius Medical Group and Research Center of Greater Long Beach, Inc., Long Beach, California, 90806, United States|LA Pain & Wellness Institute, Los Angeles, California, 90017, United States|Samaritan Center for Medical Research, Los Gatos, California, 95032, United States|Newport Beach Clinical Research Associates, Inc., Newport Beach, California, 92663, United States|Bayview Research Group, LLC, Paramount, California, 90723, United States|Pasadena Rehabilitation Institute, Pasadena, California, 91105, United States|Quality Control Research, Inc., Roseville, California, 95661, United States|Northern California Research, Sacramento, California, 95821, United States|Quality Control Research, Inc., Sacramento, California, 95842, United States|Rancho Santa Fe Medical Group, Inc., San Marcos, California, 92078, United States|Probe Clinical Research Corporation, Santa Ana, California, 92701, United States|Trinity Clinical Trials, Santa Ana, California, 92701, United States|Facility Medical Center, Upland, California, 91786, United States|Bayview Research Group, LLC, Valley Village, California, 91607, United States|Rocky Mountain Internal Medicine, PC, Aurora, Colorado, 80012, United States|Clinicos, LLC, Colorado Springs, Colorado, 80904, United States|Saint Luke's Medical Clinic, LLC, Fort Collins, Colorado, 80525, United States|ProHealth Physicians PC, Manchester, Connecticut, 06040, United States|Milford Physician Services, PC, Milford, Connecticut, 06460, United States|Orthopedic Research Institute, LLC, Boynton Beach, Florida, 33472, United States|Florida Research & Testing, LLC, Clearwater, Florida, 33755, United States|Omega Research Consultants, LLC, Debary, Florida, 32713, United States|Omega Research Consultants, LLC, DeBary, Florida, 32746, United States|West Florida Medical Associate, PA, Dunnellon, Florida, 34432, United States|International Research Associates, LLC, Hialeah, Florida, 33012, United States|Palm Springs Research Institute, Inc, Hialeah, Florida, 33012, United States|FPA Clinical Research, LLC, Kissimmee, Florida, 34741, United States|Clinical Research of Central Florida, Inc., Lakeland, Florida, 33810, United States|NextPhase Clinical Trials, Inc., Miami Beach, Florida, 33140, United States|Community Research Foundation, Inc., Miami, Florida, 33155, United States|New Horizon Research Center, Inc., Miami, Florida, 33175, United States|Harmony Clinical Research, Inc., North Miami Beach, Florida, 33162, United States|Office of Laszlo J. Mate, MD, PA, North Palm Beach, Florida, 33408, United States|Office of Richard E. Promin, MD, PA, Ocala, Florida, 34474, United States|Advent Clinical Research Centers, Inc., Pinellas Park, Florida, 33781, United States|Pain Management Strategies, Inc., Pompano Beach, Florida, 33064, United States|Sarasota Pain Medicine Research, LLC, Sarasota, Florida, 34238, United States|Stedman Clinical Trials, LLC, Tampa, Florida, 33613, United States|Clinical Research Center, LLC, Wellington, Florida, 33414, United States|Perimeter Institute for Clinical Research, Inc., Atlanta, Georgia, 30338, United States|Medical Research and Health Education Foundation, Inc., Columbus, Georgia, 31909, United States|Ialum Clinical Research, LLC, Decatur, Georgia, 30032, United States|Ialum Clinical Research, LLC, Stone Mountain, Georgia, 30088, United States|Herman Clinical Research, LLC, Suwanee, Georgia, 30024, United States|Centers for Pain Management, Tifton, Georgia, 31794, United States|Chicago Clinical Research Institute Inc., Chicago, Illinois, 60616, United States|Creve Coeur Family Practice, Creve Coeur, Illinois, 61610, United States|Office of Rebecca Knight, MD, Peoria, Illinois, 61614, United States|Josephson Wallack Munshower Neurology P.C., Indianapolis, Indiana, 46237, United States|Laporte County Institute for Clinical Research Inc., Michigan City, Indiana, 46360, United States|McKinley Research, LLC, Mishawaka, Indiana, 46545, United States|Accelovance, Inc., South Bend, Indiana, 46601, United States|Des Moines Orthopaedic Surgeons, PC, West Des Moines, Iowa, 50266, United States|The Pain Treatment Center of the Bluegrass, Lexington, Kentucky, 40503, United States|Healing Options, Louisville, Kentucky, 40223, United States|Four Rivers Clinical Research, Inc., Paducah, Kentucky, 42003, United States|Lakewood Family Practice, Russell Springs, Kentucky, 42642, United States|Diseasebusters, LLC, College Park, Maryland, 20740, United States|Office of Steven C. Miller, MD, Pikesville, Maryland, 21208, United States|Beacon Clinical Research, LLC, Brockton, Massachusetts, 02301, United States|Ronald J. Rapoport, MD, PC, Fall River, Massachusetts, 02720, United States|Boston Paincare Center, Inc., Waltham, Massachusetts, 02154, United States|Clarkston Medical Group, PC, Clarkston, Michigan, 48346, United States|Apex Medical Research, AMR, Inc., Flint, Michigan, 48504, United States|East Michigan Medical Associates, Flint, Michigan, 48507, United States|PCM Medical Services, PC, Lansing, Michigan, 48910, United States|Remedica LLC, Rochester, Michigan, 48307, United States|Michigan Lifestyle Change and Health Center, PC, Sterling, Michigan, 48314, United States|MAPS Applied Research Center, Inc., Edina, Minnesota, 55435, United States|MAPS Applied Research Center, Inc., Shakopee, Minnesota, 55379, United States|Anesthesia and Pain Control Services, Biloxi, Mississippi, 39531, United States|CRC of Jackson, LLC, Jackson, Mississippi, 39202, United States|Midsouth Anesthesia Consultants, PLLC, Southhaven, Mississippi, 38671, United States|Patterson Medical Clinic, Inc., Florissant, Missouri, 63031, United States|Quality Clinical Research Inc., Florissant, Missouri, 63033, United States|Primary Care Medicine, PC, Jefferson City, Missouri, 65109, United States|The Reiter Foundation, Inc., Anaconda, Montana, 59711, United States|Medical Pain Relief Clinic, Omaha, Nebraska, 68114, United States|Omaha Clinical Research, PC, Omaha, Nebraska, 68116, United States|Atco Medical Associates, PC, Atco, New Jersey, 08004, United States|Office of John V. Bernard, MD, Belvidere, New Jersey, 07823, United States|Central Jersey Medical Research Center, Inc., Elizabeth, New Jersey, 07202, United States|Center for Pain Management, Hackensack, New Jersey, 07601, United States|Advocare Heights Primary Care, Haddon Heights, New Jersey, 08035, United States|NJ Heart, LLC, Linden, New Jersey, 07036, United States|Spine and Pain Centers, PA, Shrewsbury, New Jersey, 07702, United States|Premier Research, Inc., Trenton, New Jersey, 08611, United States|Adirondack Medical Research Center, Glens Falls, New York, 12801, United States|Long Island Gastrointestinal Research Group LLP, Great Neck, New York, 11023, United States|Drug Trials America, Inc., Hartsdale, New York, 10530, United States|Office of Roger Kasendorf, DO, Long Beach, New York, 11561, United States|Family Health Medical Services PLLC, Mayville, New York, 14757, United States|New York Spine & Wellness Center, North Syracuse, New York, 13212, United States|North American Partners in Pain Management, LLP, Valley Stream, New York, 11580, United States|Carolina Clinical Research and Consulting, LLC, Asheboro, North Carolina, 27203, United States|Carolina Clinical Research and Consulting, LLC, Asheboro, North Carolina, 27205, United States|Joint and Muscle Research Institute, Inc., Charlotte, North Carolina, 28204, United States|Catawba Valley Internal Medicine, Hickory, North Carolina, 28602, United States|Profen Research Network at ECMA, Jacksonville, North Carolina, 28546, United States|The Center For Clinical Research, LLC, Winston-Salem, North Carolina, 27103, United States|Medical Frontiers, LLC, Carlisle, Ohio, 45005, United States|Valley Medical Research, Centerville, Ohio, 45459, United States|Hightop Medical Research Center, Cincinnati, Ohio, 45224, United States|Sentral Clinical Research Services, Cincinnati, Ohio, 45236, United States|Delaware Smith Clinic Research, Delaware, Ohio, 43015, United States|Medical Frontiers, LLC, Franklin, Ohio, 45005, United States|Jeffrey J. Haggenjos, DO, Inc., New Lexington, Ohio, 43764, United States|Whole Family Medical Care LLC, Perrysburg, Ohio, 43551, United States|Office of Jocelyn F. Shimek, DO, Salem, Ohio, 44460, United States|Office of James Lassiter, Tiffin, Ohio, 44883, United States|Health Research Institute, LLC, Oklahoma City, Oklahoma, 73109, United States|Office of Siavash Nael, MD, Inc., Oklahoma City, Oklahoma, 73109, United States|Associates of Medicine/John D. Williams, MD, PLLC, Stillwater, Oklahoma, 74074, United States|Portland Rheumatology Clinic, LLC, Lake Oswego, Oregon, 97035, United States|Office of Joseph E. Yankee, DO, PC, Milwaukie, Oregon, 97222, United States|Pennsylvania Pain Specialists, PC, Allentown, Pennsylvania, 18102, United States|Ware Medical Associates, PC, Aston, Pennsylvania, 19014, United States|Altoona Center for Clinical Research, PC, Duncansville, Pennsylvania, 16635, United States|Kandra, Fierer, Kuskin Associates, Ltd., Harrisburg, Pennsylvania, 17112, United States|Onuorah Umeh, M.D. P.C, Philadelphia, Pennsylvania, 19104, United States|Founders Research Corporation, Philadelphia, Pennsylvania, 19152, United States|Progressive Pain Solutions, LLC, Wind Gap, Pennsylvania, 18091, United States|Hartwell Research Group, LLC, Anderson, South Carolina, 29621, United States|Low Country Rheumatology, PA, Charleston, South Carolina, 29406, United States|Pharmacorp Clinical Trials, Inc., Charleston, South Carolina, 29412, United States|Internal Medicine of Greer Research LLC, Greer, South Carolina, 29650, United States|Clinical Research Authority, LLC, Murrells Inlet, South Carolina, 29576, United States|Trident Institute of Medical Research, LLC, North Charleston, South Carolina, 29406, United States|Low Country Pain Center, LLC, Orangeburg, South Carolina, 29118, United States|Brown Clinic, PLLP, Watertown, South Dakota, 57201, United States|Chattanooga Medical Research, LLC, Chattanooga, Tennessee, 37404, United States|Comprehensive Pain Specialists, Hendersonville, Tennessee, 37075, United States|Corsicana Medical Research, PLLC, Corsicana, Texas, 75110, United States|DCT - Genesis Neighborhood Research, LLC, Dallas, Texas, 75254, United States|Southwest Urgent Care Center, El Paso, Texas, 79902, United States|Westbury Medical Clinic, Houston, Texas, 77005, United States|Accurate Clinical Research, Inc., Houston, Texas, 77034, United States|Medstar Clinical Research, Houston, Texas, 77083, United States|Texas Medical Research Associates, LLC, San Antonio, Texas, 78238, United States|Hillcrest Family Health Center, Division of Clinical Research, Waco, Texas, 76710, United States|Hillcrest Family Health Center, Waco, Texas, 76710, United States|Progressive Clinical Research, LLC, Bountiful, Utah, 84010, United States|Sentara Medical Group, NDC Medical Center, Norfolk, Virginia, 23502, United States|Washington Center for Pain Management PLLC, Edmonds, Washington, 98026, United States|Pain Care, PLLC, Huntington, West Virginia, 25701, United States"
NCT02022462,Project Bridge: Peer Health Navigator Intervention,https://clinicaltrials.gov/study/NCT02022462,COMPLETED,YES,Schizophrenia|Depression|Medical Disorders|Serious Mental Illness,BEHAVIORAL: Health Navigation,University of Southern California,"University of California, Los Angeles",ALL,"ADULT, OLDER_ADULT",151,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-04,2020-03,"Pacific Clinics El Camino, Santa Fe Springs, California, 90670, United States"
NCT06345872,Improving Sleep and Reducing Opioid Use in Individuals With Chronic Pain,https://clinicaltrials.gov/study/NCT06345872,RECRUITING,NO,Chronic Pain|Chronic Insomnia|Opioid Use,BEHAVIORAL: CBT-I|BEHAVIORAL: Treatment as usual|OTHER: Tapered Withdrawal,University of South Florida,National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA),ALL,"ADULT, OLDER_ADULT",165,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2024-04,2028-07,"University of South Florida, Tampa, Florida, 33612, United States"
NCT04028219,Transgender In Transition,https://clinicaltrials.gov/study/NCT04028219,RECRUITING,NO,Gender Incongruence,DIAGNOSTIC_TEST: Online surveys,Universitätsklinikum Hamburg-Eppendorf,,ALL,"ADULT, OLDER_ADULT",750,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-05-15,2034-05-15,"Universitätsklinikum Frankfurt, Frankfurt, Hessen, 60590, Germany|University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany|Medical Center of the Ludwig-Maximilians-University of Munich, Munich, Germany|Universitätsspital Basel, Basel, 4031, Switzerland|UniversitätsSpital Zürich, Zürich, 8091, Switzerland"
NCT06071936,Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy,https://clinicaltrials.gov/study/NCT06071936,RECRUITING,NO,"Pain|Pain Syndrome|Pain, Chronic|Chronic Pain|Chronic Pain Syndrome|Neuropathic Pain|Peripheral Neuropathy|Peripheral Neuralgia|Peripheral Nerve Injury|Post Operative Pain|Post-Traumatic Neuralgia|Plexopathy",DRUG: Adezunap (AP707)|DRUG: Placebo,Apurano Pharmaceuticals GmbH,,ALL,"ADULT, OLDER_ADULT",558,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11-02,2024-12-31,"Klinikum Rechts der Isar (Zentrum für Interdisziplinäre Schmerztherapie), Munich, Bavaria, 81675, Germany"
NCT05632601,Reexamining Her Cardiovascular Risk - Ottawa WomeN's Longitudinal Cohort Study,https://clinicaltrials.gov/study/NCT05632601,RECRUITING,NO,Cardiovascular Diseases,DIAGNOSTIC_TEST: PET scan,Ottawa Heart Institute Research Corporation,,FEMALE,ADULT,210,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2023-04-25,2025-05,"University of Ottawa Heart Institute, Ottawa, Ontario, K1Y 4W7, Canada"
NCT02053272,A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes,https://clinicaltrials.gov/study/NCT02053272,COMPLETED,NO,"Diabetes Mellitus, Type 2",DRUG: GWP42004|DRUG: Placebo,Jazz Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",207,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-02,2016-02,"Diabol SRL, Brasov, 500365, Romania|Nicodiab SRL, Bucuresti, 010507, Romania|Spitalul Universitar de Urgenta Militar Central ""Dr. Carol Davila"", Bucuresti, 010825, Romania|Institutul National de Diabet, Bucuresti, 020475, Romania|Centrul Medical 'Sanatatea Ta' SRL, Bucuresti, 020614, Romania|ArtMedical Clinic, Bucuresti, 021107, Romania|Societatea Civila Medicala dr. Paveliu, Bucuresti, 050538, Romania|Consultmed SRL, Iasi, 700547, Romania|Cabinet Medical Individual Diabet Nutritie si Boli Metabolice, Maramures, 430123, Romania|Grandmed SRL, Oradea, 410159, Romania|Spitalul Judetean de Urgente Satu Mare, Satu Mare, 440055, Romania|Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, 550245, Romania|Gagiu D. Remus Cabinet Medical Individual, Targoviste, 130083, Romania|Mediab SRL Diabet Zaharat, Targu Mures, 540142, Romania|Avondale Surgery, Chesterfield, Derbyshire, S40 4TF, United Kingdom|Hull and East Yorkshire Hospitals NHS Trust, Hull, East Yorkshire, HU3 2JZ, United Kingdom|Salford Royal NHS Foundation Trust, Salford, Greater Manchester, M6 8HD, United Kingdom|University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, LE5 4QF, United Kingdom|Aintree University Hospitals NHS Foundation Trust, Liverpool, Merseyside, L9 7AL, United Kingdom|Strensall Medical Practice, York, North Yorkshire, YO32 5UA, United Kingdom|Churchill Hospital, Oxford, Oxfordshire, OX3 9DU, United Kingdom|Hathaway Surgery, Chippenham, Wiltshire, SN14 6GT, United Kingdom|Avenue Surgery, Warminster, Wiltshire, BA12 9AA, United Kingdom|St Chad's Surgery, Bath, BA3 2UH, United Kingdom|Barts and The London NHS Trust, London, E1 1BB, United Kingdom"
NCT03704337,Effects Of Ingesting An Energy Bar On Performance And Recovery,https://clinicaltrials.gov/study/NCT03704337,COMPLETED,NO,Healthy,DIETARY_SUPPLEMENT: Commercially Available Food Bar|DIETARY_SUPPLEMENT: Placebo,Texas A&M University,,ALL,ADULT,20,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2017-12-13,2018-06-01,"Exercise & Sport Nutrition Lab - Human Clinical Research Facility, College Station, Texas, 77845, United States"
NCT04885166,Preventing Prescription Stimulant Diversion and Medication Misuse Via a Web-Based Simulation Intervention,https://clinicaltrials.gov/study/NCT04885166,COMPLETED,NO,Prescription Drug Abuse (Not Dependent)|Intentional Misuse,OTHER: Web-based placebo presentation|BEHAVIORAL: Web-based simulation active intervention,Trinity College,Texas State University|University of Wyoming,ALL,"CHILD, ADULT",249,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2021-05-04,2024-05-21,"Trinity College, Hartford, Connecticut, 06106, United States|Texas State University, San Marcos, Texas, 78666, United States|University of Wyoming, Laramie, Wyoming, 82071, United States"
NCT03938077,A Community-University Approach to Preventing HIV,https://clinicaltrials.gov/study/NCT03938077,WITHDRAWN,NO,HIV/AIDS and Infections|Drug Abuse|Adolescent Behavior|Drug Usage|Alcohol Use|Mental Health|Tobacco Use|HIV Testing,DEVICE: Storytelling 4 Empowerment,University of Michigan,,ALL,"CHILD, ADULT",0,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2019-10-01,2019-11-30,"University of Michigan, Ann Arbor, Michigan, 48109, United States|YOUR Center, Flint, Michigan, 48504, United States"
NCT01741311,Secondary HIV Prevention and Adherence Among HIV-infected Drug Users,https://clinicaltrials.gov/study/NCT01741311,COMPLETED,NO,Risk Behavior|Medication Adherence|HIV,BEHAVIORAL: 3H+ (Holistic Health for HIV)|BEHAVIORAL: HHRP+ (Holistic Health Recovery Program),University of Connecticut,"National Institute on Drug Abuse (NIDA)|Yale University|APT Foundation, Inc.",ALL,"ADULT, OLDER_ADULT",133,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2012-09,2018-06,"APT Foundation, New Haven, Connecticut, 06511, United States"
NCT06324318,Parenting in 2 Worlds Multisite Trial,https://clinicaltrials.gov/study/NCT06324318,RECRUITING,NO,Parenting|Mental Health Wellness 1|Substance Use|Risky Health Behavior,BEHAVIORAL: Parenting in 2 Worlds (P2W)|BEHAVIORAL: Healthy Families in 2 Worlds (HF2W),Arizona State University,Phoenix Indian Center|Ain Dah Yung Center|Denver Indian Center Inc|Native American Community Services of Erie and Niagara Counties|National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT, OLDER_ADULT",1440,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2023-09-14,2027-06-30,"Phoenix Indian Center, Phoenix, Arizona, 85012, United States|Denver Indian Center, Denver, Colorado, 80219, United States|Ain Dah Yung Center, Saint Paul, Minnesota, 55104, United States|Native American Community Services Erie and Niagara Counties, Buffalo, New York, 14207, United States"
NCT03368456,Preventing HIV/STI in Urban Adolescents Via an mHealth Primary Care Intervention,https://clinicaltrials.gov/study/NCT03368456,COMPLETED,NO,HIV/AIDS and Infections|Drug Abuse|Adolescent Behavior|Drug Usage,BEHAVIORAL: S4E|BEHAVIORAL: Usual Care,University of Michigan,,ALL,"CHILD, ADULT",100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2018-05-01,2020-08-12,"Corner Health Center, Ypsilanti, Michigan, 48198, United States"
NCT04358705,"C-FLASH (Cigarillo Flavor and Abuse Liability, Attention, and Substitution in youtH)",https://clinicaltrials.gov/study/NCT04358705,COMPLETED,NO,Smoking Behaviors,OTHER: Aim 1: Online survey|BEHAVIORAL: Eye Tracking Activity|OTHER: Eye tracking survey|BEHAVIORAL: Online Experimental Marketplace (ETM)|OTHER: Aim 3 survey|OTHER: Cognitive Interviews|OTHER: Supplemental Aim 1 Interviews,Case Comprehensive Cancer Center,,ALL,"CHILD, ADULT",658,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-05-29,2023-02-10,"Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, Ohio, 44106, United States"
NCT04312867,Dating Violence Prevention Program Focusing on Middle School Boys,https://clinicaltrials.gov/study/NCT04312867,ACTIVE_NOT_RECRUITING,NO,Adolescent Dating Violence,BEHAVIORAL: Project STRONG|BEHAVIORAL: Health Promotion,Rhode Island Hospital,,MALE,CHILD,340,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2019-10-01,2025-05-31,"Rhode Island Hospital, Providence, Rhode Island, 09203, United States"
NCT05311085,Cytisine and E-cigarettes With Supportive Text-messaging for Smoking Cessation (Cess@Tion),https://clinicaltrials.gov/study/NCT05311085,COMPLETED,NO,Smoking Cessation,DRUG: Cytisine|DRUG: Nicotine delivered via an e-cigarette|COMBINATION_PRODUCT: Cytisine plus nicotine delivered via an e-cigarette,"University of Auckland, New Zealand",,ALL,"ADULT, OLDER_ADULT",807,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2022-05-05,2024-07-26,"National Institute for Health Innovation, School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, 1142, New Zealand"
NCT04446910,Using Technology to Reduce Youth Substance Use,https://clinicaltrials.gov/study/NCT04446910,RECRUITING,NO,Drug Use,BEHAVIORAL: SMS Text Messaging|BEHAVIORAL: Standard of Care Engagement Practices,"University of California, San Francisco",National Institute on Drug Abuse (NIDA),ALL,"CHILD, ADULT",162,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-05-01,2024-12-30,"UCSF Zuckerberg San Francisco General Hospital, San Francisco, California, 94131, United States"
NCT00249756,Re-Entry MTC for Offenders With MICA Disorders,https://clinicaltrials.gov/study/NCT00249756,COMPLETED,NO,Mental Disorders|Substance-Related Disorders,BEHAVIORAL: Re-entry Modified Therapeutic Community (Re-entry MTC)|BEHAVIORAL: Parole Supervision and Case Management,"National Development and Research Institutes, Inc.",National Institute on Drug Abuse (NIDA),MALE,"ADULT, OLDER_ADULT",610,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2005-08,2010-04,"Arrowhead Correctional Facility, Caqon City, Colorado, 81215 0300, United States|San Carlos Correctional Facility, Pueblo, Colorado, 81002, United States|Sterling Correctional Facility, Sterling, Colorado, 80751, United States"
NCT05108649,Impact of Nicotine Messaging on Beliefs and Behavior,https://clinicaltrials.gov/study/NCT05108649,COMPLETED,NO,Smoking Behaviors|Cigarette Smoking,OTHER: Nicotine Messaging|OTHER: Cigarette Condition,Andrew Strasser,Food and Drug Administration (FDA)|National Institute on Drug Abuse (NIDA)|Rutgers University,ALL,"ADULT, OLDER_ADULT",74,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2022-03-02,2024-06-20,"Center for Interdisciplinary Research for Nicotine Addiction, Philadelphia, Pennsylvania, 19104, United States"
NCT06646692,Mindful Self-Compassion to Address PTSD and Substance Use in Unhoused Women,https://clinicaltrials.gov/study/NCT06646692,RECRUITING,NO,Posttraumatic Stress Disorder (PTSD)|Anxiety|Depression - Major Depressive Disorder,BEHAVIORAL: Mindful Self Compassion|BEHAVIORAL: Treatment as Usual (TAU),"University of California, Los Angeles",,FEMALE,"ADULT, OLDER_ADULT",202,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-05-05,2025-01-31,"Prototypes, Pomona, California, 91767, United States"
NCT04584294,Patient-Centered Reproductive Decision Support Tool for Women Veterans,https://clinicaltrials.gov/study/NCT04584294,ACTIVE_NOT_RECRUITING,NO,Contraception|Contraception Behavior|Prepregnancy Health|Reproductive Health,BEHAVIORAL: MyPath Web-Based Informational and Decision Support Tool,VA Office of Research and Development,"Kaiser Permanente|University of California, San Francisco",FEMALE,ADULT,391,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-03-01,2025-09-30,"VA San Diego Healthcare System, San Diego, CA, San Diego, California, 92161, United States|Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, 80045, United States|Orlando VA Medical Center, Orlando, FL, Orlando, Florida, 32803, United States|Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, 30033, United States|Durham VA Medical Center, Durham, NC, Durham, North Carolina, 27705, United States|VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania, 15240, United States|El Paso VA Health Care System, El Paso, TX, El Paso, Texas, 79930-4211, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, 77030, United States|South Texas Health Care System, San Antonio, TX, San Antonio, Texas, 78229-4404, United States|Central Texas Veterans Health Care System, Temple, TX, Temple, Texas, 76504-7451, United States|VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, 84148-0001, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, 98108-1532, United States"
NCT05838378,Cigarillo Warnings Image Sorting Study,https://clinicaltrials.gov/study/NCT05838378,RECRUITING,NO,"Smoking, Cigar",OTHER: Package image sorting with pictorial warnings|OTHER: Package image sorting with Surgeon General text-only warnings|OTHER: Package image sorting with FDA text-only warnings,Boston University,National Cancer Institute (NCI)|Wake Forest University Health Sciences|Brown University,ALL,ADULT,900,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2025-01-14,2025-04,"Boston University School of Public Health, study online, Boston, Massachusetts, 02118, United States"
NCT03893565,"Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis",https://clinicaltrials.gov/study/NCT03893565,TERMINATED,YES,"Colitis, Ulcerative",DRUG: GSK2831781 - Double Blind Phase|DRUG: Placebo|DRUG: GSK2831781 - Open Label phase,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",104,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-05-06,2021-05-17,"GSK Investigational Site, Northridge, California, 91324, United States|GSK Investigational Site, Rialto, California, 92337, United States|GSK Investigational Site, New York, New York, 10065, United States|GSK Investigational Site, San Antonio, Texas, 78229, United States|GSK Investigational Site, Sofia, 1612, Bulgaria|GSK Investigational Site, Brno, 63600, Czechia|GSK Investigational Site, Olomouc, 77900, Czechia|GSK Investigational Site, Slany, 274 01, Czechia|GSK Investigational Site, Tallinn, 10117, Estonia|GSK Investigational Site, Tallinn, 10617, Estonia|GSK Investigational Site, Grenoble Cedex 9, 38043, France|GSK Investigational Site, Nice Cedex 3, 06202, France|GSK Investigational Site, Saint-Priest en Jarez, 42270, France|GSK Investigational Site, Toulouse, 31059, France|GSK Investigational Site, Vandoeuvre les Nancy, 54511, France|GSK Investigational Site, Jaipur, 302001, India|GSK Investigational Site, Ludhiana, 141001, India|GSK Investigational Site, Nagpur, 440010, India|GSK Investigational Site, Rajkot, 360005, India|GSK Investigational Site, Varanasi, 221005, India|GSK Investigational Site, Osaka, 530-0011, Japan|GSK Investigational Site, Amsterdam, 1105 AZ, Netherlands|GSK Investigational Site, Bydgoszcz, 85-168, Poland|GSK Investigational Site, Elblag, 82-300, Poland|GSK Investigational Site, Kamieniec Zabkowicki, 57-230, Poland|GSK Investigational Site, Katowice, 40-659, Poland|GSK Investigational Site, Knurow, 44-190, Poland|GSK Investigational Site, Krakow, 31-009, Poland|GSK Investigational Site, Krakow, 31-501, Poland|GSK Investigational Site, Lodz, 90-302, Poland|GSK Investigational Site, Rzeszow, 35-326, Poland|GSK Investigational Site, Sopot, 81-756, Poland|GSK Investigational Site, Staszow, 28-200, Poland|GSK Investigational Site, Torun, 87-100, Poland|GSK Investigational Site, Warsaw, 03-340, Poland|GSK Investigational Site, Wroclaw, 50-449, Poland|GSK Investigational Site, Zamosc, 22-400, Poland|GSK Investigational Site, Krasnoyarsk, 660022, Russian Federation|GSK Investigational Site, Nizhniy Novgorod, 603126, Russian Federation|GSK Investigational Site, Novosibirsk, 630005, Russian Federation|GSK Investigational Site, Saint Petersburg, 197022, Russian Federation|GSK Investigational Site, Samara, 443011, Russian Federation|GSK Investigational Site, Saratov, 410053, Russian Federation|GSK Investigational Site, St.Petersburg, 195257, Russian Federation|GSK Investigational Site, Zrenjanin, 23000, Serbia|GSK Investigational Site, Presov, 080 01, Slovakia|GSK Investigational Site, Port Elizabeth, Eastern Cape, 6001, South Africa|GSK Investigational Site, Bloemfontein, 9301, South Africa|GSK Investigational Site, Gauteng, 1619, South Africa|GSK Investigational Site, Pretoria, 0002, South Africa|GSK Investigational Site, Kharkiv, 61037, Ukraine|GSK Investigational Site, Kiev, 02000, Ukraine|GSK Investigational Site, Lviv, 79059, Ukraine|GSK Investigational Site, Odessa, 65025, Ukraine|GSK Investigational Site, Vinnytsia, 21009, Ukraine|GSK Investigational Site, Vinnytsia, 21018, Ukraine|GSK Investigational Site, Zaporizhzhia, 69050, Ukraine|GSK Investigational Site, Zaporizhzhya, 69065, Ukraine|GSK Investigational Site, Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom|GSK Investigational Site, Headington, Oxfordshire, OX3 9DU, United Kingdom|GSK Investigational Site, London, E11 1NR, United Kingdom"
NCT04038021,Phosphatidylethanol-Based Contingency Management for Housing,https://clinicaltrials.gov/study/NCT04038021,COMPLETED,NO,Alcohol Use Disorder,BEHAVIORAL: Phosphatidylethanol-based Contingency Management|BEHAVIORAL: Non-Contingent Control,Washington State University,National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"ADULT, OLDER_ADULT",17,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-13,2022-10-27,"Catholic Charities of Eastern Washington, Spokane, Washington, 99202, United States"
NCT05772221,The Role of Social Determinants in Cardiovascular Health and Vascular Function,https://clinicaltrials.gov/study/NCT05772221,RECRUITING,NO,Social Determinants of Health|Major Depressive Disorder|Cardiovascular Diseases,OTHER: Screening,Baylor Research Institute,The University of Texas at Arlington,ALL,"ADULT, OLDER_ADULT",100,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2023-06-29,2023-12-31,"Baylor Scott & White Family Health Center at Juanita J. Craft Recreation Center, Dallas, Texas, 75210, United States"
NCT04081415,"Longitudinal Study of the Intestinal, Cutaneous and Salivary Microbiota in Children With Food-induced Enterocolitis Syndrome (SEIPA)",https://clinicaltrials.gov/study/NCT04081415,UNKNOWN,NO,FPIES,,Assistance Publique - Hôpitaux de Paris,,ALL,"CHILD, ADULT",25,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-12-26,2024-04,"Trousseau Hospital, Service : Nutrition et Gastroentérologie Pédiatrique, Paris, France"
NCT03359473,Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD),https://clinicaltrials.gov/study/NCT03359473,COMPLETED,YES,Cachexia,DRUG: GSK2881078|DRUG: Matching Placebo,GlaxoSmithKline,Parexel,ALL,"ADULT, OLDER_ADULT",97,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-02-28,2019-11-19,"GSK Investigational Site, Torrance, California, 90502, United States|GSK Investigational Site, Jacksonville, Florida, 32216, United States|GSK Investigational Site, High Point, North Carolina, 27262, United States|GSK Investigational Site, Philadelphia, Pennsylvania, 19140, United States|GSK Investigational Site, Spartanburg, South Carolina, 29303, United States|GSK Investigational Site, Frankfurt, Hessen, 60596, Germany|GSK Investigational Site, Grosshansdorf, Schleswig-Holstein, 22927, Germany|GSK Investigational Site, Leicester, Leicestershire, LE3 9QP, United Kingdom|GSK Investigational Site, Harefield, Middlesex, UB9 6JH, United Kingdom|GSK Investigational Site, London, Greater London, SE1 7EH, United Kingdom|GSK Investigational Site, London, SW3 6HP, United Kingdom"
NCT02426957,Brief Alcohol Intervention for Adolescents Who Have Attempted Suicide,https://clinicaltrials.gov/study/NCT02426957,COMPLETED,NO,Suicide|Alcohol Drinking,BEHAVIORAL: motivational enhancement therapy,Boston Children's Hospital,American Foundation for Suicide Prevention,ALL,CHILD,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2014-10,2018-05,"Boston Children's Hospital, Boston, Massachusetts, 02115, United States"
NCT04602494,Varenicline For Nicotine Vaping Cessation In Non Smoker Vaper Adolescents,https://clinicaltrials.gov/study/NCT04602494,TERMINATED,YES,Vaping|Nicotine Dependence,DRUG: Varenicline|DRUG: Placebo,Massachusetts General Hospital,National Institute on Drug Abuse (NIDA),ALL,ADULT,5,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-18,2022-06-27,"Center for Addiction Medicine, Boston, Massachusetts, 02114, United States"
NCT05569915,Project QueST 2023: Queer Survivors of Trauma,https://clinicaltrials.gov/study/NCT05569915,ACTIVE_NOT_RECRUITING,NO,"Stress Disorders, Post-Traumatic|Drinking Heavy",BEHAVIORAL: Trauma Expressive Writing|BEHAVIORAL: Stigma Expressive Writing|BEHAVIORAL: Control,Syracuse University,Yale University|Massachusetts General Hospital,ALL,"ADULT, OLDER_ADULT",131,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-06-01,2024-11-30,"Syracuse University, Syracuse, New York, 13244, United States"
NCT02941926,Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC,https://clinicaltrials.gov/study/NCT02941926,COMPLETED,YES,Breast Cancer,DRUG: Ribociclib|DRUG: Letrozole|DRUG: Goserelin|DRUG: Leuprolide,Novartis Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",3246,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-11-30,2022-11-09,"Alaska Cancer Research and Education Center, Anchorage, Alaska, 99508, United States|Ironwood Cancer and Research Centers, Chandler, Arizona, 85224, United States|Arizona Oncology Associates, Phoenix, Arizona, 85016, United States|Arizona Oncology Associates Arizona Oncology Assoc. (2), Tucson, Arizona, 85745, United States|Highlands Oncology Group, Fayetteville, Arkansas, 72703, United States|Beverly Hills Cancer Center, Beverly Hills, California, 90211, United States|Pacific Shores Medical Group SC, Long Beach, California, 90813, United States|USC Norris Cancer Center, Los Angeles, California, 90033, United States|University of California Irvine UC Irvine (11), Orange, California, 92868, United States|Ventura County Hematology and Oncology, Oxnard, California, 93030, United States|PCR Oncology, Pismo Beach, California, 93449, United States|California Pacific Medical Center Onc Dept, San Francisco, California, 94120-7999, United States|Centura Health Research Center Centura Health Research Center, Denver, Colorado, 80210, United States|Poudre Valley Hospital Poudre Valley Health System, Fort Collins, Colorado, 80528, United States|Valley View Hospital Cancer Center, Glenwood Springs, Colorado, 81601, United States|Florida Cancer Research Institute Dept of Oncology, Davie, Florida, 33328, United States|Foundation for Sickle Cell Disease Research, Hollywood, Florida, 33021, United States|Watson Clinic Center for Research 1730 Location, Lakeland, Florida, 33805, United States|Mid Florida Hematology and Onc Ctr, Orange, Florida, 32763, United States|Summit Cancer Care Summit Cancer Care (SC), Savannah, Georgia, 31405, United States|John D Archbold Memorial Hospital John D. Archbold Mem Hosp (4), Thomasville, Georgia, 31792, United States|Saint Alphonsus Regional Medical Center, Boise, Idaho, 83706, United States|Stroger Cook County Hospital Division of Hematology & Onc, Chicago, Illinois, 60612, United States|Joliet Oncology-Hematology Associates Presence Cancer Center, Joliet, Illinois, 60435, United States|Mid Illinois Hematology Oncology Mid Illinois Hema/Onc (3), Normal, Illinois, 61761, United States|Alpha Med Physician Group, LLC, Tinley Park, Illinois, 60487, United States|Indian Univ Health Goshen Center forCancer SC, Goshen, Indiana, 46526, United States|Northwest Oncology, Munster, Indiana, 46321, United States|June E. Nylan Cancer Center, Sioux City, Iowa, 51101, United States|University of Kansas Medical Center University of Kansas Med Ctr 9, Kansas City, Kansas, 66160-7330, United States|Sarah Cannon at Overland Park Regional Medical Center, Overland Park, Kansas, 66209, United States|John Ochsner Heart and Vascular Institute Clinical Trials, New Orleans, Louisiana, 70121, United States|Northern Light Mercy Hospital SC, Portland, Maine, 04102, United States|Greater Baltimore Medical Center Cancer Center Greater Baltimore Medical Ctr, Baltimore, Maryland, 21204-6831, United States|Maryland Oncology Hematology P A Columbia, Rockville, Maryland, 20850, United States|Kaiser Permanente, Rockville, Maryland, 20879, United States|Medical Faculty Assc Inc Medical Faculty Assc., Inc. (2, Washington DC, Maryland, 20037, United States|Jackson Oncology Associates, Jackson, Mississippi, 39202, United States|Nebraska Hematology-Oncology, P.C., Lincoln, Nebraska, 68506, United States|Nebraska Cancer Specialists Oncology Hematology West, Omaha, Nebraska, 68154, United States|Comprehensive Cancer Centers of Nevada CCC of Nevada Henderson (4), Henderson, Nevada, 89052, United States|Trinitas Comprehensive Cancer Center, Elizabeth, New Jersey, 07207, United States|Englewood Health, Englewood, New Jersey, 07631, United States|The Valley Hospital / Luckow Pavillion, Paramus, New Jersey, 07652, United States|Somerset Hematology Oncology Associates Somerset Hematolgy Onc -MI, Somerset, New Jersey, 08873, United States|New Mexico Cancer Care Alliance ., Albuquerque, New Mexico, 87106, United States|San Juan Oncology Associates, Farmington, New Mexico, 87401, United States|Eastchester Center for Cancer Care, Bronx, New York, 10469, United States|Clinical Research Alliance, Lake Success, New York, 11042, United States|Oncology Speciialists of Charlotte, Charlotte, North Carolina, 28207, United States|Aultman Cancer Center Main Centre, Canton, Ohio, 44710, United States|The Christ Hospital Cancer Center Research Program Linder Research Center, Cincinnati, Ohio, 45219, United States|University Hospitals of Cleveland Seidman Cancer Center Cleveland Medical Center, Cleveland, Ohio, 44106, United States|Cleveland Clinic Foundation Cleveland Clinic (5), Cleveland, Ohio, 44195, United States|Dayton Physicians, Kettering, Ohio, 45409, United States|Oklahoma Cancer Specialists and Research Institute SC-2, Tulsa, Oklahoma, 74136, United States|Oregon Health Sciences University SC-5, Portland, Oregon, 97239, United States|McLeod Center for Cancer Treatment and Research, Florence, South Carolina, 29506, United States|Carolina Blood and Cancer Care of South Carolina, Rock Hill, South Carolina, 29732, United States|Millennium Research Clin Develop Millennium Oncology - FL, Houston, Texas, 77090, United States|Mays Cancer Ctr Uthsa Mdacc, San Antonio, Texas, 78229, United States|Hope Cancer Center of East Texas, Tyler, Texas, 75701, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|PeaceHealth St Joseph Medical Center, Bellingham, Washington, 98225, United States|Providence Regional Medical Centre of Everett, Everett, Washington, 98201, United States|Kadlec Clinic Hematology and Onco, Kennewick, Washington, 99336, United States|Valley Medical Center Research Valley Medical Center, Renton, Washington, 98055, United States|Virginia Mason Medical Center-Oncology SC, Seattle, Washington, 98101, United States|Northwest Medical Specialties Dept.ofNW Med. Specialties, Tacoma, Washington, 98405, United States|Columbia St Mary s Hospital of Milwaukee St. Mary's Hospital Ozaukee, Milwaukee, Wisconsin, 53211, United States|Cheyenne Regional Medical Center Cheyenne Regional Med Ctr (3), Cheyenne, Wyoming, 82001, United States|Novartis Investigative Site, Caba, Buenos Aires, C1125ABD, Argentina|Novartis Investigative Site, Caba, Buenos Aires, C1426ANZ, Argentina|Novartis Investigative Site, Rosario, Santa Fe, S2000KZE, Argentina|Novartis Investigative Site, San Miguel De Tucuman, Tucuman, T4000IAK, Argentina|Novartis Investigative Site, La Rioja, 5300, Argentina|Novartis Investigative Site, Innsbruck, Tyrol, 6020, Austria|Novartis Investigative Site, Graz, 8036, Austria|Novartis Investigative Site, Leoben, A 8700, Austria|Novartis Investigative Site, Rankweil, A-6830, Austria|Novartis Investigative Site, Salzburg, 5020, Austria|Novartis Investigative Site, Vienna, 1090, Austria|Novartis Investigative Site, Vienna, A 1090, Austria|Novartis Investigative Site, Wien, A-1130, Austria|Novartis Investigative Site, Sint Niklaas, Oost Vlaanderen, 9100, Belgium|Novartis Investigative Site, Antwerp, 2020, Belgium|Novartis Investigative Site, Bonheiden, 2820, Belgium|Novartis Investigative Site, Brugge, 8000, Belgium|Novartis Investigative Site, Brussels, BE-B-1200, Belgium|Novartis Investigative Site, Brussel, 1090, Belgium|Novartis Investigative Site, Bruxelles, 1000, Belgium|Novartis Investigative Site, Charleroi, 6000, Belgium|Novartis Investigative Site, Genk, 3600, Belgium|Novartis Investigative Site, Gent, 9000, Belgium|Novartis Investigative Site, Hasselt, 3500, Belgium|Novartis Investigative Site, Kortrijk, 8500, Belgium|Novartis Investigative Site, Leuven, 3000, Belgium|Novartis Investigative Site, Liege, 4000, Belgium|Novartis Investigative Site, Luxembourg, 1210, Belgium|Novartis Investigative Site, Mons, 7000, Belgium|Novartis Investigative Site, Namur, 5000, Belgium|Novartis Investigative Site, Roeselare, 8800, Belgium|Novartis Investigative Site, Verviers, 4800, Belgium|Novartis Investigative Site, Wilrijk, 2610, Belgium|Novartis Investigative Site, Gabrovo, 5300, Bulgaria|Novartis Investigative Site, Plovdiv, 4004, Bulgaria|Novartis Investigative Site, Sofia, 1303, Bulgaria|Novartis Investigative Site, Sofia, 1527, Bulgaria|Novartis Investigative Site, Sofia, 1606, Bulgaria|Novartis Investigative Site, Sofia, 1756, Bulgaria|Novartis Investigative Site, Calgary, Alberta, T2N 4N2, Canada|Novartis Investigative Site, Edmonton, Alberta, T6G 1Z2, Canada|Novartis Investigative Site, Kelowna, British Columbia, V1Y 5L3, Canada|Novartis Investigative Site, Surrey, British Columbia, V3V 1Z2, Canada|Novartis Investigative Site, Vancouver, British Columbia, V5Z 4E6, Canada|Novartis Investigative Site, Winnipeg, Manitoba, R3E 0V9, Canada|Novartis Investigative Site, Moncton, New Brunswick, E1C 6Z8, Canada|Novartis Investigative Site, Halifax, Nova Scotia, B3H 2Y9, Canada|Novartis Investigative Site, Barrie, Ontario, L4M 6M2, Canada|Novartis Investigative Site, Cambridge, Ontario, N1R 3G2, Canada|Novartis Investigative Site, Hamilton, Ontario, L8V 5C2, Canada|Novartis Investigative Site, Kingston, Ontario, K7L 5P9, Canada|Novartis Investigative Site, Kitchener, Ontario, N2G 1G3, Canada|Novartis Investigative Site, London, Ontario, N6A 4G4, Canada|Novartis Investigative Site, Newmarket, Ontario, L3Y 2P9, Canada|Novartis Investigative Site, North York, Ontario, M2K1E1, Canada|Novartis Investigative Site, Oshawa, Ontario, L1G 2B9, Canada|Novartis Investigative Site, Ottawa, Ontario, KIH 7W9, Canada|Novartis Investigative Site, Sault Ste Marie, Ontario, P6B 0A8, Canada|Novartis Investigative Site, Sudbury, Ontario, P3E 5J1, Canada|Novartis Investigative Site, Toronto, Ontario, M3M 0B2, Canada|Novartis Investigative Site, Toronto, Ontario, M4N 3M5, Canada|Novartis Investigative Site, Toronto, Ontario, M5B 1W8, Canada|Novartis Investigative Site, Greenfield Park, Quebec, J4V 2H1, Canada|Novartis Investigative Site, Laval, Quebec, H7M 3L9, Canada|Novartis Investigative Site, Montreal, Quebec, H3T 1E2, Canada|Novartis Investigative Site, Montreal, Quebec, H3T 1M5, Canada|Novartis Investigative Site, Montreal, Quebec, H4J 1C5, Canada|Novartis Investigative Site, Sherbrooke, Quebec, J1H 5N4, Canada|Novartis Investigative Site, Regina, Saskatchewan, S4T 7T1, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, S7N 4H4, Canada|Novartis Investigative Site, Quebec, G1S 4L8, Canada|Novartis Investigative Site, Santiago, 8420383, Chile|Novartis Investigative Site, Brno, Czech Republic, 656 53, Czechia|Novartis Investigative Site, Liberec, Czech Republic, 46063, Czechia|Novartis Investigative Site, Prague 8, Czech Republic, 180 00, Czechia|Novartis Investigative Site, Zlin, Czech Republic, 762 75, Czechia|Novartis Investigative Site, Hradec Kralove, CZE, 500 05, Czechia|Novartis Investigative Site, Olomouc, CZE, 779 00, Czechia|Novartis Investigative Site, Brno, 625 00, Czechia|Novartis Investigative Site, Ceske Budejovice, 370 87, Czechia|Novartis Investigative Site, Pardubice, 532 03, Czechia|Novartis Investigative Site, Prague 5, 150 00, Czechia|Novartis Investigative Site, Praha 10, 100 34, Czechia|Novartis Investigative Site, Praha 4, 140 59, Czechia|Novartis Investigative Site, Praha, 12808, Czechia|Novartis Investigative Site, Copenhagen, DK-2100, Denmark|Novartis Investigative Site, Vejle, 7100, Denmark|Novartis Investigative Site, Helsinki, 00029, Finland|Novartis Investigative Site, Oulu, FIN-90220, Finland|Novartis Investigative Site, Tampere, FIN-33521, Finland|Novartis Investigative Site, Nice Cedex 2, Alpes Maritimes, 06189, France|Novartis Investigative Site, Dijon, Cote D Or, 21034, France|Novartis Investigative Site, Limoges, Haute Vienne, 87000, France|Novartis Investigative Site, Saint-Cloud, Hauts De Seine, 92210, France|Novartis Investigative Site, Tours 9, Indre Et Loire, 37044, France|Novartis Investigative Site, Reims, Marne, 51056, France|Novartis Investigative Site, Albi, 81000, France|Novartis Investigative Site, Angers Cedex 02, 49055, France|Novartis Investigative Site, Avignon, 84082, France|Novartis Investigative Site, Besancon Cedex, 25030, France|Novartis Investigative Site, Bobigny Cedex, 93009, France|Novartis Investigative Site, Bordeaux Cedex, 33000, France|Novartis Investigative Site, Bordeaux, 33076, France|Novartis Investigative Site, Caen, 14021, France|Novartis Investigative Site, Clermont-Ferrand, 63011, France|Novartis Investigative Site, Colmar Cedex, 68024, France|Novartis Investigative Site, Corbeil Essonnes, 91100, France|Novartis Investigative Site, Creteil, 94010, France|Novartis Investigative Site, Le Mans Cedex, 72015, France|Novartis Investigative Site, Lille Cedex, 59020, France|Novartis Investigative Site, Limoges, 87000, France|Novartis Investigative Site, Lyon Cedex 08, 69373, France|Novartis Investigative Site, Lyon, 69373, France|Novartis Investigative Site, Marseille, 13273, France|Novartis Investigative Site, Mont de Marsan cedex, 40024, France|Novartis Investigative Site, Montpellier, 34070, France|Novartis Investigative Site, Montpellier, 34298, France|Novartis Investigative Site, Nancy, 54000, France|Novartis Investigative Site, Nantes Cedex, 44277, France|Novartis Investigative Site, Paris 10, 75475, France|Novartis Investigative Site, Paris 13, 75651, France|Novartis Investigative Site, Paris, 75012, France|Novartis Investigative Site, Paris, 75231, France|Novartis Investigative Site, Paris, 75970, France|Novartis Investigative Site, Perigueux Cedex, 24004, France|Novartis Investigative Site, Pierre Benite, 69495, France|Novartis Investigative Site, Plerin Sur Mer, 22190, France|Novartis Investigative Site, Reims, 51100, France|Novartis Investigative Site, Rouen, 76038, France|Novartis Investigative Site, Saint Herblain, 44805, France|Novartis Investigative Site, Strasbourg Cedex, 67091, France|Novartis Investigative Site, Strasbourg, 67010, France|Novartis Investigative Site, Toulon La Seyne Sur Mer, 83056, France|Novartis Investigative Site, Troyes, 10003, France|Novartis Investigative Site, Vandoeuvre-les-Nancy, 54519, France|Novartis Investigative Site, Ioannina, GR, 455 00, Greece|Novartis Investigative Site, Thessaloniki, GR, 54645, Greece|Novartis Investigative Site, Athens, 115 28, Greece|Novartis Investigative Site, Athens, GR 115 22, Greece|Novartis Investigative Site, Athens, GR14564, Greece|Novartis Investigative Site, Patras, 265 00, Greece|Novartis Investigative Site, Thessaloniki, 540 07, Greece|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Pokfulam, Hong Kong|Novartis Investigative Site, Budapest, 1134, Hungary|Novartis Investigative Site, Budapest, H 1122, Hungary|Novartis Investigative Site, Budapest, H-1032, Hungary|Novartis Investigative Site, Debrecen, 4032, Hungary|Novartis Investigative Site, Szeged, 6725, Hungary|Novartis Investigative Site, Hyderabad, Andhra Pradesh, 500 034, India|Novartis Investigative Site, Tamil Nadu, Chennai, 600035, India|Novartis Investigative Site, New Delhi, Delhi, 110092, India|Novartis Investigative Site, Admedabad, Gujarat, 380060, India|Novartis Investigative Site, Bangalore, Karnataka, 560027, India|Novartis Investigative Site, Nashik, Maharashtra, 422 004, India|Novartis Investigative Site, Pune, Maharashtra, 411013, India|Novartis Investigative Site, Jaipur, Rajasthan, 302017, India|Novartis Investigative Site, Vellore, Tamil Nadu, 632 004, India|Novartis Investigative Site, Kolkata, West Bengal, 700160, India|Novartis Investigative Site, Delhi, 110 085, India|Novartis Investigative Site, Beer-Sheva, 8457108, Israel|Novartis Investigative Site, Haifa, 3109601, Israel|Novartis Investigative Site, Jerusalem, 9112001, Israel|Novartis Investigative Site, Petach Tikva, 4941492, Israel|Novartis Investigative Site, Ramat Gan, 52621, Israel|Novartis Investigative Site, Tel Aviv, 6423906, Israel|Novartis Investigative Site, Alessandria, AL, 15100, Italy|Novartis Investigative Site, Ancona, AN, 60126, Italy|Novartis Investigative Site, L'Aquila, AQ, 67100, Italy|Novartis Investigative Site, Arezzo, AR, 52100, Italy|Novartis Investigative Site, Asti, AT, 14100, Italy|Novartis Investigative Site, Avellino, AV, 83100, Italy|Novartis Investigative Site, Bari, BA, 70124, Italy|Novartis Investigative Site, Bergamo, BG, 24127, Italy|Novartis Investigative Site, Treviglio, BG, 24047, Italy|Novartis Investigative Site, Benevento, BN, 82100, Italy|Novartis Investigative Site, Bologna, BO, 40138, Italy|Novartis Investigative Site, Bologna, BO, 40139, Italy|Novartis Investigative Site, Brindisi, BR, 72100, Italy|Novartis Investigative Site, Brescia, BS, 25123, Italy|Novartis Investigative Site, Brescia, BS, 25124, Italy|Novartis Investigative Site, Monserrato, CA, 09042, Italy|Novartis Investigative Site, Cuneo, CN, 12100, Italy|Novartis Investigative Site, Cremona, CR, 26100, Italy|Novartis Investigative Site, Catania, CT, 95124, Italy|Novartis Investigative Site, Cona, FE, 44100, Italy|Novartis Investigative Site, San Giovanni Rotondo, FG, 71013, Italy|Novartis Investigative Site, Firenze, FI, 50134, Italy|Novartis Investigative Site, Genova, GE, 16132, Italy|Novartis Investigative Site, Grosseto, GR, 58100, Italy|Novartis Investigative Site, Lecco, LC, 23900, Italy|Novartis Investigative Site, Livorno, LI, 57124, Italy|Novartis Investigative Site, Lucca, LU, 55100, Italy|Novartis Investigative Site, Monza, MB, 20900, Italy|Novartis Investigative Site, Macerata, MC, 62100, Italy|Novartis Investigative Site, Messina, ME, 98158, Italy|Novartis Investigative Site, Taormina, ME, 98039, Italy|Novartis Investigative Site, Milano, MI, 20121, Italy|Novartis Investigative Site, Milano, MI, 20132, Italy|Novartis Investigative Site, Milano, MI, 20133, Italy|Novartis Investigative Site, Milano, MI, 20141, Italy|Novartis Investigative Site, Milano, MI, 20162, Italy|Novartis Investigative Site, Rozzano, MI, 20089, Italy|Novartis Investigative Site, Modena, MO, 41124, Italy|Novartis Investigative Site, Nuoro, NU, 08100, Italy|Novartis Investigative Site, Palermo, PA, 90127, Italy|Novartis Investigative Site, Palermo, PA, 90146, Italy|Novartis Investigative Site, Padova, PD, 35100, Italy|Novartis Investigative Site, Pisa, PI, 56126, Italy|Novartis Investigative Site, Aviano, PN, 33081, Italy|Novartis Investigative Site, Prato, PO, 59100, Italy|Novartis Investigative Site, Parma, PR, 43100, Italy|Novartis Investigative Site, Fano, PU, 61032, Italy|Novartis Investigative Site, Pavia, PV, 27100, Italy|Novartis Investigative Site, Reggio Calabria, RC, 89124, Italy|Novartis Investigative Site, Reggio Emilia, RE, 42123, Italy|Novartis Investigative Site, Roma, RM, 00128, Italy|Novartis Investigative Site, Roma, RM, 00152, Italy|Novartis Investigative Site, Roma, RM, 00161, Italy|Novartis Investigative Site, Roma, RM, 00168, Italy|Novartis Investigative Site, Roma, RM, 00189, Italy|Novartis Investigative Site, Salerno, SA, 84131, Italy|Novartis Investigative Site, Siena, SI, 53100, Italy|Novartis Investigative Site, Sassari, SS, 07100, Italy|Novartis Investigative Site, Savona, SV, 17100, Italy|Novartis Investigative Site, Trento, TN, 38100, Italy|Novartis Investigative Site, Candiolo, TO, 10060, Italy|Novartis Investigative Site, Torino, TO, 10126, Italy|Novartis Investigative Site, Terni, TR, 05100, Italy|Novartis Investigative Site, Udine, UD, 33100, Italy|Novartis Investigative Site, Saronno, VA, 21047, Italy|Novartis Investigative Site, Mirano, VE, 30035, Italy|Novartis Investigative Site, Negrar, VR, 37024, Italy|Novartis Investigative Site, Verona, VR, 37126, Italy|Novartis Investigative Site, Viterbo, VT, 01100, Italy|Novartis Investigative Site, Napoli, 80131, Italy|Novartis Investigative Site, Napoli, 80138, Italy|Novartis Investigative Site, Novara, 28100, Italy|Novartis Investigative Site, Amman, 11941, Jordan|Novartis Investigative Site, Ashrafieh, 166830, Lebanon|Novartis Investigative Site, Beirut, 10999, Lebanon|Novartis Investigative Site, Saida, 652, Lebanon|Novartis Investigative Site, Tanjong Bungah, Penang, 11200, Malaysia|Novartis Investigative Site, Petaling Jaya, Selangor, 46050, Malaysia|Novartis Investigative Site, Kuala Lumpur, Wilayah Persekutuan, 50586, Malaysia|Novartis Investigative Site, Putrajaya, Wilayah Persekutuan, 62250, Malaysia|Novartis Investigative Site, Kuala Lumpur, 59100, Malaysia|Novartis Investigative Site, Monterrey, Nuevo Leon, 64710, Mexico|Novartis Investigative Site, Ciudad de Mexico, 04700, Mexico|Novartis Investigative Site, Mexico City, 01120, Mexico|Novartis Investigative Site, Maastricht, AZ, 5800, Netherlands|Novartis Investigative Site, Venray, CE, 5801, Netherlands|Novartis Investigative Site, Apeldoorn, DZ, 7334, Netherlands|Novartis Investigative Site, Arnhem, Gelderland, 6815 AD, Netherlands|Novartis Investigative Site, Beverwijk, 1942 LE, Netherlands|Novartis Investigative Site, Breda, 4818 CK, Netherlands|Novartis Investigative Site, Delft, 2625 AD, Netherlands|Novartis Investigative Site, Den Bosch, 5223 GZ, Netherlands|Novartis Investigative Site, Den Haag, 2545 CH, Netherlands|Novartis Investigative Site, Dordrecht, 3318AT, Netherlands|Novartis Investigative Site, Ede, 6716 RP, Netherlands|Novartis Investigative Site, Eindhoven, 5623EJ, Netherlands|Novartis Investigative Site, Enschede, 7513 ER, Netherlands|Novartis Investigative Site, Goes, 4462 RA, Netherlands|Novartis Investigative Site, Groningen, 9728 NZ, Netherlands|Novartis Investigative Site, Hilversum, XZ1213, Netherlands|Novartis Investigative Site, Hoofddorp, 2134 TM, Netherlands|Novartis Investigative Site, Leeuwarden, 8934 AD, Netherlands|Novartis Investigative Site, Roermond, 6043 CV, Netherlands|Novartis Investigative Site, Rotterdam, 3079 DZ, Netherlands|Novartis Investigative Site, Sittard-Geleen, 6162 BG, Netherlands|Novartis Investigative Site, Utrecht, 3543 AZ, Netherlands|Novartis Investigative Site, Zutphen, 7207 AE, Netherlands|Novartis Investigative Site, Zwolle, 8025 AB, Netherlands|Novartis Investigative Site, Gralum, 1714, Norway|Novartis Investigative Site, Oslo, 0379, Norway|Novartis Investigative Site, Oslo, NO 0450, Norway|Novartis Investigative Site, Stavanger, NO-4068, Norway|Novartis Investigative Site, Muscat, 123, Oman|Novartis Investigative Site, Panama City, 0801, Panama|Novartis Investigative Site, Taguig City, Metro Manila, 1634, Philippines|Novartis Investigative Site, Las Pinas, 1740, Philippines|Novartis Investigative Site, San Juan City, 1500, Philippines|Novartis Investigative Site, Zory, Slaskie, 44-240, Poland|Novartis Investigative Site, Bydgoszcz, 85 796, Poland|Novartis Investigative Site, Bytom, 41-902, Poland|Novartis Investigative Site, Gdansk, 80 952, Poland|Novartis Investigative Site, Krakow, 31-501, Poland|Novartis Investigative Site, Lublin, 20 090, Poland|Novartis Investigative Site, Opole, 45-061, Poland|Novartis Investigative Site, Rzeszow, 35-021, Poland|Novartis Investigative Site, Warszawa, 02 781, Poland|Novartis Investigative Site, Wroclaw, 53 413, Poland|Novartis Investigative Site, Braga, 4710243, Portugal|Novartis Investigative Site, Guimaraes, 4835-044, Portugal|Novartis Investigative Site, Lisboa, 1400-038, Portugal|Novartis Investigative Site, Lisboa, 1500 650, Portugal|Novartis Investigative Site, Lisboa, 1649-035, Portugal|Novartis Investigative Site, Lisboa, 1998-018, Portugal|Novartis Investigative Site, Porto, 4099-001, Portugal|Novartis Investigative Site, Porto, 4200-072, Portugal|Novartis Investigative Site, Porto, 4200-319, Portugal|Novartis Investigative Site, Leningrad Region, Russia, 188663, Russian Federation|Novartis Investigative Site, Kazan, Tatarstan Republic, 420029, Russian Federation|Novartis Investigative Site, Chelyabinsk, 454087, Russian Federation|Novartis Investigative Site, Irkutsk, 664035, Russian Federation|Novartis Investigative Site, Kaluga, 248007, Russian Federation|Novartis Investigative Site, Krasnoyarsk, 660022, Russian Federation|Novartis Investigative Site, Moscow Region Istra Village, 143423, Russian Federation|Novartis Investigative Site, Moscow Rerion Balashiha, 143900, Russian Federation|Novartis Investigative Site, Moscow, 115478, Russian Federation|Novartis Investigative Site, Moscow, 125284, Russian Federation|Novartis Investigative Site, Rostov-na-Donu, 344037, Russian Federation|Novartis Investigative Site, Samara, 443031, Russian Federation|Novartis Investigative Site, St Petersburg, 197022, Russian Federation|Novartis Investigative Site, St Petersburg, 197758, Russian Federation|Novartis Investigative Site, Ufa, 450054, Russian Federation|Novartis Investigative Site, Yaroslavl, 150054, Russian Federation|Novartis Investigative Site, Dammam, 15215, Saudi Arabia|Novartis Investigative Site, Makkah, 57657, Saudi Arabia|Novartis Investigative Site, Riyadh, 11211, Saudi Arabia|Novartis Investigative Site, Riyadh, 11426, Saudi Arabia|Novartis Investigative Site, Singapore, 217562, Singapore|Novartis Investigative Site, Singapore, 258500, Singapore|Novartis Investigative Site, Singapore, 308433, Singapore|Novartis Investigative Site, Banska Bystrica, Slovak Republic, 97401, Slovakia|Novartis Investigative Site, Kosice, 04191, Slovakia|Novartis Investigative Site, Poprad, 058 01, Slovakia|Novartis Investigative Site, Ljubljana, 1000, Slovenia|Novartis Investigative Site, Maribor, 2000, Slovenia|Novartis Investigative Site, Elche, Alicante, 03203, Spain|Novartis Investigative Site, Almeria, Andalucia, 04009, Spain|Novartis Investigative Site, Cordoba, Andalucia, 14004, Spain|Novartis Investigative Site, Granada, Andalucia, 18014, Spain|Novartis Investigative Site, Huelva, Andalucia, 21005, Spain|Novartis Investigative Site, Jaen, Andalucia, 23007, Spain|Novartis Investigative Site, Malaga, Andalucia, 29010, Spain|Novartis Investigative Site, Sevilla, Andalucia, 41009, Spain|Novartis Investigative Site, Sevilla, Andalucia, 41013, Spain|Novartis Investigative Site, Sevilla, Andalucia, 41014, Spain|Novartis Investigative Site, Sabadell, Barcelona, 08208, Spain|Novartis Investigative Site, Jerez, Cadiz, 11407, Spain|Novartis Investigative Site, Toledo, Castilla La Mancha, 45071, Spain|Novartis Investigative Site, Salamanca, Castilla Y Leon, 37007, Spain|Novartis Investigative Site, Barcelona, Cataluna, 08024, Spain|Novartis Investigative Site, Lerida, Cataluna, 25198, Spain|Novartis Investigative Site, Badalona, Catalunya, 08916, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08036, Spain|Novartis Investigative Site, Girona, Catalunya, 17007, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, 08907, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, 03010, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, 03550, Spain|Novartis Investigative Site, Castellon, Comunidad Valenciana, 12002, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46009, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46010, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46014, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, 46015, Spain|Novartis Investigative Site, Badajoz, Extremadura, 06080, Spain|Novartis Investigative Site, Caceres, Extremadura, 10003, Spain|Novartis Investigative Site, La Coruna, Galicia, 15006, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, 15706, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, 07120, Spain|Novartis Investigative Site, Las Palmas De Gran Canarias, Las Palmas De Gran Canaria, 35016, Spain|Novartis Investigative Site, El Palmar, Murcia, 30120, Spain|Novartis Investigative Site, Pamplona, Navarra, 31008, Spain|Novartis Investigative Site, Bilbao, Pais Vasco, 48013, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, 20080, Spain|Novartis Investigative Site, Vigo, Pontevedra, 36212, Spain|Novartis Investigative Site, La Laguna, Santa Cruz De Tenerife, 38320, Spain|Novartis Investigative Site, Reus, Tarragona, 43201, Spain|Novartis Investigative Site, Barcelona, 08041, Spain|Novartis Investigative Site, Burgos, 09006, Spain|Novartis Investigative Site, Granollers, 08402, Spain|Novartis Investigative Site, Madrid, 28006, Spain|Novartis Investigative Site, Madrid, 28009, Spain|Novartis Investigative Site, Madrid, 28034, Spain|Novartis Investigative Site, Madrid, 28040, Spain|Novartis Investigative Site, Madrid, 28041, Spain|Novartis Investigative Site, Madrid, 28046, Spain|Novartis Investigative Site, Madrid, 28222, Spain|Novartis Investigative Site, Murcia, 30008, Spain|Novartis Investigative Site, Valencia, 46026, Spain|Novartis Investigative Site, Zaragoza, 50009, Spain|Novartis Investigative Site, Gothenburg, SE-431 45, Sweden|Novartis Investigative Site, Orebro, 701 85, Sweden|Novartis Investigative Site, Stockholm, SE-118 83, Sweden|Novartis Investigative Site, Uppsala, 751 85, Sweden|Novartis Investigative Site, Vaxjo, SE-351 85, Sweden|Novartis Investigative Site, Taichung, 40447, Taiwan|Novartis Investigative Site, Tainan, 70403, Taiwan|Novartis Investigative Site, Taipei, 114, Taiwan|Novartis Investigative Site, Songkhla, Hat Yai, 90110, Thailand|Novartis Investigative Site, Khon Kaen, THA, 40002, Thailand|Novartis Investigative Site, Bangkok, 10400, Thailand|Novartis Investigative Site, Chiang Mai, 50200, Thailand|Novartis Investigative Site, Peterborough, Cambridgeshire, PE3 9GZ, United Kingdom|Novartis Investigative Site, Truro, Cornwall, TR1 3LJ, United Kingdom|Novartis Investigative Site, Portsmouth, Hants, PO6 3LY, United Kingdom|Novartis Investigative Site, Maidstone, Kent, ME16 9QQ, United Kingdom|Novartis Investigative Site, York, North Yorkshire, YO31 8HE, United Kingdom|Novartis Investigative Site, Aberdeen, Scotland, AB25 2ZN, United Kingdom|Novartis Investigative Site, Ipswich, Suffolk, IP4 5PD, United Kingdom|Novartis Investigative Site, Guildford, Surrey, GU2 7XX, United Kingdom|Novartis Investigative Site, Sutton, Surrey, SM2 5PT, United Kingdom|Novartis Investigative Site, Bristol, BS2 8ED, United Kingdom|Novartis Investigative Site, Cardiff, CF14 2TL, United Kingdom|Novartis Investigative Site, East Sussex, BN2 5BE, United Kingdom|Novartis Investigative Site, Edinburgh, EH4 2XU, United Kingdom|Novartis Investigative Site, Exeter, EX2 5DW, United Kingdom|Novartis Investigative Site, Glasgow, G12 0YN, United Kingdom|Novartis Investigative Site, Leeds, LS9 7TF, United Kingdom|Novartis Investigative Site, Leicester, LE1 5WW, United Kingdom|Novartis Investigative Site, London, NW1 2PJ, United Kingdom|Novartis Investigative Site, London, SW3 6JJ, United Kingdom|Novartis Investigative Site, London, W8 6RF, United Kingdom|Novartis Investigative Site, Manchester, M20 4BX, United Kingdom|Novartis Investigative Site, Newcastle upon Tyne, NE7 7DN, United Kingdom|Novartis Investigative Site, Nottingham, NG5 1PB, United Kingdom|Novartis Investigative Site, Oxford, OX3 7LJ, United Kingdom|Novartis Investigative Site, Plymouth, PL6 8DH, United Kingdom|Novartis Investigative Site, Preston, PR2 9HT, United Kingdom|Novartis Investigative Site, Sheffield, S10 2SJ, United Kingdom|Novartis Investigative Site, Stoke-on-Trent, ST4 6QG, United Kingdom"
NCT06235333,Exploring a Lottery-promoted Gambling Disorder Screening Day Intervention,https://clinicaltrials.gov/study/NCT06235333,NOT_YET_RECRUITING,NO,Gambling Problem,BEHAVIORAL: Gambling Disorder Screening Day screener|BEHAVIORAL: Gambling Disorder Screening Day information sheet,Cambridge Health Alliance,"International Center for Responsible Gaming|Hoosier Lottery, Indiana",ALL,"ADULT, OLDER_ADULT",4500,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SCREENING,2024-03-12,2024-12-31,
NCT00358449,Intravenous Mepolizumab In Children With Eosinophilic Esophagitis,https://clinicaltrials.gov/study/NCT00358449,COMPLETED,YES,"Oesophagitis, Eosinophilic",DRUG: mepolizumab,GlaxoSmithKline,,ALL,CHILD,84,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-09-11,2008-11-25,"GSK Investigational Site, Birmingham, Alabama, 35205, United States|GSK Investigational Site, San Diego, California, 92123, United States|GSK Investigational Site, Tampa, Florida, 33613, United States|GSK Investigational Site, Atlanta, Georgia, 30322, United States|GSK Investigational Site, Springfield, Illinois, 62794, United States|GSK Investigational Site, Evansville, Indiana, 47713, United States|GSK Investigational Site, Indianapolis, Indiana, 46202, United States|GSK Investigational Site, Worcester, Massachusetts, 01655, United States|GSK Investigational Site, Southfield, Michigan, 48075, United States|GSK Investigational Site, Troy, Michigan, 48098, United States|GSK Investigational Site, Minneapolis, Minnesota, 55402, United States|GSK Investigational Site, Kansas City, Missouri, 64108, United States|GSK Investigational Site, Saint Louis, Missouri, 63104, United States|GSK Investigational Site, New York, New York, 10029, United States|GSK Investigational Site, Cincinnati, Ohio, 45229, United States|GSK Investigational Site, Sioux Falls, South Dakota, 57108, United States|GSK Investigational Site, Dallas, Texas, 75230, United States|GSK Investigational Site, Dallas, Texas, 75235, United States|GSK Investigational Site, Norfolk, Virginia, 23507, United States|GSK Investigational Site, Milwaukee, Wisconsin, 53215, United States|GSK Investigational Site, Brisbane, Queensland, 4029, Australia|GSK Investigational Site, Hamilton, Ontario, L8N 3Z5, Canada|GSK Investigational Site, Kingston, Ontario, K7L 5G2, Canada|GSK Investigational Site, London, Ontario, N6A 5W9, Canada|GSK Investigational Site, Montreal, Quebec, H3T 1C5, Canada|GSK Investigational Site, Liverpool, L12 2AP, United Kingdom|GSK Investigational Site, London, WC1N 3JH, United Kingdom|GSK Investigational Site, Sheffield, S10 2TH, United Kingdom|GSK Investigational Site, Watford, WD18 0HB, United Kingdom"
NCT05917782,A Study to Evaluate the Pharmacokinetics Similarity of CBP-201 in Healthy Adult Chinese Subjects,https://clinicaltrials.gov/study/NCT05917782,COMPLETED,NO,Healthy Adult Subjects,"BIOLOGICAL: Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)|BIOLOGICAL: Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL)|BIOLOGICAL: Reference drug (R): CBP-201 injection (vial, 150 mg/1 mL)","Suzhou Connect Biopharmaceuticals, Ltd.",,ALL,ADULT,324,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-07-18,2023-10-06,"The Second Hospital of Anhui Medical University, Hefei, Anhui, 230000, China"
NCT03525678,A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody,https://clinicaltrials.gov/study/NCT03525678,COMPLETED,YES,Multiple Myeloma,DRUG: Belantamab mafodotin frozen liquid|DRUG: Belantamab mafodotin lyophilized powder,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",221,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-06-18,2024-09-12,"GSK Investigational Site, New Haven, Connecticut, 06510, United States|GSK Investigational Site, Atlanta, Georgia, 30322, United States|GSK Investigational Site, Atlanta, Georgia, 30342, United States|GSK Investigational Site, Chicago, Illinois, 60612, United States|GSK Investigational Site, Chicago, Illinois, 60637, United States|GSK Investigational Site, Indianapolis, Indiana, 46202, United States|GSK Investigational Site, Fairway, Kansas, 66205, United States|GSK Investigational Site, Baton Rouge, Louisiana, 70121, United States|GSK Investigational Site, Baltimore, Maryland, 21201, United States|GSK Investigational Site, Boston, Massachusetts, 02215, United States|GSK Investigational Site, Rochester, Minnesota, 55905, United States|GSK Investigational Site, New York, New York, 10029, United States|GSK Investigational Site, New York, New York, 10065, United States|GSK Investigational Site, Charlotte, North Carolina, 28204, United States|GSK Investigational Site, Columbus, Ohio, 43210, United States|GSK Investigational Site, Philadelphia, Pennsylvania, 19104, United States|GSK Investigational Site, Nashville, Tennessee, 37232, United States|GSK Investigational Site, Houston, Texas, 77030, United States|GSK Investigational Site, Salt Lake City, Utah, 84112, United States|GSK Investigational Site, Seattle, Washington, 98109, United States|GSK Investigational Site, Madison, Wisconsin, 53792, United States|GSK Investigational Site, Woodville, South Australia, 5011, Australia|GSK Investigational Site, Fitzroy, Victoria, 3065, Australia|GSK Investigational Site, Melbourne, Victoria, 3004, Australia|GSK Investigational Site, Calgary, Alberta, T2N 4N2, Canada|GSK Investigational Site, Winnipeg, Manitoba, R3E 0V9, Canada|GSK Investigational Site, Toronto, Ontario, M5G 2M9, Canada|GSK Investigational Site, Lille, 59037, France|GSK Investigational Site, Nantes cedex 1, 44093, France|GSK Investigational Site, Paris, 75010, France|GSK Investigational Site, Pessac cedex, 33600, France|GSK Investigational Site, Pierre BEnite, 69495, France|GSK Investigational Site, Toulouse cedex 9, 31059, France|GSK Investigational Site, Dresden, 01307, Germany|GSK Investigational Site, Hannover, 30625, Germany|GSK Investigational Site, Koblenz, 56068, Germany|GSK Investigational Site, Schwerin, 19049, Germany|GSK Investigational Site, Tuebingen, 72076, Germany|GSK Investigational Site, Wuerzburg, 97080, Germany|GSK Investigational Site, Aviano PN, 33081, Italy|GSK Investigational Site, Parma, 43126, Italy|GSK Investigational Site, Rionero In Vulture PZ, 85028, Italy|GSK Investigational Site, Torino, 10126, Italy|GSK Investigational Site, Badalona, 08916, Spain|GSK Investigational Site, Barcelona, 08036, Spain|GSK Investigational Site, Granada, 18014, Spain|GSK Investigational Site, Madrid, 28041, Spain|GSK Investigational Site, Madrid, 28223, Spain|GSK Investigational Site, Murcia, 30008, Spain|GSK Investigational Site, PamplonaNavarra, 31008, Spain|GSK Investigational Site, Salamanca, 37007, Spain|GSK Investigational Site, Valencia, 46017, Spain|GSK Investigational Site, Birmingham, B9 5SS, United Kingdom|GSK Investigational Site, Bournemouth, BH7 7DW, United Kingdom|GSK Investigational Site, London, NW1 2BU, United Kingdom|GSK Investigational Site, Nottingham, NG5 1PB, United Kingdom|GSK Investigational Site, Oxford, OX3 7LE, United Kingdom|GSK Investigational Site, Stoke on Trent, ST4 6QG, United Kingdom|GSK Investigational Site, Sutton, SM2 5PT, United Kingdom"
NCT06360029,The LvL UP Pilot Trial,https://clinicaltrials.gov/study/NCT06360029,COMPLETED,NO,Health Behavior|Noncommunicable Diseases|Mental Health Issue|Lifestyle Risk Reduction,BEHAVIORAL: LvL UP|BEHAVIORAL: LvL UP + MI|BEHAVIORAL: Comparison,Singapore ETH Centre,ETH Zurich|National University of Singapore|Nanyang Technological University,ALL,ADULT,201,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2024-04-15,2024-08-01,"Saw Swee Hock School of Public Health, Singapore, 117549, Singapore|Singapore ETH Center, Singapore, 138602, Singapore"
NCT04368689,The Feasibility and Examination of the Effects of Floatation-based REST on a Community Sample With PTSD,https://clinicaltrials.gov/study/NCT04368689,RECRUITING,NO,Post-Traumatic Stress Disorders,OTHER: Floatation-based reduced environmental stimulation therapy,Medical College of Wisconsin,,ALL,ADULT,30,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-06-18,2025-12,"Medical College of Wisconsin, Milwaukee, Wisconsin, 53226-3548, United States"
NCT06432985,Smoking Cessation CM for Veterans With or at Risk for Cancer,https://clinicaltrials.gov/study/NCT06432985,RECRUITING,NO,Tobacco Use Disorder|Substance Use Disorder,"BEHAVIORAL: Focus Group|BEHAVIORAL: Contingency Management|BEHAVIORAL: Behavioral Counseling (Cognitive Behavioral Therapy, CBT)|BEHAVIORAL: TUD Treatment as Usual (TAU)",VA Office of Research and Development,"University of California, San Francisco",ALL,"ADULT, OLDER_ADULT",95,FED,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2024-10-01,2030-03-30,"San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, 94121-1563, United States"
NCT06265506,Virtual Incentive Treatment for Alcohol,https://clinicaltrials.gov/study/NCT06265506,RECRUITING,NO,Alcohol Use Disorder|Alcohol Drinking|Alcohol Abuse|Alcohol Dependence,BEHAVIORAL: Contingency Management|BEHAVIORAL: Computer Based Training for Cognitive Behavioral Therapy for AUD (CBT4CBT),Washington State University,The University of Texas Health Science Center at San Antonio|Weill Medical College of Cornell University|National Institute on Alcohol Abuse and Alcoholism (NIAAA),ALL,"ADULT, OLDER_ADULT",200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2024-06-18,2028-04-04,"Washington State University, Spokane, Washington, 99201, United States"
NCT03773354,Somatic Symptom and Related Disorders: A Treatment Group and Mixed-Methods Investigation,https://clinicaltrials.gov/study/NCT03773354,UNKNOWN,NO,Somatic Symptom Disorders,BEHAVIORAL: Cognitive-behavioural therapy group for individuals with somatic symptom disorders,St. Joseph's Healthcare Hamilton,,ALL,"ADULT, OLDER_ADULT",40,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-05-01,2020-02-03,
NCT04162977,Adapting Personality-Targeted Interventions for Reducing Substance Misuse and Related Outcomes in Youth in Youth Protection Services,https://clinicaltrials.gov/study/NCT04162977,COMPLETED,NO,Substance Use Disorders|Youth Protection Services|Early Intervention|Prevention|Adolescent Development,BEHAVIORAL: Personality-targeted Interventions,St. Justine's Hospital,Batshaw Youth and Family Centres,ALL,"CHILD, ADULT",62,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2019-10-02,2020-08-01,"Batshaw Youth and Family Centres, Montreal, Quebec, H9S 1X4, Canada"
NCT06704958,Augmented Momentary Personal Ecological Risk Evaluation,https://clinicaltrials.gov/study/NCT06704958,NOT_YET_RECRUITING,NO,Suicidal Ideation|Self Harm,OTHER: AMPERE EMA app,University of Washington,National Institute of Mental Health (NIMH),ALL,"CHILD, ADULT",50,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2025-01,2025-09,
NCT03970005,Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis,https://clinicaltrials.gov/study/NCT03970005,ENROLLING_BY_INVITATION,NO,Prodromal Schizophrenia,BEHAVIORAL: Step-Based Care Model,Ohio State University,Substance Abuse and Mental Health Services Administration (SAMHSA),ALL,"CHILD, ADULT",100,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-04-19,2026-09,"OSU Harding Hospital, Columbus, Ohio, 43210, United States"
NCT05674799,NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks,https://clinicaltrials.gov/study/NCT05674799,RECRUITING,NO,Overweight or Obesity,BEHAVIORAL: NDPP-NextGen,Wake Forest University Health Sciences,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),FEMALE,ADULT,403,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2023-04-08,2028-05-31,"Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27157, United States"
NCT03345407,Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD),https://clinicaltrials.gov/study/NCT03345407,TERMINATED,YES,"Pulmonary Disease, Chronic Obstructive",DRUG: Placebo ELLIPTA|DRUG: Nemiralisib ELLIPTA 50 µg|DRUG: Nemiralisib ELLIPTA 100 µg|DRUG: Nemiralisib ELLIPTA 250 µg|DRUG: Nemiralisib ELLIPTA 500 µg|DRUG: Nemiralisib ELLIPTA 750 µg|DRUG: Albuterol (Salbutamol) MDI or nebules|DRUG: Standard of care therapy,GlaxoSmithKline,,ALL,"ADULT, OLDER_ADULT",943,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-11-28,2019-01-10,"GSK Investigational Site, Mobile, Alabama, 36608, United States|GSK Investigational Site, Colorado Springs, Colorado, 80907, United States|GSK Investigational Site, Daytona Beach, Florida, 32117, United States|GSK Investigational Site, Saint Petersburg, Florida, 33704, United States|GSK Investigational Site, Adairsville, Georgia, 30103, United States|GSK Investigational Site, Woodstock, Georgia, 30189, United States|GSK Investigational Site, Columbia, Maryland, 21044, United States|GSK Investigational Site, Chesterfield, Missouri, 63017, United States|GSK Investigational Site, Saint Charles, Missouri, 63301, United States|GSK Investigational Site, Omaha, Nebraska, 68134, United States|GSK Investigational Site, Gastonia, North Carolina, 28054, United States|GSK Investigational Site, Cincinnati, Ohio, 45231, United States|GSK Investigational Site, Dayton, Ohio, 45459, United States|GSK Investigational Site, Erie, Pennsylvania, 16508, United States|GSK Investigational Site, Charleston, South Carolina, 29406-7108, United States|GSK Investigational Site, Spartanburg, South Carolina, 29303, United States|GSK Investigational Site, Rapid City, South Dakota, 57702, United States|GSK Investigational Site, Abingdon, Virginia, 24210, United States|GSK Investigational Site, Richmond, Virginia, 23225, United States|GSK Investigational Site, Richmond, Virginia, 23229, United States|GSK Investigational Site, Morgantown, West Virginia, 26505, United States|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, C1414AIF, Argentina|GSK Investigational Site, Florida, Buenos Aires, 1602, Argentina|GSK Investigational Site, Mar del Plata, Buenos Aires, 7600, Argentina|GSK Investigational Site, San Rafael, Mendoza, 5600, Argentina|GSK Investigational Site, Rosario, Santa Fe, 2000, Argentina|GSK Investigational Site, Santo Tome, Santa Fe, 3016, Argentina|GSK Investigational Site, Buenos Aires, C1280AEB, Argentina|GSK Investigational Site, Buenos Aires, C1424BSF, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, C1425BEN, Argentina|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, C1426ABP, Argentina|GSK Investigational Site, Mendoza, 5500, Argentina|GSK Investigational Site, Mendoza, M5500CCG, Argentina|GSK Investigational Site, Tucuman, 4000, Argentina|GSK Investigational Site, Gosford, New South Wales, 2250, Australia|GSK Investigational Site, Westmead, New South Wales, 2145, Australia|GSK Investigational Site, Woolloongabba, Queensland, 4102, Australia|GSK Investigational Site, Woodville South, South Australia, 5011, Australia|GSK Investigational Site, Clayton, Victoria, 3168, Australia|GSK Investigational Site, Murdoch, Western Australia, 6150, Australia|GSK Investigational Site, Edmonton, Alberta, T6G 2G3, Canada|GSK Investigational Site, Sherwood Park, Alberta, T8H 0N2, Canada|GSK Investigational Site, Winnipeg, Manitoba, R2H 2A6, Canada|GSK Investigational Site, Windsor, Ontario, N8X 5A6, Canada|GSK Investigational Site, Montreal, Quebec, H3T1E2, Canada|GSK Investigational Site, Quebec City, Quebec, G1V 4G5, Canada|GSK Investigational Site, St-Charles-Borromée, Quebec, J6E 2B4, Canada|GSK Investigational Site, Brest cedex, 29609, France|GSK Investigational Site, Lyon, 69004, France|GSK Investigational Site, Montpellier cedex 5, 34295, France|GSK Investigational Site, Rennes Cedex 9, 35033, France|GSK Investigational Site, Vandoeuvre-lès-Nancy cedex, 54511, France|GSK Investigational Site, Aschaffenburg, Bayern, 63739, Germany|GSK Investigational Site, Bamberg, Bayern, 96049, Germany|GSK Investigational Site, Rosenheim, Bayern, 83022, Germany|GSK Investigational Site, Potsdam, Brandenburg, 14467, Germany|GSK Investigational Site, Darmstadt, Hessen, 64283, Germany|GSK Investigational Site, Frankfurt, Hessen, 60389, Germany|GSK Investigational Site, Frankfurt, Hessen, 60596, Germany|GSK Investigational Site, Hannover, Niedersachsen, 30173, Germany|GSK Investigational Site, Rheine, Nordrhein-Westfalen, 48431, Germany|GSK Investigational Site, Warendorf, Nordrhein-Westfalen, 48231, Germany|GSK Investigational Site, Koblenz, Rheinland-Pfalz, 56068, Germany|GSK Investigational Site, Leipzig, Sachsen, 04103, Germany|GSK Investigational Site, Geesthacht, Schleswig-Holstein, 21502, Germany|GSK Investigational Site, Luebeck, Schleswig-Holstein, 23558, Germany|GSK Investigational Site, Schleswig, Schleswig-Holstein, 24837, Germany|GSK Investigational Site, Berlin, 12203, Germany|GSK Investigational Site, Reggio Emilia, Emilia-Romagna, 42100, Italy|GSK Investigational Site, Roma, Lazio, 00133, Italy|GSK Investigational Site, Roma, Lazio, 00189, Italy|GSK Investigational Site, Milano, Lombardia, 20122, Italy|GSK Investigational Site, Pavia, Lombardia, 27100, Italy|GSK Investigational Site, Tradate (VA), Lombardia, 21049, Italy|GSK Investigational Site, Catania, Sicilia, 95123, Italy|GSK Investigational Site, Messina, Sicilia, 98125, Italy|GSK Investigational Site, Negrar, Veneto, 37024, Italy|GSK Investigational Site, Daejon, 35365, Korea, Republic of|GSK Investigational Site, Incheon, 21431, Korea, Republic of|GSK Investigational Site, Jeonju-si, Jeollabuk-do, 54907, Korea, Republic of|GSK Investigational Site, Seongnam-si, Gyeonggi-do, 463-707, Korea, Republic of|GSK Investigational Site, Seoul, 02559, Korea, Republic of|GSK Investigational Site, Seoul, 136-705, Korea, Republic of|GSK Investigational Site, Seoul, 137-701, Korea, Republic of|GSK Investigational Site, Seoul, 143-729, Korea, Republic of|GSK Investigational Site, Seoul, 150-713, Korea, Republic of|GSK Investigational Site, Seoul, 156-755, Korea, Republic of|GSK Investigational Site, Guadalajara, Jalisco, 44100, Mexico|GSK Investigational Site, Zapopan, Jalisco, 45070, Mexico|GSK Investigational Site, Monterrey, Nuevo León, 64020, Mexico|GSK Investigational Site, Alkmaar, 1815 JD, Netherlands|GSK Investigational Site, Breda, 4818 CK, Netherlands|GSK Investigational Site, Eindhoven, 5623 EJ, Netherlands|GSK Investigational Site, Groningen, 9728 NT, Netherlands|GSK Investigational Site, Harderwijk, 3844 DG, Netherlands|GSK Investigational Site, Hoorn, 1624 NP, Netherlands|GSK Investigational Site, Rotterdam, 3083 AN, Netherlands|GSK Investigational Site, Utrecht, 3543 AZ, Netherlands|GSK Investigational Site, Zwolle, 8025 AB, Netherlands|GSK Investigational Site, Bialystok, 15-044, Poland|GSK Investigational Site, Elblag, 82-300, Poland|GSK Investigational Site, Krakow, 31-209, Poland|GSK Investigational Site, Lubin, 59-300, Poland|GSK Investigational Site, Olawa, 55-200, Poland|GSK Investigational Site, Ruda Slaska, 41-709, Poland|GSK Investigational Site, Slupsk, 76-200, Poland|GSK Investigational Site, Sosnowiec, 41-200, Poland|GSK Investigational Site, Tarnow, 33-100, Poland|GSK Investigational Site, Bucarest, 050159, Romania|GSK Investigational Site, Bucharest, 030303, Romania|GSK Investigational Site, Bucharest, 050159, Romania|GSK Investigational Site, Cluj Napoca, 400015, Romania|GSK Investigational Site, Comuna Alexandru Cel Bun, 617507, Romania|GSK Investigational Site, Iasi, 700115, Romania|GSK Investigational Site, Oradea, 410176, Romania|GSK Investigational Site, Ramnicu Valcea, 240564, Romania|GSK Investigational Site, Suceava, 720284, Romania|GSK Investigational Site, Timisoara, 300310, Romania|GSK Investigational Site, Barnaul, 656 045, Russian Federation|GSK Investigational Site, Belgorod, 308007, Russian Federation|GSK Investigational Site, Blagoveshchensk, 675000, Russian Federation|GSK Investigational Site, Chelyabinsk, 454048, Russian Federation|GSK Investigational Site, Chelyabinsk, 454106, Russian Federation|GSK Investigational Site, Ivanovo, 153005, Russian Federation|GSK Investigational Site, Kemerovo, 650000, Russian Federation|GSK Investigational Site, Nizhniy Novgorod, 603011, Russian Federation|GSK Investigational Site, Novgorod, 173008, Russian Federation|GSK Investigational Site, Novosibirsk, 630102, Russian Federation|GSK Investigational Site, Perm, 614109, Russian Federation|GSK Investigational Site, Ryazan, 390039, Russian Federation|GSK Investigational Site, Saratov, 410028, Russian Federation|GSK Investigational Site, Tomsk, 634003, Russian Federation|GSK Investigational Site, Ulyanovsk, 432063, Russian Federation|GSK Investigational Site, Voronezh, 394066, Russian Federation|GSK Investigational Site, Laredo, Cantabria, 39770, Spain|GSK Investigational Site, Barcelona, 08003, Spain|GSK Investigational Site, Basurto/Bilbao, 48013, Spain|GSK Investigational Site, Cartagena (Murcia), 30202, Spain|GSK Investigational Site, Cáceres, 10003, Spain|GSK Investigational Site, Elda (Alicante), 03600, Spain|GSK Investigational Site, Gerona, 17007, Spain|GSK Investigational Site, Logroño, 26006, Spain|GSK Investigational Site, Madrid, 28007, Spain|GSK Investigational Site, Madrid, 28034, Spain|GSK Investigational Site, Madrid, 28046, Spain|GSK Investigational Site, Mérida (Badajoz), 06800, Spain|GSK Investigational Site, Orihuela (Alicante), 03314, Spain|GSK Investigational Site, Palma de Mallorca, 07198, Spain|GSK Investigational Site, Pama de Mallorca, 07010, Spain|GSK Investigational Site, Ponferrada (León), 24411, Spain|GSK Investigational Site, Pozuelo De Alarcón/Madrid, 28223, Spain|GSK Investigational Site, Göteborg, SE-413 45, Sweden|GSK Investigational Site, Lund, SE-221 85, Sweden|GSK Investigational Site, Chesterfield, Derbyshire, S40 4AA, United Kingdom|GSK Investigational Site, Wishaw, Lanarkshire, ML2 0DP, United Kingdom|GSK Investigational Site, Blackburn, BB2 3HH, United Kingdom|GSK Investigational Site, Bradford, BD9 6RJ, United Kingdom|GSK Investigational Site, Edgbaston, B15 2GW, United Kingdom|GSK Investigational Site, Edinburgh, EH16 4SA, United Kingdom|GSK Investigational Site, Liverpool, L9 7AL, United Kingdom|GSK Investigational Site, Sheffield, S5 7AU, United Kingdom|GSK Investigational Site, Stockton-on-Tees, TS19 8PE, United Kingdom"
NCT00510276,Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes,https://clinicaltrials.gov/study/NCT00510276,COMPLETED,YES,Attention Deficit Hyperactivity Disorder,DRUG: Atomoxetine hydrochloride|DRUG: Placebo,Eli Lilly and Company,,ALL,ADULT,445,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-08,2009-02,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, 90024, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rolling Hills Est., California, 90274, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spring Valley, California, 91978, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wildomar, California, 92595, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gainesville, Florida, 32607, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, 32216, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., South Miami, Florida, 33143, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Petersburg, Florida, 33709, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eagle, Idaho, 83616, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Topeka, Kansas, 66606, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, 40509, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belmont, Massachusetts, 02478, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Farmington Hills, Michigan, 48336, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, 68198, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Las Vegas, Nevada, 89128, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Piscataway, New Jersey, 08854, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, 10010, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charlotte, North Carolina, 28211, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beachwood, Ohio, 44122, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, 45267, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, 73103, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, South Carolina, 29405, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Burlington, Vermont, 05401, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Woodstock, Vermont, 05091, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Midlothian, Virginia, 23112, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, 98104, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spokane, Washington, 99202, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hato Rey, 00918, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, 00907, Puerto Rico"
NCT03093402,JBT-101 in Systemic Lupus Erythematosus (SLE),https://clinicaltrials.gov/study/NCT03093402,COMPLETED,YES,Systemic Lupus Erythematosus|SLE|Lupus,DRUG: JBT-101|DRUG: Placebo,National Institute of Allergy and Infectious Diseases (NIAID),"Corbus Pharmaceuticals Inc.|Autoimmunity Centers of Excellence|Rho Federal Systems Division, Inc.",ALL,"ADULT, OLDER_ADULT",109,NIH,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-12-21,2021-07-28,"University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology, La Jolla, California, 92093, United States|UCLA Medical Center: Division of Rheumatology, Los Angeles, California, 90095, United States|University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center, San Francisco, California, 94143, United States|Yale University, New Haven, Connecticut, 06520, United States|Emory University: Division of Rheumatology, Atlanta, Georgia, 30322, United States|Bronx-Lebanon Hospital Center: Division of Rheumatology, Bronx, New York, 10457, United States|Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases, Manhasset, New York, 11030, United States|New York University Langone Medical Center: Department of Medicine, Division of Rheumatology, New York, New York, 10016, United States|Columbia University Medical Center: Department of Medicine, Division of Rheumatology, New York, New York, 10032, United States|Duke University, Durham, North Carolina, 27710, United States|MetroHealth Medical Center, Cleveland, Ohio, 44109, United States|Penn State MS Hershey Medical Center, Hershey, Pennsylvania, 17033, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Temple University, Philadelphia, Pennsylvania, 19140, United States|University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology, Pittsburgh, Pennsylvania, 15217, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States"
NCT05782231,Improving Health for Older Adults With Pain Through Engagement (Open-pilot),https://clinicaltrials.gov/study/NCT05782231,ACTIVE_NOT_RECRUITING,NO,Chronic Pain|Musculoskeletal Pain,BEHAVIORAL: GetActive+,Massachusetts General Hospital,,ALL,"ADULT, OLDER_ADULT",33,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-04-18,2024-07-01,"Massachusetts General Hospital, Boston, Massachusetts, 02114, United States"
NCT06592443,The LvL UP Trial: Assessing the Effectiveness of a mHealth Intervention,https://clinicaltrials.gov/study/NCT06592443,RECRUITING,NO,Health Behavior|Noncommunicable Diseases|Mental Health Issue|Lifestyle Risk Reduction,BEHAVIORAL: LvL UP|BEHAVIORAL: LvL UP + MI|BEHAVIORAL: Comparison,Singapore ETH Centre,ETH Zurich|National University of Singapore|Nanyang Technological University,ALL,ADULT,1073,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2024-10-21,2026-01,"Saw Swee Hock School of Public Health, Singapore, 117549, Singapore|Singapore ETH Center, Singapore, 138602, Singapore"
NCT06063902,Long-Term Opioid Therapy in Chronic Non-Cancer Pain: Risks and Benefits,https://clinicaltrials.gov/study/NCT06063902,ENROLLING_BY_INVITATION,NO,Chronic Non-Cancer Pain|Opioid Use Disorder,,Uppsala University,,ALL,"ADULT, OLDER_ADULT",1000,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-01-14,2027-01-14,"Uppsala Univeristy Hospital, Uppsala, Sweden"
NCT03953495,Better Together: A Web-based Relationship Education Tool,https://clinicaltrials.gov/study/NCT03953495,COMPLETED,NO,Same-Sex Relationships,BEHAVIORAL: Better Together,Sharon Scales Rostosky,,FEMALE,"ADULT, OLDER_ADULT",22,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-06-25,2020-12-03,"University of Kentucky, Lexington, Kentucky, 40506, United States"
NCT04738123,A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3),https://clinicaltrials.gov/study/NCT04738123,COMPLETED,YES,Schizophrenia|Schizophrenia; Psychosis,DRUG: Xanomeline and Trospium Chloride Capsules|DRUG: Placebo,Karuna Therapeutics,,ALL,"ADULT, OLDER_ADULT",256,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-06,2022-12-07,"Pillar Clinical Research, Bentonville, Arkansas, 72712, United States|Woodland International Research Group, Little Rock, Arkansas, 72211, United States|Advanced Research Center, Inc., Anaheim, California, 92805, United States|Clinical Innovations, Inc, Bellflower, California, 90706, United States|ProScience Research Group, Culver City, California, 90230, United States|Collaborative Neuroscience Research, LLC., Garden Grove, California, 92845, United States|CNS Network, Long Beach, California, 90806, United States|NRC Research Institute, Orange, California, 92868, United States|Artemis Institute for Clinical Research, San Diego, California, 92103, United States|Behavioral Clinical Research, Inc., Hollywood, Florida, 33021, United States|Larkin Behavioral Health Services, Hollywood, Florida, 33021, United States|Atlanta Center for Medical Research, Atlanta, Georgia, 30331, United States|iResearch Atlanta, LLC, Decatur, Georgia, 30030, United States|AMITA Health Center for Psychiatric Research, Chicago, Illinois, 60622, United States|Uptown Research Institute, Chicago, Illinois, 60640, United States|AMITA Health Center for Psychiatric Research, Hoffman Estates, Illinois, 60169, United States|Hassman Research Institute, Berlin, New Jersey, 08009, United States|Hassman Research Institute, Marlton, New Jersey, 08053, United States|Community Clinical Research, Inc., Austin, Texas, 78754, United States|InSite Clinical Research, LLC, DeSoto, Texas, 75115, United States|Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnikov, Dnipro, 49005, Ukraine|Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine, Kharkiv, 61068, Ukraine|Regional Clinical Psychiatric Hospital No. 3, Adult Psychiatric Department No. 3, Kharkiv, 61068, Ukraine|Regional Clinical Psychiatric Hospital No. 3, Psychiatric Department for First Episode Psychosis, Kharkiv, 61068, Ukraine|Kherson Regional Institution of Mental Care, Kherson, 73488, Ukraine|Kyiv City Psychoneurological Hospital #2, Kyiv, 02192, Ukraine|Kyiv Regional Medical Incorporation ""Psychiatry"", Center for Novel Treatment and Rehabilitation of Psychotic Disorders, Kyiv, 04080, Ukraine|Lviv Regional Clinical Psychiatric Hospital, Department #20, Lviv, 79021, Ukraine|Lviv Regional Clinical Psychiatric Hospital, Department #25, Lviv, 79021, Ukraine|Regional Institution of Mental Psychiatric Care of the Poltava Regional Council, Poltava, 36013, Ukraine|Cherkasy Regional Psychiatric Hospital of Cherkasy Regional Council, Smila, 20708, Ukraine|M.I. Pyrogov Vinnytsya National Medical University, Vinnytsya, 21037, Ukraine"
NCT02290223,Patient Activation to Address Chronic Pain and Opioid Management in Primary Care,https://clinicaltrials.gov/study/NCT02290223,COMPLETED,YES,Chronic Pain,BEHAVIORAL: Behavioral Based Treatment Model,Kaiser Permanente,Patient-Centered Outcomes Research Institute,ALL,"ADULT, OLDER_ADULT",376,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-06,2017-09-06,"Kaiser Permanente, San Jose Medical Center, San Jose, California, 95119, United States|Kaiser Permanente, Santa Clara Medical Center, Santa Clara, California, 95051, United States"
NCT06169527,A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab,https://clinicaltrials.gov/study/NCT06169527,RECRUITING,NO,Atopic Dermatitis,DRUG: Dupilumab,Sanofi,Regeneron Pharmaceuticals,ALL,"CHILD, ADULT, OLDER_ADULT",500,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-11-28,2027-11-29,"Investigational Site Number: 2500041, Amiens, 80054, France|Investigational Site Number: 2500037, Angers, 49000, France|Investigational Site Number: 2500021, Argenteuil, 95100, France|Investigational Site Number: 2500044, Armentières, 59280, France|Investigational Site Number: 2500018, Arras, 62022, France|Investigational Site Number: 2500011, Ars Laquenexy, 57530, France|Investigational Site Number: 2500023, Avignon, 84000, France|Investigational Site Number: 2500001, Besançon, 25000, France|Investigational Site Number: 2500003, Bron, 69500, France|Investigational Site Number: 2500043, Caen, 14033, France|Investigational Site Number: 2500050, Chambery, 73000, France|Investigational Site Number: 2500006, Clermont Ferrand, 63003, France|Investigational Site Number: 2500005, Dijon, 21079, France|Investigational Site Number: 2500004, Epagny Metz Tessy, 74374, France|Investigational Site Number: 2500039, Fort-de-France, 97261, France|Investigational Site Number: 2500045, La Tronche, 38700, France|Investigational Site Number: 2500040, Le Mans, 72037, France|Investigational Site Number: 2500038, Les Sables d'Olonne, 85100, France|Investigational Site Number: 2500048, Levallois-Perret, 92300, France|Investigational Site Number: 2500032, Lille, 59037, France|Investigational Site Number: 2500002, Limoges, 87042, France|Investigational Site Number: 2500036, Lorient, 56100, France|Investigational Site Number: 2500029, Marseille, 13008, France|Investigational Site Number: 2500019, Montivilliers, 76290, France|Investigational Site Number: 2500028, Montpellier, 34295, France|Investigational Site Number: 2500024, Nantes, 44093, France|Investigational Site Number: 2500020, Nice, 06000, France|Investigational Site Number: 2500025, Nice, 06000, France|Investigational Site Number: 2500016, Pau, 64000, France|Investigational Site Number: 2500042, Poitiers, 86000, France|Investigational Site Number: 2500022, Pontoise, 95300, France|Investigational Site Number: 2500009, Périgueux, 24000, France|Investigational Site Number: 2500014, Romans sur Isère, 26102, France|Investigational Site Number: 2500008, Rouen, 76038, France|Investigational Site Number: 2500015, Saint Germain en Laye, 78100, France|Investigational Site Number: 2500027, Saint Mandé, 94163, France|Investigational Site Number: 2500026, Saint Nazaire, 44600, France|Investigational Site Number: 2500035, Saint-Pierre, 97410, France|Investigational Site Number: 2500013, Saint-Pierre, 97448, France|Investigational Site Number: 2500012, Toulouse, 31059, France|Investigational Site Number: 2500010, Valence, 26953, France|Investigational Site Number: 2500031, Vandoeuvre-lès-Nancy, 54500, France"
NCT01802294,Sinovuyo Caring Families Project - Pilot Trial,https://clinicaltrials.gov/study/NCT01802294,COMPLETED,NO,Child Behavior|Parenting|Child Abuse,BEHAVIORAL: Parenting Program,University of Cape Town,University of Oxford|Bangor University|Ilifa Labantwana,ALL,"ADULT, OLDER_ADULT",68,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2013-02,2013-08,"Ikamva Labantu Wellness Centre, Cape Town, Western Cape, 7784, South Africa"
NCT03447314,Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT03447314,COMPLETED,YES,Neoplasms,DRUG: GSK1795091|DRUG: GSK3174998|DRUG: GSK3359609|DRUG: Pembrolizumab,GlaxoSmithKline,Iqvia Pty Ltd,ALL,"ADULT, OLDER_ADULT",54,INDUSTRY,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2018-03-26,2022-03-11,"GSK Investigational Site, Boston, Massachusetts, 02215, United States|GSK Investigational Site, Saint Louis, Missouri, 63110, United States|GSK Investigational Site, Dallas, Texas, 75230, United States|GSK Investigational Site, Houston, Texas, 77030, United States|GSK Investigational Site, Tacoma, Washington, 98405, United States|GSK Investigational Site, Toronto, Ontario, M5G 2M9, Canada|GSK Investigational Site, Amsterdam, 1066 CX, Netherlands|GSK Investigational Site, Barcelona, 08035, Spain"
NCT02224573,An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes,https://clinicaltrials.gov/study/NCT02224573,COMPLETED,YES,Epilepsy|Dravet Syndrome|Lennox-Gastaut Syndrome,DRUG: GWP42003-P,GW Research Ltd,,ALL,"CHILD, ADULT, OLDER_ADULT",681,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-06-11,2020-09-24,
NCT05833503,Integrative Couple Treatment for Gambling/Substance Use Disorder,https://clinicaltrials.gov/study/NCT05833503,RECRUITING,NO,Gambling Disorder|Substance Use Disorders,BEHAVIORAL: Integrative Couple Treatment for Addiction (ICT-A)|BEHAVIORAL: Treatment individual as usually offered,Université du Québec à Trois-Rivières,Université du Québec a Montréal|Université de Sherbrooke|Laval University|Université de Montréal,ALL,"ADULT, OLDER_ADULT",100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-01,2026-02,"Centre Intégré de Santé et de Services Sociaux de Lanaudière, Joliette, Quebec, J6E 5X7, Canada|Centre intégré de Santé et de Services Sociaux de Chaudière-Appalaches (CISSS-CA), Lévis, Quebec, G6V 0M4, Canada|Centre Universitaire Intégré de Santé et de Services Sociaux du Centre Sud de l'Ile de Montréal, Montréal, Quebec, H2L 4M1, Canada|Centre Intégré de Santé et de Services Sociaux des Laurentides, Saint-Jérôme, Quebec, J7Z 5T3, Canada|Centre Universitaire Intégré de Santé et de Services Sociaux de l'Estrie, Sherbrooke, Quebec, J1G 1B1, Canada|Centre Intégré de Santé et de Services Sociaux de la Montérégie-Ouest, St-Hubert, Quebec, J3Y 6W9, Canada|Centre Universitaire Intégré de Santé et de Services Sociaux de la Capitale Nationale, Québec, G1J 0A4, Canada"
NCT01428583,Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain,https://clinicaltrials.gov/study/NCT01428583,COMPLETED,YES,Chronic Noncancer Pain,DRUG: oxycodone HCl and naltrexone HCl extended-release capsules,Pfizer,,ALL,"ADULT, OLDER_ADULT",395,INDUSTRY,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2010-12,2012-05,"Avail Clinical Research, LLC, Deland, Florida, 32720, United States|Florida Institute of Medical Research, Jacksonville, Florida, 32257, United States|Drug Study Institute, Jupiter, Florida, 33458, United States|Ormond Medical Arts Pharmaceutical Research Center, Ormond Beach, Florida, 32174, United States|Peninsula Research, Inc., Ormond Beach, Florida, 32174, United States|Accord Clinical Research, Port Orange, Florida, 32129, United States|Sarasota Pain Medicine Research, Sarasota, Florida, 34238, United States|Clinical Research of West Florida, Tampa, Florida, 33603, United States|Center for Prospective Outcome Studies, Inc., Atlanta, Georgia, 30327, United States|Drug Studies America, Marietta, Georgia, 30060, United States|Georgia Institute for Clinical Research, LLC, Marietta, Georgia, 30060, United States|The Pain Treatment Center of the Bluegrass, Lexington, Kentucky, 40503, United States|Commonwealth Biomedical Research, Madisonville, Kentucky, 42431, United States|Crossroads Research, Owings Mills, Maryland, 21117, United States|DM Clinical Research, Springfield, Massachusetts, 01103, United States|MAPS Applied Research Center, Edina, Minnesota, 55435, United States|Mid-South Anesthesia Consultants, Southaven, Mississippi, 38671, United States|Healthcare Research, LLC, Hazelwood, Missouri, 64042, United States|Montana Neuroscience Institute, Missoula, Montana, 59802, United States|Comprehensive Clinical Research, Berlin, New Jersey, 08009, United States|Drug Trials America - New York, Hartsdale, New York, 10530, United States|New York Spine and Wellness Center, North Syracuse, New York, 13212, United States|Upstate Clinical Research Associates, Williamsville, New York, 14221, United States|Center for Clinical Research, LLC - Winston-Salem, Winston-Salem, North Carolina, 27103, United States|Columbus Clinical Research, Inc., Columbus, Ohio, 43213, United States|Allegheny Pain Management, PC, Altoona, Pennsylvania, 16602, United States|FutureSearch Trials of Neurology, Austin, Texas, 78731, United States|KRK Medical Research, Dallas, Texas, 75230, United States|Benchmark Research - Fort Worth, Fort Worth, Texas, 76135, United States|Quality Research, Inc., San Antonio, Texas, 78209, United States|Lifetree Clinical Research, Salt Lake City, Utah, 84106, United States|Hypothetest, LLC, Roanoke, Virginia, 24018, United States"
NCT03100279,Process and Outcomes in CBT for Anxious and Depressed Youth,https://clinicaltrials.gov/study/NCT03100279,UNKNOWN,NO,Anxiety Disorders|Depression,BEHAVIORAL: Coping Cat/CAT Project|BEHAVIORAL: Primary and Secondary Coping Enhancement Therapy,Rutgers University,,ALL,CHILD,400,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-07-01,2022-08-31,"Rutgers University (Youth Anxiety and Depression Clinic), Piscataway, New Jersey, 08854, United States"
NCT04462367,Northeast COVID-19 and Pregnancy Study Group,https://clinicaltrials.gov/study/NCT04462367,ACTIVE_NOT_RECRUITING,NO,COVID19|Coronavirus Infection|Pregnancy Disease|Severe Acute Respiratory Syndrome,,Instituto Materno Infantil Prof. Fernando Figueira,,FEMALE,"CHILD, ADULT, OLDER_ADULT",180,OTHER,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-07-01,2024-12-20,"Instituto Materno Infantil Prof. Fernando Figueira, Recife, Pernambuco, 50.070-550, Brazil"
